assays_ss_d,assays_dscrptn,assays_src_d,assays_rltnshp_tp,assays_src_ss_d,assays_ss_rgnsm,assays_vrnt_d,assays_ss_sbclllr_frctn,assays_ss_ctgr,assays_ss_tss,assays_ss_cll_tp,assays_tss_d,assays_b_frmt,assays_chmbl_d,assays_cnfdnc_scr,assays_crtd_b,assays_ss_tx_d,assays_ss_strn,assays_td,assays_cll_d
1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615117,8,Autocuration,,,12052,
2,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,1,U,,,,,,,,,BAO_0000219,CHEMBL615118,0,Autocuration,,,22226,
3,,1,U,,,,,,,,,BAO_0000019,CHEMBL615119,0,Autocuration,,,22226,
4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,1,H,,Bos taurus,,,,,,,BAO_0000249,CHEMBL615120,4,Autocuration,9913.0,,104729,
5,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615121,1,Intermediate,9606.0,,80001,163.0
6,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615122,1,Intermediate,9606.0,,80001,163.0
7,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,1,N,,Mus musculus,,,,,143B,,BAO_0000219,CHEMBL615123,1,Intermediate,10090.0,,80001,163.0
8,In vitro cell cytotoxicity was determined against 143B cell line,1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615124,1,Expert,9606.0,,80001,163.0
9,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615125,1,Intermediate,9606.0,,80001,163.0
10,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615126,1,Intermediate,9606.0,,80001,163.0
11,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615127,1,Intermediate,9606.0,,80001,163.0
12,In vitro cell cytotoxicity was determined against 143B-LTK cell line,1,N,,Homo sapiens,,,,,143B,,BAO_0000219,CHEMBL615128,1,Expert,9606.0,,80001,163.0
13,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,N,,Staphylococcus aureus,,,,,,,BAO_0000218,CHEMBL857900,1,Intermediate,1280.0,,50185,
14,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,N,,Staphylococcus aureus,,,,,,,BAO_0000218,CHEMBL615129,1,Intermediate,1280.0,,50185,
15,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,N,,Staphylococcus aureus,,,,,,,BAO_0000218,CHEMBL615130,1,Intermediate,1280.0,,50185,
16,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,N,,Staphylococcus aureus,,,,,,,BAO_0000218,CHEMBL615131,1,Intermediate,1280.0,,50185,
17,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL884521,9,Expert,10116.0,,100122,
18,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),1,H,,,,,,,,,BAO_0000357,CHEMBL615132,8,Autocuration,,,12054,
19,Inhibition of partially purified 15-lipoxygenase from human leukocytes,1,H,,,,,,,,,BAO_0000019,CHEMBL615133,8,Autocuration,,,12054,
20,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,H,,,,,,,,,BAO_0000357,CHEMBL615134,8,Autocuration,,,12054,
21,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),1,H,,,,,,,,,BAO_0000357,CHEMBL615135,8,Autocuration,,,12054,
22,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,H,,,,,,,,,BAO_0000357,CHEMBL615136,8,Autocuration,,,12054,
23,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL615137,8,Autocuration,,,12054,
24,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL615138,8,Autocuration,,,12054,
25,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",1,U,,,,,,,,,BAO_0000219,CHEMBL836324,0,Autocuration,,,22226,
26,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL615139,8,Autocuration,9986.0,,12054,
27,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL615140,8,Autocuration,9986.0,,12054,
28,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,1,H,,,,,,,,,BAO_0000219,CHEMBL615141,8,Autocuration,,,12426,
29,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,1,H,,soya bean,,,,,,,BAO_0000357,CHEMBL615142,8,Autocuration,3847.0,,12054,
30,Inhibitory activity against soybean 15-lipoxygenase was evaluated,1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL615143,8,Autocuration,3847.0,,12054,
31,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL615144,8,Autocuration,3847.0,,12054,
32,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL872867,8,Autocuration,3847.0,,12054,
33,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL615145,8,Autocuration,3847.0,,12054,
34,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL615146,8,Autocuration,3847.0,,12054,
35,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL615147,8,Autocuration,3847.0,,12054,
36,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615148,0,Autocuration,10116.0,,22226,
37,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,1,U,,Escherichia coli,,,,,,,BAO_0000019,CHEMBL615149,0,Autocuration,562.0,,22226,
38,Dissociation constant with dimeric 16S rRNA RNA construct B,1,U,,,,,,,,,BAO_0000019,CHEMBL615150,0,Autocuration,,,22226,
39,Dissociation constant towards 16S rRNA construct A,1,M,,,,,,,,,BAO_0000225,CHEMBL615151,3,Intermediate,,,22222,
40,Dissociation constant towards 16S rRNA construct B,1,M,,,,,,,,,BAO_0000225,CHEMBL615152,3,Intermediate,,,22222,
41,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,1,M,,Escherichia coli,,,,,,,BAO_0000225,CHEMBL615153,3,Expert,562.0,,100263,
42,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,1,M,,Escherichia coli,,,,,,,BAO_0000225,CHEMBL615154,3,Expert,562.0,,100263,
43,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,H,,,,,,,,,BAO_0000019,CHEMBL615155,8,Autocuration,,,13053,
44,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,H,,,,,,,,,BAO_0000019,CHEMBL615156,8,Autocuration,,,13053,
45,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,H,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615157,8,Autocuration,9606.0,,20001,
46,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,H,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615158,8,Autocuration,9606.0,,20001,
47,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615159,9,Expert,10116.0,,12971,
48,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615172,9,Expert,10116.0,,12971,
49,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615173,9,Expert,10116.0,,12971,
50,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615174,9,Expert,10116.0,,12971,
51,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,H,,,,,,,,,BAO_0000019,CHEMBL884518,8,Autocuration,,,13053,
52,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),1,H,,,,,,,,,BAO_0000357,CHEMBL615175,8,Autocuration,,,11512,
53,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL615176,8,Autocuration,,,11512,
54,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL615177,8,Autocuration,,,11512,
55,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL615178,5,Autocuration,10116.0,,104740,
56,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615179,1,Intermediate,9606.0,,80002,506.0
57,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,1,D,,Rattus norvegicus,,,,,Oocytes,,BAO_0000219,CHEMBL615180,7,Autocuration,10116.0,,104835,
58,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,1,D,,Rattus norvegicus,,,,,Oocytes,,BAO_0000219,CHEMBL615181,7,Autocuration,10116.0,,104821,
59,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,1,D,,Rattus norvegicus,,,,,Oocytes,,BAO_0000219,CHEMBL615182,7,Autocuration,10116.0,,104848,
60,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615183,1,Expert,9606.0,,80002,506.0
61,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615184,1,Intermediate,9606.0,,80002,506.0
62,Cytotoxic activity against human ovarian cancer (1A9) cell line,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615185,1,Intermediate,9606.0,,80002,506.0
63,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615186,1,Intermediate,9606.0,,80002,506.0
64,Effective dose of compound against replication of 1A9 cell line was evaluated,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615187,1,Intermediate,9606.0,,80002,506.0
65,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL885343,1,Expert,9606.0,,80002,506.0
66,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615188,1,Intermediate,9606.0,,80002,506.0
67,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615189,1,Intermediate,9606.0,,80002,506.0
68,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615190,1,Intermediate,9606.0,,80002,506.0
69,Inhibitory activity against Taxol resistant 1A9 cell lines,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615191,1,Intermediate,9606.0,,80002,506.0
70,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615192,1,Expert,9606.0,,80002,506.0
71,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL827083,1,Expert,9606.0,,80002,506.0
72,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615193,1,Expert,9606.0,,80002,506.0
73,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615194,1,Intermediate,9606.0,,80002,506.0
74,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615195,1,Intermediate,9606.0,,80002,506.0
75,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1,N,,Homo sapiens,,,,,1A9,,BAO_0000219,CHEMBL615196,1,Intermediate,9606.0,,80002,506.0
76,Inhibitory concentration against Jurkat cells,1,N,,Homo sapiens,,,,,Jurkat,,BAO_0000219,CHEMBL615197,1,Intermediate,9606.0,,81072,503.0
77,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL615198,0,Intermediate,,,22226,
78,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615199,9,Expert,10116.0,,100121,
79,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,H,,,,,,,,,BAO_0000357,CHEMBL615200,8,Expert,,,11231,
80,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,H,,,,,,,,,BAO_0000357,CHEMBL615201,8,Expert,,,11231,
81,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",1,H,,,,,,,,,BAO_0000357,CHEMBL615202,8,Expert,,,11231,
82,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",1,H,,Candida albicans,,Microsomes,,,,,BAO_0000251,CHEMBL615203,8,Autocuration,5476.0,,11231,
83,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",1,H,,Candida albicans,,Microsomes,,,,,BAO_0000251,CHEMBL615204,8,Autocuration,5476.0,,11231,
84,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",1,H,,Saccharomyces cerevisiae,,Microsomes,,,,,BAO_0000251,CHEMBL615205,8,Autocuration,4932.0,,11231,
85,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",1,H,,Saccharomyces cerevisiae,,Microsomes,,,,,BAO_0000251,CHEMBL615206,8,Autocuration,4932.0,,11231,
86,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",1,H,,Sus scrofa,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615207,8,Autocuration,9823.0,,12083,
87,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",1,H,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL827084,8,Autocuration,10116.0,,11231,
88,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",1,H,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615208,8,Autocuration,10116.0,,11231,
89,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",1,H,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615209,8,Autocuration,10116.0,,11231,
90,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615210,9,Autocuration,10116.0,,12083,
91,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615211,9,Autocuration,10116.0,,12083,
92,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615212,9,Autocuration,10116.0,,12083,
93,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),1,H,,,,,,,,,BAO_0000357,CHEMBL615213,8,Expert,,,11377,
94,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,1,H,,,,,,,,,BAO_0000357,CHEMBL615273,8,Expert,,,11377,
95,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615274,1,Expert,9606.0,,81020,726.0
96,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615275,1,Intermediate,9606.0,,81020,726.0
97,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615276,1,Intermediate,9606.0,,81020,726.0
98,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615277,1,Intermediate,9606.0,,81020,726.0
99,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615326,1,Intermediate,9606.0,,81020,726.0
100,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,N,,Hepatitis B virus,,,,,,,BAO_0000218,CHEMBL883130,1,Expert,10407.0,,50606,
101,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL884519,1,Intermediate,9606.0,,81020,726.0
102,Concentration required to inhibit 50% of 2.2.15 cell line,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615327,1,Intermediate,9606.0,,81020,726.0
103,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615328,1,Intermediate,9606.0,,81020,726.0
104,Cytotoxic activity of compound against uninfected 2.2.15 cells.,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615329,1,Intermediate,9606.0,,50587,
105,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615330,1,Intermediate,9606.0,,50587,
106,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",1,N,,Hepatitis B virus,,,,,2.2.15,,BAO_0000218,CHEMBL615331,1,Expert,10407.0,,50606,
107,In vitro anti-HBV activity in 2.2.15 cells,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615332,1,Intermediate,9606.0,,50587,
108,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615333,1,Intermediate,9606.0,,50587,
109,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615334,1,Intermediate,9606.0,,50587,
110,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615335,1,Intermediate,9606.0,,50587,
111,Cytotoxicity in 2.2.15 cells,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615336,1,Intermediate,9606.0,,50587,
112,Cytotoxicity in 2.2.15 cells; Not determined,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615337,1,Intermediate,9606.0,,50587,
113,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615338,1,Intermediate,9606.0,,50587,
114,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615339,1,Intermediate,9606.0,,50587,
115,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,1,N,,Homo sapiens,,,,,2.2.15,,BAO_0000218,CHEMBL615340,1,Intermediate,9606.0,,50587,
116,Antiviral activity against HBV was determined in 2.215 cell line,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615341,1,Intermediate,9606.0,,81020,726.0
117,Inhibition of 20-HETE synthesis in human renal microsomes,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL615342,0,Autocuration,9606.0,,22226,
118,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,1,U,,,,,,,,,BAO_0000019,CHEMBL615343,0,Autocuration,,,22226,
119,Inhibitory concentration against 2008 (ovarian) cells,1,N,,Homo sapiens,,,,,2008,,BAO_0000219,CHEMBL615344,1,Intermediate,9606.0,,80612,388.0
120,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,1,N,,Homo sapiens,,,,,2008,,BAO_0000219,CHEMBL615345,1,Intermediate,9606.0,,80612,388.0
121,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),1,N,,Homo sapiens,,,,,2008,,BAO_0000219,CHEMBL615346,1,Intermediate,9606.0,,80612,388.0
122,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,1,N,,Homo sapiens,,,,,2008,,BAO_0000219,CHEMBL615347,1,Intermediate,9606.0,,80612,388.0
123,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,1,N,,Homo sapiens,,,,,2008,,BAO_0000219,CHEMBL615348,1,Intermediate,9606.0,,80612,388.0
124,In vitro inhibition of 2008/R ovarian cancer cell line,1,N,,Homo sapiens,,,,,2008/R,,BAO_0000219,CHEMBL827085,1,Intermediate,9606.0,,80613,561.0
125,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,1,N,,Homo sapiens,,,,,2008/R,,BAO_0000219,CHEMBL615349,1,Intermediate,9606.0,,80613,561.0
126,In vitro inhibition of 2008/S ovarian cancer cell line,1,N,,Homo sapiens,,,,,2008/S,,BAO_0000219,CHEMBL615350,1,Intermediate,9606.0,,80614,389.0
127,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,1,N,,Homo sapiens,,,,,2008/S,,BAO_0000219,CHEMBL615351,1,Intermediate,9606.0,,80614,389.0
128,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,1,S,,Homo sapiens,,,,,,,BAO_0000220,CHEMBL615352,2,Expert,9606.0,,100256,
129,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,1,S,,Homo sapiens,,,,,,,BAO_0000220,CHEMBL615353,2,Intermediate,9606.0,,100256,
130,Inhibition of chymotrypsin-like activity of 20S proteasome,1,S,,,,,,,,,BAO_0000220,CHEMBL615354,2,Expert,,,100256,
131,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,1,S,,,,,,,,,BAO_0000220,CHEMBL615355,2,Expert,,,100256,
132,Inhibitory activity against 20S proteosome,1,S,,,,,,,,,BAO_0000220,CHEMBL615356,2,Intermediate,,,100256,
133,Compound was tested for inhibitory activity against tryptase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615357,0,Autocuration,9606.0,,22226,
134,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL615358,1,Intermediate,9606.0,,81020,726.0
135,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,1,N,,Homo sapiens,,,,,HepG2,,BAO_0000219,CHEMBL827086,1,Intermediate,9606.0,,81020,726.0
136,Compound was tested for the inhibition of Alpha-glucosidase,1,U,,,,,,,,,BAO_0000019,CHEMBL615359,0,Autocuration,,,22226,
137,Inhibitory concentration against human neutrophil elastase (HNE),1,H,,,,,,,,,BAO_0000357,CHEMBL615360,8,Autocuration,,,235,
138,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,1,U,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL615361,0,Autocuration,10116.0,,22226,
139,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,H,,,,,,,,,BAO_0000019,CHEMBL615362,8,Autocuration,,,19640,
140,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,H,,,,,,,,,BAO_0000019,CHEMBL615363,8,Expert,,,19640,
141,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,H,,,,,,,,,BAO_0000357,CHEMBL615364,8,Autocuration,,,19640,
142,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,H,,,,,,,,,BAO_0000019,CHEMBL615365,8,Expert,,,19640,
143,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,1,N,,Mus musculus,,,,,P338,,BAO_0000219,CHEMBL615366,1,Intermediate,10090.0,,80360,524.0
144,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,1,N,,Mus musculus,,,,,P338,,BAO_0000219,CHEMBL615367,1,Intermediate,10090.0,,80360,524.0
145,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,1,N,,Homo sapiens,,,,,PBL,,BAO_0000219,CHEMBL615368,1,Intermediate,9606.0,,80384,554.0
146,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,1,U,,Ovis aries,,,,,,,BAO_0000019,CHEMBL615369,0,Autocuration,9940.0,,22226,
147,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,1,U,,Ovis aries,,,,,,,BAO_0000019,CHEMBL615370,0,Autocuration,9940.0,,22226,
148,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),1,H,,,,,,,,,BAO_0000357,CHEMBL615673,8,Autocuration,,,191,
149,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615674,0,Autocuration,9606.0,,22226,
150,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615675,0,Autocuration,9606.0,,22226,
151,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,1,U,,Homo sapiens,,,,,CCRF-CEM,,BAO_0000219,CHEMBL615676,0,Autocuration,9606.0,,22226,635.0
152,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,1,U,,Homo sapiens,,,,,CCRF-CEM,,BAO_0000219,CHEMBL615677,0,Autocuration,9606.0,,22226,635.0
153,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,1,U,,Homo sapiens,,,,,CCRF-CEM,,BAO_0000219,CHEMBL615678,0,Autocuration,9606.0,,22226,635.0
154,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,1,U,,Homo sapiens,,,,,CCRF-CEM,,BAO_0000219,CHEMBL615679,0,Autocuration,9606.0,,22226,635.0
155,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615680,0,Autocuration,9606.0,,22226,
156,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615681,0,Autocuration,9606.0,,22226,
157,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,1,H,,,,,,,,,BAO_0000249,CHEMBL857972,6,Autocuration,,,104290,
158,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1,N,,Streptococcus pyogenes,,,,,,,BAO_0000218,CHEMBL857899,1,Intermediate,1314.0,,50264,
159,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),1,N,,Human herpesvirus 3,,,,,,,BAO_0000218,CHEMBL615371,1,Intermediate,10335.0,,50527,
160,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,1,N,,vericilla zoster virus,,,,,HEL,,BAO_0000218,CHEMBL615372,1,Expert,10335.0,,50527,468.0
161,Antiviral activity against 07/1 strain of VZV; ND: No data,1,N,,vericilla zoster virus,,,,,,,BAO_0000218,CHEMBL615373,1,Intermediate,10335.0,,50527,
162,Antiviral activity against 07/1 strain of VZV; ND=No data,1,N,,vericilla zoster virus,,,,,,,BAO_0000218,CHEMBL615374,1,Intermediate,10335.0,,50527,
163,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",1,N,,escherichia cloac,,,,,,,BAO_0000218,CHEMBL615375,1,Intermediate,561.0,,50145,
164,Ratio of Ki at A2 to Ki at A1 receptors,1,U,,,,,,,,,BAO_0000019,CHEMBL615376,0,Autocuration,,,22226,
165,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",1,H,,Candida albicans,,,,,,,BAO_0000249,CHEMBL615377,8,Expert,5476.0,,11143,
166,"Inhibition of 1,3-beta-glucan synthase",1,H,,Candida glabrata CBS 138,,,,,,,BAO_0000357,CHEMBL615378,8,Expert,284593.0,,18077,
167,Inhibition of growth of 1-87 human tumor cell line,1,N,,Homo sapiens,,,,,1-87 tumor cell line,,BAO_0000219,CHEMBL615379,1,Intermediate,9606.0,,80609,832.0
168,Inhibition of 1-lipoxygenase (LOX)in RBL cells,1,D,,Rattus norvegicus,,,,,,,BAO_0000219,CHEMBL615380,9,Expert,10116.0,,12166,
169,Inhibitory activity against soybean 1-lipoxygenase (SLO),1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615381,9,Autocuration,3847.0,,100171,
170,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615382,9,Autocuration,3847.0,,100171,
171,% inhibition against soybean 1-lipoxygenase (SLO),1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615383,9,Autocuration,3847.0,,100171,
172,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615384,9,Autocuration,3847.0,,100171,
173,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615385,9,Autocuration,3847.0,,100171,
174,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615386,9,Autocuration,3847.0,,100171,
175,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615387,9,Autocuration,3847.0,,100171,
176,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615388,9,Autocuration,3847.0,,100171,
177,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615214,9,Autocuration,3847.0,,100171,
178,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL827087,9,Autocuration,3847.0,,100171,
179,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615215,9,Autocuration,3847.0,,100171,
180,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615216,9,Autocuration,3847.0,,100171,
181,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615217,9,Autocuration,3847.0,,100171,
182,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615218,9,Autocuration,3847.0,,100171,
183,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,1,D,,Glycine max,,,,,,,BAO_0000357,CHEMBL615219,9,Autocuration,3847.0,,100171,
184,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL615220,0,Autocuration,10090.0,,22226,
185,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),1,N,,Mus musculus,,,,,C3H 10T1/2,,BAO_0000219,CHEMBL615221,1,Intermediate,10090.0,,80049,294.0
186,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL615222,0,Intermediate,,,22226,
187,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,H,,,,,,,,,BAO_0000357,CHEMBL615223,8,Autocuration,,,11489,
188,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,H,,,,,,,,,BAO_0000357,CHEMBL615224,8,Autocuration,,,11862,
189,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,1,H,,,,,,,,,BAO_0000357,CHEMBL615225,8,Autocuration,,,11862,
190,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,1,H,,,,,,,,,BAO_0000357,CHEMBL615226,8,Autocuration,,,11489,
191,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL615227,8,Autocuration,,,11862,
192,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,1,D,,Bos taurus,,,,,,,BAO_0000019,CHEMBL615228,9,Expert,9913.0,,12347,
193,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615229,9,Expert,10116.0,,100120,
194,Inhibition of 11 beta-hydroxylase from rat adrenal gland,1,D,,Rattus norvegicus,,,,Adrenal gland,,2369.0,BAO_0000357,CHEMBL615230,9,Expert,10116.0,,100120,
195,Inhibition of rat adrenal 11-beta-hydroxylase,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615231,9,Expert,10116.0,,100120,
196,Inhibition of rat adrenal 11-beta-hydroxylase,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL884520,9,Expert,10116.0,,100120,
197,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615232,9,Expert,10116.0,,100120,
198,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,1,H,,,,,,,,,BAO_0000019,CHEMBL615233,8,Autocuration,,,10328,
199,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,H,,,,,,,,,BAO_0000357,CHEMBL827088,8,Autocuration,,,11490,
200,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,H,,,,,,,,,BAO_0000357,CHEMBL615234,8,Autocuration,,,11490,
201,Compound was tested for the percent of inhibition against 12-LO at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615235,8,Autocuration,,,11134,
202,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615236,8,Autocuration,,,12052,
203,Compound was tested in vitro for inhibition of 12-LO human platelet,1,H,,,,,,,,,BAO_0000019,CHEMBL615237,8,Autocuration,,,11134,
204,Inhibitory concentration against human platelet 12-lipoxygenase,1,H,,,,,,,,,BAO_0000019,CHEMBL615238,8,Autocuration,,,11134,
205,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,1,H,,,,,,,,,BAO_0000019,CHEMBL615239,8,Autocuration,,,11134,
206,Inhibitory concentration against human platelet 12-lipoxygenase,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615240,9,Autocuration,9606.0,,11134,
207,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL615241,8,Expert,,,11835,
208,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL615242,8,Expert,,,11601,
209,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),1,H,,,,,,,,,BAO_0000019,CHEMBL615243,8,Autocuration,,,11134,
210,Inhibitory activity against human platelet 12-lipoxygenase,1,H,,,,,,,,,BAO_0000019,CHEMBL615244,8,Autocuration,,,11134,
211,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,1,H,,,,,,,,,BAO_0000019,CHEMBL615245,8,Autocuration,,,11134,
212,% inhibition against human platelet 12-lipoxygenase (12-HLO),1,H,,,,,,,,,BAO_0000019,CHEMBL615246,8,Autocuration,,,11134,
213,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615247,8,Autocuration,,,11134,
214,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,1,H,,,,,,,,,BAO_0000019,CHEMBL615248,8,Autocuration,,,11134,
215,Inhibitory activity towards porcine 12-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL615249,8,Autocuration,,,11601,
216,Tested for inhibition against porcine 12-LO,1,H,,,,,,,,,BAO_0000357,CHEMBL615250,8,Autocuration,,,11601,
217,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,1,H,,,,,,,,,BAO_0000019,CHEMBL615251,8,Autocuration,,,12052,
218,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,1,H,,,,,,,,,BAO_0000019,CHEMBL615252,8,Autocuration,,,12052,
219,In vitro inhibition of rat platelet 12-lipoxygenase,1,H,,,,,,,,,BAO_0000019,CHEMBL828340,8,Expert,,,12052,
220,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615253,8,Autocuration,,,12052,
221,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615254,8,Autocuration,,,12052,
222,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615255,8,Autocuration,,,12052,
223,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615256,8,Autocuration,,,12052,
224,In vitro inhibitory activity against rat platelet 12-lipoxygenase,1,H,,,,,,,,,BAO_0000019,CHEMBL615257,8,Autocuration,,,12052,
225,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615258,8,Autocuration,,,12052,
226,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL615259,1,Intermediate,9606.0,,80007,621.0
227,In vitro antitumor activity against 41M cell line.,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL615260,1,Expert,9606.0,,80007,621.0
228,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL615261,1,Intermediate,9606.0,,80007,621.0
229,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL615262,1,Intermediate,9606.0,,80007,621.0
230,In vitro antitumor activity against 41McisR cell line.,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL615263,1,Expert,9606.0,,80007,621.0
231,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL838393,1,Expert,9606.0,,80007,621.0
232,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,1,N,,Homo sapiens,,,,,41M,,BAO_0000219,CHEMBL615264,1,Intermediate,9606.0,,80007,621.0
233,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615265,9,Expert,9606.0,,84,
234,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615266,9,Expert,9606.0,,68,
235,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,H,,,,,,,,,BAO_0000357,CHEMBL615267,8,Expert,,,68,
236,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,H,,,,,,,,,BAO_0000357,CHEMBL615268,8,Expert,,,10201,
237,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL615269,8,Expert,,,10201,
238,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,H,,,,,,,,,BAO_0000357,CHEMBL615270,8,Expert,,,10201,
239,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,H,,,,,,,,,BAO_0000357,CHEMBL615271,8,Autocuration,,,12220,
240,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL615272,8,Autocuration,562.0,,11303,
241,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL615103,8,Autocuration,562.0,,11303,
242,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL615104,8,Autocuration,562.0,,11303,
243,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,H,,,,,,,,,BAO_0000357,CHEMBL615105,8,Autocuration,,,12220,
244,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",1,H,,,,,,,,,BAO_0000357,CHEMBL872866,8,Autocuration,,,12220,
245,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL615106,8,Autocuration,9823.0,,11303,
246,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615107,8,Autocuration,9823.0,,11303,
247,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL615108,8,Autocuration,9823.0,,11303,
248,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL615109,8,Autocuration,9823.0,,11303,
249,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL615110,8,Autocuration,9823.0,,11303,
250,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL840105,8,Autocuration,9823.0,,11303,
251,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615111,8,Autocuration,9823.0,,11303,
252,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615112,8,Autocuration,9823.0,,11303,
253,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615113,8,Autocuration,9823.0,,11303,
254,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615114,8,Autocuration,9823.0,,11303,
255,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL615115,8,Autocuration,9823.0,,11303,
256,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615116,8,Autocuration,9823.0,,11303,
257,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",1,H,,,,,,,,,BAO_0000357,CHEMBL615698,8,Autocuration,,,11303,
258,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615699,0,Autocuration,9823.0,,22226,
259,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615700,0,Autocuration,9823.0,,22226,
260,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,1,H,,Saccharomyces cerevisiae,,,,,,,BAO_0000357,CHEMBL615701,8,Expert,4932.0,,100249,
261,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615702,0,Autocuration,10116.0,,22226,
262,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615703,0,Autocuration,10116.0,,22226,
263,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615704,0,Autocuration,10116.0,,22226,
264,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,H,,,,,,,,,BAO_0000019,CHEMBL615705,6,Autocuration,,,104698,
265,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,H,,,,,,,,,BAO_0000019,CHEMBL615706,6,Autocuration,,,104698,
266,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615707,9,Intermediate,10141.0,,20033,
267,Stimulatory activity of intragastric pressure was tested in the rat,1,H,,,,,,,,,BAO_0000019,CHEMBL615708,8,Expert,,,10623,
268,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL615709,8,Autocuration,,,121,
269,Dose to reduce neuronal firing against 5-HT cells in rats (iv),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615710,0,Autocuration,10116.0,,22226,
270,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL615711,8,Autocuration,,,12688,
271,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615712,9,Expert,9606.0,,121,
272,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL836325,9,Expert,9606.0,,121,
273,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615713,8,Autocuration,,,12198,
274,Inhibition constant of high-affinity 5-HT uptake,1,H,,,,,,,,,BAO_0000357,CHEMBL615714,8,Autocuration,,,12198,
275,Michaelis-Menten constant was reported for high affinity transport of 5-HT,1,H,,,,,,,,,BAO_0000019,CHEMBL615715,8,Autocuration,,,12198,
276,Maximum rate was determined for high affinity transport of 5-HT,1,H,,,,,,,,,BAO_0000019,CHEMBL615716,8,Autocuration,,,12198,
277,Compound was tested for agonistic activity against 5-HT uptake,1,H,,,,,,,,,BAO_0000019,CHEMBL615717,4,Autocuration,,,104714,
278,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,1,H,,,,,,,,,BAO_0000019,CHEMBL881818,8,Expert,,,10577,
279,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL884540,8,Expert,9913.0,,105,
280,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL615718,5,Autocuration,10116.0,,104744,
281,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL615719,4,Autocuration,,,104744,
282,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL615720,4,Autocuration,,,104744,
283,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL615721,4,Autocuration,,,104744,
284,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL615722,4,Autocuration,,,104744,
285,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,1,H,,,,,,,,,BAO_0000019,CHEMBL615723,8,Autocuration,,,51,
286,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615724,8,Autocuration,,,51,
287,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615725,8,Autocuration,,,51,
288,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615726,8,Autocuration,,,51,
289,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),1,H,,,,,,,,,BAO_0000218,CHEMBL615727,8,Autocuration,,,10576,
290,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL615728,9,Intermediate,10141.0,,105570,
291,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL857971,8,Autocuration,,,279,449.0
292,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615729,8,Autocuration,,,107,
293,Efficacy against 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615730,9,Expert,10116.0,,12687,
294,Intrinsic activity towards 5-HT2A receptor of rat tail artery,1,H,,,,,,,,,BAO_0000019,CHEMBL615731,8,Expert,,,12687,
295,Relative potency towards 5-HT2A receptor of rat tail artery,1,H,,,,,,,,,BAO_0000019,CHEMBL615732,8,Expert,,,12687,
296,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,H,,,,,,,,,BAO_0000019,CHEMBL615733,8,Expert,,,12687,
297,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,1,H,,,,,,,,,BAO_0000019,CHEMBL615734,8,Expert,,,12687,
298,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,1,H,,,,,,,,,BAO_0000019,CHEMBL615735,8,Autocuration,,,12687,
299,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,H,,,,,,,,,BAO_0000019,CHEMBL615736,8,Expert,,,12687,
300,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615737,9,Intermediate,10141.0,,20033,
301,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615738,9,Intermediate,10141.0,,20033,
302,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615739,9,Intermediate,10141.0,,20033,
303,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL615278,8,Autocuration,,,10623,
304,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615279,9,Expert,10116.0,,10623,
305,Binding affinity against 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615280,8,Expert,,,168,
306,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,1,U,,Gallus gallus,,,,,,,BAO_0000019,CHEMBL615281,0,Autocuration,9031.0,,22226,
307,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615282,0,Autocuration,9606.0,,22226,
308,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615283,0,Autocuration,9606.0,,22226,
309,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,1,N,,Homo sapiens,,,,,HL-60,,BAO_0000219,CHEMBL615284,1,Autocuration,9606.0,,80156,649.0
310,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615285,0,Autocuration,9606.0,,22226,
311,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615286,0,Autocuration,9606.0,,22226,
312,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,1,D,,Homo sapiens,,,,,Oocytes,,BAO_0000219,CHEMBL615287,7,Autocuration,9606.0,,104703,
313,Chymotryptic inhibitory activity against 26S proteasome,1,S,,,,,,,,,BAO_0000220,CHEMBL615288,2,Intermediate,,,100256,
314,Inhibitory activity against 26S proteasome degradation of IkB,1,S,,,,,,,,,BAO_0000220,CHEMBL615289,2,Intermediate,,,100256,
315,In vitro inhibition of 2780/DOX ovarian cancer cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL615290,1,Intermediate,9606.0,,81034,478.0
316,In vitro inhibition of 2780/S ovarian cancer cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL884522,1,Intermediate,9606.0,,81034,478.0
317,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615291,0,Autocuration,9606.0,,22226,
318,Association constant for binding to AATT 28-mer AATT hairpin,1,M,,,,,,,,,BAO_0000225,CHEMBL615292,3,Intermediate,,,22222,
319,Kinetically Defined Association Constant for 28-mer AATT hairpin.,1,M,,,,,,,,,BAO_0000225,CHEMBL615293,3,Intermediate,,,22222,
320,Reaction Rate Parameter for 28-mer AATT hairpin,1,M,,,,,,,,,BAO_0000225,CHEMBL615294,3,Intermediate,,,22222,
321,Reaction Rate Parameter for 28-mer AATT hairpin,1,M,,,,,,,,,BAO_0000225,CHEMBL615295,3,Intermediate,,,22222,
322,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL825021,0,Autocuration,9606.0,,22226,
323,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615296,0,Autocuration,9606.0,,22226,
324,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615297,0,Autocuration,9606.0,,22226,
325,Cytotoxicity against cell line 2SC/20 determined by MTT test,1,U,,Cricetulus griseus,,,,,,,BAO_0000019,CHEMBL615298,0,Autocuration,10029.0,,22226,
326,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,1,U,,Cricetulus griseus,,,,,,,BAO_0000019,CHEMBL615299,0,Autocuration,10029.0,,22226,
327,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,1,U,,Cricetulus griseus,,,,,,,BAO_0000019,CHEMBL615300,0,Autocuration,10029.0,,22226,
328,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,1,H,,,,,,,,,BAO_0000357,CHEMBL615301,8,Autocuration,,,241,
329,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615302,9,Expert,9606.0,,241,
330,Selectivity ratio of ID50 in liver and heart,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615303,0,Autocuration,10116.0,,22226,
331,"Selectivity, ratio of relative ID50 in liver and heart",1,H,,,,,,,,,BAO_0000019,CHEMBL615304,8,Autocuration,,,12132,
332,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,1,H,,,,,,,,,BAO_0000019,CHEMBL615305,8,Autocuration,,,12132,
333,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000218,CHEMBL615306,8,Autocuration,,,12132,
334,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000218,CHEMBL615307,8,Autocuration,,,12132,
335,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000218,CHEMBL615308,8,Autocuration,,,12132,
336,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000218,CHEMBL615309,8,Autocuration,,,12132,
337,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",1,U,,,,,,,,,BAO_0000019,CHEMBL615310,0,Autocuration,,,22226,
338,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,1,H,,,,,,,,,BAO_0000019,CHEMBL615311,8,Autocuration,,,12132,
339,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615312,0,Autocuration,9606.0,,22226,
340,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,H,,,,,,,,,BAO_0000019,CHEMBL615313,8,Autocuration,,,12132,
341,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,H,,,,,,,,,BAO_0000019,CHEMBL615314,8,Autocuration,,,12132,
342,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL615315,8,Autocuration,,,12132,
343,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615316,0,Autocuration,10116.0,,22226,
344,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,1,H,,,,,,,,,BAO_0000218,CHEMBL615317,8,Autocuration,,,12132,
345,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000218,CHEMBL615318,8,Autocuration,,,12132,
346,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615319,0,Autocuration,10116.0,,22226,
347,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL615320,8,Autocuration,,,12132,
348,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL615321,8,Autocuration,,,12132,
349,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615322,0,Autocuration,10116.0,,22226,
350,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL615323,8,Autocuration,562.0,,19690,
351,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL615407,8,Autocuration,562.0,,19690,
352,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL857267,8,Autocuration,562.0,,19690,
353,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,H,,Escherichia coli,,,,,,,BAO_0000357,CHEMBL615408,8,Autocuration,562.0,,19690,
354,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,1,H,,,,,,,,,BAO_0000357,CHEMBL615409,8,Autocuration,,,19690,
355,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,1,H,,,,,,,,,BAO_0000357,CHEMBL615410,8,Autocuration,,,19690,
356,Inhibition constant against 3-dehydroquinate synthase,1,H,,,,,,,,,BAO_0000357,CHEMBL615411,8,Autocuration,,,19690,
357,Association rate constant against 3-dehydroquinate synthase,1,H,,,,,,,,,BAO_0000357,CHEMBL615412,8,Autocuration,,,19690,
358,Rate constant against 3-dehydroquinate synthase,1,H,,,,,,,,,BAO_0000357,CHEMBL615413,8,Autocuration,,,19690,
359,Inhibitory activity against fuc-TVII,1,U,,,,,,,,,BAO_0000019,CHEMBL615414,0,Autocuration,,,22226,
360,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615415,9,Autocuration,10116.0,,12236,
361,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615416,9,Autocuration,10116.0,,12236,
362,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615417,9,Autocuration,10116.0,,12236,
363,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615418,9,Autocuration,10116.0,,12236,
364,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615419,9,Autocuration,10116.0,,12236,
365,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615420,9,Autocuration,10116.0,,12236,
366,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615421,9,Autocuration,10116.0,,12236,
367,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615422,9,Autocuration,10116.0,,12236,
368,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615423,9,Autocuration,10116.0,,12236,
369,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL872868,9,Autocuration,10116.0,,12236,
370,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,1,D,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL615424,9,Autocuration,10116.0,,12236,
371,Inhibitory activity against 3-phosphoglycerate kinase.,1,H,,,,,,,,,BAO_0000224,CHEMBL825022,4,Autocuration,,,104832,
372,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,1,H,,,,,,,,,BAO_0000224,CHEMBL615425,4,Autocuration,,,104832,
373,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",1,H,,,,,,,,,BAO_0000224,CHEMBL615426,4,Autocuration,,,104832,
374,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615427,9,Expert,9606.0,,10612,
375,Cytotoxicity on 3677 melanoma cells,1,N,,Homo sapiens,,,,,3677 melanoma cell line,,BAO_0000219,CHEMBL615428,1,Intermediate,9606.0,,80616,844.0
376,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,1,N,,Homo sapiens,,,,,3677 melanoma cell line,,BAO_0000219,CHEMBL615429,1,Intermediate,9606.0,,80616,844.0
377,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,1,N,,Mus musculus,,,,,MC-38,,BAO_0000219,CHEMBL615430,1,Intermediate,10090.0,,80617,700.0
378,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615431,0,Intermediate,9606.0,,22226,
379,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,1,U,,,,,,,B16,,BAO_0000218,CHEMBL615432,0,Autocuration,,,22226,798.0
380,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,1,U,,,,,,,B16,,BAO_0000218,CHEMBL615433,0,Autocuration,,,22226,798.0
381,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,1,D,,Human rhinovirus 14,,,,,,,BAO_0000019,CHEMBL615434,9,Expert,12131.0,,12464,
382,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,1,N,,Human rhinovirus sp.,,,,,,,BAO_0000218,CHEMBL615435,1,Intermediate,169066.0,,50085,
383,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,1,N,,human rhinovirus type 14,,,,,,,BAO_0000218,CHEMBL615436,1,Intermediate,169066.0,,50679,
384,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,1,N,,human rhinovirus type 14,,,,,,,BAO_0000218,CHEMBL615437,1,Intermediate,169066.0,,50679,
385,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,D,,Human rhinovirus 14,,,,,,,BAO_0000019,CHEMBL615438,9,Expert,12131.0,,12464,
386,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,D,,Human rhinovirus 14,,,,,,,BAO_0000019,CHEMBL615439,9,Expert,12131.0,,12464,
387,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,D,,Human rhinovirus 14,,,,,,,BAO_0000019,CHEMBL615440,9,Expert,12131.0,,12464,
388,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,1,D,,Human rhinovirus 14,,,,,,,BAO_0000019,CHEMBL615441,9,Expert,12131.0,,12464,
389,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,1,N,,Enterovirus,,,,,,,BAO_0000218,CHEMBL615641,1,Intermediate,12059.0,,50665,
390,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,1,N,,Enterovirus,,,,,,,BAO_0000218,CHEMBL872065,1,Intermediate,12059.0,,50665,
391,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,1,N,,Enterovirus,,,,,,,BAO_0000218,CHEMBL825023,1,Intermediate,12059.0,,50665,
392,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,1,N,,Enterovirus,,,,,,,BAO_0000218,CHEMBL615642,1,Intermediate,12059.0,,50665,
393,Inhibition of human rhinovirus 3C protease,1,H,,Human rhinovirus B,,,,,,,BAO_0000357,CHEMBL615643,8,Expert,147712.0,,12464,
394,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615644,0,Autocuration,9606.0,,22226,
395,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),1,N,,Mus musculus,,,,,3EM 37,,BAO_0000218,CHEMBL615645,1,Intermediate,10090.0,,80619,833.0
396,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),1,N,,Mus musculus,,,,,3EM 37,,BAO_0000218,CHEMBL615646,1,Intermediate,10090.0,,80619,833.0
397,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),1,N,,Mus musculus,,,,,3EM 37,,BAO_0000218,CHEMBL615647,1,Intermediate,10090.0,,80619,833.0
398,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),1,N,,Mus musculus,,,,,3EM 37,,BAO_0000218,CHEMBL615648,1,Intermediate,10090.0,,80619,833.0
399,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,1,N,,Mus musculus,,,,,3EM 37,,BAO_0000218,CHEMBL615649,1,Intermediate,10090.0,,80619,833.0
400,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,1,N,,Mus musculus,,,,,3EM 37,,BAO_0000218,CHEMBL615650,1,Intermediate,10090.0,,80619,833.0
401,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000218,CHEMBL615651,1,Intermediate,10090.0,,80620,847.0
402,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000218,CHEMBL615652,1,Intermediate,10090.0,,80620,847.0
403,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000218,CHEMBL615653,1,Expert,10090.0,,80620,847.0
404,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615654,1,Intermediate,10090.0,,80620,847.0
405,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615655,1,Intermediate,10090.0,,80620,847.0
406,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL825024,1,Intermediate,10090.0,,80620,847.0
407,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615656,1,Intermediate,10090.0,,80620,847.0
408,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615657,1,Intermediate,10090.0,,80620,847.0
409,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615658,1,Intermediate,10090.0,,80620,847.0
410,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615659,1,Intermediate,10090.0,,80620,847.0
411,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615660,1,Intermediate,10090.0,,80620,847.0
412,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615661,1,Intermediate,10090.0,,80620,847.0
413,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615662,1,Intermediate,10090.0,,80620,847.0
414,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615663,1,Intermediate,10090.0,,80620,847.0
415,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615664,1,Intermediate,10090.0,,80620,847.0
416,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615665,1,Intermediate,10090.0,,80620,847.0
417,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615666,1,Intermediate,10090.0,,80620,847.0
418,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615667,1,Intermediate,10090.0,,80620,847.0
419,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615668,1,Intermediate,10090.0,,80620,847.0
420,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615669,1,Intermediate,10090.0,,80620,847.0
421,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615670,1,Intermediate,10090.0,,80620,847.0
422,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL836739,1,Intermediate,10090.0,,80620,847.0
423,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615671,1,Intermediate,10090.0,,80620,847.0
424,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615672,1,Intermediate,10090.0,,80620,847.0
425,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615791,1,Intermediate,10090.0,,80620,847.0
426,spermine levels in 3LL cells after the treatment of 1 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615792,1,Intermediate,10090.0,,80620,847.0
427,spermine levels in 3LL cells after the treatment of 10 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615793,1,Intermediate,10090.0,,80620,847.0
428,spermine levels in 3LL cells after the treatment of 250 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615794,1,Intermediate,10090.0,,80620,847.0
429,spermine levels in 3LL cells after the treatment of 50 uM of Compound,1,N,,Mus musculus,,,,,3LL cell line,,BAO_0000219,CHEMBL615795,1,Intermediate,10090.0,,80620,847.0
430,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,1,N,,Homo sapiens,,,,,3LLD122,,BAO_0000219,CHEMBL615590,1,Intermediate,9606.0,,80621,971.0
431,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,1,U,,,,,,,,,BAO_0000218,CHEMBL615591,0,Autocuration,,,22226,
432,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,1,U,,,,,,,,,BAO_0000218,CHEMBL615592,0,Autocuration,,,22226,
433,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,1,U,,,,,,,,,BAO_0000218,CHEMBL615593,0,Autocuration,,,22226,
434,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,1,U,,,,,,,,,BAO_0000218,CHEMBL615594,0,Autocuration,,,22226,
435,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615595,1,Intermediate,10090.0,,80951,723.0
436,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615596,1,Intermediate,10090.0,,80951,723.0
437,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL615597,8,Expert,,,11169,723.0
438,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615598,1,Intermediate,10090.0,,80951,723.0
439,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615599,1,Intermediate,10090.0,,80951,723.0
440,Effective dose against murine 3T3 fibroblasts cells,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615600,1,Expert,10090.0,,80951,723.0
441,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615601,1,Expert,10090.0,,80951,723.0
442,Cytotoxic effect on 3T3 cells,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615602,1,Expert,10090.0,,80951,723.0
443,Cytotoxic effect on 3T3 cells,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615603,1,Expert,10090.0,,80951,723.0
444,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615604,1,Intermediate,10090.0,,80951,723.0
445,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615605,1,Intermediate,10090.0,,80951,723.0
446,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615606,1,Intermediate,10090.0,,80951,723.0
447,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL884526,1,Expert,10090.0,,80951,723.0
448,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615607,1,Expert,10090.0,,80951,723.0
449,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615608,1,Intermediate,10090.0,,80951,723.0
450,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615609,1,Expert,10090.0,,80951,723.0
451,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615682,1,Expert,10090.0,,80951,723.0
452,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615683,1,Intermediate,10090.0,,80951,723.0
453,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000218,CHEMBL615684,1,Expert,10090.0,,80951,723.0
454,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,1,D,,Mus musculus,,,,,,,BAO_0000219,CHEMBL615685,7,Autocuration,10090.0,,104860,
455,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615686,1,Expert,10090.0,,80951,723.0
456,Inhibitory activity against 3T3 cell line,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615687,1,Intermediate,10090.0,,80951,723.0
457,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL884523,1,Intermediate,10090.0,,80951,723.0
458,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,1,H,,,,,,,,,BAO_0000019,CHEMBL615688,8,Expert,,,11169,
459,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615689,1,Intermediate,10090.0,,80951,723.0
460,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615690,1,Intermediate,10090.0,,80951,723.0
461,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,1,H,,,,,,,,,BAO_0000019,CHEMBL615691,8,Expert,,,11169,
462,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL615692,8,Expert,,,11169,
463,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615693,1,Intermediate,10090.0,,80951,723.0
464,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615324,1,Expert,10090.0,,80951,723.0
465,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,1,D,,Homo sapiens,,,,,NIH3T3,,BAO_0000219,CHEMBL615325,9,Expert,9606.0,,9,723.0
466,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),1,D,,Homo sapiens,,,,,NIH3T3,,BAO_0000219,CHEMBL615490,9,Expert,9606.0,,9,723.0
467,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,1,D,,Homo sapiens,,,,,NIH3T3,,BAO_0000219,CHEMBL615491,9,Expert,9606.0,,188,723.0
468,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),1,D,,Homo sapiens,,,,,NIH3T3,,BAO_0000219,CHEMBL615492,9,Expert,9606.0,,188,723.0
469,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615493,1,Intermediate,10090.0,,80951,723.0
470,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615494,1,Intermediate,10090.0,,80951,723.0
471,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615495,1,Intermediate,10090.0,,80951,723.0
472,Inhibitory concentration was calculated on 3T3 cells by using growth assay,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615496,1,Intermediate,10090.0,,80951,723.0
473,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615497,1,Intermediate,10090.0,,80951,723.0
474,Inhibition of Swiss 3T3 mouse fibroblast proliferation,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615498,1,Expert,10090.0,,80951,723.0
475,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615499,1,Intermediate,10090.0,,80951,723.0
476,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL835522,1,Expert,10090.0,,80951,723.0
477,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615500,1,Intermediate,10090.0,,80951,723.0
478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615501,1,Intermediate,10090.0,,80951,723.0
479,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615502,1,Intermediate,10090.0,,80951,723.0
480,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615503,1,Intermediate,10090.0,,80951,723.0
481,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615504,1,Intermediate,10090.0,,80951,723.0
482,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615505,1,Intermediate,10090.0,,80951,723.0
483,Inhibition of swiss 3T3 mouse fibroblast proliferation,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615506,1,Expert,10090.0,,80951,723.0
484,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,1,N,,Mus musculus,,,,,NIH3T3,,BAO_0000219,CHEMBL615507,1,Intermediate,10090.0,,80951,723.0
485,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615508,1,Intermediate,,,80006,620.0
486,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615509,1,Intermediate,10090.0,,80006,620.0
487,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615510,1,Intermediate,10090.0,,80006,620.0
488,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615511,1,Intermediate,10090.0,,80006,620.0
489,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615512,1,Intermediate,10090.0,,80006,620.0
490,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000218,CHEMBL615513,1,Intermediate,10090.0,,80006,620.0
491,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000218,CHEMBL615514,1,Intermediate,10090.0,,80006,620.0
492,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615515,1,Intermediate,,,80006,620.0
493,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615516,1,Intermediate,,,80006,620.0
494,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615517,1,Intermediate,,,80006,620.0
495,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615518,1,Intermediate,,,80006,620.0
496,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615519,1,Intermediate,,,80006,620.0
497,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615520,1,Intermediate,,,80006,620.0
498,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615521,1,Intermediate,,,80006,620.0
499,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615522,1,Intermediate,,,80006,620.0
500,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615523,1,Intermediate,,,80006,620.0
501,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615524,1,Expert,,,80006,620.0
502,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615525,1,Expert,,,80006,620.0
503,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615526,1,Intermediate,,,80006,620.0
504,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615527,1,Intermediate,,,80006,620.0
505,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615528,1,Intermediate,,,80006,620.0
506,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615529,1,Expert,,,80006,620.0
507,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615530,1,Expert,,,80006,620.0
508,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615531,1,Expert,,,80006,620.0
509,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615532,1,Intermediate,,,80006,620.0
510,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615533,1,Intermediate,,,80006,620.0
511,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,N,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615534,1,Intermediate,,,80006,620.0
512,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615535,1,Intermediate,,,80006,620.0
513,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615536,1,Intermediate,,,80006,620.0
514,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615537,1,Intermediate,,,80006,620.0
515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL615538,1,Intermediate,,,80006,620.0
516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,N,,,,,,,3T3-L1,,BAO_0000218,CHEMBL836166,1,Intermediate,,,80006,620.0
517,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,1,H,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615539,8,Expert,,,11214,620.0
518,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615540,1,Intermediate,10090.0,,80006,620.0
519,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,1,H,,,,,,,3T3-L1,,BAO_0000219,CHEMBL615541,8,Expert,,,11214,620.0
520,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615542,1,Expert,10090.0,,80006,620.0
521,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615543,1,Intermediate,10090.0,,80006,620.0
522,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615544,1,Expert,10090.0,,80006,620.0
523,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615545,1,Expert,10090.0,,80006,620.0
524,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615546,1,Expert,10090.0,,80006,620.0
525,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615547,1,Expert,10090.0,,80006,620.0
526,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615548,1,Expert,10090.0,,80006,620.0
527,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615549,1,Expert,10090.0,,80006,620.0
528,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,1,N,,Mus musculus,,,,,3T3-L1,,BAO_0000219,CHEMBL615550,1,Expert,10090.0,,80006,620.0
529,Inhibitory activity against rat fibroblast (3Y1) cell line,1,N,,Rattus norvegicus,,,,,3Y1 cell line,,BAO_0000219,CHEMBL615551,1,Intermediate,10116.0,,80622,1118.0
530,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1,N,,Rattus norvegicus,,,,,3Y1 cell line,,BAO_0000219,CHEMBL615552,1,Expert,10116.0,,80622,1118.0
531,Cytotoxicity in 3Y1 cells.,1,N,,Rattus norvegicus,,,,,3Y1 cell line,,BAO_0000219,CHEMBL615553,1,Expert,10116.0,,80622,1118.0
532,Cytostatic effect in 3Y1 cells.,1,N,,Rattus norvegicus,,,,,3Y1 cell line,,BAO_0000219,CHEMBL615554,1,Expert,10116.0,,80622,1118.0
533,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1,N,,Rattus norvegicus,,,,,3Y1 cell line,,BAO_0000219,CHEMBL615555,1,Intermediate,10116.0,,80622,1118.0
534,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1,N,,Rattus norvegicus,,,,,3Y1 cell line,,BAO_0000219,CHEMBL615556,1,Expert,10116.0,,80622,1118.0
535,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,1,U,,,,,,,,,BAO_0000019,CHEMBL615557,0,Autocuration,,,22226,
536,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,U,,,,,,,,,BAO_0000019,CHEMBL615558,0,Autocuration,,,22226,
537,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,U,,,,,,,,,BAO_0000019,CHEMBL872066,0,Autocuration,,,22226,
538,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,1,D,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615559,9,Expert,9823.0,,11607,
539,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,1,H,,,,,,,,,BAO_0000019,CHEMBL615560,8,Autocuration,,,11607,
540,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,1,H,,,,,,,,,BAO_0000019,CHEMBL615561,8,Autocuration,,,11607,
541,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,1,H,,,,,,,,,BAO_0000019,CHEMBL857062,8,Expert,,,11607,
542,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),1,H,,,,,,,,,BAO_0000019,CHEMBL615562,8,Expert,,,11607,
543,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,1,H,,,,,,,,,BAO_0000019,CHEMBL615563,8,Autocuration,,,11607,
544,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),1,H,,,,,,,,,BAO_0000357,CHEMBL615564,8,Autocuration,,,11607,
545,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,1,H,,,,,,,,,BAO_0000019,CHEMBL615565,8,Autocuration,,,11607,
546,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,1,H,,,,,,,,,BAO_0000019,CHEMBL615566,8,Autocuration,,,11607,
547,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,1,D,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615567,9,Expert,9823.0,,11607,
548,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,1,H,,,,,,,,,BAO_0000019,CHEMBL615568,8,Autocuration,,,11607,
549,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),1,H,,,,,,,,,BAO_0000357,CHEMBL615569,8,Autocuration,,,11607,
550,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,1,H,,,,,,,,,BAO_0000019,CHEMBL615570,8,Autocuration,,,11607,
551,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),1,H,,,,,,,,,BAO_0000019,CHEMBL615571,8,Autocuration,,,11607,
552,Binding affinity against melatonin (MT1) receptor (pC1),1,H,,,,,,,,,BAO_0000224,CHEMBL615572,4,Autocuration,,,104733,
553,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,1,U,,,,,,,,,BAO_0000019,CHEMBL615573,0,Autocuration,,,22226,
554,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,1,U,,,,,,,,,BAO_0000019,CHEMBL615574,0,Autocuration,,,22226,
555,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,1,U,,,,,,,,,BAO_0000019,CHEMBL615575,0,Autocuration,,,22226,
556,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL615576,8,Autocuration,,,10619,
557,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615577,8,Autocuration,,,10619,
558,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615578,8,Autocuration,,,51,
559,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615579,8,Expert,,,51,
560,Binding affinity for 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615580,8,Expert,,,51,
561,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,1,H,,,,,,,,,BAO_0000019,CHEMBL615581,8,Expert,,,51,
562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615582,8,Autocuration,,,51,
563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615583,8,Autocuration,,,51,
564,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615584,8,Autocuration,,,51,
565,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL833691,8,Autocuration,,,51,
566,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615585,8,Autocuration,,,51,
567,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615586,8,Autocuration,,,51,
568,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL884524,8,Autocuration,,,51,
569,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615587,8,Autocuration,,,51,
570,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615588,8,Autocuration,,,51,
571,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL615589,9,Expert,10116.0,,10576,
572,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,1,H,,Bos taurus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615442,8,Expert,9913.0,,51,
573,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615443,8,Autocuration,,,51,
574,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615444,8,Autocuration,,,51,
575,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615445,8,Expert,,,51,
576,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615446,8,Autocuration,,,51,
577,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615447,8,Autocuration,,,51,449.0
578,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615448,8,Expert,,,51,
579,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615449,8,Expert,,,51,
580,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615450,8,Autocuration,,,51,449.0
581,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615451,8,Expert,,,51,
582,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615452,8,Autocuration,,,51,
583,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615453,8,Autocuration,,,51,
584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615454,8,Autocuration,,,51,
585,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615455,8,Autocuration,,,51,
586,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615456,8,Autocuration,,,51,
587,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615457,8,Autocuration,,,51,
588,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL615458,8,Expert,,,51,
589,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615459,8,Expert,,,51,
590,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615460,9,Expert,9606.0,,51,449.0
591,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL615461,8,Autocuration,10141.0,,51,
592,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL615462,8,Autocuration,10141.0,,51,
593,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,1,H,,Cavia porcellus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615463,8,Autocuration,10141.0,,51,
594,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615464,8,Autocuration,10141.0,,51,
595,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615465,8,Autocuration,10141.0,,51,
596,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615466,8,Autocuration,10141.0,,51,
597,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615467,8,Autocuration,10141.0,,51,
598,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615468,8,Autocuration,10141.0,,51,
599,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL615469,8,Autocuration,10141.0,,51,
600,Binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL615470,8,Autocuration,10141.0,,51,
601,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL615471,8,Autocuration,10141.0,,51,
602,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL615472,8,Autocuration,10141.0,,51,
603,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,H,,Cavia porcellus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL883242,8,Autocuration,10141.0,,106,
604,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,H,,Cavia porcellus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615473,8,Autocuration,10141.0,,106,
605,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,H,,Cricetulus griseus,,,,,CHO,,BAO_0000218,CHEMBL615474,8,Autocuration,10029.0,,11863,449.0
606,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615475,8,Autocuration,,,51,
607,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL615476,8,Autocuration,,,51,308.0
608,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL615477,8,Autocuration,,,51,308.0
609,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL615478,8,Autocuration,,,51,
610,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615160,8,Autocuration,,,51,449.0
611,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615161,8,Expert,,,51,449.0
612,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615162,8,Autocuration,,,51,449.0
613,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615163,8,Autocuration,,,51,449.0
614,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615164,8,Expert,,,51,449.0
615,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615165,8,Expert,,,51,449.0
616,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615166,8,Autocuration,,,51,449.0
617,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,1,H,,,,,,,,,BAO_0000219,CHEMBL615167,8,Autocuration,,,51,
618,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL615168,9,Expert,9606.0,,51,308.0
619,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL615169,9,Expert,9606.0,,51,308.0
620,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615170,9,Expert,9606.0,,51,449.0
621,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615171,9,Expert,9606.0,,51,449.0
622,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL615694,8,Autocuration,,,51,
623,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL615695,8,Autocuration,,,51,
624,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL615696,8,Autocuration,,,51,
625,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615697,8,Autocuration,,,51,449.0
626,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL859410,9,Expert,9606.0,,51,449.0
627,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615841,8,Autocuration,,,51,449.0
628,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615842,9,Expert,9606.0,,51,449.0
629,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL835003,8,Autocuration,,,51,449.0
630,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615843,8,Autocuration,,,51,449.0
631,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615979,9,Expert,9606.0,,51,449.0
632,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615980,8,Autocuration,,,51,449.0
633,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615981,9,Expert,9606.0,,51,449.0
634,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615982,9,Expert,9606.0,,51,
635,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615983,9,Expert,9606.0,,51,
636,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615984,9,Expert,9606.0,,51,
637,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615985,9,Expert,9606.0,,51,
638,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615986,8,Autocuration,,,51,449.0
639,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615987,8,Autocuration,,,51,449.0
640,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615988,8,Autocuration,,,51,449.0
641,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615989,8,Expert,,,51,449.0
642,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615990,8,Autocuration,,,51,449.0
643,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615991,8,Autocuration,,,51,449.0
644,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615992,8,Autocuration,,,51,449.0
645,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615993,8,Autocuration,,,51,449.0
646,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615994,8,Expert,,,51,449.0
647,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615995,8,Autocuration,,,51,449.0
648,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615996,8,Autocuration,,,51,449.0
649,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615997,8,Autocuration,,,51,449.0
650,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,H,,,,,,,,,BAO_0000019,CHEMBL615998,8,Autocuration,,,51,
651,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,H,,,,,,,,,BAO_0000019,CHEMBL615999,8,Autocuration,,,51,
652,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,H,,,,,,,,,BAO_0000019,CHEMBL616000,8,Autocuration,,,51,
653,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616001,8,Autocuration,,,51,722.0
654,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616002,9,Expert,9606.0,,51,
655,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616003,8,Expert,,,51,
656,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616004,9,Expert,9606.0,,51,
657,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616005,9,Expert,9606.0,,51,
658,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616006,8,Autocuration,,,51,
659,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",1,H,,,,,,,,,BAO_0000019,CHEMBL616007,8,Expert,,,51,
660,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616008,8,Autocuration,,,51,
661,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616009,8,Autocuration,,,51,
662,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",1,H,,,,,,,,,BAO_0000019,CHEMBL616010,8,Expert,,,51,
663,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616011,9,Expert,9606.0,,51,
664,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL615740,9,Expert,9606.0,,51,
665,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL615741,8,Autocuration,,,51,
666,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,H,,,,,,,,,BAO_0000019,CHEMBL615742,8,Expert,,,51,
667,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL615743,8,Autocuration,,,51,
668,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615744,8,Autocuration,,,51,449.0
669,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615745,8,Expert,,,51,449.0
670,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,H,,,,,,,,,BAO_0000357,CHEMBL615746,8,Autocuration,,,51,
671,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,H,,,,,,,,,BAO_0000357,CHEMBL615747,8,Autocuration,,,51,
672,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,H,,,,,,,,,BAO_0000019,CHEMBL615748,8,Autocuration,,,51,
673,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",1,H,,,,,,,,,BAO_0000019,CHEMBL615749,8,Autocuration,,,51,
674,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,H,,,,,,,,,BAO_0000019,CHEMBL615750,8,Autocuration,,,51,
675,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616259,9,Expert,9606.0,,51,
676,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,H,,,,,,,,,BAO_0000019,CHEMBL616260,8,Autocuration,,,51,
677,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616261,9,Expert,9606.0,,51,
678,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616262,9,Expert,9606.0,,51,
679,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616263,9,Expert,9606.0,,51,
680,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616264,9,Expert,9606.0,,51,
681,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616265,9,Expert,9606.0,,51,
682,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616266,9,Expert,9606.0,,51,
683,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616267,9,Expert,9606.0,,51,
684,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616268,9,Expert,9606.0,,51,
685,Inhibition of human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616269,9,Expert,9606.0,,51,
686,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL884528,8,Autocuration,,,51,449.0
687,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,1,D,,,,,,,HEK293,,BAO_0000219,CHEMBL616270,9,Expert,,,105,722.0
688,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616271,8,Autocuration,,,51,449.0
689,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616272,8,Autocuration,,,51,449.0
690,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,1,H,,,,,,,,,BAO_0000357,CHEMBL616273,8,Expert,,,51,
691,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616274,9,Expert,9606.0,,51,
692,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616275,8,Autocuration,,,51,449.0
693,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616276,8,Autocuration,,,51,449.0
694,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616277,0,Autocuration,10116.0,,22226,
695,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616278,0,Autocuration,10116.0,,22226,
696,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616279,0,Autocuration,10116.0,,22226,
697,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616280,0,Autocuration,10116.0,,22226,
698,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616281,0,Autocuration,10116.0,,22226,
699,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616282,0,Autocuration,10116.0,,22226,
700,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616283,0,Autocuration,10116.0,,22226,
701,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616284,0,Autocuration,10116.0,,22226,
702,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616285,0,Autocuration,10116.0,,22226,
703,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616286,0,Autocuration,10116.0,,22226,
704,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616287,0,Autocuration,10116.0,,22226,
705,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616288,0,Autocuration,10116.0,,22226,
706,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL616289,0,Autocuration,10116.0,,22226,
707,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615610,0,Autocuration,10116.0,,22226,
708,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615611,0,Autocuration,10116.0,,22226,
709,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615612,0,Autocuration,10116.0,,22226,
710,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615613,0,Autocuration,10116.0,,22226,
711,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615614,0,Autocuration,10116.0,,22226,
712,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL615615,0,Autocuration,10116.0,,22226,
713,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,1,H,,,,,,,,,BAO_0000019,CHEMBL615616,4,Autocuration,,,105093,
714,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1,H,,,,,,Hypothalamus,,1898.0,BAO_0000249,CHEMBL615617,8,Autocuration,,,11923,
715,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,1,H,,,,,,,,,BAO_0000019,CHEMBL615618,8,Autocuration,,,10577,
716,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,1,H,,,,,,,,,BAO_0000019,CHEMBL615619,8,Autocuration,,,10577,
717,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL615620,8,Expert,,,10577,
718,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",1,H,,,,,,,,,BAO_0000357,CHEMBL615621,8,Autocuration,,,55,
719,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",1,H,,,,,,,,,BAO_0000357,CHEMBL615622,8,Autocuration,,,55,
720,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),1,H,,,,,,,,,BAO_0000019,CHEMBL615623,8,Autocuration,,,12166,
721,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,H,,,,,,,,,BAO_0000019,CHEMBL615624,8,Autocuration,,,12166,
722,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,H,,,,,,,,,BAO_0000019,CHEMBL615625,8,Autocuration,,,12166,
723,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,H,,,,,,,,,BAO_0000019,CHEMBL767045,8,Autocuration,,,12166,
724,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL615626,8,Autocuration,10141.0,,55,
725,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL615627,8,Autocuration,10141.0,,55,
726,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL615628,8,Autocuration,10141.0,,55,
727,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL615629,8,Autocuration,10141.0,,55,
728,Inhibitory concentration against 5-lipoxygenase from human whole blood,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615630,9,Expert,9606.0,,55,
729,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000219,CHEMBL615631,8,Autocuration,,,55,
730,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL615632,8,Autocuration,,,17087,
731,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,1,H,,,,,,,,,BAO_0000357,CHEMBL615633,8,Autocuration,,,17087,
732,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL615634,8,Autocuration,,,17087,
733,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL615635,8,Expert,9823.0,,55,
734,In vitro inhibition of rat 5-Lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL615636,8,Expert,,,12166,
735,Inhibitory activity against 5-Lipoxygenase,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615637,9,Expert,10116.0,,12166,
736,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL615638,8,Expert,,,12166,702.0
737,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL615639,8,Autocuration,,,12166,702.0
738,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL615640,8,Autocuration,,,12166,702.0
739,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,1,H,,,,,,,,,BAO_0000019,CHEMBL615796,8,Autocuration,,,12166,
740,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000219,CHEMBL615845,8,Autocuration,,,12166,
741,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL615846,8,Autocuration,,,12166,
742,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL615847,8,Autocuration,,,12166,702.0
743,The compound was tested for inhibition of isolated 5-Lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL615848,8,Autocuration,,,12166,
744,Ratio of IC50 against 5-LO and COX,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615849,0,Autocuration,10116.0,,22226,
745,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL615850,8,Autocuration,,,12166,
746,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,1,H,,,,,,,,,BAO_0000357,CHEMBL615851,8,Autocuration,,,12166,
747,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,1,H,,,,,,,,,BAO_0000219,CHEMBL615852,8,Autocuration,,,12166,
748,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,1,H,,,,,,,,,BAO_0000019,CHEMBL615853,8,Autocuration,,,12166,
749,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,1,H,,,,,,Prostate gland,,2367.0,BAO_0000357,CHEMBL884527,8,Autocuration,,,120,
750,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,1,U,,Columba livia,,,,,,,BAO_0000019,CHEMBL872871,0,Autocuration,8932.0,,22226,
751,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,1,U,,Columba livia,,,,,,,BAO_0000019,CHEMBL615854,0,Autocuration,8932.0,,22226,
752,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,1,U,,Columba livia,,,,,,,BAO_0000019,CHEMBL767046,0,Autocuration,8932.0,,22226,
753,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL615855,8,Autocuration,,,10732,
754,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615856,9,Expert,10116.0,,12198,
755,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615857,9,Expert,10116.0,,12198,
756,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615858,9,Expert,10116.0,,12198,
757,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615859,8,Expert,,,10576,
758,Binding affinity towards human 5-hydroxytryptamine 1 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615860,8,Autocuration,,,51,
759,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL615861,0,Autocuration,9986.0,,22226,
760,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL615862,0,Autocuration,9986.0,,22226,
761,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL615863,0,Autocuration,9986.0,,22226,
762,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL615864,0,Autocuration,9986.0,,22226,
763,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615865,4,Autocuration,,,104744,
764,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615866,4,Autocuration,,,104744,
765,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615867,4,Autocuration,,,104744,
766,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL615868,4,Autocuration,,,104744,
767,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL615869,5,Autocuration,10116.0,,104744,
768,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615870,5,Autocuration,10116.0,,104744,
769,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615871,5,Autocuration,10116.0,,104744,
770,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,1,H,,,,,,,,,BAO_0000224,CHEMBL615872,4,Autocuration,,,104744,
771,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL833492,4,Autocuration,,,104744,
772,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615873,4,Autocuration,,,104744,
773,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,1,H,,,,,,,,,BAO_0000224,CHEMBL615479,4,Autocuration,,,104744,
774,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,1,H,,,,,,,,,BAO_0000019,CHEMBL615480,4,Autocuration,,,104744,
775,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL615481,5,Autocuration,10116.0,,104744,
776,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL872869,4,Autocuration,,,104744,
777,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL615482,4,Autocuration,,,104744,
778,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615483,4,Autocuration,,,104744,
779,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615484,4,Autocuration,,,104744,
780,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL615485,4,Autocuration,,,104744,
781,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL615486,5,Autocuration,10116.0,,104744,
782,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL615487,4,Autocuration,,,104744,
783,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL615488,4,Autocuration,,,104744,
784,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL615489,4,Autocuration,,,104744,
785,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL615389,4,Autocuration,,,104744,
786,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL615390,4,Autocuration,,,104744,
787,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL615391,4,Autocuration,,,104744,
788,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL615392,4,Autocuration,,,104744,
789,Affinity for 5-hydroxytryptamine 1 receptor,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615393,0,Autocuration,10116.0,,22226,
790,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615394,4,Autocuration,,,104744,
791,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615395,4,Autocuration,,,104744,
792,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,1,H,,,,,,,,,BAO_0000224,CHEMBL615396,4,Autocuration,,,104744,
793,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615397,4,Autocuration,,,104744,
794,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL615398,4,Autocuration,,,104744,
795,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615399,0,Autocuration,10116.0,,22226,
796,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL615400,4,Autocuration,,,104744,
797,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615401,5,Autocuration,10116.0,,104744,
798,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615402,0,Autocuration,10116.0,,22226,
799,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL615403,4,Autocuration,,,104744,
800,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615404,4,Autocuration,,,104744,
801,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL615781,4,Autocuration,,,104744,
802,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,1,H,,,,,,Brain,,955.0,BAO_0000220,CHEMBL615782,4,Autocuration,,,104744,
803,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615783,4,Autocuration,,,104744,
804,Compound was tested for binding affinity against 5-HT1 receptor,1,U,,,,,,,,,BAO_0000019,CHEMBL873481,0,Autocuration,,,22226,
805,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,1,U,,,,,,,,,BAO_0000019,CHEMBL615784,0,Autocuration,,,22226,
806,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL615785,8,Expert,,,10576,
807,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000249,CHEMBL615786,8,Autocuration,,,10576,
808,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,H,,,,,,,,,BAO_0000218,CHEMBL615787,8,Autocuration,,,10576,
809,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,H,,,,,,,,,BAO_0000218,CHEMBL615788,8,Autocuration,,,10576,
810,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL767044,8,Autocuration,,,10576,
811,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,H,,,,,,,,,BAO_0000218,CHEMBL615789,8,Autocuration,,,10576,
812,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,H,,,,,,,,,BAO_0000218,CHEMBL615790,8,Autocuration,,,10576,
813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,1,H,,,,,,,,,BAO_0000019,CHEMBL615813,8,Autocuration,,,10576,
814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,1,H,,,,,,,,,BAO_0000219,CHEMBL615814,8,Autocuration,,,10576,
815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,1,H,,,,,,,,,BAO_0000219,CHEMBL615815,8,Expert,,,51,
816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,1,H,,,,,,,,,BAO_0000219,CHEMBL615816,8,Autocuration,,,10576,
817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,1,H,,,,,,,,,BAO_0000249,CHEMBL615817,8,Expert,,,10576,
818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615818,8,Autocuration,,,10576,
819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615819,8,Autocuration,,,10576,
820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL615820,8,Expert,,,10576,
821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615821,9,Expert,10116.0,,10576,
822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615822,9,Expert,10116.0,,10576,
823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615823,8,Expert,,,10576,
824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615824,9,Expert,10116.0,,10576,
825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615825,9,Expert,10116.0,,10576,
826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615826,8,Expert,,,10576,
827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL615827,8,Expert,,,10576,
828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL615828,8,Expert,,,10576,
829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615829,8,Expert,,,10576,
830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615830,8,Autocuration,,,10576,
831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615831,8,Expert,,,10576,
832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615832,8,Autocuration,,,10576,
833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL615833,8,Autocuration,,,10576,
834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615834,8,Autocuration,,,10576,
835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL615835,8,Intermediate,,,10576,
836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL615836,8,Autocuration,,,10576,
837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615837,9,Expert,10116.0,,10576,
838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615838,9,Expert,10116.0,,10576,
839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",1,H,,,,,,,,,BAO_0000249,CHEMBL615839,8,Expert,,,10576,
840,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL884525,8,Autocuration,,,10576,
841,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL615840,8,Autocuration,,,10576,
842,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615405,8,Expert,,,10576,
843,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL615406,8,Expert,,,10576,
844,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615900,8,Expert,,,10576,
845,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615901,8,Expert,,,10576,
846,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,1,H,,,,,,,,,BAO_0000357,CHEMBL615902,8,Expert,,,10576,
847,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615903,8,Autocuration,,,10576,
848,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL615904,8,Autocuration,,,10576,
849,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL615905,8,Expert,,,10576,
850,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,H,,,,,,,,,BAO_0000019,CHEMBL615906,8,Autocuration,,,10576,
851,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,H,,,,,,,,,BAO_0000019,CHEMBL615907,8,Autocuration,,,10576,
852,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL615908,8,Expert,,,10576,
853,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615909,8,Autocuration,,,10576,
854,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL615910,8,Autocuration,,,10576,
855,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",1,H,,,,,,,,,BAO_0000019,CHEMBL615911,8,Autocuration,,,10576,
856,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL615912,8,Autocuration,,,10576,
857,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL615913,8,Expert,,,10576,
858,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL615914,8,Expert,,,10576,
859,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615915,8,Autocuration,,,10576,
860,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,1,H,,,,,,,,,BAO_0000357,CHEMBL615916,8,Autocuration,,,10576,
861,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,1,H,,,,,,,,,BAO_0000357,CHEMBL615917,8,Expert,,,10576,
862,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615918,8,Expert,,,10576,
863,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL615919,8,Expert,,,10576,
864,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615920,9,Expert,10116.0,,10576,
865,Inhibition concentration against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615921,8,Autocuration,,,10576,
866,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),1,H,,,,,,,,,BAO_0000357,CHEMBL615922,8,Expert,,,10576,
867,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL881290,9,Expert,10116.0,,10576,
868,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615923,8,Autocuration,,,10576,
869,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615924,8,Autocuration,,,10576,
870,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615925,8,Autocuration,,,10576,
871,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615926,9,Expert,10116.0,,10576,
872,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615927,9,Expert,10116.0,,10576,
873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615928,8,Autocuration,,,10576,
874,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615929,9,Expert,10116.0,,10576,
875,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615930,8,Autocuration,,,10576,
876,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615931,8,Autocuration,,,51,449.0
877,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615932,8,Autocuration,,,51,449.0
878,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615933,8,Autocuration,,,51,449.0
879,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615934,8,Autocuration,,,51,
880,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,1,H,,,,,,,,,BAO_0000357,CHEMBL615935,8,Autocuration,,,51,
881,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,H,,,,,,,,,BAO_0000019,CHEMBL615936,8,Autocuration,,,51,
882,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615937,8,Autocuration,,,51,449.0
883,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615938,8,Autocuration,,,51,
884,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL615797,8,Autocuration,,,51,
885,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615798,8,Autocuration,,,51,
886,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL872870,8,Autocuration,,,51,
887,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL615799,8,Autocuration,,,51,
888,Percent binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615800,8,Autocuration,,,51,
889,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL615801,8,Autocuration,,,51,722.0
890,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,1,H,,,,,,,,,BAO_0000019,CHEMBL615802,8,Autocuration,,,51,
891,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615803,8,Autocuration,,,51,
892,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,H,,,,,,,,,BAO_0000019,CHEMBL835002,8,Expert,,,51,
893,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL615804,8,Autocuration,,,51,
894,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL615805,8,Expert,,,51,308.0
895,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615806,8,Autocuration,,,51,449.0
896,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615807,9,Expert,9606.0,,51,
897,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615808,8,Autocuration,,,51,
898,Binding affinity against 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615809,9,Expert,9606.0,,51,
899,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL615810,8,Autocuration,,,51,308.0
900,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615811,8,Autocuration,,,51,
901,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615812,8,Autocuration,,,51,449.0
902,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615751,8,Autocuration,,,51,449.0
903,Binding affinity against human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615752,8,Autocuration,,,51,
904,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615753,8,Expert,,,51,449.0
905,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615754,8,Autocuration,,,51,449.0
906,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615755,8,Autocuration,,,51,
907,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615756,9,Expert,9606.0,,51,449.0
908,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL615757,8,Autocuration,,,51,
909,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL615758,8,Autocuration,,,51,
910,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL615759,8,Expert,,,51,
911,Binding affinity towards human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615760,8,Autocuration,,,51,
912,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL615761,8,Expert,,,51,308.0
913,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL872104,8,Autocuration,,,51,
914,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615762,8,Autocuration,,,51,
915,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615763,8,Autocuration,,,51,
916,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL615764,8,Autocuration,,,51,
917,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1,H,,,,,,,Cell line,,BAO_0000219,CHEMBL615765,8,Autocuration,,,51,1167.0
918,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),1,H,,,,,,,,,BAO_0000019,CHEMBL615766,8,Autocuration,,,51,
919,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615767,8,Autocuration,,,51,
920,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615768,8,Expert,,,51,
921,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615769,8,Autocuration,,,51,
922,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL615770,8,Expert,,,51,
923,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615771,8,Autocuration,,,51,
924,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615772,8,Expert,,,51,
925,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL615773,8,Autocuration,,,51,
926,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615774,8,Expert,,,51,
927,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615775,8,Autocuration,,,51,
928,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL615776,8,Autocuration,,,51,
929,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615777,8,Expert,,,51,
930,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,1,H,,,,,,,,,BAO_0000219,CHEMBL615778,8,Autocuration,,,51,
931,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL615779,9,Expert,9606.0,,51,
932,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL615780,8,Autocuration,,,51,
933,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616298,8,Autocuration,,,51,
934,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616299,8,Autocuration,,,51,
935,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616300,8,Autocuration,,,51,485.0
936,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616301,8,Expert,,,51,485.0
937,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616302,8,Autocuration,,,51,
938,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),1,H,,,,,,,,,BAO_0000019,CHEMBL616117,8,Autocuration,,,51,
939,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),1,H,,,,,,,,,BAO_0000019,CHEMBL616118,8,Autocuration,,,51,
940,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,1,H,,,,,,,,,BAO_0000019,CHEMBL616119,8,Autocuration,,,51,
941,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL616120,9,Expert,9606.0,,51,308.0
942,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616121,8,Autocuration,,,51,
943,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616122,8,Autocuration,,,51,
944,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616123,8,Autocuration,,,51,
945,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616124,9,Expert,9606.0,,51,
946,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL616125,8,Expert,,,51,
947,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,1,H,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616126,8,Expert,10116.0,,51,
948,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616127,8,Autocuration,,,51,449.0
949,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616128,8,Expert,,,51,
950,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616129,8,Autocuration,,,51,
951,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616130,8,Expert,,,51,
952,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,1,H,,,,,,,,,BAO_0000357,CHEMBL616131,8,Autocuration,,,51,
953,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616132,8,Autocuration,,,51,308.0
954,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL616133,9,Expert,9606.0,,51,308.0
955,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616134,8,Autocuration,,,51,
956,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,1,H,,,,,,,,,BAO_0000357,CHEMBL616135,8,Autocuration,,,51,
957,Affinity for 5-hydroxytryptamine 1A receptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616136,9,Expert,9606.0,,51,
958,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL616137,8,Autocuration,,,51,
959,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,1,H,,,,,,,,,BAO_0000019,CHEMBL872105,8,Autocuration,,,51,
960,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616138,8,Autocuration,,,51,
961,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616139,9,Expert,9606.0,,51,
962,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",1,H,,,,,,,,,BAO_0000019,CHEMBL616140,8,Autocuration,,,51,
963,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL616141,8,Expert,,,51,
964,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616142,8,Autocuration,,,51,
965,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616143,8,Autocuration,,,51,
966,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616144,8,Autocuration,,,51,308.0
967,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616145,8,Autocuration,,,51,308.0
968,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616012,8,Autocuration,,,51,308.0
969,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616013,8,Autocuration,,,51,308.0
970,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,H,,,,,,,,,BAO_0000019,CHEMBL616014,8,Autocuration,,,51,
971,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,H,,,,,,,,,BAO_0000019,CHEMBL616015,8,Autocuration,,,51,
972,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,H,,,,,,,,,BAO_0000019,CHEMBL616016,8,Autocuration,,,51,
973,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,1,H,,,,,,,,,BAO_0000218,CHEMBL616017,8,Autocuration,,,51,
974,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL616018,8,Autocuration,,,51,
975,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL616019,8,Autocuration,,,51,
976,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL616020,8,Autocuration,,,51,
977,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL858018,8,Autocuration,,,51,
978,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616021,8,Autocuration,,,51,722.0
979,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",1,H,,,,,,,,,BAO_0000019,CHEMBL616022,8,Expert,,,51,
980,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616023,8,Autocuration,,,51,
981,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616024,8,Autocuration,,,51,
982,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",1,H,,,,,,,,,BAO_0000019,CHEMBL616025,8,Autocuration,,,51,
983,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616026,8,Autocuration,,,51,449.0
984,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",1,H,,,,,,,,,BAO_0000019,CHEMBL616027,8,Autocuration,,,51,
985,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616028,9,Expert,9606.0,,51,
986,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616029,9,Expert,9606.0,,51,
987,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616030,8,Expert,,,51,449.0
988,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,1,H,,,,,,,,,BAO_0000019,CHEMBL616031,8,Expert,,,51,
989,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616032,9,Expert,9606.0,,51,
990,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616033,9,Expert,9606.0,,51,
991,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,H,,,,,,,,,BAO_0000019,CHEMBL616034,8,Autocuration,,,51,
992,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,H,,,,,,,,,BAO_0000019,CHEMBL616035,8,Autocuration,,,51,
993,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616036,8,Autocuration,,,51,
994,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,H,,,,,,,,,BAO_0000019,CHEMBL616037,8,Autocuration,,,51,
995,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,H,,,,,,,,,BAO_0000019,CHEMBL616038,8,Autocuration,,,51,
996,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,H,,,,,,,,,BAO_0000019,CHEMBL616039,8,Autocuration,,,51,
997,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616040,8,Autocuration,,,51,
998,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL616041,9,Expert,9606.0,,51,308.0
999,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL616042,9,Expert,9606.0,,51,308.0
1000,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL616043,9,Expert,9606.0,,51,308.0
1001,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL616044,8,Autocuration,,,51,
1002,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL616045,8,Autocuration,,,51,
1003,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616046,8,Autocuration,,,51,722.0
1004,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616047,8,Autocuration,,,51,449.0
1005,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616048,8,Autocuration,,,51,449.0
1006,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616049,9,Expert,9606.0,,51,449.0
1007,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616050,8,Autocuration,,,51,449.0
1008,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,1,H,,,,,,,,,BAO_0000219,CHEMBL616051,8,Expert,,,51,
1009,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,1,H,,,,,,,,,BAO_0000219,CHEMBL616212,8,Autocuration,,,51,
1010,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL616213,8,Autocuration,,,51,
1011,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL616214,8,Expert,,,51,
1012,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL616215,8,Expert,,,51,
1013,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616216,8,Autocuration,,,51,
1014,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616217,8,Autocuration,,,51,
1015,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616218,8,Autocuration,,,51,
1016,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616219,8,Autocuration,,,51,
1017,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616220,8,Autocuration,,,51,
1018,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL833493,9,Expert,9606.0,,51,
1019,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616221,8,Autocuration,,,51,
1020,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616222,9,Expert,9606.0,,51,449.0
1021,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616223,8,Autocuration,,,51,
1022,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL616224,8,Autocuration,,,51,
1023,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,1,H,,,,,,,,,BAO_0000019,CHEMBL616225,8,Expert,,,51,
1024,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL616226,9,Expert,9606.0,,51,722.0
1025,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616227,8,Autocuration,,,51,722.0
1026,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616228,8,Autocuration,,,51,722.0
1027,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616229,8,Autocuration,,,51,722.0
1028,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616230,8,Autocuration,,,51,722.0
1029,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616231,8,Autocuration,,,51,722.0
1030,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616232,8,Autocuration,,,51,
1031,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616233,8,Autocuration,,,51,722.0
1032,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL857973,8,Autocuration,,,51,722.0
1033,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,1,H,,,,,,,,,BAO_0000219,CHEMBL616234,8,Autocuration,,,51,
1034,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616235,8,Autocuration,,,51,
1035,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616236,8,Expert,,,51,308.0
1036,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL616237,8,Expert,,,51,
1037,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616238,8,Autocuration,,,51,722.0
1038,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616239,8,Autocuration,,,51,722.0
1039,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL616240,8,Autocuration,,,51,
1040,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL616241,9,Expert,9606.0,,51,308.0
1041,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616242,8,Autocuration,,,51,722.0
1042,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616243,8,Autocuration,,,51,722.0
1043,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,D,,,,,,,,,BAO_0000357,CHEMBL616244,9,Expert,,,51,
1044,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616245,9,Autocuration,9606.0,,51,
1045,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,H,,,,,,,,,BAO_0000357,CHEMBL616246,8,Autocuration,,,106,
1046,Binding affinity against 5-HT1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616247,8,Autocuration,,,105,
1047,Binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616248,8,Autocuration,,,105,
1048,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,H,,,,,,,,,BAO_0000357,CHEMBL616249,8,Autocuration,,,107,
1049,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,H,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616250,8,Autocuration,9606.0,,10576,
1050,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616251,8,Autocuration,,,51,
1051,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,1,H,,,,,,,,,BAO_0000218,CHEMBL616252,8,Autocuration,,,11863,
1052,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,1,H,,,,,,,,,BAO_0000218,CHEMBL616253,8,Autocuration,,,11863,
1053,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,1,H,,,,,,,,,BAO_0000218,CHEMBL616254,8,Autocuration,,,11863,
1054,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,1,D,,Mus musculus,,,,,,,BAO_0000218,CHEMBL616255,9,Expert,10090.0,,11863,
1055,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,1,D,,Mus musculus,,,,,,,BAO_0000218,CHEMBL832872,9,Expert,10090.0,,11863,
1056,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,1,D,,Mus musculus,,,,,,,BAO_0000218,CHEMBL616256,9,Expert,10090.0,,11863,
1057,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,1,D,,Mus musculus,,,,,,,BAO_0000218,CHEMBL616257,9,Expert,10090.0,,11863,
1058,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,1,D,,Mus musculus,,,,,,,BAO_0000218,CHEMBL616258,9,Expert,10090.0,,11863,
1059,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,1,D,,Mus musculus,,,,,,,BAO_0000218,CHEMBL616384,9,Expert,10090.0,,11863,
1060,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616385,8,Autocuration,,,11863,
1061,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,1,H,,,,,,,,,BAO_0000357,CHEMBL616386,8,Expert,,,11863,
1062,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,D,,Mus musculus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616387,9,Expert,10090.0,,11863,
1063,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616388,8,Autocuration,,,11863,
1064,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,D,,Mus musculus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616389,9,Expert,10090.0,,11863,
1065,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616390,8,Autocuration,,,11863,
1066,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616391,8,Autocuration,,,11863,
1067,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,D,,Mus musculus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616392,9,Expert,10090.0,,11863,
1068,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616393,8,Autocuration,9823.0,,51,
1069,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616394,8,Autocuration,9823.0,,51,
1070,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616395,8,Autocuration,9823.0,,51,
1071,Compound was evaluated for the binding affinity at 5- HT1A receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616396,8,Autocuration,9823.0,,51,
1072,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL872907,8,Autocuration,9823.0,,51,
1073,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616397,8,Autocuration,9823.0,,51,
1074,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616398,8,Autocuration,9823.0,,51,
1075,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616399,8,Expert,9823.0,,51,
1076,Binding activity radioligand.,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL857065,8,Autocuration,9823.0,,51,
1077,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616400,8,Expert,9823.0,,51,
1078,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616401,8,Autocuration,9823.0,,51,
1079,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616402,8,Expert,,,10624,
1080,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616403,8,Expert,9823.0,,51,
1081,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,1,H,,Sus scrofa,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616404,8,Autocuration,9823.0,,51,
1082,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,1,H,,Sus scrofa,,,,,,,BAO_0000249,CHEMBL616405,8,Autocuration,9823.0,,51,
1083,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616406,8,Autocuration,9823.0,,51,
1084,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616407,8,Expert,9823.0,,51,
1085,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616408,8,Autocuration,9986.0,,51,
1086,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL616409,9,Expert,10116.0,,10576,
1087,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616410,9,Expert,10116.0,,10576,
1088,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,1,H,,,,,,,,,BAO_0000357,CHEMBL616411,8,Autocuration,,,10576,
1089,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616412,9,Expert,10116.0,,10576,
1090,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,D,,Rattus norvegicus,,Membranes,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL616413,9,Expert,10116.0,,10576,
1091,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616414,8,Autocuration,,,10576,
1092,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616415,9,Expert,10116.0,,10576,
1093,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,1,H,,,,,,,,,BAO_0000019,CHEMBL616416,8,Autocuration,,,10576,
1094,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616417,8,Expert,,,10576,
1095,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL616418,8,Autocuration,,,10576,
1096,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,H,,,,,,,,,BAO_0000219,CHEMBL616419,8,Autocuration,,,10576,
1097,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616420,8,Autocuration,,,10576,
1098,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616421,8,Autocuration,,,10576,
1099,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616422,8,Autocuration,,,10576,
1100,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616423,8,Expert,,,10576,
1101,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616424,9,Expert,10116.0,,10576,
1102,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616425,8,Expert,,,10576,
1103,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,1,H,,,,,,,,,BAO_0000357,CHEMBL616426,8,Expert,,,10576,
1104,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616427,8,Autocuration,,,10576,
1105,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616428,8,Autocuration,,,10576,
1106,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616290,8,Autocuration,,,10576,
1107,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616052,9,Expert,10116.0,,10576,
1108,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616053,8,Autocuration,,,10576,
1109,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL616054,8,Autocuration,,,10576,
1110,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616055,8,Autocuration,,,10576,
1111,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL616056,8,Autocuration,,,10576,
1112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL616057,8,Expert,,,10576,
1113,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,D,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000221,CHEMBL616058,9,Expert,10116.0,,10576,
1114,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616059,8,Autocuration,,,10576,
1115,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL616060,8,Autocuration,,,10576,
1116,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616061,9,Expert,10116.0,,10576,
1117,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616062,8,Expert,,,10576,
1118,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL616063,8,Autocuration,,,10576,
1119,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,H,,,,,,Striatum,,2435.0,BAO_0000249,CHEMBL616064,8,Autocuration,,,10576,
1120,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616065,9,Expert,10116.0,,10576,
1121,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616066,9,Expert,10116.0,,10576,
1122,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616067,8,Autocuration,,,10576,
1123,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616068,8,Autocuration,,,10576,
1124,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616069,8,Intermediate,,,10576,
1125,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL616070,8,Expert,,,10576,
1126,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616071,8,Autocuration,,,10576,
1127,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616072,8,Expert,,,10576,
1128,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616073,8,Autocuration,,,10576,
1129,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616074,8,Autocuration,,,10576,
1130,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,1,H,,,,,,,,,BAO_0000019,CHEMBL616075,8,Expert,,,10576,
1131,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616076,8,Autocuration,,,10576,
1132,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616077,9,Expert,10116.0,,10576,
1133,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616078,9,Expert,10116.0,,10576,
1134,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616079,9,Expert,10116.0,,10576,
1135,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,D,,Rattus norvegicus,,,,,CHO-K1,,BAO_0000219,CHEMBL616080,9,Expert,10116.0,,10576,485.0
1136,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616081,8,Autocuration,,,10576,
1137,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616082,9,Expert,10116.0,,10576,
1138,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616083,8,Autocuration,,,10576,
1139,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616084,8,Autocuration,,,10576,
1140,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL616085,8,Expert,,,10576,
1141,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,1,H,,,,,,,,,BAO_0000019,CHEMBL616086,8,Autocuration,,,10576,
1142,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616087,8,Autocuration,,,10576,
1143,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,1,H,,,,,,,,,BAO_0000357,CHEMBL616088,8,Expert,,,10576,
1144,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,1,H,,,,,,,,,BAO_0000019,CHEMBL616089,8,Autocuration,,,10576,
1145,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616090,9,Expert,10116.0,,10576,
1146,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616091,8,Autocuration,,,10576,
1147,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,H,,,,Membranes,,Striatum,,2435.0,BAO_0000249,CHEMBL616092,8,Autocuration,,,10576,
1148,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),1,H,,,,,,,,,BAO_0000357,CHEMBL616093,8,Autocuration,,,10576,
1149,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),1,H,,,,,,,,,BAO_0000218,CHEMBL616094,8,Autocuration,,,10576,
1150,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616095,8,Autocuration,,,10576,
1151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616096,9,Expert,10116.0,,10576,
1152,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL616097,8,Expert,,,10576,
1153,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616098,9,Expert,10116.0,,10576,
1154,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616099,8,Autocuration,,,10576,
1155,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616100,8,Autocuration,,,10576,
1156,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616101,8,Expert,,,10576,
1157,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL616102,8,Expert,,,10576,
1158,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616103,8,Autocuration,,,10576,
1159,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616104,8,Expert,,,10576,
1160,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL616105,8,Expert,,,10576,
1161,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616106,9,Expert,10116.0,,10576,
1162,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616107,8,Autocuration,,,10576,
1163,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616108,8,Expert,,,10576,
1164,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616109,8,Expert,,,10576,
1165,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,1,H,,,,,,,,,BAO_0000357,CHEMBL616110,8,Autocuration,,,10576,
1166,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616111,8,Expert,,,10576,449.0
1167,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616112,8,Expert,,,10576,
1168,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616113,8,Autocuration,,,10576,
1169,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616114,8,Autocuration,,,10576,
1170,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616115,8,Autocuration,,,10576,
1171,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616116,8,Autocuration,,,10576,
1172,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615844,8,Expert,,,10576,
1173,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615939,8,Expert,,,10576,
1174,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL615940,8,Expert,,,10576,
1175,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615941,8,Expert,,,10576,
1176,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615942,8,Autocuration,,,10576,
1177,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615943,8,Autocuration,,,10576,
1178,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615944,8,Autocuration,,,10576,
1179,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615945,8,Autocuration,,,10576,
1180,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615946,8,Autocuration,,,10576,
1181,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615947,8,Autocuration,,,10576,
1182,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615948,8,Autocuration,,,10576,
1183,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615949,8,Autocuration,,,10576,
1184,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615950,8,Autocuration,,,10576,
1185,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615951,8,Autocuration,,,10576,
1186,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615952,8,Autocuration,,,10576,
1187,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615953,8,Autocuration,,,10576,
1188,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615954,8,Autocuration,,,10576,
1189,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615955,9,Expert,10116.0,,10576,
1190,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615956,8,Autocuration,,,10576,
1191,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL615957,8,Autocuration,,,10576,
1192,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,1,H,,,,,,,,,BAO_0000019,CHEMBL615958,8,Expert,,,10576,
1193,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL615959,8,Expert,,,10576,
1194,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),1,H,,,,,,,,,BAO_0000019,CHEMBL615960,8,Autocuration,,,10576,
1195,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),1,H,,,,,,,,,BAO_0000019,CHEMBL615961,8,Autocuration,,,10576,
1196,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL615962,8,Expert,,,10576,
1197,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL615963,8,Expert,,,10576,
1198,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,1,H,,,,,,,,,BAO_0000019,CHEMBL615964,8,Autocuration,,,10576,
1199,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,1,H,,,,,,,,,BAO_0000019,CHEMBL615965,8,Autocuration,,,10576,
1200,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL615966,8,Expert,,,10576,449.0
1201,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL615967,8,Expert,,,10576,
1202,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL615968,8,Expert,,,10576,
1203,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,H,,,,,,,CHO,,BAO_0000218,CHEMBL615969,8,Autocuration,,,10576,449.0
1204,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),1,H,,,,,,,,,BAO_0000218,CHEMBL615970,8,Autocuration,,,10576,
1205,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL615971,9,Expert,10116.0,,10576,
1206,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL615972,8,Expert,,,10576,
1207,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,1,H,,,,,,,,,BAO_0000249,CHEMBL615973,8,Autocuration,,,10576,
1208,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,1,H,,,,,,,,,BAO_0000249,CHEMBL615974,8,Autocuration,,,10576,
1209,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL615975,9,Expert,9606.0,,51,449.0
1210,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL615976,8,Expert,,,10576,
1211,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL872106,9,Expert,10116.0,,10576,
1212,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL615977,8,Autocuration,,,10576,
1213,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,1,H,,,,,,,,,BAO_0000357,CHEMBL615978,8,Autocuration,,,10576,
1214,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,1,H,,,,,,,,,BAO_0000357,CHEMBL616166,8,Autocuration,,,10576,
1215,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,1,H,,,,,,,,,BAO_0000357,CHEMBL616167,8,Autocuration,,,10576,
1216,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,1,H,,,,,,,,,BAO_0000357,CHEMBL616168,8,Autocuration,,,10576,
1217,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,1,H,,,,,,,,,BAO_0000357,CHEMBL616169,8,Autocuration,,,10576,
1218,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,1,H,,,,,,,,,BAO_0000357,CHEMBL616170,8,Autocuration,,,10576,
1219,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,1,H,,,,,,,,,BAO_0000357,CHEMBL616171,8,Autocuration,,,10576,
1220,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,1,H,,,,,,,,,BAO_0000357,CHEMBL616172,8,Autocuration,,,10576,
1221,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,1,H,,,,,,,,,BAO_0000357,CHEMBL616173,8,Autocuration,,,10576,
1222,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,1,H,,,,,,,,,BAO_0000357,CHEMBL616174,8,Autocuration,,,10576,
1223,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,1,H,,,,,,,,,BAO_0000357,CHEMBL616175,8,Autocuration,,,10576,
1224,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,1,H,,,,,,,,,BAO_0000357,CHEMBL616176,8,Autocuration,,,10576,
1225,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,1,H,,,,,,,,,BAO_0000357,CHEMBL616177,8,Autocuration,,,10576,
1226,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,1,H,,,,,,,,,BAO_0000357,CHEMBL616178,8,Autocuration,,,10576,
1227,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,1,H,,,,,,,,,BAO_0000019,CHEMBL616179,8,Autocuration,,,10576,
1228,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616180,8,Autocuration,,,10576,
1229,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616181,8,Autocuration,,,10576,
1230,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,1,H,,,,,,,,,BAO_0000019,CHEMBL616182,8,Autocuration,,,10576,
1231,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616183,8,Autocuration,,,10576,
1232,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,1,H,,,,,,,,,BAO_0000019,CHEMBL615874,8,Expert,,,10576,
1233,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,D,,Rattus norvegicus,,,,,CHO-K1,,BAO_0000219,CHEMBL615875,9,Expert,10116.0,,10576,485.0
1234,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL615876,8,Autocuration,,,10576,
1235,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL615877,8,Autocuration,,,10576,
1236,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),1,H,,,,,,,,,BAO_0000357,CHEMBL615878,8,Autocuration,,,10576,
1237,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,1,H,,,,,,,,,BAO_0000357,CHEMBL615879,8,Expert,,,10576,
1238,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL615880,8,Expert,,,10576,
1239,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL615881,8,Autocuration,,,10576,
1240,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL615882,9,Expert,10116.0,,10576,
1241,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,1,H,,,,,,,,,BAO_0000218,CHEMBL615883,8,Autocuration,,,10576,
1242,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),1,H,,,,,,,,,BAO_0000218,CHEMBL615884,8,Autocuration,,,10576,
1243,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),1,H,,,,,,,,,BAO_0000218,CHEMBL615885,8,Autocuration,,,10576,
1244,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),1,H,,,,,,,,,BAO_0000218,CHEMBL615886,8,Autocuration,,,10576,
1245,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),1,H,,,,,,,,,BAO_0000218,CHEMBL615887,8,Autocuration,,,10576,
1246,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),1,H,,,,,,,,,BAO_0000218,CHEMBL615888,8,Autocuration,,,10576,
1247,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),1,H,,,,,,,,,BAO_0000218,CHEMBL615889,8,Autocuration,,,10576,
1248,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),1,H,,,,,,,,,BAO_0000218,CHEMBL615890,8,Autocuration,,,10576,
1249,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),1,H,,,,,,,,,BAO_0000218,CHEMBL615891,8,Autocuration,,,10576,
1250,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),1,H,,,,,,,,,BAO_0000218,CHEMBL615892,8,Autocuration,,,10576,
1251,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),1,H,,,,,,,,,BAO_0000218,CHEMBL615893,8,Autocuration,,,10576,
1252,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),1,H,,,,,,,,,BAO_0000218,CHEMBL615894,8,Autocuration,,,10576,
1253,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),1,H,,,,,,,,,BAO_0000218,CHEMBL615895,8,Autocuration,,,10576,
1254,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),1,H,,,,,,,,,BAO_0000218,CHEMBL615896,8,Autocuration,,,10576,
1255,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,1,H,,,,,,,,,BAO_0000218,CHEMBL615897,8,Autocuration,,,10576,
1256,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL615898,9,Expert,10116.0,,10576,
1257,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL615899,8,Autocuration,,,10576,
1258,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL616291,8,Autocuration,,,10576,
1259,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL616292,8,Autocuration,,,10576,
1260,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,H,,,,,,,,,BAO_0000249,CHEMBL616293,8,Autocuration,,,10576,
1261,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616294,8,Expert,,,10576,
1262,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL616295,8,Autocuration,,,10576,
1263,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616296,8,Autocuration,,,10576,
1264,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616297,8,Autocuration,,,10576,
1265,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616605,8,Autocuration,,,10576,
1266,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616606,8,Autocuration,,,10576,
1267,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616607,8,Autocuration,,,10576,
1268,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616608,8,Expert,,,10576,
1269,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616609,8,Autocuration,,,10576,
1270,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616610,9,Expert,10116.0,,10576,
1271,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616611,8,Autocuration,,,10576,
1272,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616612,8,Expert,,,10576,
1273,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616613,8,Autocuration,,,10576,
1274,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616614,8,Expert,,,10576,
1275,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616615,8,Autocuration,,,10576,
1276,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616616,8,Expert,,,10576,
1277,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616617,8,Autocuration,,,10576,
1278,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616618,8,Autocuration,,,10576,
1279,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616619,8,Autocuration,,,10576,
1280,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616620,8,Expert,,,10576,
1281,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616621,8,Expert,,,10576,
1282,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616622,8,Autocuration,,,10576,
1283,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616146,8,Expert,,,10576,
1284,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL832873,8,Autocuration,,,10576,
1285,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616147,8,Autocuration,,,10576,
1286,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL872872,8,Autocuration,,,10576,
1287,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616148,8,Autocuration,,,10576,
1288,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616149,8,Autocuration,,,10576,
1289,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616150,8,Expert,,,10576,
1290,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616151,9,Expert,10116.0,,10576,
1291,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL872873,8,Expert,,,10576,
1292,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616670,8,Autocuration,,,10576,
1293,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616671,8,Autocuration,,,10576,
1294,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL884861,9,Expert,10116.0,,10576,
1295,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616672,8,Autocuration,,,10576,
1296,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL616673,8,Autocuration,,,10576,
1297,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616674,8,Expert,,,10576,
1298,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616675,8,Autocuration,,,10576,
1299,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616676,8,Autocuration,,,10576,
1300,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616677,8,Autocuration,,,10576,
1301,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616678,8,Autocuration,,,10576,
1302,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616679,9,Expert,10116.0,,10576,
1303,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616680,8,Expert,,,10576,
1304,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616681,8,Autocuration,,,10576,
1305,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616682,8,Autocuration,,,10576,
1306,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616683,8,Autocuration,,,10576,
1307,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616684,8,Autocuration,,,10576,
1308,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616685,8,Autocuration,,,10576,
1309,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616686,8,Autocuration,,,10576,
1310,Affinity for 5-hydroxytryptamine 1A receptor site,1,H,,,,,,,,,BAO_0000357,CHEMBL616687,8,Autocuration,,,10576,
1311,Affinity for 5-hydroxytryptamine 1A receptor site,1,H,,,,,,,,,BAO_0000357,CHEMBL616688,8,Autocuration,,,10576,
1312,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616689,8,Autocuration,,,10576,
1313,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616690,8,Autocuration,,,10576,
1314,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616691,8,Expert,,,10576,
1315,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616692,9,Expert,10116.0,,10576,
1316,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL616693,8,Expert,,,10576,
1317,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616694,9,Expert,10116.0,,10576,
1318,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616695,8,Autocuration,,,10576,
1319,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL616696,8,Autocuration,,,10576,
1320,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616697,8,Autocuration,,,10576,
1321,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616698,8,Autocuration,,,10576,
1322,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616949,9,Expert,10116.0,,10576,
1323,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616950,8,Autocuration,,,10576,
1324,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL832875,8,Autocuration,,,10576,
1325,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616951,8,Expert,,,10576,
1326,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616952,8,Expert,,,10576,
1327,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL616953,8,Expert,,,10576,
1328,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,1,H,,,,,,,,,BAO_0000357,CHEMBL616954,8,Autocuration,,,10576,
1329,GTPgammaS radioligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL616955,8,Autocuration,,,106,
1330,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616956,8,Autocuration,,,106,
1331,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL616957,8,Autocuration,,,106,
1332,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,1,H,,,,,,,,,BAO_0000019,CHEMBL616958,8,Autocuration,,,106,
1333,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616959,8,Autocuration,,,106,
1334,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616960,8,Autocuration,,,106,
1335,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,1,H,,,,,,,,,BAO_0000019,CHEMBL616961,8,Autocuration,,,106,
1336,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616962,8,Expert,,,106,308.0
1337,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616963,8,Autocuration,,,106,308.0
1338,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616524,9,Expert,9606.0,,106,
1339,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616525,8,Autocuration,,,106,449.0
1340,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL872908,8,Autocuration,,,106,
1341,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616526,8,Autocuration,,,106,
1342,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616527,9,Expert,9606.0,,106,
1343,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL616528,8,Expert,,,106,
1344,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616529,8,Autocuration,,,106,
1345,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616530,8,Autocuration,,,106,
1346,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616531,8,Expert,,,106,
1347,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616532,8,Autocuration,,,106,
1348,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616533,8,Autocuration,,,106,
1349,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616534,8,Expert,,,106,
1350,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616535,8,Expert,,,106,
1351,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616536,8,Autocuration,,,106,
1352,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616537,8,Autocuration,,,106,
1353,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616538,8,Expert,,,106,485.0
1354,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616539,8,Expert,,,106,
1355,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616540,8,Expert,,,106,
1356,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616429,8,Autocuration,,,106,
1357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616430,8,Expert,,,106,
1358,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,1,D,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL616431,9,Expert,9606.0,,106,
1359,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616432,9,Expert,9606.0,,106,
1360,Affinity for 5-hydroxytryptamine 1B receptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616433,9,Expert,9606.0,,106,
1361,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616434,9,Expert,9606.0,,106,
1362,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616435,8,Autocuration,,,106,449.0
1363,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL616436,8,Expert,,,106,
1364,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616437,8,Autocuration,,,106,308.0
1365,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616438,8,Autocuration,,,106,308.0
1366,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL616439,8,Autocuration,,,106,308.0
1367,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616440,9,Expert,9606.0,,106,
1368,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616441,8,Autocuration,,,106,485.0
1369,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616442,8,Expert,,,106,
1370,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616443,8,Autocuration,,,106,
1371,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616444,8,Expert,,,106,485.0
1372,Binding activity against human 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616445,9,Expert,9606.0,,106,
1373,Binding activity against human 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616446,9,Expert,9606.0,,106,
1374,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616447,9,Expert,9606.0,,106,449.0
1375,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616448,8,Autocuration,,,106,
1376,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616449,8,Autocuration,,,106,449.0
1377,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616450,8,Autocuration,,,106,449.0
1378,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL857974,8,Autocuration,,,106,449.0
1379,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616451,8,Autocuration,,,106,449.0
1380,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616452,8,Autocuration,,,106,449.0
1381,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616453,8,Autocuration,,,106,449.0
1382,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616454,8,Autocuration,,,106,449.0
1383,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616455,9,Expert,9606.0,,106,
1384,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616456,8,Autocuration,,,106,449.0
1385,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616457,8,Autocuration,,,106,
1386,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616458,8,Autocuration,,,106,449.0
1387,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616459,8,Autocuration,,,106,449.0
1388,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616460,8,Expert,,,106,
1389,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616461,8,Expert,,,106,
1390,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616462,8,Autocuration,,,106,449.0
1391,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616463,8,Autocuration,,,106,449.0
1392,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",1,H,,,,,,,,,BAO_0000019,CHEMBL616464,8,Autocuration,,,105,
1393,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616465,8,Autocuration,,,105,449.0
1394,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL832874,8,Autocuration,,,17105,
1395,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616184,8,Autocuration,9986.0,,106,
1396,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616185,8,Autocuration,9986.0,,106,
1397,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616186,8,Intermediate,9986.0,,106,
1398,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616187,8,Autocuration,9986.0,,106,
1399,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616188,8,Expert,,,10577,
1400,Binding affinity for 5-hydroxytryptamine 1B receptor,1,D,,,,,,,,,BAO_0000357,CHEMBL873475,9,Intermediate,,,10577,
1401,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,1,D,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616189,9,Expert,10116.0,,10577,
1402,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL616190,8,Expert,,,10577,
1403,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,1,H,,,,,,,,,BAO_0000357,CHEMBL616191,8,Autocuration,,,10576,
1404,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,1,H,,,,,,,,,BAO_0000357,CHEMBL616192,8,Autocuration,,,10576,
1405,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,1,H,,,,,,,,,BAO_0000357,CHEMBL616193,8,Autocuration,,,10576,
1406,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,1,H,,,,,,,,,BAO_0000357,CHEMBL616194,8,Autocuration,,,10576,
1407,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,1,H,,,,,,,,,BAO_0000357,CHEMBL616195,8,Autocuration,,,10576,
1408,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,1,H,,,,,,,,,BAO_0000357,CHEMBL616196,8,Autocuration,,,10576,
1409,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL616197,8,Autocuration,,,10576,
1410,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616198,8,Intermediate,,,10576,
1411,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616199,8,Autocuration,,,10576,
1412,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616200,8,Expert,,,10576,
1413,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616201,8,Expert,,,10576,
1414,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616202,8,Expert,,,10576,
1415,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616203,8,Expert,,,10576,
1416,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616204,8,Expert,,,10576,
1417,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616205,8,Expert,,,10576,
1418,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616206,8,Expert,,,10576,
1419,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL616207,8,Expert,,,10576,
1420,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL616208,8,Autocuration,,,10576,
1421,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,1,H,,,,,,,,,BAO_0000249,CHEMBL616209,8,Autocuration,,,10576,
1422,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616210,8,Expert,,,10576,
1423,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616211,8,Expert,,,10576,
1424,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616504,8,Autocuration,,,10576,
1425,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616505,9,Expert,10116.0,,10576,
1426,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616506,8,Autocuration,,,10576,
1427,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL872107,8,Autocuration,,,10576,
1428,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616507,9,Expert,10116.0,,10576,
1429,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL616303,8,Autocuration,,,10576,
1430,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616304,8,Autocuration,,,10576,
1431,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616305,8,Expert,,,10576,
1432,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616306,8,Intermediate,,,10576,
1433,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616307,8,Autocuration,,,10576,
1434,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL881829,9,Expert,10116.0,,10576,
1435,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,1,H,,,,,,,,,BAO_0000357,CHEMBL616308,8,Expert,,,10576,
1436,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,1,H,,,,,,,,,BAO_0000019,CHEMBL616309,8,Autocuration,,,10576,
1437,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,1,H,,,,,,,,,BAO_0000019,CHEMBL616310,8,Expert,,,10576,
1438,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616311,8,Autocuration,,,10576,449.0
1439,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616312,8,Expert,,,10576,
1440,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616313,8,Autocuration,,,10576,
1441,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616314,9,Expert,10116.0,,10576,
1442,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616315,8,Autocuration,,,10576,
1443,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616567,8,Autocuration,,,10576,
1444,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616568,8,Autocuration,,,10576,
1445,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL616569,8,Intermediate,,,10576,
1446,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,1,H,,,,,,,,,BAO_0000357,CHEMBL616570,8,Expert,,,10576,
1447,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616571,8,Autocuration,,,10576,
1448,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616572,8,Autocuration,,,10576,
1449,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,1,H,,,,,,,,,BAO_0000249,CHEMBL616573,8,Expert,,,10576,
1450,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616574,9,Expert,10116.0,,10576,
1451,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616575,8,Expert,,,10576,
1452,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL872108,8,Autocuration,,,10576,
1453,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616576,8,Autocuration,,,10576,
1454,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,1,H,,,,,,,,,BAO_0000249,CHEMBL616577,8,Autocuration,,,10576,
1455,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,1,H,,,,,,,,,BAO_0000249,CHEMBL616578,8,Autocuration,,,10576,
1456,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL616579,8,Expert,,,10576,
1457,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616580,9,Expert,10116.0,,10576,
1458,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL616581,8,Autocuration,,,10576,
1459,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616582,8,Autocuration,,,10576,
1460,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616583,8,Expert,,,10576,
1461,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616584,9,Expert,10116.0,,10576,
1462,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616585,8,Expert,,,10576,
1463,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616586,9,Expert,10116.0,,10576,
1464,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616587,8,Autocuration,,,10576,
1465,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616588,8,Autocuration,,,10576,
1466,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616589,8,Autocuration,,,10576,
1467,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616590,8,Expert,,,10576,
1468,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616591,8,Expert,,,10576,449.0
1469,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616592,8,Expert,,,10576,
1470,The inhibition activity of 5-HT1A at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL616593,8,Autocuration,,,10576,
1471,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616594,8,Expert,,,10576,485.0
1472,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL616595,8,Expert,,,10576,
1473,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,1,H,,,,,,,,,BAO_0000357,CHEMBL616596,8,Autocuration,,,10576,
1474,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616597,8,Autocuration,,,10576,
1475,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616598,8,Expert,,,10576,
1476,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616599,9,Expert,10116.0,,10576,
1477,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,D,,Rattus norvegicus,,Membranes,,Hippocampus,,10000000.0,BAO_0000249,CHEMBL616600,9,Expert,10116.0,,10576,
1478,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,1,H,,,,,,,,,BAO_0000019,CHEMBL616601,8,Autocuration,,,10576,
1479,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,1,H,,,,,,,,,BAO_0000019,CHEMBL616602,8,Autocuration,,,10576,
1480,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,1,H,,,,,,,,,BAO_0000019,CHEMBL616603,8,Autocuration,,,10576,
1481,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,1,H,,,,,,,,,BAO_0000019,CHEMBL616604,8,Autocuration,,,10576,
1482,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,1,H,,,,,,,,,BAO_0000249,CHEMBL616316,8,Autocuration,,,10576,
1483,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,1,H,,,,,,,,,BAO_0000249,CHEMBL616317,8,Autocuration,,,10576,
1484,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616318,9,Expert,10116.0,,10576,
1485,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616319,8,Autocuration,,,10576,
1486,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616320,8,Autocuration,,,10576,
1487,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616321,9,Expert,10116.0,,10576,
1488,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL616322,8,Autocuration,,,10576,
1489,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL616323,8,Autocuration,,,10576,
1490,Ratio of binding affinity to 5-HT 1A and D2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616324,8,Autocuration,,,10576,
1491,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616325,8,Autocuration,,,10576,
1492,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616326,8,Autocuration,,,10576,
1493,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616327,8,Autocuration,,,10576,
1494,Percentage inhibition against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616328,8,Autocuration,,,10576,
1495,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,H,,,,,,,,,BAO_0000249,CHEMBL858110,8,Autocuration,,,10576,
1496,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,H,,,,,,,,,BAO_0000249,CHEMBL616329,8,Autocuration,,,10576,
1497,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,H,,,,,,,,,BAO_0000249,CHEMBL616330,8,Autocuration,,,10576,
1498,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,H,,,,,,,,,BAO_0000249,CHEMBL616331,8,Autocuration,,,10576,
1499,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,H,,,,,,,,,BAO_0000249,CHEMBL616332,8,Autocuration,,,10576,
1500,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,H,,,,,,Brain,,955.0,BAO_0000249,CHEMBL857063,8,Autocuration,,,10576,
1501,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616333,8,Autocuration,,,10576,
1502,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616334,8,Expert,,,10576,
1503,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616335,8,Autocuration,,,10576,
1504,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,1,H,,,,,,,,,BAO_0000019,CHEMBL616336,8,Autocuration,,,10576,
1505,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000249,CHEMBL616337,8,Expert,,,10576,
1506,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,1,H,,,,,,,,,BAO_0000019,CHEMBL616338,8,Autocuration,,,10576,
1507,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616339,8,Autocuration,,,10576,
1508,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616340,8,Autocuration,,,10576,
1509,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616341,8,Autocuration,,,10576,
1510,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616342,9,Expert,10116.0,,10576,
1511,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616343,9,Expert,10116.0,,10576,
1512,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,1,H,,,,,,,,,BAO_0000019,CHEMBL616344,8,Expert,,,10576,
1513,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616345,8,Expert,,,10576,
1514,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616346,8,Expert,,,10576,
1515,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616347,8,Autocuration,,,10576,
1516,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,1,H,,,,,,,,,BAO_0000019,CHEMBL616348,8,Expert,,,10576,
1517,Binding affinity at 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616349,8,Expert,,,10576,
1518,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL616152,9,Expert,10116.0,,10576,
1519,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,H,,,,,,,,,BAO_0000249,CHEMBL616153,8,Autocuration,,,10576,
1520,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL616154,8,Expert,,,10576,
1521,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616155,8,Autocuration,,,10576,
1522,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616156,9,Expert,10116.0,,10576,
1523,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616157,9,Expert,10116.0,,10576,
1524,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616158,8,Autocuration,,,10576,
1525,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616159,8,Autocuration,,,10576,
1526,pKi value against rat 5-hydroxytryptamine 1A receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL616160,8,Expert,,,10576,
1527,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,1,H,,,,,,,,,BAO_0000019,CHEMBL616161,8,Autocuration,,,10576,
1528,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL616162,8,Autocuration,,,10576,
1529,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616163,9,Expert,10116.0,,12687,
1530,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616164,8,Expert,,,10626,
1531,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616165,8,Autocuration,,,10576,
1532,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,1,H,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616355,8,Autocuration,10116.0,,51,
1533,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,H,,,,,,,,,BAO_0000019,CHEMBL616356,8,Autocuration,,,10576,
1534,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616357,8,Autocuration,,,10576,
1535,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL616358,8,Autocuration,,,10576,
1536,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616359,8,Autocuration,,,51,
1537,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,1,H,,,,,,,,,BAO_0000357,CHEMBL616360,8,Expert,,,51,
1538,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616361,8,Expert,,,51,
1539,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616362,8,Autocuration,,,51,
1540,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL616363,8,Autocuration,,,51,
1541,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL616364,8,Autocuration,,,51,
1542,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616365,8,Autocuration,,,51,
1543,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616366,8,Expert,,,51,
1544,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL872906,8,Expert,,,51,
1545,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL616367,8,Autocuration,,,51,
1546,Binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616368,8,Autocuration,,,51,
1547,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616369,8,Autocuration,,,51,
1548,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616370,9,Expert,9606.0,,51,
1549,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616371,9,Expert,9606.0,,51,
1550,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616372,8,Autocuration,,,51,449.0
1551,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,1,H,,,,,,,,,BAO_0000219,CHEMBL616373,8,Expert,,,51,
1552,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000218,CHEMBL616374,8,Autocuration,,,51,
1553,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL616375,8,Autocuration,,,51,
1554,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616376,8,Autocuration,,,51,
1555,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,1,H,,,,,,,,,BAO_0000357,CHEMBL857064,8,Expert,,,51,
1556,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616377,8,Autocuration,,,51,
1557,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616378,8,Autocuration,,,51,
1558,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616379,8,Autocuration,,,51,
1559,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616380,8,Autocuration,,,11863,
1560,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616381,8,Autocuration,,,11863,
1561,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616382,8,Autocuration,,,11863,
1562,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616383,8,Autocuration,,,11863,
1563,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,1,D,,Mus musculus,,,,,CHO,,BAO_0000219,CHEMBL616350,9,Expert,10090.0,,11863,449.0
1564,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616351,8,Autocuration,,,11863,
1565,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL616352,8,Autocuration,,,11863,
1566,Binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616353,8,Autocuration,,,11863,
1567,Binding affinity against serotonergic 5-HT1a receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616354,8,Autocuration,,,11863,
1568,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616508,8,Autocuration,,,11863,
1569,Binding affinity for 5-hydroxytryptamine 1A receptor,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL616559,9,Expert,10090.0,,11863,
1570,Binding affinity at 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616560,8,Autocuration,,,11863,
1571,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",1,H,,,,,,,,,BAO_0000357,CHEMBL616561,8,Autocuration,,,11863,
1572,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616562,8,Autocuration,,,11863,449.0
1573,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616563,8,Autocuration,,,11863,449.0
1574,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616564,8,Autocuration,,,11863,
1575,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616565,8,Autocuration,,,11863,
1576,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000218,CHEMBL616566,8,Autocuration,,,11863,
1577,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL616989,8,Autocuration,,,11863,
1578,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL857975,8,Autocuration,,,11863,
1579,Binding affinity against 5-hydroxytryptamine 1A receptor,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL616990,9,Expert,10090.0,,11863,
1580,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL616991,8,Autocuration,,,11863,
1581,Tested against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616992,8,Autocuration,,,11863,
1582,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616993,8,Autocuration,,,11863,
1583,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616994,8,Expert,9986.0,,106,
1584,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616995,8,Autocuration,9986.0,,106,
1585,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,D,,Gorilla gorilla,,,,,HEK293,,BAO_0000219,CHEMBL616996,9,Intermediate,9593.0,,105571,722.0
1586,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,H,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL616997,8,Autocuration,10141.0,,106,
1587,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,H,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL616998,8,Autocuration,10141.0,,106,
1588,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616999,8,Autocuration,10141.0,,106,
1589,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617000,8,Autocuration,10141.0,,106,
1590,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617001,8,Autocuration,10141.0,,106,
1591,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL858111,8,Autocuration,10141.0,,106,
1592,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,1,H,,,,,,,,,BAO_0000019,CHEMBL617002,8,Autocuration,,,106,
1593,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),1,H,,,,,,,,,BAO_0000019,CHEMBL617003,8,Autocuration,,,106,
1594,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),1,H,,,,,,,,,BAO_0000019,CHEMBL617004,8,Autocuration,,,106,
1595,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL617005,9,Expert,9606.0,,106,
1596,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,1,D,,Homo sapiens,,,,,CHO-K1,,BAO_0000219,CHEMBL616623,9,Expert,9606.0,,106,485.0
1597,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616624,8,Autocuration,,,106,449.0
1598,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL883243,8,Autocuration,,,106,
1599,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL616625,8,Autocuration,,,106,
1600,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616626,8,Expert,,,106,449.0
1601,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616627,8,Autocuration,,,106,449.0
1602,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616628,8,Autocuration,,,106,449.0
1603,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616629,8,Autocuration,,,106,449.0
1604,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616630,8,Autocuration,,,106,449.0
1605,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL616631,8,Expert,,,106,
1606,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL616632,8,Autocuration,,,106,
1607,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616633,9,Expert,9606.0,,106,
1608,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616634,8,Expert,,,106,449.0
1609,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,1,H,,,,,,,,,BAO_0000357,CHEMBL616635,8,Autocuration,,,106,
1610,Binding affinity against 5-hydroxytryptamine 1B receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL885358,9,Expert,9606.0,,106,
1611,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616636,9,Expert,9606.0,,106,449.0
1612,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616637,8,Expert,,,106,449.0
1613,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616638,8,Autocuration,,,106,
1614,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616639,8,Expert,,,106,449.0
1615,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616640,8,Expert,,,106,449.0
1616,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616641,8,Expert,,,106,449.0
1617,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616642,8,Expert,,,106,449.0
1618,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616643,8,Expert,,,106,449.0
1619,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL616644,8,Autocuration,,,106,
1620,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,1,H,,,,,,,,,BAO_0000357,CHEMBL616645,8,Autocuration,,,106,
1621,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616646,8,Autocuration,9986.0,,105,
1622,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616647,8,Expert,9986.0,,105,
1623,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),1,H,,,,,,,,,BAO_0000357,CHEMBL616509,8,Autocuration,,,105,
1624,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),1,H,,,,,,,,,BAO_0000357,CHEMBL616510,8,Autocuration,,,105,
1625,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616511,8,Autocuration,,,105,
1626,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616512,8,Expert,9913.0,,105,
1627,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616513,8,Autocuration,9913.0,,105,
1628,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,H,,Bos taurus,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616514,8,Autocuration,9913.0,,105,
1629,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616515,8,Expert,9913.0,,105,
1630,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616516,8,Autocuration,9913.0,,105,
1631,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616517,8,Autocuration,9913.0,,105,
1632,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616518,8,Autocuration,9913.0,,105,
1633,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616519,8,Autocuration,9913.0,,105,
1634,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616520,8,Autocuration,9913.0,,105,
1635,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616521,8,Autocuration,9913.0,,105,
1636,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616522,8,Autocuration,9913.0,,105,
1637,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL884531,8,Autocuration,9913.0,,105,
1638,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616523,8,Autocuration,9913.0,,105,
1639,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,H,,Bos taurus,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616731,8,Autocuration,9913.0,,105,
1640,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616732,8,Autocuration,9913.0,,105,
1641,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616733,8,Autocuration,9913.0,,105,
1642,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616734,8,Autocuration,9913.0,,105,
1643,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,1,H,,Bos taurus,,,,,,,BAO_0000249,CHEMBL616735,8,Autocuration,9913.0,,105,
1644,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,1,H,,Bos taurus,,,,,,,BAO_0000249,CHEMBL616736,8,Autocuration,9913.0,,105,
1645,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616737,8,Expert,9913.0,,105,
1646,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616738,8,Autocuration,9913.0,,105,
1647,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616739,8,Expert,9913.0,,105,
1648,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616740,8,Expert,9913.0,,105,
1649,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL616741,8,Expert,9913.0,,105,
1650,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,H,,Gorilla gorilla,,,,,HEK293,,BAO_0000219,CHEMBL616742,8,Autocuration,9593.0,,105,722.0
1651,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616743,9,Intermediate,10141.0,,105570,
1652,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616744,9,Intermediate,10141.0,,105570,
1653,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616745,9,Intermediate,10141.0,,105570,
1654,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616746,9,Intermediate,10141.0,,105570,
1655,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616747,9,Intermediate,10141.0,,105570,
1656,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616748,9,Intermediate,10141.0,,105570,
1657,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616648,9,Intermediate,10141.0,,105570,
1658,Binding affinity against 5-hydroxytryptamine 1D receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL616649,9,Intermediate,10141.0,,105570,
1659,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL616650,9,Intermediate,10141.0,,105570,
1660,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,D,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL616651,9,Intermediate,10141.0,,105570,
1661,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,D,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL616652,9,Intermediate,10141.0,,105570,
1662,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,D,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL616653,9,Intermediate,10141.0,,105570,
1663,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,1,D,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL616654,9,Intermediate,10141.0,,105570,
1664,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616655,9,Intermediate,10141.0,,105570,
1665,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL616656,9,Intermediate,10141.0,,105570,
1666,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL616657,8,Autocuration,10141.0,,105,
1667,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL616658,9,Intermediate,10141.0,,105570,
1668,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL616659,9,Intermediate,10141.0,,105570,
1669,Binding affinity against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616660,8,Autocuration,,,51,
1670,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,1,H,,,,,,,,,BAO_0000357,CHEMBL616661,8,Autocuration,,,106,
1671,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616662,8,Expert,,,105,
1672,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616663,8,Autocuration,,,105,
1673,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616664,8,Autocuration,,,105,
1674,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL881820,9,Expert,9606.0,,105,449.0
1675,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616665,8,Autocuration,,,105,449.0
1676,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616666,8,Expert,,,105,449.0
1677,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616667,8,Autocuration,,,105,449.0
1678,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616668,8,Expert,,,105,449.0
1679,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616669,9,Expert,9606.0,,105,449.0
1680,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617040,8,Expert,,,105,449.0
1681,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617041,8,Autocuration,,,105,449.0
1682,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617042,8,Expert,,,105,449.0
1683,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617043,8,Expert,,,105,449.0
1684,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617044,8,Autocuration,,,105,
1685,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617045,8,Expert,,,105,449.0
1686,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617046,9,Expert,9606.0,,105,449.0
1687,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617047,9,Expert,9606.0,,105,449.0
1688,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL617048,8,Expert,,,105,
1689,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",1,H,,,,,,,,,BAO_0000019,CHEMBL616897,8,Autocuration,,,105,
1690,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL616898,9,Expert,9606.0,,105,
1691,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL858201,9,Expert,9606.0,,105,449.0
1692,Intrinsic activity for 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616899,8,Autocuration,,,105,
1693,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),1,H,,,,,,,,,BAO_0000219,CHEMBL616900,8,Autocuration,,,105,
1694,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616901,8,Expert,,,105,449.0
1695,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,1,H,,,,,,,,,BAO_0000357,CHEMBL616902,8,Autocuration,,,105,
1696,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616903,9,Expert,9606.0,,105,449.0
1697,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616904,8,Expert,,,105,449.0
1698,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616905,8,Autocuration,,,105,
1699,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616906,8,Expert,,,105,449.0
1700,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616907,8,Expert,,,105,449.0
1701,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616908,8,Expert,,,105,449.0
1702,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616909,9,Expert,9606.0,,105,449.0
1703,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616910,9,Expert,9606.0,,105,449.0
1704,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616911,8,Expert,,,105,449.0
1705,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616912,8,Expert,,,105,449.0
1706,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL616913,8,Autocuration,,,105,
1707,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616914,9,Expert,9606.0,,105,449.0
1708,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616915,8,Autocuration,,,105,449.0
1709,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616916,8,Autocuration,,,105,
1710,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616917,9,Expert,9606.0,,105,
1711,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",1,H,,,,,,,,,BAO_0000357,CHEMBL616918,8,Autocuration,,,105,
1712,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL616919,8,Expert,,,105,
1713,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616920,8,Autocuration,,,105,
1714,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL872914,8,Autocuration,,,105,
1715,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616921,8,Autocuration,,,105,
1716,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616922,8,Expert,,,105,
1717,Binding affinity towards 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616923,8,Autocuration,,,105,
1718,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616924,8,Expert,,,105,
1719,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL875909,8,Expert,,,105,
1720,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616925,8,Autocuration,,,105,
1721,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616926,8,Autocuration,,,105,
1722,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616927,8,Autocuration,,,105,
1723,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616928,8,Expert,,,105,485.0
1724,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),1,D,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL616929,9,Expert,9606.0,,105,
1725,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616930,9,Expert,9606.0,,105,
1726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616931,8,Expert,,,105,
1727,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616932,8,Autocuration,,,105,
1728,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616933,8,Expert,,,105,
1729,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,1,D,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL616934,9,Expert,9606.0,,105,
1730,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616935,9,Expert,9606.0,,105,
1731,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL616936,8,Autocuration,,,105,
1732,Affinity for 5-hydroxytryptamine 1D receptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616937,9,Expert,9606.0,,105,
1733,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616938,9,Expert,9606.0,,105,
1734,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616939,8,Autocuration,,,105,
1735,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL616940,8,Expert,,,105,
1736,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616941,9,Expert,9606.0,,105,
1737,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616942,8,Autocuration,,,105,485.0
1738,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616943,8,Autocuration,,,105,485.0
1739,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616944,4,Autocuration,,,104802,449.0
1740,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",1,H,,,,,,,,,BAO_0000019,CHEMBL616945,8,Autocuration,,,105,
1741,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616946,8,Autocuration,,,105,
1742,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616947,8,Autocuration,,,105,
1743,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616948,8,Expert,,,105,485.0
1744,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616851,8,Autocuration,,,105,
1745,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616852,8,Autocuration,,,105,
1746,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616853,8,Autocuration,,,105,
1747,Binding activity against human 5-hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616854,9,Expert,9606.0,,105,
1748,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616855,9,Expert,9606.0,,105,449.0
1749,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616856,8,Autocuration,,,105,449.0
1750,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616857,8,Autocuration,,,105,449.0
1751,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616858,8,Autocuration,,,105,
1752,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616859,8,Autocuration,,,105,449.0
1753,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616860,8,Autocuration,,,105,449.0
1754,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616861,8,Autocuration,,,105,722.0
1755,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616541,8,Autocuration,,,105,722.0
1756,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616542,8,Autocuration,,,105,722.0
1757,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616543,8,Autocuration,,,105,449.0
1758,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616544,9,Expert,9606.0,,105,
1759,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616545,8,Autocuration,,,105,449.0
1760,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616546,8,Autocuration,,,105,
1761,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616547,8,Autocuration,,,105,449.0
1762,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616548,8,Autocuration,,,105,449.0
1763,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616549,8,Expert,,,105,
1764,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL616550,8,Expert,,,105,
1765,Binding affinity against 5-HT2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL857066,8,Autocuration,,,108,
1766,Binding affinity against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616551,8,Autocuration,,,108,
1767,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,H,,,,,,,,,BAO_0000357,CHEMBL616552,8,Autocuration,,,10577,
1768,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,H,,,,,,,,,BAO_0000019,CHEMBL832876,8,Autocuration,,,10577,
1769,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",1,H,,,,,,,,,BAO_0000019,CHEMBL616553,8,Expert,,,10577,
1770,Binding affinity towards 5-HT1B was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616554,8,Autocuration,,,10577,
1771,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,1,H,,,,,,,,,BAO_0000019,CHEMBL616555,8,Expert,,,10577,
1772,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",1,H,,,,,,,,,BAO_0000019,CHEMBL616556,8,Expert,,,10577,
1773,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",1,H,,,,,,,,,BAO_0000019,CHEMBL616557,8,Autocuration,,,10577,
1774,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616558,8,Expert,,,10577,
1775,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616749,9,Expert,10116.0,,10577,
1776,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL616750,8,Autocuration,,,10577,
1777,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",1,H,,,,,,,,,BAO_0000357,CHEMBL616751,8,Autocuration,,,10577,
1778,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL616752,8,Autocuration,,,10577,
1779,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616753,8,Autocuration,,,10577,
1780,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616754,9,Expert,10116.0,,10577,
1781,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616755,8,Autocuration,,,10577,
1782,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616756,8,Autocuration,,,10577,
1783,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616757,8,Autocuration,,,10577,
1784,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,1,H,,,,,,Striatum,,2435.0,BAO_0000357,CHEMBL616758,8,Autocuration,,,10577,
1785,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL616759,8,Autocuration,,,10577,
1786,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,1,H,,,,,,,,,BAO_0000357,CHEMBL616760,8,Autocuration,,,10577,
1787,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616761,8,Autocuration,,,10577,
1788,Binding affinity against 5-HT1B serotonin receptor in rat striatum,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616762,8,Autocuration,,,10577,
1789,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616763,8,Autocuration,,,10577,
1790,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL872909,8,Expert,,,10577,
1791,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616764,8,Autocuration,,,10577,
1792,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616765,9,Expert,10116.0,,10577,
1793,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,1,H,,,,,,Striatum,,2435.0,BAO_0000357,CHEMBL616766,8,Autocuration,,,10577,
1794,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,1,H,,,,,,Striatum,,2435.0,BAO_0000357,CHEMBL616767,8,Autocuration,,,10577,
1795,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616768,8,Autocuration,,,10577,
1796,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616769,8,Autocuration,,,10577,
1797,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,1,H,,,,,,,,,BAO_0000019,CHEMBL616770,8,Autocuration,,,10577,
1798,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,1,H,,,,,,,,,BAO_0000019,CHEMBL616771,8,Autocuration,,,10577,
1799,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616772,8,Autocuration,,,10577,
1800,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616773,8,Expert,,,10577,
1801,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,1,H,,,,,,,,,BAO_0000019,CHEMBL616774,8,Autocuration,,,10577,
1802,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616775,8,Autocuration,,,10577,
1803,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL616776,8,Autocuration,,,10577,
1804,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616777,8,Autocuration,,,10577,
1805,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL616778,8,Autocuration,,,10577,
1806,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL616779,9,Expert,10116.0,,10577,
1807,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616780,9,Expert,10116.0,,10577,
1808,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616781,8,Autocuration,,,10577,
1809,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616782,8,Autocuration,,,10577,
1810,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616783,8,Autocuration,,,10577,
1811,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL616784,8,Expert,,,10577,
1812,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL616785,8,Autocuration,,,10577,
1813,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,H,,,,,,Brain,,955.0,BAO_0000249,CHEMBL857067,8,Autocuration,,,10577,
1814,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616786,8,Autocuration,,,10577,
1815,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,H,,,,,,Brain,,955.0,BAO_0000249,CHEMBL616787,8,Autocuration,,,10577,
1816,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,1,H,,,,,,,,,BAO_0000357,CHEMBL616788,8,Autocuration,,,10577,
1817,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616789,8,Autocuration,,,10577,
1818,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616790,9,Expert,10116.0,,10577,
1819,Binding affinity at 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616791,8,Expert,,,10577,
1820,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616792,8,Autocuration,,,10577,
1821,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL616793,9,Expert,10116.0,,10577,
1822,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616794,8,Autocuration,,,10577,
1823,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616795,8,Autocuration,,,10577,
1824,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616796,4,Autocuration,,,104686,
1825,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616797,8,Autocuration,,,106,
1826,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL616798,8,Autocuration,,,106,
1827,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616799,8,Autocuration,,,106,
1828,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL616800,8,Autocuration,,,106,
1829,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616801,8,Autocuration,,,106,
1830,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL616802,8,Autocuration,,,106,
1831,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616803,8,Autocuration,,,106,
1832,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,1,H,,,,,,,,,BAO_0000357,CHEMBL857068,8,Expert,,,106,
1833,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,1,H,,,,,,,,,BAO_0000357,CHEMBL616804,8,Autocuration,,,106,
1834,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616805,8,Autocuration,,,106,
1835,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616806,8,Autocuration,,,106,
1836,Binding affinity against 5-hydroxytryptamine 1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616807,8,Autocuration,,,106,
1837,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616808,8,Autocuration,,,106,
1838,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL616809,8,Autocuration,,,106,
1839,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616810,8,Autocuration,,,106,
1840,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL616811,4,Autocuration,,,104802,
1841,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL616812,8,Autocuration,9913.0,,108,
1842,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616813,8,Autocuration,9823.0,,108,
1843,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616814,8,Autocuration,9823.0,,108,
1844,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616815,8,Autocuration,9823.0,,108,
1845,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616816,8,Autocuration,9823.0,,108,
1846,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616817,8,Autocuration,9823.0,,108,
1847,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616818,8,Autocuration,9823.0,,108,
1848,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616819,8,Expert,9823.0,,108,
1849,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616820,8,Expert,9823.0,,108,
1850,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL616821,8,Expert,9823.0,,108,
1851,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL616822,8,Autocuration,9823.0,,108,
1852,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616823,8,Autocuration,9986.0,,108,
1853,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616824,9,Autocuration,10116.0,,12689,
1854,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616825,9,Autocuration,10116.0,,12689,
1855,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616826,9,Autocuration,10116.0,,12689,
1856,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616827,9,Expert,10116.0,,12689,
1857,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616828,9,Autocuration,10116.0,,12689,
1858,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616829,9,Autocuration,10116.0,,12689,
1859,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616830,9,Autocuration,10116.0,,12689,
1860,Binding affinity against 5-hydroxytryptamine 1C receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616831,9,Expert,10116.0,,12689,
1861,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616832,9,Autocuration,10116.0,,12689,
1862,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616833,9,Autocuration,10116.0,,12689,
1863,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616834,9,Expert,10116.0,,12689,
1864,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL829595,9,Autocuration,10116.0,,12689,
1865,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616835,9,Autocuration,10116.0,,12689,
1866,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL872910,9,Autocuration,10116.0,,12689,
1867,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616836,8,Expert,,,12689,
1868,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL616837,9,Autocuration,10116.0,,12689,
1869,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616466,9,Autocuration,10116.0,,12689,
1870,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,1,D,,Rattus norvegicus,,,,,HEK293,,BAO_0000219,CHEMBL616467,9,Autocuration,10116.0,,12689,722.0
1871,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616468,8,Autocuration,,,108,
1872,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616469,8,Autocuration,,,108,
1873,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616470,8,Autocuration,,,108,
1874,Binding affinity against 5-hydroxytryptamine 1C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616471,8,Autocuration,,,12689,
1875,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616472,8,Autocuration,,,12689,
1876,Binding affinity against 5-hydroxytryptamine 1C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616473,8,Autocuration,,,12689,
1877,Binding affinity against serotonergic 5-HT1c receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616474,8,Autocuration,,,12689,
1878,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616475,8,Autocuration,,,12689,
1879,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616476,8,Autocuration,,,12689,
1880,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616477,8,Autocuration,9986.0,,105,
1881,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL616478,4,Autocuration,,,104686,
1882,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL616479,4,Autocuration,,,104686,
1883,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616480,4,Autocuration,,,104686,
1884,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL616481,5,Autocuration,10116.0,,104686,
1885,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,1,D,,Rattus norvegicus,,,,,,,BAO_0000249,CHEMBL616482,5,Autocuration,10116.0,,104686,
1886,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,1,D,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000221,CHEMBL884713,5,Autocuration,10116.0,,104686,
1887,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,1,H,,,,,,,,,BAO_0000224,CHEMBL616483,4,Autocuration,,,104686,
1888,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,1,H,,,,,,,,,BAO_0000224,CHEMBL616484,4,Autocuration,,,104686,
1889,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL616485,4,Autocuration,,,104686,
1890,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL616486,4,Autocuration,,,104686,
1891,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,1,H,,,,,,,,,BAO_0000224,CHEMBL616487,4,Autocuration,,,104686,
1892,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,H,,,,,,,,,BAO_0000224,CHEMBL616488,4,Autocuration,,,104686,
1893,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616489,4,Autocuration,,,104686,
1894,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616490,4,Autocuration,,,104686,
1895,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL616491,4,Autocuration,,,104686,
1896,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL616492,4,Autocuration,,,104686,
1897,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616493,4,Autocuration,,,104686,
1898,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616494,4,Autocuration,,,104686,
1899,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616495,4,Autocuration,,,104686,
1900,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616496,4,Autocuration,,,104686,
1901,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616497,4,Autocuration,,,104686,
1902,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL616498,4,Autocuration,,,104686,
1903,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL616499,4,Autocuration,,,104686,
1904,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL616500,4,Autocuration,,,104686,
1905,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,D,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000221,CHEMBL616501,5,Autocuration,10116.0,,104686,
1906,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL616502,4,Autocuration,,,104686,
1907,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL884529,4,Autocuration,,,104686,
1908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616503,4,Autocuration,,,104686,
1909,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL616964,4,Autocuration,,,104686,
1910,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616965,4,Autocuration,,,104686,
1911,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,1,H,,,,,,,,,BAO_0000224,CHEMBL616966,4,Autocuration,,,104686,
1912,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,1,H,,,,,,,,,BAO_0000224,CHEMBL616967,4,Autocuration,,,104686,
1913,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL616968,5,Autocuration,10116.0,,104686,
1914,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,1,H,,,,,,,,,BAO_0000224,CHEMBL616969,4,Autocuration,,,104686,
1915,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL884530,4,Autocuration,,,104686,
1916,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL616970,4,Autocuration,,,104686,
1917,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,H,,,,,,,,,BAO_0000224,CHEMBL616971,4,Autocuration,,,104686,
1918,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,H,,,,,,,,,BAO_0000224,CHEMBL616972,4,Autocuration,,,104686,
1919,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,1,H,,,,,,,,,BAO_0000224,CHEMBL616973,4,Autocuration,,,104686,
1920,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,1,H,,,,,,,,,BAO_0000224,CHEMBL616974,4,Autocuration,,,104686,
1921,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,1,H,,,,,,,,,BAO_0000019,CHEMBL616975,4,Autocuration,,,104686,
1922,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616976,4,Autocuration,,,104686,
1923,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL616977,4,Autocuration,,,104686,
1924,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,H,,,,,,,,,BAO_0000224,CHEMBL616978,4,Autocuration,,,104686,
1925,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL616979,4,Autocuration,,,104686,
1926,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL616980,4,Autocuration,,,104686,
1927,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616981,4,Autocuration,,,104686,
1928,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL616982,4,Autocuration,,,104686,
1929,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,1,H,,,,,,,,,BAO_0000224,CHEMBL616983,4,Autocuration,,,104686,
1930,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL616984,4,Autocuration,,,104686,
1931,Inhibitory activity against 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL616985,5,Autocuration,10116.0,,104686,
1932,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL616986,4,Autocuration,,,104686,
1933,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL616987,4,Autocuration,,,104686,
1934,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,1,H,,,,,,,,,BAO_0000019,CHEMBL616988,4,Autocuration,,,104686,
1935,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617243,4,Autocuration,,,104686,
1936,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,1,H,,,,,,,,,BAO_0000019,CHEMBL617244,4,Autocuration,,,104686,
1937,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,D,,Rattus norvegicus,,,,,CHO-K1,,BAO_0000219,CHEMBL617245,5,Autocuration,10116.0,,104686,485.0
1938,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL617246,4,Autocuration,,,104686,
1939,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),1,H,,,,,,,,,BAO_0000224,CHEMBL617546,4,Autocuration,,,104686,
1940,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL617547,4,Autocuration,,,104686,
1941,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,H,,,,,,,,,BAO_0000219,CHEMBL617548,4,Autocuration,,,104686,
1942,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617549,4,Autocuration,,,104686,
1943,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,H,,,,,,,,,BAO_0000224,CHEMBL617550,4,Autocuration,,,104686,
1944,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,H,,,,,,,,,BAO_0000224,CHEMBL617551,4,Autocuration,,,104686,
1945,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL617552,4,Autocuration,,,104686,
1946,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL617553,4,Autocuration,,,104686,
1947,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1,H,,,,,,Thoracic aorta,,1515.0,BAO_0000019,CHEMBL617554,4,Autocuration,,,104686,
1948,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617555,4,Autocuration,,,104686,
1949,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,H,,,,,,,,,BAO_0000224,CHEMBL617556,4,Autocuration,,,104686,
1950,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617557,8,Autocuration,,,10624,
1951,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617558,8,Autocuration,,,10624,
1952,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617559,8,Expert,,,17106,
1953,Binding affinity for 5-hydroxytryptamine 1D receptor,1,D,,,,,,,,,BAO_0000357,CHEMBL617560,9,Expert,,,17106,
1954,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL617561,8,Autocuration,,,17106,
1955,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL617562,8,Autocuration,,,17106,
1956,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,1,H,,,,,,Striatum,,2435.0,BAO_0000357,CHEMBL617563,8,Autocuration,,,17106,
1957,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617564,8,Autocuration,,,17106,
1958,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617565,8,Expert,,,17106,
1959,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL856076,8,Autocuration,,,17106,
1960,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617566,8,Autocuration,,,17106,
1961,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL875911,8,Expert,,,17106,
1962,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,H,,,,,,,,,BAO_0000019,CHEMBL617567,8,Autocuration,,,17106,
1963,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL617568,8,Autocuration,,,17106,
1964,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,1,H,,,,,,,,,BAO_0000019,CHEMBL617569,8,Expert,,,17106,
1965,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617570,8,Expert,,,17106,
1966,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,1,H,,,,,,,,,BAO_0000357,CHEMBL617571,8,Autocuration,,,17106,
1967,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL617572,8,Autocuration,9823.0,,105,
1968,The compound was tested for intrinsic activity against 5-HT1D receptor,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL617573,8,Expert,9986.0,,105,
1969,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617574,8,Autocuration,9986.0,,105,
1970,The compound was tested for binding affinity against 5-HT1D receptor,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL617575,8,Expert,9986.0,,105,
1971,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,1,H,,,,,,,,,BAO_0000357,CHEMBL617576,8,Autocuration,,,10578,
1972,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,1,H,,,,,,,,,BAO_0000019,CHEMBL617577,8,Autocuration,,,10578,
1973,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617578,8,Autocuration,,,10578,
1974,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617579,8,Autocuration,,,10578,
1975,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617580,8,Expert,,,10578,
1976,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL617581,8,Autocuration,,,10578,
1977,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617582,8,Autocuration,,,10578,
1978,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL617583,8,Expert,,,10578,
1979,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL617584,8,Autocuration,,,105,
1980,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617585,8,Autocuration,,,105,
1981,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL875912,8,Autocuration,,,105,
1982,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617586,8,Autocuration,,,105,
1983,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL617587,8,Autocuration,,,105,
1984,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617588,8,Autocuration,,,105,
1985,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL857980,8,Autocuration,,,105,
1986,Tested against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617589,8,Autocuration,,,105,
1987,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617590,8,Autocuration,,,105,
1988,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617591,8,Autocuration,,,105,722.0
1989,Binding affinity against 5-Hydroxytryptamine 1D receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617592,9,Expert,9606.0,,105,
1990,,1,H,,,,,,,,,BAO_0000357,CHEMBL617593,8,Autocuration,,,105,
1991,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617594,8,Autocuration,,,106,485.0
1992,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617595,8,Autocuration,,,105,485.0
1993,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617596,8,Autocuration,,,105,722.0
1994,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617597,8,Autocuration,,,105,722.0
1995,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,H,,,,,,,,,BAO_0000019,CHEMBL617598,8,Autocuration,,,105,
1996,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,1,H,,,,,,,,,BAO_0000357,CHEMBL872916,8,Autocuration,,,105,
1997,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL617599,8,Expert,,,105,
1998,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617091,8,Autocuration,,,105,
1999,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617092,8,Expert,,,105,485.0
2000,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617093,8,Autocuration,,,105,485.0
2001,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,1,H,,,,,,,,,BAO_0000019,CHEMBL617094,8,Autocuration,,,105,
2002,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,H,,,,,,,,,BAO_0000019,CHEMBL617095,8,Autocuration,,,105,
2003,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,H,,,,,,,,,BAO_0000019,CHEMBL617096,8,Autocuration,,,105,
2004,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,H,,,,,,,,,BAO_0000019,CHEMBL617097,8,Autocuration,,,105,
2005,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,H,,,,,,,,,BAO_0000019,CHEMBL617098,8,Autocuration,,,105,
2006,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617301,8,Autocuration,,,105,
2007,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617302,8,Autocuration,,,105,
2008,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617303,8,Autocuration,,,105,
2009,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617304,8,Expert,,,105,
2010,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617305,8,Expert,,,105,449.0
2011,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,1,D,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL617306,9,Autocuration,9606.0,,105,
2012,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL617307,8,Autocuration,,,17106,
2013,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617308,8,Autocuration,9986.0,,105,
2014,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617309,8,Autocuration,,,105,
2015,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617310,8,Autocuration,,,105,
2016,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617311,8,Autocuration,,,105,
2017,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617312,8,Autocuration,,,105,
2018,Affinity against 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617313,8,Autocuration,,,105,
2019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL617314,8,Expert,,,105,
2020,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,H,,,,,,,,,BAO_0000019,CHEMBL617315,8,Autocuration,,,106,
2021,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617316,8,Autocuration,,,106,722.0
2022,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617317,8,Autocuration,,,106,722.0
2023,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617318,8,Autocuration,,,106,449.0
2024,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,H,,,,,,,,,BAO_0000019,CHEMBL617319,8,Autocuration,,,106,
2025,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,D,,,,,,,,,BAO_0000357,CHEMBL617320,9,Expert,,,106,
2026,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,D,,,,,,,,,BAO_0000357,CHEMBL617321,9,Expert,,,106,
2027,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,D,,,,,,,,,BAO_0000357,CHEMBL617322,9,Expert,,,106,
2028,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616862,8,Autocuration,,,106,
2029,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616863,8,Autocuration,,,106,
2030,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616864,8,Autocuration,,,106,449.0
2031,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616865,8,Autocuration,,,106,485.0
2032,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616866,8,Autocuration,,,106,485.0
2033,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,H,,,,,,,,,BAO_0000019,CHEMBL616867,8,Autocuration,,,106,
2034,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616868,8,Expert,,,106,485.0
2035,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,1,H,,,,,,,,,BAO_0000357,CHEMBL616869,8,Expert,,,105,
2036,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616870,8,Expert,,,106,449.0
2037,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616871,8,Autocuration,,,105,485.0
2038,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616872,8,Autocuration,,,105,485.0
2039,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616873,8,Autocuration,,,105,485.0
2040,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616838,8,Autocuration,,,105,485.0
2041,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616839,8,Autocuration,,,105,
2042,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL616840,8,Autocuration,9986.0,,106,
2043,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616841,8,Autocuration,,,105,
2044,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616842,8,Autocuration,,,105,
2045,Binding affinity against 5-hydroxytryptamine 1D receptor beta,1,H,,,,,,,,,BAO_0000357,CHEMBL857976,8,Expert,,,105,
2046,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616843,8,Autocuration,,,10618,449.0
2047,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616844,9,Expert,9606.0,,10618,
2048,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,1,H,,,,,,,,,BAO_0000357,CHEMBL616845,8,Autocuration,,,10618,
2049,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616846,9,Expert,9606.0,,10618,
2050,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616847,8,Autocuration,,,10618,
2051,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL616848,8,Autocuration,,,10618,
2052,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616849,8,Autocuration,,,10618,
2053,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL872911,8,Autocuration,,,10618,
2054,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616850,8,Autocuration,,,10618,
2055,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616699,9,Expert,9606.0,,10618,449.0
2056,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616700,8,Autocuration,,,10618,
2057,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616701,8,Autocuration,,,10618,449.0
2058,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616702,8,Autocuration,,,10618,449.0
2059,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616703,8,Autocuration,,,10618,449.0
2060,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616704,8,Autocuration,,,10618,
2061,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616705,8,Autocuration,,,10618,449.0
2062,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616706,8,Autocuration,,,10618,
2063,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616707,8,Autocuration,,,10618,449.0
2064,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616708,8,Autocuration,,,10618,
2065,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616709,8,Autocuration,,,10618,
2066,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616710,8,Autocuration,,,10618,449.0
2067,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616711,8,Autocuration,,,10618,449.0
2068,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616712,8,Autocuration,,,10618,449.0
2069,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616713,8,Autocuration,,,10618,
2070,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616714,8,Autocuration,,,10618,
2071,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616715,8,Autocuration,,,10618,
2072,Binding affinity towards 5-hydroxytryptamine 1E receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616716,8,Autocuration,,,10618,
2073,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL616717,8,Autocuration,,,279,
2074,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL616718,8,Expert,,,279,
2075,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL875905,8,Autocuration,,,279,
2076,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616719,8,Autocuration,,,279,
2077,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",1,H,,,,,,,,,BAO_0000019,CHEMBL616720,8,Expert,,,279,
2078,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616721,8,Autocuration,,,279,
2079,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616722,8,Autocuration,,,279,449.0
2080,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL616723,8,Autocuration,,,279,
2081,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL616724,8,Autocuration,,,279,449.0
2082,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616725,8,Autocuration,,,279,
2083,Binding affinity towards human 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616726,8,Autocuration,,,279,
2084,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL616727,8,Autocuration,,,279,
2085,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL616728,8,Autocuration,,,279,
2086,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL616729,8,Autocuration,,,279,
2087,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616730,8,Expert,,,279,
2088,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617125,8,Autocuration,,,279,
2089,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL857977,8,Autocuration,,,279,
2090,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617126,8,Autocuration,,,279,449.0
2091,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617127,8,Autocuration,,,279,449.0
2092,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617128,8,Autocuration,,,279,
2093,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617129,8,Autocuration,,,279,449.0
2094,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617130,8,Autocuration,,,279,
2095,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617131,8,Autocuration,,,279,449.0
2096,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617132,8,Autocuration,,,279,449.0
2097,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617133,8,Autocuration,,,279,449.0
2098,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617134,8,Autocuration,,,279,
2099,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617135,8,Autocuration,,,279,
2100,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617136,8,Autocuration,,,279,
2101,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL617137,4,Autocuration,,,104686,
2102,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL617138,4,Autocuration,,,104686,
2103,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,H,,,,,,,,,BAO_0000019,CHEMBL617139,4,Autocuration,,,104686,
2104,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617140,8,Autocuration,,,12687,
2105,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",1,H,,,,,,,,,BAO_0000218,CHEMBL617141,4,Autocuration,,,104686,
2106,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,H,,,,,,,,,BAO_0000019,CHEMBL858112,4,Autocuration,,,104686,
2107,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617142,8,Intermediate,,,17005,
2108,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL617143,0,Autocuration,9913.0,,22226,
2109,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL617144,0,Autocuration,9913.0,,22226,
2110,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL617145,0,Autocuration,9913.0,,22226,
2111,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL617146,0,Autocuration,,,22226,
2112,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617147,4,Autocuration,10141.0,,104784,
2113,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617148,4,Autocuration,10141.0,,104784,
2114,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617149,4,Autocuration,10141.0,,104784,
2115,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL617150,4,Autocuration,,,104784,
2116,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL617151,4,Autocuration,,,104784,
2117,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617201,4,Autocuration,,,104784,
2118,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,H,,,,,,,,,BAO_0000357,CHEMBL617202,8,Autocuration,,,10209,
2119,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,H,,,,,,,,,BAO_0000218,CHEMBL617203,4,Autocuration,,,104826,
2120,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617204,4,Autocuration,,,104826,
2121,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,1,H,,,,,,,,,BAO_0000224,CHEMBL617205,4,Autocuration,,,104826,
2122,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,1,D,,Mus musculus,,,,,,,BAO_0000019,CHEMBL617206,5,Autocuration,10090.0,,104826,
2123,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,H,,,,,,,,,BAO_0000218,CHEMBL617207,4,Autocuration,,,104826,
2124,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,1,D,,Mus musculus,,,,,,,BAO_0000019,CHEMBL617208,5,Autocuration,10090.0,,104826,
2125,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617209,4,Autocuration,,,104826,
2126,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,1,H,,,,,,,,,BAO_0000224,CHEMBL617210,4,Autocuration,,,104826,
2127,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,1,H,,,,,,,,,BAO_0000224,CHEMBL617211,4,Autocuration,,,104826,
2128,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,D,,Mus musculus,,,,,,,BAO_0000019,CHEMBL617212,5,Autocuration,10090.0,,104826,
2129,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,1,H,,Sus scrofa,,,,,,,BAO_0000224,CHEMBL617213,4,Autocuration,9823.0,,104784,
2130,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,1,H,,Sus scrofa,,,,,,,BAO_0000224,CHEMBL617214,4,Autocuration,9823.0,,104784,
2131,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,U,,,,,,,,,BAO_0000221,CHEMBL617215,0,Autocuration,,,22226,
2132,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,U,,,,,,,,,BAO_0000221,CHEMBL617216,0,Autocuration,,,22226,
2133,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL617217,8,Autocuration,9823.0,,17005,
2134,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617218,4,Autocuration,,,104686,
2135,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL872913,4,Autocuration,,,104686,
2136,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,1,H,,,,,,,,,BAO_0000019,CHEMBL617219,4,Autocuration,,,104826,
2137,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL873482,4,Autocuration,,,104686,
2138,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617220,5,Autocuration,10116.0,,104686,
2139,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,1,H,,,,,,,,,BAO_0000019,CHEMBL617221,4,Autocuration,,,104686,
2140,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,1,H,,,,,,,,,BAO_0000019,CHEMBL617222,4,Autocuration,,,104686,
2141,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,1,H,,,,,,,,,BAO_0000019,CHEMBL875906,4,Autocuration,,,104686,
2142,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,1,H,,,,,,,,,BAO_0000019,CHEMBL617223,4,Autocuration,,,104686,
2143,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617224,4,Autocuration,,,104686,
2144,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617225,5,Autocuration,10116.0,,104686,
2145,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,1,H,,,,,,,,,BAO_0000224,CHEMBL617226,4,Autocuration,,,104686,
2146,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL617227,4,Autocuration,,,104686,
2147,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL617228,4,Autocuration,,,104686,
2148,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,H,,,,,,,,,BAO_0000224,CHEMBL617229,4,Autocuration,,,104686,
2149,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,H,,,,,,,,,BAO_0000224,CHEMBL617230,4,Autocuration,,,104686,
2150,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,H,,,,,,,,,BAO_0000224,CHEMBL617231,4,Autocuration,,,104686,
2151,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617232,4,Autocuration,,,104686,
2152,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617233,4,Autocuration,,,104686,
2153,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,1,H,,,,,,,,,BAO_0000224,CHEMBL617234,4,Autocuration,,,104686,
2154,Compound was tested for the inhibition of quipazine induced head twitches in rats,1,H,,,,,,,,,BAO_0000019,CHEMBL617235,4,Autocuration,,,104686,
2155,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617236,4,Autocuration,,,104686,
2156,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL617237,4,Autocuration,,,104686,
2157,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL617238,4,Autocuration,,,104686,
2158,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,1,D,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000221,CHEMBL617239,5,Autocuration,10116.0,,104686,
2159,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617240,4,Autocuration,,,104686,
2160,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL617241,4,Autocuration,,,104686,
2161,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL875907,4,Autocuration,,,104686,
2162,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL617242,4,Autocuration,,,104686,
2163,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,1,H,,,,,,,,,BAO_0000019,CHEMBL617152,4,Autocuration,,,104686,
2164,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,D,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000221,CHEMBL617153,5,Autocuration,10116.0,,104686,
2165,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL617154,5,Autocuration,10116.0,,104686,
2166,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617155,4,Autocuration,,,104686,
2167,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,H,,,,,,,,,BAO_0000019,CHEMBL617156,4,Autocuration,,,104686,
2168,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,1,H,,,,,,,,,BAO_0000019,CHEMBL617157,4,Autocuration,,,104686,
2169,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,H,,,,,,,,,BAO_0000019,CHEMBL617158,4,Autocuration,,,104686,
2170,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,H,,,,,,,,,BAO_0000019,CHEMBL617159,4,Autocuration,,,104686,
2171,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,H,,,,,,,,,BAO_0000019,CHEMBL617160,4,Autocuration,,,104686,
2172,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,H,,,,,,,,,BAO_0000019,CHEMBL858113,4,Autocuration,,,104686,
2173,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,1,H,,,,,,Brain,,955.0,BAO_0000220,CHEMBL617247,4,Autocuration,,,104686,
2174,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617248,4,Autocuration,,,104686,
2175,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,H,,,,,,Brain,,955.0,BAO_0000249,CHEMBL617249,4,Autocuration,,,104686,
2176,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617250,4,Autocuration,,,104686,
2177,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617251,4,Autocuration,,,104686,
2178,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617252,5,Autocuration,10116.0,,104686,
2179,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617006,4,Autocuration,,,104686,
2180,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617007,4,Autocuration,,,104686,
2181,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",1,H,,,,,,,,,BAO_0000019,CHEMBL617008,4,Autocuration,,,104686,
2182,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,1,H,,,,,,,,,BAO_0000019,CHEMBL617009,4,Autocuration,,,104686,
2183,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617010,5,Autocuration,10116.0,,104686,
2184,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL857978,5,Autocuration,10116.0,,104686,
2185,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617011,5,Autocuration,10116.0,,104686,
2186,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617012,5,Autocuration,10116.0,,104686,
2187,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL617013,4,Autocuration,,,104686,
2188,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617014,4,Autocuration,,,104686,
2189,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617015,4,Autocuration,,,104686,
2190,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617016,4,Autocuration,,,104686,
2191,pKi value for 5-hydroxytryptamine 2 receptor binding site,1,H,,,,,,,,,BAO_0000224,CHEMBL617017,4,Autocuration,,,104686,
2192,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617018,4,Autocuration,,,104686,
2193,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,H,,,,,,,,,BAO_0000019,CHEMBL617019,4,Autocuration,,,104686,
2194,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617020,4,Autocuration,,,105075,
2195,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617021,4,Autocuration,,,105075,
2196,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617022,4,Autocuration,,,105075,
2197,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617023,4,Autocuration,,,105075,
2198,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617024,4,Autocuration,,,105075,
2199,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617025,4,Autocuration,,,105075,
2200,Hill coefficient of compound was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL617026,4,Autocuration,,,105075,
2201,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,1,U,,,,,,,,,BAO_0000019,CHEMBL617027,0,Autocuration,,,22226,
2202,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617028,5,Autocuration,10116.0,,104686,
2203,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617029,8,Expert,,,12687,
2204,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,1,H,,,,,,,,,BAO_0000019,CHEMBL875908,8,Expert,,,12687,
2205,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),1,H,,,,,,,,,BAO_0000357,CHEMBL617030,8,Autocuration,,,12687,
2206,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),1,H,,,,,,,,,BAO_0000019,CHEMBL617031,8,Autocuration,,,12687,
2207,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617032,8,Autocuration,,,12687,
2208,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617033,5,Autocuration,10116.0,,104686,
2209,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",1,H,,,,,,,,,BAO_0000224,CHEMBL617034,4,Autocuration,,,104686,
2210,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL617035,4,Autocuration,,,104686,
2211,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,H,,,,,,,,,BAO_0000019,CHEMBL617036,4,Autocuration,,,104686,
2212,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617037,4,Autocuration,,,104784,
2213,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,1,U,,,,,,,,,BAO_0000219,CHEMBL617038,0,Autocuration,,,22226,
2214,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",1,H,,,,,,,,,BAO_0000219,CHEMBL617039,4,Autocuration,,,104784,
2215,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617161,4,Autocuration,,,104784,
2216,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617162,4,Autocuration,,,104784,
2217,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617163,4,Autocuration,,,104784,
2218,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617164,4,Autocuration,,,104784,
2219,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL617165,4,Autocuration,,,104784,
2220,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL617166,4,Autocuration,,,104784,
2221,Binding affinity towards 5-HT2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617167,4,Autocuration,,,104784,
2222,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL872912,4,Autocuration,,,104784,
2223,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,1,H,,,,,,,,,BAO_0000224,CHEMBL617168,4,Autocuration,,,104784,
2224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,1,H,,,,,,,,,BAO_0000224,CHEMBL617169,4,Autocuration,,,104686,
2225,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617170,4,Autocuration,,,104784,
2226,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL617171,4,Autocuration,,,104784,
2227,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL617172,4,Autocuration,,,104784,
2228,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617173,4,Autocuration,,,104784,
2229,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,U,,,,,,,,,BAO_0000019,CHEMBL617174,0,Autocuration,,,22226,
2230,5-hydroxytryptamine 2 receptor binding affinity,1,H,,,,,,,,,BAO_0000224,CHEMBL617175,4,Autocuration,,,104784,
2231,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617176,8,Autocuration,,,17005,
2232,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617177,8,Autocuration,,,17005,
2233,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,H,,,,,,,,,BAO_0000224,CHEMBL617178,4,Autocuration,,,104784,
2234,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,1,H,,,,,,,,,BAO_0000224,CHEMBL617179,4,Autocuration,,,104784,
2235,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,H,,,,,,,,,BAO_0000224,CHEMBL617180,4,Autocuration,,,104784,
2236,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL617181,8,Autocuration,,,17005,
2237,Binding affinity against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617182,8,Autocuration,,,17005,
2238,Binding affinity against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617183,8,Autocuration,,,17005,
2239,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617184,8,Autocuration,,,17005,
2240,Binding affinity against serotonergic 5-HT2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617185,8,Autocuration,,,17005,
2241,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617186,8,Autocuration,,,17005,
2242,Compound was evaluated for the binding affinity at 5- HT2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617187,8,Autocuration,,,17005,
2243,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617188,8,Autocuration,,,17005,
2244,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000218,CHEMBL617189,8,Autocuration,,,17005,
2245,Inhibitory activity against cloned human 5-HT2 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000224,CHEMBL617190,5,Autocuration,9606.0,,104784,
2246,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617191,5,Autocuration,9606.0,,104784,449.0
2247,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617192,5,Autocuration,9606.0,,104784,449.0
2248,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617193,5,Autocuration,9606.0,,104784,449.0
2249,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617194,5,Autocuration,9606.0,,104784,449.0
2250,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617195,4,Autocuration,,,104784,
2251,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL881830,4,Autocuration,,,104784,
2252,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617196,8,Autocuration,,,17005,
2253,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,1,H,,,,,,,,,BAO_0000224,CHEMBL617197,4,Autocuration,,,104686,
2254,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617198,8,Expert,,,17005,
2255,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL873476,8,Expert,,,17005,
2256,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,1,H,,,,,,,,,BAO_0000019,CHEMBL617199,8,Expert,,,17005,
2257,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL617200,8,Autocuration,10141.0,,107,
2258,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617484,8,Autocuration,,,51,
2259,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617485,8,Autocuration,,,107,
2260,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617486,8,Autocuration,,,51,
2261,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL858022,8,Autocuration,,,107,
2262,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617049,8,Autocuration,,,107,449.0
2263,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617050,9,Expert,9606.0,,107,449.0
2264,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,H,,,,,,,,,BAO_0000219,CHEMBL617051,8,Autocuration,,,107,
2265,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,1,H,,,,,,,,,BAO_0000219,CHEMBL617052,8,Autocuration,,,107,
2266,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,H,,,,,,,,,BAO_0000219,CHEMBL617053,8,Autocuration,,,107,
2267,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617054,8,Autocuration,,,107,449.0
2268,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617055,8,Autocuration,,,107,449.0
2269,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,1,H,,,,,,,,,BAO_0000357,CHEMBL882924,8,Autocuration,,,107,
2270,Inhibition of human 5-hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617056,9,Expert,9606.0,,107,
2271,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617057,8,Autocuration,,,107,449.0
2272,Inhibitory concentration against human 5-HT2A receptor in BEK cells,1,H,,,,,,,,,BAO_0000219,CHEMBL617058,8,Expert,,,107,
2273,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL617059,8,Autocuration,,,107,
2274,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617060,8,Autocuration,,,107,449.0
2275,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617061,8,Expert,,,107,449.0
2276,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,1,H,,,,,,,L929,,BAO_0000219,CHEMBL617062,8,Expert,,,107,307.0
2277,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617063,8,Expert,,,107,449.0
2278,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617064,8,Autocuration,,,107,
2279,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617065,8,Autocuration,,,107,
2280,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617066,8,Autocuration,,,107,449.0
2281,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617067,8,Autocuration,,,107,449.0
2282,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617068,8,Autocuration,,,107,
2283,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617069,8,Autocuration,,,107,
2284,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617070,8,Autocuration,,,107,
2285,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617071,8,Autocuration,,,107,
2286,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL872915,8,Autocuration,,,107,
2287,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617072,8,Autocuration,,,107,
2288,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,1,H,,,,,,,,,BAO_0000357,CHEMBL617073,8,Autocuration,,,107,
2289,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617074,8,Autocuration,,,107,
2290,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617075,8,Expert,,,107,449.0
2291,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617076,8,Autocuration,,,107,
2292,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL617077,9,Expert,9606.0,,107,
2293,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617078,8,Expert,,,107,
2294,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617079,9,Expert,9606.0,,107,
2295,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617080,8,Autocuration,,,107,
2296,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617081,8,Expert,,,107,449.0
2297,Binding affinity towards human 5-HT2A receptor in BEK cells,1,H,,,,,,,,,BAO_0000219,CHEMBL617082,8,Expert,,,107,
2298,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617083,8,Autocuration,,,107,
2299,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617084,8,Autocuration,,,107,
2300,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617085,9,Expert,9606.0,,107,
2301,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617086,8,Autocuration,,,107,
2302,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,1,H,,,,,,,,,BAO_0000219,CHEMBL617087,8,Autocuration,,,107,
2303,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617088,8,Autocuration,,,107,
2304,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617089,8,Autocuration,,,107,
2305,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL617090,8,Expert,,,107,
2306,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617513,8,Autocuration,,,107,
2307,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617514,8,Autocuration,,,107,722.0
2308,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617515,8,Autocuration,,,107,
2309,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617516,8,Autocuration,,,107,
2310,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617517,9,Expert,9606.0,,107,
2311,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617518,9,Expert,9606.0,,107,449.0
2312,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617519,8,Autocuration,,,107,
2313,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617520,9,Expert,9606.0,,107,
2314,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,1,H,,,,,,,,,BAO_0000357,CHEMBL617521,8,Autocuration,,,107,
2315,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617522,9,Expert,9606.0,,107,
2316,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617523,8,Autocuration,,,107,
2317,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617524,8,Autocuration,,,107,
2318,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617525,4,Autocuration,,,104686,
2319,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617526,5,Autocuration,10116.0,,104686,
2320,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,1,H,,,,,,,,,BAO_0000224,CHEMBL617527,4,Autocuration,,,104686,
2321,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL617528,4,Autocuration,,,104686,
2322,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL617529,4,Autocuration,,,104686,
2323,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,1,H,,,,,,,,,BAO_0000224,CHEMBL617530,4,Autocuration,,,104686,
2324,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617531,4,Autocuration,,,104686,
2325,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617532,4,Autocuration,,,104686,
2326,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617533,4,Autocuration,,,104686,
2327,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617534,4,Autocuration,,,104686,
2328,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL617535,4,Autocuration,,,104686,
2329,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,H,,,,,,,,,BAO_0000224,CHEMBL617536,4,Autocuration,,,104686,
2330,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617537,4,Autocuration,,,104686,
2331,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617538,4,Autocuration,,,104686,
2332,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,H,,,,,,,,,BAO_0000219,CHEMBL617539,4,Autocuration,,,104686,
2333,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617540,5,Autocuration,10116.0,,104686,
2334,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617541,5,Autocuration,10116.0,,104686,
2335,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617542,4,Autocuration,,,104686,
2336,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,1,H,,,,,,,,,BAO_0000224,CHEMBL617543,4,Autocuration,,,104686,
2337,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,D,,Rattus norvegicus,,,,,CHO-K1,,BAO_0000219,CHEMBL617544,5,Autocuration,10116.0,,104686,485.0
2338,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,D,,Rattus norvegicus,,,,,CHO-K1,,BAO_0000219,CHEMBL617545,5,Autocuration,10116.0,,104686,485.0
2339,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617413,5,Autocuration,10116.0,,104686,
2340,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617414,4,Autocuration,,,104686,
2341,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617415,5,Autocuration,10116.0,,104686,
2342,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617416,4,Autocuration,,,104686,
2343,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,H,,,,,,,,,BAO_0000224,CHEMBL617417,4,Autocuration,,,104686,
2344,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",1,H,,,,,,,,,BAO_0000019,CHEMBL617418,4,Autocuration,,,104686,
2345,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617419,4,Autocuration,,,104686,
2346,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,H,,,,,,,,,BAO_0000224,CHEMBL617420,4,Autocuration,,,104686,
2347,Affinity for 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617421,5,Autocuration,10116.0,,104686,
2348,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,1,H,,,,,,,,,BAO_0000224,CHEMBL617422,4,Autocuration,,,104686,
2349,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,1,H,,,,,,,,,BAO_0000019,CHEMBL617423,4,Autocuration,,,104686,
2350,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617424,4,Autocuration,,,104686,
2351,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617425,4,Autocuration,,,104686,
2352,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),1,H,,,,,,,,,BAO_0000224,CHEMBL617426,4,Autocuration,,,104686,
2353,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),1,H,,,,,,,,,BAO_0000218,CHEMBL617427,4,Autocuration,,,104686,
2354,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617428,4,Autocuration,,,104686,
2355,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,1,H,,,,,,,,,BAO_0000224,CHEMBL617429,4,Autocuration,,,104686,
2356,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617430,4,Autocuration,,,104686,
2357,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617431,4,Autocuration,,,104686,
2358,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1,H,,,,,,Frontal cortex,,1870.0,BAO_0000019,CHEMBL617432,4,Autocuration,,,104686,
2359,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617433,4,Autocuration,,,104686,
2360,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617434,4,Autocuration,,,104686,
2361,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617435,5,Autocuration,10116.0,,104686,
2362,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,1,H,,,,,,,,,BAO_0000019,CHEMBL617436,4,Autocuration,,,104686,
2363,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,1,D,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000019,CHEMBL617437,5,Autocuration,10116.0,,104686,
2364,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,H,,,,,,,,,BAO_0000019,CHEMBL617438,4,Autocuration,,,104686,
2365,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,H,,,,,,,,,BAO_0000019,CHEMBL617439,4,Autocuration,,,104686,
2366,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617440,4,Autocuration,,,104686,
2367,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617441,4,Autocuration,,,104686,
2368,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL872918,5,Autocuration,10116.0,,104686,
2369,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617442,5,Autocuration,10116.0,,104686,
2370,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,H,,,,,,,,,BAO_0000019,CHEMBL617443,4,Autocuration,,,104686,
2371,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617444,4,Autocuration,,,104686,
2372,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,H,,,,,,,,,BAO_0000019,CHEMBL617445,4,Autocuration,,,104686,
2373,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617446,4,Autocuration,,,104686,
2374,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL617447,4,Autocuration,,,104686,
2375,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL617448,4,Autocuration,,,104686,
2376,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,1,H,,,,,,,,,BAO_0000019,CHEMBL617449,4,Autocuration,,,104686,
2377,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,1,H,,,,,,,,,BAO_0000019,CHEMBL617450,4,Autocuration,,,104686,
2378,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,1,H,,,,,,,,,BAO_0000019,CHEMBL617451,4,Autocuration,,,104686,
2379,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,1,H,,,,,,,,,BAO_0000019,CHEMBL617452,4,Autocuration,,,104686,
2380,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,1,H,,,,,,,,,BAO_0000019,CHEMBL617453,4,Autocuration,,,104686,
2381,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,1,H,,,,,,,,,BAO_0000019,CHEMBL617660,4,Autocuration,,,104686,
2382,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,1,H,,,,,,,,,BAO_0000019,CHEMBL617661,4,Autocuration,,,104686,
2383,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,1,H,,,,,,,,,BAO_0000019,CHEMBL617662,4,Autocuration,,,104686,
2384,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,1,H,,,,,,,,,BAO_0000019,CHEMBL872919,4,Autocuration,,,104686,
2385,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,1,H,,,,,,,,,BAO_0000019,CHEMBL617663,4,Autocuration,,,104686,
2386,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,1,H,,,,,,,,,BAO_0000019,CHEMBL617664,4,Autocuration,,,104686,
2387,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,1,H,,,,,,,,,BAO_0000019,CHEMBL617665,4,Autocuration,,,104686,
2388,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,1,H,,,,,,,,,BAO_0000019,CHEMBL617666,4,Autocuration,,,104686,
2389,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,1,H,,,,,,,,,BAO_0000019,CHEMBL617667,4,Autocuration,,,104686,
2390,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL617668,4,Autocuration,,,104686,
2391,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL617669,4,Autocuration,,,104686,
2392,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617670,4,Autocuration,,,104686,
2393,Inhibitory constant against 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617671,5,Autocuration,10116.0,,104686,
2394,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617672,4,Autocuration,,,104686,
2395,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,1,H,,,,,,,,,BAO_0000019,CHEMBL617673,4,Autocuration,,,104686,
2396,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL617674,4,Autocuration,,,104686,
2397,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617675,4,Autocuration,,,104686,
2398,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,1,H,,,,,,,,,BAO_0000019,CHEMBL617676,4,Autocuration,,,104686,
2399,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL617677,4,Autocuration,,,104686,
2400,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,1,D,,,,,,,,,BAO_0000019,CHEMBL617678,5,Autocuration,,,104686,
2401,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,1,H,,,,,,,,,BAO_0000224,CHEMBL617679,4,Autocuration,,,104686,
2402,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,1,H,,,,,,,,,BAO_0000224,CHEMBL617680,4,Autocuration,,,104686,
2403,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,1,H,,,,,,,,,BAO_0000019,CHEMBL617681,4,Autocuration,,,104686,
2404,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617682,4,Autocuration,,,104686,
2405,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,1,H,,,,,,,,,BAO_0000224,CHEMBL617683,4,Autocuration,,,104686,
2406,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,1,H,,,,,,,,,BAO_0000224,CHEMBL617684,4,Autocuration,,,104686,
2407,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617685,5,Autocuration,10116.0,,104686,
2408,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617686,4,Autocuration,,,104686,
2409,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,1,H,,,,,,,,,BAO_0000224,CHEMBL617687,4,Autocuration,,,104686,
2410,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617688,4,Autocuration,,,104686,
2411,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,H,,,,,,,,,BAO_0000019,CHEMBL617689,4,Autocuration,,,104686,
2412,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,H,,,,,,,,,BAO_0000019,CHEMBL617690,4,Autocuration,,,104686,
2413,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,H,,,,,,,,,BAO_0000218,CHEMBL617691,4,Autocuration,,,104686,
2414,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,H,,,,,,,,,BAO_0000218,CHEMBL617692,4,Autocuration,,,104686,
2415,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,H,,,,,,,,,BAO_0000218,CHEMBL617693,4,Autocuration,,,104686,
2416,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,H,,,,,,,,,BAO_0000218,CHEMBL617694,4,Autocuration,,,104686,
2417,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL857985,8,Expert,,,12687,
2418,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617695,9,Expert,10116.0,,12687,
2419,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL617696,8,Autocuration,,,12687,
2420,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617697,8,Autocuration,,,12687,
2421,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617257,9,Expert,10116.0,,12687,
2422,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617258,9,Expert,10116.0,,12687,
2423,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,1,H,,,,,,,,,BAO_0000019,CHEMBL617259,8,Expert,,,12687,
2424,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617260,8,Autocuration,,,12687,
2425,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617261,9,Expert,10116.0,,12687,
2426,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617262,8,Autocuration,,,12687,
2427,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617263,8,Expert,,,12687,
2428,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617264,8,Autocuration,,,12687,
2429,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617265,9,Expert,10116.0,,12687,
2430,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL617266,8,Autocuration,,,12687,
2431,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,1,H,,,,,,,,,BAO_0000019,CHEMBL617267,8,Autocuration,,,12687,
2432,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617268,8,Expert,,,12687,
2433,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617269,8,Autocuration,,,12687,449.0
2434,Kinetic inhibition constant evaluated by measuring serotonergic activity,1,H,,,,,,,,,BAO_0000357,CHEMBL617323,8,Expert,,,12687,
2435,Serotonergic activity of the compound.,1,H,,,,,,,,,BAO_0000357,CHEMBL617324,8,Autocuration,,,12687,
2436,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL617325,8,Autocuration,,,12687,
2437,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617326,9,Expert,10116.0,,12687,
2438,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,1,H,,,,,,,,,BAO_0000249,CHEMBL617327,8,Expert,,,12687,
2439,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617328,9,Expert,10116.0,,12687,
2440,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617329,9,Expert,10116.0,,12687,
2441,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617330,9,Expert,10116.0,,12687,
2442,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617331,8,Autocuration,,,12687,
2443,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617332,8,Autocuration,,,12687,
2444,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617333,8,Expert,,,107,
2445,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,1,H,,,,,,,,,BAO_0000357,CHEMBL617334,8,Autocuration,,,107,
2446,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,1,H,,,,,,,,,BAO_0000357,CHEMBL617335,8,Autocuration,,,107,
2447,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,1,H,,,,,,,,,BAO_0000357,CHEMBL617336,8,Autocuration,,,107,
2448,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL617337,8,Autocuration,,,107,
2449,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617338,9,Expert,9606.0,,107,
2450,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617339,8,Autocuration,,,107,
2451,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617340,8,Expert,,,107,
2452,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL617341,8,Autocuration,,,107,
2453,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617342,8,Expert,,,107,
2454,Affinity for 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617343,8,Expert,,,107,
2455,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617344,8,Expert,,,107,723.0
2456,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,H,,,,,,,,,BAO_0000357,CHEMBL617345,8,Expert,,,107,
2457,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617346,8,Expert,,,107,
2458,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617347,8,Autocuration,,,107,
2459,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617348,8,Autocuration,,,107,
2460,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617349,8,Autocuration,,,107,
2461,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617350,8,Autocuration,,,107,
2462,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,1,H,,,,,,,,,BAO_0000357,CHEMBL872339,8,Expert,,,107,
2463,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617351,8,Autocuration,,,107,
2464,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617352,8,Expert,,,107,
2465,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617353,8,Autocuration,,,107,
2466,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617354,8,Autocuration,,,107,
2467,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617355,8,Autocuration,,,107,
2468,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,1,H,,Mus musculus,,,,,CHO,,BAO_0000219,CHEMBL617356,8,Expert,10090.0,,107,449.0
2469,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617357,8,Autocuration,,,107,
2470,Binding affinity at 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617358,8,Autocuration,,,107,
2471,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617359,8,Expert,,,107,
2472,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617360,8,Autocuration,,,107,
2473,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL875913,8,Autocuration,,,107,
2474,Affinity against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617361,8,Autocuration,,,107,
2475,Binding affinity against 5-Hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617362,9,Expert,9606.0,,107,
2476,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL617363,8,Autocuration,,,107,
2477,Tested against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617364,8,Autocuration,,,107,
2478,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL617365,4,Autocuration,,,105075,
2479,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL617366,4,Autocuration,,,105075,
2480,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,1,H,,,,,,,,,BAO_0000224,CHEMBL617367,4,Autocuration,,,105075,
2481,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,H,,,,,,,,,BAO_0000224,CHEMBL617368,4,Autocuration,,,105075,
2482,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),1,H,,,,,,,,,BAO_0000357,CHEMBL617369,8,Autocuration,,,107,
2483,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617370,9,Expert,9606.0,,227,722.0
2484,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617371,9,Expert,9606.0,,227,449.0
2485,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL617372,8,Autocuration,,,227,
2486,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617373,9,Expert,9606.0,,227,
2487,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617374,8,Autocuration,,,227,
2488,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617375,8,Autocuration,,,227,
2489,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617376,8,Autocuration,,,227,
2490,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617377,8,Autocuration,,,227,
2491,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617378,8,Autocuration,,,227,
2492,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617379,8,Autocuration,,,227,
2493,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617380,8,Autocuration,,,227,
2494,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617381,8,Autocuration,,,227,
2495,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617382,8,Autocuration,,,227,
2496,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617383,8,Autocuration,,,107,
2497,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,1,H,,,,,,,,,BAO_0000357,CHEMBL617384,8,Expert,,,107,
2498,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,1,H,,,,,,,,,BAO_0000357,CHEMBL617385,8,Expert,,,107,
2499,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL617386,8,Autocuration,,,107,
2500,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,1,H,,,,,,,,,BAO_0000019,CHEMBL617387,8,Autocuration,,,107,
2501,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617388,8,Autocuration,,,107,723.0
2502,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617389,8,Autocuration,,,107,449.0
2503,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617390,9,Expert,9606.0,,107,449.0
2504,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,1,H,,,,,,,,,BAO_0000224,CHEMBL617391,4,Autocuration,,,104817,
2505,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617392,8,Autocuration,,,107,
2506,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617393,8,Autocuration,,,107,
2507,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,H,,,,,,,L929,,BAO_0000219,CHEMBL617394,8,Autocuration,,,107,307.0
2508,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,H,,,,,,,L929,,BAO_0000219,CHEMBL617395,8,Expert,,,107,307.0
2509,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,1,H,,,,,,,L929,,BAO_0000219,CHEMBL617396,8,Expert,,,107,307.0
2510,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,1,H,,,,,,,L929,,BAO_0000219,CHEMBL617397,8,Autocuration,,,107,307.0
2511,Binding affinity against 5-HT2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617398,8,Autocuration,,,107,
2512,Binding affinity against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617399,8,Autocuration,,,107,
2513,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617400,8,Autocuration,,,107,722.0
2514,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617401,8,Autocuration,,,107,722.0
2515,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617402,9,Expert,9606.0,,107,722.0
2516,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617403,9,Expert,9606.0,,107,722.0
2517,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,1,H,,,,,,,,,BAO_0000357,CHEMBL617404,8,Expert,,,107,
2518,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL857981,9,Expert,9606.0,,107,722.0
2519,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617405,9,Expert,9606.0,,107,722.0
2520,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617253,9,Expert,9606.0,,107,722.0
2521,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL617254,8,Expert,,,107,
2522,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617255,8,Autocuration,,,107,722.0
2523,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617256,8,Autocuration,,,107,722.0
2524,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616874,8,Autocuration,,,107,722.0
2525,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL616875,9,Expert,9606.0,,107,722.0
2526,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616876,8,Expert,,,107,722.0
2527,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616877,8,Expert,,,107,722.0
2528,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL616878,9,Expert,9606.0,,107,722.0
2529,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616879,8,Expert,,,107,722.0
2530,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616880,8,Expert,,,107,722.0
2531,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL616881,9,Expert,9606.0,,107,722.0
2532,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL616882,8,Autocuration,,,107,723.0
2533,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL616883,8,Autocuration,,,107,723.0
2534,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL616884,8,Autocuration,,,107,723.0
2535,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616885,8,Autocuration,,,107,722.0
2536,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616886,8,Autocuration,,,107,485.0
2537,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL616887,8,Expert,,,107,485.0
2538,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL616888,9,Expert,9606.0,,107,
2539,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616889,8,Autocuration,,,107,722.0
2540,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616890,8,Autocuration,,,107,722.0
2541,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL616891,9,Expert,9606.0,,107,449.0
2542,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616892,8,Autocuration,,,107,722.0
2543,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL616893,8,Autocuration,,,107,722.0
2544,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL616894,8,Autocuration,,,10620,723.0
2545,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL616895,8,Expert,,,107,723.0
2546,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL616896,8,Autocuration,,,10620,
2547,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617099,8,Autocuration,,,10621,
2548,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617100,8,Autocuration,,,10621,
2549,Binding affinity against rabbit aorta 5-HT2A receptor,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL884532,8,Autocuration,9986.0,,107,
2550,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL617101,8,Expert,9986.0,,107,
2551,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL617102,8,Expert,9986.0,,107,
2552,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617103,8,Autocuration,9986.0,,107,
2553,The compound was tested for binding affinity against 5-HT2A receptor,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000357,CHEMBL617104,8,Expert,9986.0,,107,
2554,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL857979,8,Autocuration,,,10576,485.0
2555,Binding affinity analysed towards 5-HT 2A in rat jugular vein,1,H,,,,,,,,,BAO_0000019,CHEMBL857502,8,Autocuration,,,12687,
2556,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,H,,,,,,,,,BAO_0000019,CHEMBL617105,8,Autocuration,,,12687,
2557,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL858021,8,Autocuration,,,12687,
2558,Binding affinity for 5-HT 2A in rat stomach fundus,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000019,CHEMBL875910,9,Expert,10116.0,,12687,
2559,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,H,,,,,,,,,BAO_0000019,CHEMBL617106,8,Autocuration,,,12687,
2560,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617107,8,Expert,,,12687,723.0
2561,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617108,8,Autocuration,,,12687,
2562,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617109,8,Autocuration,,,12687,
2563,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617110,8,Autocuration,,,12687,
2564,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,1,H,,,,,,,,,BAO_0000357,CHEMBL617111,8,Autocuration,,,12687,
2565,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617112,9,Expert,10116.0,,12687,
2566,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617113,8,Autocuration,,,12687,
2567,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617114,8,Autocuration,,,12687,
2568,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617115,8,Autocuration,,,12687,
2569,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,H,,,,,,,,,BAO_0000219,CHEMBL617116,8,Autocuration,,,12687,
2570,Efficacy at 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617117,8,Autocuration,,,12687,
2571,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,H,,,,,,,,,BAO_0000357,CHEMBL617118,8,Autocuration,,,12687,
2572,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617119,9,Expert,10116.0,,12687,
2573,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617120,9,Expert,10116.0,,12687,
2574,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,D,,Rattus norvegicus,,,,,,,BAO_0000219,CHEMBL617121,9,Expert,10116.0,,12687,
2575,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,H,,,,,,,,,BAO_0000219,CHEMBL617122,8,Autocuration,,,12687,
2576,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617123,8,Autocuration,,,12687,
2577,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,1,H,,,,,,,,,BAO_0000019,CHEMBL617124,8,Expert,,,12687,
2578,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,1,H,,,,,,,,,BAO_0000249,CHEMBL617600,8,Expert,,,12687,
2579,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617601,8,Expert,,,12687,
2580,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL882923,8,Expert,,,12687,
2581,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617602,8,Autocuration,,,12687,
2582,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL617603,8,Autocuration,,,12687,
2583,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617604,8,Autocuration,,,12687,
2584,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617605,8,Expert,,,12687,
2585,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617606,8,Expert,,,12687,
2586,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617607,9,Expert,10116.0,,12687,
2587,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617455,8,Autocuration,,,12687,
2588,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617456,9,Expert,10116.0,,12687,
2589,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),1,H,,,,,,,,,BAO_0000357,CHEMBL617457,8,Expert,,,12687,
2590,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617458,9,Expert,10116.0,,12687,
2591,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617459,9,Expert,10116.0,,12687,
2592,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,1,H,,,,,,,,,BAO_0000357,CHEMBL617460,8,Expert,,,12687,
2593,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",1,H,,,,,,,,,BAO_0000357,CHEMBL617461,8,Expert,,,12687,
2594,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617462,9,Expert,10116.0,,12687,
2595,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,1,H,,,,,,,,,BAO_0000357,CHEMBL617463,8,Autocuration,,,12687,
2596,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",1,H,,,,,,,,,BAO_0000019,CHEMBL617464,8,Autocuration,,,12687,
2597,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",1,H,,,,,,,,,BAO_0000019,CHEMBL617465,8,Autocuration,,,12687,
2598,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617466,8,Expert,,,12687,
2599,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617467,8,Autocuration,,,12687,
2600,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,1,H,,,,,,,,,BAO_0000019,CHEMBL617468,8,Expert,,,12687,
2601,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617469,8,Autocuration,,,12687,
2602,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617470,8,Autocuration,,,12687,
2603,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617471,8,Autocuration,,,12687,
2604,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617472,8,Expert,,,12687,723.0
2605,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL617473,8,Expert,,,12687,
2606,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617474,9,Expert,10116.0,,12687,
2607,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617475,9,Expert,10116.0,,12687,
2608,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617476,8,Autocuration,,,12687,
2609,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617477,8,Expert,,,12687,
2610,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617478,8,Expert,,,12687,723.0
2611,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",1,H,,,,,,,,,BAO_0000221,CHEMBL617479,8,Autocuration,,,12687,
2612,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617480,8,Autocuration,,,12687,
2613,Binding affinity against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617481,8,Expert,,,12687,
2614,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,1,H,,,,,,,,,BAO_0000019,CHEMBL617482,8,Expert,,,12687,
2615,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617483,8,Autocuration,,,12687,
2616,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621528,8,Autocuration,,,12687,
2617,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,1,D,,Rattus norvegicus,,,,,NIH3T3,,BAO_0000219,CHEMBL621529,9,Expert,10116.0,,12687,723.0
2618,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621530,8,Expert,,,12687,
2619,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621531,8,Expert,,,12687,
2620,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL621532,9,Expert,10116.0,,12687,
2621,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621533,8,Expert,,,12687,
2622,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621534,8,Expert,,,12687,449.0
2623,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,1,H,,,,,,,,,BAO_0000019,CHEMBL621535,8,Autocuration,,,12687,
2624,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL621536,8,Autocuration,,,12687,
2625,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621537,8,Autocuration,,,12687,
2626,Binding affinity for 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL621538,9,Expert,10116.0,,12687,
2627,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL621539,8,Autocuration,,,12687,
2628,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL621540,8,Autocuration,,,12687,
2629,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL621541,8,Autocuration,,,12687,
2630,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL621542,8,Autocuration,,,12687,
2631,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,1,H,,,,,,,,,BAO_0000357,CHEMBL621543,8,Expert,,,12687,
2632,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621544,8,Expert,,,12687,
2633,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL621545,9,Expert,10116.0,,12687,
2634,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621546,8,Autocuration,,,12687,
2635,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,1,H,,,,,,,,,BAO_0000357,CHEMBL621547,8,Autocuration,,,12687,
2636,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL618692,8,Expert,,,12687,723.0
2637,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618693,8,Autocuration,,,12687,
2638,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL872922,8,Autocuration,,,12687,
2639,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618694,8,Autocuration,,,12687,
2640,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL618695,9,Expert,10116.0,,12687,
2641,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,1,H,,,,,,,,,BAO_0000357,CHEMBL618696,8,Autocuration,,,12687,
2642,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL618697,8,Expert,,,12687,
2643,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618892,8,Autocuration,,,12687,
2644,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618893,8,Autocuration,,,12687,
2645,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618894,8,Autocuration,,,12687,
2646,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL618895,8,Expert,,,12687,723.0
2647,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL618896,9,Expert,10116.0,,12687,
2648,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,1,H,,,,,,Caudate-putamen,,5383.0,BAO_0000019,CHEMBL618897,8,Autocuration,,,12687,
2649,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618898,8,Autocuration,,,12687,
2650,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL618899,8,Autocuration,,,12687,
2651,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,1,H,,,,,,,,,BAO_0000357,CHEMBL618900,8,Autocuration,,,12687,
2652,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL618901,8,Autocuration,,,12687,
2653,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618902,8,Autocuration,,,12687,
2654,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL618903,9,Expert,10116.0,,12687,
2655,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618904,8,Autocuration,,,12687,
2656,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL618905,8,Autocuration,,,12687,
2657,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL618906,8,Autocuration,,,12687,
2658,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL618907,8,Expert,,,12687,723.0
2659,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,1,H,,,,,,,,,BAO_0000019,CHEMBL618908,8,Autocuration,,,12687,
2660,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617909,8,Autocuration,,,12687,
2661,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617910,8,Expert,,,12687,
2662,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617911,8,Autocuration,,,12687,
2663,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL872923,8,Autocuration,,,12687,
2664,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617912,8,Autocuration,,,12687,
2665,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617913,9,Expert,10116.0,,12687,
2666,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617914,8,Expert,,,12687,
2667,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617915,8,Autocuration,,,12687,
2668,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617916,8,Autocuration,,,12687,
2669,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617917,9,Expert,10116.0,,12687,
2670,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617918,8,Expert,,,12687,
2671,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,1,H,,,,,,,,,BAO_0000019,CHEMBL617919,8,Autocuration,,,12687,
2672,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617920,9,Expert,10116.0,,12687,
2673,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617921,9,Expert,10116.0,,12687,
2674,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL617922,5,Expert,10116.0,,105102,
2675,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617923,8,Autocuration,,,12687,
2676,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617924,8,Autocuration,,,12687,
2677,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617925,8,Autocuration,,,12687,
2678,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617926,9,Expert,10116.0,,12687,
2679,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,1,H,,,,,,,,,BAO_0000357,CHEMBL617927,8,Autocuration,,,12687,
2680,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617928,8,Autocuration,,,12687,
2681,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617929,9,Expert,10116.0,,12687,
2682,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617930,8,Expert,,,12687,
2683,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL617931,8,Autocuration,,,12687,
2684,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL617932,8,Autocuration,,,12687,
2685,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617933,8,Autocuration,,,12687,449.0
2686,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,H,,,,,,,,,BAO_0000019,CHEMBL617934,8,Autocuration,,,12687,
2687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,H,,,,,,,,,BAO_0000019,CHEMBL617935,8,Autocuration,,,12687,
2688,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617936,8,Autocuration,,,12687,
2689,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617937,8,Autocuration,,,12687,
2690,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617938,8,Autocuration,,,12687,
2691,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,1,H,,,,,,,,,BAO_0000218,CHEMBL617939,8,Autocuration,,,12687,
2692,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,1,H,,,,,,,,,BAO_0000218,CHEMBL617940,8,Autocuration,,,12687,
2693,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,1,H,,,,,,,,,BAO_0000218,CHEMBL617941,8,Autocuration,,,12687,
2694,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617942,8,Expert,,,12687,
2695,Ratio of pKi of 5-HT2A to that of D2 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617943,8,Expert,,,12687,
2696,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617944,4,Expert,,,105093,
2697,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617945,4,Expert,,,105093,
2698,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL617946,4,Expert,,,105075,
2699,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,1,H,,,,,,,,,BAO_0000357,CHEMBL617947,8,Autocuration,,,12687,
2700,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL617948,8,Expert,,,12687,
2701,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,1,H,,,,,,,,,BAO_0000019,CHEMBL858116,8,Autocuration,,,12687,
2702,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,1,H,,,,,,,,,BAO_0000019,CHEMBL617949,8,Autocuration,,,12687,
2703,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,1,H,,,,,,,,,BAO_0000019,CHEMBL617950,8,Autocuration,,,12687,
2704,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1,H,,,,,,Thoracic aorta,,1515.0,BAO_0000019,CHEMBL617951,8,Expert,,,12687,
2705,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1,H,,,,,,Thoracic aorta,,1515.0,BAO_0000019,CHEMBL617952,8,Expert,,,12687,
2706,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1,H,,,,,,Thoracic aorta,,1515.0,BAO_0000019,CHEMBL617953,8,Autocuration,,,12687,
2707,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617954,8,Autocuration,,,12687,
2708,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617955,8,Expert,,,12687,
2709,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,H,,,,,,,,,BAO_0000019,CHEMBL857071,8,Autocuration,,,12687,
2710,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL617270,8,Expert,,,12687,
2711,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,1,H,,,,,,,N1E-115,,BAO_0000219,CHEMBL617271,8,Autocuration,,,12687,339.0
2712,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,1,H,,,,,,,N1E-115,,BAO_0000219,CHEMBL617272,8,Autocuration,,,12687,339.0
2713,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,1,H,,,,,,,,,BAO_0000019,CHEMBL617273,8,Autocuration,,,12687,
2714,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617274,9,Expert,10116.0,,12687,
2715,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617275,8,Autocuration,,,108,
2716,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617276,8,Autocuration,,,108,
2717,Binding affinity towards human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617277,8,Autocuration,,,108,
2718,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617278,8,Expert,,,108,
2719,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL617279,8,Expert,,,108,
2720,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617280,8,Expert,,,108,
2721,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617281,8,Autocuration,,,108,
2722,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617282,8,Autocuration,,,108,
2723,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,1,H,,,,,,,,,BAO_0000019,CHEMBL617283,8,Expert,,,108,
2724,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,1,H,,,,,,,,,BAO_0000019,CHEMBL617284,8,Expert,,,108,
2725,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617285,8,Autocuration,,,108,722.0
2726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617286,8,Autocuration,,,108,
2727,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617287,9,Expert,9606.0,,108,
2728,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL617288,8,Expert,,,108,
2729,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617289,8,Autocuration,,,108,
2730,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL872917,8,Autocuration,,,108,
2731,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617290,8,Autocuration,,,108,
2732,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617291,8,Autocuration,,,108,449.0
2733,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617292,8,Autocuration,,,108,449.0
2734,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617293,8,Autocuration,,,108,723.0
2735,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617294,9,Expert,9606.0,,108,449.0
2736,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL617295,8,Expert,,,108,
2737,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617296,8,Autocuration,,,108,
2738,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617297,8,Autocuration,,,108,
2739,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617298,8,Expert,,,108,449.0
2740,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617299,8,Expert,,,108,449.0
2741,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617300,8,Autocuration,,,108,449.0
2742,Binding affinity against 5-HT2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617454,8,Autocuration,,,108,
2743,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617505,8,Autocuration,,,108,722.0
2744,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617506,9,Expert,9606.0,,108,722.0
2745,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617507,9,Expert,9606.0,,108,722.0
2746,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,1,H,,,,,,,,,BAO_0000357,CHEMBL617508,8,Expert,,,108,
2747,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL857982,9,Expert,9606.0,,108,722.0
2748,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617509,9,Expert,9606.0,,108,722.0
2749,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617510,9,Expert,9606.0,,108,722.0
2750,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617511,8,Autocuration,,,108,
2751,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617512,8,Autocuration,,,108,722.0
2752,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617749,8,Autocuration,,,108,722.0
2753,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617750,8,Autocuration,,,108,722.0
2754,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617751,8,Autocuration,,,108,722.0
2755,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617752,8,Expert,,,108,722.0
2756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617753,8,Autocuration,,,108,722.0
2757,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617754,8,Expert,,,108,722.0
2758,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617755,9,Expert,9606.0,,108,722.0
2759,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617756,8,Autocuration,,,108,722.0
2760,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617757,8,Expert,,,108,722.0
2761,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617758,8,Expert,,,108,722.0
2762,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617759,8,Autocuration,,,108,723.0
2763,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617760,8,Autocuration,,,108,722.0
2764,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617761,8,Expert,,,108,485.0
2765,Binding affinity against 5-hydroxytryptamine 2C receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617762,9,Expert,9606.0,,108,
2766,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617763,8,Autocuration,,,108,
2767,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL857983,8,Autocuration,,,108,722.0
2768,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617764,8,Autocuration,,,108,722.0
2769,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL617765,8,Autocuration,,,108,308.0
2770,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617766,8,Autocuration,,,108,
2771,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL617767,8,Autocuration,,,108,
2772,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617768,8,Autocuration,,,108,722.0
2773,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617769,8,Autocuration,,,108,722.0
2774,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL858023,8,Autocuration,,,11864,
2775,Binding affinity analysed on 5-HT 2C in rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617770,8,Autocuration,,,11864,
2776,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617771,8,Autocuration,,,11864,
2777,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,1,H,,,,,,,A9,,BAO_0000219,CHEMBL617772,8,Autocuration,,,11864,625.0
2778,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617773,8,Autocuration,,,11864,723.0
2779,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617850,8,Autocuration,,,11864,723.0
2780,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617851,8,Autocuration,,,11864,723.0
2781,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617852,8,Autocuration,,,11864,
2782,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,1,H,,Mus musculus,,,,Stomach,,945.0,BAO_0000019,CHEMBL858024,8,Autocuration,10090.0,,12689,
2783,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000019,CHEMBL617853,9,Expert,10116.0,,12689,
2784,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617854,8,Expert,,,108,
2785,Binding affinity for 5-hydroxytryptamine 2C receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL873477,8,Expert,9823.0,,108,
2786,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617855,8,Expert,,,108,
2787,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,1,H,,,,,,,,,BAO_0000019,CHEMBL617856,8,Expert,,,108,
2788,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617857,8,Autocuration,,,108,
2789,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617858,8,Autocuration,,,108,
2790,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617859,8,Autocuration,,,108,
2791,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617860,8,Autocuration,,,108,
2792,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617861,8,Autocuration,,,108,
2793,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617862,8,Expert,,,108,
2794,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,H,,,,,,,,,BAO_0000019,CHEMBL617863,8,Autocuration,,,108,
2795,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,1,H,,,,,,,,,BAO_0000249,CHEMBL617864,8,Autocuration,,,108,
2796,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,1,H,,,,,,,,,BAO_0000249,CHEMBL617649,8,Autocuration,,,108,
2797,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL617650,8,Expert,9823.0,,108,
2798,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL617651,8,Expert,9823.0,,108,
2799,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL617652,8,Autocuration,9823.0,,108,
2800,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL857072,8,Autocuration,9823.0,,108,
2801,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL617653,8,Autocuration,9823.0,,108,
2802,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL617654,8,Autocuration,,,12687,
2803,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617655,8,Autocuration,,,12689,
2804,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617656,8,Expert,,,12689,
2805,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617657,8,Autocuration,,,12689,
2806,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,1,H,,,,,,,,,BAO_0000357,CHEMBL617658,8,Autocuration,,,12689,
2807,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617659,9,Expert,10116.0,,12689,
2808,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL617838,9,Expert,10116.0,,12689,
2809,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,1,D,,Rattus norvegicus,,Brain membranes,,,,,BAO_0000249,CHEMBL617839,9,Expert,10116.0,,12689,
2810,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,1,H,,,,,,,,,BAO_0000357,CHEMBL617840,8,Autocuration,,,12689,
2811,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617841,8,Autocuration,,,12689,
2812,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL875915,8,Autocuration,,,12689,
2813,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL617842,8,Expert,,,12689,
2814,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617843,8,Expert,,,12689,723.0
2815,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL617844,8,Expert,,,12689,
2816,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617845,8,Expert,,,12689,
2817,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,1,H,,,,,,,NIH3T3,,BAO_0000219,CHEMBL617846,8,Expert,,,12689,723.0
2818,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617847,8,Autocuration,,,12689,
2819,Binding affinity against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617848,8,Expert,,,12689,
2820,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617849,8,Autocuration,,,12689,
2821,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621507,8,Expert,,,12689,
2822,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621508,8,Expert,,,12689,
2823,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL621509,8,Autocuration,,,12689,
2824,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL621510,8,Autocuration,,,12689,
2825,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL621511,8,Autocuration,,,12689,
2826,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,1,H,,,,,,,A9,,BAO_0000219,CHEMBL621512,8,Expert,,,12689,625.0
2827,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621513,8,Autocuration,,,12689,
2828,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,1,H,,,,,,,,,BAO_0000357,CHEMBL621514,8,Expert,,,12689,
2829,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL621515,8,Expert,,,12689,
2830,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,1,H,,,,,,,,,BAO_0000219,CHEMBL621516,8,Autocuration,,,12689,
2831,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,1,H,,,,,,Caudate-putamen,,5383.0,BAO_0000019,CHEMBL621517,8,Autocuration,,,12689,
2832,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,1,H,,,,,,,,,BAO_0000357,CHEMBL621518,8,Autocuration,,,12689,
2833,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,1,H,,,,,,,,,BAO_0000019,CHEMBL621519,8,Autocuration,,,12689,
2834,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621520,8,Autocuration,,,12689,
2835,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621521,8,Autocuration,,,12689,
2836,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621522,8,Autocuration,,,12689,
2837,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,1,H,,,,,,,,,BAO_0000219,CHEMBL621523,8,Expert,,,12689,
2838,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621524,8,Autocuration,,,12689,
2839,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL621525,9,Expert,10116.0,,12689,
2840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,1,H,,,,,,,,,BAO_0000357,CHEMBL872921,8,Autocuration,,,12689,
2841,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621526,8,Autocuration,,,12689,
2842,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,1,H,,,,,,,,,BAO_0000219,CHEMBL621527,8,Expert,,,12689,
2843,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617865,9,Expert,10116.0,,12689,
2844,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617866,8,Autocuration,,,12689,
2845,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL617867,8,Autocuration,,,12689,
2846,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL617487,8,Autocuration,,,12689,
2847,Binding affinity for 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617488,8,Expert,,,12689,
2848,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617489,8,Autocuration,,,12689,
2849,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617490,8,Autocuration,,,12689,
2850,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617491,8,Autocuration,,,12689,
2851,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,1,H,,,,,,,,,BAO_0000019,CHEMBL617492,8,Autocuration,,,12689,
2852,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,1,H,,,,,,,,,BAO_0000019,CHEMBL617493,8,Autocuration,,,12689,
2853,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617494,8,Autocuration,,,12689,
2854,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617495,9,Expert,10116.0,,12689,
2855,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617496,8,Autocuration,,,12689,
2856,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617497,8,Autocuration,,,12689,485.0
2857,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617498,8,Autocuration,,,12689,
2858,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617499,8,Autocuration,,,12689,
2859,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617500,8,Autocuration,,,12689,
2860,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617501,8,Autocuration,,,108,
2861,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617502,8,Expert,,,108,
2862,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,1,H,,,,,,,,,BAO_0000357,CHEMBL617503,8,Autocuration,,,227,
2863,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617504,8,Autocuration,,,227,
2864,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617406,8,Autocuration,,,227,
2865,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL617407,9,Expert,9606.0,,227,
2866,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617408,8,Autocuration,,,227,
2867,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617409,8,Autocuration,,,227,
2868,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617410,8,Autocuration,,,227,
2869,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617411,8,Autocuration,,,227,
2870,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617412,8,Autocuration,,,227,
2871,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617774,9,Expert,9606.0,,227,
2872,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617775,9,Expert,9606.0,,227,722.0
2873,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617776,9,Expert,9606.0,,227,722.0
2874,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617777,9,Expert,9606.0,,227,449.0
2875,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617778,9,Expert,9606.0,,227,449.0
2876,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617779,8,Autocuration,,,227,722.0
2877,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617780,8,Expert,,,227,722.0
2878,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617781,8,Autocuration,,,227,722.0
2879,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617782,9,Expert,9606.0,,227,722.0
2880,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617783,9,Expert,9606.0,,227,722.0
2881,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617784,8,Autocuration,,,227,
2882,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617785,8,Autocuration,,,227,722.0
2883,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL857984,8,Expert,,,227,722.0
2884,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617786,8,Expert,,,227,722.0
2885,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617787,8,Expert,,,227,722.0
2886,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617788,9,Expert,9606.0,,227,722.0
2887,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL617789,9,Expert,9606.0,,227,722.0
2888,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617790,8,Autocuration,,,227,722.0
2889,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,1,H,,,,,,,CHO-K1,,BAO_0000219,CHEMBL617791,8,Expert,,,227,485.0
2890,Binding affinity against 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617608,8,Expert,,,227,
2891,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617609,8,Autocuration,,,227,722.0
2892,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617610,8,Autocuration,,,227,722.0
2893,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617611,8,Autocuration,,,227,722.0
2894,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617612,8,Autocuration,,,227,722.0
2895,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL617613,8,Autocuration,,,227,722.0
2896,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617614,8,Autocuration,9986.0,,227,
2897,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617615,8,Expert,,,12688,
2898,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000357,CHEMBL858114,8,Expert,,,12688,
2899,Affinity against serotonergic receptor in the isolated rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000357,CHEMBL617616,8,Autocuration,,,12688,
2900,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000019,CHEMBL617617,9,Expert,10116.0,,12688,
2901,Antagonistic against 5-hydroxytryptamine 2B receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL875914,9,Expert,10116.0,,12688,
2902,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617618,8,Autocuration,,,12688,
2903,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000357,CHEMBL617619,9,Expert,10116.0,,12688,
2904,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617620,8,Autocuration,,,12688,
2905,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,1,H,,,,,,,,,BAO_0000019,CHEMBL617621,8,Autocuration,,,12688,
2906,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL617622,8,Autocuration,,,12688,
2907,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000357,CHEMBL617623,9,Expert,10116.0,,12688,
2908,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000357,CHEMBL617624,9,Expert,10116.0,,12688,
2909,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000357,CHEMBL617625,9,Expert,10116.0,,12688,
2910,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000357,CHEMBL617626,9,Expert,10116.0,,12688,
2911,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617627,8,Autocuration,,,12688,
2912,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617628,8,Expert,,,12688,
2913,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL617629,8,Autocuration,,,12688,
2914,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL858115,8,Autocuration,,,12688,
2915,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000019,CHEMBL617630,9,Expert,10116.0,,12688,
2916,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1,H,,,,,,Thoracic aorta,,1515.0,BAO_0000019,CHEMBL617631,8,Autocuration,,,12688,
2917,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,H,,,,,,,,,BAO_0000357,CHEMBL617632,8,Autocuration,,,12688,
2918,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,1,H,,,,,,,,,BAO_0000357,CHEMBL617633,8,Expert,,,12688,
2919,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,H,,,,,,,,,BAO_0000357,CHEMBL617634,8,Autocuration,,,12688,
2920,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,1,H,,,,,,,,,BAO_0000357,CHEMBL617635,8,Autocuration,,,12688,
2922,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000019,CHEMBL617637,9,Autocuration,10116.0,,12688,
2923,Binding affinity against 5-hydroxytryptamine 1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617638,8,Autocuration,,,227,
2924,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617639,8,Autocuration,,,227,
2925,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617640,8,Autocuration,,,227,
2926,Evaluated for the binding affinity to 5-HT 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617641,8,Autocuration,,,227,
2927,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617642,8,Autocuration,,,227,
2928,Binding affinities against 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617643,8,Autocuration,,,227,
2929,Binding affinities towards 5-hydroxytryptamine 2B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617644,8,Autocuration,,,227,
2930,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617645,8,Autocuration,,,227,
2931,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,H,,,,,,,,,BAO_0000357,CHEMBL617646,8,Expert,,,108,
2932,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617647,8,Autocuration,9913.0,,108,
2933,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617648,8,Autocuration,9913.0,,108,
2934,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617875,8,Autocuration,9913.0,,108,
2935,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617876,8,Autocuration,9913.0,,108,
2936,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617877,8,Expert,9913.0,,108,
2937,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617878,8,Expert,9913.0,,108,
2938,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617879,8,Autocuration,9913.0,,108,
2939,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617880,8,Autocuration,10141.0,,108,
2940,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL617881,9,Intermediate,10141.0,,20033,
2941,Binding affinity against 5-HT1A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL857073,8,Autocuration,,,51,
2942,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617882,8,Expert,,,108,449.0
2943,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL617883,9,Expert,9606.0,,108,449.0
2944,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,1,H,,,,,,,,,BAO_0000219,CHEMBL617884,8,Autocuration,,,108,
2945,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617885,8,Autocuration,,,108,449.0
2946,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617886,8,Autocuration,,,108,449.0
2947,Inhibition of human 5-hydroxytryptamine 2C receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617887,9,Expert,9606.0,,108,
2948,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL617888,8,Autocuration,,,108,
2949,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL617889,8,Autocuration,,,108,
2950,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL617890,8,Autocuration,,,108,
2951,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617891,8,Autocuration,,,108,
2952,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL617892,8,Autocuration,,,108,
2953,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617893,8,Expert,,,108,449.0
2954,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617894,8,Expert,,,108,449.0
2955,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617895,8,Expert,,,108,449.0
2956,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL617896,8,Autocuration,,,108,449.0
2957,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL617897,9,Expert,9606.0,,108,
2958,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617898,8,Autocuration,,,108,
2959,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617899,8,Autocuration,,,108,
2960,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,1,H,,Rattus norvegicus,,,,,CHO,,BAO_0000219,CHEMBL617900,8,Expert,10116.0,,108,449.0
2961,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617901,8,Autocuration,,,108,
2962,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL617902,8,Autocuration,,,108,
2963,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617903,8,Autocuration,,,108,
2964,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617904,8,Autocuration,,,108,
2965,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617905,8,Autocuration,,,108,
2966,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,1,H,,,,,,,,,BAO_0000357,CHEMBL617906,8,Autocuration,,,108,
2967,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL617907,8,Autocuration,,,108,
2968,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL617908,8,Autocuration,,,108,
2969,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620617,8,Expert,,,108,449.0
2970,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620618,9,Expert,9606.0,,108,
2971,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL620619,8,Expert,,,108,
2972,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620620,9,Expert,9606.0,,108,
2973,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620621,8,Autocuration,,,108,
2974,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL872920,7,Autocuration,10116.0,,104698,
2975,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,1,H,,,,,,,,,BAO_0000223,CHEMBL620622,6,Autocuration,,,104698,
2976,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620623,7,Autocuration,10116.0,,104698,
2977,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL620624,6,Autocuration,,,104698,
2978,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL620625,6,Autocuration,,,104698,
2979,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,1,H,,,,,,,,,BAO_0000219,CHEMBL620626,6,Autocuration,,,104698,
2980,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL621307,6,Autocuration,,,104698,
2981,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL621308,6,Autocuration,,,104698,
2982,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,1,H,,,,,,,,,BAO_0000223,CHEMBL621309,6,Autocuration,,,104698,
2983,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,1,H,,,,,,,,,BAO_0000223,CHEMBL621310,6,Autocuration,,,104698,
2984,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,1,H,,,,,,,,,BAO_0000223,CHEMBL621311,6,Autocuration,,,104698,
2985,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,H,,,,,,,,,BAO_0000249,CHEMBL621502,6,Autocuration,,,104698,
2986,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,H,,,,,,,,,BAO_0000249,CHEMBL621503,6,Autocuration,,,104698,
2987,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL621504,6,Autocuration,,,104698,
2988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL621505,6,Autocuration,,,104698,
2989,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL621506,6,Autocuration,,,104698,
2990,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,1,H,,,,,,,,,BAO_0000223,CHEMBL619781,6,Autocuration,,,104698,
2991,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,1,H,,,,,,,,,BAO_0000223,CHEMBL619782,6,Autocuration,,,104698,
2992,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL619783,6,Autocuration,,,104698,
2993,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619784,7,Autocuration,10116.0,,104698,
2994,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL619785,6,Autocuration,,,104698,
2995,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL619786,6,Autocuration,,,104698,
2996,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL619787,6,Autocuration,,,104698,
2997,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL872925,6,Autocuration,,,104698,
2998,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL619788,6,Autocuration,,,104698,
2999,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL619789,6,Autocuration,,,104698,
3000,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL619790,6,Autocuration,,,104698,
3001,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL619791,6,Autocuration,,,104698,
3002,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL619792,6,Autocuration,,,104698,
3003,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL619793,6,Autocuration,,,104698,
3004,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL619794,7,Autocuration,10116.0,,104698,
3005,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL619795,6,Autocuration,,,104698,
3006,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,1,H,,,,,,,,,BAO_0000019,CHEMBL619796,6,Autocuration,,,104698,
3007,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,1,H,,,,,,,,,BAO_0000223,CHEMBL620448,6,Autocuration,,,104698,
3008,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,H,,,,,,,,,BAO_0000223,CHEMBL620449,6,Autocuration,,,104698,
3009,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,1,H,,,,,,,,,BAO_0000223,CHEMBL620450,6,Autocuration,,,104698,
3010,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,1,H,,,,,,,,,BAO_0000223,CHEMBL620451,6,Autocuration,,,104698,
3011,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,1,H,,,,,,,,,BAO_0000223,CHEMBL620631,6,Autocuration,,,104698,
3012,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL620632,6,Autocuration,,,104698,
3013,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,1,H,,,,,,,,,BAO_0000019,CHEMBL620633,6,Autocuration,,,104698,
3014,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,1,H,,,,,,,,,BAO_0000223,CHEMBL620634,6,Autocuration,,,104698,
3015,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,H,,,,,,,,,BAO_0000019,CHEMBL620635,6,Autocuration,,,104698,
3016,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620636,6,Autocuration,,,104698,
3017,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620637,6,Autocuration,,,104698,
3018,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620638,6,Autocuration,,,104698,
3019,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620639,6,Autocuration,,,104698,
3020,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620640,6,Autocuration,,,104698,
3021,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620641,6,Autocuration,,,104698,
3022,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620642,6,Autocuration,,,104698,
3023,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620643,6,Autocuration,,,104698,
3024,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620644,6,Autocuration,,,104698,
3025,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620645,6,Autocuration,,,104698,
3026,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620646,6,Autocuration,,,104698,
3027,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620647,6,Autocuration,,,104698,
3028,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620648,6,Autocuration,,,104698,
3029,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620649,6,Autocuration,,,104698,
3030,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620650,6,Autocuration,,,104698,
3031,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620651,6,Autocuration,,,104698,
3032,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL872875,6,Autocuration,,,104698,
3033,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL620652,6,Autocuration,,,104698,
3034,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,1,H,,,,,,,,,BAO_0000019,CHEMBL620653,6,Autocuration,,,104698,
3035,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL857076,6,Autocuration,,,104698,
3036,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620654,7,Autocuration,10116.0,,104698,
3037,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000223,CHEMBL620655,6,Autocuration,,,104698,
3038,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL620656,6,Autocuration,,,104698,
3039,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL620657,6,Autocuration,,,104698,
3040,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,1,H,,,,,,,,,BAO_0000357,CHEMBL620658,8,Autocuration,,,108,
3041,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,1,H,,,,,,,,,BAO_0000357,CHEMBL620659,8,Autocuration,,,108,
3042,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL620660,8,Autocuration,,,108,
3043,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620661,8,Autocuration,,,108,
3044,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620662,8,Autocuration,,,108,
3045,Affinity for 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620663,8,Expert,,,108,
3046,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620664,8,Autocuration,,,108,
3047,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL620665,8,Expert,,,108,
3048,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620666,8,Autocuration,,,108,
3049,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,1,H,,,,,,,,,BAO_0000357,CHEMBL620667,8,Autocuration,,,108,
3050,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,1,H,,,,,,,,,BAO_0000357,CHEMBL620668,8,Expert,,,108,
3051,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620669,8,Autocuration,,,108,
3052,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620670,8,Expert,,,108,
3053,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620671,8,Autocuration,,,108,
3054,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,1,H,,,,,,,,,BAO_0000357,CHEMBL620672,8,Autocuration,,,108,
3055,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,1,H,,,,,,,,,BAO_0000357,CHEMBL620673,8,Autocuration,,,108,
3056,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620674,8,Autocuration,,,108,
3057,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620675,8,Autocuration,,,108,
3058,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL620676,8,Autocuration,,,108,
3059,Affinity against 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL621382,8,Autocuration,,,108,
3060,Binding affinity against 5-hydroxytryptamine 2C receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL621383,9,Expert,9606.0,,108,
3061,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL621384,8,Autocuration,,,108,
3062,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL621385,8,Autocuration,9913.0,,144,
3063,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,1,H,,Bos taurus,,,,,,,BAO_0000357,CHEMBL617989,8,Autocuration,9913.0,,144,
3064,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617990,4,Expert,10141.0,,104714,
3065,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL875085,4,Autocuration,10141.0,,104714,
3066,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617991,4,Autocuration,10141.0,,104714,
3067,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617992,4,Autocuration,10141.0,,104714,
3068,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617993,4,Autocuration,10141.0,,104714,
3069,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617994,4,Autocuration,10141.0,,104714,
3070,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617995,4,Autocuration,10141.0,,104714,
3071,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617996,4,Autocuration,10141.0,,104714,
3072,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617997,4,Autocuration,10141.0,,104714,
3073,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617998,4,Autocuration,10141.0,,104714,
3074,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617999,4,Autocuration,10141.0,,104714,
3075,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618000,4,Autocuration,10141.0,,104714,
3076,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617815,4,Autocuration,10141.0,,104714,
3077,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617816,4,Autocuration,10141.0,,104714,
3078,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617817,4,Autocuration,10141.0,,104714,
3079,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617818,4,Autocuration,10141.0,,104714,
3080,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617819,4,Autocuration,10141.0,,104714,
3081,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,1,H,,Cavia porcellus,,,,,,,BAO_0000223,CHEMBL617820,4,Autocuration,10141.0,,104714,
3082,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617821,4,Autocuration,10141.0,,104714,
3083,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617822,4,Autocuration,10141.0,,104714,
3084,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617823,4,Autocuration,10141.0,,104714,
3085,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617824,4,Autocuration,10141.0,,104714,
3086,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617825,4,Autocuration,10141.0,,104714,
3087,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617826,4,Autocuration,10141.0,,104714,
3088,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617827,4,Autocuration,10141.0,,104714,
3089,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617828,4,Autocuration,10141.0,,104714,
3090,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617829,4,Autocuration,10141.0,,104714,
3091,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617830,4,Autocuration,10141.0,,104714,
3092,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617831,4,Autocuration,10141.0,,104714,
3093,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617832,4,Autocuration,10141.0,,104714,
3094,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,U,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL617833,0,Autocuration,10141.0,,22226,
3095,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,1,H,,,,,,,,,BAO_0000357,CHEMBL617834,8,Autocuration,,,51,
3096,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000223,CHEMBL617835,5,Expert,9606.0,,104714,
3097,Binding affinity towards 5-HT3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL617836,4,Autocuration,,,104714,
3098,Binding activity radioligand.,1,H,,,,,,,,,BAO_0000223,CHEMBL617837,4,Autocuration,,,104714,
3099,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL620392,4,Autocuration,,,104714,
3100,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL620393,4,Autocuration,,,104714,
3101,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL620394,4,Autocuration,,,104714,
3102,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,1,H,,,,,,,,,BAO_0000223,CHEMBL620395,4,Autocuration,,,104714,
3103,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,1,U,,,,,,,,,BAO_0000019,CHEMBL620396,0,Autocuration,,,22226,
3104,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,1,H,,,,,,,NG108-15,,BAO_0000219,CHEMBL620582,4,Expert,,,105030,433.0
3105,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",1,H,,,,,,,,,BAO_0000218,CHEMBL620583,4,Autocuration,,,105030,
3106,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,H,,,,,,,,,BAO_0000019,CHEMBL620584,4,Autocuration,,,105030,
3107,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,1,H,,,,,,,,,BAO_0000224,CHEMBL620585,4,Autocuration,,,105030,
3108,Compound was evaluated for the binding affinity at 5- HT3 receptor,1,H,,,,,,,,,BAO_0000224,CHEMBL620586,4,Autocuration,,,105030,
3109,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,H,,,,,,,,,BAO_0000019,CHEMBL620587,4,Autocuration,,,105030,
3110,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL620588,4,Autocuration,,,105030,
3111,5-hydroxytryptamine 3 receptor agonism in mouse,1,H,,,,,,,,,BAO_0000218,CHEMBL620589,4,Autocuration,,,105030,
3112,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL620590,4,Autocuration,,,105030,
3113,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,H,,,,,,,,,BAO_0000019,CHEMBL617956,4,Autocuration,,,105030,
3114,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,H,,,,,,,,,BAO_0000019,CHEMBL617957,4,Autocuration,,,105030,
3115,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,1,H,,,,,,,,,BAO_0000224,CHEMBL617958,4,Autocuration,,,105030,
3116,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL617959,4,Autocuration,,,105030,
3117,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL617960,4,Autocuration,,,105030,
3118,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,H,,,,,,,,,BAO_0000224,CHEMBL617961,4,Autocuration,,,105030,
3119,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL617962,4,Autocuration,,,105030,
3120,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,1,H,,,,,,,N1E-115,,BAO_0000219,CHEMBL617963,4,Autocuration,,,105030,339.0
3121,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,H,,,,,,,,,BAO_0000019,CHEMBL617964,8,Autocuration,,,11765,
3122,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,1,H,,,,,,,,,BAO_0000219,CHEMBL617965,8,Autocuration,,,11765,
3123,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL617966,9,Autocuration,10090.0,,10630,
3124,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL857074,8,Autocuration,,,17106,
3125,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL617967,8,Autocuration,9823.0,,144,
3126,Binding activity radioligand.,1,H,,Sus scrofa,,,,,,,BAO_0000357,CHEMBL617968,8,Autocuration,9823.0,,144,
3127,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000223,CHEMBL617969,4,Autocuration,9986.0,,104714,
3128,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000223,CHEMBL617970,4,Autocuration,9986.0,,104714,
3129,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000223,CHEMBL617971,4,Autocuration,9986.0,,104714,
3130,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617972,4,Autocuration,9986.0,,104714,
3131,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617973,4,Autocuration,9986.0,,104714,
3132,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617974,4,Autocuration,9986.0,,104714,
3133,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,H,,Oryctolagus cuniculus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617975,4,Autocuration,9986.0,,104714,
3134,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617976,4,Autocuration,9986.0,,104714,
3135,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617977,4,Autocuration,9986.0,,104714,
3136,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617978,4,Autocuration,9986.0,,104714,
3137,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL617979,4,Autocuration,9986.0,,104714,
3138,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,1,H,,Oryctolagus cuniculus,,,,,CHO,,BAO_0000219,CHEMBL617980,4,Autocuration,9986.0,,104714,449.0
3139,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617981,7,Autocuration,10116.0,,104698,
3140,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),1,H,,,,,,,,,BAO_0000019,CHEMBL617982,8,Autocuration,,,12020,
3141,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),1,H,,,,,,,,,BAO_0000357,CHEMBL617983,8,Autocuration,,,12020,
3142,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617984,7,Autocuration,10116.0,,104698,
3143,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",1,H,,,,,,,,,BAO_0000019,CHEMBL617985,6,Autocuration,,,104698,
3144,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,H,,,,,,Heart,,948.0,BAO_0000218,CHEMBL617986,6,Autocuration,,,104698,
3145,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,H,,,,,,Heart,,948.0,BAO_0000019,CHEMBL617987,6,Autocuration,,,104698,
3146,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,H,,,,,,Heart,,948.0,BAO_0000019,CHEMBL617988,6,Autocuration,,,104698,
3147,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",1,H,,,,,,Heart,,948.0,BAO_0000019,CHEMBL617792,6,Autocuration,,,104698,
3148,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,H,,,,,,Heart,,948.0,BAO_0000019,CHEMBL617793,6,Autocuration,,,104698,
3149,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",1,H,,,,,,,,,BAO_0000019,CHEMBL617794,6,Autocuration,,,104698,
3150,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,H,,,,,,,,,BAO_0000019,CHEMBL617795,6,Autocuration,,,104698,
3151,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,H,,,,,,,,,BAO_0000019,CHEMBL617796,6,Autocuration,,,104698,
3152,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",1,H,,,,,,,,,BAO_0000019,CHEMBL617797,6,Autocuration,,,104698,
3153,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),1,D,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL617798,7,Autocuration,10116.0,,104698,
3154,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),1,H,,,,,,,,,BAO_0000218,CHEMBL617799,6,Autocuration,,,104698,
3155,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,D,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL617800,7,Autocuration,10116.0,,104698,
3156,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617801,7,Autocuration,10116.0,,104698,
3157,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,1,D,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL617802,7,Autocuration,10116.0,,104698,
3158,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617803,7,Autocuration,10116.0,,104698,
3159,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,H,,,,,,,,,BAO_0000019,CHEMBL617804,6,Autocuration,,,104698,
3160,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617805,7,Autocuration,10116.0,,104698,
3161,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL617806,6,Autocuration,,,104698,
3162,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL617807,6,Autocuration,,,104698,
3163,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL617808,6,Autocuration,,,104698,
3164,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL617809,6,Autocuration,,,104698,
3165,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL617810,6,Autocuration,,,104698,
3166,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,1,H,,,,,,Brain,,955.0,BAO_0000249,CHEMBL617811,6,Autocuration,,,104698,
3167,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL617812,6,Autocuration,,,104698,
3168,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617813,6,Autocuration,,,104698,
3169,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,H,,,,,,,,,BAO_0000249,CHEMBL617814,6,Autocuration,,,104698,
3170,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,1,H,,,,,,,,,BAO_0000019,CHEMBL617698,6,Autocuration,,,104698,
3171,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617699,7,Autocuration,10116.0,,104698,
3172,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617700,7,Autocuration,10116.0,,104698,
3173,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL617701,7,Autocuration,10116.0,,104698,
3174,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617702,6,Autocuration,,,104698,
3175,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",1,H,,,,Membranes,,,,,BAO_0000249,CHEMBL617703,6,Autocuration,,,104698,
3176,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617704,7,Autocuration,10116.0,,104698,
3177,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,H,,,,,,,,,BAO_0000223,CHEMBL617705,6,Autocuration,,,104698,
3178,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL617706,7,Autocuration,10116.0,,104698,
3179,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),1,H,,,,,,,NG108-15,,BAO_0000219,CHEMBL617707,6,Autocuration,,,104698,433.0
3180,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,1,H,,,,,,,NG108-15,,BAO_0000219,CHEMBL617708,6,Autocuration,,,104698,433.0
3181,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL617709,6,Autocuration,,,104698,
3182,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,1,H,,,,,,,,,BAO_0000019,CHEMBL617710,6,Autocuration,,,104698,
3183,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,1,H,,,,,,,,,BAO_0000019,CHEMBL882925,6,Autocuration,,,104698,
3184,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,1,H,,,,,,,,,BAO_0000019,CHEMBL617711,6,Autocuration,,,104698,
3185,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,1,H,,,,,,,,,BAO_0000019,CHEMBL617712,6,Autocuration,,,104698,
3186,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL617713,7,Autocuration,10116.0,,104698,
3187,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",1,H,,,,,,,,,BAO_0000019,CHEMBL617714,6,Autocuration,,,104698,
3188,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617715,6,Autocuration,,,104698,
3189,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617716,6,Autocuration,,,104698,
3190,Inhibition of 5-HT evoked reflex bradycardia in rat.,1,H,,,,,,,,,BAO_0000218,CHEMBL617717,6,Autocuration,,,104698,
3191,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617718,6,Autocuration,,,104698,
3192,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617719,6,Autocuration,,,104698,
3193,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),1,H,,,,,,,,,BAO_0000218,CHEMBL617720,6,Autocuration,,,104698,
3194,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,1,D,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL617721,7,Autocuration,10116.0,,104698,
3195,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617722,6,Autocuration,,,104698,
3196,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617723,6,Autocuration,,,104698,
3197,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617724,6,Autocuration,,,104698,
3198,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617725,6,Autocuration,,,104698,
3199,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617726,6,Autocuration,,,104698,
3200,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617727,6,Autocuration,,,104698,
3201,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617728,6,Autocuration,,,104698,
3202,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617729,6,Autocuration,,,104698,
3203,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617730,6,Autocuration,,,104698,
3204,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617731,6,Autocuration,,,104698,
3205,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617732,6,Autocuration,,,104698,
3206,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617733,6,Autocuration,,,104698,
3207,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617734,6,Autocuration,,,104698,
3208,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,1,H,,,,,,,,,BAO_0000218,CHEMBL872874,6,Autocuration,,,104698,
3209,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,1,H,,,,,,,,,BAO_0000218,CHEMBL617735,6,Autocuration,,,104698,
3210,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,1,H,,,,,,,,,BAO_0000218,CHEMBL617736,6,Autocuration,,,104698,
3211,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,1,H,,,,,,,,,BAO_0000218,CHEMBL617737,6,Autocuration,,,104698,
3212,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,1,H,,,,,,,,,BAO_0000218,CHEMBL617738,6,Autocuration,,,104698,
3213,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617739,6,Autocuration,,,104698,
3214,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617740,6,Autocuration,,,104698,
3215,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617741,6,Autocuration,,,104698,
3216,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617742,6,Autocuration,,,104698,
3217,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617743,6,Autocuration,,,104698,
3218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617744,6,Autocuration,,,104698,
3219,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,1,H,,,,,,,,,BAO_0000218,CHEMBL617745,6,Autocuration,,,104698,
3220,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",1,H,,,,,,,,,BAO_0000218,CHEMBL617746,6,Autocuration,,,104698,
3221,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",1,H,,,,,,,,,BAO_0000218,CHEMBL617747,6,Autocuration,,,104698,
3222,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL617748,6,Autocuration,,,104698,
3223,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL618909,6,Autocuration,,,104698,
3224,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL618910,6,Autocuration,,,104698,
3225,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL618911,6,Autocuration,,,104698,
3226,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,1,H,,,,,,,,,BAO_0000218,CHEMBL618912,6,Autocuration,,,104698,
3227,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),1,H,,,,,,,,,BAO_0000218,CHEMBL618913,6,Autocuration,,,104698,
3228,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL618914,6,Autocuration,,,104698,
3229,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL618915,6,Autocuration,,,104698,
3230,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL618916,7,Autocuration,10116.0,,104698,
3231,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL618917,6,Autocuration,,,104698,
3232,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,1,D,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL618918,7,Intermediate,,,104698,
3233,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL618919,7,Autocuration,10116.0,,104698,
3234,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL618920,7,Autocuration,10116.0,,104698,
3235,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL618921,6,Autocuration,,,104698,
3236,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL618922,6,Autocuration,,,104698,
3237,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,1,H,,,,,,,,,BAO_0000019,CHEMBL618923,6,Autocuration,,,104698,
3238,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,1,H,,,,,,,,,BAO_0000019,CHEMBL618924,6,Autocuration,,,104698,
3239,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL618925,6,Autocuration,,,104698,
3240,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,H,,,,,,,,,BAO_0000019,CHEMBL618926,6,Autocuration,,,104698,
3241,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL618927,9,Intermediate,10141.0,,20033,
3242,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL618928,9,Intermediate,10141.0,,20033,
3243,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL618929,9,Intermediate,10141.0,,20033,
3244,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL618930,9,Intermediate,10141.0,,20033,
3245,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL618931,9,Intermediate,10141.0,,20033,
3246,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619594,9,Intermediate,10141.0,,20033,
3247,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619595,9,Intermediate,10141.0,,20033,
3248,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619596,9,Intermediate,10141.0,,20033,
3249,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619755,9,Intermediate,10141.0,,20033,
3250,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619756,9,Intermediate,10141.0,,20033,
3251,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619757,9,Intermediate,10141.0,,20033,
3252,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619758,9,Intermediate,10141.0,,20033,
3253,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619759,9,Intermediate,10141.0,,20033,
3254,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619760,9,Intermediate,10141.0,,20033,
3255,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619761,9,Intermediate,10141.0,,20033,
3256,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619762,9,Intermediate,10141.0,,20033,
3257,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619763,9,Intermediate,10141.0,,20033,
3258,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL617868,9,Intermediate,10141.0,,20033,
3259,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL617869,9,Intermediate,10141.0,,20033,
3260,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000249,CHEMBL882926,9,Intermediate,10141.0,,20033,
3261,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000249,CHEMBL617870,9,Intermediate,10141.0,,20033,
3262,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL617871,9,Intermediate,10141.0,,20033,
3263,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL617872,9,Intermediate,10141.0,,20033,
3264,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL617873,9,Intermediate,10141.0,,20033,
3265,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL617874,9,Intermediate,10141.0,,20033,
3266,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619067,9,Intermediate,10141.0,,20033,
3267,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619068,9,Intermediate,10141.0,,20033,
3268,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619069,9,Intermediate,10141.0,,20033,
3269,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619070,9,Intermediate,10141.0,,20033,
3270,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619071,9,Intermediate,10141.0,,20033,
3271,Agonistic activity against 5-hydroxytryptamine 4 receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619072,9,Intermediate,10141.0,,20033,
3272,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619073,9,Intermediate,10141.0,,20033,
3273,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619074,9,Intermediate,10141.0,,20033,
3274,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619075,9,Intermediate,10141.0,,20033,
3275,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL619076,9,Intermediate,10141.0,,20033,
3276,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL619077,9,Intermediate,10141.0,,20033,
3277,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000249,CHEMBL619078,9,Intermediate,10141.0,,20033,
3278,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000249,CHEMBL619079,9,Intermediate,10141.0,,20033,
3279,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619080,9,Intermediate,10141.0,,20033,
3280,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619081,9,Expert,10141.0,,20033,
3281,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619082,9,Intermediate,10141.0,,20033,
3282,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619083,9,Intermediate,10141.0,,20033,
3283,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619084,9,Intermediate,10141.0,,20033,
3284,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL859397,9,Intermediate,10141.0,,20033,
3285,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619085,9,Intermediate,10141.0,,20033,
3286,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619086,9,Intermediate,10141.0,,20033,
3287,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619087,9,Intermediate,10141.0,,20033,
3288,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619088,9,Intermediate,10141.0,,20033,
3289,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619089,9,Intermediate,10141.0,,20033,
3290,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619090,8,Autocuration,10141.0,,168,
3291,Antagonistic activity against 5-hydroxytryptamine 4 receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619091,9,Intermediate,10141.0,,20033,
3292,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619092,9,Intermediate,10141.0,,20033,
3293,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619093,9,Intermediate,10141.0,,20033,
3294,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,1,H,,Cavia porcellus,,,,,HEK293,,BAO_0000219,CHEMBL619094,8,Autocuration,10141.0,,168,722.0
3295,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619095,9,Intermediate,10141.0,,20033,
3296,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL857988,9,Intermediate,10141.0,,20033,
3297,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619096,9,Intermediate,10141.0,,20033,
3298,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,1,D,,Cavia porcellus,,,,Striatum,,2435.0,BAO_0000357,CHEMBL619097,9,Intermediate,10141.0,,20033,
3299,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,1,D,,Cavia porcellus,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619098,9,Intermediate,10141.0,,20033,
3300,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619751,9,Intermediate,10141.0,,20033,
3301,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619752,9,Intermediate,10141.0,,20033,
3302,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL875096,9,Intermediate,10141.0,,20033,
3303,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,1,H,,,,,,,,,BAO_0000357,CHEMBL619004,8,Autocuration,,,108,
3304,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL619005,8,Autocuration,,,168,
3305,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL619006,8,Autocuration,,,168,
3306,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL619007,8,Autocuration,,,168,308.0
3307,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619008,8,Autocuration,,,168,
3308,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619009,8,Autocuration,,,168,
3309,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL619010,8,Autocuration,,,168,308.0
3310,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,1,H,,,,,,,,,BAO_0000357,CHEMBL619011,8,Autocuration,,,10622,
3311,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,1,H,,,,,,,,,BAO_0000357,CHEMBL619012,8,Autocuration,,,10622,
3312,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL619013,8,Autocuration,,,10622,
3313,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,1,H,,,,,,,,,BAO_0000357,CHEMBL619014,8,Autocuration,,,10622,
3314,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,1,H,,,,,,Cardiac atrium,,2081.0,BAO_0000019,CHEMBL857503,8,Autocuration,,,11249,
3315,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,1,H,,,,,,Cardiac atrium,,2081.0,BAO_0000019,CHEMBL619015,8,Autocuration,,,11249,
3316,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619016,8,Autocuration,,,11249,
3317,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619017,8,Autocuration,,,11249,
3318,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,1,H,,Sus scrofa,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619018,8,Autocuration,9823.0,,168,
3319,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL619019,8,Autocuration,9986.0,,168,
3320,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL619020,9,Expert,10116.0,,10623,
3321,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,H,,,,,,,,,BAO_0000019,CHEMBL619021,8,Autocuration,,,10623,
3322,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,1,H,,,,,,,,,BAO_0000357,CHEMBL619022,8,Autocuration,,,10623,
3323,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,1,H,,,,,,,,,BAO_0000357,CHEMBL619023,8,Autocuration,,,10623,
3324,lntrinsic activity relative to 5-HT receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL619024,8,Autocuration,,,10623,
3325,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,1,H,,,,,,,,,BAO_0000019,CHEMBL619025,8,Autocuration,,,10623,
3326,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,1,H,,,,,,,,,BAO_0000019,CHEMBL619026,8,Expert,,,10623,
3327,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,1,H,,,,,,,,,BAO_0000019,CHEMBL619027,8,Autocuration,,,10623,
3328,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,1,H,,,,,,,,,BAO_0000019,CHEMBL619028,8,Autocuration,,,10623,
3329,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,1,H,,,,,,,,,BAO_0000019,CHEMBL619029,8,Autocuration,,,10623,
3330,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,1,H,,,,,,,,,BAO_0000019,CHEMBL619030,8,Autocuration,,,10623,
3331,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,1,H,,,,,,,,,BAO_0000357,CHEMBL619031,8,Expert,,,10623,
3332,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,1,H,,,,,,,,,BAO_0000019,CHEMBL619032,8,Autocuration,,,10623,
3333,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL619033,9,Expert,10116.0,,10623,
3334,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,H,,,,,,,,,BAO_0000357,CHEMBL619034,8,Autocuration,,,10623,
3335,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,1,H,,,,,,,,,BAO_0000357,CHEMBL619035,8,Autocuration,,,10623,
3336,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL619036,8,Autocuration,,,10623,
3337,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619037,9,Expert,10116.0,,10623,
3338,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,1,H,,,,,,Striatum,,2435.0,BAO_0000249,CHEMBL619038,8,Autocuration,,,10623,
3339,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,1,H,,,,,,,,,BAO_0000249,CHEMBL619039,8,Autocuration,,,10623,
3340,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,1,H,,,,,,,,,BAO_0000249,CHEMBL619040,8,Expert,,,10623,
3341,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,D,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619041,9,Expert,10116.0,,10623,
3342,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619042,8,Autocuration,,,10623,
3343,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,1,H,,,,,,Striatum,,2435.0,BAO_0000249,CHEMBL619043,8,Expert,,,10623,
3344,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619044,8,Expert,,,10623,
3345,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,1,H,,,,,,Striatum,,2435.0,BAO_0000249,CHEMBL619045,8,Expert,,,10623,
3346,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,H,,,,,,Striatum,,2435.0,BAO_0000249,CHEMBL619046,8,Expert,,,10623,
3347,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL619047,8,Expert,,,10623,
3348,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL619048,8,Autocuration,,,10623,
3349,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,1,H,,,,,,,,,BAO_0000019,CHEMBL859398,8,Autocuration,,,10623,
3350,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,1,H,,,,,,,,,BAO_0000019,CHEMBL619049,8,Autocuration,,,10623,
3351,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,1,H,,,,,,,,,BAO_0000019,CHEMBL857886,8,Autocuration,,,10623,
3352,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL619050,8,Autocuration,,,10623,
3353,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,H,,,,,,,,,BAO_0000019,CHEMBL620591,8,Autocuration,,,10623,
3354,Binding affinity against rat 5-hydroxytryptamine 4 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL620592,9,Expert,10116.0,,10623,
3355,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,H,,,,,,Striatum,,2435.0,BAO_0000249,CHEMBL620593,8,Expert,,,10623,
3356,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620594,9,Expert,10116.0,,10623,
3357,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL875079,8,Expert,,,10623,
3358,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL620595,8,Expert,,,10623,
3359,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620596,9,Expert,10116.0,,10623,
3360,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL620597,8,Autocuration,,,10623,
3361,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL620598,8,Expert,,,10623,
3362,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),1,H,,,,,,,,,BAO_0000218,CHEMBL620599,8,Expert,,,10623,
3363,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,H,,,,,,,,,BAO_0000019,CHEMBL620600,8,Autocuration,,,10623,
3364,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,1,H,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620601,8,Autocuration,10116.0,,168,
3365,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620602,8,Autocuration,,,168,
3366,Tested for affinity towards 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620603,8,Autocuration,,,168,
3367,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL620604,8,Autocuration,,,168,
3368,Compound was tested for 5-hydroxytryptamine 4 binding affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL620605,8,Autocuration,,,168,
3369,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620606,8,Autocuration,,,168,
3370,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,H,,,,,,,,,BAO_0000019,CHEMBL620607,8,Autocuration,,,168,
3371,In vitro binding affinity towards 5-HT4 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620608,8,Autocuration,,,168,
3372,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,H,,,,,,,,,BAO_0000019,CHEMBL620609,8,Autocuration,,,168,
3373,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL620610,8,Autocuration,,,168,
3374,Tested for selectivity for 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620611,8,Autocuration,,,168,
3375,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,1,H,,,,,,,,,BAO_0000357,CHEMBL620612,8,Autocuration,,,168,
3376,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,1,H,,,,,,,,,BAO_0000357,CHEMBL620613,8,Autocuration,,,168,
3377,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,1,H,,,,,,,,,BAO_0000357,CHEMBL620614,8,Autocuration,,,168,
3378,Binding affinity against 5-Hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620615,8,Expert,,,168,
3379,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL857075,6,Autocuration,,,104698,
3380,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL620616,6,Autocuration,,,104698,
3381,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,1,H,,,,Brain membranes,,,,,BAO_0000249,CHEMBL619411,6,Autocuration,,,104698,
3382,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,1,H,,,,,,,,,BAO_0000019,CHEMBL619412,6,Autocuration,,,104698,
3383,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619413,7,Autocuration,10116.0,,104698,
3384,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619414,6,Autocuration,,,104698,
3385,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL619415,6,Autocuration,,,104698,
3386,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL619416,6,Autocuration,,,104698,
3387,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,1,H,,,,,,,,,BAO_0000019,CHEMBL619417,6,Autocuration,,,104698,
3388,Binding affinity against rat 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL619418,7,Autocuration,10116.0,,104698,
3389,Binding affinity against 5-Hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL619419,7,Autocuration,10116.0,,104698,
3390,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL619420,6,Autocuration,,,104698,
3391,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,1,H,,,,,,,,,BAO_0000249,CHEMBL619421,6,Autocuration,,,104698,
3392,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619422,7,Autocuration,10116.0,,104698,
3393,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL619423,6,Autocuration,,,104698,
3394,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,1,H,,,,,,,,,BAO_0000019,CHEMBL875080,6,Autocuration,,,104698,
3395,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,1,H,,,,,,,,,BAO_0000019,CHEMBL619424,6,Autocuration,,,104698,
3396,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL619425,6,Autocuration,,,104698,
3397,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,1,H,,,,,,,,,BAO_0000223,CHEMBL619426,6,Autocuration,,,104698,
3398,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,1,H,,,,,,,,,BAO_0000223,CHEMBL619427,6,Autocuration,,,104698,
3399,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000223,CHEMBL619645,7,Autocuration,10116.0,,104698,
3400,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",1,D,,,,,,,,,BAO_0000249,CHEMBL619646,9,Expert,,,10576,
3401,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,1,H,,,,,,Brain,,955.0,BAO_0000221,CHEMBL619647,8,Autocuration,,,12020,
3402,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL619648,8,Autocuration,,,12020,
3403,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,1,H,,,,,,,,,BAO_0000019,CHEMBL619165,8,Autocuration,,,12020,
3404,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000218,CHEMBL620719,8,Autocuration,,,12020,
3405,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL872924,8,Autocuration,,,12020,
3406,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620720,8,Autocuration,,,12020,
3407,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL620721,8,Autocuration,,,12020,
3408,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL620722,8,Autocuration,,,12020,
3409,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",1,H,,,,,,,,,BAO_0000019,CHEMBL620723,6,Autocuration,,,104698,
3410,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,H,,,,,,,,,BAO_0000019,CHEMBL620724,8,Autocuration,,,12020,
3411,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,1,H,,,,,,,,,BAO_0000249,CHEMBL620725,6,Autocuration,,,104698,
3412,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620726,9,Autocuration,10116.0,,12020,
3413,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620727,8,Expert,,,144,
3414,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,1,H,,,,,,,,,BAO_0000223,CHEMBL620728,4,Autocuration,,,104714,
3415,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,U,,,,,,,,,BAO_0000019,CHEMBL620729,0,Autocuration,,,22226,
3416,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,1,H,,,,,,,,,BAO_0000019,CHEMBL858288,4,Autocuration,,,104714,
3417,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL620730,4,Autocuration,,,104714,
3418,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL620731,4,Autocuration,,,104714,
3419,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL620732,4,Autocuration,10141.0,,104714,
3420,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618042,4,Autocuration,10141.0,,104714,
3421,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618043,4,Autocuration,10141.0,,104714,
3422,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL618044,4,Autocuration,,,104714,
3423,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,1,H,,,,,,,,,BAO_0000019,CHEMBL618045,4,Autocuration,,,104714,
3424,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,1,H,,,,,,,,,BAO_0000223,CHEMBL618046,4,Autocuration,,,104714,
3425,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL618047,4,Autocuration,,,104714,
3426,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL875084,4,Autocuration,,,104714,
3427,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,1,H,,,,,,,,,BAO_0000019,CHEMBL618048,4,Autocuration,,,104714,
3428,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,1,H,,,,,,,,,BAO_0000223,CHEMBL618049,4,Autocuration,,,104714,
3429,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL619764,4,Autocuration,,,104714,
3430,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL619765,4,Autocuration,,,104714,
3431,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,1,H,,,,,,,,,BAO_0000019,CHEMBL619766,4,Autocuration,,,104714,
3432,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,1,H,,,,,,,,,BAO_0000223,CHEMBL619767,4,Autocuration,,,104714,
3433,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,1,H,,,,,,,,,BAO_0000223,CHEMBL619768,4,Autocuration,,,104714,
3434,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,1,H,,,,,,,,,BAO_0000019,CHEMBL619769,4,Autocuration,,,104714,
3435,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,1,H,,,,,,,,,BAO_0000223,CHEMBL619770,4,Autocuration,,,104714,
3436,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL619771,4,Autocuration,,,104714,
3437,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,1,H,,,,,,,,,BAO_0000219,CHEMBL619772,4,Autocuration,,,104714,
3438,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,1,H,,,,,,,,,BAO_0000223,CHEMBL619773,4,Autocuration,,,104714,
3439,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,1,H,,,,,,,NG108-15,,BAO_0000219,CHEMBL619774,4,Autocuration,,,104714,433.0
3440,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL875083,4,Autocuration,,,104714,
3441,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,1,H,,,,,,,NG108-15,,BAO_0000219,CHEMBL620718,4,Autocuration,,,104714,433.0
3442,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,H,,,,,,,,,BAO_0000223,CHEMBL618127,4,Autocuration,,,104714,
3443,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,1,H,,,,,,,,,BAO_0000223,CHEMBL618128,4,Autocuration,,,104714,
3444,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,1,H,,,,,,,,,BAO_0000219,CHEMBL618129,4,Autocuration,,,104714,
3445,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,H,,,,,,,,,BAO_0000223,CHEMBL618130,4,Autocuration,,,104714,
3446,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,1,H,,,,,,,,,BAO_0000019,CHEMBL618131,4,Autocuration,,,104714,
3447,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618132,4,Autocuration,10141.0,,104714,
3448,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618133,4,Autocuration,10141.0,,104714,
3449,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618134,4,Autocuration,10141.0,,104714,
3450,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618135,4,Autocuration,10141.0,,104714,
3451,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,1,H,,,,,,,,,BAO_0000223,CHEMBL618136,4,Autocuration,,,104714,
3452,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL618137,4,Autocuration,,,104714,
3453,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,1,H,,,,,,,,,BAO_0000223,CHEMBL618138,4,Autocuration,,,104714,
3454,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,1,H,,,,,,,,,BAO_0000223,CHEMBL618139,4,Autocuration,,,104714,
3455,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,1,H,,,,,,,,,BAO_0000223,CHEMBL618140,4,Autocuration,,,104714,
3456,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,1,H,,,,,,,,,BAO_0000223,CHEMBL618141,4,Autocuration,,,104714,
3457,Binding affinity for 5-hydroxytryptamine 2C receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL873478,8,Expert,,,108,
3458,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL618142,6,Autocuration,,,104698,
3459,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618143,8,Autocuration,,,144,
3460,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618144,8,Autocuration,,,144,
3461,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618145,8,Autocuration,,,144,
3462,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,H,,,,,,,,,BAO_0000223,CHEMBL618146,4,Autocuration,,,104714,
3463,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,1,H,,,,,,,,,BAO_0000223,CHEMBL618147,4,Autocuration,,,104714,
3464,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,H,,,,,,,,,BAO_0000223,CHEMBL618148,4,Autocuration,,,104714,
3465,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,H,,,,,,,,,BAO_0000019,CHEMBL618149,8,Autocuration,,,144,
3466,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL872927,8,Autocuration,,,144,
3467,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618150,8,Autocuration,,,144,
3468,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL618151,8,Autocuration,,,144,
3469,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL875094,8,Autocuration,,,144,
3470,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,H,,,,,,,,,BAO_0000019,CHEMBL618152,8,Autocuration,,,144,
3471,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL618153,8,Autocuration,,,144,
3472,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618888,8,Autocuration,,,144,
3473,Tested for 5-hydroxytryptamine 3 receptor agonist activity,1,H,,,,,,,,,BAO_0000019,CHEMBL618889,8,Autocuration,,,144,
3474,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL618890,8,Autocuration,,,144,
3475,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL618891,8,Autocuration,,,144,
3476,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,1,H,,,,,,,,,BAO_0000019,CHEMBL619054,8,Autocuration,,,144,
3477,Binding affinity against the 5-hydroxytryptamine 3 receptor,1,H,,,,,,,,,BAO_0000223,CHEMBL619055,4,Autocuration,,,104714,
3478,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619056,8,Autocuration,,,144,
3479,Percent efficacy against 5-hydroxytryptamine 3A receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL619057,8,Autocuration,,,144,
3480,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619058,8,Autocuration,,,144,
3481,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,1,D,,Rattus norvegicus,,,,,Oocytes,,BAO_0000219,CHEMBL619059,9,Expert,10116.0,,12020,
3482,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,1,D,,Rattus norvegicus,,,,,Oocytes,,BAO_0000219,CHEMBL619060,9,Expert,10116.0,,12020,
3483,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,1,D,,Rattus norvegicus,,,,,Oocytes,,BAO_0000219,CHEMBL875095,9,Expert,10116.0,,12020,
3484,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619061,9,Intermediate,10141.0,,20033,
3485,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619062,9,Intermediate,10141.0,,20033,
3486,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,1,D,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619063,9,Intermediate,10141.0,,20033,
3487,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619064,9,Intermediate,10141.0,,20033,
3488,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL619065,9,Intermediate,10141.0,,20033,
3489,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,1,D,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619066,9,Intermediate,10141.0,,20033,
3490,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,H,,,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619775,8,Autocuration,,,10209,
3491,Affinity against 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619776,8,Autocuration,,,10209,
3492,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,H,,Cavia porcellus,,,,,,,BAO_0000224,CHEMBL619777,4,Autocuration,10141.0,,104841,
3493,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,H,,Cavia porcellus,,,,,,,BAO_0000224,CHEMBL619778,4,Autocuration,10141.0,,104841,
3494,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619779,4,Autocuration,10141.0,,104841,
3495,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,H,,Cavia porcellus,,,,,,,BAO_0000224,CHEMBL619780,4,Autocuration,10141.0,,104841,
3496,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,H,,Cavia porcellus,,,,,,,BAO_0000224,CHEMBL619166,4,Autocuration,10141.0,,104841,
3497,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619167,4,Autocuration,10141.0,,104841,
3498,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL619168,4,Autocuration,10141.0,,104841,
3499,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,1,D,,Homo sapiens,,,,Cardiac atrium,,2081.0,BAO_0000219,CHEMBL619169,9,Expert,9606.0,,168,
3500,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,1,D,,Homo sapiens,,,,Cardiac atrium,,2081.0,BAO_0000219,CHEMBL619170,9,Expert,9606.0,,168,
3501,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619171,5,Autocuration,9606.0,,104841,
3502,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",1,D,,Homo sapiens,,,,Cardiac atrium,,2081.0,BAO_0000219,CHEMBL619172,9,Expert,9606.0,,168,
3503,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL619173,0,Autocuration,10090.0,,22226,
3504,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL619174,0,Autocuration,10090.0,,22226,
3505,5-hydroxytryptamine receptor binding affinity was determined in rats,1,H,,,,,,,,,BAO_0000019,CHEMBL619175,4,Autocuration,,,104705,
3506,Binding affinity at rat 5-hydroxytryptamine receptor.,1,H,,,,,,,,,BAO_0000224,CHEMBL619176,4,Autocuration,,,104705,
3507,Affinity against 5-hydroxytryptamine receptors in rat fundus model,1,H,,,,,,,,,BAO_0000019,CHEMBL619177,4,Autocuration,,,104705,
3508,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,1,H,,,,,,,,,BAO_0000224,CHEMBL619178,4,Autocuration,,,104705,
3509,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,1,H,,,,,,,,,BAO_0000224,CHEMBL619179,4,Autocuration,,,104705,
3510,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL619180,4,Autocuration,,,104705,
3511,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,1,H,,,,,,Stomach,,945.0,BAO_0000019,CHEMBL619181,4,Autocuration,,,104705,
3512,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL619182,4,Autocuration,,,104705,
3513,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,1,H,,,,,,,,,BAO_0000224,CHEMBL619183,4,Autocuration,,,104705,
3514,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",1,H,,,,,,,,,BAO_0000224,CHEMBL619184,4,Autocuration,,,104705,
3515,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619185,8,Autocuration,,,10576,
3516,Binding affinity for rat 5-hydroxytryptamine transporter.,1,H,,,,,,,,,BAO_0000357,CHEMBL619186,8,Expert,,,12198,
3517,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,1,H,,,,,,,,,BAO_0000019,CHEMBL619187,4,Autocuration,,,104705,
3518,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619188,5,Autocuration,10116.0,,104705,
3519,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL619189,5,Autocuration,10116.0,,104705,
3520,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,1,D,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000019,CHEMBL619190,9,Expert,10116.0,,12198,
3521,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,1,D,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000221,CHEMBL619191,9,Expert,10116.0,,12198,
3522,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619192,5,Autocuration,10116.0,,104705,
3523,Percent binding affinity against 5-hydroxytryptamine receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL619193,5,Autocuration,10116.0,,104705,
3524,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,1,U,,,,,,,,,BAO_0000019,CHEMBL619194,0,Autocuration,,,22226,
3525,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL619195,5,Autocuration,10116.0,,104705,
3526,Affinity against 5-hydroxytryptamine receptor was determined,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL619196,5,Autocuration,10116.0,,104705,
3527,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,1,D,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000019,CHEMBL619197,5,Autocuration,10116.0,,104705,
3528,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,D,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL619198,9,Expert,9606.0,,121,
3529,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,D,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL875081,9,Expert,9606.0,,121,
3530,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,1,H,,,,,,,,,BAO_0000357,CHEMBL884712,8,Autocuration,,,18065,
3531,Inhibition of 5-hydroxytryptamine reuptake,1,H,,,,,,,,,BAO_0000357,CHEMBL884710,8,Expert,,,121,
3532,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",1,H,,,,,,,,,BAO_0000019,CHEMBL619199,8,Autocuration,,,18065,
3533,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",1,H,,,,,,,,,BAO_0000019,CHEMBL619200,8,Autocuration,,,18065,
3534,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",1,H,,,,,,,,,BAO_0000019,CHEMBL619201,8,Autocuration,,,18065,
3535,Tested for 5-hydroxytryptamine receptor uptake,1,H,,,,,,,,,BAO_0000019,CHEMBL619202,8,Autocuration,,,18065,
3536,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL619203,9,Expert,9606.0,,51,449.0
3537,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619204,9,Expert,9606.0,,51,
3538,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,1,H,,Homo sapiens,,,,,,,BAO_0000249,CHEMBL619205,8,Autocuration,9606.0,,10576,
3539,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,1,H,,,,,,,,,BAO_0000357,CHEMBL619206,8,Autocuration,,,10576,
3540,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,1,H,,,,,,,,,BAO_0000249,CHEMBL619207,8,Expert,,,10576,
3541,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619208,8,Autocuration,,,10825,
3542,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619209,8,Autocuration,,,10825,
3543,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619210,8,Autocuration,,,10825,
3544,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619211,8,Autocuration,,,10825,
3545,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL619212,8,Autocuration,,,10825,
3546,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL620681,8,Autocuration,,,10825,
3547,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL620682,8,Autocuration,,,10825,
3548,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL620683,8,Autocuration,,,10825,
3549,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL620684,8,Autocuration,,,10825,
3550,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL620685,8,Autocuration,,,10825,
3551,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,1,H,,,,,,Striatum,,2435.0,BAO_0000019,CHEMBL620686,8,Autocuration,,,10825,
3552,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620687,8,Autocuration,,,10825,
3553,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620688,8,Autocuration,,,10825,
3554,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620689,8,Autocuration,,,10825,
3555,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620690,8,Autocuration,,,10825,
3556,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620691,8,Autocuration,,,10825,
3557,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620692,8,Autocuration,,,10825,
3558,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL620693,8,Autocuration,,,10825,
3559,Binding affinity against 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620694,8,Expert,,,168,
3560,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,H,,,,,,,,,BAO_0000019,CHEMBL857986,8,Autocuration,,,168,
3561,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL620695,8,Autocuration,,,168,
3562,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620696,8,Expert,,,168,
3563,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620697,8,Autocuration,,,168,
3564,Binding affinity towards 5-hydroxytryptamine 4 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620698,8,Autocuration,,,168,
3565,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,H,,,,,,,,,BAO_0000357,CHEMBL620699,8,Autocuration,,,168,
3566,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,H,,,,,,,,,BAO_0000357,CHEMBL620700,8,Autocuration,,,168,
3567,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL620701,8,Autocuration,,,168,643.0
3568,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL875082,8,Autocuration,,,168,643.0
3569,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL620702,8,Autocuration,,,168,643.0
3570,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL620703,8,Autocuration,,,168,643.0
3571,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,H,,,,,,,C6,,BAO_0000219,CHEMBL620704,8,Autocuration,,,168,673.0
3572,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,H,,,,,,,C6,,BAO_0000219,CHEMBL620705,8,Expert,,,168,673.0
3573,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,1,H,,,,,,,C6,,BAO_0000219,CHEMBL620706,8,Expert,,,168,673.0
3574,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,1,H,,,,,,,C6,,BAO_0000219,CHEMBL620707,8,Expert,,,168,673.0
3575,Binding affinity towards 5-hydroxytryptamine 5 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620708,8,Expert,,,10624,
3576,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620709,8,Autocuration,,,105,
3577,Binding affinity against 5-hydroxytryptamine 5A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620710,9,Expert,9606.0,,10624,
3578,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620711,8,Autocuration,,,10624,449.0
3579,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620712,9,Expert,9606.0,,10624,
3580,Binding affinity towards human 5-hydroxytryptamine 5A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620713,9,Expert,9606.0,,10624,
3581,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620714,9,Expert,9606.0,,10624,
3582,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620715,9,Expert,9606.0,,10624,
3583,Binding affinity towards 5-HT5A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620716,8,Autocuration,,,10624,
3584,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620717,8,Expert,,,10624,
3585,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618072,8,Autocuration,,,10624,
3586,Binding affinity towards cloned human 5-HT5A receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL857987,8,Autocuration,,,10624,
3587,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618073,8,Autocuration,,,10624,722.0
3588,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618074,8,Autocuration,,,10624,722.0
3589,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618075,8,Autocuration,,,10624,722.0
3590,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL618076,9,Expert,10090.0,,10625,
3591,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL618077,9,Expert,10090.0,,10625,
3592,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL618078,9,Expert,10090.0,,10625,
3593,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL881821,9,Expert,10090.0,,10625,
3594,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL618079,9,Expert,10090.0,,10625,
3595,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618080,8,Expert,,,10625,
3596,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618081,8,Autocuration,,,10576,722.0
3597,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618082,8,Autocuration,,,10626,722.0
3598,Binding affinity towards 5-HT5a receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618083,8,Expert,,,10624,
3599,Binding affinity towards 5-hydroxytryptamine 5A receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618084,9,Expert,9606.0,,10624,
3600,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618085,8,Expert,,,10624,
3601,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618086,8,Expert,,,10624,
3602,Binding affinities against 5-hydroxytryptamine 5A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL875092,8,Autocuration,,,10624,
3603,Binding affinities towards 5-hydroxytryptamine 5A receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618087,8,Autocuration,,,10624,
3604,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL872926,8,Autocuration,,,10624,
3605,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618088,4,Autocuration,10141.0,,104714,
3606,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,1,H,,,,,,,,,BAO_0000223,CHEMBL618089,4,Autocuration,,,104714,
3607,Inhibition of human 5-hydroxytryptamine 6 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618090,9,Expert,9606.0,,10627,
3608,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618091,9,Expert,9606.0,,10627,
3609,Inhibition against human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618092,8,Autocuration,,,10627,
3610,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618093,9,Expert,9606.0,,10627,
3611,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL618094,8,Expert,,,10627,308.0
3612,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618095,9,Expert,9606.0,,10627,
3613,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL875093,9,Expert,9606.0,,10627,
3614,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618096,9,Expert,9606.0,,10627,
3615,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618118,9,Expert,9606.0,,10627,
3616,Binding affinity against 5-hydroxytryptamine 6 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618119,9,Expert,9606.0,,10627,
3617,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618120,8,Expert,,,10627,
3618,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618121,8,Autocuration,,,10627,
3619,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618122,8,Expert,,,10627,722.0
3620,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618123,8,Autocuration,,,10627,
3621,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618124,8,Expert,,,10627,722.0
3622,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL618125,8,Autocuration,,,10627,
3623,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL618126,9,Expert,9606.0,,10627,722.0
3624,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,1,H,,,,,,,,,BAO_0000019,CHEMBL618236,8,Expert,,,10627,
3625,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,H,,,,,,,,,BAO_0000019,CHEMBL618237,8,Expert,,,10627,
3626,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL618238,8,Expert,,,10627,643.0
3627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618239,9,Expert,9606.0,,10627,
3628,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL618240,8,Autocuration,,,10627,
3629,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618241,8,Autocuration,,,10627,
3630,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL859399,8,Autocuration,,,10627,722.0
3631,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,1,H,,,,,,,,,BAO_0000019,CHEMBL618242,8,Autocuration,,,10627,
3632,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL857991,8,Autocuration,,,10627,
3633,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619951,8,Expert,,,10627,
3634,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL619952,9,Expert,9606.0,,10627,308.0
3635,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL619953,9,Expert,9606.0,,10627,308.0
3636,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL619954,8,Autocuration,,,10627,308.0
3637,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL619955,8,Autocuration,,,10627,308.0
3638,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL619956,8,Autocuration,,,10627,308.0
3639,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619957,8,Autocuration,,,10627,449.0
3640,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619958,8,Autocuration,,,10627,722.0
3641,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620627,8,Autocuration,,,10627,722.0
3642,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620628,8,Autocuration,,,10627,722.0
3643,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620629,8,Autocuration,,,10627,308.0
3644,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620630,8,Autocuration,,,10627,
3645,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620782,8,Autocuration,,,10627,308.0
3646,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620783,8,Autocuration,,,10627,
3647,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620784,8,Expert,,,10627,
3648,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620785,8,Expert,,,10627,308.0
3649,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),1,H,,,,,,,,,BAO_0000357,CHEMBL857992,8,Autocuration,,,10627,
3650,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL620786,8,Autocuration,,,10627,
3651,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620787,8,Autocuration,,,10627,308.0
3652,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620788,8,Autocuration,,,10627,308.0
3653,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620789,8,Autocuration,,,10627,308.0
3654,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",1,H,,,,,,,HeLa,,BAO_0000219,CHEMBL620790,8,Autocuration,,,10627,308.0
3655,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620791,8,Autocuration,,,10628,449.0
3656,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL620792,8,Autocuration,,,10628,
3657,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620793,8,Autocuration,,,10628,
3658,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620794,8,Autocuration,,,10628,
3659,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,1,D,,Homo sapiens,,,,,HeLa,,BAO_0000219,CHEMBL620795,9,Autocuration,9606.0,,10627,308.0
3660,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620796,8,Expert,,,10627,
3661,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,1,H,,,,,,,,,BAO_0000357,CHEMBL620797,8,Autocuration,,,10627,
3662,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620798,9,Expert,9606.0,,10627,
3663,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL620799,8,Autocuration,,,10627,
3664,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620800,8,Expert,,,10627,
3665,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL620801,8,Autocuration,,,10627,
3666,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL875100,8,Autocuration,,,10627,
3667,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620802,8,Autocuration,,,10627,
3668,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL620803,8,Expert,,,10627,
3669,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,H,,,,,,,,,BAO_0000019,CHEMBL620804,8,Expert,,,10627,
3670,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620805,8,Autocuration,,,10627,
3671,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620806,8,Autocuration,,,10627,
3672,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,1,H,,,,,,,,,BAO_0000357,CHEMBL620807,8,Autocuration,,,10627,
3673,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,1,H,,,,,,,,,BAO_0000357,CHEMBL620808,8,Autocuration,,,10627,
3674,Binding affinities against 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620809,8,Autocuration,,,10627,
3675,Binding affinities towards 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620810,8,Autocuration,,,10627,
3676,Binding affinity towards 5-hydroxytryptamine 6 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620811,9,Expert,9606.0,,10627,
3677,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL620812,8,Autocuration,,,10627,
3678,Affinity against 5-hydroxytryptamine 6 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620813,8,Autocuration,,,10627,
3679,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],1,H,,,,,,,,,BAO_0000357,CHEMBL620814,8,Autocuration,,,10627,
3680,Inhibition of human 5-hydroxytryptamine 7 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620815,9,Expert,9606.0,,10209,
3681,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620816,8,Autocuration,,,10209,722.0
3682,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620817,8,Autocuration,,,10209,
3683,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),1,H,,,,,,,,,BAO_0000357,CHEMBL620818,8,Autocuration,,,10209,
3684,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620819,8,Expert,,,10209,722.0
3685,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620820,9,Expert,9606.0,,10209,
3686,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620821,8,Autocuration,,,10209,449.0
3687,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620822,9,Expert,9606.0,,10209,
3688,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620823,9,Expert,9606.0,,10209,
3689,Binding affinity against 5-hydroxytryptamine 7 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620824,9,Expert,9606.0,,10209,
3690,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620825,8,Expert,,,10209,449.0
3691,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL872930,8,Autocuration,,,10209,
3692,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620826,8,Autocuration,,,10209,
3693,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620827,8,Autocuration,,,10209,
3694,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620828,8,Autocuration,,,10209,
3695,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620829,8,Autocuration,,,10209,
3696,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620830,8,Expert,,,10209,722.0
3697,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,1,H,,,,,,,,,BAO_0000019,CHEMBL620831,8,Expert,,,10209,
3698,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,H,,,,,,,,,BAO_0000019,CHEMBL620832,8,Expert,,,10209,
3699,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL621548,9,Expert,9606.0,,10209,
3700,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000019,CHEMBL621549,8,Autocuration,,,10209,
3701,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL621550,8,Autocuration,,,10209,
3702,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621551,8,Autocuration,,,10209,449.0
3703,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,1,H,,,,,,,,,BAO_0000019,CHEMBL621552,8,Autocuration,,,10209,
3704,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL857077,8,Autocuration,,,10209,
3705,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,1,H,,,,,,,,,BAO_0000357,CHEMBL618158,8,Autocuration,,,10209,
3706,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,D,,Homo sapiens,,,,,COS-7,,BAO_0000219,CHEMBL618159,9,Expert,9606.0,,10209,643.0
3707,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL875101,8,Autocuration,,,10209,643.0
3708,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL618160,9,Expert,9606.0,,10209,722.0
3709,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL618161,8,Expert,,,10209,
3710,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618162,8,Expert,,,10209,722.0
3711,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL618163,8,Expert,,,10209,
3712,Binding affinity against 5-hydroxytryptamine 7 human receptors,1,H,,,,,,,,,BAO_0000357,CHEMBL618164,8,Autocuration,,,10209,
3713,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,1,H,,,,,,,,,BAO_0000219,CHEMBL618165,8,Expert,,,10209,
3714,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL618166,8,Autocuration,,,10209,722.0
3715,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL857989,8,Autocuration,,,10209,722.0
3716,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619888,8,Autocuration,,,10209,722.0
3717,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619889,8,Autocuration,,,10209,722.0
3718,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619890,8,Autocuration,,,10209,722.0
3719,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619891,8,Autocuration,,,10209,449.0
3720,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619892,8,Autocuration,,,10209,722.0
3721,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,1,D,,,,,,,HEK293,,BAO_0000219,CHEMBL619893,9,Expert,,,10209,722.0
3722,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619894,8,Autocuration,,,10209,722.0
3723,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,1,D,,,,,,,HEK293,,BAO_0000219,CHEMBL619895,9,Intermediate,,,10209,722.0
3724,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,1,D,,,,,,,,,BAO_0000357,CHEMBL619896,9,Intermediate,,,10209,
3725,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,1,H,,,,,,,COS-7,,BAO_0000219,CHEMBL619897,8,Autocuration,,,10209,643.0
3726,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619898,8,Autocuration,,,10209,722.0
3727,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619899,8,Expert,,,10209,722.0
3728,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL619900,8,Autocuration,,,10209,722.0
3729,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL619901,9,Expert,9606.0,,10209,722.0
3730,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620580,8,Autocuration,,,10209,722.0
3731,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620581,8,Autocuration,,,10209,722.0
3732,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",1,H,,,,,,,HEK293,,BAO_0000219,CHEMBL620733,8,Autocuration,,,10209,722.0
3733,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620734,9,Autocuration,9606.0,,10209,
3734,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL620735,9,Expert,10090.0,,10022,
3735,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL620736,8,Autocuration,9986.0,,10209,
3736,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620737,8,Autocuration,,,11923,449.0
3737,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620738,8,Autocuration,,,11923,449.0
3738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620739,8,Autocuration,,,11923,449.0
3739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620740,8,Autocuration,,,11923,449.0
3740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620741,8,Autocuration,,,11923,449.0
3741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620742,8,Autocuration,,,11923,449.0
3742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620743,8,Autocuration,,,11923,449.0
3743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620744,8,Autocuration,,,11923,449.0
3744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620745,8,Autocuration,,,11923,449.0
3745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620746,8,Autocuration,,,11923,449.0
3746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620747,8,Autocuration,,,11923,449.0
3747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620748,8,Autocuration,,,11923,449.0
3748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620749,8,Autocuration,,,11923,449.0
3749,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620750,8,Expert,,,11923,
3750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL620751,9,Expert,10116.0,,11923,
3751,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620752,8,Expert,,,11923,
3752,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL872929,8,Autocuration,,,11923,
3753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL620753,9,Expert,10116.0,,11923,
3754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL620754,9,Expert,10116.0,,11923,
3755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,1,D,,Rattus norvegicus,,,,,CHO,,BAO_0000219,CHEMBL620755,9,Expert,10116.0,,11923,449.0
3756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620756,8,Autocuration,,,11923,
3757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL620757,8,Autocuration,,,11923,
3758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620758,8,Autocuration,,,11923,449.0
3759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620759,8,Autocuration,,,11923,449.0
3760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620760,8,Autocuration,,,11923,449.0
3761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL620761,8,Autocuration,,,11923,449.0
3762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,H,,,,,,Ileum,,2116.0,BAO_0000221,CHEMBL620762,8,Autocuration,,,11923,
3763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,H,,,,,,Ileum,,2116.0,BAO_0000221,CHEMBL620763,8,Autocuration,,,11923,
3764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,1,H,,,,,,Ileum,,2116.0,BAO_0000221,CHEMBL620764,8,Autocuration,,,11923,
3765,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,1,D,,Rattus norvegicus,,Membranes,,,,,BAO_0000249,CHEMBL857990,9,Expert,10116.0,,11923,
3766,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL620765,8,Autocuration,,,11923,
3767,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,1,H,,,,,,,,,BAO_0000357,CHEMBL620766,8,Expert,,,11923,
3768,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,1,H,,,,,,Hypothalamus,,1898.0,BAO_0000019,CHEMBL620767,8,Expert,,,11923,
3769,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,1,H,,,,,,,,,BAO_0000357,CHEMBL620768,8,Autocuration,,,11923,
3770,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,1,H,,,,,,Hypothalamus,,1898.0,BAO_0000249,CHEMBL619051,8,Expert,,,11923,
3771,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619052,8,Expert,,,11923,
3772,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,1,D,,Rattus norvegicus,,,,,HEK293,,BAO_0000219,CHEMBL619053,9,Expert,10116.0,,11923,722.0
3773,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,1,D,,Rattus norvegicus,,,,,HEK293,,BAO_0000219,CHEMBL619703,9,Expert,10116.0,,11923,722.0
3774,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,1,D,,Rattus norvegicus,,,,,HEK293,,BAO_0000219,CHEMBL619704,9,Autocuration,10116.0,,11923,722.0
3775,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619851,8,Expert,,,10209,
3776,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,1,H,,,,,,,,,BAO_0000357,CHEMBL619852,8,Autocuration,,,10209,
3777,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL619853,8,Autocuration,,,10209,
3778,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL619854,9,Expert,9606.0,,10209,
3779,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619855,8,Expert,,,10209,
3780,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL619856,8,Autocuration,,,10209,
3781,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL619857,8,Autocuration,,,10209,
3782,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,1,H,,,,,,,,,BAO_0000019,CHEMBL619858,8,Expert,,,10209,
3783,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL619859,8,Autocuration,,,10209,
3784,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL619860,8,Autocuration,,,10209,
3785,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619861,8,Autocuration,,,10209,
3786,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619862,8,Expert,,,10209,
3787,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,1,H,,,,,,,,,BAO_0000357,CHEMBL619863,8,Autocuration,,,10209,
3788,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,1,H,,,,,,,,,BAO_0000357,CHEMBL619864,8,Autocuration,,,10209,
3789,Binding affinities against 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL872928,8,Autocuration,,,10209,
3790,Binding affinities towards 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619865,8,Autocuration,,,10209,
3791,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL619866,8,Expert,,,10209,
3792,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,1,H,,,,,,,,,BAO_0000357,CHEMBL619867,8,Autocuration,,,10209,
3793,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,H,,,,,,Ileum,,2116.0,BAO_0000221,CHEMBL619868,8,Autocuration,,,10209,
3794,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,1,H,,,,,,,,,BAO_0000019,CHEMBL619869,8,Autocuration,,,55,
3795,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619870,9,Expert,9606.0,,55,
3796,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,1,H,,,,,,,,,BAO_0000357,CHEMBL619871,8,Autocuration,,,55,
3797,In vitro inhibition of human recombinant lipoxygenase enzyme,1,H,,,,,,,,,BAO_0000357,CHEMBL619872,8,Autocuration,,,55,
3798,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL619873,8,Autocuration,,,55,
3799,Inhibition of 5-lipoxygenase in human whole blood.,1,H,,,,,,Blood,,178.0,BAO_0000357,CHEMBL619874,8,Expert,,,55,
3800,Inhibition of 5-lipoxygenase in human whole blood.,1,H,,,,,,Blood,,178.0,BAO_0000357,CHEMBL619875,8,Expert,,,55,
3801,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,1,H,,,,,,,,,BAO_0000357,CHEMBL619876,8,Autocuration,,,55,
3802,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),1,H,,,,,,,,,BAO_0000357,CHEMBL619877,8,Autocuration,,,55,
3803,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,1,H,,,,,,,,,BAO_0000219,CHEMBL619878,8,Expert,,,55,
3804,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,1,H,,,,,,Blood,,178.0,BAO_0000019,CHEMBL619879,8,Autocuration,,,55,
3805,In vitro inhibition of 5-lipoxygenase from human polymorphs,1,H,,,,,,,,,BAO_0000357,CHEMBL619880,8,Autocuration,,,55,
3806,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),1,H,,,,,,,,,BAO_0000357,CHEMBL619881,8,Autocuration,,,55,
3807,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619882,8,Expert,,,55,
3808,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,1,H,,,,,,,,,BAO_0000357,CHEMBL619883,8,Autocuration,,,55,
3809,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),1,D,,Homo sapiens,,,,Blood,,178.0,BAO_0000357,CHEMBL619884,9,Expert,9606.0,,55,
3810,In vitro potency against human 5-Lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619885,8,Autocuration,,,55,
3811,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619886,9,Expert,9606.0,,55,
3812,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,1,H,,,,,,Blood,,178.0,BAO_0000019,CHEMBL619887,8,Autocuration,,,55,
3813,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,H,,,,,,,,,BAO_0000019,CHEMBL875097,8,Autocuration,,,55,
3814,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,1,H,,,,,,,,,BAO_0000219,CHEMBL618001,8,Autocuration,,,55,
3815,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,1,H,,,,,,,,,BAO_0000219,CHEMBL618002,8,Autocuration,,,55,
3816,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,1,H,,,,,,,,,BAO_0000219,CHEMBL618003,8,Autocuration,,,55,
3817,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,1,H,,,,,,,,,BAO_0000219,CHEMBL618004,8,Autocuration,,,55,
3818,Inhibition of human 5-lipoxygenase in human cells,1,H,,,,,,,,,BAO_0000219,CHEMBL618005,8,Autocuration,,,55,
3819,Inhibition of human neutrophil 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618006,8,Expert,,,55,
3820,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,1,H,,,,,,,,,BAO_0000019,CHEMBL875086,8,Autocuration,,,55,
3821,Inhibition of 5-lipoxygenase from human whole blood,1,H,,,,,,Blood,,178.0,BAO_0000357,CHEMBL618007,8,Expert,,,55,
3822,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,H,,,,,,,,,BAO_0000357,CHEMBL618008,8,Autocuration,,,55,
3823,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,1,H,,,,,,,,,BAO_0000219,CHEMBL618009,8,Autocuration,,,55,
3824,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618010,8,Expert,,,55,
3825,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618011,8,Autocuration,,,55,
3826,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618012,8,Expert,,,55,
3827,Tested against 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL882927,8,Autocuration,,,55,
3828,Tested for activity against 5-Lipoxygenase (5-LO),1,H,,,,,,,,,BAO_0000357,CHEMBL618013,8,Autocuration,,,55,
3829,Tested for activity against 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618014,8,Autocuration,,,55,
3830,Tested for inhibition of 5-HPETE production by human 5-LO,1,H,,,,,,,,,BAO_0000357,CHEMBL618015,8,Autocuration,,,55,
3831,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,H,,,,,,,,,BAO_0000019,CHEMBL618016,8,Autocuration,,,55,
3832,Inhibition of Human 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618017,8,Expert,,,55,
3833,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,1,H,,,,,,,,,BAO_0000019,CHEMBL618018,8,Autocuration,,,55,
3834,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000219,CHEMBL875087,8,Autocuration,,,55,
3835,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000219,CHEMBL618019,8,Autocuration,,,55,
3836,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,1,H,,,,,,,,,BAO_0000019,CHEMBL618020,8,Autocuration,,,55,
3837,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL618021,8,Autocuration,,,55,
3838,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),1,H,,,,,,Blood,,178.0,BAO_0000357,CHEMBL618022,8,Autocuration,,,55,
3839,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,1,H,,,,,,,,,BAO_0000357,CHEMBL618023,8,Autocuration,,,55,
3840,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,H,,,,,,,,,BAO_0000357,CHEMBL618024,8,Autocuration,,,55,
3841,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,1,H,,,,,,,,,BAO_0000019,CHEMBL873950,8,Expert,,,55,
3842,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618025,8,Autocuration,,,55,
3843,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,1,H,,,,,,,,,BAO_0000219,CHEMBL618026,8,Autocuration,,,55,
3844,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,1,H,,,,,,,,,BAO_0000219,CHEMBL618027,8,Autocuration,,,55,
3845,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,1,H,,,,,,,,,BAO_0000219,CHEMBL618028,8,Autocuration,,,55,
3846,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,1,H,,,,,,,,,BAO_0000219,CHEMBL618029,8,Autocuration,,,55,
3847,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL618030,8,Expert,,,55,
3848,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL618031,8,Expert,,,55,
3849,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,1,H,,,,,,,,,BAO_0000357,CHEMBL618032,8,Autocuration,,,55,
3850,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,H,,,,,,,,,BAO_0000357,CHEMBL618033,8,Autocuration,,,55,
3851,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618034,8,Autocuration,,,55,
3852,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL875088,8,Autocuration,,,55,
3853,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,1,H,,,,,,,,,BAO_0000019,CHEMBL618035,8,Autocuration,,,55,
3854,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,1,H,,,,,,,,,BAO_0000019,CHEMBL618036,8,Autocuration,,,55,
3855,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618037,8,Expert,,,55,
3856,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618038,8,Expert,,,55,
3857,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL618761,8,Autocuration,,,55,
3858,Inhibition of lipoxygenase at the concentration of 0.1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618762,8,Expert,,,55,
3859,Inhibition of lipoxygenase at the concentration of 1 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618763,8,Expert,,,55,
3860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,1,H,,,,,,,,,BAO_0000357,CHEMBL618764,8,Autocuration,,,55,
3861,Inhibition of 5-Lipoxygenase (5-LOX),1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL618765,9,Expert,9606.0,,55,
3862,Inhibition of 5-lipoxygenase in mouse macrophages.,1,H,,,,,,,,,BAO_0000357,CHEMBL618766,8,Expert,,,17087,
3863,Inhibition of 5-lipoxygenase in mouse macrophages.,1,H,,,,,,,,,BAO_0000357,CHEMBL618767,8,Expert,,,17087,
3864,Inhibitory activity against lipoxygenase-2 in mice,1,H,,,,,,,,,BAO_0000357,CHEMBL619380,8,Autocuration,,,17087,
3865,Inhibitory activity against murine lipoxygenase-2.,1,H,,,,,,,,,BAO_0000357,CHEMBL619381,8,Expert,,,17087,
3866,Inhibition of 5-lipoxygenase from mouse macrophage,1,D,,Mus musculus,,,,,,,BAO_0000357,CHEMBL619382,9,Expert,10090.0,,17087,
3867,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,1,H,,,,,,,,,BAO_0000357,CHEMBL619383,8,Autocuration,,,17087,
3868,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL619384,8,Autocuration,9823.0,,55,
3869,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,1,H,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL619385,8,Autocuration,9823.0,,55,
3870,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,1,H,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL882928,8,Autocuration,9986.0,,55,
3871,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619386,9,Expert,10116.0,,12166,
3872,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",1,H,,,,,,,,,BAO_0000019,CHEMBL619387,8,Autocuration,,,12166,
3873,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,H,,,,,,,,,BAO_0000019,CHEMBL619388,8,Autocuration,,,12166,
3874,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",1,H,,,,,,,,,BAO_0000019,CHEMBL619389,8,Autocuration,,,12166,
3875,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),1,H,,,,,,,,,BAO_0000019,CHEMBL619390,8,Expert,,,12166,
3876,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",1,H,,,,,,,,,BAO_0000019,CHEMBL619391,8,Expert,,,12166,
3877,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,1,H,,,,,,,,,BAO_0000019,CHEMBL619392,8,Autocuration,,,12166,
3878,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),1,H,,,,,,,,,BAO_0000019,CHEMBL619393,8,Autocuration,,,12166,
3879,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,1,H,,,,,,,,,BAO_0000019,CHEMBL619394,8,Autocuration,,,12166,
3880,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619395,8,Autocuration,,,12166,702.0
3881,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619396,8,Autocuration,,,12166,702.0
3882,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),1,H,,,,,,,,,BAO_0000357,CHEMBL619397,8,Autocuration,,,12166,
3883,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",1,H,,,,,,,,,BAO_0000357,CHEMBL619398,8,Autocuration,,,12166,
3884,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",1,H,,,,,,,,,BAO_0000357,CHEMBL619399,8,Autocuration,,,12166,
3885,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL619400,8,Autocuration,,,12166,
3886,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,H,,,,,,,,,BAO_0000019,CHEMBL619401,8,Autocuration,,,12166,
3887,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",1,H,,,,,,,,,BAO_0000019,CHEMBL619402,8,Autocuration,,,12166,
3888,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,1,D,,Rattus norvegicus,,,,,RBL-2H3,,BAO_0000219,CHEMBL619403,9,Expert,10116.0,,12166,663.0
3889,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL619404,8,Autocuration,,,12166,
3890,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,1,H,,,,,,,,,BAO_0000357,CHEMBL619405,8,Autocuration,,,12166,
3891,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619406,8,Expert,,,12166,702.0
3892,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL619407,9,Expert,10116.0,,12166,702.0
3893,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),1,H,,,,,,,,,BAO_0000357,CHEMBL619408,8,Autocuration,,,12166,
3894,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619409,8,Autocuration,,,12166,702.0
3895,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619410,8,Expert,,,12166,702.0
3896,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619753,8,Autocuration,,,12166,702.0
3897,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619754,8,Autocuration,,,12166,702.0
3898,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619903,8,Expert,,,12166,
3899,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",1,H,,,,,,,,,BAO_0000357,CHEMBL619904,8,Expert,,,12166,
3900,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,1,H,,,,,,,,,BAO_0000357,CHEMBL619905,8,Expert,,,12166,
3901,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,1,H,,,,,,,,,BAO_0000019,CHEMBL619906,8,Autocuration,,,12166,
3902,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,1,H,,,,,,,,,BAO_0000019,CHEMBL619907,8,Autocuration,,,12166,
3903,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,1,H,,,,,,,,,BAO_0000019,CHEMBL619908,8,Autocuration,,,12166,
3904,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,1,H,,,,,,,,,BAO_0000019,CHEMBL619909,8,Autocuration,,,12166,
3905,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619910,8,Expert,,,12166,702.0
3906,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL882929,8,Expert,,,12166,702.0
3907,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619911,8,Expert,,,12166,702.0
3908,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,1,H,,,,,,,,,BAO_0000019,CHEMBL619912,8,Autocuration,,,12166,
3909,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL619913,9,Expert,10116.0,,12166,
3910,In vitro inhibitory activity against RBL-1 5-LO,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619914,8,Expert,,,12166,702.0
3911,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619915,8,Autocuration,,,12166,702.0
3912,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619916,8,Autocuration,,,12166,702.0
3913,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,1,H,,,,,,,,,BAO_0000218,CHEMBL619917,8,Autocuration,,,12166,
3914,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,1,H,,,,,,,,,BAO_0000357,CHEMBL619918,8,Autocuration,,,12166,
3915,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,1,H,,,,,,,,,BAO_0000218,CHEMBL619919,8,Autocuration,,,12166,
3916,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL883710,8,Autocuration,,,12166,702.0
3917,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,1,H,,,,,,Blood,,178.0,BAO_0000019,CHEMBL619920,8,Autocuration,,,12166,
3918,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619921,8,Expert,,,12166,
3919,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,1,H,,,,,,,,,BAO_0000019,CHEMBL619922,8,Autocuration,,,12166,
3920,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,1,H,,,,,,,,,BAO_0000219,CHEMBL619923,8,Autocuration,,,12166,
3921,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619924,8,Expert,,,12166,702.0
3922,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,1,H,,,,,,,,,BAO_0000357,CHEMBL619925,8,Expert,,,12166,
3923,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619926,8,Expert,,,12166,702.0
3924,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619927,8,Autocuration,,,12166,702.0
3925,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619928,8,Expert,,,12166,702.0
3926,In vitro inhibition of RBL-1 5-lipoxygenase,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619929,8,Autocuration,,,12166,702.0
3927,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL875089,8,Autocuration,,,12166,702.0
3928,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619930,8,Autocuration,,,12166,702.0
3929,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619931,8,Autocuration,,,12166,702.0
3930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619932,8,Autocuration,,,12166,702.0
3931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619933,8,Autocuration,,,12166,702.0
3932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619934,8,Autocuration,,,12166,702.0
3933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619935,8,Autocuration,,,12166,702.0
3934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619936,8,Autocuration,,,12166,702.0
3935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619937,8,Autocuration,,,12166,702.0
3936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619938,8,Autocuration,,,12166,702.0
3937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619939,8,Autocuration,,,12166,702.0
3938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619940,8,Autocuration,,,12166,702.0
3939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL875090,8,Autocuration,,,12166,702.0
3940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619941,8,Autocuration,,,12166,702.0
3941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619942,8,Autocuration,,,12166,702.0
3942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL883711,8,Autocuration,,,12166,702.0
3943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619943,8,Autocuration,,,12166,702.0
3944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619944,8,Autocuration,,,12166,702.0
3945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619945,8,Autocuration,,,12166,702.0
3946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619946,8,Autocuration,,,12166,702.0
3947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619947,8,Autocuration,,,12166,702.0
3948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619948,8,Autocuration,,,12166,702.0
3949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619949,8,Autocuration,,,12166,702.0
3950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,1,H,,,,,,,,,BAO_0000019,CHEMBL619950,8,Expert,,,12166,
3951,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,1,H,,,,,,,,,BAO_0000019,CHEMBL618050,8,Autocuration,,,12166,
3952,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL875091,8,Expert,,,12166,663.0
3953,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL618051,8,Expert,,,12166,663.0
3954,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL618052,9,Expert,10116.0,,12166,702.0
3955,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,1,H,,,,,,,,,BAO_0000019,CHEMBL618053,8,Autocuration,,,12166,
3956,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),1,H,,,,,,,,,BAO_0000019,CHEMBL618054,8,Expert,,,12166,
3957,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL618055,9,Expert,10116.0,,12166,702.0
3958,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618056,8,Expert,,,12166,702.0
3959,In vitro inhibitory activity against 5-lipoxygenase was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL618057,8,Autocuration,,,12166,
3960,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618058,8,Autocuration,,,12166,702.0
3961,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618059,8,Expert,,,12166,702.0
3962,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL618060,9,Expert,10116.0,,12166,
3963,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618061,8,Autocuration,,,12166,702.0
3964,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,1,H,,,,,,,,,BAO_0000019,CHEMBL618062,8,Autocuration,,,12166,
3965,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618063,8,Expert,,,12166,702.0
3966,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,1,H,,,,,,,,,BAO_0000357,CHEMBL618064,8,Autocuration,,,12166,
3967,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL618065,9,Expert,10116.0,,12166,702.0
3968,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL618066,9,Expert,10116.0,,12166,702.0
3969,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618067,8,Autocuration,,,12166,702.0
3970,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618068,8,Autocuration,,,12166,702.0
3971,Inhibition of 5-lipoxygenase in rat RBL-1 cells,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL618069,9,Expert,10116.0,,12166,702.0
3972,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618070,8,Expert,,,12166,702.0
3973,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL618071,8,Autocuration,,,10825,
3974,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,H,,,,,,Limbic system,,349.0,BAO_0000019,CHEMBL619247,8,Autocuration,,,10825,
3975,Approximate dose levels for a half maximal reduction of 5-HTP levels,1,H,,,,,,,,,BAO_0000019,CHEMBL619248,8,Autocuration,,,10825,
3976,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619249,8,Autocuration,,,10576,
3977,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,H,,,,,,Hippocampus,,10000000.0,BAO_0000221,CHEMBL619250,8,Autocuration,,,10576,
3978,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,H,,,,,,,,,BAO_0000019,CHEMBL619251,8,Autocuration,,,10577,
3979,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000019,CHEMBL619252,8,Autocuration,9615.0,,55,
3980,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,1,H,,,,,,Blood,,178.0,BAO_0000019,CHEMBL619253,8,Autocuration,,,55,
3981,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000219,CHEMBL619254,8,Autocuration,,,12166,
3982,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,1,H,,,,,,,,,BAO_0000219,CHEMBL619255,8,Expert,,,17140,
3983,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,1,H,,,,,,,,,BAO_0000219,CHEMBL619256,8,Expert,,,17140,
3984,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),1,H,,,,,,,,,BAO_0000219,CHEMBL875418,8,Autocuration,,,17140,
3985,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,H,,,,,,,,,BAO_0000219,CHEMBL619257,8,Expert,,,17140,
3986,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,H,,,,,,,,,BAO_0000219,CHEMBL619258,8,Autocuration,,,17140,
3987,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,1,H,,,,,,,,,BAO_0000357,CHEMBL619259,8,Expert,,,17140,
3988,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,1,H,,,,,,,,,BAO_0000357,CHEMBL619260,8,Expert,,,17140,
3989,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619261,8,Autocuration,9615.0,,55,
3990,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619263,8,Autocuration,9615.0,,55,
3991,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619264,8,Autocuration,9615.0,,55,
3992,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619265,8,Autocuration,9615.0,,55,
3993,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619266,8,Autocuration,9615.0,,55,
3994,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619902,8,Autocuration,9615.0,,55,
3995,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620058,8,Autocuration,9615.0,,55,
3996,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620059,8,Autocuration,9615.0,,55,
3997,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620060,8,Autocuration,9615.0,,55,
3998,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620061,8,Autocuration,9615.0,,55,
3999,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620062,8,Autocuration,9615.0,,55,
4000,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620063,8,Autocuration,9615.0,,55,
4001,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620064,8,Autocuration,9615.0,,55,
4002,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620065,8,Autocuration,9615.0,,55,
4003,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620066,8,Autocuration,9615.0,,55,
4004,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620067,8,Autocuration,9615.0,,55,
4005,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620068,8,Autocuration,9615.0,,55,
4006,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620069,8,Autocuration,9615.0,,55,
4007,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620070,8,Autocuration,9615.0,,55,
4008,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620071,8,Autocuration,9615.0,,55,
4009,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620072,8,Autocuration,9615.0,,55,
4010,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620036,8,Autocuration,9615.0,,55,
4011,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL857702,8,Autocuration,9615.0,,55,
4012,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620037,8,Autocuration,9615.0,,55,
4013,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620038,8,Autocuration,9615.0,,55,
4014,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620039,8,Autocuration,9615.0,,55,
4015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620040,8,Autocuration,9615.0,,55,
4016,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620041,8,Autocuration,9615.0,,55,
4017,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620042,8,Autocuration,9615.0,,55,
4018,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620043,8,Autocuration,9615.0,,55,
4019,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620044,8,Autocuration,9615.0,,55,
4020,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620045,8,Autocuration,9615.0,,55,
4021,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620046,8,Autocuration,9615.0,,55,
4022,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620047,8,Autocuration,9615.0,,55,
4023,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620048,8,Autocuration,9615.0,,55,
4024,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL857703,8,Autocuration,9615.0,,55,
4025,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620049,8,Autocuration,9615.0,,55,
4026,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620050,8,Autocuration,9615.0,,55,
4027,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL620051,8,Autocuration,9615.0,,55,
4028,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619213,8,Autocuration,9615.0,,55,
4029,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619214,8,Autocuration,9615.0,,55,
4030,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619804,8,Autocuration,9615.0,,55,
4031,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619805,8,Autocuration,9615.0,,55,
4032,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619806,8,Autocuration,9615.0,,55,
4033,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619807,8,Autocuration,9615.0,,55,
4034,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619808,8,Autocuration,9615.0,,55,
4035,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619809,8,Autocuration,9615.0,,55,
4036,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619810,8,Autocuration,9615.0,,55,
4037,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619811,8,Autocuration,9615.0,,55,
4038,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620769,8,Autocuration,9615.0,,55,
4039,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620770,8,Autocuration,9615.0,,55,
4040,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620771,8,Autocuration,9615.0,,55,
4041,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620772,8,Autocuration,9615.0,,55,
4042,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,1,H,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620773,8,Autocuration,9615.0,,55,
4043,Ability to inhibit 5-lipoxygenase in guinea pig,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL620774,8,Autocuration,10141.0,,55,
4044,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL620775,8,Expert,10141.0,,55,
4045,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL620776,8,Autocuration,10141.0,,55,
4046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",1,H,,Cavia porcellus,,,,Blood,,178.0,BAO_0000218,CHEMBL620777,8,Autocuration,10141.0,,55,
4047,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL620778,8,Autocuration,10141.0,,55,
4048,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL620779,8,Autocuration,10141.0,,55,
4049,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL621500,8,Expert,10141.0,,55,
4050,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL621501,8,Expert,10141.0,,55,
4051,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618098,8,Autocuration,10141.0,,55,
4052,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618099,8,Autocuration,10141.0,,55,
4053,Inhibitory activity against 5-lipoxygenase,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618100,8,Autocuration,10141.0,,55,
4054,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618101,8,Autocuration,10141.0,,55,
4055,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618102,8,Autocuration,10141.0,,55,
4056,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618103,8,Autocuration,10141.0,,55,
4057,Inhibitory activity uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618104,8,Autocuration,10141.0,,55,
4058,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,1,H,,Cavia porcellus,,,,,,,BAO_0000219,CHEMBL883712,8,Autocuration,10141.0,,55,
4059,Inhibitory activity against 5-lipoxygenase at 10 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618105,8,Autocuration,10141.0,,55,
4060,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618106,8,Autocuration,10141.0,,55,
4061,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618107,8,Autocuration,10141.0,,55,
4062,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618108,8,Autocuration,10141.0,,55,
4063,Inhibitory activity uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618109,8,Autocuration,10141.0,,55,
4064,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618110,8,Autocuration,10141.0,,55,
4065,Inhibitory activity uM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618111,8,Expert,10141.0,,55,
4066,Inhibitory activity uM,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618112,8,Autocuration,10141.0,,55,
4067,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,H,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618113,8,Autocuration,10141.0,,55,
4068,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,H,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618114,8,Autocuration,10141.0,,55,
4069,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,1,H,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000221,CHEMBL620871,8,Expert,10141.0,,55,
4070,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,H,,,,,,,,,BAO_0000357,CHEMBL620872,8,Autocuration,,,55,
4071,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,H,,,,,,,,,BAO_0000357,CHEMBL620873,8,Autocuration,,,55,
4072,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),1,H,,,,,,,,,BAO_0000357,CHEMBL620874,8,Autocuration,,,55,
4073,In vitro inhibition of human 5-Lipoxygenase.,1,H,,,,,,,,,BAO_0000357,CHEMBL620875,8,Expert,,,55,
4074,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620876,0,Autocuration,10116.0,,22226,
4075,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620877,0,Autocuration,10116.0,,22226,
4076,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL857854,0,Autocuration,10116.0,,22226,
4077,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620878,0,Autocuration,10116.0,,22226,
4078,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620879,0,Autocuration,10116.0,,22226,
4079,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620880,0,Autocuration,10116.0,,22226,
4080,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620881,0,Autocuration,10116.0,,22226,
4081,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620882,0,Autocuration,10116.0,,22226,
4082,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620883,0,Autocuration,10116.0,,22226,
4083,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620884,0,Autocuration,10116.0,,22226,
4084,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620885,0,Autocuration,10116.0,,22226,
4085,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620886,0,Autocuration,10116.0,,22226,
4086,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620887,0,Autocuration,10116.0,,22226,
4087,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618039,0,Autocuration,10116.0,,22226,
4088,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618040,0,Autocuration,10116.0,,22226,
4089,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618041,0,Autocuration,10116.0,,22226,
4090,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618216,0,Autocuration,10116.0,,22226,
4091,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618217,0,Autocuration,10116.0,,22226,
4092,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618218,0,Autocuration,10116.0,,22226,
4093,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618219,0,Autocuration,10116.0,,22226,
4094,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618220,0,Autocuration,10116.0,,22226,
4095,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618221,0,Autocuration,10116.0,,22226,
4096,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618222,0,Autocuration,10116.0,,22226,
4097,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618223,0,Autocuration,10116.0,,22226,
4098,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618224,0,Autocuration,10116.0,,22226,
4099,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618225,0,Autocuration,10116.0,,22226,
4100,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618226,0,Autocuration,10116.0,,22226,
4101,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618227,0,Autocuration,10116.0,,22226,
4102,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618228,0,Autocuration,10116.0,,22226,
4103,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618229,0,Autocuration,10116.0,,22226,
4104,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618230,0,Autocuration,10116.0,,22226,
4105,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618231,0,Autocuration,10116.0,,22226,
4106,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618232,0,Autocuration,10116.0,,22226,
4107,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618233,0,Autocuration,10116.0,,22226,
4108,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618234,0,Autocuration,10116.0,,22226,
4109,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618235,0,Autocuration,10116.0,,22226,
4110,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618115,0,Autocuration,10116.0,,22226,
4111,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618116,0,Autocuration,10116.0,,22226,
4112,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618117,0,Autocuration,10116.0,,22226,
4113,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619968,0,Autocuration,10116.0,,22226,
4114,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619969,0,Autocuration,10116.0,,22226,
4115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619970,0,Autocuration,10116.0,,22226,
4116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619971,0,Autocuration,10116.0,,22226,
4117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619972,0,Autocuration,10116.0,,22226,
4118,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619973,0,Autocuration,10116.0,,22226,
4119,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619974,0,Autocuration,10116.0,,22226,
4120,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619975,0,Autocuration,10116.0,,22226,
4121,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,1,U,,Rattus norvegicus,,Microsomes,,,,,BAO_0000251,CHEMBL619976,0,Autocuration,10116.0,,22226,
4122,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619977,0,Autocuration,10116.0,,22226,
4123,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619978,0,Autocuration,10116.0,,22226,
4124,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619979,0,Autocuration,10116.0,,22226,
4125,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619980,0,Autocuration,10116.0,,22226,
4126,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619981,0,Autocuration,10116.0,,22226,
4127,In vitro inhibition of 7226/S myeloma cancer cell line,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619982,1,Intermediate,9606.0,,80433,741.0
4128,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),1,N,,Homo sapiens,,,,,BEL-7404 tumor cell line,,BAO_0000219,CHEMBL619983,1,Intermediate,9606.0,,80698,993.0
4129,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL620031,1,Intermediate,9606.0,,80640,391.0
4130,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL620032,1,Intermediate,9606.0,,80640,391.0
4131,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,1,N,,Cricetulus griseus,,,,,V79,,BAO_0000219,CHEMBL620033,1,Expert,10029.0,,81264,505.0
4132,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,1,N,,Cricetulus griseus,,,,,V79,,BAO_0000219,CHEMBL620034,1,Expert,10029.0,,81264,505.0
4133,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1,N,,Rattus norvegicus,,,,,7800C1 cell line,,BAO_0000219,CHEMBL620035,1,Intermediate,10116.0,,80635,1119.0
4134,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1,N,,Rattus norvegicus,,,,,7800C1 cell line,,BAO_0000219,CHEMBL618318,1,Intermediate,10116.0,,80635,1119.0
4135,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1,N,,Rattus norvegicus,,,,,7800C1 cell line,,BAO_0000219,CHEMBL618319,1,Intermediate,10116.0,,80635,1119.0
4136,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1,N,,Rattus norvegicus,,,,,7800C1 cell line,,BAO_0000219,CHEMBL618320,1,Intermediate,10116.0,,80635,1119.0
4137,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1,N,,Rattus norvegicus,,,,,7800C1 cell line,,BAO_0000219,CHEMBL618321,1,Intermediate,10116.0,,80635,1119.0
4138,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1,N,,Rattus norvegicus,,,,,7800C1 cell line,,BAO_0000219,CHEMBL883118,1,Intermediate,10116.0,,80635,1119.0
4139,In vitro antitumor activity against renal 786-0 tumor cell lines,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL883795,1,Intermediate,9606.0,,80640,391.0
4140,Cytotoxic activity against 786-0 Renal cancer cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL618322,1,Intermediate,9606.0,,80640,391.0
4141,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL618323,1,Intermediate,9606.0,,80640,391.0
4142,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL618324,1,Intermediate,9606.0,,80640,391.0
4143,In vitro antitumor activity against human renal 786-0 cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL618325,1,Intermediate,9606.0,,80640,391.0
4144,Inhibition of Renal cancer in 786-0 cancer cell lines,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL875416,1,Intermediate,9606.0,,80640,391.0
4145,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL618326,1,Intermediate,9606.0,,80640,391.0
4146,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL618327,1,Intermediate,9606.0,,80640,391.0
4147,inhibition of the growth of renal cancer(786-0) cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619215,1,Intermediate,9606.0,,80640,391.0
4148,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619216,1,Intermediate,9606.0,,80640,391.0
4149,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619217,1,Intermediate,9606.0,,80640,391.0
4150,The IC50 value was measured on 786-0 cell line in ovarian tumor,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619218,1,Intermediate,9606.0,,80640,391.0
4151,The IC50 value was measured on 786-0 cell line in ovarian tumor t,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619219,1,Intermediate,9606.0,,80640,391.0
4152,The IC50 value was measured on 786-0 cell line in renal tumor type.,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619220,1,Intermediate,9606.0,,80640,391.0
4153,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619221,1,Intermediate,9606.0,,80640,391.0
4154,Tested for cytotoxic activity against renal cancer 786-0 cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619222,1,Intermediate,9606.0,,80640,391.0
4155,Compound was tested for growth inhibitory activity against 786-0 cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL857454,1,Intermediate,9606.0,,80640,391.0
4156,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619223,8,Autocuration,,,12166,702.0
4157,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619224,8,Autocuration,,,12166,702.0
4158,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,H,,,,,,,,,BAO_0000019,CHEMBL619225,8,Autocuration,,,12166,
4159,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619226,8,Expert,,,12166,702.0
4160,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619227,8,Expert,,,12166,702.0
4161,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619228,8,Autocuration,,,12166,
4162,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,1,H,,,,,,,,,BAO_0000219,CHEMBL619229,8,Autocuration,,,12166,
4163,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619230,8,Autocuration,,,12166,702.0
4164,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,1,H,,,,,,,,,BAO_0000357,CHEMBL619231,8,Autocuration,,,12166,
4165,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",1,H,,,,,,,,,BAO_0000357,CHEMBL619232,8,Autocuration,,,12166,
4166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,1,H,,,,,,,,,BAO_0000357,CHEMBL619233,8,Expert,,,12166,
4167,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619234,8,Autocuration,,,12166,
4168,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),1,H,,,,,,,,,BAO_0000357,CHEMBL619235,8,Autocuration,,,12166,
4169,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL619236,9,Expert,10116.0,,12166,
4170,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619237,8,Autocuration,,,12166,702.0
4171,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,1,H,,,,,,,,,BAO_0000357,CHEMBL619238,8,Autocuration,,,12166,
4172,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619239,8,Expert,,,12166,
4173,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,1,H,,,,,,,,,BAO_0000357,CHEMBL619240,8,Autocuration,,,12166,
4174,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,H,,,,,,,,,BAO_0000019,CHEMBL875417,8,Autocuration,,,12166,
4175,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619241,8,Autocuration,,,12166,702.0
4176,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,H,,,,,,,,,BAO_0000019,CHEMBL619242,8,Expert,,,12166,
4177,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL883796,8,Autocuration,,,12166,702.0
4178,Tested for its inhibitory activity against 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL619243,8,Autocuration,,,12166,
4179,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,1,H,,,,,,,,,BAO_0000357,CHEMBL619244,8,Autocuration,,,12166,
4180,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",1,H,,,,,,,,,BAO_0000019,CHEMBL619245,8,Expert,,,12166,
4181,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,H,,,,,,,,,BAO_0000019,CHEMBL619246,8,Expert,,,12166,
4182,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619984,8,Expert,,,12166,702.0
4183,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619985,8,Autocuration,,,12166,702.0
4184,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619986,8,Autocuration,,,12166,702.0
4185,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619987,8,Expert,,,12166,702.0
4186,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,1,H,,,,,,,,,BAO_0000218,CHEMBL619988,8,Autocuration,,,12166,
4187,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619989,8,Autocuration,,,12166,702.0
4188,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL619990,8,Autocuration,,,12166,702.0
4189,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000219,CHEMBL619991,8,Autocuration,,,12166,
4190,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),1,H,,,,,,,,,BAO_0000219,CHEMBL619992,8,Autocuration,,,12166,
4191,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),1,H,,,,,,,,,BAO_0000218,CHEMBL619993,8,Autocuration,,,12166,
4192,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL619994,8,Autocuration,,,12166,663.0
4193,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL619995,8,Autocuration,,,12166,663.0
4194,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],1,H,,,,,,,,,BAO_0000019,CHEMBL619996,8,Autocuration,,,12166,
4195,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,1,H,,,,,,,,,BAO_0000019,CHEMBL619997,8,Autocuration,,,12166,
4196,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,1,H,,,,,,,,,BAO_0000019,CHEMBL619998,8,Expert,,,12166,
4197,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,1,H,,,,,,,,,BAO_0000019,CHEMBL619999,8,Expert,,,12166,
4198,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,1,H,,,,,,,,,BAO_0000019,CHEMBL620000,8,Autocuration,,,12166,
4199,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620001,8,Autocuration,,,12166,702.0
4200,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL620002,9,Expert,10116.0,,12166,
4201,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620003,8,Autocuration,,,12166,702.0
4202,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620004,8,Expert,,,12166,702.0
4203,Compound was evaluated for the inhibition of 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL874063,8,Autocuration,,,12166,
4204,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620005,8,Autocuration,,,12166,702.0
4205,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620006,8,Autocuration,,,12166,702.0
4206,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620007,8,Autocuration,,,12166,702.0
4207,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620008,8,Autocuration,,,12166,702.0
4208,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL620009,9,Expert,10116.0,,12166,702.0
4209,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620010,8,Autocuration,,,12166,702.0
4210,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620011,8,Autocuration,,,12166,702.0
4211,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620677,8,Autocuration,,,12166,702.0
4212,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620678,8,Autocuration,,,12166,702.0
4213,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620679,8,Autocuration,,,12166,702.0
4214,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620680,8,Autocuration,,,12166,702.0
4215,Inhibitory activity against 5-lipoxygenase at 10 uM,1,D,,Rattus norvegicus,,,,,,,BAO_0000357,CHEMBL620838,9,Expert,10116.0,,12166,
4216,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL620839,8,Autocuration,,,12166,
4217,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL620840,8,Expert,,,12166,
4218,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620841,8,Expert,,,12166,702.0
4219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620842,8,Autocuration,,,12166,702.0
4220,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620843,8,Autocuration,,,12166,702.0
4221,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620844,8,Autocuration,,,12166,702.0
4222,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620845,8,Autocuration,,,12166,702.0
4223,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,1,H,,,,,,,,,BAO_0000019,CHEMBL620846,8,Autocuration,,,12166,
4224,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL873951,8,Autocuration,,,12166,
4225,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL620847,8,Autocuration,,,12166,
4226,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620848,8,Autocuration,,,12166,702.0
4227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620849,8,Autocuration,,,12166,702.0
4228,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620850,8,Autocuration,,,12166,702.0
4229,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620851,8,Autocuration,,,12166,702.0
4230,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620852,8,Autocuration,,,12166,702.0
4231,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL875098,8,Autocuration,,,12166,702.0
4232,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL620853,9,Expert,10116.0,,12166,702.0
4233,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,1,H,,,,,,,,,BAO_0000019,CHEMBL620854,8,Autocuration,,,12166,
4234,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620855,8,Autocuration,,,12166,702.0
4235,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL839884,8,Expert,,,12166,702.0
4236,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620856,8,Autocuration,,,12166,702.0
4237,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620857,8,Autocuration,,,12166,702.0
4238,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620858,8,Autocuration,,,12166,
4239,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620859,8,Autocuration,,,12166,
4240,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620860,8,Autocuration,,,12166,
4241,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620861,8,Autocuration,,,12166,
4242,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),1,H,,,,,,,,,BAO_0000357,CHEMBL620862,8,Expert,,,12166,
4243,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL620863,8,Autocuration,,,12166,
4244,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,H,,,,,,,,,BAO_0000019,CHEMBL620864,8,Autocuration,,,12166,
4245,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620865,8,Autocuration,,,12166,702.0
4246,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620866,8,Autocuration,,,12166,702.0
4247,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL620867,8,Autocuration,,,12166,663.0
4248,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL620868,8,Autocuration,,,12166,663.0
4249,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL620869,8,Autocuration,,,12166,663.0
4250,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,1,H,,,,,,,,,BAO_0000019,CHEMBL873952,8,Autocuration,,,12166,
4251,The compound was tested for inhibition of isolated 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL875099,8,Autocuration,,,12166,
4252,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,1,H,,,,,,,RBL-2H3,,BAO_0000219,CHEMBL620870,8,Autocuration,,,12166,663.0
4253,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL618261,8,Autocuration,,,12166,
4254,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL618262,8,Autocuration,,,12166,
4255,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL619428,8,Autocuration,,,12166,
4256,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,H,,,,,,,,,BAO_0000019,CHEMBL619429,8,Autocuration,,,12166,
4257,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,H,,,,,,,,,BAO_0000019,CHEMBL619430,8,Autocuration,,,12166,
4258,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620017,8,Autocuration,,,12166,702.0
4259,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620018,8,Autocuration,,,12166,702.0
4260,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620019,8,Autocuration,,,12166,702.0
4261,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620020,8,Autocuration,,,12166,702.0
4262,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620021,8,Autocuration,,,12166,702.0
4263,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620022,8,Autocuration,,,12166,702.0
4264,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620023,8,Autocuration,,,12166,702.0
4265,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620024,8,Autocuration,,,12166,702.0
4266,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620025,8,Autocuration,,,12166,702.0
4267,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620026,8,Autocuration,,,12166,702.0
4268,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL620027,8,Autocuration,,,12166,702.0
4269,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620028,9,Expert,10116.0,,12166,
4270,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL620029,8,Autocuration,,,12166,
4271,Compound was tested for the percent of inhibition against 5-LO at 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL620030,8,Autocuration,,,12166,
4272,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL875415,8,Autocuration,,,12166,702.0
4273,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618256,8,Autocuration,,,12166,702.0
4274,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618257,8,Autocuration,,,12166,702.0
4275,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618258,8,Autocuration,,,12166,702.0
4276,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618259,8,Autocuration,,,12166,702.0
4277,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL618260,8,Autocuration,,,12166,
4278,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618215,8,Autocuration,,,12166,702.0
4279,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618390,8,Autocuration,,,12166,702.0
4280,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618391,8,Autocuration,,,12166,702.0
4281,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618392,8,Autocuration,,,12166,702.0
4282,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618393,8,Autocuration,,,12166,702.0
4283,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,1,H,,,,,,,,,BAO_0000219,CHEMBL618394,8,Autocuration,,,12166,
4284,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,H,,Homo sapiens,,,,,RBL-1,,BAO_0000219,CHEMBL618395,8,Expert,9606.0,,12166,702.0
4285,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL618396,9,Expert,10116.0,,12166,702.0
4286,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),1,D,,Rattus norvegicus,,,,,RBL-1,,BAO_0000219,CHEMBL858253,9,Expert,10116.0,,12166,702.0
4287,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL618397,9,Autocuration,10116.0,,12166,
4288,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),1,H,,Glycine max,,,,,,,BAO_0000357,CHEMBL618398,8,Autocuration,3847.0,,12054,
4289,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",1,U,,,,,,,,,BAO_0000019,CHEMBL618399,0,Autocuration,,,22226,
4290,In vitro inhibition of 5-Lipoxygenase; Inactive.,1,H,,,,,,,,,BAO_0000357,CHEMBL618400,8,Expert,,,55,
4291,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL618401,8,Autocuration,,,55,
4292,Inhibitory concentration against 5-lipoxygenase; No inhibition,1,H,,,,,,,,,BAO_0000357,CHEMBL618402,8,Autocuration,,,55,
4293,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL876400,8,Autocuration,,,55,702.0
4294,Inhibitory activity against 5-lipoxygenase.,1,H,,,,,,,,,BAO_0000357,CHEMBL618403,8,Expert,,,55,
4295,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,1,H,,,,,,,,,BAO_0000357,CHEMBL618404,8,Autocuration,,,55,
4296,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618405,8,Autocuration,,,55,
4297,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL618406,8,Autocuration,,,55,
4298,Inhibitory concentration against arachidonic acid 5-lipoxygenation,1,H,,,,,,,,,BAO_0000019,CHEMBL618407,8,Expert,,,55,
4299,Tested for the inhibitory activity against 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618408,8,Autocuration,,,55,
4300,Compound was tested for its inhibitory activity against 5-lipoxygenase,1,H,,,,,,,,,BAO_0000357,CHEMBL618409,8,Autocuration,,,55,
4301,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,1,H,,,,,,,,,BAO_0000357,CHEMBL618410,8,Autocuration,,,55,
4302,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,1,H,,,,,,,,,BAO_0000357,CHEMBL618411,8,Autocuration,,,55,
4303,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,1,H,,,,,,,,,BAO_0000357,CHEMBL618412,8,Autocuration,,,55,
4304,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,1,H,,,,,,,RBL-1,,BAO_0000219,CHEMBL618413,8,Autocuration,,,12166,702.0
4305,,1,H,,,,,,,,,BAO_0000357,CHEMBL618414,8,Autocuration,,,12166,
4306,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),1,H,,,,,,,,,BAO_0000357,CHEMBL618415,8,Autocuration,,,10102,
4307,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,1,H,,,,,,,,,BAO_0000019,CHEMBL618416,8,Autocuration,,,10102,
4308,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL876401,8,Autocuration,,,10102,
4309,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,1,H,,,,,,,,,BAO_0000357,CHEMBL618417,8,Expert,,,10102,
4310,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,1,H,,,,,,,,,BAO_0000357,CHEMBL618418,8,Autocuration,,,10102,
4311,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",1,H,,,,,,,,,BAO_0000357,CHEMBL618419,8,Autocuration,,,10102,
4312,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",1,H,,,,,,,,,BAO_0000357,CHEMBL618420,8,Autocuration,,,10102,
4313,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,1,H,,,,,,,,,BAO_0000357,CHEMBL618421,8,Autocuration,,,10102,
4314,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,1,H,,,,,,,,,BAO_0000019,CHEMBL618422,8,Autocuration,,,11238,
4315,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),1,H,,,,,,,,,BAO_0000019,CHEMBL618423,8,Autocuration,,,11238,
4316,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),1,H,,,,,,,,,BAO_0000019,CHEMBL618424,8,Autocuration,,,11238,
4317,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,1,S,,,,,,,,,BAO_0000220,CHEMBL618425,2,Intermediate,,,100284,
4318,The dark toxicity against 543 human galactophore carcinoma cells,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618426,0,Autocuration,9606.0,,22226,
4319,Tested in vitro for cytotoxicity against 56 human tumor cell lines,1,N,,Homo sapiens,,,,,Panel (56 tumour cell lines),,BAO_0000219,CHEMBL618427,1,Expert,9606.0,,80623,390.0
4320,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL618428,1,Expert,9606.0,,80008,345.0
4321,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL618429,1,Intermediate,9606.0,,80008,345.0
4322,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL618430,1,Intermediate,9606.0,,80008,345.0
4323,Growth inhibition against human 5637 cell lines,1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL618431,1,Expert,9606.0,,80008,345.0
4324,Antitumor activity against human bladder carcinoma 5637 cells.,1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL883799,1,Expert,9606.0,,80008,345.0
4325,Antitumor activity against human bladder carcinoma 5637 cells,1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL618432,1,Intermediate,9606.0,,80008,345.0
4326,Antitumor activity against human bladder carcinoma 5637 cells,1,N,,Homo sapiens,,,,,5637,,BAO_0000219,CHEMBL618433,1,Intermediate,9606.0,,80008,345.0
4327,In vitro inhibition of bovine trypsin(Trp).,1,D,,Bos taurus,,,,,,,BAO_0000357,CHEMBL618434,9,Expert,9913.0,,10443,
4328,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,1,H,,Cercopithecidae,,,,,CV-1,,BAO_0000219,CHEMBL618435,8,Expert,9527.0,,240,407.0
4329,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,1,H,,,,,,,,,BAO_0000357,CHEMBL876402,8,Autocuration,,,10577,
4330,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,1,H,,,,,,,,,BAO_0000019,CHEMBL618436,6,Autocuration,,,104698,
4331,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,1,U,,,,,,,,,BAO_0000218,CHEMBL618437,0,Autocuration,,,22226,
4332,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,1,D,,Cavia porcellus,,,,,,,BAO_0000357,CHEMBL618438,9,Intermediate,10141.0,,20033,
4333,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,H,,Rattus norvegicus,,Microsomes,,,,,BAO_0000251,CHEMBL883800,8,Expert,10116.0,,17045,
4334,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,H,,Rattus norvegicus,,Microsomes,,,,,BAO_0000251,CHEMBL618439,8,Expert,10116.0,,17045,
4335,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL618440,0,Intermediate,,,22226,
4336,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL618441,0,Intermediate,,,22226,
4337,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,1,H,,Trypanosoma brucei,,,,,,,BAO_0000019,CHEMBL618442,8,Expert,5691.0,,11938,
4338,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,1,H,,Trypanosoma brucei,,,,,,,BAO_0000019,CHEMBL618443,8,Autocuration,5691.0,,11938,
4339,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,1,H,,Ovis aries,,,,,,,BAO_0000019,CHEMBL619158,8,Expert,9940.0,,11938,
4340,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,1,H,,Ovis aries,,,,,,,BAO_0000019,CHEMBL620974,8,Autocuration,9940.0,,11938,
4341,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,1,H,,,,,,,,,BAO_0000357,CHEMBL620975,8,Autocuration,,,11938,
4342,Average inhibitory concentration against 60 human cell lines was reported,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620976,0,Intermediate,9606.0,,22226,
4343,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620977,0,Expert,9606.0,,22226,
4344,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,1,N,,Homo sapiens,,,,,Panel NCI-60 (60 carcinoma cell lines),,BAO_0000219,CHEMBL620978,1,Intermediate,9606.0,,80315,542.0
4345,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,1,N,,Homo sapiens,,,,,Panel NCI-60 (60 carcinoma cell lines),,BAO_0000219,CHEMBL620979,1,Intermediate,9606.0,,80315,542.0
4346,In vitro mean growth inhibitory activity against 60-cell panel,1,N,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,BAO_0000219,CHEMBL620980,1,Expert,,,80315,542.0
4347,In vitro mean growth lethal concentration against 60-cell panel,1,N,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,BAO_0000219,CHEMBL620981,1,Expert,,,80315,542.0
4348,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,1,N,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,BAO_0000219,CHEMBL620982,1,Expert,,,80315,542.0
4349,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,1,N,,,,,,,Panel NCI-60 (60 carcinoma cell lines),,BAO_0000219,CHEMBL620983,1,Expert,,,80315,542.0
4350,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620984,4,Autocuration,,,104775,
4351,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,H,,,,,,,,,BAO_0000019,CHEMBL620985,4,Autocuration,,,104775,
4352,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,1,H,,,,,,,,,BAO_0000357,CHEMBL620986,8,Expert,,,275,
4353,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,1,N,,Plasmodium falciparum,,,,,,,BAO_0000218,CHEMBL620987,1,Expert,5833.0,,50425,
4354,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,1,N,,Plasmodium falciparum,,,,,,,BAO_0000218,CHEMBL620988,1,Expert,5833.0,,50425,
4355,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,1,N,,Plasmodium falciparum,,,,,,,BAO_0000218,CHEMBL620989,1,Expert,5833.0,,50425,
4356,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,1,N,,Plasmodium falciparum,,,,,,,BAO_0000218,CHEMBL620990,1,Expert,5833.0,,50425,
4357,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,1,N,,Plasmodium falciparum,,,,,,,BAO_0000218,CHEMBL620991,1,Intermediate,5833.0,,50425,
4358,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL620992,1,Intermediate,10090.0,,80628,850.0
4359,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL620993,1,Intermediate,10090.0,,80628,850.0
4360,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL620994,1,Intermediate,10090.0,,80628,850.0
4361,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL620995,1,Intermediate,10090.0,,80628,850.0
4362,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL620996,1,Intermediate,10090.0,,80628,850.0
4363,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL875581,1,Intermediate,10090.0,,80628,850.0
4364,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620997,0,Autocuration,10090.0,,22224,
4365,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620998,0,Autocuration,10090.0,,22224,
4366,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620999,0,Autocuration,10090.0,,22224,
4367,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621000,0,Autocuration,10090.0,,22224,
4368,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621001,0,Autocuration,10090.0,,22224,
4369,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621002,0,Autocuration,10090.0,,22224,
4370,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621003,0,Autocuration,10090.0,,22224,
4371,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621004,0,Autocuration,10090.0,,22224,
4372,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621005,0,Autocuration,10090.0,,22224,
4373,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621006,0,Autocuration,10090.0,,22224,
4374,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621007,0,Autocuration,10090.0,,22224,
4375,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621008,0,Autocuration,10090.0,,22224,
4376,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621009,0,Autocuration,10090.0,,22224,
4377,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL857705,0,Autocuration,10090.0,,22224,
4378,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619828,0,Autocuration,10090.0,,22224,
4379,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619829,0,Autocuration,10090.0,,22224,
4380,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619830,0,Autocuration,10090.0,,22224,
4381,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619831,0,Autocuration,10090.0,,22224,
4382,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619832,0,Autocuration,10090.0,,22224,
4383,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619833,0,Autocuration,10090.0,,22224,
4384,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619834,0,Autocuration,10090.0,,22224,
4385,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619835,0,Autocuration,10090.0,,22224,
4386,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619836,0,Autocuration,10090.0,,22224,
4387,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL619837,1,Intermediate,10090.0,,80628,850.0
4388,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL619838,0,Autocuration,,,22224,
4389,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619839,1,Intermediate,10090.0,,50594,
4390,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL619840,1,Intermediate,10090.0,,80628,850.0
4391,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL619841,1,Intermediate,10090.0,,80628,850.0
4392,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL857704,1,Expert,10090.0,,80628,850.0
4393,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL619842,1,Intermediate,10090.0,,80628,850.0
4394,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),1,N,,Mus musculus,,,,,6C3HED,,BAO_0000218,CHEMBL619843,1,Expert,10090.0,,80628,850.0
4395,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",1,U,,Staphylococcus aureus,,,,,,,BAO_0000019,CHEMBL619844,0,Autocuration,1280.0,,22226,
4396,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL857855,0,Autocuration,10116.0,,22226,
4397,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619845,0,Autocuration,10116.0,,22226,
4398,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619846,0,Autocuration,10116.0,,22226,
4399,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619847,0,Autocuration,10116.0,,22226,
4400,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619848,0,Autocuration,10116.0,,22226,
4401,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620893,0,Autocuration,10116.0,,22226,
4402,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620894,0,Autocuration,10116.0,,22226,
4403,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620895,0,Autocuration,10116.0,,22226,
4404,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620896,0,Autocuration,10116.0,,22226,
4405,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620897,0,Autocuration,10116.0,,22226,
4406,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620898,0,Autocuration,10116.0,,22226,
4407,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,U,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620899,0,Autocuration,10116.0,,22226,
4408,The apparent total plasma clearance in monkey,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620900,0,Autocuration,9527.0,,22224,
4409,Compound was evaluated for Hepatic clearance in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620901,0,Autocuration,9527.0,,22224,
4410,Lower clearance in monkey (i.v.) at 0.5 mpk,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620902,0,Autocuration,9527.0,,22224,
4411,Plasma clearance in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620903,0,Autocuration,9527.0,,22224,
4412,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620904,0,Autocuration,9527.0,,22224,
4413,Plasma clearance of compound was determined in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620905,0,Autocuration,9527.0,,22224,
4414,Plasma clearance was calculated in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620906,0,Autocuration,9527.0,,22224,
4415,Plasma clearance in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL875420,0,Autocuration,9527.0,,22224,
4416,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620907,0,Autocuration,9527.0,,22224,
4417,Plasma clearance was evaluated in rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620908,0,Autocuration,9527.0,,22224,
4418,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620909,0,Autocuration,9527.0,,22224,
4419,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620910,0,Autocuration,9527.0,,22224,
4420,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620911,0,Autocuration,9527.0,,22224,
4421,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620912,0,Autocuration,9527.0,,22224,
4422,Cmax 24 hr after 2 mg/kg oral administration in monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620913,0,Autocuration,9527.0,,22224,
4423,Cmax in monkey after administration of 1 mg/kg iv,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620914,0,Autocuration,9527.0,,22224,
4424,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620915,0,Autocuration,9527.0,,22224,
4425,Cmax in cynomolgus monkey by iv administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620916,0,Autocuration,9527.0,,22224,
4426,Cmax in cynomolgus monkey by po administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620917,0,Autocuration,9527.0,,22224,
4427,Cmax value evaluated in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620918,0,Autocuration,9527.0,,22224,
4428,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620919,0,Autocuration,9527.0,,22224,
4429,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620920,0,Autocuration,9527.0,,22224,
4430,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620921,0,Autocuration,9527.0,,22224,
4431,Maximal plasma concentration in squirrel monkeys,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620922,0,Autocuration,9527.0,,22224,
4432,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620923,0,Autocuration,9527.0,,22224,
4433,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620924,0,Autocuration,9527.0,,22224,
4434,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620925,0,Autocuration,9527.0,,22224,
4435,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620926,0,Autocuration,9527.0,,22224,
4436,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620927,0,Autocuration,9527.0,,22224,
4437,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620928,0,Autocuration,9527.0,,22224,
4438,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620929,0,Autocuration,9527.0,,22224,
4439,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620930,0,Autocuration,9527.0,,22224,
4440,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620931,0,Autocuration,9527.0,,22224,
4441,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620932,0,Autocuration,9527.0,,22224,
4442,Absolute bioavailability was evaluated in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620933,0,Autocuration,9443.0,,22224,
4443,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620934,0,Autocuration,9443.0,,22224,
4444,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620935,0,Autocuration,9443.0,,22224,
4445,Bioavailability of compound was determined in rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620936,0,Autocuration,9544.0,,22224,
4446,Bioavailability determined after oral administration in marmoset,1,U,,marmosets,,,,,,,BAO_0000218,CHEMBL620937,0,Autocuration,38020.0,,22224,
4447,Oral bioavailability in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL620938,0,Autocuration,9541.0,,22224,
4448,Bioavailability in monkey (p.o.) at 2.0 mpk,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620939,0,Autocuration,9443.0,,22224,
4449,Bioavailability was evaluated after oral administration in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620940,0,Autocuration,9443.0,,22224,
4450,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL620941,0,Autocuration,9541.0,,22224,
4451,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620942,0,Autocuration,9544.0,,22224,
4452,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620943,0,Autocuration,9544.0,,22224,
4453,Bioavailability of the compound was determined in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620944,0,Autocuration,9443.0,,22224,
4454,Bioavailability in squirrel monkey (dose 5 mg/kg),1,U,,Saimiri sciureus,,,,,,,BAO_0000218,CHEMBL620945,0,Autocuration,9521.0,,22224,
4455,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620946,0,Autocuration,9443.0,,22224,
4456,Oral bioavailability in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620947,0,Autocuration,9443.0,,22224,
4457,Compound was tested for bioavailability in squirrel monkey,1,U,,Saimiri sciureus,,,,,,,BAO_0000218,CHEMBL620948,0,Autocuration,9521.0,,22224,
4458,Oral bioavailability in Rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620949,0,Autocuration,9544.0,,22224,
4459,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620950,0,Autocuration,9544.0,,22224,
4460,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL620951,0,Autocuration,9541.0,,22224,
4461,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL620952,0,Autocuration,9541.0,,22224,
4462,Oral bioavailability in monkey (dose 5 mg/kg),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL875421,0,Autocuration,9443.0,,22224,
4463,Oral bioavailability of compound at 5 mg/kg in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620953,0,Autocuration,9443.0,,22224,
4464,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873491,1,Intermediate,9615.0,,50588,
4465,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620954,1,Intermediate,9615.0,,50588,
4466,Plasma half life determined,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620955,1,Intermediate,9615.0,,50588,
4467,Plasma half life in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618097,1,Intermediate,9615.0,,50588,
4468,Plasma half-life in Beagle dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618268,1,Intermediate,9615.0,,50588,
4469,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618269,1,Intermediate,9615.0,,50588,
4470,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618270,1,Intermediate,9615.0,,50588,
4471,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618271,1,Intermediate,9615.0,,50588,
4472,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873493,1,Intermediate,9615.0,,50588,
4473,Tested for the half life period in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621031,1,Intermediate,9615.0,,50588,
4474,Tested for the half life period in dog at dosage of 10 mpk,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621032,1,Intermediate,9615.0,,50588,
4475,The compound was tested for half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621033,1,Intermediate,9615.0,,50588,
4476,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621034,1,Intermediate,9615.0,,50588,
4477,The half life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621035,1,Intermediate,9615.0,,50588,
4478,The plasma half-life in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621036,1,Intermediate,9615.0,,50588,
4479,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621037,1,Intermediate,9615.0,,50588,
4480,Half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619812,1,Intermediate,9615.0,,50588,
4481,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619813,1,Intermediate,9615.0,,50588,
4482,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873335,1,Intermediate,9615.0,,50588,
4483,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619814,1,Intermediate,9615.0,,50588,
4484,Cmax in ferrets after 30 mg/kg oral dose,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL619815,1,Expert,9669.0,,50506,
4485,Emesis in ferrets at 30 mg/kg oral dose,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL619816,1,Expert,9669.0,,50506,
4486,Bioavailability in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL619817,0,Autocuration,9541.0,,22224,
4487,Volume of distribution in cynomolgus,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL619818,1,Intermediate,9541.0,,100710,
4488,AUC tested in guinea pig when 3 mg/kg dose was given perorally,1,U,,Cavia porcellus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619819,0,Autocuration,10141.0,,22224,
4489,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL619820,0,Autocuration,10141.0,,22224,
4490,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL875419,0,Autocuration,10141.0,,22224,
4491,AUC in guinea pig after 3mg/kg oral dose,1,U,,Cavia porcellus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619821,0,Autocuration,10141.0,,22224,
4492,Bioavailability in guinea pig was tested,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL619822,0,Autocuration,10141.0,,22224,
4493,Tested for oral bioavailability in guinea pig at 5 mg/kg,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL619823,0,Autocuration,10141.0,,22224,
4494,Tested for the oral bioavailability of the compound,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL619824,0,Autocuration,10141.0,,22224,
4495,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL619825,0,Autocuration,10141.0,,22224,
4496,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL619826,0,Autocuration,10141.0,,22224,
4497,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,U,,Cavia porcellus,,,,Lung,,2048.0,BAO_0000218,CHEMBL619827,0,Autocuration,10141.0,,22224,
4498,Cmax in guinea pig after 3mg/kg oral dose,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618167,0,Autocuration,10141.0,,22224,
4499,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,Blood,,178.0,BAO_0000019,CHEMBL618168,0,Autocuration,10141.0,,22224,
4500,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,Brain,,955.0,BAO_0000019,CHEMBL618169,0,Autocuration,10141.0,,22224,
4501,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618170,0,Autocuration,10141.0,,22224,
4502,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,Intestine,,160.0,BAO_0000019,CHEMBL618171,0,Autocuration,10141.0,,22224,
4503,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,Kidney,,2113.0,BAO_0000019,CHEMBL618172,0,Autocuration,10141.0,,22224,
4504,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,Liver,,2107.0,BAO_0000019,CHEMBL618173,0,Autocuration,10141.0,,22224,
4505,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618174,0,Autocuration,10141.0,,22224,
4506,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,1,U,,Cavia porcellus,,,,Spleen,,2106.0,BAO_0000019,CHEMBL875408,0,Autocuration,10141.0,,22224,
4507,Elimination T1/2 in Guinea pig (PO dose),1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL839827,0,Autocuration,10141.0,,22224,
4508,Partition coefficient was measured as -log (counts per min ),1,U,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618175,0,Autocuration,10141.0,,22224,
4509,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618176,0,Autocuration,10141.0,,22224,
4510,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618177,0,Autocuration,10141.0,,22224,
4511,Elimination T1/2 in Guinea pig (PO dose),1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618178,0,Autocuration,10141.0,,22224,
4512,"Tested for the half life period of the compound, intravenously",1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618179,0,Autocuration,10141.0,,22224,
4513,Half-life was measured,1,U,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL873489,0,Autocuration,10141.0,,22224,
4514,The time required for onset of inotropy after addition of a single dose of delta F75,1,U,,Cavia porcellus,,,,,,,BAO_0000019,CHEMBL618180,0,Autocuration,10141.0,,22224,
4515,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618181,0,Autocuration,10141.0,,22224,
4516,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL618182,0,Autocuration,10141.0,,22224,
4517,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL618183,0,Autocuration,10029.0,,22224,
4518,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618184,1,Intermediate,10090.0,,50594,
4519,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618185,1,Intermediate,10090.0,,50594,
4520,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618186,1,Intermediate,10090.0,,50594,
4521,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618187,1,Intermediate,10090.0,,50594,
4522,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618188,1,Intermediate,10090.0,,50594,
4523,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875409,1,Intermediate,10090.0,,50594,
4524,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618189,1,Intermediate,10090.0,,50594,
4525,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL618190,1,Intermediate,10090.0,,50594,
4526,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL618191,1,Intermediate,10090.0,,50594,
4527,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL618192,1,Intermediate,10090.0,,50594,
4528,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618193,1,Intermediate,10090.0,,50594,
4529,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618194,1,Intermediate,10090.0,,50594,
4530,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618195,1,Intermediate,10090.0,,50594,
4531,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618196,1,Intermediate,10090.0,,50594,
4532,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618197,1,Intermediate,10090.0,,50594,
4533,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618198,1,Intermediate,10090.0,,50594,
4534,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL618199,1,Intermediate,10090.0,,50594,
4535,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL618200,1,Intermediate,10090.0,,50594,
4536,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL618201,1,Intermediate,10090.0,,50594,
4537,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL618202,1,Intermediate,10090.0,,50594,
4538,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL618203,1,Intermediate,10090.0,,50594,
4539,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL618204,1,Intermediate,10090.0,,50594,
4540,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618205,1,Intermediate,10090.0,,50594,
4541,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618206,1,Intermediate,10090.0,,50594,
4542,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618207,1,Intermediate,10090.0,,50594,
4543,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618208,1,Intermediate,10090.0,,50594,
4544,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618932,1,Intermediate,10090.0,,50594,
4545,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618933,1,Intermediate,10090.0,,50594,
4546,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618934,1,Intermediate,10090.0,,50594,
4547,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618935,1,Intermediate,10090.0,,50594,
4548,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618936,1,Intermediate,10090.0,,50594,
4549,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618937,1,Intermediate,10090.0,,50594,
4550,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618938,1,Intermediate,10090.0,,50594,
4551,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL619104,1,Intermediate,10090.0,,50594,
4552,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL619105,1,Intermediate,10090.0,,50594,
4553,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL619106,1,Intermediate,10090.0,,50594,
4554,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL619107,1,Intermediate,10090.0,,50594,
4555,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL875410,1,Intermediate,10090.0,,50594,
4556,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL619108,1,Intermediate,10090.0,,50594,
4557,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL619109,1,Intermediate,10090.0,,50594,
4558,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619110,1,Intermediate,10090.0,,50594,
4559,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619111,1,Intermediate,10090.0,,50594,
4560,MRT value at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619112,1,Intermediate,10090.0,,50594,
4561,MRT value at a dose of 10 mg/kg peroral administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619113,1,Intermediate,10090.0,,50594,
4562,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619114,1,Intermediate,10090.0,,50594,
4563,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619115,1,Intermediate,10090.0,,50594,
4564,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619116,1,Intermediate,9606.0,,81034,478.0
4565,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619117,1,Intermediate,9606.0,,81034,478.0
4566,Compound was evaluated for cytotoxicity against A2780 cell lines.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619118,1,Intermediate,9606.0,,81034,478.0
4567,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619119,1,Intermediate,9606.0,,81034,478.0
4568,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619120,1,Intermediate,9606.0,,81034,478.0
4569,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619121,1,Intermediate,9606.0,,81034,478.0
4570,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619122,1,Intermediate,9606.0,,81034,478.0
4571,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619123,1,Intermediate,9606.0,,81034,478.0
4572,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619124,1,Intermediate,9606.0,,81034,478.0
4573,Compound was evaluated for cytotoxicity against A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619125,1,Intermediate,9606.0,,81034,478.0
4574,In vitro inhibitory activity against human tumor cell line A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL875411,1,Intermediate,9606.0,,81034,478.0
4575,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619126,1,Intermediate,9606.0,,81034,478.0
4576,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619127,1,Intermediate,9606.0,,81034,478.0
4577,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619128,1,Intermediate,9606.0,,81034,478.0
4578,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619129,1,Intermediate,9606.0,,81034,478.0
4579,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619130,1,Intermediate,9606.0,,81034,478.0
4580,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619131,1,Intermediate,9606.0,,81034,478.0
4581,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619132,1,Intermediate,9606.0,,81034,478.0
4582,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL619133,1,Expert,9606.0,,81034,478.0
4583,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619134,1,Intermediate,9606.0,,81034,478.0
4584,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619135,1,Intermediate,9606.0,,81034,478.0
4585,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619136,1,Intermediate,9606.0,,81034,478.0
4586,Relative resistance factor in A2780 cisplatin-resistant line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619137,1,Intermediate,9606.0,,81034,478.0
4587,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL883713,1,Intermediate,9606.0,,81034,478.0
4588,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL875412,1,Intermediate,9606.0,,81034,478.0
4589,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL619138,1,Expert,9606.0,,81034,478.0
4590,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL619262,1,Expert,9606.0,,81034,478.0
4591,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619139,1,Intermediate,9606.0,,81034,478.0
4592,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619140,1,Intermediate,9606.0,,81034,478.0
4593,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619141,1,Intermediate,9606.0,,81034,478.0
4594,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619142,1,Intermediate,9606.0,,81034,478.0
4595,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619143,1,Intermediate,9606.0,,81034,478.0
4596,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619144,1,Intermediate,9606.0,,81034,478.0
4597,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619145,1,Intermediate,9606.0,,81034,478.0
4598,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619146,1,Intermediate,9606.0,,81034,478.0
4599,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619147,1,Intermediate,9606.0,,81034,478.0
4600,Antiproliferative effect of compound on A2780/DX cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619148,1,Intermediate,9606.0,,81034,478.0
4601,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619149,1,Intermediate,9606.0,,81034,478.0
4602,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619150,1,Intermediate,9606.0,,81034,478.0
4603,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619151,1,Intermediate,9606.0,,81034,478.0
4604,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL883794,1,Intermediate,9606.0,,81034,478.0
4605,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619152,1,Intermediate,9606.0,,81034,478.0
4606,In vitro cytotoxicity against A2780ADR cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619153,1,Intermediate,9606.0,,81034,478.0
4607,In vitro cytotoxicity against A2780CIS cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619154,1,Intermediate,9606.0,,81034,478.0
4608,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619155,1,Intermediate,9606.0,,81034,478.0
4609,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619156,1,Intermediate,9606.0,,81034,478.0
4610,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619157,1,Intermediate,9606.0,,81034,478.0
4611,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619797,1,Intermediate,9606.0,,81034,478.0
4612,Oral bioavailability of compound in rhesus macaques,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL619798,0,Autocuration,9544.0,,22224,
4613,Oral bioavailability in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL619799,0,Autocuration,9443.0,,22224,
4614,Oral bioavailability evaluated in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL619800,0,Autocuration,9443.0,,22224,
4615,Oral bioavailability in monkey (dose 1 mg/kg p.o.),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL619801,0,Autocuration,9443.0,,22224,
4616,Oral bioavailability in Rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL619802,0,Autocuration,9544.0,,22224,
4617,Oral bioavailability was calculated in rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL619803,0,Autocuration,9544.0,,22224,
4618,Oral bioavailability in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL619965,0,Autocuration,9541.0,,22224,
4619,Oral bioavailability in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL619966,0,Autocuration,9443.0,,22224,
4620,Oral bioavailability in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL619967,0,Autocuration,9443.0,,22224,
4621,Oral bioavailability in monkey (dose 1 mg/kg),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620073,0,Autocuration,9443.0,,22224,
4622,Oral bioavailability in monkey (dose 5 mg/kg),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620074,0,Autocuration,9443.0,,22224,
4623,Oral bioavailability in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620075,0,Autocuration,9443.0,,22224,
4624,Oral bioavailability in monkey,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620076,0,Autocuration,9443.0,,22224,
4625,Oral bioavailability in rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620077,0,Autocuration,9544.0,,22224,
4626,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620078,0,Autocuration,9544.0,,22224,
4627,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,1,U,,Saimiri sciureus,,,,,,,BAO_0000218,CHEMBL620079,0,Autocuration,9521.0,,22224,
4628,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620080,0,Autocuration,9443.0,,22224,
4629,Oral bioavailability in Rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620081,0,Autocuration,9544.0,,22224,
4630,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620082,0,Autocuration,9544.0,,22224,
4631,Oral bioavailability in monkey at 10 mg/kg of the compound,1,U,,monkey,,,,,,,BAO_0000218,CHEMBL620083,0,Autocuration,9443.0,,22224,
4632,Bioavailability in Rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620084,0,Autocuration,9544.0,,22224,
4633,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620085,0,Autocuration,9527.0,,22224,
4634,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL874595,0,Autocuration,9527.0,,22224,
4635,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL873352,0,Autocuration,9527.0,,22224,
4636,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620086,0,Autocuration,9527.0,,22224,
4637,Mean residence time was determined after intravenous administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620087,0,Autocuration,9527.0,,22224,
4638,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620088,0,Autocuration,9527.0,,22224,
4639,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620089,0,Autocuration,9527.0,,22224,
4640,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620090,0,Autocuration,9527.0,,22224,
4641,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620091,0,Autocuration,9527.0,,22224,
4642,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),1,U,,Cercopithecidae,,Microsomes,,,,,BAO_0000251,CHEMBL620092,0,Autocuration,9527.0,,22224,
4643,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),1,U,,Cercopithecidae,,Microsomes,,,,,BAO_0000251,CHEMBL620093,0,Autocuration,9527.0,,22224,
4644,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),1,U,,Cercopithecidae,,Microsomes,,,,,BAO_0000251,CHEMBL620094,0,Autocuration,9527.0,,22224,
4645,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),1,U,,Cercopithecidae,,Microsomes,,,,,BAO_0000251,CHEMBL620095,0,Autocuration,9527.0,,22224,
4646,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620096,0,Autocuration,9527.0,,22224,
4647,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620097,0,Autocuration,9527.0,,22224,
4648,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL620098,0,Autocuration,9527.0,,22224,
4649,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620099,0,Autocuration,9527.0,,22224,
4650,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620100,0,Autocuration,9527.0,,22224,
4651,Elimination Half-life of compound was determined in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL620101,0,Autocuration,9527.0,,22224,
4652,Half life of compound was determined in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL620102,0,Autocuration,9527.0,,22224,
4653,Half life in monkey plasma,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000366,CHEMBL620103,0,Autocuration,9527.0,,22224,
4654,Half life in monkey plasma; Not detected,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000366,CHEMBL620104,0,Autocuration,9527.0,,22224,
4655,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL874596,0,Autocuration,9527.0,,22224,
4656,Half-life 24 hr after 2 mg/kg iv administration in monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL873490,0,Autocuration,9527.0,,22224,
4657,Terminal half life of the compound.,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL620105,0,Autocuration,9527.0,,22224,
4658,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620780,0,Autocuration,9527.0,,22224,
4659,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620781,0,Autocuration,9527.0,,22224,
4660,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620956,0,Autocuration,9527.0,,22224,
4661,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,Urine,,1088.0,BAO_0000218,CHEMBL620957,0,Autocuration,9527.0,,22224,
4662,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,Urine,,1088.0,BAO_0000218,CHEMBL620958,0,Autocuration,9527.0,,22224,
4663,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620959,0,Autocuration,9527.0,,22224,
4664,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620960,0,Autocuration,9527.0,,22224,
4665,Volume of distribution was evaluated in rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL620961,0,Autocuration,9527.0,,22224,
4666,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL620962,0,Autocuration,10029.0,,22224,
4667,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL620963,0,Autocuration,10029.0,,22224,
4668,Bioavailability in hamster was determined,1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL620964,0,Autocuration,10029.0,,22224,
4669,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL620965,0,Autocuration,10029.0,,22224,
4670,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL620966,0,Autocuration,10029.0,,22224,
4671,Half life of compound was determined in hamster blood,1,U,,Cricetulus griseus,,,,Blood,,178.0,BAO_0000221,CHEMBL620967,0,Autocuration,10029.0,,22224,
4672,Michaelis-Menten constant of the compound.,1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL620968,0,Autocuration,9823.0,,22224,
4673,Vmax value was measured at 0 uM concentration of silyl ether.,1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL874597,0,Autocuration,9823.0,,22224,
4674,Vmax value was measured at 10 uM concentration of silyl ether.,1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL620969,0,Autocuration,9823.0,,22224,
4675,Vmax value was measured at 5 uM concentration of silyl ether.,1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL620970,0,Autocuration,9823.0,,22224,
4676,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL620971,9,Expert,9606.0,,235,
4677,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL620972,0,Autocuration,9606.0,,22224,
4678,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620973,0,Autocuration,9606.0,,22224,
4679,Active metabolite of ifosfamide determined in humans; A-Active,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618243,0,Autocuration,9606.0,,22224,
4680,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618244,0,Autocuration,9606.0,,22224,
4681,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618245,0,Autocuration,9606.0,,22224,
4682,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618246,0,Autocuration,9606.0,,22224,
4683,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618247,0,Autocuration,9606.0,,22224,
4684,Compound was evaluated for oral bioavailability in human,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL618248,0,Autocuration,9606.0,,22224,
4685,Metabolite of ifosfamide determined in urine; NF-Not found,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618249,0,Autocuration,9606.0,,22224,
4686,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618250,0,Autocuration,9606.0,,22224,
4687,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL874598,0,Autocuration,9606.0,,22224,
4688,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618251,0,Autocuration,9606.0,,22224,
4689,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618252,0,Autocuration,9606.0,,22224,
4690,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618253,0,Autocuration,9606.0,,22224,
4691,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618254,0,Autocuration,9606.0,,22224,
4692,Percent of compound in healthy individuals (Group D),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618255,0,Autocuration,9606.0,,22224,
4693,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618983,0,Autocuration,9606.0,,22224,
4694,Binding towards human plasma protein at 10 uM,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618984,0,Autocuration,9606.0,,22224,
4695,Binding towards human plasma protein at 100 uM,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618985,0,Autocuration,9606.0,,22224,
4696,Human plasma protein binding activity was determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618986,0,Autocuration,9606.0,,22224,
4697,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618987,0,Autocuration,9606.0,,22224,
4698,Percent binding of compound towards human plasma protein was determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618988,0,Autocuration,9606.0,,22224,
4699,Plasma clearance in human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618989,0,Autocuration,9606.0,,22224,
4700,In vitro intrinsic clearance in human liver microsome,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618990,0,Autocuration,9606.0,,22224,
4701,In vitro intrinsic clearance in human liver microsome,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618991,0,Autocuration,9606.0,,22224,
4702,In vitro microsome metabolism clearance in human was determined,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL876725,0,Autocuration,9606.0,,22224,
4703,In vitro microsome metabolism clearance in human was determined; High,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL618992,0,Autocuration,9606.0,,22224,
4704,In vitro microsome metabolism clearance in human was determined; ND denotes no data,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL618993,0,Autocuration,9606.0,,22224,
4705,Pharmacokinetic property (clearance) in human liver microsome,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618994,0,Autocuration,9606.0,,22224,
4706,Plasma clearance in human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618995,0,Autocuration,9606.0,,22224,
4707,In vitro clearance in human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618996,0,Autocuration,9606.0,,22224,
4708,Intrinsic clearance in human liver microsomes was determined,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618997,0,Autocuration,9606.0,,22224,
4709,Intrinsic clearance in human liver microsomes was determined,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618998,0,Autocuration,9606.0,,22224,
4710,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL618999,0,Autocuration,9606.0,,22224,
4711,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL620223,0,Autocuration,9606.0,,22224,
4712,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL620224,0,Autocuration,9606.0,,22224,
4713,Stability in human plasma 2 hr after incubation expressed as percent concentration,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620225,0,Autocuration,9606.0,,22224,
4714,Stability in human plasma 4 hr after incubation expressed as percent concentration,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620226,0,Autocuration,9606.0,,22224,
4715,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL620227,0,Autocuration,9606.0,,22224,
4716,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL876726,0,Autocuration,9606.0,,22224,
4717,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL620228,0,Autocuration,9606.0,,22224,
4718,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL620229,0,Autocuration,9606.0,,22224,
4719,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620230,1,Intermediate,10090.0,,50594,
4720,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620231,1,Intermediate,10090.0,,50594,
4721,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620232,1,Intermediate,10090.0,,50594,
4722,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620233,1,Intermediate,10090.0,,50594,
4723,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620234,1,Intermediate,10090.0,,50594,
4724,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620235,1,Intermediate,10090.0,,50594,
4725,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620236,1,Intermediate,10090.0,,50594,
4726,In vitro metabolic potential in mouse liver microsomes,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL620237,1,Intermediate,10090.0,,50594,
4727,Ability of compound to bind to plasma protein was evaluated in HSA cells,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620238,1,Intermediate,10090.0,,50594,
4728,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),1,N,,Mus musculus,,,,Adrenal gland,,2369.0,BAO_0000218,CHEMBL620239,1,Intermediate,10090.0,,50594,
4729,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL620240,1,Intermediate,10090.0,,50594,
4730,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL620241,1,Intermediate,10090.0,,50594,
4731,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876727,1,Intermediate,10090.0,,50594,
4732,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL620242,1,Intermediate,10090.0,,50594,
4733,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620243,1,Intermediate,10090.0,,50594,
4734,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620244,1,Intermediate,10090.0,,50594,
4735,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1,N,,Mus musculus,,,,Serum,,1977.0,BAO_0000218,CHEMBL620245,1,Intermediate,10090.0,,50594,
4736,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1,N,,Mus musculus,,,,Serum,,1977.0,BAO_0000218,CHEMBL620246,1,Intermediate,10090.0,,50594,
4737,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1,N,,Mus musculus,,,,Serum,,1977.0,BAO_0000218,CHEMBL620247,1,Intermediate,10090.0,,50594,
4738,Half life of compound was determined in plasma of mice at 24 mg/Kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620248,1,Intermediate,10090.0,,50594,
4739,Half life of compound was determined in plasma of mice at 40 mg/Kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873497,1,Intermediate,10090.0,,50594,
4740,Half life of compound was determined in plasma of mice at 5 mg/Kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620249,1,Intermediate,10090.0,,50594,
4741,Half life after intraperitoneal administration in mice at 18 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620250,1,Intermediate,10090.0,,50594,
4742,Half life after intraperitoneal administration in mice at 23 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620251,1,Intermediate,10090.0,,50594,
4743,Half life after intraperitoneal administration in mice at 25 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620252,1,Intermediate,10090.0,,50594,
4744,Half life after intraperitoneal administration in mice at 26 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620253,1,Intermediate,10090.0,,50594,
4745,Half life after intravenous administration in mice at 23 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620254,1,Intermediate,10090.0,,50594,
4746,Half life after intravenous administration in mice at 24 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620255,1,Intermediate,10090.0,,50594,
4747,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620256,1,Intermediate,10090.0,,50594,
4748,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876728,1,Intermediate,10090.0,,50594,
4749,Maximum time required to reach Cp max was evaluated in mice after oral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620257,1,Intermediate,10090.0,,50594,
4750,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620258,1,Intermediate,10090.0,,50594,
4751,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620259,1,Intermediate,10090.0,,50594,
4752,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620260,1,Intermediate,10090.0,,50594,
4753,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL620261,1,Intermediate,10090.0,,50594,
4754,Half life at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620262,1,Intermediate,10090.0,,50594,
4755,Half life at a dose of 10 mg/kg peroral administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620263,1,Intermediate,10090.0,,50594,
4756,Half life in ob/ob mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620264,1,Intermediate,10090.0,,50594,
4757,Half-life at a single subcutaneous administration of 40 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620265,1,Intermediate,10090.0,,50594,
4758,Half-life was measured in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620266,1,Intermediate,10090.0,,50594,
4759,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620267,1,Intermediate,10090.0,,50594,
4760,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619364,1,Intermediate,10090.0,,50594,
4761,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619365,1,Intermediate,10090.0,,50594,
4762,T2 in brain of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL619366,1,Intermediate,10090.0,,50594,
4763,T2 in kidney of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619367,1,Intermediate,10090.0,,50594,
4764,T2 in liver of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL619368,1,Intermediate,10090.0,,50594,
4765,T2 in lungs of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL619369,1,Intermediate,10090.0,,50594,
4766,T2 in spleen of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL876729,1,Intermediate,10090.0,,50594,
4767,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619370,1,Intermediate,10090.0,,50594,
4768,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619371,1,Intermediate,10090.0,,50594,
4769,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619372,1,Intermediate,10090.0,,50594,
4770,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620012,1,Intermediate,10090.0,,50594,
4771,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620013,1,Intermediate,10090.0,,50594,
4772,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL620014,1,Intermediate,9606.0,,81034,478.0
4773,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL620015,1,Intermediate,9606.0,,81034,478.0
4774,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621010,1,Intermediate,9606.0,,81034,478.0
4775,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621011,1,Intermediate,9606.0,,81034,478.0
4776,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621012,1,Intermediate,9606.0,,81034,478.0
4777,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621013,1,Intermediate,9606.0,,81034,478.0
4778,In vitro cytotoxicity against A2780TAX cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621014,1,Intermediate,9606.0,,81034,478.0
4779,In vitro inhibitory activity against human tumor cell line A2780cis,1,N,,Homo sapiens,,,,,A2780cisR,,BAO_0000219,CHEMBL618154,1,Intermediate,9606.0,,80017,481.0
4780,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618155,1,Expert,9606.0,,81034,478.0
4781,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,1,N,,Homo sapiens,,,,,A2780cisR,,BAO_0000219,CHEMBL618156,1,Intermediate,9606.0,,80017,481.0
4782,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,N,,Homo sapiens,,,,,A2780cisR,,BAO_0000219,CHEMBL618157,1,Intermediate,9606.0,,80017,481.0
4783,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618328,1,Intermediate,9606.0,,81034,478.0
4784,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618329,1,Intermediate,9606.0,,81034,478.0
4785,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618330,1,Intermediate,9606.0,,81034,478.0
4786,In vitro antitumor activity against A2780cisR cell line.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618331,1,Expert,9606.0,,81034,478.0
4787,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618332,1,Intermediate,9606.0,,81034,478.0
4788,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618333,1,Expert,9606.0,,81034,478.0
4789,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,1,N,,Homo sapiens,,,,,A2780cisR,,BAO_0000219,CHEMBL618334,1,Intermediate,9606.0,,80017,481.0
4790,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618335,1,Expert,9606.0,,81034,478.0
4791,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL618336,9,Expert,10116.0,,11736,
4792,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,H,,,,,,,,,BAO_0000019,CHEMBL618337,8,Expert,,,11736,
4793,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,D,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL618338,9,Expert,10116.0,,11736,
4794,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL618339,9,Expert,9606.0,,278,722.0
4795,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,1,D,,Homo sapiens,,,,,HEK293,,BAO_0000219,CHEMBL618340,9,Expert,9606.0,,278,722.0
4796,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,1,D,,Mus musculus,,,,,,,BAO_0000019,CHEMBL618341,9,Expert,10090.0,,11831,
4797,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,H,,,,,,,,,BAO_0000019,CHEMBL618342,8,Expert,,,11831,
4798,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,D,,Mus musculus,,,,,,,BAO_0000019,CHEMBL618343,9,Expert,10090.0,,11831,
4799,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,1,H,,,,,,,,,BAO_0000357,CHEMBL621038,8,Expert,,,280,
4800,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),1,U,,Homo sapiens,,,,,T-cells,,BAO_0000219,CHEMBL621039,0,Autocuration,9606.0,,22226,574.0
4801,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,1,U,,Homo sapiens,,,,,T-cells,,BAO_0000219,CHEMBL621040,0,Autocuration,9606.0,,22226,574.0
4802,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621041,1,Intermediate,9606.0,,80018,455.0
4803,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621042,1,Intermediate,9606.0,,80018,455.0
4804,In vitro antitumor activity against A375cell line extracted form melanoma,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621043,1,Intermediate,9606.0,,80018,455.0
4805,Inhibition of cell growth in (A375) melan cell line,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621044,1,Expert,9606.0,,80018,455.0
4806,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621045,1,Intermediate,9606.0,,80018,455.0
4807,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621046,1,Intermediate,9606.0,,80018,455.0
4808,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL621047,1,Intermediate,9606.0,,80018,455.0
4809,Antiproliferative activity measured against A427 human lung carcinoma,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621048,1,Intermediate,9606.0,,80019,797.0
4810,Antiproliferative activity measured against A427 human lung carcinoma,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL883798,1,Intermediate,9606.0,,80019,797.0
4811,Cytotoxicity against lung carcinoma A427 tumor cell lines,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621049,1,Intermediate,9606.0,,80019,797.0
4812,Inhibition of large cell lung carcinoma (A427),1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621050,1,Intermediate,9606.0,,80019,797.0
4813,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621051,1,Intermediate,9606.0,,80019,797.0
4814,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621052,1,Intermediate,9606.0,,80019,797.0
4815,Inhibitory concentration in human lung carcinoma A427 cell line,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621053,1,Intermediate,9606.0,,80019,797.0
4816,Inhibitory concentration in human lung carcinoma A427/VCR cell line,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL621054,1,Intermediate,9606.0,,80019,797.0
4817,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621055,0,Autocuration,9527.0,,22224,
4818,Tested for volume of distribution upon iv administration to african green monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL876398,0,Autocuration,9527.0,,22224,
4819,Volume of distribution in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621056,0,Autocuration,9527.0,,22224,
4820,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL621057,0,Autocuration,9544.0,,22224,
4821,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL621058,0,Autocuration,9544.0,,22224,
4822,Pharmacokinetic property(Vdss) in cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621059,0,Autocuration,9527.0,,22224,
4823,The distribution volume after intravenous administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621060,0,Autocuration,9527.0,,22224,
4824,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621061,0,Autocuration,9527.0,,22224,
4825,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621062,0,Autocuration,9527.0,,22224,
4826,Volume displacement was calculated in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621063,0,Autocuration,9527.0,,22224,
4827,Volume of distribution in steady state was determined in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621064,0,Autocuration,9527.0,,22224,
4828,Volume of distribution of compound was determined in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621065,0,Autocuration,9527.0,,22224,
4829,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621066,0,Autocuration,9527.0,,22224,
4830,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621067,0,Autocuration,9527.0,,22224,
4831,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621068,0,Autocuration,9527.0,,22224,
4832,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL876399,0,Autocuration,9527.0,,22224,
4833,Volume distribution in monkey after administration of 1 mg/kg iv,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621069,0,Autocuration,9527.0,,22224,
4834,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621070,0,Autocuration,9527.0,,22224,
4835,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621071,0,Autocuration,9527.0,,22224,
4836,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621072,0,Autocuration,9527.0,,22224,
4837,Oral systemic bioavailability upon iv administration to african green monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618209,0,Autocuration,9527.0,,22224,
4838,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618210,0,Autocuration,9527.0,,22224,
4839,Baboon plasma free fraction. ,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618211,0,Autocuration,9527.0,,22224,
4840,Area under the curve was calculated in rhesus monkey after iv administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618212,0,Autocuration,9527.0,,22224,
4841,Area under the curve was calculated in rhesus monkey after peroral administration,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618213,0,Autocuration,9527.0,,22224,
4842,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618214,0,Autocuration,9527.0,,22224,
4843,Half life period in monkey after 5 mg/kg dose,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL873492,0,Autocuration,9527.0,,22224,
4844,Half-life was determined in monkey after 3 mg/kg of i.v. dose,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618272,0,Autocuration,9527.0,,22224,
4845,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618273,0,Autocuration,9527.0,,22224,
4846,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618274,0,Autocuration,9527.0,,22224,
4847,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618275,0,Autocuration,9527.0,,22224,
4848,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618276,0,Autocuration,9527.0,,22224,
4849,Compound was evaluated for terminal half life in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618277,0,Autocuration,9527.0,,22224,
4850,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618278,0,Autocuration,9527.0,,22224,
4851,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,U,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618279,0,Autocuration,9544.0,,22224,
4852,Half life of compound was determined in squirrel monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618280,0,Autocuration,9527.0,,22224,
4853,Half life after iv administration in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL618281,0,Autocuration,9541.0,,22224,
4854,Half life in monkey plasma after administration of 1 mg/kg iv,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618282,0,Autocuration,9527.0,,22224,
4855,Half life was calculated in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618283,0,Autocuration,9527.0,,22224,
4856,Half life in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618284,0,Autocuration,9527.0,,22224,
4857,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618285,0,Autocuration,9527.0,,22224,
4858,Half life was evaluated in rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618286,0,Autocuration,9527.0,,22224,
4859,Half life period after oral administration (2.5 mg/kg) in monkey was determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618287,0,Autocuration,9527.0,,22224,
4860,Half life period was determine after peroral administration at 10 mpk in Rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618288,0,Autocuration,9527.0,,22224,
4861,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL876393,0,Autocuration,9527.0,,22224,
4862,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618289,0,Autocuration,9527.0,,22224,
4863,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618290,0,Autocuration,9527.0,,22224,
4864,Half-life was calculated in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618291,0,Autocuration,9527.0,,22224,
4865,Half-life in Squirrel monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618292,0,Autocuration,9527.0,,22224,
4866,Half-life in rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618293,0,Autocuration,9527.0,,22224,
4867,Half-life was measured in monkey after an iv dose of 1 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618294,0,Autocuration,9527.0,,22224,
4868,Half-life period after intravenous administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618295,0,Autocuration,9527.0,,22224,
4869,Half-life period after oral administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618296,0,Autocuration,9527.0,,22224,
4870,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618297,0,Autocuration,9527.0,,22224,
4871,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618298,0,Autocuration,9606.0,,22224,
4872,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618299,0,Autocuration,9606.0,,22224,
4873,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618300,0,Autocuration,9606.0,,22224,
4874,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618301,0,Autocuration,9606.0,,22224,
4875,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618302,0,Autocuration,9606.0,,22224,
4876,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL876394,0,Autocuration,9606.0,,22224,
4877,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618303,0,Autocuration,9606.0,,22224,
4878,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618304,0,Autocuration,9606.0,,22224,
4879,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL618305,0,Autocuration,9606.0,,22224,
4880,Oral bioavailability in human,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL618306,0,Autocuration,9606.0,,22224,
4881,Compound was tested for human plasma protein binding,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618307,0,Autocuration,9606.0,,22224,
4882,Compound was tested for human plasma protein binding; Not determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618308,0,Autocuration,9606.0,,22224,
4883,Protein binding activity of compound in human plasma; % Free,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618309,0,Autocuration,9606.0,,22224,
4884,Unbound fraction (plasma),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618310,0,Autocuration,9606.0,,22224,
4885,Half life for the hydrolysis of compound in human blood serum,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL873353,0,Autocuration,9606.0,,22224,
4886,Half life period in human plasma using phosphate buffer (0.08 M),1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618311,0,Autocuration,9606.0,,22224,
4887,Half life period in human plasma using phosphate buffer (0.1 M),1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618312,0,Autocuration,9606.0,,22224,
4888,Half-life in human plasma was determined,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618313,0,Autocuration,9606.0,,22224,
4889,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618314,0,Autocuration,9606.0,,22224,
4890,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618315,0,Autocuration,9606.0,,22224,
4891,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618316,0,Autocuration,9606.0,,22224,
4892,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618317,0,Autocuration,9606.0,,22224,
4893,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620138,0,Autocuration,9606.0,,22224,
4894,Partition coefficient (logP),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL858280,0,Autocuration,9606.0,,22224,
4895,In vitro metabolic stability in human was measured as pmol/min/mg/protein,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620139,0,Autocuration,9606.0,,22224,
4896,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL620140,0,Autocuration,9606.0,,22224,
4897,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620141,0,Autocuration,9606.0,,22224,
4898,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620142,0,Autocuration,9606.0,,22224,
4899,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL620143,0,Autocuration,9606.0,,22224,
4900,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL620144,0,Autocuration,9606.0,,22224,
4901,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL620145,0,Autocuration,9606.0,,22224,
4902,Metabolism of compound in human microsomes; Trace,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL620146,0,Autocuration,9606.0,,22224,
4903,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620147,0,Autocuration,9606.0,,22224,
4904,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL620148,0,Autocuration,9606.0,,22224,
4905,In vitro metabolic potential in human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL620149,0,Autocuration,9606.0,,22224,
4906,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL876412,0,Autocuration,9606.0,,22224,
4907,Tested for human plasma protein binding of the compound; Not tested,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619352,0,Autocuration,9606.0,,22224,
4908,Compound was tested for percent protein binding (PB) in human,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619353,0,Autocuration,9606.0,,22224,
4909,Protein binding in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000019,CHEMBL619354,0,Autocuration,9606.0,,22224,
4910,Permeability coefficient (B to A) in Caco-2 cell,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619355,0,Autocuration,9606.0,,22224,
4911,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619356,0,Autocuration,9606.0,,22224,
4912,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619357,0,Autocuration,9606.0,,22224,
4913,In vitro rate of absorption observed as Caco-2 permeability in humans,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619358,0,Autocuration,9606.0,,22224,
4914,Cellular permeability of compound was determined in Caco-2 cells; High,1,U,,Homo sapiens,,,,,Caco-2,,BAO_0000219,CHEMBL619359,0,Autocuration,9606.0,,22224,495.0
4915,Permeability in Caco-2 cells of compound,1,U,,Homo sapiens,,,,,Caco-2,,BAO_0000219,CHEMBL619360,0,Autocuration,9606.0,,22224,495.0
4916,Permeability coefficient (A to B) in Caco-2 cell,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619361,0,Autocuration,9606.0,,22224,
4917,Permeability coefficient (B to A) in Caco-2 cell,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619362,0,Autocuration,9606.0,,22224,
4918,Permeability coefficient (Papp) (Caco-2 cell monolayer),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619363,0,Autocuration,9606.0,,22224,
4919,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618942,0,Autocuration,9606.0,,22224,
4920,Compound was tested for protein binding in human plasma,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618943,0,Autocuration,9606.0,,22224,
4921,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618944,0,Autocuration,9606.0,,22224,
4922,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL618945,0,Autocuration,9606.0,,22224,
4923,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618946,1,Intermediate,10090.0,,50594,
4924,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876413,1,Intermediate,10090.0,,50594,
4925,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618947,1,Intermediate,10090.0,,50594,
4926,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618948,1,Intermediate,10090.0,,50594,
4927,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618949,1,Intermediate,10090.0,,50594,
4928,Tmax after intraperitoneal administration in mice at 23 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618950,1,Intermediate,10090.0,,50594,
4929,Tmax after oral administration at 30 mg/kg in ICR mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618951,1,Intermediate,10090.0,,50594,
4930,Tmax after peroral administration in mice at 2.4 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618952,1,Intermediate,10090.0,,50594,
4931,Tmax at a single subcutaneous administration of 40 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618953,1,Intermediate,10090.0,,50594,
4932,Tmax in brain of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618954,1,Intermediate,10090.0,,50594,
4933,Tmax in kidney of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618955,1,Intermediate,10090.0,,50594,
4934,Tmax in liver of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618956,1,Intermediate,10090.0,,50594,
4935,Tmax in lungs of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618957,1,Intermediate,10090.0,,50594,
4936,Tmax in mice at 18 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618958,1,Intermediate,10090.0,,50594,
4937,Tmax in mice at 23 uM/kg i.v. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618959,1,Intermediate,10090.0,,50594,
4938,Tmax in mice at 25 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618960,1,Intermediate,10090.0,,50594,
4939,Tmax in mice at 26 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876723,1,Intermediate,10090.0,,50594,
4940,Tmax in spleen of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618961,1,Intermediate,10090.0,,50594,
4941,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618962,1,Intermediate,10090.0,,50594,
4942,Tmax value at a dose of 10 mg/kg peroral administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618963,1,Intermediate,10090.0,,50594,
4943,Tmax value in IRC mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618964,1,Intermediate,10090.0,,50594,
4944,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618965,1,Intermediate,10090.0,,50594,
4945,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618966,1,Intermediate,10090.0,,50594,
4946,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618967,1,Intermediate,10090.0,,50594,
4947,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618968,1,Intermediate,10090.0,,50594,
4948,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618969,1,Intermediate,10090.0,,50594,
4949,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618970,1,Intermediate,10090.0,,50594,
4950,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618971,1,Intermediate,10090.0,,50594,
4951,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618972,1,Intermediate,10090.0,,50594,
4952,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618973,1,Intermediate,10090.0,,50594,
4953,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618974,1,Intermediate,10090.0,,50594,
4954,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618975,1,Intermediate,10090.0,,50594,
4955,Vd in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618976,1,Intermediate,10090.0,,50594,
4956,Volume of distribution in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618977,1,Intermediate,10090.0,,50594,
4957,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876724,1,Intermediate,10090.0,,50594,
4958,Volume of distribution of compound in plasma was determined at 24 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618978,1,Intermediate,10090.0,,50594,
4959,Volume of distribution of compound in plasma was determined at 40 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618979,1,Intermediate,10090.0,,50594,
4960,Volume of distribution of compound in plasma was determined at 5 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618980,1,Intermediate,10090.0,,50594,
4961,Pharmacokinetic property (vdss) was measured in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618981,1,Intermediate,10090.0,,50594,
4962,Value distribution upon iv administration in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618982,1,Intermediate,10090.0,,50594,
4963,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620150,1,Intermediate,10090.0,,50594,
4964,Volume of distribution was evaluated in mice after intravenous administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620151,1,Intermediate,10090.0,,50594,
4965,Volume of distribution was evaluated in mice after oral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620152,1,Intermediate,10090.0,,50594,
4966,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620153,1,Intermediate,10090.0,,50594,
4967,Steady state volume of distribution was determined in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876395,1,Intermediate,10090.0,,50594,
4968,Volume distribution (steady state) of compound was determined in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620154,1,Intermediate,10090.0,,50594,
4969,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620155,1,Intermediate,10090.0,,50594,
4970,Vss value at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620156,1,Intermediate,10090.0,,50594,
4971,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620157,1,Intermediate,10090.0,,50594,
4972,Biodistribution of compound (oxidized form) in in kidney tissue,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL620158,1,Intermediate,10090.0,,50594,
4973,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL620159,1,Intermediate,10090.0,,50594,
4974,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL620160,1,Intermediate,10090.0,,50594,
4975,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL620161,1,Intermediate,10090.0,,50594,
4976,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL620162,1,Intermediate,9606.0,,80019,797.0
4977,Inhibition of A431 human squamous cell carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL620163,1,Expert,9606.0,,80852,500.0
4978,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL620833,1,Expert,9606.0,,80852,500.0
4979,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL876396,1,Expert,9606.0,,80852,500.0
4980,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL620834,1,Expert,9606.0,,80852,500.0
4981,Inhibition of A431 human carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL620835,1,Expert,9606.0,,80852,500.0
4982,In vitro inhibition of A431 (human carcinoma) cell basal growth.,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL620836,1,Expert,9606.0,,80852,500.0
4983,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL620837,1,Intermediate,9606.0,,80852,500.0
4984,In vitro cytotoxicity against epidermoid carcinoma cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621017,1,Intermediate,9606.0,,80852,500.0
4985,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",1,D,,Homo sapiens,,,,,A-431,,BAO_0000218,CHEMBL621018,9,Expert,9606.0,,9,500.0
4986,Antiproliferative activity of compound was measured on human tumor cell line A431.,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621019,1,Intermediate,9606.0,,80852,500.0
4987,Antiproliferative effect of compound on A431 cell line expressing mutant p53,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621020,1,Intermediate,9606.0,,80852,500.0
4988,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621021,1,Intermediate,9606.0,,80852,500.0
4989,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,1,H,,,,,,,A-431,,BAO_0000219,CHEMBL621022,8,Expert,,,9,500.0
4990,Tested for antiproliferative activity against human A431 cells,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621023,1,Expert,9606.0,,80852,500.0
4991,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621024,9,Expert,9606.0,,9,500.0
4992,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621025,1,Expert,9606.0,,80852,500.0
4993,Inhibition of A431 cell proliferation,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621026,1,Expert,9606.0,,80852,500.0
4994,Cytotoxic effect on A431 human epidermoid carcinoma cells,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621027,1,Expert,9606.0,,80852,500.0
4995,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL876397,1,Expert,9606.0,,80852,500.0
4996,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL883797,1,Intermediate,9606.0,,80852,500.0
4997,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621028,1,Intermediate,9606.0,,80852,500.0
4998,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621029,1,Intermediate,9606.0,,80852,500.0
4999,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621030,1,Intermediate,9606.0,,80852,500.0
5000,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,1,H,,,,,,,A-431,,BAO_0000219,CHEMBL621147,8,Expert,,,9,500.0
5001,In vivo antiproliferative activity against A431 cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000218,CHEMBL621148,1,Intermediate,9606.0,,80852,500.0
5002,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621149,9,Expert,9606.0,,9,500.0
5003,Inhibition of A431 human epidermoid carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621150,1,Expert,9606.0,,80852,500.0
5004,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621151,9,Expert,9606.0,,9,500.0
5005,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621152,1,Intermediate,9606.0,,80852,500.0
5006,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621153,1,Intermediate,9606.0,,80852,500.0
5007,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL884000,1,Intermediate,9606.0,,80852,500.0
5008,Inhibition of EGFR overexpressing A431 cell proliferation,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL621154,9,Expert,9606.0,,9,
5009,Inhibition of A431 cell proliferation,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621155,1,Expert,9606.0,,80852,500.0
5010,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621156,9,Expert,9606.0,,9,500.0
5011,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621157,9,Expert,9606.0,,9,500.0
5012,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),1,H,,,,,,,A-431,,BAO_0000219,CHEMBL621158,8,Expert,,,9,500.0
5013,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621159,1,Intermediate,9606.0,,80852,500.0
5014,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621160,1,Intermediate,9606.0,,80852,500.0
5015,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621161,1,Intermediate,9606.0,,80852,500.0
5016,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621162,1,Intermediate,9606.0,,80852,500.0
5017,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621163,1,Intermediate,9606.0,,80852,500.0
5018,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621164,1,Intermediate,9606.0,,80852,500.0
5019,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621165,1,Intermediate,9606.0,,80852,500.0
5020,Half-life period in cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619159,0,Autocuration,9527.0,,22224,
5021,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000366,CHEMBL619160,0,Autocuration,9527.0,,22224,
5022,Longer half-life in monkey (i.v.) at 0.5 mpk,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL619161,0,Autocuration,9527.0,,22224,
5023,Plasma half life in monkey,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000366,CHEMBL619162,0,Autocuration,9527.0,,22224,
5024,Plasma half-life in rhesus monkey,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000366,CHEMBL619163,0,Autocuration,9527.0,,22224,
5025,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619164,0,Autocuration,9527.0,,22224,
5026,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619320,0,Autocuration,9527.0,,22224,
5027,Tested for half life upon iv administration to african green monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL619321,0,Autocuration,9527.0,,22224,
5028,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL873336,0,Autocuration,9527.0,,22224,
5029,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL619322,0,Autocuration,9527.0,,22224,
5030,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL619323,0,Autocuration,9527.0,,22224,
5031,The time for peak concentration value after oral administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL619324,0,Autocuration,9527.0,,22224,
5032,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619325,0,Autocuration,9527.0,,22224,
5033,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL876411,0,Autocuration,9527.0,,22224,
5034,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619326,0,Autocuration,9527.0,,22224,
5035,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619327,0,Autocuration,9527.0,,22224,
5036,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619328,0,Autocuration,9527.0,,22224,
5037,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619329,0,Autocuration,9527.0,,22224,
5038,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619330,0,Autocuration,9527.0,,22224,
5039,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619331,0,Autocuration,9527.0,,22224,
5040,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619332,0,Autocuration,9527.0,,22224,
5041,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619333,0,Autocuration,9527.0,,22224,
5042,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619334,0,Autocuration,9527.0,,22224,
5043,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619335,0,Autocuration,9527.0,,22224,
5044,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619336,0,Autocuration,9527.0,,22224,
5045,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619337,0,Autocuration,9527.0,,22224,
5046,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619338,0,Autocuration,9527.0,,22224,
5047,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL619339,0,Autocuration,9527.0,,22224,
5048,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619340,1,Intermediate,10116.0,,50597,
5049,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873496,1,Intermediate,10116.0,,50597,
5050,AUC value in rat after IV administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619341,1,Intermediate,10116.0,,50597,
5051,AUC value in rat after oral administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619342,1,Intermediate,10116.0,,50597,
5052,Cmax value in rat after oral administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619343,1,Intermediate,10116.0,,50597,
5053,Bioavailability in rat after oral administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619344,1,Intermediate,10116.0,,50597,
5054,Tmax value in rat after oral administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619345,1,Intermediate,10116.0,,50597,
5055,Vc value in rat after IV administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619346,1,Intermediate,10116.0,,50597,
5056,Half life period in rat after IV administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619347,1,Intermediate,10116.0,,50597,
5057,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL619348,0,Autocuration,9557.0,,22224,
5058,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL619349,0,Autocuration,9557.0,,22224,
5059,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL619350,0,Autocuration,9557.0,,22224,
5060,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL619351,0,Autocuration,9557.0,,22224,
5061,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL875953,0,Autocuration,9557.0,,22224,
5062,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL621716,0,Autocuration,9557.0,,22224,
5063,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL621717,0,Autocuration,9557.0,,22224,
5064,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,U,,Papio hamadryas,,,,,,,BAO_0000019,CHEMBL621718,0,Autocuration,9557.0,,22224,
5065,Area under curve after 1 mpk peroral administration to beagles,1,U,,beagle,,,,,,,BAO_0000019,CHEMBL621719,0,Autocuration,9615.0,,22224,
5066,Area under curve after 2 mpk peroral administration to beagles,1,U,,beagle,,,,,,,BAO_0000019,CHEMBL621720,0,Autocuration,9615.0,,22224,
5067,Cmax value after 1 mpk peroral administration to beagles,1,U,,beagle,,,,,,,BAO_0000218,CHEMBL621721,0,Autocuration,9615.0,,22224,
5068,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL621722,0,Autocuration,9606.0,,22224,
5069,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL621723,0,Autocuration,9606.0,,22224,
5070,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL621724,0,Autocuration,9606.0,,22224,
5071,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL623443,0,Autocuration,9606.0,,22224,
5072,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL623444,0,Autocuration,9606.0,,22224,
5073,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL623445,0,Autocuration,9606.0,,22224,
5074,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,1,U,,Homo sapiens,,,,Urine,,1088.0,BAO_0000019,CHEMBL623446,0,Autocuration,9606.0,,22224,
5075,Metabolic stability observed at 30 min after administration in human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL623447,0,Autocuration,9606.0,,22224,
5076,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL623448,0,Autocuration,9606.0,,22224,
5077,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL623449,0,Autocuration,9606.0,,22224,
5078,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL623450,0,Autocuration,9606.0,,22224,
5079,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL623451,0,Autocuration,9606.0,,22224,
5080,Metabolic stability (% remaining at 30 mins) in human S9.,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL623452,0,Autocuration,9606.0,,22224,
5081,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL623453,0,Autocuration,9606.0,,22224,
5082,Percent parent compound remaining after 20 min incubation with human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL623454,0,Autocuration,9606.0,,22224,
5083,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL623455,0,Autocuration,9606.0,,22224,
5084,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624371,0,Autocuration,9606.0,,22224,
5085,First pass metabolism and metabolic bioavailability using human hepatic microsomes,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624372,0,Autocuration,9606.0,,22224,
5086,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624373,0,Autocuration,9606.0,,22224,
5087,Percent remaining in human plasma after incubation for 60 min at 37 C.,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624374,0,Autocuration,9606.0,,22224,
5088,The percent remaining in human plasma after 30 min was determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624556,0,Autocuration,9606.0,,22224,
5089,Conversion rate of the prodrug in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL624557,0,Autocuration,9606.0,,22224,
5090,Conversion rate of the prodrug in human plasma; ND means no data,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL624558,0,Autocuration,9606.0,,22224,
5091,Half life of compound was determined in human blood,1,U,,Homo sapiens,,,,Blood,,178.0,BAO_0000221,CHEMBL624559,0,Autocuration,9606.0,,22224,
5092,Half life of compound was determined in man with once daily dosing,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624560,0,Autocuration,9606.0,,22224,
5093,Half life in human microsomes,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL624561,0,Autocuration,9606.0,,22224,
5094,Half life in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL624562,0,Autocuration,9606.0,,22224,
5095,Half life in human plasma; Not detected,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL624563,0,Autocuration,9606.0,,22224,
5096,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624564,0,Autocuration,9606.0,,22224,
5097,Half-life for oxidative metabolic stability was determined using rat liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624565,0,Autocuration,9606.0,,22224,
5098,Half-life in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL875152,0,Autocuration,9606.0,,22224,
5099,Half-life of the parent prodrug in plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL624566,0,Autocuration,9606.0,,22224,
5100,In vitro half life in human plasma was determined,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL873805,0,Autocuration,9606.0,,22224,
5101,The compound was tested In Vitro for half life in human liver microsomes.,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624567,0,Autocuration,9606.0,,22224,
5102,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624568,0,Autocuration,9606.0,,22224,
5103,Observed volume of distribution,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624569,0,Autocuration,9606.0,,22224,
5104,Oral bioavailability in human,1,U,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624570,0,Autocuration,9606.0,,22224,
5105,Tested for human plasma protein binding of the compound,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624571,0,Autocuration,9606.0,,22224,
5106,"First order rate constant, k was determined in human plasma",1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624572,0,Autocuration,9606.0,,22224,
5107,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624573,0,Autocuration,9606.0,,22224,
5108,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL875153,0,Autocuration,9606.0,,22224,
5109,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624574,0,Autocuration,9606.0,,22224,
5110,The compound was tested for the plasma binding in human,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624575,0,Autocuration,9606.0,,22224,
5111,Plasma protein binding (human),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL624576,0,Autocuration,9606.0,,22224,
5112,Compound was evaluated for half-life in human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624577,0,Autocuration,9606.0,,22224,
5113,Half life measured in vitro for its stability in human blood,1,U,,Homo sapiens,,,,Blood,,178.0,BAO_0000221,CHEMBL624578,0,Autocuration,9606.0,,22224,
5114,Half life in human serum,1,U,,Homo sapiens,,,,Serum,,1977.0,BAO_0000019,CHEMBL622796,0,Autocuration,9606.0,,22224,
5115,Half life in human serum; ND=not determined,1,U,,Homo sapiens,,,,Serum,,1977.0,BAO_0000019,CHEMBL622797,0,Autocuration,9606.0,,22224,
5116,Half life were determined in CEM-SS cell extract in decomposition step 1,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL622798,0,Autocuration,9606.0,,22224,
5117,Half life were determined in CEM-SS cell extract in decomposition step 2,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL622799,0,Autocuration,9606.0,,22224,
5118,Half life of the in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL622800,0,Autocuration,9606.0,,22224,
5119,Half life period in human hepatic S9 fraction was determined,1,U,,Homo sapiens,,S9,,,,,BAO_0000220,CHEMBL622801,0,Autocuration,9606.0,,22224,
5120,Half life period in human liver microsome was determined,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL622802,0,Autocuration,9606.0,,22224,
5121,Half life period was determined; 6-7,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL622803,0,Autocuration,9606.0,,22224,
5122,Half life period was evaluated in human,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL875154,0,Autocuration,9606.0,,22224,
5123,Half life time in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL622804,0,Autocuration,9606.0,,22224,
5124,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622805,1,Intermediate,10090.0,,50594,
5125,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622611,1,Intermediate,10090.0,,50594,
5126,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622612,1,Intermediate,10090.0,,50594,
5127,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL875160,1,Intermediate,10090.0,,50594,
5128,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622613,1,Intermediate,10090.0,,50594,
5129,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622614,1,Intermediate,10090.0,,50594,
5130,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622615,1,Intermediate,10090.0,,50594,
5131,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622616,1,Intermediate,10090.0,,50594,
5132,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622617,1,Intermediate,10090.0,,50594,
5133,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622618,1,Intermediate,10090.0,,50594,
5134,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622619,1,Intermediate,10090.0,,50594,
5135,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622620,1,Intermediate,10090.0,,50594,
5136,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622621,1,Intermediate,10090.0,,50594,
5137,Biodistribution of compound (oxidized form) in blood tissue,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622622,1,Intermediate,10090.0,,50594,
5138,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622623,1,Intermediate,10090.0,,50594,
5139,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622624,1,Intermediate,10090.0,,50594,
5140,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622625,1,Intermediate,10090.0,,50594,
5141,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622626,1,Intermediate,10090.0,,50594,
5142,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622627,1,Intermediate,10090.0,,50594,
5143,Biodistribution of compound (oxidized form) in brain tissue of mice,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622628,1,Intermediate,10090.0,,50594,
5144,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622629,1,Intermediate,10090.0,,50594,
5145,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622630,1,Intermediate,10090.0,,50594,
5146,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622631,1,Intermediate,10090.0,,50594,
5147,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622632,1,Intermediate,10090.0,,50594,
5148,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622633,1,Intermediate,10090.0,,50594,
5149,Biodistribution of compound (oxidized form) in heart tissue of mice,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622634,1,Intermediate,10090.0,,50594,
5150,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622635,1,Intermediate,10090.0,,50594,
5151,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL875161,1,Intermediate,10090.0,,50594,
5152,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622636,1,Intermediate,10090.0,,50594,
5153,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL623335,1,Intermediate,10090.0,,50594,
5154,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL623336,1,Intermediate,10090.0,,50594,
5155,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623337,1,Intermediate,10090.0,,50594,
5156,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623338,1,Intermediate,10090.0,,50594,
5157,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623339,1,Intermediate,10090.0,,50594,
5158,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623524,1,Intermediate,10090.0,,50594,
5159,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623525,1,Intermediate,10090.0,,50594,
5160,Biodistribution of compound (oxidized form) in liver tissue,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623526,1,Intermediate,10090.0,,50594,
5161,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623527,1,Intermediate,10090.0,,50594,
5162,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623528,1,Intermediate,10090.0,,50594,
5163,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL624615,1,Intermediate,9606.0,,80852,500.0
5164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621672,1,Intermediate,9606.0,,80852,500.0
5165,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL621673,1,Expert,,,80852,500.0
5166,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL621674,1,Expert,,,80852,500.0
5167,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL884002,9,Expert,9606.0,,9,500.0
5168,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621850,1,Intermediate,9606.0,,80852,500.0
5169,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621851,1,Intermediate,9606.0,,80852,500.0
5170,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621852,9,Expert,9606.0,,9,500.0
5171,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL621853,9,Expert,9606.0,,9,500.0
5172,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL621854,1,Expert,,,80852,500.0
5173,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL621855,1,Expert,,,80852,500.0
5174,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL623724,1,Expert,,,80852,500.0
5175,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL623725,1,Expert,,,80852,500.0
5176,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL623726,1,Expert,,,80852,500.0
5177,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL623727,9,Expert,9606.0,,9,500.0
5178,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,1,H,,,,,,,A-431,,BAO_0000219,CHEMBL623728,8,Expert,,,9,500.0
5179,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL623729,1,Expert,,,80852,500.0
5180,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL623730,1,Expert,,,80852,500.0
5181,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,N,,,,,,,A-431,,BAO_0000218,CHEMBL623731,1,Expert,,,80852,500.0
5182,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",1,N,,Mus musculus,,,,,A-431,,BAO_0000218,CHEMBL623732,1,Expert,10090.0,,80852,500.0
5183,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",1,N,,Mus musculus,,,,,A-431,,BAO_0000218,CHEMBL623733,1,Expert,10090.0,,80852,500.0
5184,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,N,,Mus musculus,,,,,A-431,,BAO_0000218,CHEMBL623734,1,Expert,10090.0,,80852,500.0
5185,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,N,,Mus musculus,,,,,A-431,,BAO_0000218,CHEMBL623735,1,Expert,10090.0,,80852,500.0
5186,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL623736,1,Expert,9606.0,,80852,500.0
5187,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL623737,1,Intermediate,9606.0,,80852,500.0
5188,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL623738,1,Intermediate,9606.0,,80852,500.0
5189,Dose giving a 50% decrease in the living cell number (A437 cells),1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL875168,1,Intermediate,9606.0,,80852,500.0
5190,In vitro inhibitory concentration against proliferation of A459 cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623739,1,Expert,9606.0,,80682,646.0
5191,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623740,1,Intermediate,9606.0,,80682,646.0
5192,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624424,1,Intermediate,9606.0,,80682,646.0
5193,In vitro antitumor activity against renal A498 tumor cell lines,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624425,1,Intermediate,9606.0,,80021,624.0
5194,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624426,1,Intermediate,9606.0,,80021,624.0
5195,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624427,1,Intermediate,9606.0,,80021,624.0
5196,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624428,1,Intermediate,9606.0,,80021,624.0
5197,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624429,1,Intermediate,9606.0,,80021,624.0
5198,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624620,1,Intermediate,9606.0,,80021,624.0
5199,Cytotoxicity on kidney carcinoma (A-498) cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624621,1,Intermediate,9606.0,,80021,624.0
5200,Compound was evaluated against Human cell line renal A498,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624622,1,Intermediate,9606.0,,80021,624.0
5201,Compound was tested for inhibition of A498 human renal cancer cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624623,1,Intermediate,9606.0,,80021,624.0
5202,Growth inhibitory activity against A498 human cancer cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL874365,1,Intermediate,9606.0,,80021,624.0
5203,In vitro antitumor activity against human renal A498 cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624624,1,Intermediate,9606.0,,80021,624.0
5204,In vitro cytotoxic activity against renal (A498) cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624625,1,Intermediate,9606.0,,80021,624.0
5205,In vitro cytotoxic activity against human renal cancer (A498) cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624626,1,Intermediate,9606.0,,80021,624.0
5206,Tested for cytostatic activity against renal A498 cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624627,1,Intermediate,9606.0,,80021,624.0
5207,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL883157,1,Intermediate,9606.0,,80021,624.0
5208,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624628,1,Expert,9606.0,,80021,624.0
5209,Cmax value after 2 mpk peroral administration to beagles,1,U,,beagle,,,,,,,BAO_0000218,CHEMBL624629,0,Autocuration,9615.0,,22224,
5210,Bioavailability,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623551,0,Autocuration,9615.0,beagle,22224,
5211,Bioavailability after 1 mpk peroral administration to beagles,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623552,0,Autocuration,9615.0,beagle,22224,
5212,Bioavailability after 2 mpk peroral administration to beagles,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623553,0,Autocuration,9615.0,beagle,22224,
5213,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623554,0,Autocuration,9913.0,,22224,
5214,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623555,0,Autocuration,9913.0,,22224,
5215,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623556,0,Autocuration,9913.0,,22224,
5216,Solubility against bovine alpha-chymotrypsin,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623557,0,Autocuration,9913.0,,22224,
5217,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623558,0,Autocuration,9913.0,,22224,
5218,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623559,0,Autocuration,9913.0,,22224,
5219,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,1,U,,Bos taurus,,,,Spleen,,2106.0,BAO_0000221,CHEMBL623560,0,Autocuration,9913.0,,22224,
5220,Half life in culture medium containing 10% of heat inactivated foetal calf serum,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623561,0,Autocuration,9913.0,,22224,
5221,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623562,0,Autocuration,9913.0,,22224,
5222,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623563,0,Autocuration,9913.0,,22224,
5223,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,1,U,,Bos taurus,,,,Spleen,,2106.0,BAO_0000221,CHEMBL623564,0,Autocuration,9913.0,,22224,
5224,Half life in presence of 2 mg/mL BSA at pH 8.8,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL873806,0,Autocuration,9913.0,,22224,
5225,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623565,0,Autocuration,9913.0,,22224,
5226,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623566,0,Autocuration,9913.0,,22224,
5227,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623567,0,Autocuration,9913.0,,22224,
5228,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),1,U,,Bos taurus,,,,,,,BAO_0000019,CHEMBL623568,0,Autocuration,9913.0,,22224,
5229,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623569,1,Intermediate,9615.0,,50588,
5230,AUC after administration at 100 mg/kg/day in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623570,1,Intermediate,9615.0,,50588,
5231,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624254,1,Intermediate,9615.0,,50588,
5232,AUC value after 15 mg/kg iv dose in Dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624255,1,Intermediate,9615.0,,50588,
5233,AUC value after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624256,1,Intermediate,9615.0,,50588,
5234,AUC value after administration of 4 mg/Kg oral dose in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624257,1,Intermediate,9615.0,,50588,
5235,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624258,1,Intermediate,9615.0,,50588,
5236,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875277,1,Intermediate,9615.0,,50588,
5237,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622667,1,Intermediate,9615.0,,50588,
5238,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622668,1,Intermediate,9615.0,,50588,
5239,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622669,1,Intermediate,9615.0,,50588,
5240,Area under curve determined in dogs after intravenous administration of 3 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622670,1,Intermediate,9615.0,,50588,
5241,Area under curve determined in dogs after oral administration of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622671,1,Intermediate,9615.0,,50588,
5242,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622672,1,Intermediate,9615.0,,50588,
5243,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622673,1,Expert,9615.0,,50588,
5244,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622674,1,Expert,9615.0,,50588,
5245,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622675,1,Intermediate,9615.0,,50588,
5246,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622676,1,Intermediate,9615.0,,50588,
5247,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622677,1,Intermediate,9615.0,,50588,
5248,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622678,1,Intermediate,9615.0,,50588,
5249,Area under curve in dog after administration of 20 mg/kg dose through peroral route,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622679,1,Intermediate,9615.0,,50588,
5250,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622680,1,Intermediate,9615.0,,50588,
5251,Area under curve was determine after peroral administration at 10 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622681,1,Intermediate,9615.0,,50588,
5252,Area under curve was determine after peroral administration at 5 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875278,1,Intermediate,9615.0,,50588,
5253,Area under curve was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622682,1,Intermediate,9615.0,,50588,
5254,Area under curve in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622683,1,Intermediate,9615.0,,50588,
5255,Area under curve in dogs at 10 mg/kg dose fo oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622684,1,Intermediate,9615.0,,50588,
5256,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622685,1,Intermediate,9615.0,,50588,
5257,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622686,1,Intermediate,9615.0,,50588,
5258,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618344,1,Intermediate,9615.0,,50588,
5259,Area under curve value in dog at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875582,1,Intermediate,9615.0,,50588,
5260,Area under curve was determined after 0.1 mg/kg iv administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618345,1,Intermediate,9615.0,,50588,
5261,Area under curve was determined after 0.3 mg/kg po administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618346,1,Intermediate,9615.0,,50588,
5262,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618347,1,Intermediate,9615.0,,50588,
5263,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618348,1,Intermediate,9615.0,,50588,
5264,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618349,0,Autocuration,9606.0,,22224,
5265,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618350,0,Autocuration,9606.0,,22224,
5266,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618351,0,Autocuration,9606.0,,22224,
5267,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618352,0,Autocuration,9606.0,,22224,
5268,Time taken to reduce 50% of the concentration of compound in blood plasma,1,U,,Homo sapiens,,,,Blood,,178.0,BAO_0000221,CHEMBL873494,0,Autocuration,9606.0,,22224,
5269,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618353,0,Autocuration,9606.0,,22224,
5270,Half life in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618354,0,Autocuration,9606.0,,22224,
5271,Half life in human plasma was reported,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL875583,0,Autocuration,9606.0,,22224,
5272,Half life in human serum,1,U,,Homo sapiens,,,,Serum,,1977.0,BAO_0000019,CHEMBL618355,0,Autocuration,9606.0,,22224,
5273,Half life upon exposure to human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618356,0,Autocuration,9606.0,,22224,
5274,t1/2 in human microsomes,1,U,,Homo sapiens,,Microsomes,,,,,BAO_0000251,CHEMBL618357,0,Autocuration,9606.0,,22224,
5275,Half life period in 80% human plasma at 37 degree Centigrade,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618358,0,Autocuration,9606.0,,22224,
5276,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),1,U,,Homo sapiens,,,,Zone of skin,,14.0,BAO_0000221,CHEMBL618359,0,Autocuration,9606.0,,22224,
5277,Half-life measured in in vitro Cathepsin B assay in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618360,0,Autocuration,9606.0,,22224,
5278,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618361,0,Autocuration,9606.0,,22224,
5279,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618362,0,Autocuration,9606.0,,22224,
5280,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618363,0,Autocuration,9606.0,,22224,
5281,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618364,0,Autocuration,9606.0,,22224,
5282,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL875584,0,Autocuration,9606.0,,22224,
5283,Half-life in the CEM cell extracts,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618365,0,Autocuration,9606.0,,22224,
5284,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL873495,0,Autocuration,9606.0,,22224,
5285,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618366,0,Autocuration,9606.0,,22224,
5286,Half-life was determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618367,0,Autocuration,9606.0,,22224,
5287,Half-life (human blood stability),1,U,,Homo sapiens,,,,Blood,,178.0,BAO_0000221,CHEMBL618368,0,Autocuration,9606.0,,22224,
5288,Half-life (human blood stability); no data,1,U,,Homo sapiens,,,,Blood,,178.0,BAO_0000221,CHEMBL618369,0,Autocuration,9606.0,,22224,
5289,Half-life in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618370,0,Autocuration,9606.0,,22224,
5290,CYP3A4 metabolism half-life (t1/2),1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618371,0,Autocuration,9606.0,,22224,
5291,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),1,U,,Homo sapiens,,,,Blood,,178.0,BAO_0000221,CHEMBL618372,0,Autocuration,9606.0,,22224,
5292,In vitro half life in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618373,0,Autocuration,9606.0,,22224,
5293,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618374,0,Autocuration,9606.0,,22224,
5294,In vitro hydrolysis in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618375,0,Autocuration,9606.0,,22224,
5295,In vitro hydrolysis in human plasma; no data,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618376,0,Autocuration,9606.0,,22224,
5296,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL618377,0,Autocuration,9606.0,,22224,
5297,Plasma half life in human,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618378,0,Autocuration,9606.0,,22224,
5298,Stability after incubation with human plasma (at 37 degree C),1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618379,0,Autocuration,9606.0,,22224,
5299,T1/2 was evaluated in human plasma,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618380,0,Autocuration,9606.0,,22224,
5300,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618381,0,Autocuration,9606.0,,22224,
5301,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL618382,0,Autocuration,9606.0,,22224,
5302,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618383,0,Autocuration,9606.0,,22224,
5303,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618384,0,Autocuration,9606.0,,22224,
5304,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL618385,0,Autocuration,9606.0,,22224,
5305,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL619099,0,Autocuration,9606.0,,22224,
5306,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL619100,0,Autocuration,9606.0,,22224,
5307,Time taken for 50% to be consumed by serum PON1 was determined,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619101,0,Autocuration,9606.0,,22224,
5308,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,1,U,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL619102,0,Autocuration,9606.0,,22224,
5309,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,U,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL619103,0,Autocuration,9606.0,,22224,
5310,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL619268,0,Autocuration,10095.0,,22224,
5311,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL619269,0,Autocuration,10095.0,,22224,
5312,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL619270,0,Autocuration,10095.0,,22224,
5313,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL619271,0,Autocuration,10095.0,,22224,
5314,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL875585,0,Autocuration,10095.0,,22224,
5315,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL619272,0,Autocuration,10095.0,,22224,
5316,Compound tested for growth inhibition of renal cancer cell line 786-0,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619273,1,Intermediate,9606.0,,80640,391.0
5317,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619274,1,Intermediate,9606.0,,80640,391.0
5318,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619275,1,Expert,9606.0,,80640,391.0
5319,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619276,1,Intermediate,9606.0,,80640,391.0
5320,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619277,1,Intermediate,9606.0,,80640,391.0
5321,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619278,1,Intermediate,9606.0,,80640,391.0
5322,Tested for cytotoxicity against 786-0 cell lines in renal cancer,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619279,1,Intermediate,9606.0,,80640,391.0
5323,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL858458,1,Intermediate,9606.0,,80640,391.0
5324,Cytotoxic effect on renal cancer line 786-0,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619280,1,Expert,9606.0,,80640,391.0
5325,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619281,1,Intermediate,9606.0,,80640,391.0
5326,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619282,1,Intermediate,9606.0,,80640,391.0
5327,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619283,1,Intermediate,9606.0,,80640,391.0
5328,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619284,1,Intermediate,9606.0,,80640,391.0
5329,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619285,1,Intermediate,9606.0,,80640,391.0
5330,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619286,1,Intermediate,9606.0,,80640,391.0
5331,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619287,1,Intermediate,9606.0,,80640,391.0
5332,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL857455,1,Intermediate,9606.0,,80640,391.0
5333,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL883801,1,Intermediate,9606.0,,80640,391.0
5334,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619288,1,Intermediate,9606.0,,80641,972.0
5335,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619289,1,Intermediate,9606.0,,80641,972.0
5336,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619290,1,Intermediate,9606.0,,80641,972.0
5337,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619291,1,Intermediate,9606.0,,80641,972.0
5338,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619292,1,Intermediate,9606.0,,80641,972.0
5339,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619293,1,Intermediate,9606.0,,80641,972.0
5340,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619294,1,Intermediate,9606.0,,80641,972.0
5341,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619295,1,Intermediate,9606.0,,80641,972.0
5342,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619296,1,Intermediate,9606.0,,80641,972.0
5343,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,1,N,,Homo sapiens,,,,,791T cell line,,BAO_0000219,CHEMBL619297,1,Intermediate,9606.0,,80641,972.0
5344,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,1,N,,Homo sapiens,,,,,786-0,,BAO_0000219,CHEMBL619298,1,Intermediate,9606.0,,80640,391.0
5345,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL619299,0,Intermediate,,,22226,
5346,Inhibition of cell growth in drug resistant 8226 myeloma cell line,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619300,1,Expert,9606.0,,80433,741.0
5347,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619301,1,Expert,9606.0,,80433,741.0
5348,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619302,1,Intermediate,9606.0,,80433,741.0
5349,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619303,1,Intermediate,9606.0,,80433,741.0
5350,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619304,1,Intermediate,9606.0,,80433,741.0
5351,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL857706,1,Intermediate,9606.0,,80433,741.0
5352,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619305,1,Intermediate,9606.0,,80433,741.0
5353,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619306,1,Intermediate,9606.0,,80433,741.0
5354,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619307,1,Intermediate,9606.0,,80433,741.0
5355,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619308,1,Intermediate,9606.0,,80433,741.0
5356,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619309,1,Intermediate,9606.0,,80433,741.0
5357,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL619310,1,Intermediate,9606.0,,80433,741.0
5358,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619311,1,Intermediate,9606.0,,80021,624.0
5359,Compound was tested for the growth inhibition of A498 renal tumor cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619312,1,Intermediate,9606.0,,80021,624.0
5360,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619313,1,Intermediate,9606.0,,80021,624.0
5361,In vitro inhibitory concentration against renal cancer cell line A498,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619314,1,Intermediate,9606.0,,80021,624.0
5362,Cytotoxicity against A 498 tumor cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619959,1,Intermediate,9606.0,,80021,624.0
5363,In vitro antitumor activity against A498 human cancer cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619960,1,Intermediate,9606.0,,80021,624.0
5364,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619961,1,Intermediate,9606.0,,80021,624.0
5365,Inhibitory dose required against A498 human tumor cell lines,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619962,1,Intermediate,9606.0,,80021,624.0
5366,Anticancer activity against one renal cancer (A498 cell line),1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL875586,1,Intermediate,9606.0,,80021,624.0
5367,In vitro cytotoxicity against melanoma A498 cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619963,1,Intermediate,9606.0,,80021,624.0
5368,Compound was tested for growth inhibitory activity against A498 cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619964,1,Intermediate,9606.0,,80021,624.0
5369,Compound tested for growth inhibition of renal cancer cell line A498,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620108,1,Intermediate,9606.0,,80021,624.0
5370,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620109,1,Intermediate,9606.0,,80021,624.0
5371,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620110,1,Intermediate,9606.0,,80021,624.0
5372,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620111,1,Intermediate,9606.0,,80021,624.0
5373,Tested for cytotoxicity against A498 cell lines in renal cancer,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620112,1,Intermediate,9606.0,,80021,624.0
5374,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620113,1,Intermediate,9606.0,,80021,624.0
5375,Cytotoxic effect on renal cancer lines A498,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620114,1,Expert,9606.0,,80021,624.0
5376,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620115,1,Intermediate,9606.0,,80021,624.0
5377,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620116,1,Intermediate,9606.0,,80021,624.0
5378,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620117,1,Intermediate,9606.0,,80021,624.0
5379,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620118,1,Intermediate,9606.0,,80021,624.0
5380,Cytotoxicity against human kidney carcinoma cell lines A4982LM,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620119,1,Intermediate,9606.0,,80021,624.0
5381,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620120,1,Intermediate,9606.0,,80021,624.0
5382,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620121,1,Expert,9606.0,,80682,646.0
5383,Antitumor activity against A549 human lung carcinoma cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620122,1,Intermediate,9606.0,,80682,646.0
5384,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620123,1,Intermediate,9606.0,,80682,646.0
5385,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620124,1,Intermediate,9606.0,,80682,646.0
5386,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620125,1,Intermediate,9606.0,,80682,646.0
5387,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620126,1,Expert,9606.0,,80682,646.0
5388,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL883027,1,Intermediate,9606.0,,80682,646.0
5389,In vitro cytotoxic activity against human lung A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620127,1,Expert,9606.0,,80682,646.0
5390,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620128,1,Intermediate,9606.0,,80682,646.0
5391,In vitro cytotoxic activity against human lung A549 cell line),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620129,1,Intermediate,9606.0,,80682,646.0
5392,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620130,1,Intermediate,9606.0,,80682,646.0
5393,In vitro cytotoxicity against human non small-cell-lung cell line A549.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620131,1,Expert,9606.0,,80682,646.0
5394,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620132,1,Intermediate,9606.0,,80682,646.0
5395,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620133,1,Intermediate,9606.0,,80682,646.0
5396,Inhibition of A549 human lung carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620134,1,Expert,9606.0,,80682,646.0
5397,Inhibitory activity against A549 lung adenocarcinoma cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620135,1,Intermediate,9606.0,,80682,646.0
5398,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620136,1,Intermediate,9606.0,,80682,646.0
5399,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620137,1,Intermediate,9606.0,,80682,646.0
5400,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620268,1,Intermediate,9606.0,,80682,646.0
5401,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620269,1,Intermediate,9606.0,,80682,646.0
5402,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620270,1,Intermediate,9606.0,,80682,646.0
5403,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620271,1,Intermediate,9606.0,,80682,646.0
5404,Inhibition of A549 cancer cell proliferation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620272,1,Expert,9606.0,,80682,646.0
5405,Inhibition of A549 cancer cell proliferation (Not tested),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620273,1,Expert,9606.0,,80682,646.0
5406,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620274,1,Intermediate,9606.0,,80682,646.0
5407,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620275,1,Intermediate,9606.0,,80682,646.0
5408,Antiproliferative potency determined as inhibitory concentration against A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620276,1,Intermediate,9606.0,,80682,646.0
5409,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620277,1,Intermediate,9606.0,,80682,646.0
5410,Cytotoxicity against Renal cell lines A549 was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620278,1,Intermediate,9606.0,,80682,646.0
5411,Area under curve was determined in dog after a 3 mg/kg of oral dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620279,1,Intermediate,9615.0,,50588,
5412,Area under curve was determined in dog after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620280,1,Intermediate,9615.0,,50588,
5413,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620281,1,Intermediate,9615.0,,50588,
5414,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620282,1,Intermediate,9615.0,,50588,
5415,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621134,1,Intermediate,9615.0,,50588,
5416,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621135,1,Intermediate,9615.0,,50588,
5417,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621136,1,Intermediate,9615.0,,50588,
5418,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621137,1,Intermediate,9615.0,,50588,
5419,Area under plasma concentration time curve in dog upon oral administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621138,1,Intermediate,9615.0,,50588,
5420,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875587,1,Intermediate,9615.0,,50588,
5421,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621139,1,Intermediate,9615.0,,50588,
5422,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621140,1,Intermediate,9615.0,,50588,
5423,Area under the curve for the compound was obtained when tested in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621141,1,Intermediate,9615.0,,50588,
5424,Area under the curve at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621142,1,Intermediate,9615.0,,50588,
5425,Area under the curve at a dose of 1 mg/kg (oral),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621143,1,Intermediate,9615.0,,50588,
5426,Area under the curve at i.v. dose of 0.2 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621144,1,Intermediate,9615.0,,50588,
5427,Area under the curve was measured in dog after an iv dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621145,1,Intermediate,9615.0,,50588,
5428,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621146,1,Intermediate,9615.0,,50588,
5429,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622567,1,Intermediate,9615.0,,50588,
5430,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622568,1,Intermediate,9615.0,,50588,
5431,Compound was evaluated for area under the curve in dog blood.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622569,1,Intermediate,9615.0,,50588,
5432,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622570,1,Intermediate,9615.0,,50588,
5433,AUC in dog after oral dose (1 mg/kg),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622571,1,Intermediate,9615.0,,50588,
5434,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622572,1,Intermediate,9615.0,,50588,
5435,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622573,1,Intermediate,9615.0,,50588,
5436,Pharmacokinetic parameter AUC after intravenous administration to dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622574,1,Intermediate,9615.0,,50588,
5437,Pharmacokinetic parameter AUC after oral administration to dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622575,1,Intermediate,9615.0,,50588,
5438,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622576,1,Intermediate,9615.0,,50588,
5439,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622577,1,Intermediate,9615.0,,50588,
5440,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622578,1,Intermediate,9615.0,,50588,
5441,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622579,1,Intermediate,9615.0,,50588,
5442,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622580,1,Intermediate,9615.0,,50588,
5443,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622581,1,Intermediate,9615.0,,50588,
5444,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622582,1,Intermediate,9615.0,,50588,
5445,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622583,1,Intermediate,9615.0,,50588,
5446,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622584,1,Intermediate,9615.0,,50588,
5447,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622585,1,Intermediate,9615.0,,50588,
5448,Compound was evaluated for oral bioavailability in dog; 90-100,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622586,1,Intermediate,9615.0,,50588,
5449,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623281,1,Intermediate,9615.0,,50588,
5450,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623282,1,Intermediate,9615.0,,50588,
5451,PAPP (membrane permeability) in dog kidney cell monolayer assay,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623283,1,Intermediate,9615.0,,50588,
5452,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623284,1,Intermediate,9615.0,,50588,
5453,Bioavailability administered orally at a dose of 10 mg/kg to dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623285,1,Intermediate,9615.0,,50588,
5454,Plasma protein binding towards dog plasma at 10 uM,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623463,1,Intermediate,9615.0,,50588,
5455,Plasma protein binding towards dog plasma at 100 uM,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875952,1,Intermediate,9615.0,,50588,
5456,Bioavailability in dog (dose 4 mg/kg p.o.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621705,1,Intermediate,9615.0,,50588,
5457,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621706,1,Intermediate,9615.0,,50588,
5458,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621707,1,Intermediate,9615.0,,50588,
5459,Bioavailability in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621708,1,Intermediate,9615.0,,50588,
5460,Bioavailability,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621709,1,Intermediate,9615.0,,50588,
5461,Oral bioavailability in dog (dose 10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621710,1,Intermediate,9615.0,,50588,
5462,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621711,1,Intermediate,9615.0,,50588,
5463,Bioavailability in dog (dose 10.0 mg/kg p.o.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621712,1,Intermediate,9615.0,,50588,
5464,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621713,1,Intermediate,9615.0,,50588,
5465,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621714,1,Intermediate,9615.0,,50588,
5466,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL621715,0,Autocuration,10095.0,,22224,
5467,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,Liver,,2107.0,BAO_0000218,CHEMBL623717,0,Autocuration,10095.0,,22224,
5468,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,U,,Mus sp.,,,,Liver,,2107.0,BAO_0000218,CHEMBL623718,0,Autocuration,10095.0,,22224,
5469,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,Liver,,2107.0,BAO_0000218,CHEMBL623719,0,Autocuration,10095.0,,22224,
5470,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL623720,0,Autocuration,10095.0,,22224,
5471,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL623721,0,Autocuration,10095.0,,22224,
5472,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623722,0,Autocuration,10095.0,,22224,
5473,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,U,,Mus sp.,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623723,0,Autocuration,10095.0,,22224,
5474,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618543,0,Autocuration,10095.0,,22224,
5475,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618544,0,Autocuration,10095.0,,22224,
5476,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,Spleen,,2106.0,BAO_0000218,CHEMBL875155,0,Autocuration,10095.0,,22224,
5477,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL618545,0,Autocuration,10095.0,,22224,
5478,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL618546,0,Autocuration,10095.0,,22224,
5479,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL623529,0,Autocuration,10095.0,,22224,
5480,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL623530,0,Autocuration,10095.0,,22224,
5481,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,U,,Mus sp.,,,,,,,BAO_0000218,CHEMBL621764,0,Autocuration,10095.0,,22224,
5482,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621765,0,Autocuration,9527.0,,22224,
5483,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,U,,Cercopithecidae,,,,Cerebellum,,2037.0,BAO_0000019,CHEMBL621766,0,Autocuration,9527.0,,22224,
5484,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,U,,Cercopithecidae,,,,Frontal cortex,,1870.0,BAO_0000019,CHEMBL621767,0,Autocuration,9527.0,,22224,
5485,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621768,0,Autocuration,9527.0,,22224,
5486,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),1,U,,Cercopithecidae,,,,Striatum,,2435.0,BAO_0000019,CHEMBL621769,0,Autocuration,9527.0,,22224,
5487,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621770,0,Autocuration,9527.0,,22224,
5488,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,U,,Cercopithecidae,,,,Cerebellum,,2037.0,BAO_0000019,CHEMBL621771,0,Autocuration,9527.0,,22224,
5489,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,U,,Cercopithecidae,,,,Frontal cortex,,1870.0,BAO_0000019,CHEMBL621772,0,Autocuration,9527.0,,22224,
5490,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621773,0,Autocuration,9527.0,,22224,
5491,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),1,U,,Cercopithecidae,,,,Striatum,,2435.0,BAO_0000019,CHEMBL621774,0,Autocuration,9527.0,,22224,
5492,Compound was evaluated for oral bioavailability in rats,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621775,0,Autocuration,9527.0,,22224,
5493,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621776,0,Autocuration,9527.0,,22224,
5494,Half life period was evaluated in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621777,0,Autocuration,9527.0,,22224,
5495,Half-life in rhesus monkeys by intravenous administration of dose,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL875162,0,Autocuration,9527.0,,22224,
5496,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621778,1,Intermediate,10090.0,,50594,
5497,AUC after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621779,1,Intermediate,10090.0,,50594,
5498,AUC value was determined after oral administration,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622479,1,Intermediate,10090.0,,50594,
5499,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622480,1,Intermediate,10090.0,,50594,
5500,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622481,1,Intermediate,10090.0,,50594,
5501,Area under curve by ioral administration in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622482,1,Intermediate,10090.0,,50594,
5502,Area under curve by iv administration in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622483,1,Intermediate,10090.0,,50594,
5503,Area under curve at 0-8 hr in IRC mice after peroral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622484,1,Intermediate,10090.0,,50594,
5504,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622641,1,Intermediate,10090.0,,50594,
5505,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622642,1,Intermediate,10090.0,,50594,
5506,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622643,1,Intermediate,10090.0,,50594,
5507,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622644,1,Intermediate,10090.0,,50594,
5508,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL622645,1,Intermediate,9606.0,,80433,741.0
5509,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL622646,1,Intermediate,9606.0,,80433,741.0
5510,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL621238,1,Intermediate,9606.0,,80433,741.0
5511,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL621239,1,Intermediate,9606.0,,80433,741.0
5512,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL621240,1,Intermediate,9606.0,,80433,741.0
5513,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL621241,1,Intermediate,9606.0,,80433,741.0
5514,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL621242,1,Intermediate,9606.0,,80433,741.0
5515,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620350,1,Intermediate,9606.0,,80433,741.0
5516,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620351,1,Intermediate,9606.0,,80433,741.0
5517,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620352,1,Intermediate,9606.0,,80433,741.0
5518,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620353,1,Intermediate,9606.0,,80433,741.0
5519,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620354,1,Intermediate,9606.0,,80433,741.0
5520,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620355,1,Intermediate,9606.0,,80433,741.0
5521,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620356,1,Intermediate,9606.0,,80433,741.0
5522,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620357,1,Intermediate,9606.0,,80433,741.0
5523,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620358,1,Intermediate,9606.0,,80433,741.0
5524,In vitro inhibition of human 8226 myeloma tumor cell line growth.,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620359,1,Expert,9606.0,,80433,741.0
5525,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620360,1,Intermediate,9606.0,,80433,741.0
5526,Cytotoxicity of compound against 8226/DOX1V cells,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620361,1,Intermediate,9606.0,,80433,741.0
5527,Cytotoxicity of compound against 8226/S cells,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620362,1,Intermediate,9606.0,,80433,741.0
5528,Inhibitory concentration against 8226 myeloma cancer cell line,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620363,1,Intermediate,9606.0,,80433,741.0
5529,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,1,N,,Homo sapiens,,,,,RPMI-8226,,BAO_0000219,CHEMBL620364,1,Intermediate,9606.0,,80433,741.0
5530,Inhibition of cell growth was studied in human teratocarcinoma (833K).,1,N,,Homo sapiens,,,,,833K,,BAO_0000219,CHEMBL620365,1,Intermediate,9606.0,,80647,854.0
5531,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',1,N,,Homo sapiens,,,,,833K,,BAO_0000219,CHEMBL620366,1,Intermediate,9606.0,,80647,854.0
5532,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,1,N,,Homo sapiens,,,,,833K,,BAO_0000219,CHEMBL620367,1,Expert,9606.0,,80647,854.0
5533,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,1,N,,Homo sapiens,,,,,833K,,BAO_0000219,CHEMBL620368,1,Intermediate,9606.0,,80647,854.0
5534,Inhibitory activity against caspase-1,1,U,,,,,,,,,BAO_0000019,CHEMBL620369,0,Autocuration,,,22226,
5535,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,1,H,,Enterococcus faecalis,,,,,,,BAO_0000357,CHEMBL620370,8,Autocuration,1351.0,,45,
5536,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,1,N,,Homo sapiens,,,,,8701-BC,,BAO_0000219,CHEMBL620371,1,Intermediate,9606.0,,80648,705.0
5537,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,1,N,,Homo sapiens,,,,,8701-BC,,BAO_0000219,CHEMBL620372,1,Intermediate,9606.0,,80648,705.0
5538,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL876492,0,Intermediate,,,22226,
5539,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL620373,0,Intermediate,,,22226,
5540,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL620374,0,Intermediate,,,22226,
5541,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,1,U,,,,,,,,,BAO_0000019,CHEMBL620375,0,Autocuration,,,22226,
5542,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,U,,Streptococcus pyogenes,,,,,,,BAO_0000019,CHEMBL857902,0,Autocuration,1314.0,,22226,
5543,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,U,,Streptococcus pyogenes,,,,,,,BAO_0000019,CHEMBL620376,0,Autocuration,1314.0,,22226,
5544,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,1,H,,,,,,,,,BAO_0000357,CHEMBL620377,8,Autocuration,,,11922,
5545,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,N,,Homo sapiens,,,,,KB ,,BAO_0000219,CHEMBL620378,1,Intermediate,9606.0,,81115,324.0
5546,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,N,,Homo sapiens,,,,,KB ,,BAO_0000219,CHEMBL620379,1,Intermediate,9606.0,,81115,324.0
5547,In vitro cytotoxicity of compound was tested against 9KB cells.,1,U,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL620380,0,Autocuration,9606.0,,22226,
5548,Cytotoxic concentration against 9L cells was determined on day 3,1,N,,Rattus norvegicus,,,,,9L,,BAO_0000219,CHEMBL884006,1,Intermediate,10116.0,,80653,392.0
5549,Tested in vitro for anticancer activity against 9L cells,1,N,,Rattus norvegicus,,,,,9L,,BAO_0000219,CHEMBL620381,1,Expert,10116.0,,80653,392.0
5550,Tested in vitro for anticancer activity against 9L cells; Not determined,1,N,,Rattus norvegicus,,,,,9L,,BAO_0000219,CHEMBL620382,1,Expert,10116.0,,80653,392.0
5551,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620383,1,Intermediate,9606.0,,80682,646.0
5552,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876493,1,Intermediate,9606.0,,80682,646.0
5553,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620384,1,Intermediate,9606.0,,80682,646.0
5554,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620385,1,Intermediate,9606.0,,80682,646.0
5555,Cytotoxicity against human lung carcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620386,1,Expert,9606.0,,80682,646.0
5556,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,1,D,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620387,9,Expert,9606.0,,25,646.0
5557,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",1,D,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621404,9,Expert,9606.0,,25,646.0
5558,"In vitro growth inhibition of A549, lung carcinoma",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621405,1,Intermediate,9606.0,,80682,646.0
5559,"In vitro growth inhibition of A549, lung carcinoma.",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621406,1,Intermediate,9606.0,,80682,646.0
5560,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621407,1,Expert,9606.0,,80682,646.0
5561,Cytotoxic activity against human lung cancer A549 cell line was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621408,1,Intermediate,9606.0,,80682,646.0
5562,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL885345,1,Expert,9606.0,,80682,646.0
5563,Cytotoxicity concentration against human lung carcinoma A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621409,1,Intermediate,9606.0,,80682,646.0
5564,Cytotoxicity in A549 (human carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876034,1,Expert,9606.0,,80682,646.0
5565,Cytotoxicity on lung carcinoma (A-549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621410,1,Intermediate,9606.0,,80682,646.0
5566,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621411,1,Expert,9606.0,,80682,646.0
5567,Effective dose of compound against replication of A549 cell line was evaluated,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621412,1,Intermediate,9606.0,,80682,646.0
5568,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621413,1,Expert,9606.0,,80682,646.0
5569,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621414,1,Intermediate,9606.0,,80682,646.0
5570,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621415,1,Intermediate,9606.0,,80682,646.0
5571,The compound was evaluated for antiproliferative activity against A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621416,1,Intermediate,9606.0,,80682,646.0
5572,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621417,1,Intermediate,9606.0,,80682,646.0
5573,Concentration required for growth inhibition of human lung carcinoma cell line A549,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621418,1,Intermediate,9606.0,,80682,646.0
5574,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621419,1,Intermediate,9606.0,,80682,646.0
5575,Growth inhibition against A549 cell line was evaluated,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621420,1,Intermediate,9606.0,,80682,646.0
5576,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL875823,1,Intermediate,9606.0,,80682,646.0
5577,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621421,1,Expert,9606.0,,80682,646.0
5578,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621422,1,Intermediate,9606.0,,80682,646.0
5579,Chemosensitivity against DT-diaphorase rich A549 cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884014,1,Expert,9606.0,,80682,646.0
5580,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621423,1,Intermediate,9606.0,,80682,646.0
5581,In vitro cytotoxicity against human A549 (lung cancer) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621424,1,Expert,9606.0,,80682,646.0
5582,In vitro antitumor activity against A549 (lung) human tumor cell lines.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621425,1,Intermediate,9606.0,,80682,646.0
5583,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621426,1,Expert,9606.0,,80682,646.0
5584,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621427,1,Intermediate,9606.0,,80682,646.0
5585,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621428,1,Intermediate,9606.0,,80682,646.0
5586,Tested against A549 lung carcinoma in the sulforhodamine B assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621429,1,Expert,9606.0,,80682,646.0
5587,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621430,1,Intermediate,9606.0,,80682,646.0
5588,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621431,1,Intermediate,9606.0,,80682,646.0
5589,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621432,1,Intermediate,9606.0,,80682,646.0
5590,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621433,1,Expert,9606.0,,80682,646.0
5591,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL875824,1,Intermediate,9606.0,,80682,646.0
5592,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621434,1,Intermediate,9606.0,,80682,646.0
5593,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621435,1,Intermediate,9606.0,,80682,646.0
5594,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621436,1,Intermediate,9606.0,,80682,646.0
5595,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621437,1,Intermediate,9606.0,,80682,646.0
5596,Compound was tested for the growth inhibition of A549 lung tumor cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621438,1,Intermediate,9606.0,,80682,646.0
5597,Growth inhibition of human non-small-lung carcinoma (A549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621439,1,Expert,9606.0,,80682,646.0
5598,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621440,1,Intermediate,9606.0,,80682,646.0
5599,Oral bioavailability in dog (conscious),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621441,1,Intermediate,9615.0,,50588,
5600,Compound was evaluated for the oral bioavailability after oral administration in dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621442,1,Intermediate,9615.0,,50588,
5601,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621443,1,Intermediate,9615.0,,50588,
5602,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621444,1,Intermediate,9615.0,,50588,
5603,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625133,1,Intermediate,9615.0,,50588,
5604,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625134,1,Intermediate,9615.0,,50588,
5605,Oral bioavailability in dog (fasted),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625135,1,Intermediate,9615.0,,50588,
5606,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625136,1,Intermediate,9615.0,,50588,
5607,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625137,1,Intermediate,9615.0,,50588,
5608,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625138,1,Intermediate,9615.0,,50588,
5609,Percent bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625139,1,Intermediate,9615.0,,50588,
5610,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL872264,1,Intermediate,9615.0,,50588,
5611,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625140,1,Intermediate,9615.0,,50588,
5612,The compound was evaluated for bioavailability in dogs; 34-44,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624436,1,Intermediate,9615.0,,50588,
5613,Bioavailability in dog (dose 4 mg/kg p.o.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624437,1,Intermediate,9615.0,,50588,
5614,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL872261,1,Intermediate,9615.0,,50588,
5615,8 hour trough Blood level in dog was measured after administration of compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624438,1,Intermediate,9615.0,,50588,
5616,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624439,1,Intermediate,9615.0,,50588,
5617,C24 after oral administration at 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624440,1,Intermediate,9615.0,,50588,
5618,Clearance after oral and iv dosing in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624441,1,Intermediate,9615.0,,50588,
5619,Clearance of the drug was measured in the plasma of dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624442,1,Intermediate,9615.0,,50588,
5620,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624443,1,Intermediate,9615.0,,50588,
5621,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624444,1,Intermediate,9615.0,,50588,
5622,Clearance of compound was determined in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624445,1,Intermediate,9615.0,,50588,
5623,Clearance on i.v. administration of 2 mg/kg was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624446,1,Intermediate,9615.0,,50588,
5624,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624447,1,Intermediate,9615.0,,50588,
5625,Plasma clearance in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624448,1,Intermediate,9615.0,,50588,
5626,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624449,1,Intermediate,9615.0,,50588,
5627,Plasma clearance in dog after administration of 0.25 mg/kg iv,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624450,1,Intermediate,9615.0,,50588,
5628,Plasma clearance in dog after administration of 1 mg/kg iv,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875942,1,Intermediate,9615.0,,50588,
5629,Plasma clearance in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624451,1,Intermediate,9615.0,,50588,
5630,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624452,1,Intermediate,9615.0,,50588,
5631,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624453,1,Intermediate,9615.0,,50588,
5632,Plasma clearance after 15 mg/kg iv dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624454,1,Intermediate,9615.0,,50588,
5633,Plasma clearance after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624455,1,Intermediate,9615.0,,50588,
5634,Plasma administration to dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624456,1,Intermediate,9615.0,,50588,
5635,Plasma clearance was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624457,1,Intermediate,9615.0,,50588,
5636,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624458,1,Intermediate,9615.0,,50588,
5637,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624459,1,Intermediate,9615.0,,50588,
5638,Intrinsic clearance in human liver microsomes,1,S,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624460,2,Intermediate,9606.0,,102164,
5639,Intrinsic clearance in human liver microsomes,1,S,,Homo sapiens,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL624461,2,Intermediate,9606.0,,102164,
5640,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875943,1,Intermediate,9615.0,,50588,
5641,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624462,1,Intermediate,9615.0,,50588,
5642,Clearance in dog (dose 1 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624463,1,Intermediate,9615.0,,50588,
5643,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624464,1,Intermediate,9615.0,,50588,
5644,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624465,1,Intermediate,9615.0,,50588,
5645,Plasma clearance after peroral administration at 10 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624466,1,Intermediate,9615.0,,50588,
5646,Plasma clearance after peroral administration at 5 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624467,1,Intermediate,9615.0,,50588,
5647,Plasma clearance after peroral administration at 5 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624468,1,Intermediate,9615.0,,50588,
5648,Plasma clearance was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624469,1,Intermediate,9615.0,,50588,
5649,Plasma clearance was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624470,1,Intermediate,9615.0,,50588,
5650,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624471,1,Intermediate,9615.0,,50588,
5651,Total clearance was determined after 0.1 mg/kg iv administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624472,1,Intermediate,9615.0,,50588,
5652,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622775,1,Intermediate,9615.0,,50588,
5653,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622776,1,Intermediate,9615.0,,50588,
5654,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622777,1,Intermediate,9615.0,,50588,
5655,Clearance after peroral administration of 0.2 mg/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622778,1,Intermediate,9615.0,,50588,
5656,Clearance by intravenous administration of 1.2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622779,1,Intermediate,9615.0,,50588,
5657,Clearance by iv administration in dogs at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622780,1,Intermediate,9615.0,,50588,
5658,Clearance value was evaluated in dog plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622781,1,Intermediate,9615.0,,50588,
5659,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622782,1,Intermediate,9615.0,,50588,
5660,Compound was tested for plasma clearance in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622783,1,Intermediate,9615.0,,50588,
5661,Pharmacokinetic property (Plasma clearance) was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622784,1,Intermediate,9615.0,,50588,
5662,Area under curve when injected perorally in mice at a dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622785,1,Intermediate,10090.0,,50594,
5663,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622786,1,Intermediate,10090.0,,50594,
5664,Area under curve value in mouse at a dose of 10 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622787,1,Intermediate,10090.0,,50594,
5665,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875949,1,Intermediate,10090.0,,50594,
5666,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622788,1,Intermediate,10090.0,,50594,
5667,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622789,1,Intermediate,10090.0,,50594,
5668,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622790,1,Intermediate,10090.0,,50594,
5669,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622791,1,Intermediate,10090.0,,50594,
5670,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622792,1,Intermediate,10090.0,,50594,
5671,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622793,1,Intermediate,10090.0,,50594,
5672,Area under curve was determined for the compound at 24 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622794,1,Intermediate,10090.0,,50594,
5673,Area under curve was determined for the compound at 40 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622795,1,Intermediate,10090.0,,50594,
5674,Area under curve was determined for the compound at 5 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621803,1,Intermediate,10090.0,,50594,
5675,Area under the curve for the compound is obtained at dose 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621804,1,Intermediate,10090.0,,50594,
5676,Area under the curve for the compound was obtained when tested in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621805,1,Intermediate,10090.0,,50594,
5677,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621806,1,Intermediate,10090.0,,50594,
5678,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621807,1,Intermediate,10090.0,,50594,
5679,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621808,1,Intermediate,10090.0,,50594,
5680,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621809,1,Intermediate,10090.0,,50594,
5681,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621810,1,Intermediate,10090.0,,50594,
5682,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875164,1,Intermediate,10090.0,,50594,
5683,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621811,1,Intermediate,10090.0,,50594,
5684,"Compound was evaluated for the pharmacokinetic parameter, area under curve",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621812,1,Intermediate,10090.0,,50594,
5685,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621813,1,Intermediate,10090.0,,50594,
5686,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621814,1,Intermediate,10090.0,,50594,
5687,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621815,1,Intermediate,10090.0,,50594,
5688,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621816,1,Intermediate,10090.0,,50594,
5689,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621817,1,Intermediate,10090.0,,50594,
5690,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621818,1,Intermediate,10090.0,,50594,
5691,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621819,1,Intermediate,10090.0,,50594,
5692,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621820,1,Intermediate,10090.0,,50594,
5693,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621821,1,Intermediate,10090.0,,50594,
5694,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621822,1,Intermediate,10090.0,,50594,
5695,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619474,1,Intermediate,10090.0,,50594,
5696,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619475,1,Intermediate,10090.0,,50594,
5697,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619476,1,Intermediate,10090.0,,50594,
5698,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619477,1,Intermediate,10090.0,,50594,
5699,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619478,1,Intermediate,10090.0,,50594,
5700,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619479,1,Intermediate,10090.0,,50594,
5701,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619480,1,Intermediate,10090.0,,50594,
5702,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619481,1,Intermediate,10090.0,,50594,
5703,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619482,1,Intermediate,10090.0,,50594,
5704,Area under the curve was evaluated in mice after intravenous administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619483,1,Intermediate,10090.0,,50594,
5705,Area under the curve was evaluated in mice after oral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619484,1,Intermediate,10090.0,,50594,
5706,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619485,1,Intermediate,10090.0,,50594,
5707,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619486,1,Intermediate,10090.0,,50594,
5708,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619487,1,Intermediate,10090.0,,50594,
5709,AUMC after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619488,1,Intermediate,10090.0,,50594,
5710,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL620106,1,Intermediate,10090.0,,50594,
5711,The compound was tested in vitro for anticancer activity against 9L cells,1,N,,,,,,,9L,,BAO_0000219,CHEMBL620107,1,Intermediate,,,80653,392.0
5712,Anti proliferation activity determined; Weak effect,1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620283,0,Autocuration,10116.0,,22226,
5713,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,1,U,,Rattus norvegicus,,,,,,,BAO_0000219,CHEMBL875176,0,Autocuration,10116.0,,22226,
5714,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,1,U,,Rattus norvegicus,,,,,,,BAO_0000219,CHEMBL620284,0,Autocuration,10116.0,,22226,
5715,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,1,U,,Rattus norvegicus,,,,,,,BAO_0000219,CHEMBL623515,0,Autocuration,10116.0,,22226,
5716,The cytotoxic activity was in vitro tested by 9PS assay method,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL623516,0,Autocuration,10090.0,,22226,
5717,The cytotoxic activity was in vitro tested by 9PS assay method.,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL623517,0,Autocuration,10090.0,,22226,
5718,Partition coefficient (logD6.5),1,U,,,,,,,,,BAO_0000019,CHEMBL857878,0,Autocuration,,,22224,
5719,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623518,1,Expert,9606.0,,81034,478.0
5720,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL624195,1,Intermediate,9606.0,,80018,455.0
5721,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL624196,1,Expert,9606.0,,80852,500.0
5722,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,D,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL624197,9,Expert,9606.0,,9,500.0
5723,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL624198,1,Intermediate,9606.0,,80021,624.0
5724,in vitro cytotoxicity against A 498 cancer cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL621287,1,Intermediate,9606.0,,80021,624.0
5725,In vitro cytotoxic activity against renal (A 498) cancer cell line.,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL621288,1,Intermediate,9606.0,,80021,624.0
5726,Cytotoxic activity against A 498 renal cancer cell lines.,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL876496,1,Intermediate,9606.0,,80021,624.0
5727,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL621289,1,Intermediate,9606.0,,80021,624.0
5728,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,U,,Staphylococcus aureus,,,,,,,BAO_0000019,CHEMBL621290,0,Autocuration,1280.0,,22226,
5729,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,U,,Staphylococcus aureus,,,,,,,BAO_0000019,CHEMBL621291,0,Autocuration,1280.0,,22226,
5730,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,U,,Staphylococcus aureus,,,,,,,BAO_0000019,CHEMBL621292,0,Autocuration,1280.0,,22226,
5731,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,U,,Staphylococcus aureus,,,,,,,BAO_0000019,CHEMBL621293,0,Autocuration,1280.0,,22226,
5732,Inhibitory concentration required against A 549 lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621294,1,Intermediate,9606.0,,80682,646.0
5733,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621295,1,Intermediate,9606.0,,80682,646.0
5734,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884007,1,Intermediate,9606.0,,80682,646.0
5735,In vitro cytotoxicity against lung cancer A 549 cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621296,1,Intermediate,9606.0,,80682,646.0
5736,Compound was tested for its cytotoxicity against A 549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621297,1,Intermediate,9606.0,,80682,646.0
5737,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL839828,1,Expert,9606.0,,80682,646.0
5738,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620397,1,Intermediate,9606.0,,80682,646.0
5739,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620398,1,Expert,9606.0,,80682,646.0
5740,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620399,1,Intermediate,9606.0,,80682,646.0
5741,In vitro inhibition of A549 (human lung cancer) cell growth.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620400,1,Expert,9606.0,,80682,646.0
5742,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620401,1,Intermediate,9606.0,,80682,646.0
5743,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620402,1,Expert,9606.0,,80682,646.0
5744,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620403,1,Expert,9606.0,,80682,646.0
5745,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,1,U,,,,,,,,,BAO_0000218,CHEMBL620404,0,Autocuration,,,22226,
5746,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,1,H,,,,,,,,,BAO_0000218,CHEMBL620405,4,Autocuration,,,104694,
5747,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,1,H,,,,,,,,,BAO_0000218,CHEMBL620406,4,Autocuration,,,104694,
5748,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,1,H,,,,,,,,,BAO_0000218,CHEMBL620407,4,Autocuration,,,104694,
5749,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,1,H,,,,,,,,,BAO_0000218,CHEMBL620408,4,Autocuration,,,104694,
5750,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,1,H,,,,,,,,,BAO_0000218,CHEMBL620409,4,Autocuration,,,104694,
5751,Inhibition of A-498 human Renal cell proliferation,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL620410,1,Expert,9606.0,,80021,624.0
5752,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620411,0,Autocuration,10116.0,,22226,
5753,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL620412,0,Autocuration,10116.0,,22226,
5754,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",1,U,,Rattus norvegicus,,,,,,,BAO_0000019,CHEMBL876596,0,Autocuration,10116.0,,22226,
5755,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL620413,1,Expert,9606.0,,80012,622.0
5756,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL620414,1,Intermediate,9606.0,,80012,622.0
5757,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL620415,1,Intermediate,9606.0,,80012,622.0
5758,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620416,1,Expert,9606.0,,80682,646.0
5759,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620417,1,Intermediate,9606.0,,80682,646.0
5760,Cytotoxic activity evaluated against A549 tumor cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620418,1,Expert,9606.0,,80682,646.0
5761,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620419,1,Intermediate,9606.0,,80682,646.0
5762,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620420,1,Intermediate,9606.0,,80682,646.0
5763,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620421,1,Intermediate,9606.0,,80682,646.0
5764,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620422,1,Intermediate,9606.0,,80682,646.0
5765,Cytotoxicity of compound against A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620423,1,Intermediate,9606.0,,80682,646.0
5766,Cytotoxicity against human lung cell carcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620424,1,Expert,9606.0,,80682,646.0
5767,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620425,1,Intermediate,9606.0,,80682,646.0
5768,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620426,1,Intermediate,9606.0,,80682,646.0
5769,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620427,1,Intermediate,9606.0,,80682,646.0
5770,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620428,1,Intermediate,9606.0,,80682,646.0
5771,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620429,1,Intermediate,9606.0,,80682,646.0
5772,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620430,1,Expert,9606.0,,80682,646.0
5773,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL839887,1,Expert,9606.0,,80682,646.0
5774,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620431,1,Intermediate,9606.0,,80682,646.0
5775,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884010,1,Intermediate,9606.0,,80682,646.0
5776,In vitro cytotoxicity against A549 (human lung cancer),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620538,1,Intermediate,9606.0,,80682,646.0
5777,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620539,1,Expert,9606.0,,80682,646.0
5778,In vivo antiproliferative activity against A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL623373,1,Intermediate,9606.0,,80682,646.0
5779,Inhibition of non-small-cell lung adenocarcinoma (A549),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623374,1,Intermediate,9606.0,,80682,646.0
5780,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623375,1,Intermediate,9606.0,,80682,646.0
5781,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623376,1,Intermediate,9606.0,,80682,646.0
5782,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623377,1,Intermediate,9606.0,,80682,646.0
5783,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623378,1,Intermediate,9606.0,,80682,646.0
5784,Inhibitory activity of compound against human A549 lung carcinoma cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623379,1,Intermediate,9606.0,,80682,646.0
5785,Inhibitory activity against A549 lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623380,1,Intermediate,9606.0,,80682,646.0
5786,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623381,1,Intermediate,9606.0,,80682,646.0
5787,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623382,1,Intermediate,9606.0,,80682,646.0
5788,Inhibitory concentration against A549 (lung cancer) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623383,1,Intermediate,9606.0,,80682,646.0
5789,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623384,1,Expert,9606.0,,80682,646.0
5790,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623385,1,Intermediate,9606.0,,80682,646.0
5791,Activity against A549 cancer cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623386,1,Expert,9606.0,,80682,646.0
5792,The compound was evaluated for cytotoxicity against A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884105,1,Intermediate,9606.0,,80682,646.0
5793,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623387,1,Intermediate,9606.0,,80682,646.0
5794,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621568,1,Intermediate,9606.0,,80682,646.0
5795,Growth inhibitory activity was measured for human A549 tumor cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621569,1,Intermediate,9606.0,,80682,646.0
5796,Inhibitory activity against A549 lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621570,1,Intermediate,9606.0,,80682,646.0
5797,Inhibitory activity against A549 cell line; inactive,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621571,1,Intermediate,9606.0,,80682,646.0
5798,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621572,1,Expert,9606.0,,80682,646.0
5799,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621573,1,Expert,9606.0,,80682,646.0
5800,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621574,1,Intermediate,9606.0,,80682,646.0
5801,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621575,1,Intermediate,9606.0,,80682,646.0
5802,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621576,1,Intermediate,9606.0,,80682,646.0
5803,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621577,1,Intermediate,9606.0,,80682,646.0
5804,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621578,1,Intermediate,9606.0,,80682,646.0
5805,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621579,1,Intermediate,9606.0,,80682,646.0
5806,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621580,1,Intermediate,9606.0,,80682,646.0
5807,Plasma clearance (in vivo) in mongrel dogs was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621581,1,Intermediate,9615.0,,50588,
5808,Plasma clearance was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621582,1,Intermediate,9615.0,,50588,
5809,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621583,1,Intermediate,9615.0,,50588,
5810,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621584,1,Intermediate,9615.0,,50588,
5811,Tested for plasma clearance in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621585,1,Intermediate,9615.0,,50588,
5812,The compound was tested for clearance in dog plasma.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621586,1,Intermediate,9615.0,,50588,
5813,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875835,1,Intermediate,9615.0,,50588,
5814,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621587,1,Intermediate,9615.0,,50588,
5815,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621588,1,Intermediate,9615.0,,50588,
5816,In vitro clearance in dog liver microsomes,1,N,,Canis lupus familiaris,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL621589,1,Intermediate,9615.0,,50588,
5817,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621590,1,Intermediate,9615.0,,50588,
5818,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621591,1,Intermediate,9615.0,,50588,
5819,Plasma clearance in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621592,1,Intermediate,9615.0,,50588,
5820,Clearance rate in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621593,1,Intermediate,9615.0,,50588,
5821,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621594,1,Intermediate,9615.0,,50588,
5822,Clearance in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621595,1,Intermediate,9615.0,,50588,
5823,Plasma clearance in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621596,1,Intermediate,9615.0,,50588,
5824,Plasma clearance was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621597,1,Intermediate,9615.0,,50588,
5825,Lower clearance in dog (i.v.) at 0.5 mpk,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621598,1,Intermediate,9615.0,,50588,
5826,Plasma clearance in Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621599,1,Intermediate,9615.0,,50588,
5827,Plasma clearance (Clp) in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875836,1,Intermediate,9615.0,,50588,
5828,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621600,1,Intermediate,9615.0,,50588,
5829,Plasma clearance (pharmacokinetic parameter) in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621601,1,Intermediate,9615.0,,50588,
5830,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618474,1,Intermediate,9615.0,,50588,
5831,Plasma clearance of compound was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618475,1,Intermediate,9615.0,,50588,
5832,Plasma clearance after intravenous administration of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624524,1,Intermediate,9615.0,,50588,
5833,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624525,1,Intermediate,9615.0,,50588,
5834,Plasma clearance in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624526,1,Intermediate,9615.0,,50588,
5835,Plasma clearance was calculated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624527,1,Intermediate,9615.0,,50588,
5836,Plasma clearance at the dose of 2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624528,1,Intermediate,9615.0,,50588,
5837,Plasma clearance in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624529,1,Intermediate,9615.0,,50588,
5838,Plasma clearance in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624530,1,Intermediate,9615.0,,50588,
5839,Plasma clearance in dog; Unable to calculate,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624531,1,Intermediate,9615.0,,50588,
5840,Plasma clearance in rhesus monkey,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624532,1,Intermediate,9615.0,,50588,
5841,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624533,1,Intermediate,9615.0,,50588,
5842,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624534,1,Intermediate,9615.0,,50588,
5843,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624535,1,Intermediate,9615.0,,50588,
5844,Plasma clearance was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624536,1,Intermediate,9615.0,,50588,
5845,Plasma clearance was evaluated in dog; Not tested,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624537,1,Intermediate,9615.0,,50588,
5846,Plasma clearance was evaluated in rhesus,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624538,1,Intermediate,9615.0,,50588,
5847,Plasma clearance was evaluated in rhesus; Not tested,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624539,1,Intermediate,9615.0,,50588,
5848,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624540,1,Intermediate,9615.0,,50588,
5849,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624541,1,Intermediate,9615.0,,50588,
5850,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624542,1,Intermediate,9615.0,,50588,
5851,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624543,1,Intermediate,9615.0,,50588,
5852,Clearance value at a dose of 0.2 mg/kg i.v.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624544,1,Intermediate,9615.0,,50588,
5853,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624545,1,Intermediate,9615.0,,50588,
5854,Cmax after oral dose of compound at 3 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624546,1,Intermediate,9615.0,,50588,
5855,Cmax after single intravenous bolus of 1 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875957,1,Intermediate,9615.0,,50588,
5856,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624547,1,Intermediate,9615.0,,50588,
5857,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624548,1,Intermediate,9615.0,,50588,
5858,Cmax in dog after administration of 1 mg/kg iv,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624549,1,Intermediate,9615.0,,50588,
5859,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624550,1,Intermediate,9615.0,,50588,
5860,Cmax on p.o. administration of 10 mg/kg was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621613,1,Intermediate,9615.0,,50588,
5861,Cmax was determine after peroral administration at 10 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621614,1,Intermediate,9615.0,,50588,
5862,Cmax was determine after peroral administration at 5 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623431,1,Intermediate,9615.0,,50588,
5863,Cmax was determine after peroral administration at 5 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623432,1,Intermediate,9615.0,,50588,
5864,Cmax after 0.3 mg/kg po administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623433,1,Intermediate,9615.0,,50588,
5865,Cmax after peroral administration in dogs at 2.4 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623434,1,Intermediate,9615.0,,50588,
5866,Cmax in dog after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623435,1,Intermediate,9615.0,,50588,
5867,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623436,1,Intermediate,9615.0,,50588,
5868,Cmax upon oral administration in male Beagle dog at 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875958,1,Intermediate,9615.0,,50588,
5869,Cmax value after 15 mg/kg iv dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623437,1,Intermediate,9615.0,,50588,
5870,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL623438,1,Intermediate,10090.0,,50594,
5871,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL623439,1,Intermediate,10090.0,,50594,
5872,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL623440,1,Intermediate,10090.0,,50594,
5873,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL623441,1,Intermediate,10090.0,,50594,
5874,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL623442,1,Intermediate,10090.0,,50594,
5875,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623469,1,Intermediate,10090.0,,50594,
5876,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623470,1,Intermediate,10090.0,,50594,
5877,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623471,1,Intermediate,10090.0,,50594,
5878,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL623472,1,Intermediate,10090.0,,50594,
5879,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL623473,1,Intermediate,10090.0,,50594,
5880,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL623474,1,Intermediate,10090.0,,50594,
5881,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623475,1,Intermediate,10090.0,,50594,
5882,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623476,1,Intermediate,10090.0,,50594,
5883,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623477,1,Intermediate,10090.0,,50594,
5884,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621896,1,Intermediate,10090.0,,50594,
5885,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621897,1,Intermediate,10090.0,,50594,
5886,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621898,1,Intermediate,10090.0,,50594,
5887,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621899,1,Intermediate,10090.0,,50594,
5888,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621900,1,Intermediate,10090.0,,50594,
5889,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621901,1,Intermediate,10090.0,,50594,
5890,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL621902,1,Intermediate,10090.0,,50594,
5891,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL621903,1,Intermediate,10090.0,,50594,
5892,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622587,1,Intermediate,10090.0,,50594,
5893,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620285,1,Intermediate,10090.0,,50594,
5894,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL875285,1,Intermediate,10090.0,,50594,
5895,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620286,1,Intermediate,10090.0,,50594,
5896,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620287,1,Intermediate,10090.0,,50594,
5897,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620288,1,Intermediate,10090.0,,50594,
5898,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620289,1,Intermediate,10090.0,,50594,
5899,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL620290,1,Intermediate,10090.0,,50594,
5900,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL620291,1,Intermediate,10090.0,,50594,
5901,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL620292,1,Intermediate,10090.0,,50594,
5902,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620293,1,Intermediate,10090.0,,50594,
5903,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620294,1,Intermediate,10090.0,,50594,
5904,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618614,1,Intermediate,10090.0,,50594,
5905,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL618615,1,Intermediate,10090.0,,50594,
5906,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL618616,1,Intermediate,10090.0,,50594,
5907,Cytotoxicity against A-172 human tumor cell lines,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL618617,1,Expert,9606.0,,80012,622.0
5908,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL618618,1,Intermediate,9606.0,,80012,622.0
5909,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1,N,,Homo sapiens,,,,,A204,,BAO_0000219,CHEMBL618619,1,Intermediate,9606.0,,80014,623.0
5910,Tested for antiproliferative activity against A-2780 tumoral cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618620,1,Intermediate,9606.0,,81034,478.0
5911,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL618621,1,Intermediate,9606.0,,80018,455.0
5912,Tested in vitro against A-375 cell line human melanoma,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL618622,1,Intermediate,9606.0,,80018,455.0
5913,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618623,1,Expert,9606.0,,80019,797.0
5914,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618624,1,Intermediate,9606.0,,80019,797.0
5915,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618625,1,Expert,9606.0,,80019,797.0
5916,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618626,1,Intermediate,9606.0,,80019,797.0
5917,Antitumor activity on A-427 lung carcinoma cell lines,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618627,1,Intermediate,9606.0,,80019,797.0
5918,Cytotoxic activity against human A-427 lung tumor cell line,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618628,1,Intermediate,9606.0,,80019,797.0
5919,In vitro antitumor effects against human A-427 cell lines.,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618629,1,Expert,9606.0,,80019,797.0
5920,In vitro inhibition of A-427 (human lung cancer) cell growth.,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618630,1,Expert,9606.0,,80019,797.0
5921,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618631,1,Intermediate,9606.0,,80019,797.0
5922,Cytotoxic activity of compound against A-427 lung human tumor cell line,1,N,,Homo sapiens,,,,,A-427,,BAO_0000219,CHEMBL618632,1,Intermediate,9606.0,,80019,797.0
5923,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,1,N,,Homo sapiens,,,,,A-431,,BAO_0000219,CHEMBL618633,1,Expert,9606.0,,80852,500.0
5924,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619315,1,Intermediate,9606.0,,80021,624.0
5925,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619316,1,Expert,9606.0,,80021,624.0
5926,Cytotoxicity against human kidney carcinoma A-498cell lines,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619317,1,Intermediate,9606.0,,80021,624.0
5927,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619318,1,Intermediate,9606.0,,80021,624.0
5928,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619319,1,Intermediate,9606.0,,80021,624.0
5929,Antitumor cytotoxic activity against A-498 cell line was determined,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619739,1,Intermediate,9606.0,,80021,624.0
5930,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619740,1,Intermediate,9606.0,,80021,624.0
5931,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL883158,1,Intermediate,9606.0,,80021,624.0
5932,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL884012,1,Intermediate,9606.0,,80021,624.0
5933,In vitro inhibitory activity against A-498 ovarian cancer cell lines,1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619741,1,Intermediate,9606.0,,80021,624.0
5934,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",1,N,,Homo sapiens,,,,,A498,,BAO_0000219,CHEMBL619742,1,Intermediate,9606.0,,80021,624.0
5935,Inhibition of growth lung non-small cell carcinoma A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876610,1,Intermediate,9606.0,,80682,646.0
5936,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619743,1,Intermediate,9606.0,,80682,646.0
5937,In vitro antiproliferative activity against human A-549 NSCL cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619744,1,Intermediate,9606.0,,80682,646.0
5938,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619745,1,Intermediate,9606.0,,80682,646.0
5939,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619746,1,Intermediate,9606.0,,80682,646.0
5940,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619747,1,Intermediate,9606.0,,80682,646.0
5941,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619748,1,Intermediate,9606.0,,80682,646.0
5942,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619749,1,Intermediate,9606.0,,80682,646.0
5943,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619750,1,Intermediate,9606.0,,80682,646.0
5944,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624014,1,Intermediate,9606.0,,80682,646.0
5945,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624015,1,Intermediate,9606.0,,80682,646.0
5946,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL885344,1,Expert,9606.0,,80682,646.0
5947,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623224,1,Intermediate,9606.0,,80682,646.0
5948,Cytotoxic activity against A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL623225,1,Intermediate,9606.0,,80682,646.0
5949,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622698,1,Intermediate,9606.0,,80682,646.0
5950,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622699,1,Intermediate,9606.0,,80682,646.0
5951,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622700,1,Expert,9606.0,,80682,646.0
5952,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622701,1,Intermediate,9606.0,,80682,646.0
5953,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622702,1,Intermediate,9606.0,,80682,646.0
5954,Cytotoxic activity against human lung carcinoma (A-549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622703,1,Intermediate,9606.0,,80682,646.0
5955,Cytotoxic activity towards A-549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622704,1,Expert,9606.0,,80682,646.0
5956,"In vitro percent inhibition of A549, lung carcinoma.",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622705,1,Intermediate,9606.0,,80682,646.0
5957,"In vitro percent inhibition of A549, lung carcinoma",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622706,1,Intermediate,9606.0,,80682,646.0
5958,"In vitro percent inhibition of A549, lung carcinoma.",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622707,1,Intermediate,9606.0,,80682,646.0
5959,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622708,1,Intermediate,9606.0,,80682,646.0
5960,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622709,1,Intermediate,9606.0,,80682,646.0
5961,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622710,1,Intermediate,9606.0,,80682,646.0
5962,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622711,1,Intermediate,9606.0,,80682,646.0
5963,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL622712,1,Intermediate,9606.0,,80682,646.0
5964,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL622713,1,Intermediate,9606.0,,80682,646.0
5965,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL622714,1,Intermediate,9606.0,,80682,646.0
5966,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL622715,1,Intermediate,9606.0,,80682,646.0
5967,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL622716,1,Intermediate,9606.0,,80682,646.0
5968,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622717,1,Intermediate,9606.0,,80682,646.0
5969,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL622718,1,Intermediate,9606.0,,80682,646.0
5970,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622719,1,Expert,9606.0,,80682,646.0
5971,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622720,1,Intermediate,9606.0,,80682,646.0
5972,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622721,1,Intermediate,9606.0,,80682,646.0
5973,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622722,1,Intermediate,9606.0,,80682,646.0
5974,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876030,1,Intermediate,9606.0,,80682,646.0
5975,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620206,1,Intermediate,9606.0,,80682,646.0
5976,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620207,1,Expert,9606.0,,80682,646.0
5977,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620208,1,Expert,9606.0,,80682,646.0
5978,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620209,1,Expert,9606.0,,80682,646.0
5979,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620210,1,Expert,9606.0,,80682,646.0
5980,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621639,1,Expert,9606.0,,80682,646.0
5981,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621640,1,Intermediate,9606.0,,80682,646.0
5982,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621641,1,Expert,9606.0,,80682,646.0
5983,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621642,1,Expert,9606.0,,80682,646.0
5984,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621643,1,Intermediate,9606.0,,80682,646.0
5985,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621644,1,Intermediate,9606.0,,80682,646.0
5986,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL621645,1,Intermediate,9606.0,,80682,646.0
5987,In vitro antiproliferative activity against A549 cell line,1,N,,Mus musculus,,,,,A549,,BAO_0000219,CHEMBL621646,1,Intermediate,10090.0,,80682,646.0
5988,Synergism with indomethacin in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621647,1,Intermediate,,,80682,646.0
5989,Synergism with tolmetin in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621648,1,Intermediate,,,80682,646.0
5990,Synergism with sulindac in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621649,1,Intermediate,,,80682,646.0
5991,Antagonism of indomethacin in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621650,1,Intermediate,,,80682,646.0
5992,Antagonism of sulindac in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621651,1,Intermediate,,,80682,646.0
5993,Antagonism of tolmetin in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621652,1,Intermediate,,,80682,646.0
5994,Synergism with indomethacin in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621653,1,Intermediate,,,80682,646.0
5995,Synergism with sulindac in A549 cells,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621654,1,Intermediate,,,80682,646.0
5996,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,1,N,,,,,,,A549,,BAO_0000219,CHEMBL621655,1,Intermediate,,,80682,646.0
5997,Cmax value after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621656,1,Intermediate,9615.0,,50588,
5998,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621657,1,Intermediate,9615.0,,50588,
5999,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621658,1,Intermediate,9615.0,,50588,
6000,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621659,1,Intermediate,9615.0,,50588,
6001,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621660,1,Intermediate,9615.0,,50588,
6002,Cmax value after administration of 4 mg/Kg oral dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621661,1,Intermediate,9615.0,,50588,
6003,Cmax value in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621662,1,Intermediate,9615.0,,50588,
6004,Cmax value in dogs after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621663,1,Intermediate,9615.0,,50588,
6005,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621664,1,Intermediate,9615.0,,50588,
6006,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621665,1,Intermediate,9615.0,,50588,
6007,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621666,1,Intermediate,9615.0,,50588,
6008,Concentration maxima after oral dosing in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621667,1,Intermediate,9615.0,,50588,
6009,Concentration maxima after oral dosing in dogs; not available,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876738,1,Intermediate,9615.0,,50588,
6010,Concentration maxima after oral dosing in dogs; not available,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621668,1,Intermediate,9615.0,,50588,
6011,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621669,1,Intermediate,9615.0,,50588,
6012,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621670,1,Intermediate,9615.0,,50588,
6013,In vivo maximal concentration was calculated at 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621671,1,Intermediate,9615.0,,50588,
6014,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622360,1,Intermediate,9615.0,,50588,
6015,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622361,1,Intermediate,9615.0,,50588,
6016,Cmax in dog plasma after oral dose (1 mg/kg),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622362,1,Intermediate,9615.0,,50588,
6017,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622363,1,Intermediate,9615.0,,50588,
6018,Maximal plasma concentration at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622364,1,Intermediate,9615.0,,50588,
6019,Maximal plasma concentration at a dose of 1 mg/kg (oral),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622365,1,Intermediate,9615.0,,50588,
6020,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622533,1,Intermediate,9615.0,,50588,
6021,Maximum concentration of compound in dog was evaluated.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622534,1,Intermediate,9615.0,,50588,
6022,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622535,1,Intermediate,9615.0,,50588,
6023,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876739,1,Intermediate,9615.0,,50588,
6024,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622536,1,Intermediate,9615.0,,50588,
6025,Maximum concentration obtained in dog plasma was determined,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622537,1,Intermediate,9615.0,,50588,
6026,Maximum concentration was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622538,1,Intermediate,9615.0,,50588,
6027,Maximum concentration at the dose of 2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL627867,1,Intermediate,9615.0,,50588,
6028,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL627868,1,Intermediate,9615.0,,50588,
6029,Maximum concentration was evaluated in dog plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627869,1,Intermediate,9615.0,,50588,
6030,Maximum concentration was evaluated after 75 min after administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL627870,1,Intermediate,9615.0,,50588,
6031,Maximum plasma concentration determined in dog after oral administration of 17b,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627871,1,Intermediate,9615.0,,50588,
6032,Maximum plasma concentration determined in dog after oral administration of 2b,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627872,1,Intermediate,9615.0,,50588,
6033,Maximum plasma concentration in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627873,1,Intermediate,9615.0,,50588,
6034,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627874,1,Intermediate,9615.0,,50588,
6035,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627875,1,Intermediate,9615.0,,50588,
6036,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627876,1,Intermediate,9615.0,,50588,
6037,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627877,1,Intermediate,9615.0,,50588,
6038,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627878,1,Intermediate,9615.0,,50588,
6039,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627879,1,Intermediate,9615.0,,50588,
6040,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875355,1,Intermediate,9615.0,,50588,
6041,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627880,1,Intermediate,9615.0,,50588,
6042,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627881,1,Intermediate,9615.0,,50588,
6043,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627882,1,Intermediate,9615.0,,50588,
6044,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627883,1,Intermediate,9615.0,,50588,
6045,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628526,1,Intermediate,9615.0,,50588,
6046,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628527,1,Intermediate,9615.0,,50588,
6047,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628528,1,Intermediate,9615.0,,50588,
6048,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628529,1,Intermediate,9615.0,,50588,
6049,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628530,1,Intermediate,9615.0,,50588,
6050,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625243,1,Intermediate,9615.0,,50588,
6051,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625244,1,Expert,9615.0,,50588,
6052,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625245,1,Intermediate,9615.0,,50588,
6053,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625246,1,Intermediate,9615.0,,50588,
6054,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL625247,1,Intermediate,10090.0,,50594,
6055,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625248,1,Intermediate,10090.0,,50594,
6056,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625249,1,Intermediate,10090.0,,50594,
6057,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625250,1,Intermediate,10090.0,,50594,
6058,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625251,1,Intermediate,10090.0,,50594,
6059,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875356,1,Intermediate,10090.0,,50594,
6060,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625252,1,Intermediate,10090.0,,50594,
6061,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL625253,1,Intermediate,10090.0,,50594,
6062,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625254,1,Intermediate,10090.0,,50594,
6063,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625255,1,Intermediate,10090.0,,50594,
6064,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625256,1,Intermediate,10090.0,,50594,
6065,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL625257,1,Intermediate,10090.0,,50594,
6066,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL625258,1,Intermediate,10090.0,,50594,
6067,Compound was evaluated for washout rate in mice (Radiolabeled compound),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625259,1,Intermediate,10090.0,,50594,
6068,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625260,1,Intermediate,10090.0,,50594,
6069,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625261,1,Intermediate,10090.0,,50594,
6070,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625262,1,Intermediate,10090.0,,50594,
6071,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622639,1,Intermediate,10090.0,,50594,
6072,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622640,1,Intermediate,10090.0,,50594,
6073,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622812,1,Intermediate,10090.0,,50594,
6074,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622813,1,Intermediate,10090.0,,50594,
6075,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622814,1,Intermediate,10090.0,,50594,
6076,Time at maximum activity in mice (Radiolabeled compound),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622815,1,Intermediate,10090.0,,50594,
6077,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625342,1,Intermediate,10090.0,,50594,
6078,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625343,1,Intermediate,10090.0,,50594,
6079,Binding towards mouse plasma protein at 10 uM,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL877591,1,Intermediate,10090.0,,50594,
6080,Binding towards mouse plasma protein at 100 uM,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625344,1,Intermediate,10090.0,,50594,
6081,Bioavailability was evaluated in mice after intravenous administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625345,1,Intermediate,10090.0,,50594,
6082,Bioavailability was evaluated in mice after oral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625346,1,Intermediate,10090.0,,50594,
6083,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625347,1,Intermediate,10090.0,,50594,
6084,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625348,1,Intermediate,10090.0,,50594,
6085,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625349,1,Intermediate,10090.0,,50594,
6086,Oral bioavailability in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625350,1,Intermediate,10090.0,,50594,
6087,Oral bioavailability after intravenous administration in mice at 24 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL882952,1,Intermediate,10090.0,,50594,
6088,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625351,1,Intermediate,10090.0,,50594,
6089,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625352,1,Intermediate,10090.0,,50594,
6090,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL877592,1,Intermediate,10090.0,,50594,
6091,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625353,1,Intermediate,10090.0,,50594,
6092,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625354,1,Intermediate,10090.0,,50594,
6093,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL626019,1,Intermediate,10090.0,,50594,
6094,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL626020,1,Intermediate,10090.0,,50594,
6095,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL626021,1,Intermediate,10090.0,,50594,
6096,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL626022,1,Intermediate,10090.0,,50594,
6097,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL626192,1,Intermediate,10090.0,,50594,
6098,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626193,1,Intermediate,9606.0,,80682,646.0
6099,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626194,1,Expert,9606.0,,80682,646.0
6100,Cytotoxicity against human lung carcinoma A-549 cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626195,1,Intermediate,9606.0,,80682,646.0
6101,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626196,1,Intermediate,9606.0,,80682,646.0
6102,In vitro cytotoxicity against human lung carcinoma cell line A-549,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626197,1,Intermediate,9606.0,,80682,646.0
6103,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626198,1,Intermediate,9606.0,,80682,646.0
6104,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626199,1,Intermediate,9606.0,,80682,646.0
6105,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626200,1,Intermediate,9606.0,,80682,646.0
6106,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626201,1,Intermediate,9606.0,,80682,646.0
6107,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626202,1,Intermediate,9606.0,,80682,646.0
6108,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626203,1,Intermediate,9606.0,,80682,646.0
6109,In vitro cytotoxicity against A-549 human lung cancer cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL626204,1,Intermediate,9606.0,,80682,646.0
6110,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624701,1,Intermediate,9606.0,,80682,646.0
6111,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624702,1,Intermediate,9606.0,,80682,646.0
6112,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624703,1,Expert,9606.0,,80682,646.0
6113,Tested in vitro for cytotoxicity against A-549 lung cancer cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624704,1,Intermediate,9606.0,,80682,646.0
6114,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624705,1,Intermediate,9606.0,,80682,646.0
6115,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624706,1,Expert,9606.0,,80682,646.0
6116,Antitumor cytotoxic activity against A-549 cell line was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624707,1,Intermediate,9606.0,,80682,646.0
6117,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624708,1,Intermediate,9606.0,,80682,646.0
6118,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624709,1,Intermediate,9606.0,,80682,646.0
6119,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884107,1,Expert,9606.0,,80682,646.0
6120,Antitumoral activity was assayed against A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624710,1,Intermediate,9606.0,,80682,646.0
6121,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624711,1,Intermediate,9606.0,,80682,646.0
6122,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624712,1,Intermediate,9606.0,,80682,646.0
6123,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624713,1,Expert,9606.0,,80682,646.0
6124,Compound was tested for inhibition of cell growth of A-549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624714,1,Intermediate,9606.0,,80682,646.0
6125,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624715,1,Intermediate,9606.0,,80682,646.0
6126,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624716,1,Intermediate,9606.0,,80682,646.0
6127,In vitro cytotoxicity against A549-human lung carcinoma cells.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619505,1,Expert,9606.0,,80682,646.0
6128,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619506,1,Expert,9606.0,,80682,646.0
6129,Cytotoxic activity against A-549 cell lines.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619507,1,Intermediate,9606.0,,80682,646.0
6130,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619508,1,Expert,9606.0,,80682,646.0
6131,Cytotoxicity against human A549 non small cell lung cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619509,1,Intermediate,9606.0,,80682,646.0
6132,Inhibition of cell growth in (A-549) lung cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619510,1,Expert,9606.0,,80682,646.0
6133,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619511,1,Intermediate,9606.0,,80682,646.0
6134,In vitro antitumor activity against A-549 tumor cells.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619512,1,Intermediate,9606.0,,80682,646.0
6135,In vitro antitumor effects against human A-549 cell lines.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619513,1,Expert,9606.0,,80682,646.0
6136,In vitro cytotoxic activity of compound against A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619514,1,Intermediate,9606.0,,80682,646.0
6137,In vitro cytotoxicity against human lung carcinoma A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619515,1,Intermediate,9606.0,,80682,646.0
6138,In vitro cytotoxicity against human non-small cell lung carcinoma A549,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619516,1,Intermediate,9606.0,,80682,646.0
6139,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884005,1,Intermediate,9606.0,,80682,646.0
6140,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619517,1,Expert,9606.0,,80682,646.0
6141,Inhibitory concentration of compound against A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619518,1,Intermediate,9606.0,,80682,646.0
6142,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619519,1,Intermediate,9606.0,,80682,646.0
6143,cytotoxic activity against leukemia (A-549) cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876489,1,Intermediate,9606.0,,80682,646.0
6144,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619520,1,Expert,9606.0,,80682,646.0
6145,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619521,1,Intermediate,9606.0,,80682,646.0
6146,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619522,1,Intermediate,9606.0,,80682,646.0
6147,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619523,1,Intermediate,9606.0,,80682,646.0
6148,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619524,1,Intermediate,9606.0,,80682,646.0
6149,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619525,1,Intermediate,9606.0,,80682,646.0
6150,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,1,N,,,,,,,A549,,BAO_0000219,CHEMBL619526,1,Intermediate,,,80682,646.0
6151,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619527,1,Intermediate,9606.0,,80682,646.0
6152,Cytotoxicity against A549 cells; No cytotoxicity,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619528,1,Intermediate,9606.0,,80682,646.0
6153,Cytotoxicity against human lung carcinoma (A549) cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619529,1,Expert,9606.0,,80682,646.0
6154,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619530,1,Expert,9606.0,,80682,646.0
6155,In vitro anticancer activity against human lung (A549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876490,1,Intermediate,9606.0,,80682,646.0
6156,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619531,1,Intermediate,9606.0,,80682,646.0
6157,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619532,1,Intermediate,9606.0,,80682,646.0
6158,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619533,1,Intermediate,9606.0,,80682,646.0
6159,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619534,1,Intermediate,9606.0,,80682,646.0
6160,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620164,1,Intermediate,9606.0,,80682,646.0
6161,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620165,1,Intermediate,9606.0,,80682,646.0
6162,Inhibition of A549 human lung tumor cell proliferation,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620166,1,Expert,9606.0,,80682,646.0
6163,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620167,1,Intermediate,9606.0,,80682,646.0
6164,In vitro cytotoxicity against human tumor cell line A549,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620168,1,Expert,9606.0,,80682,646.0
6165,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620338,1,Intermediate,9606.0,,80682,646.0
6166,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620339,1,Intermediate,9606.0,,80682,646.0
6167,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620340,1,Intermediate,9606.0,,80682,646.0
6168,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620341,1,Intermediate,9606.0,,80682,646.0
6169,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876491,1,Intermediate,9606.0,,80682,646.0
6170,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620342,1,Intermediate,9606.0,,80682,646.0
6171,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620343,1,Intermediate,9606.0,,80682,646.0
6172,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620344,1,Intermediate,9606.0,,80682,646.0
6173,In vitro anticancer activity against human lung (A549) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620345,1,Intermediate,9606.0,,80682,646.0
6174,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620346,1,Intermediate,9606.0,,80682,646.0
6175,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620347,1,Intermediate,9606.0,,80682,646.0
6176,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620348,1,Intermediate,9606.0,,80682,646.0
6177,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620349,1,Intermediate,9606.0,,80682,646.0
6178,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL618667,1,Intermediate,9606.0,,80682,646.0
6179,Percentage inhibition of human lung carcinoma (A549) cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL618668,1,Expert,9606.0,,80682,646.0
6180,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876031,1,Intermediate,9606.0,,80682,646.0
6181,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL618759,1,Intermediate,9606.0,,80682,646.0
6182,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL618760,1,Intermediate,9606.0,,80682,646.0
6183,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619000,1,Intermediate,9606.0,,80682,646.0
6184,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619001,1,Intermediate,9606.0,,80682,646.0
6185,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619002,1,Intermediate,9606.0,,80682,646.0
6186,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619003,1,Intermediate,9606.0,,80682,646.0
6187,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619597,1,Intermediate,9606.0,,80682,646.0
6188,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619598,1,Intermediate,9606.0,,80682,646.0
6189,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619599,1,Intermediate,9606.0,,80682,646.0
6190,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619600,1,Intermediate,9606.0,,80682,646.0
6191,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619601,1,Intermediate,9606.0,,80682,646.0
6192,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619602,1,Intermediate,9606.0,,80682,646.0
6193,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619603,1,Intermediate,9606.0,,80682,646.0
6194,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619604,1,Intermediate,9606.0,,80682,646.0
6195,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619605,1,Intermediate,9606.0,,80682,646.0
6196,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619606,1,Intermediate,9615.0,,50588,
6197,Pharmacokinetic activity (Cmax) in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876032,1,Intermediate,9615.0,,50588,
6198,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619607,1,Intermediate,9615.0,,50588,
6199,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619608,1,Intermediate,9615.0,,50588,
6200,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619609,1,Intermediate,9615.0,,50588,
6201,Cmax in dog plasma after 30mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619610,1,Intermediate,9615.0,,50588,
6202,Tested for the peak blood level in dog,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619611,1,Intermediate,9615.0,,50588,
6203,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619612,1,Intermediate,9615.0,,50588,
6204,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619613,1,Intermediate,9615.0,,50588,
6205,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619614,1,Intermediate,9615.0,,50588,
6206,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619615,1,Intermediate,9615.0,,50588,
6207,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619616,1,Intermediate,9615.0,,50588,
6208,Final plasma concentration in dogs after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619617,1,Intermediate,9615.0,,50588,
6209,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619618,1,Intermediate,9615.0,,50588,
6210,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876033,1,Intermediate,9615.0,,50588,
6211,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619619,1,Intermediate,9615.0,,50588,
6212,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619620,1,Intermediate,9615.0,,50588,
6213,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL619621,1,Intermediate,9615.0,,50588,
6214,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL619622,1,Intermediate,9615.0,,50588,
6215,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL618874,1,Intermediate,9615.0,,50588,
6216,Absolute bioavailability was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618875,1,Intermediate,9615.0,,50588,
6217,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618876,1,Intermediate,9615.0,,50588,
6218,Bioavailability after peroral administration (1 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618877,1,Intermediate,9615.0,,50588,
6219,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618878,1,Intermediate,9615.0,,50588,
6220,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618879,1,Intermediate,9615.0,,50588,
6221,Bioavailability after intravenous administration in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618880,1,Intermediate,9615.0,,50588,
6222,Bioavailability after peroral administration in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618881,1,Intermediate,9615.0,,50588,
6223,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618882,1,Intermediate,9615.0,,50588,
6224,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624226,1,Intermediate,9615.0,,50588,
6225,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624227,1,Intermediate,9615.0,,50588,
6226,Bioavailability,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624228,1,Intermediate,9615.0,,50588,
6227,Bioavailability,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624229,1,Intermediate,9615.0,,50588,
6228,Bioavailability by intravenous administration of 1.2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624230,1,Intermediate,9615.0,,50588,
6229,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624231,1,Intermediate,9615.0,,50588,
6230,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624232,1,Intermediate,9615.0,,50588,
6231,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625127,1,Intermediate,9615.0,,50588,
6232,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625128,1,Intermediate,9615.0,,50588,
6233,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621675,1,Intermediate,9615.0,,50588,
6234,Bioavailability in dog (p.o.) at 2.0 mpk,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621676,1,Intermediate,9615.0,,50588,
6235,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621677,1,Intermediate,9615.0,,50588,
6236,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621678,1,Intermediate,9615.0,,50588,
6237,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621679,1,Intermediate,9615.0,,50588,
6238,Bioavailability was evaluated after oral administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621680,1,Intermediate,9615.0,,50588,
6239,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621681,1,Intermediate,9615.0,,50588,
6240,Bioavailability was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876740,1,Intermediate,9615.0,,50588,
6241,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621682,1,Intermediate,9615.0,,50588,
6242,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621683,1,Intermediate,9615.0,,50588,
6243,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621684,1,Intermediate,9615.0,,50588,
6244,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621685,1,Intermediate,9615.0,,50588,
6245,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621686,1,Intermediate,9615.0,,50588,
6246,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621687,1,Intermediate,9615.0,,50588,
6247,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621688,1,Intermediate,9615.0,,50588,
6248,Bioavailability of compound in dog was determined after peroral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621689,1,Intermediate,9615.0,,50588,
6249,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621690,1,Intermediate,9615.0,,50588,
6250,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621691,1,Intermediate,9615.0,,50588,
6251,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875941,1,Intermediate,9615.0,,50588,
6252,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621692,1,Intermediate,9615.0,,50588,
6253,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621693,1,Intermediate,9615.0,,50588,
6254,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621694,1,Intermediate,9615.0,,50588,
6255,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621695,1,Intermediate,10090.0,,50594,
6256,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621696,1,Intermediate,10090.0,,50594,
6257,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621697,1,Intermediate,10090.0,,50594,
6258,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621698,1,Intermediate,10090.0,,50594,
6259,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623420,1,Intermediate,10090.0,,50594,
6260,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623421,1,Intermediate,10090.0,,50594,
6261,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623422,1,Intermediate,10090.0,,50594,
6262,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623423,1,Intermediate,10090.0,,50594,
6263,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623424,1,Intermediate,10090.0,,50594,
6264,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623425,1,Intermediate,10090.0,,50594,
6265,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623426,1,Intermediate,10090.0,,50594,
6266,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623427,1,Intermediate,10090.0,,50594,
6267,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623428,1,Intermediate,10090.0,,50594,
6268,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL875947,1,Intermediate,10090.0,,50594,
6269,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623429,1,Intermediate,10090.0,,50594,
6270,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623430,1,Intermediate,10090.0,,50594,
6271,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622588,1,Intermediate,10090.0,,50594,
6272,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622589,1,Intermediate,10090.0,,50594,
6273,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622751,1,Intermediate,10090.0,,50594,
6274,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622752,1,Intermediate,10090.0,,50594,
6275,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL622753,1,Intermediate,10090.0,,50594,42.0
6276,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL622647,1,Intermediate,10090.0,,50594,42.0
6277,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL875163,1,Intermediate,10090.0,,50594,42.0
6278,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL622648,1,Intermediate,10090.0,,50594,42.0
6279,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL622649,1,Intermediate,10090.0,,50594,42.0
6280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Brain,CCRF S-180,955.0,BAO_0000218,CHEMBL622650,1,Intermediate,10090.0,,50594,42.0
6281,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Brain,CCRF S-180,955.0,BAO_0000218,CHEMBL622651,1,Intermediate,10090.0,,50594,42.0
6282,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Brain,CCRF S-180,955.0,BAO_0000218,CHEMBL622652,1,Intermediate,10090.0,,50594,42.0
6283,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Brain,CCRF S-180,955.0,BAO_0000218,CHEMBL622653,1,Intermediate,10090.0,,50594,42.0
6284,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Brain,CCRF S-180,955.0,BAO_0000218,CHEMBL622654,1,Intermediate,10090.0,,50594,42.0
6285,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL622655,1,Intermediate,10090.0,,50594,42.0
6286,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL622656,1,Intermediate,10090.0,,50594,42.0
6287,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL622657,1,Intermediate,10090.0,,50594,42.0
6288,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL622658,1,Intermediate,10090.0,,50594,42.0
6289,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL622659,1,Intermediate,10090.0,,50594,42.0
6290,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Kidney,CCRF S-180,2113.0,BAO_0000218,CHEMBL624630,1,Intermediate,10090.0,,50594,42.0
6291,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Kidney,CCRF S-180,2113.0,BAO_0000218,CHEMBL624631,1,Intermediate,10090.0,,50594,42.0
6292,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Kidney,CCRF S-180,2113.0,BAO_0000218,CHEMBL624632,1,Intermediate,10090.0,,50594,42.0
6293,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624633,1,Intermediate,9606.0,,80682,646.0
6294,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624634,1,Intermediate,9606.0,,80682,646.0
6295,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624635,1,Intermediate,9606.0,,80682,646.0
6296,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624636,1,Intermediate,9606.0,,80682,646.0
6297,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL857055,1,Expert,9606.0,,80682,646.0
6298,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624637,1,Expert,9606.0,,80682,646.0
6299,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624638,1,Expert,9606.0,,80682,646.0
6300,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL874366,1,Expert,9606.0,,80682,646.0
6301,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624639,1,Expert,9606.0,,80682,646.0
6302,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624640,1,Expert,9606.0,,80682,646.0
6303,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624641,1,Intermediate,9606.0,,80682,646.0
6304,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624642,1,Intermediate,9606.0,,80682,646.0
6305,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624643,1,Intermediate,9606.0,,80682,646.0
6306,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624644,1,Intermediate,9606.0,,80682,646.0
6307,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL624645,1,Intermediate,9606.0,,80682,646.0
6308,The compound was evaluated for its cytotoxic potency against A-549 cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619445,1,Intermediate,9606.0,,80682,646.0
6309,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL839886,1,Expert,9606.0,,80682,646.0
6310,Cytotoxic activity of compound against A-549 tumor cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619446,1,Intermediate,9606.0,,80682,646.0
6311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619447,1,Intermediate,9606.0,,80682,646.0
6312,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619448,1,Intermediate,9606.0,,80682,646.0
6313,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619449,1,Intermediate,9606.0,,80682,646.0
6314,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619450,1,Intermediate,9606.0,,80682,646.0
6315,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619451,1,Intermediate,9606.0,,80682,646.0
6316,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619452,1,Expert,9606.0,,80682,646.0
6317,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619453,1,Intermediate,9606.0,,80682,646.0
6318,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL874367,1,Intermediate,9606.0,,80682,646.0
6319,Cytotoxic concentration against A-549 tumor cells.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619454,1,Intermediate,9606.0,,80682,646.0
6320,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619455,1,Intermediate,9606.0,,80682,646.0
6321,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619456,1,Intermediate,9606.0,,80682,646.0
6322,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,1,N,,Acinetobacter baumannii,,,,,,,BAO_0000218,CHEMBL619457,1,Expert,470.0,,50191,
6323,Activity against Acinetobacter calcoaceticus (AC54),1,N,,Acinetobacter calcoaceticus,,,,,,,BAO_0000218,CHEMBL619458,1,Intermediate,471.0,,50192,
6324,In vitro antifungal activity against Aspergillus flavus CM74,1,N,,Aspergillus flavus,,,,,,,BAO_0000218,CHEMBL619459,1,Expert,5059.0,,50274,
6325,In vitro antifungal activity against Aspergillus flavus CM74,1,N,,Aspergillus flavus,,,,,,,BAO_0000218,CHEMBL619460,1,Expert,5059.0,,50274,
6326,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL619461,1,Intermediate,746128.0,,50416,
6327,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL619462,1,Intermediate,746128.0,,50416,
6328,Antimicrobial activity against Aspergillus fumigatus (MIC),1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL620388,1,Intermediate,746128.0,,50416,
6329,Antimicrobial activity against Aspergillus fumigatus (MIC),1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL620389,1,Intermediate,746128.0,,50416,
6330,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL620390,1,Intermediate,746128.0,,50416,
6331,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL620391,1,Expert,746128.0,,50416,
6332,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,N,,Aspergillus fumigatus,,,,,,,BAO_0000218,CHEMBL621073,1,Expert,746128.0,,50416,
6333,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL621074,1,Intermediate,1655.0,,50296,
6334,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL621075,1,Intermediate,1656.0,,50366,
6335,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL619554,1,Intermediate,6277.0,,50535,
6336,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL619555,1,Intermediate,6277.0,,50535,
6337,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,1,N,,Aggregatibacter actinomycetemcomitans,,,,,,,BAO_0000218,CHEMBL619556,1,Intermediate,714.0,,50169,
6338,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,1,N,,Aggregatibacter actinomycetemcomitans,,,,,,,BAO_0000218,CHEMBL619557,1,Intermediate,714.0,,50169,
6339,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,1,N,,Aggregatibacter actinomycetemcomitans,,,,,,,BAO_0000218,CHEMBL619558,1,Intermediate,714.0,,50169,
6340,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619559,1,Intermediate,9606.0,,80682,646.0
6341,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619560,1,Intermediate,9606.0,,80682,646.0
6342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619561,1,Intermediate,9606.0,,80682,646.0
6343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619562,1,Intermediate,9606.0,,80682,646.0
6344,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619563,1,Intermediate,9606.0,,80682,646.0
6345,GI values against A549 cells (lung cancer),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL857457,1,Intermediate,9606.0,,80682,646.0
6346,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619564,1,Intermediate,9606.0,,80682,646.0
6347,Inhibitory activity against A549 human adenocarcinoma,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619565,1,Intermediate,9606.0,,80682,646.0
6348,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL619566,1,Intermediate,9606.0,,80682,646.0
6349,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL619567,1,Intermediate,9606.0,,80682,646.0
6350,Inhibitory activity against A549 lung adenocarcinoma cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619568,1,Intermediate,9606.0,,80682,646.0
6351,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619569,1,Intermediate,9606.0,,80682,646.0
6352,Cytotoxicity against human A549 lung cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619570,1,Intermediate,9606.0,,80682,646.0
6353,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,1,N,,Homo sapiens,,,,,A549,,BAO_0000218,CHEMBL619571,1,Intermediate,9606.0,,80682,646.0
6354,Growth inhibition of A549 (human lung carcinoma) cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619572,1,Expert,9606.0,,80682,646.0
6355,Effective dose required for inhibitory activity against A549 human tumor cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619573,1,Expert,9606.0,,80682,646.0
6356,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619574,1,Intermediate,9606.0,,80682,646.0
6357,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619575,1,Intermediate,9606.0,,80682,646.0
6358,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619576,1,Expert,9606.0,,80682,646.0
6359,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619577,1,Intermediate,9606.0,,80682,646.0
6360,In vitro inhibitory activity against A549 tumor cell culture,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619578,1,Intermediate,9606.0,,80682,646.0
6361,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884009,1,Intermediate,9606.0,,80682,646.0
6362,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619579,1,Intermediate,9606.0,,80682,646.0
6363,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619580,1,Intermediate,9606.0,,80682,646.0
6364,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619581,1,Intermediate,9606.0,,80682,646.0
6365,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619582,1,Intermediate,9606.0,,80682,646.0
6366,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619583,1,Intermediate,9606.0,,80682,646.0
6367,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL876502,1,Intermediate,9606.0,,80682,646.0
6368,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619584,1,Intermediate,9606.0,,80682,646.0
6369,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619585,1,Intermediate,9606.0,,80682,646.0
6370,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619586,1,Intermediate,9606.0,,80682,646.0
6371,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619587,1,Intermediate,9606.0,,80682,646.0
6372,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619588,1,Intermediate,9606.0,,80682,646.0
6373,Tested in vitro for cytotoxicity in A549/ATCC cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619589,1,Intermediate,9606.0,,80682,646.0
6374,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619590,1,Intermediate,9606.0,,80682,646.0
6375,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619591,1,Intermediate,9606.0,,80682,646.0
6376,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619592,1,Intermediate,9606.0,,80682,646.0
6377,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL619593,1,Intermediate,9606.0,,80682,646.0
6378,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620217,1,Intermediate,9606.0,,80682,646.0
6379,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620218,1,Intermediate,9606.0,,80682,646.0
6380,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620219,1,Intermediate,9606.0,,80682,646.0
6381,Antitumor activity against A549/ATCC cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL620220,1,Intermediate,9606.0,,80682,646.0
6382,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL625141,1,Intermediate,9606.0,,80682,646.0
6383,In vitro cytotoxicity against A549/ATCC cell line.,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL625142,1,Expert,9606.0,,80682,646.0
6384,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL625143,1,Intermediate,9606.0,,80682,646.0
6385,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL625144,1,Intermediate,9606.0,,80682,646.0
6386,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL622474,1,Intermediate,9606.0,,80682,646.0
6387,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,1,N,,Homo sapiens,,,,,A549,,BAO_0000219,CHEMBL884104,1,Intermediate,9606.0,,80682,646.0
6388,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,1,U,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL622475,0,Autocuration,9606.0,,22226,
6389,Compound was tested for oral bioavailability in dogs,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622476,0,Intermediate,9615.0,,22224,
6390,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875831,1,Intermediate,9615.0,,50588,
6391,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622477,1,Intermediate,9615.0,,50588,
6392,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622478,1,Intermediate,9615.0,,50588,
6393,Compound was tested for the oral bioavailability in dog; No availability,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623172,1,Intermediate,9615.0,,50588,
6394,Oral bioavailability in dog (dose 5 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623173,1,Intermediate,9615.0,,50588,
6395,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623174,1,Intermediate,9615.0,,50588,
6396,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623175,1,Intermediate,9615.0,,50588,
6397,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623340,1,Intermediate,9615.0,,50588,
6398,Oral bioavailability in dog (dose 5 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623341,1,Intermediate,9615.0,,50588,
6399,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623342,1,Intermediate,9615.0,,50588,
6400,Oral bioavailability of active FTIs in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623343,1,Intermediate,9615.0,,50588,
6401,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623344,1,Intermediate,9615.0,,50588,
6402,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623345,1,Expert,9615.0,,50588,
6403,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875832,1,Intermediate,9615.0,,50588,
6404,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623346,1,Intermediate,9615.0,,50588,
6405,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623347,1,Intermediate,9615.0,,50588,
6406,Oral bioavailability of compound was determined in dog; Not tested,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623348,1,Intermediate,9615.0,,50588,
6407,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623349,1,Intermediate,9615.0,,50588,
6408,Oral bioavailability (10 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623350,1,Intermediate,9615.0,,50588,
6409,Oral bioavailability,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623351,1,Intermediate,9615.0,,50588,
6410,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623352,1,Intermediate,9615.0,,50588,
6411,Oral bioavailability administered in solution in rats,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623353,1,Intermediate,9615.0,,50588,
6412,Oral bioavailability after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875833,1,Intermediate,9615.0,,50588,
6413,Oral bioavailability at a dose of 1 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623354,1,Intermediate,9615.0,,50588,
6414,Oral bioavailability in dog (dose 1 mg/kg p.o.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623355,1,Intermediate,9615.0,,50588,
6415,Oral bioavailability in Dog; ND = not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623356,1,Intermediate,9615.0,,50588,
6416,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623357,1,Intermediate,9615.0,,50588,
6417,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623358,1,Intermediate,9615.0,,50588,
6418,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623359,1,Intermediate,9615.0,,50588,
6419,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623360,1,Intermediate,9615.0,,50588,
6420,Oral bioavailability in dogs; No data,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623361,1,Intermediate,9615.0,,50588,
6421,Oral bioavailability measured in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623362,1,Intermediate,9615.0,,50588,
6422,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623363,1,Intermediate,9615.0,,50588,
6423,Oral bioavailability was calculated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623364,1,Intermediate,9615.0,,50588,
6424,Oral bioavailability after 0.3 mg/kg po administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875834,1,Intermediate,9615.0,,50588,
6425,Oral bioavailability in dog (i.v. dosing),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623365,1,Intermediate,9615.0,,50588,
6426,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623366,1,Intermediate,9615.0,,50588,
6427,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623367,1,Intermediate,9615.0,,50588,
6428,Oral bioavailability in Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623368,1,Intermediate,9615.0,,50588,
6429,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623369,1,Intermediate,9615.0,,50588,
6430,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623370,1,Intermediate,9615.0,,50588,
6431,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623371,1,Intermediate,9615.0,,50588,
6432,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623372,1,Intermediate,9615.0,,50588,
6433,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621351,1,Intermediate,9615.0,,50588,
6434,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621352,1,Intermediate,9615.0,,50588,
6435,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621353,1,Intermediate,9615.0,,50588,
6436,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621354,1,Intermediate,9615.0,,50588,
6437,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621355,1,Intermediate,9615.0,,50588,
6438,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621356,1,Intermediate,9615.0,,50588,
6439,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621357,1,Intermediate,9615.0,,50588,
6440,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621358,1,Intermediate,9615.0,,50588,
6441,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621359,1,Intermediate,9615.0,,50588,
6442,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621360,1,Intermediate,9615.0,,50588,
6443,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621361,1,Intermediate,9615.0,,50588,
6444,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621362,1,Intermediate,9615.0,,50588,
6445,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621363,1,Intermediate,9615.0,,50588,
6446,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621364,1,Intermediate,9615.0,,50588,
6447,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621166,1,Intermediate,9615.0,,50588,
6448,Oral bioavailability in dog (dose 1 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621167,1,Intermediate,9615.0,,50588,
6449,Oral bioavailability (F) in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621168,1,Intermediate,9615.0,,50588,
6450,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621169,1,Intermediate,9615.0,,50588,
6451,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875950,1,Intermediate,9615.0,,50588,
6452,Oral bioavailability in dog (dose 10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621170,1,Intermediate,9615.0,,50588,
6453,Oral bioavailability after peroral administration at 5 mpk in Dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621171,1,Intermediate,9615.0,,50588,
6454,Oral bioavailability in dog (dose 5 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621172,1,Intermediate,9615.0,,50588,
6455,Oral bioavailability in dog (dose 10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621173,1,Intermediate,9615.0,,50588,
6456,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Kidney,CCRF S-180,2113.0,BAO_0000218,CHEMBL621174,1,Intermediate,10090.0,,50594,42.0
6457,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Kidney,CCRF S-180,2113.0,BAO_0000218,CHEMBL621175,1,Intermediate,10090.0,,50594,42.0
6458,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL621176,1,Intermediate,10090.0,,50594,42.0
6459,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL621177,1,Intermediate,10090.0,,50594,42.0
6460,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL621178,1,Intermediate,10090.0,,50594,42.0
6461,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL621179,1,Intermediate,10090.0,,50594,42.0
6462,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL621180,1,Intermediate,10090.0,,50594,42.0
6463,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL875951,1,Intermediate,10090.0,,50594,42.0
6464,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL621181,1,Intermediate,10090.0,,50594,42.0
6465,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL621182,1,Intermediate,10090.0,,50594,42.0
6466,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL621183,1,Intermediate,10090.0,,50594,42.0
6467,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL621184,1,Intermediate,10090.0,,50594,42.0
6468,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621185,1,Intermediate,10090.0,,50594,42.0
6469,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621186,1,Intermediate,10090.0,,50594,42.0
6470,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621187,1,Intermediate,10090.0,,50594,42.0
6471,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621188,1,Intermediate,10090.0,,50594,42.0
6472,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621189,1,Intermediate,10090.0,,50594,42.0
6473,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Spleen,CCRF S-180,2106.0,BAO_0000218,CHEMBL621190,1,Intermediate,10090.0,,50594,42.0
6474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Spleen,CCRF S-180,2106.0,BAO_0000218,CHEMBL618520,1,Intermediate,10090.0,,50594,42.0
6475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Spleen,CCRF S-180,2106.0,BAO_0000218,CHEMBL621739,1,Intermediate,10090.0,,50594,42.0
6476,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Spleen,CCRF S-180,2106.0,BAO_0000218,CHEMBL621740,1,Intermediate,10090.0,,50594,42.0
6477,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Spleen,CCRF S-180,2106.0,BAO_0000218,CHEMBL621741,1,Intermediate,10090.0,,50594,42.0
6478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621742,1,Intermediate,10090.0,,50594,42.0
6479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621743,1,Intermediate,10090.0,,50594,42.0
6480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621744,1,Intermediate,10090.0,,50594,42.0
6481,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621745,1,Intermediate,10090.0,,50594,42.0
6482,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621746,1,Intermediate,10090.0,,50594,42.0
6483,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621747,1,Intermediate,10090.0,,50594,42.0
6484,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621748,1,Intermediate,10090.0,,50594,42.0
6485,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621749,1,Intermediate,10090.0,,50594,42.0
6486,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621750,1,Intermediate,10090.0,,50594,42.0
6487,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL621751,1,Intermediate,10090.0,,50594,42.0
6488,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL621752,1,Intermediate,10090.0,,50594,42.0
6489,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL621753,1,Intermediate,10090.0,,50594,42.0
6490,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL875955,1,Intermediate,10090.0,,50594,42.0
6491,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL621754,1,Intermediate,10090.0,,50594,42.0
6492,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Heart,CCRF S-180,948.0,BAO_0000218,CHEMBL621755,1,Intermediate,10090.0,,50594,42.0
6493,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL621756,1,Intermediate,10090.0,,50594,42.0
6494,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL624199,1,Intermediate,10090.0,,50594,42.0
6495,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL624200,1,Intermediate,10090.0,,50594,42.0
6496,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL624375,1,Intermediate,10090.0,,50594,42.0
6497,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Liver,CCRF S-180,2107.0,BAO_0000218,CHEMBL624376,1,Intermediate,10090.0,,50594,42.0
6498,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL624377,1,Intermediate,10090.0,,50594,42.0
6499,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL624378,1,Intermediate,10090.0,,50594,42.0
6500,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,N,,aeinetobacter anitrotap,,,,,,,BAO_0000218,CHEMBL857901,1,Intermediate,107673.0,,50067,
6501,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,N,,Acinetobacter calcoaceticus subsp. anitratus,,,,,,,BAO_0000218,CHEMBL875274,1,Intermediate,107673.0,,50067,
6502,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,N,,Acinetobacter calcoaceticus subsp. anitratus,,,,,,,BAO_0000218,CHEMBL624379,1,Intermediate,107673.0,,50067,
6503,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,N,,aeinetobacter anitrotap,,,,,,,BAO_0000218,CHEMBL624380,1,Intermediate,107673.0,,50067,
6504,Activity against Acinetobacter calcoaceticus (AC54),1,N,,Acinetobacter calcoaceticus,,,,,,,BAO_0000218,CHEMBL624381,1,Intermediate,471.0,,50192,
6505,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,1,N,,Anolis carolinensis,,,,,,,BAO_0000218,CHEMBL624382,1,Intermediate,28377.0,,50714,
6506,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,1,N,,Anolis carolinensis,,,,,,,BAO_0000218,CHEMBL624383,1,Intermediate,28377.0,,50714,
6507,Chlorohexidine coefficient for Actinomyces naeslundii 631,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624384,1,Intermediate,1655.0,,50296,
6508,Chlorohexidine coefficient for Actinomyces naeslundii B74,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624385,1,Intermediate,1655.0,,50296,
6509,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624386,1,Intermediate,1655.0,,50296,
6510,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624387,1,Intermediate,1655.0,,50296,
6511,Plaque bactericidal index against Actinomyces naeslundii 631,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624388,1,Intermediate,1655.0,,50296,
6512,Plaque bactericidal index against Actinomyces naeslundii N/9,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624389,1,Intermediate,1655.0,,50296,
6513,Plaque bactericidal index against Actinomyces naeslundii B74,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL624390,1,Intermediate,1655.0,,50296,
6514,Plaque bactericidal index against Actinomyces naeslundii N/3,1,N,,Actinomyces naeslundii,,,,,,,BAO_0000218,CHEMBL875275,1,Intermediate,1655.0,,50296,
6515,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,1,N,,Artemia salina,,,,,,,BAO_0000218,CHEMBL624391,1,Intermediate,85549.0,,50056,
6516,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",1,N,,Artemia salina,,,,,,,BAO_0000218,CHEMBL623636,1,Intermediate,85549.0,,50056,
6517,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623637,1,Intermediate,6253.0,,50532,
6518,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623638,1,Intermediate,6253.0,,50532,
6519,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623639,1,Intermediate,6253.0,,50532,
6520,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623640,1,Intermediate,6253.0,,50532,
6521,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623641,1,Intermediate,6253.0,,50532,
6522,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623642,1,Intermediate,6253.0,,50532,
6523,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623643,1,Intermediate,6253.0,,50532,
6524,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623644,1,Intermediate,6253.0,,50532,
6525,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623645,1,Intermediate,6253.0,,50532,
6526,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623646,1,Intermediate,6253.0,,50532,
6527,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623647,1,Intermediate,6253.0,,50532,
6528,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,1,N,,Ascaris suum,,,,,,,BAO_0000218,CHEMBL623648,1,Intermediate,6253.0,,50532,
6529,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623649,1,Intermediate,1656.0,,50366,
6530,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623650,1,Intermediate,1656.0,,50366,
6531,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623651,1,Intermediate,1656.0,,50366,
6532,Chlorohexidine coefficient for Actinomyces viscosus M-100,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623652,1,Expert,1656.0,,50366,
6533,Chlorohexidine coefficient for Actinomyces viscosus M-626,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623653,1,Intermediate,1656.0,,50366,
6534,Chlorohexidine coefficient for Actinomyces viscosus T14V,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623654,1,Intermediate,1656.0,,50366,
6535,Plaque bactericidal index against Actinomyces viscosus 8A06,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623655,1,Intermediate,1656.0,,50366,
6536,Plaque bactericidal index against Actinomyces viscosus M-100,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623656,1,Intermediate,1656.0,,50366,
6537,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623657,1,Expert,1656.0,,50366,
6538,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623658,1,Intermediate,1656.0,,50366,
6539,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623659,1,Intermediate,1656.0,,50366,
6540,Plaque bactericidal index against Actinomyces viscosus 626,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623660,1,Intermediate,1656.0,,50366,
6541,Plaque bactericidal index against Actinomyces viscosus T14V,1,N,,Actinomyces viscosus,,,,,,,BAO_0000218,CHEMBL623661,1,Intermediate,1656.0,,50366,
6542,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL875281,1,Intermediate,6277.0,,50535,
6543,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL623662,1,Intermediate,6277.0,,50535,
6544,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL623663,1,Intermediate,6277.0,,50535,
6545,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL623664,1,Intermediate,6277.0,,50535,
6546,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL623665,1,Intermediate,6277.0,,50535,
6547,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,1,N,,Homo sapiens,,,,,A673,,BAO_0000219,CHEMBL621856,1,Intermediate,9606.0,,80023,165.0
6548,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,1,N,,Homo sapiens,,,,,A704,,BAO_0000219,CHEMBL620432,1,Intermediate,9606.0,,80661,645.0
6549,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,1,U,,Rattus norvegicus,,,,,,,BAO_0000219,CHEMBL620433,0,Autocuration,10116.0,,22226,
6550,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL620434,1,Intermediate,10090.0,,80024,625.0
6551,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL620435,1,Intermediate,10090.0,,80024,625.0
6552,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,1,N,,Homo sapiens,,,,,A9,,BAO_0000219,CHEMBL620436,1,Intermediate,9606.0,,80024,625.0
6553,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,1,N,,Homo sapiens,,,,,A9,,BAO_0000219,CHEMBL876597,1,Intermediate,9606.0,,80024,625.0
6554,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,1,N,,Homo sapiens,,,,,Human ovarian carcinoma cell line,,BAO_0000219,CHEMBL620437,1,Expert,9606.0,,81037,874.0
6555,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL620438,1,Expert,10090.0,,80024,625.0
6556,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL620439,1,Expert,10090.0,,80024,625.0
6557,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL619657,1,Expert,10090.0,,80024,625.0
6558,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL619658,1,Intermediate,10090.0,,80024,625.0
6559,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL619659,1,Intermediate,10090.0,,80024,625.0
6560,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",1,H,,,,,,,,,BAO_0000019,CHEMBL619660,8,Expert,,,10649,
6561,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL619661,1,Intermediate,10090.0,,80024,625.0
6562,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,1,N,,Mus musculus,,,,,A9,,BAO_0000219,CHEMBL619662,1,Intermediate,10090.0,,80024,625.0
6563,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,1,N,,Cricetulus griseus,,,,,AA6,,BAO_0000219,CHEMBL619663,1,Intermediate,10029.0,,80663,975.0
6564,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,1,U,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL619664,0,Autocuration,9606.0,,22226,
6565,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",1,U,,Homo sapiens,,,,,,,BAO_0000219,CHEMBL619665,0,Autocuration,9606.0,,22226,
6566,Anti -HIV activity was measured against AA5/HIV-1(IIIB),1,N,,Homo sapiens,,,,,AA5,,BAO_0000219,CHEMBL883244,1,Intermediate,9606.0,,80662,974.0
6567,Cytotoxicity was measured against AA5/HIV-1(IIIB),1,N,,Homo sapiens,,,,,AA5,,BAO_0000219,CHEMBL884011,1,Intermediate,9606.0,,80662,974.0
6568,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,1,N,,Homo sapiens,,,,,AA5,,BAO_0000219,CHEMBL619666,1,Intermediate,9606.0,,80662,974.0
6569,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,1,N,,Homo sapiens,,,,,U-937,,BAO_0000219,CHEMBL619667,1,Intermediate,9606.0,,80566,379.0
6570,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,1,N,,Cricetulus griseus,,,,,UV4,,BAO_0000219,CHEMBL619668,1,Intermediate,10029.0,,80578,274.0
6571,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619669,1,Expert,10029.0,,80089,185.0
6572,Average intracellular compound concentration when the hypoxic SER=1.6,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL876608,1,Intermediate,10029.0,,80089,185.0
6573,Average intracellular compound concentration when the hypoxic SER=1.6.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619670,1,Intermediate,10029.0,,80089,185.0
6574,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619671,1,Intermediate,10029.0,,80089,185.0
6575,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619672,1,Intermediate,10029.0,,80089,185.0
6576,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619673,1,Intermediate,10029.0,,80089,185.0
6577,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619674,1,Intermediate,10029.0,,80089,185.0
6578,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619675,1,Intermediate,10029.0,,80089,185.0
6579,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619676,1,Intermediate,10029.0,,80089,185.0
6580,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619677,1,Intermediate,10029.0,,80089,185.0
6581,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619678,1,Intermediate,10029.0,,80089,185.0
6582,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619679,1,Intermediate,10029.0,,80089,185.0
6583,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL619680,1,Expert,10029.0,,80089,185.0
6584,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL621457,1,Intermediate,10029.0,,80089,185.0
6585,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL876609,1,Expert,10029.0,,80089,185.0
6586,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL621458,1,Intermediate,10029.0,,80089,185.0
6587,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,1,N,,hampster,,,,,CHO-AA8,,BAO_0000219,CHEMBL621459,1,Expert,36483.0,,80089,185.0
6588,Aerobic growth inhibition in Chinese hamster cell line AA8,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL621460,1,Expert,10029.0,,80089,185.0
6589,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL621461,1,Expert,10029.0,,80089,185.0
6590,Inhibition of growth under aerobic conditions in AA8 cells,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL621462,1,Expert,10029.0,,80089,185.0
6591,Oral bioavailability in dog (dose 10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621463,1,Intermediate,9615.0,,50588,
6592,Oral bioavailability in dog at 10 mg/kg of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621464,1,Intermediate,9615.0,,50588,
6593,Oral bioavailability in dog (dose 5 uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621465,1,Intermediate,9615.0,,50588,
6594,Oral bioavailability in dog (dose 5 uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621466,1,Intermediate,9615.0,,50588,
6595,Oral bioavailability in dog (mongrel),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621467,1,Intermediate,9615.0,,50588,
6596,Oral bioavailability in dog (dose 10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621468,1,Intermediate,9615.0,,50588,
6597,Oral bioavailability in dog (dose 10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876734,1,Intermediate,9615.0,,50588,
6598,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618476,1,Intermediate,9615.0,,50588,
6599,Bioavailability in dog (dose 1 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618477,1,Intermediate,9615.0,,50588,
6600,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618478,1,Intermediate,9615.0,,50588,
6601,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618479,1,Intermediate,9615.0,,50588,
6602,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618480,1,Intermediate,9615.0,,50588,
6603,Bioavailability in dog (dose 3-10 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618481,1,Intermediate,9615.0,,50588,
6604,The compound was tested for bioavailability of compound in plasma of dog; Complete,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618482,1,Intermediate,9615.0,,50588,
6605,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618483,1,Intermediate,9615.0,,50588,
6606,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618484,1,Intermediate,9615.0,,50588,
6607,Bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618485,1,Intermediate,9615.0,,50588,
6608,oral bioavailability was measured in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618486,1,Intermediate,9615.0,,50588,
6609,Compound was tested for plasma protein binding in dog; Not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618487,1,Intermediate,9615.0,,50588,
6610,Compound was tested for plasma protein binding of dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618488,1,Intermediate,9615.0,,50588,
6611,Compound was tested for plasma protein binding of dog; Not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876735,1,Intermediate,9615.0,,50588,
6612,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618489,1,Intermediate,9615.0,,50588,
6613,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618490,1,Intermediate,9615.0,,50588,
6614,Half life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618491,1,Intermediate,9615.0,,50588,
6615,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618492,1,Intermediate,9615.0,,50588,
6616,Half life was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873354,1,Intermediate,9615.0,,50588,
6617,Half life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618493,1,Intermediate,9615.0,,50588,
6618,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618494,1,Intermediate,9615.0,,50588,
6619,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,N,,Canis lupus familiaris,,,,Heart,,948.0,BAO_0000218,CHEMBL618495,1,Intermediate,9615.0,,50588,
6620,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,N,,Canis lupus familiaris,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618496,1,Intermediate,9615.0,,50588,
6621,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL618497,1,Intermediate,9615.0,,50588,
6622,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,N,,Canis lupus familiaris,,,,Lung,,2048.0,BAO_0000218,CHEMBL618498,1,Intermediate,9615.0,,50588,
6623,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,N,,Canis lupus familiaris,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618499,1,Intermediate,9615.0,,50588,
6624,LogP in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876736,1,Intermediate,9615.0,,50588,
6625,Partition coefficient (logP),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618500,1,Intermediate,9615.0,,50588,
6626,Partition coefficient in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL857831,1,Intermediate,9615.0,,50588,
6627,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618501,1,Intermediate,9615.0,,50588,
6628,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618502,1,Intermediate,9615.0,,50588,
6629,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618503,1,Intermediate,9615.0,,50588,
6630,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618504,1,Intermediate,9615.0,,50588,
6631,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618505,1,Intermediate,9615.0,,50588,
6632,Metabolism of compound in dog S9 microsomes; Trace,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618506,1,Intermediate,9615.0,,50588,
6633,In vitro metabolic potential in dog liver microsomes,1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL618507,1,Intermediate,9615.0,,50588,
6634,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876737,1,Intermediate,9615.0,,50588,
6635,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618508,1,Intermediate,9615.0,,50588,
6636,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618509,1,Intermediate,9615.0,,50588,
6637,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618510,1,Intermediate,9615.0,,50588,
6638,The compound was tested for bioavailability in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618511,1,Intermediate,9615.0,,50588,
6639,The compound was tested for oral bioavailability in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618512,1,Intermediate,9615.0,,50588,
6640,Oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618513,1,Intermediate,9615.0,,50588,
6641,Compound was tested for percent protein binding (PB) in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618514,1,Intermediate,9615.0,,50588,
6642,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620052,1,Intermediate,9615.0,,50588,
6643,Compound was evaluated for plasma clearance.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620053,1,Intermediate,9615.0,,50588,
6644,The compound was tested for plasma clearance in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620054,1,Intermediate,9615.0,,50588,
6645,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620055,1,Intermediate,9615.0,,50588,
6646,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620056,1,Intermediate,9615.0,,50588,
6647,In vitro relative rate of metabolism was determined in dog liver microsomes,1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL620057,1,Intermediate,9615.0,,50588,
6648,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618939,1,Intermediate,9615.0,,50588,
6649,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618940,1,Intermediate,9615.0,,50588,
6650,Half life after intravenous administration in dogs at 1.2 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618941,1,Intermediate,9615.0,,50588,
6651,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL624473,1,Intermediate,10090.0,,50594,42.0
6652,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL624474,1,Intermediate,10090.0,,50594,42.0
6653,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,Lung,CCRF S-180,2048.0,BAO_0000218,CHEMBL624475,1,Intermediate,10090.0,,50594,42.0
6654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL624476,1,Intermediate,10090.0,,50594,42.0
6655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL623478,1,Intermediate,10090.0,,50594,42.0
6656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL623479,1,Intermediate,10090.0,,50594,42.0
6657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL623480,1,Intermediate,10090.0,,50594,42.0
6658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,1,N,,Mus musculus,,,,,CCRF S-180,,BAO_0000218,CHEMBL623481,1,Intermediate,10090.0,,50594,42.0
6659,C2 in brain of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL623482,1,Intermediate,10090.0,,50594,
6660,C2 in kidney of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623483,1,Intermediate,10090.0,,50594,
6661,C2 in liver of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623484,1,Intermediate,10090.0,,50594,
6662,C2 in lungs of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623485,1,Intermediate,10090.0,,50594,
6663,C2 in spleen of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL623486,1,Intermediate,10090.0,,50594,
6664,Plasma clearance in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623487,1,Intermediate,10090.0,,50594,
6665,Clearance of compound after intravenous administration in mice at 24 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623488,1,Intermediate,10090.0,,50594,
6666,Clearance from mouse blood following i.v. administration of 10 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623489,1,Intermediate,10090.0,,50594,
6667,Clearance was evaluated in mice after intravenous administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875157,1,Intermediate,10090.0,,50594,
6668,Clearance was evaluated in mice after oral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623490,1,Intermediate,10090.0,,50594,
6669,Pharmacokinetic property (Plasma clearance) was measured in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623491,1,Intermediate,10090.0,,50594,
6670,Plasma clearance of compound was determined at 40 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623492,1,Intermediate,10090.0,,50594,
6671,Plasma clearance of at 24 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623493,1,Intermediate,10090.0,,50594,
6672,Plasma clearance at 24 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623494,1,Intermediate,10090.0,,50594,
6673,Plasma clearance at 5 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623495,1,Intermediate,10090.0,,50594,
6674,Plasma clearance in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623496,1,Intermediate,10090.0,,50594,
6675,Plasma clearance value upon iv administration in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623497,1,Intermediate,10090.0,,50594,
6676,Total plasma clearance in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623498,1,Intermediate,10090.0,,50594,
6677,Clearance in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623499,1,Intermediate,10090.0,,50594,
6678,Clearance value was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623500,1,Intermediate,10090.0,,50594,
6679,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623501,1,Intermediate,10090.0,,50594,
6680,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL875158,0,Intermediate,,,22229,
6681,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623502,1,Intermediate,10090.0,,50594,
6682,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623503,1,Intermediate,10090.0,,50594,
6683,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623504,1,Intermediate,10090.0,,50594,
6684,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623505,1,Intermediate,10090.0,,50594,
6685,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623506,1,Intermediate,10090.0,,50594,
6686,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623507,1,Intermediate,10090.0,,50594,
6687,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623508,1,Intermediate,10090.0,,50594,
6688,Cmax after oral administration at 30 mg/kg in ICR mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623509,1,Intermediate,10090.0,,50594,
6689,Cmax after peroral administration in mice at 2.4 uM/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875159,1,Intermediate,10090.0,,50594,
6690,Cmax in brain of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL623510,1,Intermediate,10090.0,,50594,
6691,Cmax in kidney of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623511,1,Intermediate,10090.0,,50594,
6692,Cmax in liver of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623512,1,Intermediate,10090.0,,50594,
6693,Cmax in lungs of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623513,1,Intermediate,10090.0,,50594,
6694,Cmax in mice at 18 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623514,1,Intermediate,10090.0,,50594,
6695,Cmax in mice at 23 uM/kg i.v. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622609,1,Intermediate,10090.0,,50594,
6696,Cmax in mice at 24 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622610,1,Intermediate,10090.0,,50594,
6697,Cmax in mice at 25 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621823,1,Intermediate,10090.0,,50594,
6698,Cmax in mice at 26 uM/kg i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621824,1,Intermediate,10090.0,,50594,
6699,Cmax in spleen of mice at the oral dose of 50 mg/kg,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621825,1,Intermediate,10090.0,,50594,
6700,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621826,1,Intermediate,10090.0,,50594,
6701,Cmax value at a dose of 10 mg/kg peroral administration in mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621827,1,Intermediate,10090.0,,50594,
6702,Cmax value was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621828,1,Intermediate,10090.0,,50594,
6703,Cmax value in IRC mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621829,1,Intermediate,10090.0,,50594,
6704,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621830,1,Intermediate,10090.0,,50594,
6705,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621831,1,Intermediate,10090.0,,50594,
6706,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621832,1,Intermediate,10090.0,,50594,
6707,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624579,1,Intermediate,10090.0,,50594,
6708,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624580,1,Intermediate,10090.0,,50594,
6709,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL624581,1,Intermediate,6277.0,,50535,
6710,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL624582,1,Intermediate,6277.0,,50535,
6711,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,1,N,,Acanthocheilonema viteae,,,,,,,BAO_0000218,CHEMBL624583,1,Intermediate,6277.0,,50535,
6712,Inhibitory activity against human tumor cell line A0375 melanoma.,1,N,,Homo sapiens,,,,,A-375,,BAO_0000219,CHEMBL624584,1,Intermediate,9606.0,,80018,455.0
6713,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,1,D,,Rattus norvegicus,,Brain membranes,,,,,BAO_0000249,CHEMBL624585,9,Expert,10116.0,,12512,
6714,Forskolin-induced cAMP production at human A1 adenosine receptor,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL875165,9,Expert,9606.0,,114,
6715,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619490,8,Autocuration,,,114,449.0
6716,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619491,8,Autocuration,,,114,449.0
6717,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619492,8,Expert,,,114,449.0
6718,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619493,8,Expert,,,114,449.0
6719,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619494,8,Autocuration,,,114,449.0
6720,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619495,8,Autocuration,,,114,449.0
6721,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619496,8,Autocuration,,,114,449.0
6722,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,D,,Homo sapiens,,,,,CHO,,BAO_0000219,CHEMBL619497,9,Expert,9606.0,,114,449.0
6723,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619498,8,Autocuration,,,114,449.0
6724,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619499,8,Autocuration,,,114,449.0
6725,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619500,8,Expert,,,114,449.0
6726,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619501,8,Autocuration,,,114,449.0
6727,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619502,8,Expert,,,114,449.0
6728,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619503,8,Autocuration,,,114,449.0
6729,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL619504,8,Autocuration,,,114,449.0
6730,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621298,8,Autocuration,,,114,449.0
6731,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621299,8,Expert,,,114,449.0
6732,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621300,8,Autocuration,,,114,449.0
6733,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621301,8,Autocuration,,,114,449.0
6734,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,H,,,,,,,CHO,,BAO_0000219,CHEMBL621302,8,Expert,,,114,449.0
6735,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,1,N,,Oryctolagus cuniculus,,,,,A10,,BAO_0000219,CHEMBL621303,1,Intermediate,9986.0,,80013,164.0
6736,In vitro potassium channel opening activity in A10 (smooth muscle) cells,1,U,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL621304,0,Autocuration,10116.0,,22226,164.0
6737,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,1,U,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL621305,0,Autocuration,10116.0,,22226,164.0
6738,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL621306,1,Intermediate,10116.0,,80013,164.0
6739,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL618444,1,Intermediate,10116.0,,80013,164.0
6740,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL618445,1,Intermediate,10116.0,,80013,164.0
6741,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618446,1,Intermediate,10029.0,,80089,185.0
6742,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618447,1,Intermediate,10029.0,,80089,185.0
6743,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618448,1,Intermediate,10029.0,,80089,185.0
6744,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618449,1,Intermediate,10029.0,,80089,185.0
6745,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618637,1,Intermediate,10029.0,,80089,185.0
6746,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618638,1,Intermediate,10029.0,,80089,185.0
6747,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618639,1,Intermediate,10029.0,,80089,185.0
6748,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618640,1,Expert,10029.0,,80089,185.0
6749,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618641,1,Expert,10029.0,,80089,185.0
6750,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618642,1,Intermediate,10029.0,,80089,185.0
6751,Inhibitory activity against aerobic growth of AA8 cells.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618643,1,Intermediate,10029.0,,80089,185.0
6752,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL884013,1,Intermediate,10029.0,,80089,185.0
6753,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622723,1,Expert,10029.0,,80089,185.0
6754,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622724,1,Intermediate,10029.0,,80089,185.0
6755,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622725,1,Expert,10029.0,,80089,185.0
6756,Cytotoxicity against AA8 cell line,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622726,1,Expert,10029.0,,80089,185.0
6757,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622727,1,Intermediate,10029.0,,80089,185.0
6758,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622728,1,Intermediate,10029.0,,80089,185.0
6759,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622729,1,Intermediate,10029.0,,80089,185.0
6760,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622730,1,Intermediate,10029.0,,80089,185.0
6761,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622731,1,Intermediate,10029.0,,80089,185.0
6762,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622732,1,Intermediate,10029.0,,80089,185.0
6763,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622733,1,Intermediate,10029.0,,80089,185.0
6764,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),1,U,,Cricetulus griseus,,,,,,,BAO_0000218,CHEMBL622734,0,Autocuration,10029.0,,22224,
6765,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL622735,1,Expert,10029.0,,80089,185.0
6766,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618746,0,Autocuration,10029.0,,22224,185.0
6767,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618747,0,Autocuration,10029.0,,22224,185.0
6768,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL620540,0,Autocuration,10029.0,,22224,185.0
6769,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL620541,0,Autocuration,10029.0,,22224,185.0
6770,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL620542,0,Autocuration,10029.0,,22224,185.0
6771,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL620543,0,Autocuration,10029.0,,22224,185.0
6772,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618832,0,Autocuration,10029.0,,22224,185.0
6773,Concentration required to reduce AA8 cell survival by 10%,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618833,1,Expert,10029.0,,80089,185.0
6774,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618834,0,Autocuration,10029.0,,22224,185.0
6775,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618835,0,Autocuration,10029.0,,22224,185.0
6776,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618836,0,Autocuration,10029.0,,22224,185.0
6777,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618837,0,Autocuration,10029.0,,22224,185.0
6778,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618838,0,Autocuration,10029.0,,22224,185.0
6779,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618839,0,Autocuration,10029.0,,22224,185.0
6780,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618840,0,Autocuration,10029.0,,22224,185.0
6781,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,U,,Cricetulus griseus,,,,,,,BAO_0000019,CHEMBL618841,0,Autocuration,10029.0,,22224,
6782,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618842,0,Autocuration,10029.0,,22224,185.0
6783,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL618843,0,Autocuration,10029.0,,22224,185.0
6784,Half life period after 15 mg/kg iv dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618844,1,Intermediate,9615.0,,50588,
6785,Half life period after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618845,1,Intermediate,9615.0,,50588,
6786,Half life was measured after oral 2b administration (tested in 6 dogs),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618846,1,Intermediate,9615.0,,50588,
6787,Half life was measured in dog after oral 17b administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618847,1,Intermediate,9615.0,,50588,
6788,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618848,1,Intermediate,9615.0,,50588,
6789,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618849,1,Intermediate,9615.0,,50588,
6790,Tmax value after 15 mg/kg iv dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618850,1,Intermediate,9615.0,,50588,
6791,Tmax value after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618851,1,Intermediate,9615.0,,50588,
6792,Compound was evaluated for its half life when administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873815,1,Intermediate,9615.0,,50588,
6793,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618852,1,Intermediate,9615.0,,50588,
6794,Elimination Half-life of compound was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618853,1,Intermediate,9615.0,,50588,
6795,Half life of compound in dog following oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618854,1,Intermediate,9615.0,,50588,
6796,Half life of compound was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618855,1,Intermediate,9615.0,,50588,
6797,Half life of compound was determined in dog blood,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL618856,1,Intermediate,9615.0,,50588,
6798,Half life after oral and iv dosing in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875827,1,Intermediate,9615.0,,50588,
6799,Half life in dogs in hours,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618857,1,Intermediate,9615.0,,50588,
6800,Half life on i.v. administration of 2 mg/kg was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618858,1,Intermediate,9615.0,,50588,
6801,t1/2 in dog after oral dose (1 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618859,1,Intermediate,9615.0,,50588,
6802,Half life was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618860,1,Intermediate,9615.0,,50588,
6803,Half life period of compound was determined after intravenous administration at 2 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618861,1,Intermediate,9615.0,,50588,
6804,Half life period of compound was determined after peroral administration at 2 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622539,1,Intermediate,9615.0,,50588,
6805,Half life period (10 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622540,1,Intermediate,9615.0,,50588,
6806,Half life period (10 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873803,1,Intermediate,9615.0,,50588,
6807,Half life period by iv administration in dog at a dose of 0.3 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873804,1,Intermediate,9615.0,,50588,
6808,Half life period by po administration in dog at a dose of 0.3 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624311,1,Intermediate,9615.0,,50588,
6809,Half life period in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624312,1,Intermediate,9615.0,,50588,
6810,Half life period in dogs after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624313,1,Intermediate,9615.0,,50588,
6811,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624314,1,Intermediate,9615.0,,50588,
6812,Half-life of compound was determined in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624315,1,Intermediate,9615.0,,50588,
6813,Half-life in dog plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624316,1,Intermediate,9615.0,,50588,
6814,Half-life in mongrel dogs was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624317,1,Intermediate,9615.0,,50588,
6815,Half-life in dog upon oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624318,1,Intermediate,9615.0,,50588,
6816,Half-life in dog upon oral administration; Unable to calculate,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624319,1,Intermediate,9615.0,,50588,
6817,Half-life was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624496,1,Intermediate,9615.0,,50588,
6818,Half-life was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624497,1,Intermediate,9615.0,,50588,
6819,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624498,1,Intermediate,9615.0,,50588,
6820,Oral half life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624499,1,Intermediate,9615.0,,50588,
6821,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624500,1,Intermediate,9615.0,,50588,
6822,Plasma half life was evaluated,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624501,1,Intermediate,9615.0,,50588,
6823,Plasma half life was evaluated in Dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623666,1,Intermediate,9615.0,,50588,
6824,Plasma half life was evaluated in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623667,1,Intermediate,9615.0,,50588,
6825,T1/2 (Half-life) was after oral administration at 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623668,1,Intermediate,9615.0,,50588,
6826,Tested for the half life value in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623669,1,Intermediate,9615.0,,50588,
6827,Maximum time at the dose of 2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623670,1,Intermediate,9615.0,,50588,
6828,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623671,1,Intermediate,9615.0,,50588,
6829,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL875945,1,Intermediate,9615.0,,50588,
6830,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL623672,1,Intermediate,9615.0,,50588,
6831,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623673,1,Intermediate,9615.0,,50588,
6832,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623674,1,Intermediate,9615.0,,50588,
6833,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623675,1,Intermediate,9615.0,,50588,
6834,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL872526,1,Intermediate,9615.0,,50588,
6835,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623676,1,Intermediate,9615.0,,50588,
6836,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623677,1,Intermediate,9615.0,,50588,
6837,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623678,1,Intermediate,9615.0,,50588,
6838,Time taken for maximum plasma concentration in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623679,1,Intermediate,9615.0,,50588,
6839,Time to reach Cmax after oral administration to dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623680,1,Intermediate,9615.0,,50588,
6840,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623681,1,Intermediate,9615.0,,50588,
6841,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623682,1,Intermediate,9615.0,,50588,
6842,Tmax after peroral administration (1 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623683,1,Intermediate,9615.0,,50588,
6843,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623684,1,Expert,9615.0,,50588,
6844,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622745,1,Intermediate,9615.0,,50588,
6845,Tmax after peroral administration in dogs at 2.4 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622746,1,Intermediate,9615.0,,50588,
6846,In vivo Cmax in mice at dose of 100 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622747,1,Intermediate,10090.0,,50594,
6847,In vivo Cmax in mice at dose of 50 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622748,1,Intermediate,10090.0,,50594,
6848,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622749,1,Intermediate,10090.0,,50594,
6849,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622750,1,Intermediate,10090.0,,50594,
6850,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623411,1,Intermediate,10090.0,,50594,
6851,Maximum concentration obtained in mouse plasma was determined,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875946,1,Intermediate,10090.0,,50594,
6852,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623412,1,Intermediate,10090.0,,50594,
6853,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623413,1,Intermediate,10090.0,,50594,
6854,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623414,1,Intermediate,10090.0,,50594,
6855,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623415,1,Intermediate,10090.0,,50594,
6856,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623416,1,Intermediate,10090.0,,50594,
6857,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623417,1,Intermediate,10090.0,,50594,
6858,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623418,1,Intermediate,10090.0,,50594,
6859,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623419,1,Intermediate,10090.0,,50594,
6860,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622816,1,Intermediate,10090.0,,50594,
6861,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623313,1,Intermediate,10090.0,,50594,
6862,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623314,1,Intermediate,10090.0,,50594,
6863,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876788,1,Intermediate,10090.0,,50594,
6864,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623315,1,Intermediate,10090.0,,50594,
6865,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623316,1,Intermediate,10090.0,,50594,
6866,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623317,1,Intermediate,10090.0,,50594,
6868,Cmax in male mice after 2 mg/kg oral dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623319,1,Intermediate,10090.0,,50594,
6869,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623320,1,Intermediate,10090.0,,50594,
6870,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623321,1,Intermediate,10090.0,,50594,
6871,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623322,1,Intermediate,10090.0,,50594,
6872,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623323,1,Intermediate,10090.0,,50594,
6873,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623324,1,Intermediate,10090.0,,50594,
6874,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623325,1,Intermediate,10090.0,,50594,
6875,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623326,1,Intermediate,10090.0,,50594,
6876,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623327,1,Intermediate,10090.0,,50594,
6877,Maximum concentration in plasma upon oral administration in mouse,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623328,1,Intermediate,10090.0,,50594,
6878,Maximum plasma concentration was evaluated in mice after oral administration,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623329,1,Intermediate,10090.0,,50594,
6879,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623330,1,Intermediate,10090.0,,50594,
6880,Dose at which the compound induced fecal excretion in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876789,1,Intermediate,10090.0,,50594,
6893,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL623333,1,Expert,10116.0,,80013,164.0
6894,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL623334,1,Expert,10116.0,,80013,164.0
6895,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL627536,1,Expert,10116.0,,80013,164.0
6896,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL627537,1,Expert,10116.0,,80013,164.0
6897,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),1,N,,Rattus norvegicus,,,,,A10,,BAO_0000219,CHEMBL627538,1,Intermediate,10116.0,,80013,164.0
6898,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL884106,1,Intermediate,9606.0,,80655,393.0
6899,Anticancer activity against human ovarian carcinoma A121 cells,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625294,1,Intermediate,9606.0,,80655,393.0
6900,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625295,1,Intermediate,9606.0,,80655,393.0
6901,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625296,1,Intermediate,9606.0,,80655,393.0
6902,Growth inhibition of human ovarian carcinoma (A121) cell line,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625297,1,Expert,9606.0,,80655,393.0
6903,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625298,1,Expert,9606.0,,80655,393.0
6904,Cytotoxicity against human A121 ovarian cells,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625960,1,Intermediate,9606.0,,80655,393.0
6905,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625961,1,Intermediate,9606.0,,80655,393.0
6906,In vitro cytotoxicity against human ovarian carcinoma A21,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL625962,1,Intermediate,9606.0,,80655,393.0
6907,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL624717,1,Intermediate,9606.0,,80655,393.0
6908,Inhibitory activity of compound against human A121 ovarian cell line.,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL624718,1,Intermediate,9606.0,,80655,393.0
6909,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL624719,1,Intermediate,9606.0,,80655,393.0
6910,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,1,N,,Homo sapiens,,,,,A121,,BAO_0000219,CHEMBL624720,1,Intermediate,9606.0,,80655,393.0
6911,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL624721,1,Intermediate,9606.0,,80012,622.0
6912,In vitro cytotoxicity against A172 human tumor cell lines.,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL624722,1,Expert,9606.0,,80012,622.0
6913,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL877597,1,Intermediate,9606.0,,80012,622.0
6914,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL624723,1,Intermediate,9606.0,,80012,622.0
6915,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,1,N,,Homo sapiens,,,,,A 172,,BAO_0000219,CHEMBL624724,1,Intermediate,9606.0,,80012,622.0
6916,Association constant against A2 adenosine receptor,1,H,,Canis lupus familiaris,,,,,,,BAO_0000224,CHEMBL624725,4,Autocuration,9615.0,,104729,
6917,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1,N,,fish,,,,,A2,,BAO_0000219,CHEMBL624726,1,Intermediate,,,80656,1085.0
6918,Ratio of Ki for adenosine A2 and A1 receptor binding,1,D,,Rattus norvegicus,,,,,,,BAO_0000224,CHEMBL857535,5,Autocuration,10116.0,,104713,
6919,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,1,N,,Homo sapiens,,,,,A204,,BAO_0000219,CHEMBL624727,1,Expert,9606.0,,80014,623.0
6920,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,1,N,,Homo sapiens,,,,,A204,,BAO_0000219,CHEMBL624728,1,Expert,9606.0,,80014,623.0
6921,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,1,N,,Homo sapiens,,,,,A2058,,BAO_0000219,CHEMBL624729,1,Intermediate,9606.0,,80015,404.0
6922,Growth inhibition against Human squamous cell line(A 253),1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL624730,1,Intermediate,9606.0,,80657,973.0
6923,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL624731,1,Intermediate,9606.0,,80657,973.0
6924,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL624732,1,Intermediate,9606.0,,80657,973.0
6925,Growth inhibition of A253 cell lines.,1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL883245,1,Intermediate,9606.0,,80657,973.0
6926,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL624733,1,Intermediate,9606.0,,80657,973.0
6927,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL624734,1,Intermediate,9606.0,,80657,973.0
6928,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,N,,Homo sapiens,,,,,A253 cell line,,BAO_0000219,CHEMBL624735,1,Intermediate,9606.0,,80657,973.0
6929,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621780,1,Intermediate,9606.0,,81034,478.0
6930,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL877598,1,Intermediate,9606.0,,81034,478.0
6931,Cytotoxic activity against A2780 human ovarian carcinoma cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621781,1,Expert,9606.0,,81034,478.0
6932,Cytotoxicity against human cancer cell lines A2780 (ovarian),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621782,1,Intermediate,9606.0,,81034,478.0
6933,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621783,1,Expert,9606.0,,81034,478.0
6934,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621784,1,Intermediate,9606.0,,81034,478.0
6935,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621785,1,Intermediate,9606.0,,81034,478.0
6936,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621968,1,Expert,9606.0,,81034,478.0
6937,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621969,1,Expert,9606.0,,81034,478.0
6938,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621970,1,Expert,9606.0,,81034,478.0
6939,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621971,1,Intermediate,9606.0,,81034,478.0
6940,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621972,1,Intermediate,9606.0,,81034,478.0
6941,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL884108,1,Intermediate,9606.0,,81034,478.0
6942,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,U,,Cricetulus griseus,,,,,,,BAO_0000019,CHEMBL623826,0,Autocuration,10029.0,,22224,
6943,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623827,0,Autocuration,10029.0,,22224,185.0
6944,Evaluated for growth inhibition of AA8 cells under aerobic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623828,0,Autocuration,10029.0,,22224,185.0
6945,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623829,0,Autocuration,10029.0,,22224,185.0
6946,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623830,0,Autocuration,10029.0,,22224,185.0
6947,Growth inhibition against CHO-derived cell line AA8,1,U,,Cricetulus griseus,,,,,,,BAO_0000019,CHEMBL623831,0,Autocuration,10029.0,,22224,
6948,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623832,0,Autocuration,10029.0,,22224,185.0
6949,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,1,N,,hampster,,,,,CHO-AA8,,BAO_0000219,CHEMBL623833,1,Expert,36483.0,,80089,185.0
6950,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623834,1,Expert,10029.0,,80089,185.0
6951,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623835,0,Autocuration,10029.0,,22224,185.0
6952,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623836,0,Autocuration,10029.0,,22224,185.0
6953,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,1,U,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623837,0,Autocuration,10029.0,,22224,185.0
6954,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,1,N,,Cricetulus griseus,,,,,CHO-AA8,,BAO_0000219,CHEMBL623838,1,Expert,10029.0,,80089,185.0
6955,compound was evaluated for association constant (Ka) of isolated serum protein AAG,1,H,,,,,,,,,BAO_0000019,CHEMBL623839,8,Autocuration,,,12675,
6956,Number of binding sites (n) of isolated serum protein AAG,1,H,,,,,,,,,BAO_0000019,CHEMBL623840,8,Autocuration,,,12675,
6957,Association constant for binding to AATT duplex,1,M,,,,,,,,,BAO_0000225,CHEMBL623841,3,Intermediate,,,22222,
6958,Inhibition of ABAE human fibroblast cell proliferation,1,N,,Homo sapiens,,,,,ABAE,,BAO_0000219,CHEMBL623842,1,Expert,9606.0,,100090,416.0
6959,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1,N,,Mus musculus,,,,,AC755,,BAO_0000218,CHEMBL623843,1,Intermediate,10090.0,,80668,1064.0
6960,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,1,D,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL618669,9,Expert,9986.0,,102444,
6961,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,1,D,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL618670,9,Expert,9986.0,,102444,
6962,Inhibitory activity against angiotensin-converting enzyme (ACE).,1,H,,,,,,,,,BAO_0000357,CHEMBL618671,8,Autocuration,,,69,
6963,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,1,H,,,,,,,,,BAO_0000357,CHEMBL618672,8,Autocuration,,,69,
6964,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,1,N,,Homo sapiens,,,,,ACH-2 cell line,,BAO_0000219,CHEMBL618673,1,Intermediate,9606.0,,80669,978.0
6965,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),1,N,,Homo sapiens,,,,,ACH-2 cell line,,BAO_0000219,CHEMBL618674,1,Intermediate,9606.0,,80669,978.0
6966,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,1,U,,Human immunodeficiency virus 1,,,,,T cell line,,BAO_0000219,CHEMBL618675,0,Autocuration,11676.0,,22224,998.0
6967,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),1,U,,Human immunodeficiency virus 1,,,,,T cell line,,BAO_0000219,CHEMBL618676,0,Autocuration,11676.0,,22224,998.0
6968,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),1,U,,Human immunodeficiency virus 1,,,,,T cell line,,BAO_0000219,CHEMBL618677,0,Autocuration,11676.0,,22224,998.0
6969,Inhibition of growth of renal cancer ACHN cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618678,1,Intermediate,9606.0,,80025,626.0
6970,Inhibition of growth of ACHN renal cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618679,1,Intermediate,9606.0,,80025,626.0
6971,Inhibitory concentration required against ACHN renal cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618680,1,Intermediate,9606.0,,80025,626.0
6972,Concentration required to inhibit growth of human renal (ACHN) cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618681,1,Expert,9606.0,,80025,626.0
6973,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618682,1,Intermediate,9606.0,,80025,626.0
6974,Cytotoxic activity against ACHN Renal cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618683,1,Intermediate,9606.0,,80025,626.0
6975,Cytotoxicity evaluation against ACHN renal cancer cells,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618684,1,Intermediate,9606.0,,80025,626.0
6976,In vitro antitumor activity against human renal ACHN cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618685,1,Intermediate,9606.0,,80025,626.0
6977,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL876499,1,Intermediate,9606.0,,80025,626.0
6978,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618686,1,Intermediate,9606.0,,80025,626.0
6979,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618687,1,Intermediate,9606.0,,80025,626.0
6980,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618688,1,Intermediate,9606.0,,80025,626.0
6981,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618689,1,Expert,9606.0,,80025,626.0
6982,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618690,1,Intermediate,9606.0,,80025,626.0
6983,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL618691,1,Intermediate,9606.0,,80025,626.0
6984,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL619373,1,Intermediate,9606.0,,80025,626.0
6985,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL884008,1,Intermediate,9606.0,,80025,626.0
6986,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL619374,1,Intermediate,9606.0,,80025,626.0
6987,Compound was tested for the growth inhibition of ACHN renal tumor cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL619375,1,Intermediate,9606.0,,80025,626.0
6988,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL619376,1,Intermediate,9606.0,,80025,626.0
6989,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL619377,1,Intermediate,9606.0,,80025,626.0
6990,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL619378,1,Intermediate,9606.0,,80025,626.0
6991,Tmax value after administration of 4 mg/Kg oral dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL872527,1,Intermediate,9615.0,,50588,
6992,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876500,1,Intermediate,9615.0,,50588,
6993,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619379,1,Intermediate,9615.0,,50588,
6994,Volume distribution after 15 mg/kg iv dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619538,1,Intermediate,9615.0,,50588,
6995,Volume distribution after 30 mg/kg po dose in Dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619539,1,Intermediate,9615.0,,50588,
6996,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619540,1,Intermediate,9615.0,,50588,
6997,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619541,1,Intermediate,9615.0,,50588,
6998,Volume of distribution was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619542,1,Intermediate,9615.0,,50588,
6999,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619543,1,Intermediate,9615.0,,50588,
7000,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619544,1,Expert,9615.0,,50588,
7001,The compound was tested for volume of distribution in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619545,1,Intermediate,9615.0,,50588,
7002,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619546,1,Intermediate,9615.0,,50588,
7003,Vd (1 mg/kg) was determined in dog (in vivo),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619547,1,Intermediate,9615.0,,50588,
7004,Vd in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619548,1,Intermediate,9615.0,,50588,
7005,Volume distribution was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619549,1,Intermediate,9615.0,,50588,
7006,Volume of distribution in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619550,1,Intermediate,9615.0,,50588,
7007,Volume of distribution by as 4 fold increase by iv administration in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876501,1,Intermediate,9615.0,,50588,
7008,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619551,1,Intermediate,9615.0,,50588,
7009,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619552,1,Intermediate,9615.0,,50588,
7010,Volume distribution at the dose of 2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619553,1,Intermediate,9615.0,,50588,
7011,Steady state volume of distribution was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618722,1,Intermediate,9615.0,,50588,
7012,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618723,1,Intermediate,9615.0,,50588,
7013,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618724,1,Intermediate,9615.0,,50588,
7014,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618725,1,Intermediate,9615.0,,50588,
7015,Bioavailability in dog (dose 1 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618726,1,Intermediate,9615.0,,50588,
7016,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618727,1,Intermediate,9615.0,,50588,
7017,Pharmacokinetic property (vdss) was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624233,1,Intermediate,9615.0,,50588,
7018,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624234,1,Intermediate,9615.0,,50588,
7019,Vdss was determined after iv 0.1 mg/kg administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624235,1,Intermediate,9615.0,,50588,
7020,Volume displacement was calculated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624236,1,Intermediate,9615.0,,50588,
7021,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624237,1,Intermediate,9615.0,,50588,
7022,Volume distribution constant was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624238,1,Intermediate,9615.0,,50588,
7023,Volume distribution at a dose of 1 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624239,1,Intermediate,9615.0,,50588,
7024,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875829,1,Intermediate,9615.0,,50588,
7025,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624240,1,Intermediate,9615.0,,50588,
7026,Volume distribution (Vdss) was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624241,1,Intermediate,9615.0,,50588,
7027,Volume distribution (Vdss) was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624242,1,Intermediate,9615.0,,50588,
7028,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624243,1,Intermediate,9615.0,,50588,
7029,Volume of distribution in steady state was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624244,1,Intermediate,9615.0,,50588,
7030,Volume of distribution of compound was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624245,1,Intermediate,9615.0,,50588,
7031,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624246,1,Intermediate,9615.0,,50588,
7032,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624247,1,Intermediate,9615.0,,50588,
7033,Volume of distribution (Vdss) was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624248,1,Intermediate,9615.0,,50588,
7034,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624249,1,Intermediate,9615.0,,50588,
7035,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624250,1,Intermediate,9615.0,,50588,
7036,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624251,1,Intermediate,9615.0,,50588,
7037,Maximum rate of depolarization of the upstroke of the action potential,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624252,1,Intermediate,9615.0,,50588,
7038,Steady state volume distribution in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624253,1,Intermediate,9615.0,,50588,
7039,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624950,1,Intermediate,9615.0,,50588,
7040,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624951,1,Intermediate,9615.0,,50588,
7041,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875830,1,Intermediate,9615.0,,50588,
7042,Volume distribution in dog after administration of 1 mg/kg iv,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624952,1,Intermediate,9615.0,,50588,
7043,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624953,1,Intermediate,9615.0,,50588,
7044,Vss after intravenous administration (0.5 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624954,1,Intermediate,9615.0,,50588,
7045,Vss on i.v. administration of 2 mg/kg was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624955,1,Intermediate,9615.0,,50588,
7046,Vss was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624956,1,Intermediate,9615.0,,50588,
7047,Vss in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625129,1,Intermediate,9615.0,,50588,
7048,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625130,1,Intermediate,9615.0,,50588,
7049,Volume distribution in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625131,1,Intermediate,9615.0,,50588,
7050,Volume of distribution in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625132,1,Intermediate,9615.0,,50588,
7051,Tested for the oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL872263,1,Intermediate,9615.0,,50588,
7060,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624336,1,Intermediate,10090.0,,50594,
7061,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624337,1,Intermediate,10090.0,,50594,
7062,Bioavailability after peroral administration of 50 mg/kg of dose in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624338,1,Intermediate,10090.0,,50594,
7063,Bioavailability was measured in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624339,1,Intermediate,10090.0,,50594,
7064,Bioavailability in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624340,1,Intermediate,10090.0,,50594,
7065,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624341,1,Intermediate,10090.0,,50594,
7066,Bioavailability in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624342,1,Intermediate,10090.0,,50594,
7067,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624343,1,Intermediate,10090.0,,50594,
7068,Oral bioavailability in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624344,1,Intermediate,10090.0,,50594,
7069,Oral availability at 50 mg/kg po in male mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624345,1,Intermediate,10090.0,,50594,
7070,Oral bioavailability in mouse (dose 10 mg/kg),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624346,1,Intermediate,10090.0,,50594,
7071,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624347,1,Expert,10090.0,,50594,
7072,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624348,1,Intermediate,10090.0,,50594,
7074,Oral bioavailability in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622754,1,Intermediate,10090.0,,50594,
7075,Oral bioavailability in vivo in mice;ND=Not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622755,1,Intermediate,10090.0,,50594,
7076,Oral bioavailability in mouse at 10 mg/kg of the compound,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622756,1,Intermediate,10090.0,,50594,
7077,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622757,1,Intermediate,10090.0,,50594,
7078,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622758,1,Intermediate,10090.0,,50594,
7079,Tested for bioavailability of the compound,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622759,1,Intermediate,10090.0,,50594,
7080,Tested for half life at the dose of 10 mg/kg when administered intravenously,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622760,1,Intermediate,10090.0,,50594,
7081,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622761,1,Intermediate,10090.0,,50594,
7082,The plasma half life of compound was determined on heparin prepared by human plasma. ,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622762,1,Intermediate,10090.0,,50594,
7083,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622763,1,Intermediate,10090.0,,50594,
7084,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622764,1,Intermediate,10090.0,,50594,
7085,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622765,1,Intermediate,10090.0,,50594,
7086,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622766,1,Intermediate,10090.0,,50594,
7087,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622767,1,Intermediate,10090.0,,50594,
7088,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622768,1,Intermediate,10090.0,,50594,
7089,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL875948,1,Intermediate,10090.0,,50594,
7090,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622769,1,Intermediate,10090.0,,50594,
7091,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622770,1,Intermediate,10090.0,,50594,
7092,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622771,1,Intermediate,10090.0,,50594,
7093,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622772,1,Intermediate,10090.0,,50594,
7094,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622773,1,Intermediate,10090.0,,50594,
7095,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622774,1,Intermediate,10090.0,,50594,
7096,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL621725,1,Intermediate,10090.0,,50594,
7097,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL621726,1,Intermediate,10090.0,,50594,
7098,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621727,1,Intermediate,9606.0,,81034,478.0
7099,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622413,1,Expert,9606.0,,81034,478.0
7100,Compound was evaluated for cytotoxicity against A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622414,1,Intermediate,9606.0,,81034,478.0
7101,Inhibition of A2780 cell clonogenic assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622415,1,Expert,9606.0,,81034,478.0
7102,Cytotoxic effect on ovarian cancer cell line (A2780),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL884001,1,Expert,9606.0,,81034,478.0
7103,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622416,1,Intermediate,9606.0,,81034,478.0
7104,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622417,1,Intermediate,9606.0,,81034,478.0
7105,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622590,1,Expert,9606.0,,81034,478.0
7106,Antiproliferative activity against human A2780 cells,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622591,1,Expert,9606.0,,81034,478.0
7107,Inhibition of human A2780 cell proliferation,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622592,1,Expert,9606.0,,81034,478.0
7108,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622593,1,Expert,9606.0,,81034,478.0
7109,Inhibition of human A2780 cell proliferation (No data),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622594,1,Expert,9606.0,,81034,478.0
7110,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622595,1,Intermediate,9606.0,,81034,478.0
7111,Compound was evaluated against human Ovarian carcinoma cell line A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622596,1,Intermediate,9606.0,,81034,478.0
7112,Growth inhibition against A2780 wild-type ovarian cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622597,1,Expert,9606.0,,81034,478.0
7113,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622598,1,Intermediate,9606.0,,81034,478.0
7114,Inhibition of tubulin polymerization in human ovarian cancer cell lines,1,D,,Homo sapiens,,,,,,,BAO_0000019,CHEMBL622599,5,Autocuration,9606.0,,104766,
7115,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622600,1,Intermediate,9606.0,,81034,478.0
7116,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622601,1,Intermediate,9606.0,,81034,478.0
7117,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622602,1,Intermediate,9606.0,,81034,478.0
7118,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622603,1,Intermediate,9606.0,,81034,478.0
7119,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622604,1,Intermediate,9606.0,,81034,478.0
7120,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622605,1,Intermediate,9606.0,,81034,478.0
7121,In vitro inhibition of human ovarian cell line A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622606,1,Expert,9606.0,,81034,478.0
7122,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619463,1,Expert,9606.0,,81034,478.0
7123,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619464,1,Intermediate,9606.0,,81034,478.0
7124,Concentration required to inhibit A2780-cell growth by 50%,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619465,1,Expert,9606.0,,81034,478.0
7125,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619466,1,Expert,9606.0,,81034,478.0
7126,Cytotoxic effect on human ovarian (A2780) cancer cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619467,1,Expert,9606.0,,81034,478.0
7127,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619468,1,Intermediate,9606.0,,81034,478.0
7128,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619469,1,Expert,9606.0,,81034,478.0
7129,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619470,1,Expert,9606.0,,81034,478.0
7130,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619471,1,Intermediate,9606.0,,81034,478.0
7131,Cytotoxicity against human ovarian carcinoma A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619472,1,Intermediate,9606.0,,81034,478.0
7132,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL619473,1,Intermediate,9606.0,,81034,478.0
7133,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL874368,1,Intermediate,9606.0,,81034,478.0
7134,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL884003,1,Intermediate,9606.0,,81034,478.0
7135,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622690,1,Intermediate,9606.0,,81034,478.0
7136,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622691,1,Intermediate,9606.0,,81034,478.0
7137,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL622692,1,Intermediate,9606.0,,81034,478.0
7138,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623406,1,Intermediate,9606.0,,81034,478.0
7139,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL884004,1,Intermediate,9606.0,,81034,478.0
7140,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623407,1,Intermediate,9606.0,,81034,478.0
7141,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623408,1,Intermediate,9606.0,,81034,478.0
7142,In vitro antitumor activity against A2780 cell line.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623409,1,Expert,9606.0,,81034,478.0
7143,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623410,1,Intermediate,9606.0,,81034,478.0
7144,In vitro cytotoxicity against A2780 human ovarian cancer cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL623576,1,Expert,9606.0,,81034,478.0
7145,Inhibitory activity against kidney A-CHN tumor cell growth in culture,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623577,1,Intermediate,9606.0,,80025,626.0
7146,The IC50 value was measured on ACHN cell line in renal tumor type.,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623578,1,Intermediate,9606.0,,80025,626.0
7147,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623579,1,Intermediate,9606.0,,80025,626.0
7148,In vitro lethal concentration against most sensitive ACHN cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623580,1,Expert,9606.0,,80025,626.0
7149,Tested for cytotoxic activity against renal cancer ACHN cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623581,1,Intermediate,9606.0,,80025,626.0
7150,Compound tested for growth inhibition of renal cancer cell line ACHN,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL857456,1,Intermediate,9606.0,,80025,626.0
7151,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623582,1,Intermediate,9606.0,,80025,626.0
7152,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623583,1,Intermediate,9606.0,,80025,626.0
7153,In vitro anticancer activity against ACHN renal cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623584,1,Intermediate,9606.0,,80025,626.0
7154,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623585,1,Intermediate,9606.0,,80025,626.0
7155,Percent selectivity was evaluated in renal ACHN cell lines,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623586,1,Intermediate,9606.0,,80025,626.0
7156,In vitro inhibitory activity against renal ACHN cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623587,1,Intermediate,9606.0,,80025,626.0
7157,Tested for cytotoxicity against ACHN cell lines in renal cancer,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL875279,1,Intermediate,9606.0,,80025,626.0
7158,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623588,1,Intermediate,9606.0,,80025,626.0
7159,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623589,1,Intermediate,9606.0,,80025,626.0
7160,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623590,1,Intermediate,9606.0,,80025,626.0
7161,Cytotoxic effect on renal cancer line ACHN,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623591,1,Expert,9606.0,,80025,626.0
7162,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623592,1,Intermediate,9606.0,,80025,626.0
7163,In vitro inhibition of Renal Cancer ACHN cell lines,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623593,1,Intermediate,9606.0,,80025,626.0
7164,Antitumor activity against human renal adenocarcinoma ACHN cells,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL623594,1,Intermediate,9606.0,,80025,626.0
7165,Antitumor activity against human renal adenocarcinoma ACHN cells.,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621833,1,Expert,9606.0,,80025,626.0
7166,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621834,1,Intermediate,9606.0,,80025,626.0
7167,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621835,1,Intermediate,9606.0,,80025,626.0
7168,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621836,1,Intermediate,9606.0,,80025,626.0
7169,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621837,1,Intermediate,9606.0,,80025,626.0
7170,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL875280,1,Intermediate,9606.0,,80025,626.0
7171,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621838,1,Intermediate,9606.0,,80025,626.0
7172,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,1,N,,Homo sapiens,,,,,ACHN,,BAO_0000219,CHEMBL621839,1,Intermediate,9606.0,,80025,626.0
7173,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL621840,0,Autocuration,,,22224,
7174,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,1,H,,,,,,,,,BAO_0000019,CHEMBL621841,8,Autocuration,,,10647,
7175,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,1,N,,Cytomegalovirus,,,,,HEL,,BAO_0000218,CHEMBL622979,1,Expert,10358.0,,50529,468.0
7176,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,1,N,,Cytomegalovirus,,,,,,,BAO_0000218,CHEMBL876595,1,Intermediate,10358.0,,50529,
7177,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),1,H,,,,,,,,,BAO_0000357,CHEMBL620221,8,Autocuration,,,12159,
7178,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),1,H,,,,,,,,,BAO_0000357,CHEMBL620222,8,Autocuration,,,12159,
7179,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,1,N,,Bos taurus,,,,,ADDP cell line,,BAO_0000219,CHEMBL620506,1,Intermediate,9913.0,,80670,979.0
7180,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,1,N,,Mus musculus,,,,,ADJ/PC6,,BAO_0000219,CHEMBL620507,1,Intermediate,10090.0,,80671,980.0
7181,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,1,N,,Mus musculus,,,,,ADJ/PC6,,BAO_0000219,CHEMBL620508,1,Intermediate,10090.0,,80671,980.0
7182,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",1,N,,Mus musculus,,,,,ADJ/PC6,,BAO_0000219,CHEMBL620509,1,Intermediate,10090.0,,80671,980.0
7183,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,1,N,,Mus musculus,,,,,ADJ/PC6,,BAO_0000219,CHEMBL620510,1,Intermediate,10090.0,,80671,980.0
7184,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,1,N,,Mus musculus,,,,,ADJ/PC6,,BAO_0000219,CHEMBL620511,1,Intermediate,10090.0,,80671,980.0
7185,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,1,N,,Mus musculus,,,,,ADJ/PC6,,BAO_0000219,CHEMBL620512,1,Intermediate,10090.0,,80671,980.0
7186,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL620513,0,Autocuration,10090.0,,22224,
7187,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL620514,0,Autocuration,10090.0,,22224,
7188,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,1,U,,Mus musculus,,,,,,,BAO_0000019,CHEMBL620515,0,Autocuration,10090.0,,22224,
7189,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,U,,Bacillus subtilis,,,,,,,BAO_0000218,CHEMBL620516,0,Autocuration,1423.0,,22224,
7190,AUC value in dog after IV administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620517,1,Intermediate,9615.0,,50588,
7191,AUC value in dog after oral administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620518,1,Intermediate,9615.0,,50588,
7192,Cmax value in dog after oral administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620519,1,Intermediate,9615.0,,50588,
7193,Bioavailability in dog after oral administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621386,1,Intermediate,9615.0,,50588,
7194,Tmax value in dog after oral administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621387,1,Intermediate,9615.0,,50588,
7195,Compound was evaluated for its clearance when administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621388,1,Intermediate,9615.0,,50588,
7196,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621389,1,Intermediate,9615.0,,50588,
7197,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621390,1,Intermediate,9615.0,,50588,
7198,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL621391,0,Intermediate,,,22229,
7199,Half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621392,1,Intermediate,9615.0,,50588,
7200,Time taken for EC90 was determined when tested in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621393,1,Intermediate,9615.0,,50588,
7201,Half life (iv) was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621394,1,Intermediate,9615.0,,50588,
7202,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL621395,1,Intermediate,9615.0,,50588,
7203,Area under the curve was calculated in dog after iv administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621396,1,Intermediate,9615.0,,50588,
7204,Area under the curve was calculated in dog after peroral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621397,1,Intermediate,9615.0,,50588,
7205,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621398,1,Intermediate,9615.0,,50588,
7206,pKa was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618818,1,Intermediate,9615.0,,50588,
7207,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618819,1,Intermediate,9615.0,,50588,
7208,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618820,1,Intermediate,9615.0,,50588,
7209,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873810,1,Intermediate,9615.0,,50588,
7210,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876606,1,Intermediate,9615.0,,50588,
7211,Compound was evaluated for the half-life (t 1/2) in hours,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618821,1,Intermediate,9615.0,,50588,
7212,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL618822,1,Intermediate,9615.0,,50588,
7213,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL618823,1,Intermediate,9615.0,,50588,
7214,Half life after intravenous administration of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618824,1,Intermediate,9615.0,,50588,
7215,Half life was measured in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618825,1,Intermediate,9615.0,,50588,
7216,Half life period in dog after 5 mg/kg dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618826,1,Intermediate,9615.0,,50588,
7217,Half life period was evaluated in dog; 4-4.8,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618827,1,Intermediate,9615.0,,50588,
7218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618828,1,Intermediate,9615.0,,50588,
7219,Half-life was determined in dog after a3 mg/kg of iv dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618829,1,Intermediate,9615.0,,50588,
7220,Half-life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618830,1,Intermediate,9615.0,,50588,
7221,Half life in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618831,1,Intermediate,9615.0,,50588,
7222,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619489,1,Intermediate,9615.0,,50588,
7223,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619649,1,Intermediate,9615.0,,50588,
7224,Compound was evaluated for the half life period after iv administration in Beagle dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876607,1,Intermediate,9615.0,,50588,
7225,Compound was evaluated for the half life period after oral administration in conscious dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619650,1,Intermediate,9615.0,,50588,
7226,Compound was tested for half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619651,1,Intermediate,9615.0,,50588,
7227,Compound was tested for its half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619652,1,Intermediate,9615.0,,50588,
7228,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619653,1,Intermediate,9615.0,,50588,
7229,Half life of compound in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619654,1,Intermediate,9615.0,,50588,
7230,Half life (iv) was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619655,1,Intermediate,9615.0,,50588,
7231,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL619656,1,Intermediate,9615.0,,50588,
7232,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873812,1,Intermediate,9615.0,,50588,
7233,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621365,1,Intermediate,9615.0,,50588,
7234,Half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621366,1,Intermediate,9615.0,,50588,
7235,Half life in dog plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621367,1,Intermediate,9615.0,,50588,
7236,Half life in dog plasma after administration of 0.25 mg/kg iv,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621368,1,Intermediate,9615.0,,50588,
7237,Half life in dog plasma after administration of 1 mg/kg iv,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621369,1,Intermediate,9615.0,,50588,
7238,Half life in dog plasma was determined at dose 10 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621370,1,Intermediate,9615.0,,50588,
7239,Half life in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621371,1,Intermediate,9615.0,,50588,
7240,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621372,1,Intermediate,9615.0,,50588,
7241,Half life upon exposure to human plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621373,1,Intermediate,9615.0,,50588,
7242,Half life was calculated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621374,1,Intermediate,9615.0,,50588,
7243,Half life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621375,1,Intermediate,9615.0,,50588,
7244,Half life was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621376,1,Intermediate,9615.0,,50588,
7245,Half life by intravenous administration of 1.2 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619624,1,Intermediate,9615.0,,50588,
7246,Half life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875840,1,Intermediate,9615.0,,50588,
7247,Half life in dog after intra venous administration of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619625,1,Intermediate,9615.0,,50588,
7248,Half life in dog after intra venous administration of the compound; ND means Not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619626,1,Intermediate,9615.0,,50588,
7249,Half life in dog after po administration of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619627,1,Intermediate,9615.0,,50588,
7250,Half life in dog after po administration of the compound; ND means Not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873817,1,Intermediate,9615.0,,50588,
7251,Half life in dog at the single oral dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619628,1,Intermediate,9615.0,,50588,
7252,Half life in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619629,1,Intermediate,9615.0,,50588,
7253,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619630,1,Intermediate,9615.0,,50588,
7254,Half life in rat,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619631,1,Intermediate,9615.0,,50588,
7255,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL619632,1,Intermediate,9615.0,,50588,
7256,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL619633,1,Intermediate,10090.0,,50594,
7257,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL875841,1,Intermediate,10090.0,,50594,
7258,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL619634,1,Intermediate,10090.0,,50594,
7259,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL619635,1,Intermediate,10090.0,,50594,
7260,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL619636,1,Intermediate,10090.0,,50594,
7261,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619637,1,Intermediate,10090.0,,50594,
7262,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619638,1,Intermediate,10090.0,,50594,
7263,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619639,1,Intermediate,10090.0,,50594,
7264,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619640,1,Intermediate,10090.0,,50594,
7265,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619641,1,Intermediate,10090.0,,50594,
7266,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619642,1,Intermediate,10090.0,,50594,
7267,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Gut,,10000004.0,BAO_0000218,CHEMBL619643,1,Intermediate,10090.0,,50594,
7268,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL619644,1,Intermediate,10090.0,,50594,
7269,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621112,1,Intermediate,10090.0,,50594,
7270,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621113,1,Intermediate,10090.0,,50594,
7271,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621114,1,Intermediate,10090.0,,50594,
7272,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621115,1,Intermediate,10090.0,,50594,
7273,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621116,1,Intermediate,10090.0,,50594,
7274,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL621117,1,Intermediate,10090.0,,50594,
7275,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621118,1,Intermediate,10090.0,,50594,
7276,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621119,1,Intermediate,10090.0,,50594,
7277,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621120,1,Intermediate,10090.0,,50594,
7278,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621757,1,Intermediate,10090.0,,50594,
7279,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621758,1,Intermediate,10090.0,,50594,
7280,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621759,1,Intermediate,10090.0,,50594,
7281,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621760,1,Intermediate,10090.0,,50594,
7282,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621761,1,Intermediate,10090.0,,50594,
7283,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621762,1,Intermediate,10090.0,,50594,
7284,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621763,1,Intermediate,10090.0,,50594,
7285,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624502,1,Intermediate,10090.0,,50594,
7286,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624503,1,Intermediate,10090.0,,50594,
7287,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624504,1,Intermediate,10090.0,,50594,
7288,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624505,1,Intermediate,10090.0,,50594,
7289,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624506,1,Intermediate,10090.0,,50594,
7290,In vitro cytotoxicity against A2780 (human ovarian cancer),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624507,1,Intermediate,9606.0,,81034,478.0
7291,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624508,1,Intermediate,9606.0,,81034,478.0
7292,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624509,1,Intermediate,9606.0,,81034,478.0
7293,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624510,1,Intermediate,9606.0,,81034,478.0
7294,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL875956,1,Expert,9606.0,,81034,478.0
7295,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL839885,1,Expert,9606.0,,81034,478.0
7296,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624511,1,Expert,9606.0,,81034,478.0
7297,In vitro cytotoxicity against A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624512,1,Intermediate,9606.0,,81034,478.0
7298,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624513,1,Intermediate,9606.0,,81034,478.0
7299,In vitro inhibitory activity against human ovarian cancer A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL624514,1,Intermediate,9606.0,,81034,478.0
7300,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL618547,1,Intermediate,9606.0,,81034,478.0
7301,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618548,1,Intermediate,9606.0,,81034,478.0
7302,Inhibition of tubulin polymerization in analogy of ca.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618549,1,Intermediate,9606.0,,81034,478.0
7303,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618550,1,Intermediate,9606.0,,81034,478.0
7304,Cytotoxic effect in ovarian cancer cell line (A2780),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618551,1,Expert,9606.0,,81034,478.0
7305,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618552,1,Intermediate,9606.0,,81034,478.0
7306,Tested for the cytotoxicity in A2780 ovarian cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618553,1,Intermediate,9606.0,,81034,478.0
7307,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618554,1,Intermediate,9606.0,,81034,478.0
7308,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618555,1,Intermediate,9606.0,,81034,478.0
7309,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,1,N,,,,,,,A2780cisR,,BAO_0000219,CHEMBL618556,1,Intermediate,,,80017,481.0
7310,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,N,,,,,,,A2780cisR,,BAO_0000219,CHEMBL618557,1,Intermediate,,,80017,481.0
7311,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,1,N,,,,,,,A2780cisR,,BAO_0000219,CHEMBL618558,1,Intermediate,,,80017,481.0
7312,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),1,N,,,,,,,A2780cisR,,BAO_0000219,CHEMBL618559,1,Intermediate,,,80017,481.0
7313,In vivo log of cells killed after administration of compound in A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL618560,1,Intermediate,9606.0,,81034,478.0
7314,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL618561,1,Intermediate,9606.0,,81034,478.0
7315,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618562,1,Intermediate,9606.0,,81034,478.0
7316,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618563,1,Intermediate,9606.0,,81034,478.0
7317,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618564,1,Intermediate,9606.0,,81034,478.0
7318,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618565,1,Intermediate,9606.0,,81034,478.0
7319,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),1,N,,Homo sapiens,,,,,A2780,,BAO_0000218,CHEMBL618566,1,Intermediate,9606.0,,81034,478.0
7320,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618567,1,Intermediate,9606.0,,81034,478.0
7321,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618568,1,Expert,9606.0,,81034,478.0
7322,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL618569,1,Expert,9606.0,,81034,478.0
7323,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621857,1,Intermediate,9606.0,,81034,478.0
7324,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621858,1,Intermediate,9606.0,,81034,478.0
7325,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621859,1,Intermediate,9606.0,,81034,478.0
7326,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621860,1,Intermediate,9606.0,,81034,478.0
7327,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621861,1,Intermediate,9606.0,,81034,478.0
7328,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621862,1,Expert,9606.0,,81034,478.0
7329,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621863,1,Intermediate,9606.0,,81034,478.0
7330,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621864,1,Intermediate,9606.0,,81034,478.0
7331,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621865,1,Intermediate,9606.0,,81034,478.0
7332,In vitro antiproliferative activity against A2780 cell line,1,N,,Mus musculus,,,,,A2780,,BAO_0000219,CHEMBL621866,1,Intermediate,10090.0,,81034,478.0
7333,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,1,N,,Mus musculus,,,,,A2780,,BAO_0000219,CHEMBL621867,1,Expert,10090.0,,81034,478.0
7334,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL621868,1,Intermediate,9606.0,,81034,478.0
7335,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,1,N,,Homo sapiens,,,,,A2780,,BAO_0000219,CHEMBL875282,1,Intermediate,9606.0,,81034,478.0
7336,Vc value in dog after IV administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621869,1,Intermediate,9615.0,,50588,
7337,Half life period in dog after IV administration at a dose of 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621870,1,Intermediate,9615.0,,50588,
7338,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621871,0,Autocuration,9527.0,,22224,
7339,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621243,0,Autocuration,9527.0,,22224,
7340,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621244,0,Autocuration,9527.0,,22224,
7341,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL621245,0,Autocuration,9541.0,,22224,
7342,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL621246,0,Autocuration,9541.0,,22224,
7343,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL621247,0,Autocuration,9541.0,,22224,
7344,Oral Bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618386,0,Autocuration,10116.0,,22224,
7345,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618387,0,Autocuration,9527.0,,22224,
7346,Area under curve value in monkey at a dose of 5 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618388,0,Autocuration,9527.0,,22224,
7347,Area under curve was determined in monkey after a 3 mg/kg of oral dose,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618389,0,Autocuration,9527.0,,22224,
7348,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618574,0,Autocuration,9527.0,,22224,
7349,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618575,0,Autocuration,9527.0,,22224,
7350,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618576,0,Autocuration,9527.0,,22224,
7351,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618577,0,Autocuration,9527.0,,22224,
7352,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL876487,0,Autocuration,9527.0,,22224,
7353,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618578,0,Autocuration,9527.0,,22224,
7354,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618579,0,Autocuration,9527.0,,22224,
7355,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618580,0,Autocuration,9527.0,,22224,
7356,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618581,0,Autocuration,9527.0,,22224,
7357,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618582,0,Autocuration,9527.0,,22224,
7358,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618583,0,Autocuration,9527.0,,22224,
7359,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618584,0,Autocuration,9527.0,,22224,
7360,Oral AUCN in monkey (dosed at 0.5 mpk iv ),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618585,0,Autocuration,9527.0,,22224,
7361,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618586,0,Autocuration,9527.0,,22224,
7362,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618587,0,Autocuration,9527.0,,22224,
7363,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618588,0,Autocuration,9527.0,,22224,
7364,Binding towards monkey plasma protein at 10 uM,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618589,0,Autocuration,9527.0,,22224,
7365,Binding towards monkey plasma protein at 100 uM,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL618590,0,Autocuration,9527.0,,22224,
7366,Apparent bioavailability in squirrel monkey was determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL872262,0,Autocuration,9527.0,,22224,
7367,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618591,0,Autocuration,9527.0,,22224,
7368,Bioavailability in monkey (dose 2 mg/kg),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL618592,0,Autocuration,9443.0,,22224,
7369,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL876488,0,Autocuration,9527.0,,22224,
7370,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618593,0,Autocuration,9527.0,,22224,
7371,Bioavailability in monkey (i.d. dosing),1,U,,monkey,,,,,,,BAO_0000218,CHEMBL618594,0,Autocuration,9443.0,,22224,
7372,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL618595,0,Autocuration,9527.0,,22224,
7373,Clearance of the drug was measured in cynomolgus,1,U,,Cercopithecidae,,,,,,,BAO_0000019,CHEMBL621469,0,Autocuration,9527.0,,22224,
7374,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621470,0,Autocuration,9527.0,,22224,
7375,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621471,0,Autocuration,9527.0,,22224,
7376,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,U,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621472,0,Autocuration,9544.0,,22224,
7377,Plasma clearance in rhesus monkey was determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621473,0,Autocuration,9527.0,,22224,
7378,Plasma clearance in monkey after administration of 1 mg/kg iv,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621474,0,Autocuration,9527.0,,22224,
7379,Plasma clearance in cynomolgus monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621475,0,Autocuration,9527.0,,22224,
7380,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL621476,0,Autocuration,9527.0,,22224,
7381,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL624290,0,Autocuration,9527.0,,22224,
7382,The total clearance was determined after intravenous administration in cynomolgus monkeys,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL624291,0,Autocuration,9527.0,,22224,
7383,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL624292,0,Autocuration,9527.0,,22224,
7384,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL624293,0,Autocuration,9527.0,,22224,
7385,Tested for Clearance upon iv administration to african green monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL624294,0,Autocuration,9527.0,,22224,
7386,Clearance in monkey,1,U,,Cercopithecidae,,,,,,,BAO_0000218,CHEMBL624295,0,Autocuration,9527.0,,22224,
7387,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624296,1,Intermediate,9615.0,,50588,
7388,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624297,1,Intermediate,9615.0,,50588,
7389,Half life was evaluated after intravenous administration to dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624298,1,Intermediate,9615.0,,50588,
7390,Half life was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624299,1,Intermediate,9615.0,,50588,
7391,Half life was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624300,1,Intermediate,9615.0,,50588,
7392,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624301,1,Intermediate,9615.0,,50588,
7393,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624302,1,Intermediate,9615.0,,50588,
7394,Half life period after intravenous administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876026,1,Intermediate,9615.0,,50588,
7395,Half life period after oral administration (2.5 mg/kg) in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624303,1,Intermediate,9615.0,,50588,
7396,Half life period at a dose of 1 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624304,1,Intermediate,9615.0,,50588,
7397,Half life period was determine after peroral administration at 10 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624305,1,Intermediate,9615.0,,50588,
7398,Half life period was determine after peroral administration at 5 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624306,1,Intermediate,9615.0,,50588,
7399,Half life period was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624307,1,Intermediate,9615.0,,50588,
7400,Half life period was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624308,1,Intermediate,9615.0,,50588,
7401,Half life period by iv administration in dog at a dose of 6 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624309,1,Intermediate,9615.0,,50588,
7402,Half life period was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624310,1,Intermediate,9615.0,,50588,
7403,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625003,1,Intermediate,9615.0,,50588,
7404,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625004,1,Intermediate,9615.0,,50588,
7405,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625005,1,Intermediate,9615.0,,50588,
7406,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873813,1,Intermediate,9615.0,,50588,
7407,Half-life after oral dose of compound at 3 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625006,1,Intermediate,9615.0,,50588,
7408,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625007,1,Intermediate,9615.0,,50588,
7409,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876027,1,Intermediate,9615.0,,50588,
7410,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625008,1,Intermediate,9615.0,,50588,
7411,Half-life of compound in dog following p.o. administration of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625009,1,Intermediate,9615.0,,50588,
7412,Half-life of compound in plasma of dog was determined,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625010,1,Intermediate,9615.0,,50588,
7413,Half-life of compound was determined in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625011,1,Intermediate,9615.0,,50588,
7414,Half-life after administration of 4 mg/Kg oral dose in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621553,1,Intermediate,9615.0,,50588,
7415,Half-life after intravenous administration of 1 mg/kg/h in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621554,1,Intermediate,9615.0,,50588,
7416,Half-life in Dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621555,1,Intermediate,9615.0,,50588,
7417,Half-life in Dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621556,1,Intermediate,9615.0,,50588,
7418,Half-life in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621557,1,Intermediate,9615.0,,50588,
7419,Half-life in dog after oral administration at 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621558,1,Intermediate,9615.0,,50588,
7420,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621559,1,Intermediate,9615.0,,50588,
7421,Half-life in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621560,1,Intermediate,9615.0,,50588,
7422,Half-life in dogs; ND indicates not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL876028,1,Intermediate,9615.0,,50588,
7423,Half-life in plasma of dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621561,1,Intermediate,9615.0,,50588,
7424,Half-life in plasma of dog at dose of 3-10 mgkg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621562,1,Intermediate,9615.0,,50588,
7425,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621563,1,Intermediate,9615.0,,50588,
7426,Half-life was measured in dog after an iv dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621564,1,Intermediate,9615.0,,50588,
7427,Half-life was measured in dogs after an oral dose of 10 uM/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621565,1,Intermediate,9615.0,,50588,
7428,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621566,1,Intermediate,9615.0,,50588,
7429,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621567,1,Intermediate,9615.0,,50588,
7430,Half-life of the compound after 0.3 mg/kg po administration in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622978,1,Intermediate,9615.0,,50588,
7431,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL873814,1,Intermediate,9615.0,,50588,
7432,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623219,1,Intermediate,9615.0,,50588,
7433,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624477,1,Intermediate,9615.0,,50588,
7434,t1/2 in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624478,1,Intermediate,9615.0,,50588,
7435,Half-life period measured in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624479,1,Intermediate,9615.0,,50588,
7436,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624480,1,Intermediate,9615.0,,50588,
7437,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623595,1,Intermediate,9615.0,,50588,
7438,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623596,1,Intermediate,9615.0,,50588,
7439,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623597,1,Intermediate,9615.0,,50588,
7440,In vivo half life period was calculated at 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623598,1,Intermediate,9615.0,,50588,
7441,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623599,1,Intermediate,9615.0,,50588,
7442,Longer half-life in dog (i.v.) at 0.5 mpk,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623600,1,Intermediate,9615.0,,50588,
7443,Oral bioavailability in dog (dose 5 uM/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623601,1,Intermediate,9615.0,,50588,
7444,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623602,1,Intermediate,9615.0,,50588,
7445,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623603,1,Intermediate,9615.0,,50588,
7446,Bioavailability in dog (dose 1 mg/kg i.v.),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623604,1,Intermediate,9615.0,,50588,
7447,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623605,1,Intermediate,10090.0,,50594,
7448,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623606,1,Intermediate,10090.0,,50594,
7449,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623607,1,Intermediate,10090.0,,50594,
7450,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623608,1,Intermediate,10090.0,,50594,
7451,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623609,1,Intermediate,10090.0,,50594,
7452,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623610,1,Intermediate,10090.0,,50594,
7453,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623611,1,Intermediate,10090.0,,50594,
7454,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623612,1,Intermediate,10090.0,,50594,
7455,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623613,1,Intermediate,10090.0,,50594,
7456,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623614,1,Intermediate,10090.0,,50594,
7457,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623615,1,Intermediate,10090.0,,50594,
7458,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623616,1,Intermediate,10090.0,,50594,
7459,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623617,1,Intermediate,10090.0,,50594,
7460,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL875944,1,Intermediate,10090.0,,50594,
7461,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL623618,1,Intermediate,10090.0,,50594,
7462,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL623619,1,Intermediate,10090.0,,50594,
7463,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL623620,1,Intermediate,10090.0,,50594,
7464,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL623621,1,Intermediate,10090.0,,50594,
7465,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL623622,1,Intermediate,10090.0,,50594,
7466,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL623623,1,Intermediate,10090.0,,50594,
7467,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL623624,1,Intermediate,10090.0,,50594,
7468,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618521,1,Intermediate,10090.0,,50594,
7469,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618522,1,Intermediate,10090.0,,50594,
7470,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618523,1,Intermediate,10090.0,,50594,
7471,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618524,1,Intermediate,10090.0,,50594,
7472,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL618525,1,Intermediate,10090.0,,50594,
7473,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624586,1,Intermediate,10090.0,,50594,
7474,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624587,1,Intermediate,10090.0,,50594,
7475,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624588,1,Intermediate,10090.0,,50594,
7476,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624589,1,Intermediate,10090.0,,50594,
7477,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624590,1,Intermediate,10090.0,,50594,
7478,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624591,1,Intermediate,10090.0,,50594,
7479,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624592,1,Intermediate,10090.0,,50594,
7480,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL624593,1,Intermediate,10090.0,,50594,
7481,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624594,1,Intermediate,10116.0,,50597,
7482,Tested for the bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624595,1,Intermediate,10116.0,,50597,
7483,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624596,1,Intermediate,10116.0,,50597,
7484,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624597,1,Intermediate,10116.0,,50597,
7485,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624598,1,Intermediate,10116.0,,50597,
7486,Bioavailability in rat (dose 3-10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624599,1,Intermediate,10116.0,,50597,
7487,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875166,1,Intermediate,10116.0,,50597,
7488,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624600,1,Intermediate,10116.0,,50597,
7489,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624601,1,Intermediate,10116.0,,50597,
7490,Half life after oral administration was determined in rats at 6 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624602,1,Intermediate,10116.0,,50597,
7491,Half life was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624603,1,Intermediate,10116.0,,50597,
7492,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624604,1,Intermediate,10116.0,,50597,
7493,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624605,1,Intermediate,10116.0,,50597,
7494,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624606,1,Intermediate,10116.0,,50597,
7495,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624607,1,Intermediate,10116.0,,50597,
7496,Hill coefficient of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624608,1,Intermediate,10116.0,,50597,
7497,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624609,1,Intermediate,10116.0,,50597,
7498,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624610,1,Intermediate,10116.0,,50597,
7499,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624611,1,Intermediate,10116.0,,50597,
7500,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624612,1,Intermediate,10116.0,,50597,
7501,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL875167,1,Intermediate,10116.0,,50597,
7502,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624613,1,Intermediate,10116.0,,50597,
7503,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624614,1,Intermediate,10116.0,,50597,
7504,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624392,1,Intermediate,10116.0,,50597,
7505,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624393,1,Intermediate,10116.0,,50597,
7506,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624394,1,Intermediate,10116.0,,50597,
7507,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624395,1,Intermediate,10116.0,,50597,
7508,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624396,1,Intermediate,10116.0,,50597,
7509,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624397,1,Intermediate,10116.0,,50597,
7510,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624398,1,Intermediate,10116.0,,50597,
7511,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624399,1,Intermediate,10116.0,,50597,
7512,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624400,1,Intermediate,10116.0,,50597,
7513,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624401,1,Intermediate,10116.0,,50597,
7514,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624402,1,Intermediate,10116.0,,50597,
7515,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624403,1,Intermediate,10116.0,,50597,
7516,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624404,1,Intermediate,10116.0,,50597,
7517,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624405,1,Intermediate,10116.0,,50597,
7518,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL624406,1,Intermediate,10116.0,,50597,
7519,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL624407,1,Intermediate,10116.0,,50597,
7520,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL624408,1,Intermediate,10116.0,,50597,
7521,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL618644,1,Intermediate,10116.0,,50597,
7522,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL618645,1,Intermediate,10116.0,,50597,
7523,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL618646,1,Intermediate,10116.0,,50597,
7524,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618647,1,Intermediate,10116.0,,50597,
7525,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618648,1,Intermediate,10116.0,,50597,
7526,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618649,1,Intermediate,10116.0,,50597,
7527,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618650,1,Intermediate,10116.0,,50597,
7528,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618651,1,Intermediate,10116.0,,50597,
7529,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL876497,1,Intermediate,10116.0,,50597,
7530,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618652,1,Intermediate,10116.0,,50597,
7531,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618653,1,Intermediate,10116.0,,50597,
7532,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618654,1,Intermediate,10116.0,,50597,
7533,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618655,1,Intermediate,10116.0,,50597,
7534,Compound was tested for solubility in water,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618656,1,Intermediate,10116.0,,50597,
7535,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),1,U,,,,,,,,,BAO_0000100,CHEMBL618657,0,Intermediate,,,22229,
7536,Solubility was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618658,1,Intermediate,10116.0,,50597,
7537,solubility in water (ug/mL) at 37 degree C.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618659,1,Intermediate,10116.0,,50597,
7538,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618660,1,Intermediate,10116.0,,50597,
7539,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618661,1,Intermediate,10116.0,,50597,
7540,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873807,1,Intermediate,10116.0,,50597,
7541,Half life in Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618662,1,Intermediate,10116.0,,50597,
7542,Half life period after 3 mg/kg iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618663,1,Intermediate,10116.0,,50597,
7543,Half life period after 3 mg/kg iv administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618664,1,Intermediate,10116.0,,50597,
7544,Half life period after 3 mg/kg iv administration in the rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618665,1,Intermediate,10116.0,,50597,
7545,Half life period in female Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876498,1,Intermediate,10116.0,,50597,
7546,Half life period in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618666,1,Intermediate,10116.0,,50597,
7547,Half-life in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620440,1,Intermediate,10116.0,,50597,
7548,Half-life in rats with metabolic oxidation,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620441,1,Intermediate,10116.0,,50597,
7549,Half-life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620442,1,Intermediate,10116.0,,50597,
7550,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620443,1,Intermediate,10116.0,,50597,
7551,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620444,1,Intermediate,10116.0,,50597,
7552,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620445,1,Intermediate,10116.0,,50597,
7553,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620446,1,Intermediate,10116.0,,50597,
7554,Biological half-life measured in plasma of rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620447,1,Intermediate,10116.0,,50597,
7555,Biological half-life measured in plasma of rat; 22-25,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621129,1,Intermediate,10116.0,,50597,
7556,Biological half-life measured in plasma of rat; 9-16,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621130,1,Intermediate,10116.0,,50597,
7557,Compound was evaluated for its half life when administered intravenously in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873808,1,Intermediate,10116.0,,50597,
7558,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876598,1,Intermediate,10116.0,,50597,
7559,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621131,1,Intermediate,10116.0,,50597,
7560,Half life (T1/2) after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621132,1,Intermediate,10116.0,,50597,
7561,Half life of compound after iv administration of 20 mg/kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621133,1,Intermediate,10116.0,,50597,
7562,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621312,1,Expert,10116.0,,50597,
7563,Half life of compound was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621313,1,Intermediate,10116.0,,50597,
7564,Half life of compound was determined in rat blood,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621314,1,Intermediate,10116.0,,50597,
7565,Half life at 1 mg/kg was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621315,1,Intermediate,10116.0,,50597,
7566,Half life at 10 mg/kg was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621316,1,Intermediate,10116.0,,50597,
7567,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621317,1,Intermediate,10116.0,,50597,
7568,Half life in rats in hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621318,1,Intermediate,10116.0,,50597,
7569,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621319,1,Intermediate,10116.0,,50597,
7570,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621377,1,Intermediate,10116.0,,50597,
7571,Half life was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621378,1,Intermediate,10116.0,,50597,
7572,Half life after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876599,1,Intermediate,10116.0,,50597,
7573,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621379,1,Intermediate,10116.0,,50597,
7574,Half life in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621380,1,Intermediate,10116.0,,50597,
7575,Half life in rat plasma; Not detected,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621381,1,Intermediate,10116.0,,50597,
7576,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618515,1,Intermediate,10116.0,,50597,
7577,Half life period of compound was determined after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618516,1,Intermediate,10116.0,,50597,
7578,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618517,1,Intermediate,10116.0,,50597,
7579,Half life period in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618518,1,Intermediate,10116.0,,50597,
7580,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618519,1,Intermediate,10116.0,,50597,
7581,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618698,1,Intermediate,10116.0,,50597,
7582,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618862,1,Intermediate,10116.0,,50597,
7583,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618863,1,Intermediate,10116.0,,50597,
7584,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618864,1,Intermediate,10116.0,,50597,
7585,Half life time in rat the dose of 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618865,1,Intermediate,10116.0,,50597,
7586,Half-life 24 hr after 10 mg/kg iv administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618866,1,Intermediate,10116.0,,50597,
7587,Half-life 24 hr after 2 mg/kg iv administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618867,1,Intermediate,10116.0,,50597,
7588,Half-life consistent with the observed metabolic steady state in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875828,1,Intermediate,10116.0,,50597,
7589,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618868,1,Intermediate,10116.0,,50597,
7590,Half-life for oxidative metabolic stability was determined using male human,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618869,1,Intermediate,10116.0,,50597,
7591,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618870,1,Intermediate,10116.0,,50597,
7592,Half-life in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618871,1,Intermediate,10116.0,,50597,
7593,Half-life in rat plasma was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618872,1,Intermediate,10116.0,,50597,
7594,Half-life in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873816,1,Intermediate,10116.0,,50597,
7595,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,1,U,,,,,,,,,BAO_0000218,CHEMBL618873,0,Autocuration,,,22224,
7596,Area under curve after oral dose of 0.1 mg//kg,1,U,,,,,,,,,BAO_0000019,CHEMBL621602,0,Autocuration,,,22224,
7597,Area under curve after oral dose of 0.3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621603,0,Autocuration,,,22224,
7598,Area under curve after oral dose of 1 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621604,0,Autocuration,,,22224,
7599,Area under curve after oral dose of 10 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621605,0,Autocuration,,,22224,
7600,Area under curve after oral dose of 23.4 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621606,0,Autocuration,,,22224,
7601,Area under curve after oral dose of 3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621607,0,Autocuration,,,22224,
7602,Area under curve after oral dose of 3.87 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621608,0,Autocuration,,,22224,
7603,Area under curve was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL621609,0,Autocuration,,,22224,
7604,Area under curve at a dose of 10 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621610,0,Autocuration,,,22224,
7605,Area under curve was determined; ND=No data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621611,1,Intermediate,10116.0,,50597,
7606,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621612,1,Intermediate,10116.0,,50597,
7607,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622308,1,Intermediate,10116.0,,50597,
7608,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622309,1,Intermediate,10116.0,,50597,
7609,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622310,1,Intermediate,10116.0,,50597,
7610,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622311,1,Intermediate,10116.0,,50597,
7611,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622312,1,Intermediate,10116.0,,50597,
7612,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622931,1,Intermediate,10116.0,,50597,
7613,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622932,1,Intermediate,10116.0,,50597,
7614,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622736,1,Intermediate,10116.0,,50597,
7615,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622737,1,Intermediate,10116.0,,50597,
7616,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622738,1,Intermediate,10116.0,,50597,
7617,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622739,1,Intermediate,10116.0,,50597,
7618,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622740,1,Intermediate,10116.0,,50597,
7619,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622741,1,Intermediate,10116.0,,50597,
7620,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622742,1,Intermediate,10116.0,,50597,
7621,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622743,1,Intermediate,10116.0,,50597,
7622,AUC in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622744,1,Intermediate,10090.0,,50594,
7623,Area under curve was measured from the graph obtained from concentration Vs time,1,U,,,,,,,,,BAO_0000019,CHEMBL624134,0,Autocuration,,,22224,
7624,Area under curve value of compound per hour after oral administration,1,U,,,,,,,,,BAO_0000019,CHEMBL624135,0,Autocuration,,,22224,
7625,Area under curve was determined after oral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624136,1,Intermediate,10116.0,,50597,
7626,Area under curve was determined after oral administration in rats; No data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624137,1,Intermediate,10116.0,,50597,
7627,Area under curve was determined after oral administration in rats;No data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624320,1,Intermediate,10116.0,,50597,
7628,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624321,1,Intermediate,9615.0,,50588,
7629,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624322,1,Intermediate,10116.0,,50597,
7630,Area under curve was determined for the compound after iv dose of 5.06 in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624323,1,Intermediate,10116.0,,50597,
7631,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624324,1,Intermediate,10116.0,,50597,
7632,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624325,1,Intermediate,10116.0,,50597,
7633,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624326,1,Intermediate,10116.0,,50597,
7634,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624327,1,Intermediate,10116.0,,50597,
7635,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624328,1,Intermediate,10116.0,,50597,
7636,Area under curve was determined in Dogs after peroral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL627848,1,Intermediate,9615.0,,50588,
7637,Area under curve was determined in Rats after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627849,1,Intermediate,10116.0,,50597,
7638,Area under curve was determined in carotid blood of rat when administered intradermally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627850,1,Intermediate,10116.0,,50597,
7639,Area under curve was determined in portal blood of rat when administered intradermally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627851,1,Intermediate,10116.0,,50597,
7640,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627852,1,Intermediate,10090.0,,50594,
7641,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627853,1,Intermediate,10090.0,,50594,
7642,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627854,1,Intermediate,10090.0,,50594,
7643,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627855,1,Intermediate,10090.0,,50594,
7644,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627856,1,Intermediate,10090.0,,50594,
7645,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875339,1,Intermediate,10090.0,,50594,
7646,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627857,1,Intermediate,10090.0,,50594,
7647,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627858,1,Intermediate,10116.0,,50597,
7648,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627859,1,Intermediate,10116.0,,50597,
7649,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL627860,1,Intermediate,10116.0,,50597,
7650,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627019,1,Intermediate,10116.0,,50597,
7651,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627020,1,Intermediate,10116.0,,50597,
7652,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627021,1,Intermediate,10116.0,,50597,
7653,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627022,1,Intermediate,10116.0,,50597,
7654,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627023,1,Intermediate,10116.0,,50597,
7655,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627024,1,Intermediate,10116.0,,50597,
7656,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627025,1,Intermediate,10116.0,,50597,
7657,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627026,1,Intermediate,10116.0,,50597,
7658,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627027,1,Intermediate,10116.0,,50597,
7659,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL627028,1,Intermediate,10116.0,,50597,
7660,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627029,1,Intermediate,10116.0,,50597,
7661,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627030,1,Intermediate,10116.0,,50597,
7662,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627031,1,Intermediate,10116.0,,50597,
7663,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627032,1,Intermediate,10116.0,,50597,
7664,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627033,1,Intermediate,10116.0,,50597,
7665,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627034,1,Intermediate,10116.0,,50597,
7666,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627035,1,Intermediate,10116.0,,50597,
7667,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627036,1,Intermediate,10116.0,,50597,
7668,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL875340,1,Intermediate,10116.0,,50597,
7669,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627037,1,Intermediate,10116.0,,50597,
7670,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627038,1,Intermediate,10116.0,,50597,
7671,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627039,1,Intermediate,10116.0,,50597,
7672,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627040,1,Intermediate,10116.0,,50597,
7673,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624663,1,Intermediate,10116.0,,50597,
7674,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL625963,1,Intermediate,10116.0,,50597,
7675,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL876799,1,Intermediate,10116.0,,50597,
7676,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626133,1,Intermediate,10116.0,,50597,
7677,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626134,1,Intermediate,10116.0,,50597,
7678,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626135,1,Intermediate,10116.0,,50597,
7679,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626136,1,Intermediate,10116.0,,50597,
7680,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626137,1,Intermediate,10116.0,,50597,
7681,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626138,1,Intermediate,10116.0,,50597,
7682,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626139,1,Intermediate,10116.0,,50597,
7683,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626140,1,Intermediate,10116.0,,50597,
7684,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626141,1,Intermediate,10116.0,,50597,
7685,C24h in rat p.o. at 20 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626142,1,Intermediate,10116.0,,50597,
7686,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627930,1,Intermediate,10116.0,,50597,
7687,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627931,1,Intermediate,10116.0,,50597,
7688,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627932,1,Intermediate,10116.0,,50597,
7689,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627933,1,Intermediate,10116.0,,50597,
7690,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627934,1,Intermediate,10116.0,,50597,
7691,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627935,1,Intermediate,10116.0,,50597,
7692,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627936,1,Intermediate,10116.0,,50597,
7693,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627937,1,Intermediate,10116.0,,50597,
7694,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627938,1,Intermediate,10116.0,,50597,
7695,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627939,1,Intermediate,10116.0,,50597,
7696,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627940,1,Intermediate,10116.0,,50597,
7697,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627941,1,Intermediate,10116.0,,50597,
7698,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL876800,1,Intermediate,10116.0,,50597,
7699,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627942,1,Intermediate,10116.0,,50597,
7700,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627943,1,Intermediate,10116.0,,50597,
7701,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627944,1,Intermediate,10116.0,,50597,
7702,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627945,1,Intermediate,10116.0,,50597,
7703,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628584,1,Intermediate,10116.0,,50597,
7704,Biodistribution in rat blood in the presence of GdDTPA at 15 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628585,1,Intermediate,10116.0,,50597,
7705,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628586,1,Intermediate,10116.0,,50597,
7706,Biodistribution in rat blood in the presence of GdDTPA at 30 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628587,1,Intermediate,10116.0,,50597,
7707,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628588,1,Intermediate,10116.0,,50597,
7708,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628589,1,Intermediate,10116.0,,50597,
7709,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625304,1,Intermediate,10116.0,,50597,
7710,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625305,1,Intermediate,10116.0,,50597,
7711,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625306,1,Intermediate,10116.0,,50597,
7712,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625307,1,Intermediate,10116.0,,50597,
7713,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625308,1,Intermediate,10116.0,,50597,
7714,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627740,1,Intermediate,10116.0,,50597,
7715,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627741,1,Intermediate,10116.0,,50597,
7716,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627742,1,Intermediate,10116.0,,50597,
7717,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627743,1,Intermediate,10116.0,,50597,
7718,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627744,1,Intermediate,10116.0,,50597,
7719,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627745,1,Intermediate,10116.0,,50597,
7720,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627746,1,Intermediate,10116.0,,50597,
7721,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627747,1,Intermediate,10116.0,,50597,
7722,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL876810,1,Intermediate,10116.0,,50597,
7723,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627748,1,Intermediate,10116.0,,50597,
7724,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627749,1,Intermediate,10116.0,,50597,
7725,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627750,1,Intermediate,10116.0,,50597,
7726,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618728,1,Intermediate,10116.0,,50597,
7727,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618729,1,Intermediate,10116.0,,50597,
7728,Biodistribution in rat bone in the presence of GdDTPA at 15 min,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618730,1,Intermediate,10116.0,,50597,
7729,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618731,1,Intermediate,10116.0,,50597,
7730,Biodistribution in rat bone in the presence of GdDTPA at 30 min,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618732,1,Intermediate,10116.0,,50597,
7731,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618733,1,Intermediate,10116.0,,50597,
7732,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618734,1,Intermediate,10116.0,,50597,
7733,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618735,1,Intermediate,10116.0,,50597,
7734,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL876602,1,Intermediate,10116.0,,50597,
7735,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618736,1,Intermediate,10116.0,,50597,
7736,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618737,1,Intermediate,10116.0,,50597,
7737,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618738,1,Intermediate,10116.0,,50597,
7738,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618739,1,Intermediate,10116.0,,50597,
7739,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618740,1,Intermediate,10116.0,,50597,
7740,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618741,1,Intermediate,10116.0,,50597,
7741,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618742,1,Intermediate,10116.0,,50597,
7742,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL618743,1,Intermediate,10116.0,,50597,
7743,Half-life from rat plasma at a single oral dose of 25 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618744,1,Intermediate,10116.0,,50597,
7744,Half-life in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618745,1,Intermediate,10116.0,,50597,
7745,Half-life in rat after peroral administration at 10 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620479,1,Intermediate,10116.0,,50597,
7746,Half-life in rat after peroral administration at 5 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620480,1,Intermediate,10116.0,,50597,
7747,Half-life in rat at a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620481,1,Intermediate,10116.0,,50597,
7748,Half-life was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620482,1,Intermediate,10116.0,,50597,
7749,Half-life was measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876603,1,Intermediate,10116.0,,50597,
7750,Half-life period for the compound was determined in rats at 50 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620483,1,Intermediate,10116.0,,50597,
7751,Half-life period in rats after intravenous administration at 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620484,1,Intermediate,10116.0,,50597,
7752,Half-life period in rat at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620485,1,Intermediate,10116.0,,50597,
7753,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620486,1,Intermediate,10116.0,,50597,
7754,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620487,1,Intermediate,10116.0,,50597,
7755,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620488,1,Intermediate,10116.0,,50597,
7756,Half-life time in rat the dose of 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620489,1,Intermediate,10116.0,,50597,
7757,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620490,1,Intermediate,10116.0,,50597,
7758,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620491,1,Intermediate,10116.0,,50597,
7759,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876604,1,Intermediate,10116.0,,50597,
7760,Oral half life was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620492,1,Intermediate,10116.0,,50597,
7761,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620493,1,Intermediate,10116.0,,50597,
7762,Pharmacokinetic property (t1/2) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620494,1,Intermediate,10116.0,,50597,
7763,Plasma elimination half-life was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620495,1,Intermediate,10116.0,,50597,
7764,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620496,1,Intermediate,10116.0,,50597,
7765,Plasma half life was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620497,1,Intermediate,10116.0,,50597,
7766,Plasma half-life was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620498,1,Intermediate,10116.0,,50597,
7767,Plasma half-life following oral administration in Fisher rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620499,1,Intermediate,10116.0,,50597,
7768,Plasma half-life in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620500,1,Intermediate,10116.0,,50597,
7769,Plasmatic Half-life after intravenous administration to rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873809,1,Intermediate,10116.0,,50597,
7770,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620501,1,Intermediate,10116.0,,50597,
7771,Terminal half life after intravenous administration (1 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620502,1,Intermediate,10116.0,,50597,
7772,Terminal half life in Rat at a oral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620503,1,Intermediate,10116.0,,50597,
7773,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620504,1,Intermediate,10116.0,,50597,
7774,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876605,1,Intermediate,10116.0,,50597,
7775,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620505,1,Intermediate,10116.0,,50597,
7776,plasma half life was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873811,1,Intermediate,10116.0,,50597,
7777,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624016,1,Expert,10116.0,,50597,
7778,Half life of compound determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624017,1,Intermediate,10116.0,,50597,
7779,Mean residence time determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624018,1,Intermediate,10116.0,,50597,
7780,Plasma half life determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624019,1,Intermediate,10116.0,,50597,
7781,Compound was evaluated for Tmax in brain after intravenous administration in male rats,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624020,1,Intermediate,10116.0,,50597,
7782,Compound was evaluated for pharmacokinetic parameter maximum time period,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624201,1,Intermediate,10116.0,,50597,
7783,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL872528,1,Intermediate,10116.0,,50597,
7784,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624202,1,Intermediate,10116.0,,50597,
7785,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624203,1,Intermediate,10116.0,,50597,
7786,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624350,1,Intermediate,10116.0,,50597,
7787,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621320,1,Intermediate,10116.0,,50597,
7788,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621321,1,Intermediate,10116.0,,50597,
7789,Maximum time (Tmax) required to reach Cmax in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621322,1,Intermediate,10116.0,,50597,
7790,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621323,1,Intermediate,10116.0,,50597,
7791,Maximum time of clearance of compound in rats after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621324,1,Intermediate,10116.0,,50597,
7792,Maximum time at the dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621325,1,Intermediate,10116.0,,50597,
7793,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875837,1,Intermediate,10116.0,,50597,
7794,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621326,1,Intermediate,10116.0,,50597,
7795,Tmax in Guinea pig (PO dose),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621327,1,Intermediate,10116.0,,50597,
7796,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621328,1,Intermediate,10116.0,,50597,
7797,Pharmacokinetic parameter (Tmax) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621329,1,Intermediate,10116.0,,50597,
7798,Pharmacokinetic parameter (Tmax) was estimated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621330,1,Intermediate,10116.0,,50597,
7799,Pharmacokinetic property (Tmax) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621331,1,Intermediate,10116.0,,50597,
7800,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621332,1,Intermediate,10116.0,,50597,
7801,T max in Rat at a oral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621333,1,Intermediate,10116.0,,50597,
7802,T max was determined at 10 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621334,1,Intermediate,10116.0,,50597,
7803,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621335,1,Intermediate,10090.0,,50594,
7804,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621336,1,Intermediate,9615.0,,50588,
7805,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621337,1,Intermediate,10116.0,,50597,
7806,Area under curve was measured after i.v. administration into Beagle dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621338,1,Intermediate,9615.0,,50588,
7807,Area under curve was measured after iv administration into Beagle dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875838,1,Intermediate,9615.0,,50588,
7808,Area under curve was measured after po administration into Beagle dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621339,1,Intermediate,9615.0,,50588,
7809,Area under curve was measured after po administration into Beagle dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621340,1,Intermediate,9615.0,,50588,
7810,Area under curve was measured at peroral dose of 3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL621341,0,Autocuration,,,22224,
7811,Area under curve was measured by using concentration Vs time,1,U,,,,,,,,,BAO_0000019,CHEMBL621342,0,Autocuration,,,22224,
7812,Area under curve was measured by using concentration Vs time; not tested,1,U,,,,,,,,,BAO_0000019,CHEMBL621343,0,Autocuration,,,22224,
7813,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621344,1,Intermediate,10090.0,,50594,
7814,Area under curve(AUC) was measured in mice after oral administration.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621345,1,Intermediate,10090.0,,50594,
7815,Area under curve(AUC) value of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL621346,0,Autocuration,,,22224,
7816,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,1,U,,,,,,,,,BAO_0000218,CHEMBL621347,0,Autocuration,,,22224,
7817,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621348,1,Intermediate,9615.0,,50588,
7818,Area under curve(carotid artery) was determined by the availability in blood,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL621349,0,Autocuration,,,22224,
7819,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL621350,0,Autocuration,,,22224,
7820,Area under curve(carotid artery) was determined by the availability in blood; No data,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL875839,0,Autocuration,,,22224,
7821,Area under curve(portal vein) was determined by the availability in blood,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL620211,0,Autocuration,,,22224,
7822,Area under curve(portal vein) was determined by the availability in blood; ND means no data,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL620212,0,Autocuration,,,22224,
7823,Area under curve(portal vein) was determined by the availability in blood; No data,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL620213,0,Autocuration,,,22224,
7824,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,N,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620214,1,Intermediate,9544.0,,50797,
7825,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,N,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620215,1,Intermediate,9544.0,,50797,
7826,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1,N,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620216,1,Intermediate,9544.0,,50797,
7827,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620888,1,Intermediate,9615.0,,50588,
7828,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620889,1,Intermediate,9615.0,,50588,
7829,Area under plasma concentration vs time curve observed in rats for 0-3 h,1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL620890,0,Autocuration,,,22224,
7830,Area under plasma time curve determined in male rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL620891,1,Intermediate,10116.0,,50597,
7831,Area under the MAP curve measured over 5 min.,1,U,,,,,,,,,BAO_0000019,CHEMBL620892,0,Autocuration,,,22224,
7832,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621079,1,Intermediate,10090.0,,50594,
7833,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL621080,1,Intermediate,10090.0,,50594,
7834,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621081,1,Intermediate,9615.0,,50588,
7835,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL621082,1,Intermediate,10026.0,,100712,
7836,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621083,1,Intermediate,10116.0,,50597,
7837,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621084,1,Intermediate,9615.0,,50588,
7838,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621085,1,Intermediate,9615.0,,50588,
7839,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621086,1,Intermediate,9615.0,,50588,
7840,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621087,1,Intermediate,9615.0,,50588,
7841,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622607,1,Intermediate,9615.0,,50588,
7842,Serum AUC in marmosets (IV dose),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622608,1,Intermediate,9615.0,,50588,
7843,Area under the curve after intravenous administration at a dose of 10 umol/kg,1,U,,,,,,,,,BAO_0000019,CHEMBL624481,0,Autocuration,,,22224,
7844,Area under the curve after intravenous administration at a dose of 2 umol/kg,1,U,,,,,,,,,BAO_0000019,CHEMBL624482,0,Autocuration,,,22224,
7845,Area under the curve after intravenous administration at a dose of 4 umol/kg,1,U,,,,,,,,,BAO_0000019,CHEMBL624483,0,Autocuration,,,22224,
7846,Area under the curve after intravenous administration at a dose of 40 umol/kg,1,U,,,,,,,,,BAO_0000019,CHEMBL624484,0,Autocuration,,,22224,
7847,Area under the curve after intravenous administration at a dose of 5 umol/kg,1,U,,,,,,,,,BAO_0000019,CHEMBL624485,0,Autocuration,,,22224,
7848,Area under the curve for fumarate salt was evaluated in F344 Rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624486,1,Intermediate,10116.0,,50597,
7849,Area under the curve for the compound was calculated.,1,U,,,,,,,,,BAO_0000019,CHEMBL624487,0,Autocuration,,,22224,
7850,Area under the curve in concentration/ time,1,U,,,,,,,,,BAO_0000019,CHEMBL624488,0,Autocuration,,,22224,
7851,Area under the curve administered intraintestinal in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624489,1,Intermediate,10116.0,,50597,
7852,Area under the curve administered intravenously in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625184,1,Intermediate,10116.0,,50597,
7853,Area under the curve during intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL625185,0,Autocuration,,,22224,
7854,Area under the curve during intravenous administration; Not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL875954,0,Autocuration,,,22224,
7855,Area under the curve during systemic administration,1,U,,,,,,,,,BAO_0000019,CHEMBL625186,0,Autocuration,,,22224,
7856,Area under the curve during systemic administration; Not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL625187,0,Autocuration,,,22224,
7857,Area under the curve was calculated for the compound.,1,U,,,,,,,,,BAO_0000019,CHEMBL625188,0,Autocuration,,,22224,
7858,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625189,1,Intermediate,9615.0,,50588,
7859,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625190,1,Intermediate,9615.0,,50588,
7860,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621733,1,Intermediate,10116.0,,50597,
7861,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621734,1,Intermediate,10116.0,,50597,
7862,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621735,1,Intermediate,10116.0,,50597,
7863,Clearance of the drug was measured in the plasma of rat; No data,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621736,1,Intermediate,10116.0,,50597,
7864,The pharmacokinetic parameter plasma clearance in vivo in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621737,1,Intermediate,10116.0,,50597,
7865,Plasma clearance at the dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621738,1,Intermediate,10116.0,,50597,
7866,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622806,1,Intermediate,10116.0,,50597,
7867,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623519,1,Intermediate,10116.0,,50597,
7868,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623520,1,Intermediate,10116.0,,50597,
7869,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623521,1,Intermediate,10116.0,,50597,
7870,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623522,1,Intermediate,10116.0,,50597,
7871,Clearance rate in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623523,1,Intermediate,10116.0,,50597,
7872,Clearance rate in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623690,1,Intermediate,10116.0,,50597,
7873,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623691,1,Intermediate,10116.0,,50597,
7874,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623692,1,Intermediate,10116.0,,50597,
7875,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623693,1,Intermediate,10116.0,,50597,
7876,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623694,1,Intermediate,10116.0,,50597,
7877,Clearance of compound after iv administration of 20 mg/kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623695,1,Intermediate,10116.0,,50597,
7878,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623696,1,Intermediate,10116.0,,50597,
7879,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623697,1,Intermediate,10116.0,,50597,
7880,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,U,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623698,0,Intermediate,9544.0,,22224,
7881,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1,U,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623699,0,Intermediate,10116.0,,22224,
7882,Mean (%CV) PK parameters for CL(mL/min/kg).,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623700,1,Intermediate,10116.0,,50597,
7883,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623701,1,Intermediate,10116.0,,50597,
7884,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623702,1,Intermediate,10116.0,,50597,
7885,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623703,1,Intermediate,10116.0,,50597,
7886,Plasma clearance in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623704,1,Intermediate,10116.0,,50597,
7887,Plasma clearance in rat after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623705,1,Intermediate,10116.0,,50597,
7888,Plasma clearance in rat after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623706,1,Intermediate,10116.0,,50597,
7889,Plasma clearance was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623707,1,Intermediate,10116.0,,50597,
7890,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623708,1,Intermediate,10116.0,,50597,
7891,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623709,1,Intermediate,10116.0,,50597,
7892,Plasma clearance in rat by iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623710,1,Intermediate,10116.0,,50597,
7893,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623711,1,Intermediate,10116.0,,50597,
7894,Plasma clearance in rat p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623712,1,Intermediate,10116.0,,50597,
7895,Plasma clearance in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623713,1,Intermediate,10116.0,,50597,
7896,Plasma clearance was determined; ND denotes no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623714,1,Intermediate,10116.0,,50597,
7897,Plasma clearance was determined; ND denotes not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623715,1,Intermediate,10116.0,,50597,
7898,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623716,1,Intermediate,10116.0,,50597,
7899,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622980,1,Intermediate,10116.0,,50597,
7900,Plasma administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622981,1,Intermediate,10116.0,,50597,
7901,Plasma clearance of the compound in female Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622982,1,Intermediate,10116.0,,50597,
7902,Plasma clearance was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622983,1,Intermediate,10116.0,,50597,
7903,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622984,1,Intermediate,10116.0,,50597,
7904,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622985,1,Intermediate,10116.0,,50597,
7905,plasma clearance was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623631,1,Intermediate,10116.0,,50597,
7906,In vivo CL/F determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623632,1,Intermediate,10116.0,,50597,
7907,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623633,1,Intermediate,10116.0,,50597,
7908,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623634,1,Intermediate,10116.0,,50597,
7909,Compound was tested for the lower blood clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623635,1,Intermediate,10116.0,,50597,
7910,Evaluated for the low clearance in rat (in vivo),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621195,1,Intermediate,10116.0,,50597,
7911,Pharmacokinetic property (CLb)of the compound was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621196,1,Intermediate,10116.0,,50597,
7912,Rapid clearance after intravenous administration in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875287,1,Intermediate,10116.0,,50597,
7913,Clearance measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621197,1,Intermediate,10116.0,,50597,
7914,Compound was evaluated for plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621198,1,Intermediate,10116.0,,50597,
7915,Low plasma clearance was calculated in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621199,1,Intermediate,10116.0,,50597,
7916,Pharmacokinetic property (Clp) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621200,1,Intermediate,10116.0,,50597,
7917,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621201,1,Intermediate,10116.0,,50597,
7918,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621202,1,Intermediate,10116.0,,50597,
7919,Plasma clearance after IV dosing at 0.5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621203,1,Intermediate,10116.0,,50597,
7920,Plasma clearance after IV dosing at 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621204,1,Intermediate,10116.0,,50597,
7921,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621205,1,Intermediate,10116.0,,50597,
7922,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621206,1,Intermediate,10116.0,,50597,
7923,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621207,1,Intermediate,10116.0,,50597,
7924,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621208,1,Intermediate,10116.0,,50597,
7925,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621209,1,Intermediate,10116.0,,50597,
7926,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL876484,1,Intermediate,10116.0,,50597,
7927,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621210,1,Intermediate,10116.0,,50597,
7928,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621211,1,Intermediate,10116.0,,50597,
7929,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621212,1,Intermediate,10116.0,,50597,
7930,Biodistribution in rat heart in the presence of GdDTPA at 15 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621213,1,Intermediate,10116.0,,50597,
7931,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621214,1,Intermediate,10116.0,,50597,
7932,Biodistribution in rat heart in the presence of GdDTPA at 30 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621215,1,Intermediate,10116.0,,50597,
7933,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621216,1,Intermediate,10116.0,,50597,
7934,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621217,1,Intermediate,10116.0,,50597,
7935,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621218,1,Intermediate,10116.0,,50597,
7936,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621219,1,Intermediate,10116.0,,50597,
7937,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621220,1,Intermediate,10116.0,,50597,
7938,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621221,1,Intermediate,10116.0,,50597,
7939,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621222,1,Intermediate,10116.0,,50597,
7940,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621223,1,Intermediate,10116.0,,50597,
7941,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL876485,1,Intermediate,10116.0,,50597,
7942,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621224,1,Intermediate,10116.0,,50597,
7943,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621225,1,Intermediate,10116.0,,50597,
7944,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621226,1,Intermediate,10116.0,,50597,
7945,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621227,1,Intermediate,10116.0,,50597,
7946,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621228,1,Intermediate,10116.0,,50597,
7947,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621229,1,Intermediate,10116.0,,50597,
7948,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621230,1,Intermediate,10116.0,,50597,
7949,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621231,1,Intermediate,10116.0,,50597,
7950,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621232,1,Intermediate,10116.0,,50597,
7951,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621233,1,Intermediate,10116.0,,50597,
7952,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621234,1,Intermediate,10116.0,,50597,
7953,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621235,1,Intermediate,10116.0,,50597,
7954,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621236,1,Intermediate,10116.0,,50597,
7955,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621237,1,Intermediate,10116.0,,50597,
7956,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL876486,1,Intermediate,10116.0,,50597,
7957,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622436,1,Intermediate,10116.0,,50597,
7958,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622437,1,Intermediate,10116.0,,50597,
7959,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622438,1,Intermediate,10116.0,,50597,
7960,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622439,1,Intermediate,10116.0,,50597,
7961,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622440,1,Intermediate,10116.0,,50597,
7962,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622441,1,Intermediate,10116.0,,50597,
7963,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622442,1,Intermediate,10116.0,,50597,
7964,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622443,1,Intermediate,10116.0,,50597,
7965,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622444,1,Intermediate,10116.0,,50597,
7966,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622445,1,Intermediate,10116.0,,50597,
7967,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622446,1,Intermediate,10116.0,,50597,
7968,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622447,1,Intermediate,10116.0,,50597,
7969,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622448,1,Intermediate,10116.0,,50597,
7970,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622449,1,Intermediate,10116.0,,50597,
7971,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622450,1,Intermediate,10116.0,,50597,
7972,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622451,1,Intermediate,10116.0,,50597,
7973,Biodistribution in rat liver in the presence of GdDTPA at 15 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622452,1,Intermediate,10116.0,,50597,
7974,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622453,1,Intermediate,10116.0,,50597,
7975,Biodistribution in rat liver in the presence of GdDTPA at 30 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622454,1,Intermediate,10116.0,,50597,
7976,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622455,1,Intermediate,10116.0,,50597,
7977,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL876024,1,Intermediate,10116.0,,50597,
7978,T max was determined at 3 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622456,1,Intermediate,10116.0,,50597,
7979,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622457,1,Intermediate,10116.0,,50597,
7980,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622458,1,Intermediate,10116.0,,50597,
7981,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622459,1,Intermediate,10116.0,,50597,
7982,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873343,1,Intermediate,10116.0,,50597,
7983,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622460,1,Intermediate,10116.0,,50597,
7984,Time for maximum plasma concentration determined in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622461,1,Intermediate,10116.0,,50597,
7985,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622462,1,Intermediate,10116.0,,50597,
7986,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622463,1,Intermediate,10116.0,,50597,
7987,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622464,1,Intermediate,10116.0,,50597,
7988,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622465,1,Intermediate,10116.0,,50597,
7989,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622466,1,Intermediate,10116.0,,50597,
7990,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622467,1,Intermediate,10116.0,,50597,
7991,Time of maximum plasma concentration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622468,1,Intermediate,10116.0,,50597,
7992,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876025,1,Intermediate,10116.0,,50597,
7993,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622469,1,Intermediate,10116.0,,50597,
7994,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622470,1,Intermediate,10116.0,,50597,
7995,Time required to reach maximum concentration (Cmax) after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622471,1,Intermediate,10116.0,,50597,
7996,Time required to reach maximum concentration in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622472,1,Intermediate,10116.0,,50597,
7997,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622473,1,Intermediate,10116.0,,50597,
7998,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624282,1,Intermediate,10116.0,,50597,
7999,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624283,1,Intermediate,10116.0,,50597,
8000,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624284,1,Intermediate,10116.0,,50597,
8001,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624285,1,Intermediate,10116.0,,50597,
8002,Time to reach Cmax after oral administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624286,1,Intermediate,10116.0,,50597,
8003,Time to reach Cmax when a dose of 1 mg/kg is administered orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624287,1,Intermediate,10116.0,,50597,
8004,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624288,1,Intermediate,10116.0,,50597,
8005,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624289,1,Intermediate,10116.0,,50597,
8006,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873344,1,Intermediate,10116.0,,50597,
8007,Tmax after peroral administration (10 mg/kg) was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619623,1,Intermediate,10116.0,,50597,
8008,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621399,1,Expert,10116.0,,50597,
8009,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621400,1,Intermediate,10116.0,,50597,
8010,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621401,1,Intermediate,10116.0,,50597,
8011,Tmax was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621402,1,Intermediate,10116.0,,50597,
8012,Tmax was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621403,1,Intermediate,10116.0,,50597,
8013,Tmax after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621121,1,Intermediate,10116.0,,50597,
8014,Tmax after peroral administration in rats at 2.4 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL872525,1,Intermediate,10116.0,,50597,
8015,Tmax in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621122,1,Intermediate,10116.0,,50597,
8016,Tmax in rat at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621123,1,Intermediate,10116.0,,50597,
8017,Tmax in rat by po administration at a dose of 40 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621124,1,Intermediate,10116.0,,50597,
8018,Tmax in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621125,1,Intermediate,10116.0,,50597,
8019,Tmax was measured in rats after peroral administration at 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621126,1,Intermediate,10116.0,,50597,
8020,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621127,1,Intermediate,10116.0,,50597,
8021,Tmax value after administration of 20 mg/Kg oral dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621128,1,Intermediate,10116.0,,50597,
8022,Tmax value at a dose of 10 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618263,1,Intermediate,10116.0,,50597,
8023,Tmax value at a dose of 100 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618264,1,Intermediate,10116.0,,50597,
8024,Tmax value at a dose of 50 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618265,1,Intermediate,10116.0,,50597,
8025,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618266,1,Intermediate,10116.0,,50597,
8026,time required to reach maximum concentration (Cmax) after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618267,1,Intermediate,10116.0,,50597,
8027,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618450,1,Intermediate,10116.0,,50597,
8028,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618451,1,Intermediate,10116.0,,50597,
8029,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618452,1,Intermediate,10116.0,,50597,
8030,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618453,1,Intermediate,10116.0,,50597,
8031,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618454,1,Intermediate,10116.0,,50597,
8032,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL618455,1,Intermediate,10116.0,,50597,
8033,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618456,1,Intermediate,10116.0,,50597,
8034,Compound distribution in rat tissues was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618457,1,Intermediate,10116.0,,50597,
8035,Volume of distribution was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618458,1,Intermediate,10116.0,,50597,
8036,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618459,1,Intermediate,10116.0,,50597,
8037,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876733,1,Intermediate,10116.0,,50597,
8038,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL618460,1,Intermediate,9615.0,,50588,
8039,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618461,1,Intermediate,10116.0,,50597,
8040,Area under the curve was determined after oral administration (300 uM/Kg),1,U,,,,,,,,,BAO_0000019,CHEMBL618462,0,Autocuration,,,22224,
8041,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618463,1,Intermediate,10116.0,,50597,
8042,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618464,1,Intermediate,10116.0,,50597,
8043,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618465,1,Intermediate,10116.0,,50597,
8044,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618466,1,Intermediate,10116.0,,50597,
8045,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618467,1,Intermediate,10116.0,,50597,
8046,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618468,1,Intermediate,10116.0,,50597,
8047,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618469,1,Intermediate,9615.0,,50588,
8048,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618470,1,Intermediate,9615.0,,50588,
8049,Plasma drug AUC in rat (PO dose),1,U,,,,,,,,,BAO_0000218,CHEMBL618471,0,Autocuration,,,22224,
8050,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618472,1,Intermediate,10090.0,,50594,
8051,Area under was determined at a dose of 30 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL618473,0,Autocuration,,,22224,
8052,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL621699,1,Intermediate,9669.0,,50506,
8053,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621700,1,Intermediate,10116.0,,50597,
8054,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621701,1,Intermediate,10116.0,,50597,
8055,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL621702,1,Intermediate,9669.0,,50506,
8056,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621703,1,Intermediate,9615.0,,50588,
8057,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL621704,1,Intermediate,9615.0,,50588,
8058,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624259,1,Intermediate,10116.0,,50597,
8059,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624260,1,Intermediate,10116.0,,50597,
8060,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624430,1,Intermediate,10116.0,,50597,
8061,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624431,1,Intermediate,10116.0,,50597,
8062,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624432,1,Intermediate,10116.0,,50597,
8063,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624433,1,Intermediate,10116.0,,50597,
8064,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624434,1,Intermediate,10116.0,,50597,
8065,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624435,1,Intermediate,10116.0,,50597,
8066,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618570,1,Intermediate,10090.0,,50594,
8067,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618571,1,Intermediate,10090.0,,50594,
8068,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618572,1,Intermediate,10090.0,,50594,
8069,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618573,1,Intermediate,10090.0,,50594,
8070,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619267,1,Intermediate,10090.0,,50594,
8071,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619431,1,Intermediate,10090.0,,50594,
8072,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619432,1,Intermediate,10090.0,,50594,
8073,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619433,1,Intermediate,10090.0,,50594,
8074,AUC in mice after oral dose (50 mg/kg),1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL619434,0,Autocuration,,,22224,
8075,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1,N,,Mus musculus,,,,Serum,,1977.0,BAO_0000218,CHEMBL619435,1,Intermediate,10090.0,,50594,
8076,AUC (0-4 hr) ug/ml/h,1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL619436,0,Autocuration,,,22224,
8077,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619437,1,Intermediate,10116.0,,50597,
8078,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,1,U,,,,,,,,,BAO_0000218,CHEMBL619438,0,Autocuration,,,22224,
8079,Compound was evaluated for Area under curve in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619439,1,Intermediate,10090.0,,50594,
8080,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619440,1,Intermediate,10116.0,,50597,
8081,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,U,,,,,,,,,BAO_0000218,CHEMBL619441,0,Autocuration,,,22224,
8082,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619442,1,Intermediate,10116.0,,50597,
8083,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,1,U,,,,,,,,,BAO_0000019,CHEMBL875156,0,Autocuration,,,22224,
8084,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,1,U,,,,,,,,,BAO_0000019,CHEMBL619443,0,Autocuration,,,22224,
8085,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,1,U,,,,,,,,,BAO_0000019,CHEMBL619444,0,Autocuration,,,22224,
8086,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,1,U,,,,,,,,,BAO_0000019,CHEMBL623464,0,Autocuration,,,22224,
8087,Compound was evaluated for area under curve when administered through oral route in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623465,1,Intermediate,10090.0,,50594,
8088,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623466,1,Intermediate,10116.0,,50597,
8089,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623467,1,Intermediate,10116.0,,50597,
8090,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623468,1,Intermediate,10116.0,,50597,
8091,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622660,1,Intermediate,10116.0,,50597,
8092,Plasma clearance rate in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622661,1,Intermediate,10116.0,,50597,
8093,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622662,1,Intermediate,10116.0,,50597,
8094,Pharmacokinetic property (total body clearance) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622663,1,Intermediate,10116.0,,50597,
8095,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622664,1,Intermediate,10116.0,,50597,
8096,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622665,1,Intermediate,10116.0,,50597,
8097,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622666,1,Intermediate,10116.0,,50597,
8098,Cl in rat i.v. at 2 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621615,1,Intermediate,10116.0,,50597,
8099,Clearance of compound after intravenous administration in rats at 24 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621616,1,Intermediate,10116.0,,50597,
8100,Clearance was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621617,1,Intermediate,10116.0,,50597,
8101,Clearance by intravenous administration of 3.4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621618,1,Intermediate,10116.0,,50597,
8102,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621619,1,Intermediate,10116.0,,50597,
8103,Clearance rate after i.v. administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621620,1,Intermediate,10116.0,,50597,
8104,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621786,1,Intermediate,10116.0,,50597,
8105,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621787,1,Intermediate,10116.0,,50597,
8106,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621788,1,Intermediate,10116.0,,50597,
8107,Clearance (Cl) after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621789,1,Intermediate,10116.0,,50597,
8108,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621790,1,Intermediate,10116.0,,50597,
8109,Compound was tested for plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621791,1,Intermediate,10116.0,,50597,
8110,In vitro microsome metabolism clearance in rat was determined,1,N,,Rattus norvegicus,,Microsomes,,,,,BAO_0000218,CHEMBL621792,1,Intermediate,10116.0,,50597,
8111,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,1,N,,Rattus norvegicus,,Microsomes,,,,,BAO_0000218,CHEMBL621793,1,Intermediate,10116.0,,50597,
8112,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621794,1,Intermediate,10116.0,,50597,
8113,In vivo plasma clearance was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621795,1,Intermediate,10116.0,,50597,
8114,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621796,1,Intermediate,10116.0,,50597,
8115,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,1,N,,Rattus norvegicus,,,,Liver,Hepatocyte,2107.0,BAO_0000218,CHEMBL621797,1,Intermediate,10116.0,,50597,401.0
8116,Pharmacokinetic property (Plasma clearance) was measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621798,1,Intermediate,10116.0,,50597,
8117,Pharmacokinetic property (clearance) in rat i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621799,1,Intermediate,10116.0,,50597,
8118,"Plasma Clearance was evaluated in rats, iv",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621800,1,Intermediate,10116.0,,50597,
8119,Plasma clearance (in vivo) in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621801,1,Intermediate,10116.0,,50597,
8120,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621802,1,Intermediate,10116.0,,50597,
8121,Plasma clearance was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618596,1,Intermediate,10116.0,,50597,
8122,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618597,1,Intermediate,10116.0,,50597,
8123,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618598,1,Intermediate,10116.0,,50597,
8124,Plasma clearance in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618599,1,Intermediate,10116.0,,50597,
8125,Plasma clearance rate determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618600,1,Intermediate,10116.0,,50597,
8126,Plasma clearance was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618601,1,Intermediate,10116.0,,50597,
8127,Plasma clearance was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618602,1,Intermediate,10116.0,,50597,
8128,Plasma clearance value in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618603,1,Intermediate,10116.0,,50597,
8129,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618604,1,Intermediate,10116.0,,50597,
8130,Clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618605,1,Intermediate,10116.0,,50597,
8131,Total body clearance in rat i.v. at 2 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618606,1,Intermediate,10116.0,,50597,
8132,Clearance of compound in rats after intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618607,1,Intermediate,10116.0,,50597,
8133,Clearance after iv administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618608,1,Intermediate,10116.0,,50597,
8134,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618609,1,Intermediate,10116.0,,50597,
8135,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618610,1,Intermediate,10116.0,,50597,
8136,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618611,1,Intermediate,10116.0,,50597,
8137,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618612,1,Intermediate,10116.0,,50597,
8138,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618613,1,Intermediate,10116.0,,50597,
8139,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621076,1,Intermediate,10116.0,,50597,
8140,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621077,1,Intermediate,10116.0,,50597,
8141,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621078,1,Intermediate,10116.0,,50597,
8142,Clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621251,1,Intermediate,10116.0,,50597,
8143,Clearance in rat after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621252,1,Intermediate,10116.0,,50597,
8144,Clearance in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621253,1,Intermediate,10116.0,,50597,
8145,Clearance rate following an oral dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621254,1,Intermediate,10116.0,,50597,
8146,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621255,1,Intermediate,10116.0,,50597,
8147,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621256,1,Intermediate,10116.0,,50597,
8148,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621257,1,Intermediate,10116.0,,50597,
8149,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621258,1,Intermediate,10116.0,,50597,
8150,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621259,1,Intermediate,10116.0,,50597,
8151,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621260,1,Intermediate,10116.0,,50597,
8152,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL876494,1,Intermediate,10116.0,,50597,
8153,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621261,1,Intermediate,10116.0,,50597,
8154,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621262,1,Intermediate,10116.0,,50597,
8155,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621263,1,Intermediate,10116.0,,50597,
8156,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621264,1,Intermediate,10116.0,,50597,
8157,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621265,1,Intermediate,10116.0,,50597,
8158,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621266,1,Intermediate,10116.0,,50597,
8159,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621267,1,Intermediate,10116.0,,50597,
8160,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621268,1,Intermediate,10116.0,,50597,
8161,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621269,1,Intermediate,10116.0,,50597,
8162,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621270,1,Intermediate,10116.0,,50597,
8163,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621271,1,Intermediate,10116.0,,50597,
8164,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621272,1,Intermediate,10116.0,,50597,
8165,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621273,1,Intermediate,10116.0,,50597,
8166,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621274,1,Intermediate,10116.0,,50597,
8167,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL876495,1,Intermediate,10116.0,,50597,
8168,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621275,1,Intermediate,10116.0,,50597,
8169,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621276,1,Intermediate,10116.0,,50597,
8170,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621277,1,Intermediate,10116.0,,50597,
8171,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621278,1,Intermediate,10116.0,,50597,
8172,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621279,1,Intermediate,10116.0,,50597,
8173,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621280,1,Intermediate,10116.0,,50597,
8174,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621281,1,Intermediate,10116.0,,50597,
8175,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621282,1,Intermediate,10116.0,,50597,
8176,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621283,1,Intermediate,10116.0,,50597,
8177,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621284,1,Intermediate,10116.0,,50597,
8178,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621285,1,Intermediate,10116.0,,50597,
8179,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621286,1,Intermediate,10116.0,,50597,
8180,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL623220,1,Intermediate,10116.0,,50597,
8181,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL623221,1,Intermediate,10116.0,,50597,
8182,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL876029,1,Intermediate,10116.0,,50597,
8183,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL623222,1,Intermediate,10116.0,,50597,
8184,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL623223,1,Intermediate,10116.0,,50597,
8185,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL621445,1,Intermediate,10116.0,,50597,
8186,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621446,1,Intermediate,10116.0,,50597,
8187,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621447,1,Intermediate,10116.0,,50597,
8188,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL619681,1,Intermediate,10116.0,,50597,
8189,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL619682,1,Intermediate,10116.0,,50597,
8190,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL619683,1,Intermediate,10116.0,,50597,
8191,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619684,1,Intermediate,10116.0,,50597,
8192,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619685,1,Intermediate,10116.0,,50597,
8193,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619686,1,Intermediate,10116.0,,50597,
8194,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619687,1,Intermediate,10116.0,,50597,
8195,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619688,1,Intermediate,10116.0,,50597,
8196,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL619689,1,Intermediate,10116.0,,50597,
8197,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL619690,1,Intermediate,10116.0,,50597,
8198,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL619691,1,Intermediate,10116.0,,50597,
8199,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619692,1,Intermediate,10116.0,,50597,
8200,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619693,1,Expert,10116.0,,50597,
8201,Vc value after IV dose at a dose of 5 mg/kg in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619694,1,Intermediate,10116.0,,50597,
8202,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619695,1,Intermediate,10116.0,,50597,
8203,Compound was evaluated for pharmacokinetic parameter volume of distribution,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619696,1,Intermediate,10116.0,,50597,
8204,Compound was evaluated for volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619697,1,Intermediate,10116.0,,50597,
8205,Steady state volume distribution was determined; steady state(ss),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619698,1,Intermediate,10116.0,,50597,
8206,Steady state volume of distribution after iv administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619699,1,Intermediate,10116.0,,50597,
8207,Steady state volume of distribution dosing at 3 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619700,1,Intermediate,10116.0,,50597,
8208,The compound was evaluated for volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619701,1,Intermediate,10116.0,,50597,
8209,The compound was tested for volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL619702,1,Intermediate,10116.0,,50597,
8210,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620335,1,Intermediate,10116.0,,50597,
8211,Volume distribution (VD) after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620336,1,Intermediate,10116.0,,50597,
8212,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620337,1,Intermediate,10116.0,,50597,
8213,Volume distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620520,1,Intermediate,10116.0,,50597,
8214,Volume distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620521,1,Intermediate,10116.0,,50597,
8215,Volume distribution in rat after peroral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875825,1,Intermediate,10116.0,,50597,
8216,Volume distribution in rat after peroral administration at 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620522,1,Intermediate,10116.0,,50597,
8217,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620523,1,Intermediate,10116.0,,50597,
8218,Volume of distribution in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620524,1,Intermediate,10116.0,,50597,
8219,Volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620525,1,Intermediate,10116.0,,50597,
8220,Volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620526,1,Intermediate,10116.0,,50597,
8221,Volume of distribution in rat by iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620527,1,Intermediate,10116.0,,50597,
8222,Volume of distribution in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620528,1,Intermediate,10116.0,,50597,
8223,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620529,1,Intermediate,10116.0,,50597,
8224,Volume distribution at the dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620530,1,Intermediate,10116.0,,50597,
8225,Steady state volume of distribution was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620531,1,Intermediate,10116.0,,50597,
8226,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620532,0,Intermediate,9544.0,,22224,
8227,Compound was tested for its plasma volume distribution in Sprague Dawley rats,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620533,0,Intermediate,10116.0,,22224,
8228,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620534,0,Intermediate,10116.0,,22224,
8229,Mean (%CV) PK parameters for Vdss(mL/kg).,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620535,1,Intermediate,10116.0,,50597,
8230,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875826,1,Intermediate,10116.0,,50597,
8231,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620536,1,Intermediate,10116.0,,50597,
8232,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620537,1,Intermediate,10116.0,,50597,
8233,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618526,1,Intermediate,10116.0,,50597,
8234,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618527,1,Intermediate,10116.0,,50597,
8235,Pharmacokinetic property (Vdss) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618528,1,Intermediate,10116.0,,50597,
8236,Pharmacokinetic property (vdss) was measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618529,1,Intermediate,10116.0,,50597,
8237,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618530,1,Intermediate,10116.0,,50597,
8238,Volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618531,1,Intermediate,10116.0,,50597,
8239,The pharmacokinetic parameter volume of distribution in vivo in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618532,1,Intermediate,10116.0,,50597,
8240,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618533,1,Intermediate,10116.0,,50597,
8241,Vdss in rat i.v. at 2 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618534,1,Intermediate,10116.0,,50597,
8242,Volume distribution after intravenous administration (1 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618535,1,Intermediate,10116.0,,50597,
8243,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618536,1,Intermediate,10116.0,,50597,
8244,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618537,1,Intermediate,10116.0,,50597,
8245,Volume distribution at a dose of 10 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618538,1,Intermediate,10116.0,,50597,
8246,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618539,1,Intermediate,10116.0,,50597,
8247,Volume distribution was calculated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618540,1,Intermediate,10116.0,,50597,
8248,Volume distribution was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618541,1,Intermediate,10116.0,,50597,
8249,Volume of distribution after intravenous administration was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618542,1,Intermediate,10116.0,,50597,
8250,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622544,1,Intermediate,10116.0,,50597,
8251,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622545,1,Intermediate,10116.0,,50597,
8252,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622546,1,Intermediate,10116.0,,50597,
8253,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622547,1,Intermediate,10116.0,,50597,
8254,Volume of distribution in steady state was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622548,1,Intermediate,10116.0,,50597,
8255,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622549,1,Intermediate,10116.0,,50597,
8256,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622550,1,Intermediate,10116.0,,50597,
8257,Compound was evaluated for area under curve when administered through oral route to mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622551,1,Intermediate,10090.0,,50594,
8258,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622552,1,Intermediate,10116.0,,50597,
8259,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622553,1,Intermediate,10116.0,,50597,
8260,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,1,U,,,,,,,,,BAO_0000218,CHEMBL622554,0,Autocuration,,,22224,
8261,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622555,1,Intermediate,9615.0,,50588,
8262,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622556,1,Intermediate,10090.0,,50594,
8263,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622557,1,Intermediate,10090.0,,50594,
8264,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622558,1,Intermediate,10090.0,,50594,
8265,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622559,1,Intermediate,10090.0,,50594,
8266,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622560,1,Intermediate,9615.0,,50588,
8267,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622561,1,Intermediate,10116.0,,50597,
8268,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622562,1,Intermediate,10116.0,,50597,
8269,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622563,1,Intermediate,10116.0,,50597,
8270,Concentration of compound in Central nervous system,1,U,,,,,,,,,BAO_0000019,CHEMBL622564,0,Autocuration,,,22224,
8271,Concentration of compound in Central nervous system; Not detectable,1,U,,,,,,,,,BAO_0000019,CHEMBL622565,0,Autocuration,,,22224,
8272,"Concentration of diester in the blood, following oral administration in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622566,1,Intermediate,10090.0,,50594,
8273,"Concentration of monoester in the blood, following oral administration in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624515,1,Intermediate,10090.0,,50594,
8274,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624516,1,Intermediate,10090.0,,50594,
8275,Evaluated for Pharmacokinetic property: Area under the curve,1,U,,,,,,,,,BAO_0000019,CHEMBL624517,0,Autocuration,,,22224,
8276,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624518,1,Intermediate,10090.0,,50594,
8277,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624519,1,Intermediate,9541.0,,100710,
8278,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624520,1,Intermediate,9541.0,,100710,
8279,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624521,1,Intermediate,9541.0,,100710,
8280,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624522,1,Intermediate,9541.0,,100710,
8281,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624523,1,Intermediate,9541.0,,100710,
8282,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624409,1,Intermediate,9541.0,,100710,
8283,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624410,1,Intermediate,9541.0,,100710,
8284,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL624411,1,Intermediate,9541.0,,100710,
8285,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623531,1,Intermediate,9541.0,,100710,
8286,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623532,1,Intermediate,9541.0,,100710,
8287,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623533,1,Intermediate,9541.0,,100710,
8288,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623534,1,Intermediate,9541.0,,100710,
8289,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623535,1,Intermediate,10090.0,,50594,
8290,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623536,1,Intermediate,10090.0,,50594,
8291,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623537,1,Intermediate,10090.0,,50594,
8292,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623538,1,Intermediate,10090.0,,50594,
8293,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623539,1,Intermediate,10090.0,,50594,
8294,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623540,1,Intermediate,10090.0,,50594,
8295,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623541,1,Intermediate,10090.0,,50594,
8296,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623542,1,Intermediate,10090.0,,50594,
8297,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623543,1,Intermediate,10090.0,,50594,
8298,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623544,1,Intermediate,10090.0,,50594,
8299,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623545,1,Intermediate,10090.0,,50594,
8300,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623546,1,Intermediate,10090.0,,50594,
8301,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623547,1,Intermediate,10116.0,,50597,
8302,High i.v. clearance in Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623548,1,Intermediate,10116.0,,50597,
8303,In vitro clearance in rat liver microsomes,1,N,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL623549,1,Intermediate,10116.0,,50597,
8304,Intrinsic clearance in rat liver microsomes was determined,1,N,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL623550,1,Intermediate,10116.0,,50597,
8305,Intrinsic clearance in rat hepatocytes was determined,1,N,,Rattus norvegicus,,,,Liver,Hepatocyte,2107.0,BAO_0000218,CHEMBL875276,1,Intermediate,10116.0,,50597,401.0
8306,Plasma Clearance was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621872,1,Intermediate,10116.0,,50597,
8307,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621873,1,Intermediate,10116.0,,50597,
8308,Plasma clearance in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621874,1,Intermediate,10116.0,,50597,
8309,Plasma clearance in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621875,1,Intermediate,10116.0,,50597,
8310,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621876,1,Intermediate,10116.0,,50597,
8311,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621877,1,Intermediate,10116.0,,50597,
8312,Plasma clearance was measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621878,1,Intermediate,10116.0,,50597,
8313,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621879,1,Intermediate,10116.0,,50597,
8314,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621880,1,Intermediate,10116.0,,50597,
8315,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621881,1,Intermediate,10116.0,,50597,
8316,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621882,1,Intermediate,10116.0,,50597,
8317,Total clearance at 1 mg/kg was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875283,1,Intermediate,10116.0,,50597,
8318,Total clearance at 10 mg/kg was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621883,1,Intermediate,10116.0,,50597,
8319,Clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621884,1,Intermediate,10116.0,,50597,
8320,Plasma clearance rate determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621885,1,Intermediate,10116.0,,50597,
8321,Clearance of compound in rat was evaluated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621886,1,Intermediate,10116.0,,50597,
8322,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621887,1,Intermediate,10116.0,,50597,
8323,Pharmacokinetic property (blood clearance) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621888,1,Intermediate,10116.0,,50597,
8324,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621889,1,Intermediate,10116.0,,50597,
8325,Plasma clearance in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621890,1,Intermediate,10116.0,,50597,
8326,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,1,N,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL621891,1,Intermediate,10116.0,,50597,
8327,Clearance in Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621892,1,Intermediate,10116.0,,50597,
8328,Clearance rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621893,1,Intermediate,10116.0,,50597,
8329,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621894,1,Intermediate,10116.0,,50597,
8330,Clearance rat; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621895,1,Intermediate,10116.0,,50597,
8331,Clearance rate was determined in rat at a dose of 1 mpk i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875284,1,Intermediate,10116.0,,50597,
8332,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618699,1,Intermediate,10116.0,,50597,
8333,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618700,1,Intermediate,10116.0,,50597,
8334,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618701,1,Intermediate,10116.0,,50597,
8335,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876600,1,Intermediate,10116.0,,50597,
8336,Clearance of compound in rat after 1 mg/kg i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618702,1,Intermediate,10116.0,,50597,
8337,Compound was evaluated for Hepatic clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618703,1,Intermediate,10116.0,,50597,
8338,In vivo clearance after 5 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618704,1,Intermediate,10116.0,,50597,
8339,Compound was tested for plasma clearance in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618705,1,Intermediate,10116.0,,50597,
8340,Hepatic clearance after intravenous administration was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618706,1,Intermediate,10116.0,,50597,
8341,Lower clearance in rat (i.v.) at 0.5 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618707,1,Intermediate,10116.0,,50597,
8342,Pharmacokinetic parameter expressed as plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618708,1,Intermediate,10116.0,,50597,
8343,Pharmacokinetic property (Clp) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618709,1,Intermediate,10116.0,,50597,
8344,Plasma clearance in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618710,1,Intermediate,10116.0,,50597,
8345,Plasma clearance (Clp) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618711,1,Intermediate,10116.0,,50597,
8346,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618712,1,Intermediate,10116.0,,50597,
8347,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618713,1,Intermediate,10116.0,,50597,
8348,Plasma clearance after intravenous administration of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618714,1,Intermediate,10116.0,,50597,
8349,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618715,1,Intermediate,10116.0,,50597,
8350,Plasma clearance in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618716,1,Intermediate,10116.0,,50597,
8351,Plasma clearance measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876601,1,Intermediate,10116.0,,50597,
8352,Plasma clearance was calculated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618717,1,Intermediate,10116.0,,50597,
8353,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618718,1,Intermediate,10116.0,,50597,
8354,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618719,1,Intermediate,10116.0,,50597,
8355,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618720,1,Intermediate,10116.0,,50597,
8356,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618721,1,Intermediate,10116.0,,50597,
8357,Plasma clearance in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621477,1,Intermediate,10116.0,,50597,
8358,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621478,1,Intermediate,10116.0,,50597,
8359,Plasma clearance was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621479,1,Intermediate,10116.0,,50597,
8360,Plasma clearance was evaluated in rat; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621480,1,Intermediate,10116.0,,50597,
8361,Plasma clearance rate was determined for the compound in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621481,1,Intermediate,10116.0,,50597,
8362,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621482,1,Intermediate,10116.0,,50597,
8363,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621483,1,Intermediate,10116.0,,50597,
8364,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621484,1,Intermediate,10116.0,,50597,
8365,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621485,1,Intermediate,10116.0,,50597,
8366,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL621486,1,Intermediate,10116.0,,50597,
8367,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621487,1,Intermediate,10116.0,,50597,
8368,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621488,1,Intermediate,10116.0,,50597,
8369,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621489,1,Intermediate,10116.0,,50597,
8370,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621490,1,Intermediate,10116.0,,50597,
8371,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL621491,1,Intermediate,10116.0,,50597,
8372,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621492,1,Intermediate,10116.0,,50597,
8373,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621493,1,Intermediate,10116.0,,50597,
8374,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621494,1,Intermediate,10116.0,,50597,
8375,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621495,1,Intermediate,10116.0,,50597,
8376,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621496,1,Intermediate,10116.0,,50597,
8377,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621497,1,Intermediate,10116.0,,50597,
8378,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621498,1,Intermediate,10116.0,,50597,
8379,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621499,1,Intermediate,10116.0,,50597,
8380,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618634,1,Intermediate,10116.0,,50597,
8381,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618635,1,Intermediate,10116.0,,50597,
8382,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL618636,1,Intermediate,10116.0,,50597,
8383,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL619737,1,Intermediate,10116.0,,50597,
8384,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL619738,1,Intermediate,10116.0,,50597,
8385,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624329,1,Intermediate,10116.0,,50597,
8386,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624330,1,Intermediate,10116.0,,50597,
8387,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624331,1,Intermediate,10116.0,,50597,
8388,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624332,1,Intermediate,10116.0,,50597,
8389,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624333,1,Intermediate,10116.0,,50597,
8390,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624334,1,Intermediate,10116.0,,50597,
8391,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624335,1,Intermediate,10116.0,,50597,
8392,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620016,1,Intermediate,10116.0,,50597,
8393,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620169,1,Intermediate,10116.0,,50597,
8394,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620170,1,Intermediate,10116.0,,50597,
8395,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620171,1,Intermediate,10116.0,,50597,
8396,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL620172,1,Intermediate,10116.0,,50597,
8397,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL620173,1,Intermediate,10116.0,,50597,
8398,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL620174,1,Intermediate,10116.0,,50597,
8399,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL620175,1,Intermediate,10116.0,,50597,
8400,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL620176,1,Intermediate,10116.0,,50597,
8401,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL620177,1,Intermediate,10116.0,,50597,
8402,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL620178,1,Intermediate,10116.0,,50597,
8403,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL620179,1,Intermediate,10116.0,,50597,
8404,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620180,1,Intermediate,10116.0,,50597,
8405,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620181,1,Intermediate,10116.0,,50597,
8406,Volume of distribution of compound in rats after intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620182,1,Intermediate,10116.0,,50597,
8407,Volume of distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620183,1,Intermediate,10116.0,,50597,
8408,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620184,1,Intermediate,10116.0,,50597,
8409,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620185,1,Intermediate,10116.0,,50597,
8410,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620186,1,Intermediate,10116.0,,50597,
8411,Volume of distribution was determined in Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620187,1,Intermediate,10116.0,,50597,
8412,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620188,1,Intermediate,10116.0,,50597,
8413,Volume of distribution was reported in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620189,1,Intermediate,10116.0,,50597,
8414,Volumes of distribution in rat after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620190,1,Intermediate,10116.0,,50597,
8415,Volumes of distribution in rat after po administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620191,1,Intermediate,10116.0,,50597,
8416,Volumes of distribution in rat after po administration; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620192,1,Intermediate,10116.0,,50597,
8417,Pharmacokinetic property (Volume) in rat i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620193,1,Intermediate,10116.0,,50597,
8418,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620194,1,Intermediate,10116.0,,50597,
8419,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876730,1,Intermediate,10116.0,,50597,
8420,Volume distribution in rat after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620195,1,Intermediate,10116.0,,50597,
8421,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620196,1,Intermediate,10116.0,,50597,
8422,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620197,1,Intermediate,10116.0,,50597,
8423,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620198,1,Intermediate,10116.0,,50597,
8424,Volume of distribution in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620199,1,Intermediate,10116.0,,50597,
8425,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620200,1,Intermediate,10116.0,,50597,
8426,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620201,1,Intermediate,10116.0,,50597,
8427,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620202,1,Intermediate,10116.0,,50597,
8428,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620203,1,Intermediate,10116.0,,50597,
8429,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620204,1,Intermediate,10116.0,,50597,
8430,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620205,1,Intermediate,10116.0,,50597,
8431,Pharmacokinetic parameter (Vss) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624664,1,Intermediate,10116.0,,50597,
8432,Pharmacokinetic property (Volume) in rat i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624665,1,Intermediate,10116.0,,50597,
8433,Pharmacokinetic property (Vss) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624666,1,Intermediate,10116.0,,50597,
8434,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624667,1,Intermediate,10116.0,,50597,
8435,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624668,1,Intermediate,10116.0,,50597,
8436,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624669,1,Intermediate,10116.0,,50597,
8437,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624670,1,Intermediate,10116.0,,50597,
8438,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624671,1,Intermediate,10116.0,,50597,
8439,Steady state volume distribution in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624672,1,Intermediate,10116.0,,50597,
8440,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624673,1,Intermediate,10116.0,,50597,
8441,Steady state volume of distribution determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624674,1,Intermediate,10116.0,,50597,
8442,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624675,1,Intermediate,10116.0,,50597,
8443,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621728,1,Intermediate,10116.0,,50597,
8444,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621729,1,Intermediate,10116.0,,50597,
8445,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621730,1,Intermediate,10116.0,,50597,
8446,Volume distribution in rat after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621731,1,Intermediate,10116.0,,50597,
8447,Volume distribution in rat after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621732,1,Intermediate,10116.0,,50597,
8448,Volume in steady state distribution value was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621908,1,Intermediate,10116.0,,50597,
8449,Volume in steady state distribution value was determined; ND denotes no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875347,1,Intermediate,10116.0,,50597,
8450,Volume in steady state distribution value was determined; ND denotes not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621909,1,Intermediate,10116.0,,50597,
8451,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621910,1,Intermediate,10116.0,,50597,
8452,Volume of distribution at steady state was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621911,1,Intermediate,10116.0,,50597,
8453,Volume of distribution at steady state was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621912,1,Intermediate,10116.0,,50597,
8454,Volume of distribution in steady state was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621913,1,Intermediate,10116.0,,50597,
8455,Volume of distribution in steady state was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621914,1,Intermediate,10116.0,,50597,
8456,Volume of distribution after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621915,1,Intermediate,10116.0,,50597,
8457,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621916,1,Intermediate,10116.0,,50597,
8458,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621917,1,Intermediate,10090.0,,50594,
8459,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621918,1,Intermediate,10090.0,,50594,
8460,Biodistribution of compound (oxidized form) in spleen tissue,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621919,1,Intermediate,10090.0,,50594,
8461,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621920,1,Intermediate,10090.0,,50594,
8462,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621921,1,Intermediate,10090.0,,50594,
8463,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622401,1,Intermediate,10090.0,,50594,
8464,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL875348,1,Intermediate,10090.0,,50594,
8465,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622402,1,Intermediate,10090.0,,50594,
8466,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622403,1,Intermediate,10090.0,,50594,
8467,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL622404,1,Intermediate,10090.0,,50594,
8468,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622405,1,Intermediate,10090.0,,50594,
8469,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622406,1,Intermediate,10090.0,,50594,
8470,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622407,1,Intermediate,10090.0,,50594,
8471,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622408,1,Intermediate,10090.0,,50594,
8472,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622409,1,Intermediate,10090.0,,50594,
8473,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL622410,1,Intermediate,10090.0,,50594,
8474,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622411,1,Intermediate,10090.0,,50594,
8475,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627864,1,Intermediate,10090.0,,50594,
8476,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627865,1,Intermediate,10090.0,,50594,
8477,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627866,1,Intermediate,10090.0,,50594,
8478,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627751,1,Intermediate,10090.0,,50594,
8479,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627752,1,Intermediate,10090.0,,50594,
8480,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627753,1,Intermediate,10090.0,,50594,
8481,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627754,1,Intermediate,10090.0,,50594,
8482,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627755,1,Intermediate,10090.0,,50594,
8483,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627756,1,Intermediate,10090.0,,50594,
8484,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627757,1,Intermediate,10090.0,,50594,
8485,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627758,1,Intermediate,10090.0,,50594,
8486,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627759,1,Intermediate,10090.0,,50594,
8487,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627760,1,Intermediate,10090.0,,50594,
8488,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627761,1,Intermediate,10090.0,,50594,
8489,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL876811,1,Intermediate,10090.0,,50594,
8490,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL627762,1,Intermediate,10090.0,,50594,
8491,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL627763,1,Intermediate,10090.0,,50594,
8492,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL627764,1,Intermediate,10090.0,,50594,
8493,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL627765,1,Intermediate,10090.0,,50594,
8494,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL627766,1,Intermediate,10090.0,,50594,
8495,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627767,1,Intermediate,10090.0,,50594,
8496,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627768,1,Intermediate,10090.0,,50594,
8497,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628422,1,Intermediate,10090.0,,50594,
8498,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628423,1,Intermediate,10090.0,,50594,
8499,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628424,1,Intermediate,10116.0,,50597,
8500,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628425,1,Intermediate,10116.0,,50597,
8501,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628426,1,Intermediate,10116.0,,50597,
8502,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628427,1,Intermediate,10116.0,,50597,
8503,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626938,1,Intermediate,10116.0,,50597,
8504,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626939,1,Intermediate,10116.0,,50597,
8505,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626940,1,Intermediate,10116.0,,50597,
8506,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626941,1,Intermediate,10116.0,,50597,
8507,Plasma clearance was reported in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626942,1,Intermediate,10116.0,,50597,
8508,Plasma clearance after intravenous administration (1 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876812,1,Intermediate,10116.0,,50597,
8509,Plasma clearance of compound in rats was evaluated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626943,1,Intermediate,10116.0,,50597,
8510,Plasma clearance of compound in rats was evaluated; ND indicates not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626944,1,Intermediate,10116.0,,50597,
8511,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626945,1,Intermediate,10116.0,,50597,
8512,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626946,1,Intermediate,10116.0,,50597,
8513,Plasma clearance rate in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626856,1,Intermediate,10116.0,,50597,
8514,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626857,1,Intermediate,10116.0,,50597,
8515,The compound was evaluated for plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626858,1,Intermediate,10116.0,,50597,
8516,Total plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627018,1,Intermediate,10116.0,,50597,
8517,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625331,1,Intermediate,10116.0,,50597,
8518,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625332,1,Intermediate,10116.0,,50597,
8519,C max was determined at 10 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877590,1,Intermediate,10116.0,,50597,
8520,C max was determined at 3 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625333,1,Intermediate,10116.0,,50597,
8521,Cmax after repeated oral dose of compound at 1 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625334,1,Intermediate,10116.0,,50597,
8522,Cmax after single intravenous bolus of 1 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625335,1,Intermediate,10116.0,,50597,
8523,Cmax of compound at 5 mg/kg after po administration was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625336,1,Intermediate,10116.0,,50597,
8524,Cmax 24 hr after 10 mg/kg oral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625337,1,Intermediate,10116.0,,50597,
8525,Cmax 24 hr after 2 mg/kg oral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625338,1,Intermediate,10116.0,,50597,
8526,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625339,1,Intermediate,10116.0,,50597,
8527,Cmax in rat after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625340,1,Intermediate,10116.0,,50597,
8528,Cmax in rat after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625341,1,Intermediate,10116.0,,50597,
8529,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622687,1,Intermediate,10116.0,,50597,
8530,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622688,1,Intermediate,10116.0,,50597,
8531,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622689,1,Intermediate,10116.0,,50597,
8532,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL620295,1,Intermediate,10116.0,,50597,
8533,Cmax after 10 mg/kg oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620296,1,Intermediate,10116.0,,50597,
8534,Cmax after IV dosing at 0.5 mg/kg in rat; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620297,1,Intermediate,10116.0,,50597,
8535,Cmax after IV dosing at 1 mg/kg in rat; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620298,1,Intermediate,10116.0,,50597,
8536,Cmax after oral administration at 20 mpk in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620299,1,Intermediate,10116.0,,50597,
8537,Cmax after oral administration at 20 mpk in rats; Not performed.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620300,1,Intermediate,10116.0,,50597,
8538,Cmax after oral administration at 20 mpk in rats d; Not performed.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620301,1,Intermediate,10116.0,,50597,
8539,Cmax after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620302,1,Intermediate,10116.0,,50597,
8540,Cmax after oral administration at a dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620303,1,Intermediate,10116.0,,50597,
8541,Cmax after oral administration at a dose of 4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620304,1,Intermediate,10116.0,,50597,
8542,Cmax in rats after 20 mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620305,1,Intermediate,10116.0,,50597,
8543,Cmax after peroral administration in rats at 2.4 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620306,1,Intermediate,10116.0,,50597,
8544,Cmax at the dose of 2 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620307,1,Intermediate,10116.0,,50597,
8545,Cmax at the dose of 5 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620308,1,Intermediate,10116.0,,50597,
8546,Cmax by administering at 20 mg/kg p.o. in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620309,1,Intermediate,10116.0,,50597,
8547,Cmax in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620310,1,Intermediate,10116.0,,50597,
8548,Cmax in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620311,1,Intermediate,10116.0,,50597,
8549,Cmax in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620312,1,Intermediate,10116.0,,50597,
8550,Cmax in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620313,1,Intermediate,10116.0,,50597,
8551,Cmax in rat at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620314,1,Intermediate,10116.0,,50597,
8552,Cmax in rat at the dose of 1 mg/kg i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620315,1,Intermediate,10116.0,,50597,
8553,Cmax in rat by po administration at a dose of 40 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620316,1,Intermediate,10116.0,,50597,
8554,Cmax in rat p.o. at 20 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620317,1,Intermediate,10116.0,,50597,
8555,Cmax in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620318,1,Intermediate,10116.0,,50597,
8556,Cmax in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620319,1,Intermediate,10116.0,,50597,
8557,Cmax was evaluated after 20 uM/kg of peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620320,1,Intermediate,10116.0,,50597,
8558,Cmax was measured in rats after peroral administration at 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620321,1,Intermediate,10116.0,,50597,
8559,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620322,1,Intermediate,10116.0,,50597,
8560,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620323,1,Intermediate,10116.0,,50597,
8561,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Frontal cortex,,1870.0,BAO_0000218,CHEMBL620324,1,Intermediate,10116.0,,50597,
8562,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Frontal cortex,,1870.0,BAO_0000218,CHEMBL620325,1,Intermediate,10116.0,,50597,
8563,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL620326,1,Intermediate,10116.0,,50597,
8564,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL620327,1,Intermediate,10116.0,,50597,
8565,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620328,1,Intermediate,10116.0,,50597,
8566,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620329,1,Intermediate,10116.0,,50597,
8567,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Midbrain,,1891.0,BAO_0000218,CHEMBL620330,1,Intermediate,10116.0,,50597,
8568,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Midbrain,,1891.0,BAO_0000218,CHEMBL875286,1,Intermediate,10116.0,,50597,
8569,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620331,1,Intermediate,10116.0,,50597,
8570,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620332,1,Intermediate,10116.0,,50597,
8571,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL620333,1,Intermediate,10116.0,,50597,
8572,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL620334,1,Intermediate,10116.0,,50597,
8573,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621015,1,Intermediate,10116.0,,50597,
8574,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621016,1,Intermediate,10116.0,,50597,
8575,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621191,1,Intermediate,10116.0,,50597,
8576,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621192,1,Intermediate,10116.0,,50597,
8577,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621193,1,Intermediate,10116.0,,50597,
8578,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621194,1,Intermediate,10116.0,,50597,
8579,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624204,1,Intermediate,10116.0,,50597,
8580,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624205,1,Intermediate,10116.0,,50597,
8581,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624206,1,Intermediate,10116.0,,50597,
8582,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624207,1,Intermediate,10116.0,,50597,
8583,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624208,1,Intermediate,10116.0,,50597,
8584,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624209,1,Intermediate,10116.0,,50597,
8585,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624210,1,Intermediate,10116.0,,50597,
8586,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624211,1,Intermediate,10116.0,,50597,
8587,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624212,1,Intermediate,10116.0,,50597,
8588,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624213,1,Intermediate,10116.0,,50597,
8589,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL876611,1,Intermediate,10116.0,,50597,
8590,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624214,1,Intermediate,10116.0,,50597,
8591,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624215,1,Intermediate,10116.0,,50597,
8592,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624216,1,Intermediate,10116.0,,50597,
8593,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624217,1,Intermediate,10116.0,,50597,
8594,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624218,1,Intermediate,10116.0,,50597,
8595,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624219,1,Intermediate,10116.0,,50597,
8596,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624220,1,Intermediate,10116.0,,50597,
8597,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624221,1,Intermediate,10116.0,,50597,
8598,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624222,1,Intermediate,10116.0,,50597,
8599,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624223,1,Intermediate,10116.0,,50597,
8600,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624224,1,Intermediate,10116.0,,50597,
8601,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624225,1,Intermediate,10116.0,,50597,
8602,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622420,1,Intermediate,10116.0,,50597,
8603,Volume of steady state distribution after i.v. administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622421,1,Intermediate,10116.0,,50597,
8604,Vss after intravenous administration (5.0 mg/kg) was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622422,1,Intermediate,10116.0,,50597,
8605,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622423,1,Intermediate,10116.0,,50597,
8606,Vss was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622424,1,Intermediate,10116.0,,50597,
8607,Vss in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622425,1,Intermediate,10116.0,,50597,
8608,Vss was evaluated after 10 uM/kg of intra arterial administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876612,1,Intermediate,10116.0,,50597,
8609,volume of distribution at steady state was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622426,1,Intermediate,10116.0,,50597,
8610,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622427,1,Intermediate,10116.0,,50597,
8611,Pharmacokinetic (PK) parameter Vz in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622428,1,Intermediate,10116.0,,50597,
8612,Volume distribution in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622429,1,Intermediate,10116.0,,50597,
8613,Volume of distribution in rat; No data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622430,1,Intermediate,10116.0,,50597,
8614,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622431,1,Intermediate,10116.0,,50597,
8615,% absorption predicted from in vitro rat ileum transport studies,1,N,,Rattus norvegicus,,,,Ileum,,2116.0,BAO_0000218,CHEMBL622432,1,Intermediate,10116.0,,50597,
8616,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622433,1,Intermediate,10116.0,,50597,
8617,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622434,1,Intermediate,10116.0,,50597,
8618,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622435,1,Intermediate,10116.0,,50597,
8619,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618748,1,Intermediate,10116.0,,50597,
8620,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618749,1,Intermediate,10116.0,,50597,
8621,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618750,1,Intermediate,10116.0,,50597,
8622,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618751,1,Intermediate,10116.0,,50597,
8623,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618752,1,Intermediate,10116.0,,50597,
8624,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618753,1,Intermediate,10116.0,,50597,
8625,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL618754,1,Intermediate,10116.0,,50597,
8626,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618755,1,Intermediate,10116.0,,50597,
8627,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618756,1,Intermediate,10116.0,,50597,
8628,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618757,1,Intermediate,10116.0,,50597,
8629,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618758,1,Intermediate,10116.0,,50597,
8630,Oral bioavailability in rat (dose 30 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621088,1,Intermediate,10116.0,,50597,
8631,Pharmacokinetic property (cLogP) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621089,1,Intermediate,10116.0,,50597,
8632,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621090,1,Intermediate,10116.0,,50597,
8633,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621091,1,Intermediate,10116.0,,50597,
8634,Clearance in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876731,1,Intermediate,10116.0,,50597,
8635,Compound was evaluated for its clearance when administered intravenously in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621092,1,Intermediate,10116.0,,50597,
8636,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621093,1,Intermediate,10116.0,,50597,
8637,Blood: Brain distribution ratio is determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621094,1,Intermediate,10116.0,,50597,
8638,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621095,1,Intermediate,10116.0,,50597,
8639,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621096,1,Intermediate,10116.0,,50597,
8640,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621097,1,Intermediate,10116.0,,50597,
8641,Percent dose excreted in 0-48 hours administered ip to male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621098,1,Intermediate,10116.0,,50597,
8642,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL621099,1,Intermediate,10116.0,,50597,
8643,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL621100,1,Intermediate,10116.0,,50597,
8644,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL621101,1,Intermediate,10116.0,,50597,
8645,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL621102,1,Intermediate,10116.0,,50597,
8646,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL876732,1,Intermediate,10116.0,,50597,
8647,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621103,1,Intermediate,10116.0,,50597,
8648,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621104,1,Intermediate,10116.0,,50597,
8649,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621105,1,Intermediate,10116.0,,50597,
8650,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621106,1,Intermediate,10116.0,,50597,
8651,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621107,1,Intermediate,10116.0,,50597,
8652,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621108,1,Intermediate,10116.0,,50597,
8653,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621109,1,Intermediate,10116.0,,50597,
8654,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621110,1,Intermediate,10090.0,,50594,
8655,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621111,1,Intermediate,10090.0,,50594,
8656,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622541,1,Intermediate,10090.0,,50594,
8657,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622542,1,Intermediate,10090.0,,50594,
8658,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622543,1,Intermediate,10090.0,,50594,
8659,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624412,1,Intermediate,10090.0,,50594,
8660,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624413,1,Intermediate,10090.0,,50594,
8661,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624414,1,Intermediate,10090.0,,50594,
8662,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624415,1,Intermediate,10090.0,,50594,
8663,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624416,1,Intermediate,10090.0,,50594,
8664,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624417,1,Intermediate,10090.0,,50594,
8665,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624418,1,Intermediate,10090.0,,50594,
8666,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624419,1,Intermediate,10090.0,,50594,
8667,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624420,1,Intermediate,10090.0,,50594,
8668,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624421,1,Intermediate,10090.0,,50594,
8669,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624422,1,Intermediate,10090.0,,50594,
8670,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624423,1,Intermediate,10090.0,,50594,
8671,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625123,1,Intermediate,10090.0,,50594,
8672,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625124,1,Intermediate,10090.0,,50594,
8673,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625125,1,Intermediate,10090.0,,50594,
8674,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL625126,1,Intermediate,10090.0,,50594,
8675,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL626947,1,Intermediate,10090.0,,50594,
8676,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL626948,1,Intermediate,10090.0,,50594,
8677,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL626949,1,Intermediate,10090.0,,50594,
8678,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL626950,1,Intermediate,10090.0,,50594,
8679,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL626951,1,Intermediate,10090.0,,50594,
8680,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626952,1,Intermediate,10090.0,,50594,
8681,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626953,1,Intermediate,10090.0,,50594,
8682,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626954,1,Intermediate,10090.0,,50594,
8683,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626955,1,Intermediate,10090.0,,50594,
8684,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626956,1,Intermediate,10090.0,,50594,
8685,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626957,1,Intermediate,10090.0,,50594,
8686,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626958,1,Intermediate,10090.0,,50594,
8687,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626959,1,Intermediate,10090.0,,50594,
8688,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626960,1,Intermediate,10090.0,,50594,
8689,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626961,1,Intermediate,10090.0,,50594,
8690,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL627589,1,Intermediate,10090.0,,50594,
8691,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL627590,1,Intermediate,10090.0,,50594,
8692,Time taken for EC90 was determined when tested in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627591,1,Intermediate,10090.0,,50594,
8693,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627592,1,Intermediate,10090.0,,50594,
8694,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627593,1,Intermediate,10090.0,,50594,
8695,Half life in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627594,1,Intermediate,10090.0,,50594,
8696,Half life period in mouse after 10 mg/Kg dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876813,1,Intermediate,10090.0,,50594,
8697,Half life period in mouse after 10 mg/kg dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627595,1,Intermediate,10090.0,,50594,
8698,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627596,1,Intermediate,10090.0,,50594,
8699,Cmax value at 5 mg/kg po was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627597,1,Intermediate,10116.0,,50597,
8700,Cmax value evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627598,1,Intermediate,10116.0,,50597,
8701,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL627599,1,Intermediate,10116.0,,50597,
8702,Cmax value after administration of 20 mg/Kg oral dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627600,1,Intermediate,10116.0,,50597,
8703,Cmax value at 1 mg/kg po in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627601,1,Intermediate,10116.0,,50597,
8704,Cmax value at 5 mg/kg po in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627776,1,Intermediate,10116.0,,50597,
8705,Cmax value at a dose of 10 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627777,1,Intermediate,10116.0,,50597,
8706,Cmax value at a dose of 100 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627778,1,Intermediate,10116.0,,50597,
8707,Cmax value at a dose of 50 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627779,1,Intermediate,10116.0,,50597,
8708,Cmax value in rats at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876814,1,Intermediate,10116.0,,50597,
8709,Cmax value was evaluated in rats at a dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627780,1,Intermediate,10116.0,,50597,
8710,Cmax value was determined after peroral administration of 20 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627781,1,Intermediate,10116.0,,50597,
8711,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627782,1,Intermediate,10116.0,,50597,
8712,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627783,1,Intermediate,10116.0,,50597,
8713,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627784,1,Intermediate,10116.0,,50597,
8714,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627785,1,Intermediate,10116.0,,50597,
8715,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627786,1,Intermediate,10116.0,,50597,
8716,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627787,1,Intermediate,10116.0,,50597,
8717,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627788,1,Intermediate,10116.0,,50597,
8718,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626579,1,Intermediate,10116.0,,50597,
8719,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626580,1,Intermediate,10116.0,,50597,
8720,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876815,1,Intermediate,10116.0,,50597,
8721,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626581,1,Intermediate,10116.0,,50597,
8722,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626582,1,Intermediate,10116.0,,50597,
8723,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626583,1,Intermediate,10116.0,,50597,
8724,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626205,1,Intermediate,10116.0,,50597,
8725,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626206,1,Intermediate,10116.0,,50597,
8726,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626207,1,Intermediate,10116.0,,50597,
8727,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623882,1,Intermediate,10116.0,,50597,
8728,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623883,1,Intermediate,10116.0,,50597,
8729,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623884,1,Intermediate,10116.0,,50597,
8730,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623885,1,Intermediate,10116.0,,50597,
8731,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623886,1,Intermediate,10116.0,,50597,
8732,Maximal concentration in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623887,1,Intermediate,10116.0,,50597,
8733,Maximal concentration after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623888,1,Intermediate,10116.0,,50597,
8734,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623889,1,Intermediate,10116.0,,50597,
8735,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623890,1,Intermediate,10116.0,,50597,
8736,Cmax in rat plasma after oral dose (50 mg/Kg),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623891,1,Intermediate,10116.0,,50597,
8737,Maximal plasma concentration was determined.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623892,1,Intermediate,10116.0,,50597,
8738,Maximal plasma drug concentration was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623893,1,Intermediate,10116.0,,50597,
8739,Maximal concentration in rats after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877616,1,Intermediate,10116.0,,50597,
8740,Maximum concentration in rat after 2 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623894,1,Intermediate,10116.0,,50597,
8741,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623895,1,Intermediate,10116.0,,50597,
8742,Maximum concentration of compound in rat was evaluated.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623896,1,Intermediate,10116.0,,50597,
8743,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623897,1,Intermediate,10116.0,,50597,
8744,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623898,1,Intermediate,10116.0,,50597,
8745,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623899,1,Intermediate,10116.0,,50597,
8746,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623900,1,Intermediate,10116.0,,50597,
8747,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623901,1,Intermediate,10116.0,,50597,
8748,Maximum concentration was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623902,1,Intermediate,10116.0,,50597,
8749,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1,N,,Rattus norvegicus,,,,Cerebrospinal fluid,,1359.0,BAO_0000218,CHEMBL623903,1,Intermediate,10116.0,,50597,
8750,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623904,1,Intermediate,10116.0,,50597,
8751,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL877617,1,Intermediate,10116.0,,50597,
8752,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623905,1,Intermediate,10116.0,,50597,
8753,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623906,1,Intermediate,10116.0,,50597,
8754,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623907,1,Intermediate,10116.0,,50597,
8755,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623908,1,Intermediate,10116.0,,50597,
8756,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623909,1,Intermediate,10116.0,,50597,
8757,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623910,1,Intermediate,10116.0,,50597,
8758,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623911,1,Intermediate,10116.0,,50597,
8759,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623912,1,Intermediate,10116.0,,50597,
8760,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624616,1,Intermediate,10116.0,,50597,
8761,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624617,1,Intermediate,10116.0,,50597,
8762,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624618,1,Intermediate,10116.0,,50597,
8763,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624619,1,Intermediate,10116.0,,50597,
8764,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624794,1,Intermediate,10116.0,,50597,
8765,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624795,1,Intermediate,10116.0,,50597,
8766,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623921,1,Intermediate,10116.0,,50597,
8767,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623922,1,Intermediate,10116.0,,50597,
8768,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623923,1,Intermediate,10116.0,,50597,
8769,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623924,1,Intermediate,10116.0,,50597,
8770,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623925,1,Intermediate,10116.0,,50597,
8771,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623926,1,Intermediate,10116.0,,50597,
8772,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623927,1,Intermediate,10116.0,,50597,
8773,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623928,1,Intermediate,10116.0,,50597,
8774,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623929,1,Intermediate,10116.0,,50597,
8775,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623930,1,Intermediate,10116.0,,50597,
8776,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623931,1,Intermediate,10116.0,,50597,
8777,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622165,1,Intermediate,10116.0,,50597,
8778,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621249,1,Intermediate,10116.0,,50597,
8779,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621250,1,Intermediate,10116.0,,50597,
8780,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621448,1,Intermediate,10116.0,,50597,
8781,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621449,1,Intermediate,10116.0,,50597,
8782,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621450,1,Intermediate,10116.0,,50597,
8783,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621451,1,Intermediate,10116.0,,50597,
8784,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621452,1,Intermediate,10116.0,,50597,
8785,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621453,1,Intermediate,10116.0,,50597,
8786,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621454,1,Intermediate,10116.0,,50597,
8787,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621455,1,Intermediate,10116.0,,50597,
8788,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621456,1,Intermediate,10116.0,,50597,
8789,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625145,1,Intermediate,10116.0,,50597,
8790,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL875847,1,Intermediate,10116.0,,50597,
8791,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625146,1,Intermediate,10116.0,,50597,
8792,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625147,1,Intermediate,10116.0,,50597,
8793,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625148,1,Intermediate,10116.0,,50597,
8794,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625149,1,Intermediate,10116.0,,50597,
8795,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625150,1,Intermediate,10116.0,,50597,
8796,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625151,1,Intermediate,10116.0,,50597,
8797,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625152,1,Intermediate,10116.0,,50597,
8798,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625153,1,Intermediate,10116.0,,50597,
8799,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625154,1,Intermediate,10116.0,,50597,
8800,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625155,1,Intermediate,10116.0,,50597,
8801,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625156,1,Intermediate,10116.0,,50597,
8802,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624354,1,Intermediate,10116.0,,50597,
8803,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL624355,1,Intermediate,10116.0,,50597,
8804,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL624356,1,Intermediate,10116.0,,50597,
8805,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL624357,1,Intermediate,10116.0,,50597,
8806,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL624358,1,Intermediate,10116.0,,50597,
8807,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL624359,1,Intermediate,10116.0,,50597,
8808,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL624360,1,Intermediate,10116.0,,50597,
8809,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL624361,1,Intermediate,10116.0,,50597,
8810,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL624362,1,Intermediate,10116.0,,50597,
8811,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL624363,1,Intermediate,10116.0,,50597,
8812,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624364,1,Intermediate,10116.0,,50597,
8813,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624365,1,Intermediate,10116.0,,50597,
8814,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624366,1,Intermediate,10116.0,,50597,
8815,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624367,1,Intermediate,10116.0,,50597,
8816,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624368,1,Intermediate,10116.0,,50597,
8817,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624369,1,Intermediate,10116.0,,50597,
8818,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624370,1,Intermediate,10116.0,,50597,
8819,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625069,1,Intermediate,10116.0,,50597,
8820,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625070,1,Intermediate,10116.0,,50597,
8821,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626051,1,Intermediate,10116.0,,50597,
8822,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626052,1,Intermediate,10116.0,,50597,
8823,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626053,1,Intermediate,10116.0,,50597,
8824,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626054,1,Intermediate,10116.0,,50597,
8825,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626055,1,Intermediate,10116.0,,50597,
8826,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626056,1,Intermediate,10116.0,,50597,
8827,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626057,1,Intermediate,10116.0,,50597,
8828,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625193,1,Intermediate,10116.0,,50597,
8829,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625194,1,Intermediate,10116.0,,50597,
8830,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625195,1,Intermediate,10116.0,,50597,
8831,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625196,1,Intermediate,10116.0,,50597,
8832,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625197,1,Intermediate,10116.0,,50597,
8833,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625198,1,Intermediate,10116.0,,50597,
8834,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627929,1,Intermediate,10116.0,,50597,
8835,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627074,1,Intermediate,10116.0,,50597,
8836,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627075,1,Intermediate,10116.0,,50597,
8837,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627076,1,Intermediate,10116.0,,50597,
8838,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627077,1,Intermediate,10116.0,,50597,
8839,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627078,1,Intermediate,10116.0,,50597,
8840,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627079,1,Intermediate,10116.0,,50597,
8841,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL873824,1,Intermediate,10090.0,,50594,
8842,Half life in mouse plasma was determined at dose 25 mg/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627080,1,Intermediate,10090.0,,50594,
8843,Half life was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627081,1,Intermediate,10090.0,,50594,
8844,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627082,1,Intermediate,10090.0,,50594,
8845,Half-life in male mice after 1 mg/kg intravenous dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627083,1,Intermediate,10090.0,,50594,
8847,Half life in mice plasma,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627085,1,Intermediate,10090.0,,50594,
8848,Half life in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627086,1,Intermediate,10090.0,,50594,
8849,Half life in mouse plasma at dose 25 mg/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627087,1,Intermediate,10090.0,,50594,
8850,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627088,1,Intermediate,10090.0,,50594,
8851,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627089,1,Intermediate,10090.0,,50594,
8852,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627090,1,Intermediate,10090.0,,50594,
8853,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627091,1,Intermediate,10090.0,,50594,
8854,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627092,1,Intermediate,10090.0,,50594,
8855,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876785,1,Intermediate,10090.0,,50594,
8856,Half-life by iv administration in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627093,1,Intermediate,10090.0,,50594,
8857,Half-life by oral administration in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627094,1,Intermediate,10090.0,,50594,
8858,Half-life in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627095,1,Intermediate,10090.0,,50594,
8859,Half-life using mouse brain homogenate,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627096,1,Intermediate,10090.0,,50594,
8860,Half-life was measured in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627097,1,Intermediate,10090.0,,50594,
8861,Half-life was measured in mouse after an iv dose of 1 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627098,1,Intermediate,10090.0,,50594,
8862,Half-life period was determined in mouse blood,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL627099,1,Intermediate,10090.0,,50594,
8863,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL627100,1,Intermediate,10090.0,,50594,
8864,Plasma half life in mouse,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627101,1,Intermediate,10090.0,,50594,
8865,Stability of the peptide in the presence of mouse serum,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627102,1,Intermediate,10090.0,,50594,
8866,Terminal half life of compound was determined in mouse,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627103,1,Intermediate,10090.0,,50594,
8867,Terminal half life was evaluated in mice after intravenous administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627104,1,Intermediate,10090.0,,50594,
8868,Terminal half life was evaluated in mice after oral administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627105,1,Intermediate,10090.0,,50594,
8869,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876786,1,Intermediate,10090.0,,50594,
8870,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL873825,1,Intermediate,10090.0,,50594,
8871,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627106,1,Intermediate,10090.0,,50594,
8872,half life period is evaluated by administering intravenously at 25 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626336,1,Intermediate,10090.0,,50594,
8873,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL877462,1,Intermediate,10090.0,,50594,
8874,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626337,1,Intermediate,10090.0,,50594,
8875,Half life after intraperitoneal administration of 100 mg/kg in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626338,1,Intermediate,10090.0,,50594,
8876,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626339,1,Intermediate,10090.0,,50594,
8877,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626340,1,Intermediate,10090.0,,50594,
8878,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625377,1,Intermediate,10090.0,,50594,
8879,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625378,1,Intermediate,10090.0,,50594,
8880,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625379,1,Intermediate,10090.0,,50594,
8881,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),1,U,,Sus scrofa,,Microsomes,,,,,BAO_0000251,CHEMBL625380,0,Autocuration,9823.0,,22224,
8882,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),1,U,,Sus scrofa,,Microsomes,,,,,BAO_0000251,CHEMBL625381,0,Autocuration,9823.0,,22224,
8883,Stability to porcine renal DHP-I,1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL625382,0,Autocuration,9823.0,,22224,
8884,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,1,U,,Sus scrofa,,,,,,,BAO_0000218,CHEMBL873828,0,Autocuration,9823.0,,22224,
8885,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,1,U,,Sus scrofa,,,,,,,BAO_0000218,CHEMBL625383,0,Autocuration,9823.0,,22224,
8886,Half-life of the parent prodrug in porcine esterase solution,1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL625384,0,Autocuration,9823.0,,22224,
8887,"First order rate constant, k was determined in in pig liver Esterase",1,U,,Sus scrofa,,,,,,,BAO_0000019,CHEMBL625385,0,Autocuration,9823.0,,22224,
8888,Half life of the in pig liver Esterase,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL625386,0,Autocuration,9823.0,,22224,
8889,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623571,0,Autocuration,9823.0,,22224,
8890,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623572,0,Autocuration,9823.0,,22224,
8891,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623573,0,Autocuration,9823.0,,22224,
8892,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623574,0,Autocuration,9823.0,,22224,
8893,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623575,0,Autocuration,9823.0,,22224,
8894,Half-life in the presence of pig liver esterase(PLE) was evaluated.,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623749,0,Autocuration,9823.0,,22224,
8895,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623750,0,Autocuration,9823.0,,22224,
8896,Half-life in vitro in pig liver,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623751,0,Autocuration,9823.0,,22224,
8897,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,1,U,,Sus scrofa,,,,Liver,,2107.0,BAO_0000221,CHEMBL623752,0,Autocuration,9823.0,,22224,
8898,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623753,1,Intermediate,10116.0,,50597,
8899,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623754,1,Intermediate,10116.0,,50597,
8900,Maximum concentration in rat plasma was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623755,1,Intermediate,10116.0,,50597,
8901,Maximum concentration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623756,1,Intermediate,10116.0,,50597,
8902,Maximum concentration in rats at 1-2 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623757,1,Intermediate,10116.0,,50597,
8903,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623758,1,Intermediate,10116.0,,50597,
8904,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623759,1,Intermediate,10116.0,,50597,
8905,Maximum concentration at the dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623760,1,Intermediate,10116.0,,50597,
8906,Maximum concentration was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623761,1,Intermediate,10116.0,,50597,
8907,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623762,1,Intermediate,10116.0,,50597,
8908,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL877594,1,Intermediate,10116.0,,50597,
8909,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623763,1,Intermediate,10116.0,,50597,
8910,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623764,1,Intermediate,10116.0,,50597,
8911,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623765,1,Intermediate,10116.0,,50597,
8912,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623766,1,Intermediate,10116.0,,50597,
8913,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623767,1,Intermediate,10116.0,,50597,
8914,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623768,1,Intermediate,10116.0,,50597,
8915,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623769,1,Intermediate,10116.0,,50597,
8916,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623770,1,Intermediate,10116.0,,50597,
8917,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623771,1,Intermediate,10116.0,,50597,
8918,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623772,1,Intermediate,10116.0,,50597,
8919,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623773,1,Intermediate,10116.0,,50597,
8920,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623774,1,Intermediate,10116.0,,50597,
8921,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623775,1,Intermediate,10116.0,,50597,
8922,Cmax in rat (PO dose),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623776,1,Intermediate,10116.0,,50597,
8923,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622191,1,Intermediate,10116.0,,50597,
8924,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622192,1,Intermediate,10116.0,,50597,
8925,Maximum plasma concentration determined in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622193,1,Intermediate,10116.0,,50597,
8926,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622194,1,Intermediate,10116.0,,50597,
8927,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622195,1,Intermediate,10116.0,,50597,
8928,Maximum plasma concentration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622196,1,Intermediate,10116.0,,50597,
8929,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622197,1,Intermediate,10116.0,,50597,
8930,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622198,1,Intermediate,10116.0,,50597,
8931,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622199,1,Intermediate,10116.0,,50597,
8932,Maximum plasma concentration of compound was measured in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622200,1,Intermediate,10116.0,,50597,
8933,Maximum plasma concentration after 20 mg/kg oral administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622201,1,Intermediate,10116.0,,50597,
8934,Maximum plasma concentration after oral administration to rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623990,1,Intermediate,10116.0,,50597,
8935,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623991,1,Intermediate,10116.0,,50597,
8936,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623992,1,Intermediate,10116.0,,50597,
8937,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623993,1,Intermediate,10116.0,,50597,
8938,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623994,1,Intermediate,10116.0,,50597,
8939,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623995,1,Intermediate,10116.0,,50597,
8940,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623996,1,Intermediate,10116.0,,50597,
8941,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623997,1,Intermediate,10116.0,,50597,
8942,Maximum plasma concentration dosed orally in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623998,1,Intermediate,10116.0,,50597,
8943,Maximum plasma concentration dosed orally in rats after 6 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623999,1,Intermediate,10116.0,,50597,
8944,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624000,1,Intermediate,10116.0,,50597,
8945,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624001,1,Intermediate,10116.0,,50597,
8946,Maximum plasma concentration in rat after po administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624002,1,Intermediate,10116.0,,50597,
8947,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624003,1,Intermediate,10116.0,,50597,
8948,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624004,1,Intermediate,10116.0,,50597,
8949,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624005,1,Intermediate,10116.0,,50597,
8950,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624006,1,Intermediate,10116.0,,50597,
8951,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624007,1,Intermediate,10116.0,,50597,
8952,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624008,1,Intermediate,10116.0,,50597,
8953,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624009,1,Intermediate,10116.0,,50597,
8954,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL874387,1,Intermediate,10116.0,,50597,
8955,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624010,1,Intermediate,10116.0,,50597,
8956,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624011,1,Intermediate,10116.0,,50597,
8957,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624012,1,Intermediate,10116.0,,50597,
8958,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624013,1,Intermediate,10116.0,,50597,
8959,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624736,1,Intermediate,10116.0,,50597,
8960,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624737,1,Intermediate,10116.0,,50597,
8961,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624738,1,Intermediate,10116.0,,50597,
8962,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624739,1,Intermediate,10116.0,,50597,
8963,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624740,1,Intermediate,10116.0,,50597,
8964,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624896,1,Intermediate,10116.0,,50597,
8965,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624897,1,Intermediate,10116.0,,50597,
8966,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624108,1,Intermediate,10116.0,,50597,
8967,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624109,1,Intermediate,10116.0,,50597,
8968,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624110,1,Intermediate,10116.0,,50597,
8969,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624111,1,Intermediate,10116.0,,50597,
8970,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624112,1,Intermediate,10116.0,,50597,
8971,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624113,1,Intermediate,10116.0,,50597,
8972,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL619709,1,Intermediate,10116.0,,50597,
8973,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL619710,1,Intermediate,10116.0,,50597,
8974,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619711,1,Intermediate,10116.0,,50597,
8975,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619712,1,Intermediate,10116.0,,50597,
8976,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619713,1,Intermediate,10116.0,,50597,
8977,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619714,1,Intermediate,10116.0,,50597,
8978,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619715,1,Intermediate,10116.0,,50597,
8979,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619716,1,Intermediate,10116.0,,50597,
8980,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619717,1,Intermediate,10116.0,,50597,
8981,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619718,1,Intermediate,10116.0,,50597,
8982,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619719,1,Intermediate,10116.0,,50597,
8983,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL875329,1,Intermediate,10116.0,,50597,
8984,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619720,1,Intermediate,10116.0,,50597,
8985,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619721,1,Intermediate,10116.0,,50597,
8986,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619722,1,Intermediate,10116.0,,50597,
8987,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619723,1,Intermediate,10116.0,,50597,
8988,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619724,1,Intermediate,10116.0,,50597,
8989,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619725,1,Intermediate,10116.0,,50597,
8990,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619726,1,Intermediate,10116.0,,50597,
8991,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619727,1,Intermediate,10116.0,,50597,
8992,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619728,1,Intermediate,10116.0,,50597,
8993,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL619729,1,Intermediate,10116.0,,50597,
8994,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL619730,1,Intermediate,10116.0,,50597,
8995,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL619731,1,Intermediate,10116.0,,50597,
8996,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL619732,1,Intermediate,10116.0,,50597,
8997,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL619733,1,Intermediate,10116.0,,50597,
8998,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL619734,1,Intermediate,10116.0,,50597,
8999,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL619735,1,Intermediate,10116.0,,50597,
9000,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL875330,1,Intermediate,10116.0,,50597,
9001,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL628465,1,Intermediate,10116.0,,50597,
9002,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL628466,1,Intermediate,10116.0,,50597,
9003,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL628467,1,Intermediate,10116.0,,50597,
9004,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL628468,1,Intermediate,10116.0,,50597,
9005,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL628469,1,Intermediate,10116.0,,50597,
9006,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL628470,1,Intermediate,10116.0,,50597,
9007,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL628471,1,Intermediate,10116.0,,50597,
9008,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL628472,1,Intermediate,10116.0,,50597,
9009,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL625191,1,Intermediate,10116.0,,50597,
9010,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL625192,1,Intermediate,10116.0,,50597,
9011,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL875337,1,Intermediate,10116.0,,50597,
9012,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626341,1,Intermediate,10116.0,,50597,
9013,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626342,1,Intermediate,10116.0,,50597,
9014,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621943,1,Intermediate,10116.0,,50597,
9015,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621944,1,Intermediate,10116.0,,50597,
9016,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621945,1,Intermediate,10116.0,,50597,
9017,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621946,1,Intermediate,10116.0,,50597,
9018,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621947,1,Intermediate,10116.0,,50597,
9019,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621948,1,Intermediate,10116.0,,50597,
9020,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621949,1,Intermediate,10116.0,,50597,
9021,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621950,1,Intermediate,10116.0,,50597,
9022,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621951,1,Intermediate,10116.0,,50597,
9023,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621952,1,Intermediate,10116.0,,50597,
9024,Stability (%) in rat liver microsomes,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621953,1,Intermediate,10116.0,,50597,
9025,Area under curve was calculated after intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621954,1,Intermediate,10116.0,,50597,
9026,Area under the curve was calculated after iv administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621955,1,Intermediate,10116.0,,50597,
9027,Area under the curve was calculated in rat after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621956,1,Intermediate,10116.0,,50597,
9028,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621957,1,Intermediate,10116.0,,50597,
9029,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621958,1,Intermediate,10116.0,,50597,
9030,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621959,1,Intermediate,10116.0,,50597,
9031,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621960,1,Intermediate,10116.0,,50597,
9032,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621961,1,Intermediate,10116.0,,50597,
9033,p value of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621962,1,Intermediate,10116.0,,50597,
9034,p value of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876787,1,Intermediate,10116.0,,50597,
9035,p value of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621963,1,Intermediate,10116.0,,50597,
9036,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL622637,1,Intermediate,10116.0,,50597,
9037,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL622638,1,Intermediate,10116.0,,50597,
9038,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL626561,1,Intermediate,10116.0,,50597,
9039,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL626562,0,Autocuration,9986.0,,22224,
9040,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626563,0,Autocuration,9986.0,,22224,
9041,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626564,0,Autocuration,9986.0,,22224,
9042,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626565,0,Autocuration,9986.0,,22224,
9043,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626566,0,Autocuration,9986.0,,22224,
9044,Clearance rate in rabbits,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626567,0,Autocuration,9986.0,,22224,
9045,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626568,0,Autocuration,9986.0,,22224,
9046,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626569,0,Autocuration,9986.0,,22224,
9047,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626570,0,Autocuration,9986.0,,22224,
9048,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626571,0,Autocuration,9986.0,,22224,
9049,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626572,0,Autocuration,9986.0,,22224,
9050,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,U,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626573,0,Autocuration,9986.0,,22224,
9051,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,1,U,,Oryctolagus cuniculus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL626574,0,Autocuration,9986.0,,22224,
9052,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,1,U,,Oryctolagus cuniculus,,Microsomes,,Liver,,2107.0,BAO_0000251,CHEMBL626575,0,Autocuration,9986.0,,22224,
9053,Dose at which bioavailability of intravenously administered compound was tested in rabbit,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626576,0,Autocuration,9986.0,,22224,
9054,Dose at which bioavailability of perorally administered compound was tested in rabbit,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626577,0,Autocuration,9986.0,,22224,
9055,The compound was tested for its bioavailability in rabbit (by oral dosage).,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626578,0,Autocuration,9986.0,,22224,
9056,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625263,0,Autocuration,9986.0,,22224,
9057,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625264,0,Autocuration,9986.0,,22224,
9058,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625265,0,Autocuration,9986.0,,22224,
9059,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),1,U,,Oryctolagus cuniculus,,Microsomes,,,,,BAO_0000251,CHEMBL625266,0,Autocuration,9986.0,,22224,
9060,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),1,U,,Oryctolagus cuniculus,,Microsomes,,,,,BAO_0000251,CHEMBL876796,0,Autocuration,9986.0,,22224,
9061,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625267,0,Autocuration,9986.0,,22224,
9062,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,U,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625268,0,Autocuration,9986.0,,22224,
9063,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,U,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625269,0,Autocuration,9986.0,,22224,
9064,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,U,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624689,0,Autocuration,9986.0,,22224,
9065,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL624690,0,Autocuration,9986.0,,22224,
9066,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1,U,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624691,0,Autocuration,9986.0,,22224,
9067,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1,U,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624692,0,Autocuration,9986.0,,22224,
9068,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL624693,0,Autocuration,9986.0,,22224,
9069,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL624694,0,Autocuration,9986.0,,22224,
9070,In vitro Biological half-life in crude homogenate of rabbit renal cortex,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000221,CHEMBL877596,0,Autocuration,9986.0,,22224,
9071,Time within which only 10% of the drug was degraded,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL624695,0,Autocuration,9986.0,,22224,
9072,Half life period in rabbit liver homogenate,1,U,,Oryctolagus cuniculus,,,,Liver,,2107.0,BAO_0000221,CHEMBL624696,0,Autocuration,9986.0,,22224,
9073,Half life value in rabbits,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000019,CHEMBL624697,0,Autocuration,9986.0,,22224,
9074,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,U,,Oryctolagus cuniculus,,,,Blood,,178.0,BAO_0000218,CHEMBL624698,0,Autocuration,9986.0,,22224,
9075,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,U,,Oryctolagus cuniculus,,,,Blood,,178.0,BAO_0000218,CHEMBL624699,0,Autocuration,9986.0,,22224,
9076,Half-life period in rabbits following intravenous administration at 2 mg/kg,1,U,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL624700,0,Autocuration,9986.0,,22224,
9077,AUC 0-8 hr value in rats at 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622903,1,Intermediate,10116.0,,50597,
9078,AUC after administration at 2000 mg/kg/day in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622904,1,Intermediate,10116.0,,50597,
9079,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622905,1,Intermediate,10116.0,,50597,
9080,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622906,1,Intermediate,10116.0,,50597,
9081,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622907,1,Intermediate,10116.0,,50597,
9082,AUC in rat after oral administration at 10.5 mg/kg dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622908,1,Intermediate,10116.0,,50597,
9083,AUC in rat after oral administration at 11.2 mg/kg dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622909,1,Intermediate,10116.0,,50597,
9084,AUC in rat after oral administration at 9.7 mg/kg dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622910,1,Intermediate,10116.0,,50597,
9085,AUC in rat brain after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622911,1,Intermediate,10116.0,,50597,
9086,AUC in rat p.o.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622912,1,Intermediate,10116.0,,50597,
9087,AUC in rat p.o. at 20 mg/kg concentration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622913,1,Intermediate,10116.0,,50597,
9088,AUC in rat plasma after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622914,1,Intermediate,10116.0,,50597,
9089,AUC in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622915,1,Intermediate,10116.0,,50597,
9090,AUC value after IV dose at a dose of 5 mg/kg in rats.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622916,1,Intermediate,10116.0,,50597,
9091,AUC value after oral dose at a dose of 10 mg/kg in rats.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622917,1,Intermediate,10116.0,,50597,
9092,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622918,1,Intermediate,10116.0,,50597,
9093,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622919,1,Intermediate,10116.0,,50597,
9094,Maximum plasma concentration was evaluated in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622920,1,Intermediate,10116.0,,50597,
9095,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622921,1,Intermediate,10116.0,,50597,
9096,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622922,1,Intermediate,10116.0,,50597,
9097,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622923,1,Intermediate,10116.0,,50597,
9098,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL877604,1,Intermediate,10116.0,,50597,
9099,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622924,1,Intermediate,10116.0,,50597,
9100,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622925,1,Intermediate,10116.0,,50597,
9101,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622926,1,Intermediate,10116.0,,50597,
9102,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623625,1,Intermediate,10116.0,,50597,
9103,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623626,1,Expert,10116.0,,50597,
9104,Maximum plasma drug concentration was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623627,1,Intermediate,10116.0,,50597,
9105,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623628,1,Intermediate,10116.0,,50597,
9106,Mean peak plasma concentration was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623629,1,Intermediate,10116.0,,50597,
9107,Mean peak plasma concentration was observed after oral administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623630,1,Intermediate,10116.0,,50597,
9108,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623804,1,Intermediate,10116.0,,50597,
9109,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623805,1,Intermediate,10116.0,,50597,
9110,Peak oral plasma concentration was determined in rats by oral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623806,1,Intermediate,10116.0,,50597,
9111,Peak plasma concentration (Cmax) was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623807,1,Intermediate,10116.0,,50597,
9112,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623808,1,Intermediate,10116.0,,50597,
9113,Peak plasma concentration (Cmax) in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623809,1,Intermediate,10116.0,,50597,
9114,Peak plasma concentration at 1 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623810,1,Intermediate,10116.0,,50597,
9115,Peak plasma concentration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623811,1,Intermediate,10116.0,,50597,
9116,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623812,1,Intermediate,10116.0,,50597,
9117,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877605,1,Intermediate,10116.0,,50597,
9118,Pharmacokinetic property (Cmax) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623813,1,Intermediate,10116.0,,50597,
9119,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623814,1,Intermediate,10116.0,,50597,
9120,Cmax in rat after 3mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623815,1,Intermediate,10116.0,,50597,
9121,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623816,1,Intermediate,10116.0,Sprague-Dawley,50597,
9122,Cmax in rats after 20 mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623145,1,Intermediate,10116.0,,50597,
9123,Cmax in rat plasma after 30mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623146,1,Intermediate,10116.0,,50597,
9124,Plasma concentration after oral administration of 100 mg/kg to rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623147,1,Intermediate,10116.0,,50597,
9125,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623042,1,Intermediate,10116.0,,50597,
9126,Tested for the Cmax in rat at 10 mg/kg per orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623043,1,Intermediate,10116.0,,50597,
9127,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623044,1,Intermediate,10116.0,,50597,
9128,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623045,1,Intermediate,10116.0,,50597,
9129,Bioavailability as oral Cmax in rats at 30 mins,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623046,1,Intermediate,10116.0,,50597,
9130,Bioavailability as oral Cmax in rats at 6hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623226,1,Intermediate,10116.0,,50597,
9131,The maximum concentration of compound was measured at the dose of 100 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623227,1,Intermediate,10116.0,,50597,
9132,The maximum concentration of compound was measured at the dose of 300 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623228,1,Intermediate,10116.0,,50597,
9133,The maximum concentration of compound was measured at the dose of 30 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623229,1,Intermediate,10116.0,,50597,
9134,The maximum plasma levels for the compounds were determined by LC-MS.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623230,1,Intermediate,10116.0,,50597,
9135,mean peak plasma concentration was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623231,1,Intermediate,10116.0,,50597,
9136,mean peak plasma concentration was observed after oral administration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623232,1,Intermediate,10116.0,,50597,
9137,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623233,1,Intermediate,10116.0,,50597,
9138,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623234,1,Intermediate,10116.0,,50597,
9139,Concentration in plasma (portal) following oral dose in rats at 1 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623235,1,Intermediate,10116.0,,50597,
9140,Concentration in plasma (portal) following oral dose in rats at 2 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623236,1,Intermediate,10116.0,,50597,
9141,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623237,1,Intermediate,10116.0,,50597,
9142,Concentration in plasma (systemic) following oral dose in rats at 1 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623238,1,Intermediate,10116.0,,50597,
9143,Concentration in plasma (systemic) following oral dose in rats at 2 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623239,1,Intermediate,10116.0,,50597,
9144,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1,U,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623240,0,Intermediate,10116.0,,22224,
9145,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL623241,1,Intermediate,10116.0,,50597,
9146,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL623242,1,Intermediate,10116.0,,50597,
9147,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874394,1,Intermediate,10116.0,,50597,
9148,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623243,1,Intermediate,10116.0,,50597,
9149,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623244,1,Intermediate,10116.0,,50597,
9150,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623245,1,Intermediate,10116.0,,50597,
9151,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623246,1,Intermediate,10116.0,,50597,
9152,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623247,1,Intermediate,10116.0,,50597,
9153,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623248,1,Intermediate,10116.0,,50597,
9154,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623249,1,Intermediate,10116.0,,50597,
9155,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625072,1,Intermediate,10116.0,,50597,
9156,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625073,1,Intermediate,10116.0,,50597,
9157,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625074,1,Intermediate,10116.0,,50597,
9158,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625075,1,Intermediate,10116.0,,50597,
9159,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625076,1,Intermediate,10116.0,,50597,
9160,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625077,1,Intermediate,10116.0,,50597,
9161,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625078,1,Intermediate,10116.0,,50597,
9162,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL874395,1,Intermediate,10116.0,,50597,
9163,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625079,1,Intermediate,10116.0,,50597,
9164,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625080,1,Intermediate,10116.0,,50597,
9165,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625081,1,Intermediate,10116.0,,50597,
9166,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625082,1,Intermediate,10116.0,,50597,
9167,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625083,1,Intermediate,10116.0,,50597,
9168,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625084,1,Intermediate,10116.0,,50597,
9169,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625085,1,Intermediate,10116.0,,50597,
9170,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625086,1,Intermediate,10116.0,,50597,
9171,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625087,1,Intermediate,10116.0,,50597,
9172,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625088,1,Intermediate,10116.0,,50597,
9173,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622205,1,Intermediate,10116.0,,50597,
9174,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622206,1,Intermediate,10116.0,,50597,
9175,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622207,1,Intermediate,10116.0,,50597,
9176,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622366,1,Intermediate,10116.0,,50597,
9177,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622367,1,Intermediate,10116.0,,50597,
9178,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL875331,1,Intermediate,10116.0,,50597,
9179,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622368,1,Intermediate,10116.0,,50597,
9180,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622369,1,Intermediate,10116.0,,50597,
9181,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622370,1,Intermediate,10116.0,,50597,
9182,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622371,1,Intermediate,10116.0,,50597,
9183,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622372,1,Intermediate,10116.0,,50597,
9184,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622373,1,Intermediate,10116.0,,50597,
9185,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622374,1,Intermediate,10116.0,,50597,
9186,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622375,1,Intermediate,10116.0,,50597,
9187,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622376,1,Intermediate,10116.0,,50597,
9188,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622377,1,Intermediate,10116.0,,50597,
9189,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622378,1,Intermediate,10116.0,,50597,
9190,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622379,1,Intermediate,10116.0,,50597,
9191,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622380,1,Intermediate,10116.0,,50597,
9192,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622381,1,Intermediate,10116.0,,50597,
9193,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622382,1,Intermediate,10116.0,,50597,
9194,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622383,1,Intermediate,10116.0,,50597,
9195,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL875332,1,Intermediate,10116.0,,50597,
9196,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL622384,1,Intermediate,10116.0,,50597,
9197,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL622385,1,Intermediate,10116.0,,50597,
9198,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL622386,1,Intermediate,10116.0,,50597,
9199,The compound was tested for the plasma binding in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622387,1,Intermediate,10116.0,,50597,
9200,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622388,1,Intermediate,10116.0,,50597,
9201,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622389,1,Intermediate,10116.0,,50597,
9202,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622390,1,Intermediate,10116.0,,50597,
9203,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622391,1,Intermediate,10116.0,,50597,
9204,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622392,1,Intermediate,10116.0,,50597,
9205,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622393,1,Intermediate,10116.0,,50597,
9206,Plasma level at 2 hr after administration of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622394,1,Intermediate,10116.0,,50597,
9207,plasma level at 2 hr after administration of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622395,1,Intermediate,10116.0,,50597,
9208,Stability in rat serum measured as % recovery at 1 min,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL622396,1,Intermediate,10116.0,,50597,
9209,Stability in rat serum measured as % recovery at 10 min,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624894,1,Intermediate,10116.0,,50597,
9210,Stability in rat serum measured as % recovery at 10 mins,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624895,1,Intermediate,10116.0,,50597,
9211,Stability in rat serum measured as % recovery at 2 hr,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624058,1,Intermediate,10116.0,,50597,
9212,Stability in rat serum measured as % recovery at 3 min,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624059,1,Intermediate,10116.0,,50597,
9213,Stability in rat serum measured as % recovery at 3 mins,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624060,1,Intermediate,10116.0,,50597,
9214,Stability in rat serum measured as % recovery at 5 min,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624061,1,Intermediate,10116.0,,50597,
9215,Stability in rat serum measured as % recovery at 5 mins,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL624062,1,Intermediate,10116.0,,50597,
9216,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624063,1,Intermediate,10116.0,,50597,
9217,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624064,1,Intermediate,10116.0,,50597,
9218,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624065,1,Intermediate,10116.0,,50597,
9219,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624066,1,Intermediate,10116.0,,50597,
9220,Half life tested in mature male rat at a dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877490,1,Intermediate,10116.0,,50597,
9221,Half life after intravenous administration of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874442,1,Intermediate,10116.0,,50597,
9222,Half life period after administration (30 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626890,1,Intermediate,10116.0,,50597,
9223,Half life period in rat after 5 mg/Kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626891,1,Intermediate,10116.0,,50597,
9224,Half life period in rat after 5 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626892,1,Intermediate,10116.0,,50597,
9225,Half life period was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626893,1,Intermediate,10116.0,,50597,
9226,Half life period was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626894,1,Intermediate,10116.0,,50597,
9227,Half life period was evaluated in rat; 0.5-1.0,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626895,1,Intermediate,10116.0,,50597,
9228,Half life period was evaluated in rat; 5.9-7.5,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626896,1,Intermediate,10116.0,,50597,
9229,Half-life in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626897,1,Intermediate,10116.0,,50597,
9230,Half-life time in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626898,1,Intermediate,10116.0,,50597,
9231,Terminal half-life after iv administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626899,1,Intermediate,10116.0,,50597,
9232,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626900,1,Intermediate,10116.0,,50597,
9233,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626901,1,Intermediate,10116.0,,50597,
9234,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626902,1,Intermediate,10116.0,,50597,
9235,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626903,1,Intermediate,10116.0,,50597,
9236,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874443,1,Intermediate,10116.0,,50597,
9237,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626904,1,Intermediate,10116.0,,50597,
9238,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626905,1,Intermediate,10116.0,,50597,
9239,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873830,1,Intermediate,10116.0,,50597,
9240,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626906,1,Intermediate,10116.0,,50597,
9241,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631076,1,Intermediate,10116.0,,50597,
9242,Biological half-life was measured in plasma of rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631077,1,Intermediate,10116.0,,50597,
9243,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631078,1,Intermediate,10116.0,,50597,
9244,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631079,1,Intermediate,10116.0,,50597,
9245,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631080,1,Intermediate,10116.0,,50597,
9246,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631081,1,Intermediate,10116.0,,50597,
9247,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631239,1,Intermediate,10116.0,,50597,
9248,Compound was evaluated for plasma half life in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631240,1,Intermediate,10116.0,,50597,
9249,AUC value at a dose of 5 mg/kg (p.o.) in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631241,1,Intermediate,10116.0,,50597,
9250,AUC value after administration of 20 mg/Kg oral dose in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631242,1,Intermediate,10116.0,,50597,
9251,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631243,1,Intermediate,10116.0,,50597,
9252,AUC0-96 after administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL874444,1,Intermediate,10116.0,,50597,
9253,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631244,1,Intermediate,10116.0,,50597,
9254,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631245,1,Intermediate,10116.0,,50597,
9255,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627162,1,Intermediate,10116.0,,50597,
9256,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627163,1,Intermediate,10116.0,,50597,
9257,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627164,1,Intermediate,10116.0,,50597,
9258,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627165,1,Intermediate,10116.0,,50597,
9259,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627166,1,Intermediate,10116.0,,50597,
9260,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627167,1,Intermediate,10116.0,,50597,
9261,Area under curve (AUC) at a dose of 30 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627822,1,Intermediate,10116.0,,50597,
9262,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627823,1,Intermediate,10116.0,,50597,
9263,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627824,1,Intermediate,10116.0,,50597,
9264,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627825,1,Intermediate,10116.0,,50597,
9265,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627826,1,Intermediate,10116.0,,50597,
9266,Area under curve (Pharmacokinetic property) was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627827,1,Intermediate,10116.0,,50597,
9267,Area under curve (Pharmacokinetic property) of the compound; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627828,1,Intermediate,10116.0,,50597,
9268,Area under curve after intravenous administration (1 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627829,1,Intermediate,10116.0,,50597,
9269,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627830,1,Intermediate,10116.0,,50597,
9270,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627831,1,Intermediate,10116.0,,50597,
9271,Area under curve in male SD rats was observed after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627832,1,Intermediate,10116.0,,50597,
9272,Area under curve of compound after iv administration of 20 mg/kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627833,1,Intermediate,10116.0,,50597,
9273,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627834,1,Expert,10116.0,,50597,
9274,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628004,1,Expert,10116.0,,50597,
9275,Area under curve at 5 mg/kg po was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628005,1,Intermediate,10116.0,,50597,
9276,Area under curve in Rat at a oral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628006,1,Intermediate,10116.0,,50597,
9277,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628007,1,Intermediate,10116.0,,50597,
9278,Area under curve was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625676,1,Intermediate,10116.0,,50597,
9279,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631309,1,Intermediate,10116.0,,50597,
9280,Area under curve after intravenous administration at 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631310,1,Intermediate,10116.0,,50597,
9281,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631311,1,Intermediate,10116.0,,50597,
9282,Area under curve at 4 hr in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631312,1,Intermediate,10116.0,,50597,
9283,Area under curve at a dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631313,1,Intermediate,10116.0,,50597,
9284,Area under curve at the dose of 2 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631314,1,Intermediate,10116.0,,50597,
9285,Area under curve at the dose of 5 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631315,1,Intermediate,10116.0,,50597,
9286,Area under curve for a 2-mpk po dose in SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631316,1,Intermediate,10116.0,,50597,
9287,Area under curve in SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631317,1,Intermediate,10116.0,,50597,
9288,Area under curve in rat after oral administration at 13 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874471,1,Intermediate,10116.0,,50597,
9289,Area under curve in rat by po administration at 0-24 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631318,1,Intermediate,10116.0,,50597,
9290,Area under curve in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631319,1,Intermediate,10116.0,,50597,
9291,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631320,1,Intermediate,10116.0,,50597,
9292,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631321,1,Intermediate,10116.0,,50597,
9293,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631322,1,Intermediate,10116.0,,50597,
9294,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631323,1,Intermediate,10116.0,,50597,
9295,Area under curve value in rat at a dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631324,1,Intermediate,10116.0,,50597,
9296,Area under curve was determined after oral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631325,1,Intermediate,10116.0,,50597,
9297,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631326,1,Intermediate,10116.0,,50597,
9298,Area under curve was determined after peroral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631327,1,Intermediate,10116.0,,50597,
9299,Area under curve was determined at a dose 30 mpk administered orally.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631328,1,Intermediate,10116.0,,50597,
9300,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631329,1,Intermediate,10116.0,,50597,
9301,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627217,1,Intermediate,10116.0,,50597,
9302,Area under curve was determined in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626352,1,Intermediate,10116.0,,50597,
9303,Area under curve was determined in rat after PO administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626353,1,Intermediate,10116.0,,50597,
9304,Area under curve was determined in rat after a 3 mg/kg of oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626354,1,Intermediate,10116.0,,50597,
9305,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626355,1,Intermediate,10116.0,,50597,
9306,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626356,1,Intermediate,10116.0,,50597,
9307,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626357,1,Intermediate,10116.0,,50597,
9308,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626358,1,Intermediate,10116.0,,50597,
9309,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626359,1,Intermediate,10116.0,,50597,
9310,Peak plasma concentration in rat at a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626360,1,Intermediate,10116.0,,50597,
9311,Plasma concentration at 2 hr in rats was evaluated.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626361,1,Intermediate,10116.0,,50597,
9312,Plasma concentration at 2 hr in rats was evaluated; Not available,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626362,1,Intermediate,10116.0,,50597,
9313,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626363,1,Intermediate,10116.0,,50597,
9314,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626970,1,Intermediate,10116.0,,50597,
9315,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626971,1,Intermediate,10116.0,,50597,
9316,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626972,1,Intermediate,10116.0,,50597,
9317,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626973,1,Intermediate,10116.0,,50597,
9318,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626974,1,Intermediate,10116.0,,50597,
9319,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL874592,1,Intermediate,10116.0,,50597,
9320,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626975,1,Intermediate,10116.0,,50597,
9321,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626976,1,Intermediate,10116.0,,50597,
9322,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626977,1,Intermediate,10116.0,,50597,
9323,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626978,1,Intermediate,10116.0,,50597,
9324,PK study was carried to determine the relative absorption ranking in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626979,1,Intermediate,10116.0,,50597,
9325,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626980,1,Intermediate,10116.0,,50597,
9326,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626981,1,Intermediate,10116.0,,50597,
9327,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626982,1,Intermediate,10116.0,,50597,
9328,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626983,1,Intermediate,10116.0,,50597,
9329,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622522,1,Intermediate,10116.0,,50597,
9330,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622523,1,Intermediate,10116.0,,50597,
9331,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622524,1,Intermediate,10116.0,,50597,
9332,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622525,1,Intermediate,10116.0,,50597,
9333,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622526,1,Intermediate,10116.0,,50597,
9334,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619849,1,Intermediate,10116.0,,50597,
9335,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL619850,1,Intermediate,10116.0,,50597,
9336,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623864,1,Intermediate,10116.0,,50597,
9337,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623865,1,Intermediate,10116.0,,50597,
9338,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623866,1,Intermediate,10116.0,,50597,
9339,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623867,1,Intermediate,10116.0,,50597,
9340,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL877615,1,Intermediate,10116.0,,50597,
9341,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623868,1,Intermediate,10116.0,,50597,
9342,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623869,1,Intermediate,10116.0,,50597,
9343,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623870,1,Intermediate,10116.0,,50597,
9344,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623871,1,Intermediate,10116.0,,50597,
9345,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623872,1,Intermediate,10116.0,,50597,
9346,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622129,1,Intermediate,10116.0,,50597,
9347,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622130,1,Intermediate,10116.0,,50597,
9348,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622131,1,Intermediate,10116.0,,50597,
9349,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622132,1,Intermediate,10116.0,,50597,
9350,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622133,1,Intermediate,10116.0,,50597,
9351,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622134,1,Intermediate,10116.0,,50597,
9352,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622135,1,Intermediate,10116.0,,50597,
9353,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622136,1,Intermediate,10116.0,,50597,
9354,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622137,1,Intermediate,10116.0,,50597,
9355,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622138,1,Intermediate,10116.0,,50597,
9356,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623017,1,Intermediate,10116.0,,50597,
9357,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623018,1,Intermediate,10116.0,,50597,
9358,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623019,1,Intermediate,10116.0,,50597,
9359,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623020,1,Intermediate,10116.0,,50597,
9360,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623021,1,Intermediate,10116.0,,50597,
9361,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623022,1,Intermediate,10116.0,,50597,
9362,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623023,1,Intermediate,10116.0,,50597,
9363,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623024,1,Intermediate,10116.0,,50597,
9364,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623025,1,Intermediate,10116.0,,50597,
9365,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620545,1,Intermediate,10116.0,,50597,
9366,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620546,1,Intermediate,10116.0,,50597,
9367,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620547,1,Intermediate,10116.0,,50597,
9368,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620548,1,Intermediate,10116.0,,50597,
9369,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620549,1,Intermediate,10116.0,,50597,
9370,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620550,1,Intermediate,10116.0,,50597,
9371,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620551,1,Intermediate,10116.0,,50597,
9372,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620552,1,Intermediate,10116.0,,50597,
9373,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620553,1,Intermediate,10116.0,,50597,
9374,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620554,1,Intermediate,10116.0,,50597,
9375,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL875845,1,Intermediate,10116.0,,50597,
9376,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620555,1,Intermediate,10116.0,,50597,
9377,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620556,1,Intermediate,10116.0,,50597,
9378,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620557,1,Intermediate,10116.0,,50597,
9379,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620558,1,Intermediate,10116.0,,50597,
9380,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620559,1,Intermediate,10116.0,,50597,
9381,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622939,1,Intermediate,10116.0,,50597,
9382,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622940,1,Intermediate,10116.0,,50597,
9383,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622941,1,Intermediate,10116.0,,50597,
9384,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622942,1,Intermediate,10116.0,,50597,
9385,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622943,1,Intermediate,10116.0,,50597,
9386,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622944,1,Intermediate,10116.0,,50597,
9387,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622945,1,Intermediate,10116.0,,50597,
9388,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622946,1,Intermediate,10116.0,,50597,
9389,Compound was evaluated for terminal half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622947,1,Intermediate,10116.0,,50597,
9390,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622948,1,Intermediate,10116.0,,50597,
9391,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622949,1,Intermediate,10116.0,,50597,
9392,Compound was tested for its half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622950,1,Intermediate,10116.0,,50597,
9393,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,U,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622951,0,Intermediate,9544.0,,22224,
9394,Compound was tested for its plasma half life in Sprague Dawley rats,1,U,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000366,CHEMBL622952,0,Intermediate,10116.0,,22224,
9395,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1,U,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000366,CHEMBL622953,0,Intermediate,10116.0,,22224,
9396,Compound was tested for plasma half-life period in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873818,1,Intermediate,10116.0,,50597,
9397,Elimination half life after i.v. administration of compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622954,1,Intermediate,10116.0,,50597,
9398,Elimination half-life after IV dosing at 0.5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622955,1,Intermediate,10116.0,,50597,
9399,Elimination half-life after IV dosing at 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875229,1,Intermediate,10116.0,,50597,
9400,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622956,1,Intermediate,10116.0,,50597,
9401,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622957,1,Intermediate,10116.0,,50597,
9402,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622958,1,Intermediate,10116.0,,50597,
9403,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622959,1,Intermediate,10116.0,,50597,
9404,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622960,1,Intermediate,10116.0,,50597,
9405,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622961,1,Intermediate,10116.0,,50597,
9406,Evaluated for the half life in rat (in vivo),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622962,1,Intermediate,10116.0,,50597,
9407,Hafl life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622963,1,Intermediate,10116.0,,50597,
9408,Hafl life rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622964,1,Intermediate,10116.0,,50597,
9409,Hafl life rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622965,1,Intermediate,10116.0,,50597,
9410,Hafl life rat; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622966,1,Intermediate,10116.0,,50597,
9411,Hafl life rat; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622967,1,Intermediate,10116.0,,50597,
9412,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622968,1,Intermediate,10116.0,,50597,
9413,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622969,1,Intermediate,10116.0,,50597,
9414,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL875327,1,Intermediate,10116.0,,50597,
9415,Half life in rat after 1 mg/kg i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628638,1,Intermediate,10116.0,,50597,
9416,Half life in rat after 2 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628639,1,Intermediate,10116.0,,50597,
9417,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625840,1,Intermediate,10116.0,,50597,
9418,Half life of 10 mg/kg oral dose determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625841,1,Intermediate,10116.0,,50597,
9419,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625842,1,Intermediate,10116.0,,50597,
9420,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625843,1,Intermediate,10116.0,,50597,
9421,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625844,1,Intermediate,10116.0,,50597,
9422,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873822,1,Intermediate,10116.0,,50597,
9423,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625845,1,Intermediate,10116.0,,50597,
9424,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627059,1,Intermediate,10116.0,,50597,
9425,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627060,1,Intermediate,10116.0,,50597,
9426,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627061,1,Intermediate,10116.0,,50597,
9427,Half life of compound at 5 mg/kg after po administration was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627709,1,Intermediate,10116.0,,50597,
9428,Half life of compound determined after intravenous administration to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627710,1,Intermediate,10116.0,,50597,
9429,Half life of compound was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627711,1,Intermediate,10116.0,,50597,
9430,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627712,1,Intermediate,10116.0,,50597,
9431,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627713,1,Intermediate,10116.0,,50597,
9432,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627714,1,Intermediate,10116.0,,50597,
9433,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL627889,0,Intermediate,9541.0,,22224,
9434,Half life determined in rat by intravenous administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627890,0,Intermediate,10116.0,,22224,
9435,Half life determined in rats after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627891,1,Intermediate,10116.0,,50597,
9436,Half life in rat plasma after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627892,1,Intermediate,10116.0,,50597,
9437,Half life in rat plasma after administration of 2 mg/kg iv,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627893,1,Intermediate,10116.0,,50597,
9438,Half life in rat plasma was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627894,1,Intermediate,10116.0,,50597,
9439,Half life in rat plasma was determined; NA means not applicable,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627895,1,Intermediate,10116.0,,50597,
9440,Half life in rat was tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627896,1,Intermediate,10116.0,,50597,
9441,Half life measured in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627897,1,Intermediate,10116.0,,50597,
9442,Half life recorded in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627898,1,Intermediate,10116.0,,50597,
9443,Half life was calculated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627899,1,Intermediate,10116.0,,50597,
9444,Half life was calculated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873823,1,Intermediate,10116.0,,50597,
9445,Half life was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627900,1,Intermediate,10116.0,,50597,
9446,Half life after 10 mg/kg oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627901,1,Intermediate,10116.0,,50597,
9447,Half life after administering orally a dose of 10 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627902,1,Intermediate,10116.0,,50597,
9448,Half life after administering orally a dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627903,1,Intermediate,10116.0,,50597,
9449,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627904,1,Intermediate,10116.0,,50597,
9450,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627905,1,Intermediate,10116.0,,50597,
9451,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627906,1,Intermediate,10116.0,,50597,
9452,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627907,1,Intermediate,10116.0,,50597,
9453,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876783,1,Intermediate,10116.0,,50597,
9454,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627908,1,Intermediate,10116.0,,50597,
9455,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627909,1,Intermediate,10116.0,,50597,
9456,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627910,1,Intermediate,10116.0,,50597,
9457,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627911,1,Intermediate,10116.0,,50597,
9458,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627912,1,Intermediate,10116.0,,50597,
9459,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627913,1,Intermediate,10116.0,,50597,
9460,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627914,1,Intermediate,10116.0,,50597,
9461,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627915,1,Intermediate,10116.0,,50597,
9462,Area under the curve was evaluated after 20 uM/kg of peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627916,1,Intermediate,10116.0,,50597,
9463,Area under the curve was measured in rat after an iv dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627917,1,Intermediate,10116.0,,50597,
9464,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627918,1,Intermediate,10116.0,,50597,
9465,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627919,1,Intermediate,10116.0,,50597,
9466,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627920,1,Intermediate,10116.0,,50597,
9467,Area under the curve was evaluated at an oral dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627921,1,Intermediate,10116.0,,50597,
9468,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627922,1,Intermediate,10116.0,,50597,
9469,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876784,1,Intermediate,10116.0,,50597,
9470,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627923,1,Intermediate,10116.0,,50597,
9471,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626208,1,Intermediate,10116.0,,50597,
9472,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626209,1,Intermediate,10116.0,,50597,
9473,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626210,1,Intermediate,10116.0,,50597,
9474,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627994,1,Intermediate,10116.0,,50597,
9475,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627995,1,Intermediate,10116.0,,50597,
9476,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627996,1,Intermediate,10116.0,,50597,
9477,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627997,1,Intermediate,10116.0,,50597,
9478,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627998,1,Intermediate,10116.0,,50597,
9479,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628640,1,Intermediate,10116.0,,50597,
9480,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628641,1,Intermediate,10116.0,,50597,
9481,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628642,1,Intermediate,10116.0,,50597,
9482,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628643,1,Intermediate,10116.0,,50597,
9483,Compound was tested for area under curve in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628644,1,Intermediate,10116.0,,50597,
9484,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628645,1,Intermediate,10116.0,,50597,
9485,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628646,1,Intermediate,10116.0,,50597,
9486,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628647,1,Intermediate,10116.0,,50597,
9487,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628648,1,Intermediate,10116.0,,50597,
9488,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625358,1,Intermediate,10116.0,,50597,
9489,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625359,1,Intermediate,10116.0,,50597,
9490,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625360,1,Intermediate,10116.0,,50597,
9491,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625361,1,Intermediate,10116.0,,50597,
9492,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625362,1,Intermediate,10116.0,,50597,
9493,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625363,1,Intermediate,10116.0,,50597,
9494,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625364,1,Intermediate,10116.0,,50597,
9495,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625365,1,Intermediate,10116.0,,50597,
9496,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625366,1,Intermediate,10116.0,,50597,
9497,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625367,1,Intermediate,10116.0,,50597,
9498,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625368,1,Intermediate,10116.0,,50597,
9499,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625369,1,Intermediate,10116.0,,50597,
9500,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625370,1,Intermediate,10116.0,,50597,
9501,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625371,1,Intermediate,10116.0,,50597,
9502,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625372,1,Intermediate,10116.0,,50597,
9503,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625373,1,Intermediate,10116.0,,50597,
9504,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625374,1,Intermediate,10116.0,,50597,
9505,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL877593,1,Intermediate,10116.0,,50597,
9506,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625375,1,Intermediate,10116.0,,50597,
9507,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625376,1,Intermediate,10116.0,,50597,
9508,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621973,1,Intermediate,10116.0,,50597,
9509,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621974,1,Intermediate,10116.0,,50597,
9510,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL621975,1,Intermediate,10116.0,,50597,
9511,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622166,1,Intermediate,10116.0,,50597,
9512,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622167,1,Intermediate,10116.0,,50597,
9513,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622168,1,Intermediate,10116.0,,50597,
9514,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622169,1,Intermediate,10116.0,,50597,
9515,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622170,1,Intermediate,10116.0,,50597,
9516,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622171,1,Intermediate,10116.0,,50597,
9517,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622172,1,Intermediate,10116.0,,50597,
9518,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622173,1,Intermediate,10116.0,,50597,
9519,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622174,1,Intermediate,10116.0,,50597,
9520,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622175,1,Intermediate,10116.0,,50597,
9521,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622176,1,Intermediate,10116.0,,50597,
9522,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622177,1,Intermediate,10116.0,,50597,
9523,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622178,1,Intermediate,10116.0,,50597,
9524,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622179,1,Intermediate,10116.0,,50597,
9525,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622180,1,Intermediate,10116.0,,50597,
9526,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622181,1,Intermediate,10116.0,,50597,
9527,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622182,1,Intermediate,10116.0,,50597,
9528,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622183,1,Intermediate,10116.0,,50597,
9529,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622184,1,Intermediate,10116.0,,50597,
9530,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622185,1,Intermediate,10116.0,,50597,
9531,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622186,1,Intermediate,10116.0,,50597,
9532,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622187,1,Intermediate,10116.0,,50597,
9533,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625002,1,Intermediate,10116.0,,50597,
9534,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622090,1,Intermediate,10116.0,,50597,
9535,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622091,1,Intermediate,10116.0,,50597,
9536,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622092,1,Intermediate,10116.0,,50597,
9537,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622093,1,Intermediate,10116.0,,50597,
9538,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622094,1,Intermediate,10116.0,,50597,
9539,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622095,1,Intermediate,10116.0,,50597,
9540,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622264,1,Intermediate,10116.0,,50597,
9541,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622265,1,Intermediate,10116.0,,50597,
9542,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622266,1,Intermediate,10116.0,,50597,
9543,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622267,1,Intermediate,10116.0,,50597,
9544,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622268,1,Intermediate,10116.0,,50597,
9545,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622269,1,Intermediate,10116.0,,50597,
9546,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625071,1,Intermediate,10116.0,,50597,
9547,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621621,1,Intermediate,10116.0,,50597,
9548,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621622,1,Intermediate,10116.0,,50597,
9549,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621623,1,Intermediate,10116.0,,50597,
9550,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621624,1,Intermediate,10116.0,,50597,
9551,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621625,1,Intermediate,10116.0,,50597,
9552,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621626,1,Intermediate,10116.0,,50597,
9553,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621627,1,Intermediate,10116.0,,50597,
9554,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621628,1,Intermediate,10116.0,,50597,
9555,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL875328,1,Intermediate,10116.0,,50597,
9556,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621629,1,Intermediate,10116.0,,50597,
9557,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621630,1,Intermediate,10116.0,,50597,
9558,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621631,1,Intermediate,10116.0,,50597,
9559,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621632,1,Intermediate,10116.0,,50597,
9560,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621633,1,Intermediate,10116.0,,50597,
9561,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621634,1,Intermediate,10116.0,,50597,
9562,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621635,1,Intermediate,10116.0,,50597,
9563,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621636,1,Intermediate,10116.0,,50597,
9564,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621637,1,Intermediate,10116.0,,50597,
9565,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL621638,1,Intermediate,10116.0,,50597,
9566,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618883,1,Intermediate,10116.0,,50597,
9567,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618884,1,Intermediate,10116.0,,50597,
9568,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628627,1,Intermediate,10116.0,,50597,
9569,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628628,1,Intermediate,10116.0,,50597,
9570,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628629,1,Intermediate,10116.0,,50597,
9571,Half life after administering orally a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628630,1,Intermediate,10116.0,,50597,
9572,Half life after administering orally a dose of 3 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628631,1,Intermediate,10116.0,,50597,
9573,Half life after administering intravenously a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628632,1,Intermediate,10116.0,,50597,
9574,Half life after oral dosing in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628633,1,Intermediate,10116.0,,50597,
9575,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628634,1,Intermediate,10116.0,,50597,
9576,Half life by intravenous administration of 3.4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627789,1,Intermediate,10116.0,,50597,
9577,Half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627790,1,Intermediate,10116.0,,50597,
9578,Half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627791,1,Intermediate,10116.0,,50597,
9579,Half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627792,1,Intermediate,10116.0,,50597,
9580,Half life in rat after intravenous administration of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627793,1,Intermediate,10116.0,,50597,
9581,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627794,1,Intermediate,10116.0,,50597,
9582,Half life in rat after po administration of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627795,1,Intermediate,10116.0,,50597,
9583,Half life in rat after po administration of the compound; ND means Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627796,1,Intermediate,10116.0,,50597,
9584,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875335,1,Intermediate,10116.0,,50597,
9585,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627797,1,Intermediate,10116.0,,50597,
9586,Half life in rat i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627798,1,Intermediate,10116.0,,50597,
9587,Half life in rat i.v. at 2 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627799,1,Intermediate,10116.0,,50597,
9588,Half life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627800,1,Intermediate,10116.0,,50597,
9589,Half life in rats after intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627801,1,Intermediate,10116.0,,50597,
9590,Half life in rats at the dose of 1.0 mpk by i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627802,1,Intermediate,10116.0,,50597,
9591,Half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627803,1,Expert,10116.0,,50597,
9592,Half life was evaluated after intravenous administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873820,1,Intermediate,10116.0,,50597,
9593,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627804,1,Intermediate,10116.0,,50597,
9594,Half life was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627805,1,Intermediate,10116.0,,50597,
9595,Half life was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627806,1,Intermediate,10116.0,,50597,
9596,Half life was evaluated in rat; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627107,1,Intermediate,10116.0,,50597,
9597,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627108,1,Intermediate,10116.0,,50597,
9598,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627109,1,Intermediate,10116.0,,50597,
9599,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627110,1,Intermediate,10116.0,,50597,
9600,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,U,,Primates,,,,,,,BAO_0000218,CHEMBL627111,0,Intermediate,9443.0,,22224,
9601,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,U,,Primates,,,,,,,BAO_0000218,CHEMBL627112,0,Intermediate,9443.0,,22224,
9602,Half life was measured in rat at dose of 30 mg/kg by iv administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627113,0,Intermediate,10116.0,,22224,
9603,Half life was measured in rat at dose of 30 mg/kg by po administration,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627114,0,Intermediate,10116.0,,22224,
9604,Half life (t1/2) was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627115,1,Intermediate,10116.0,,50597,
9605,Half life period at a dose of 10 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627116,1,Intermediate,10116.0,,50597,
9606,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627117,1,Intermediate,10116.0,,50597,
9607,Half life period was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627118,1,Intermediate,10116.0,,50597,
9608,Half life period after intravenous administration at 20 mpk in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627119,1,Intermediate,10116.0,,50597,
9609,Half life period after intravenous administration at 20 mpk in rats; Not performed.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627120,1,Intermediate,10116.0,,50597,
9610,Half life period after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626922,1,Intermediate,10116.0,,50597,
9611,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626923,1,Intermediate,10116.0,,50597,
9612,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626924,1,Intermediate,10116.0,,50597,
9613,Half life period in 80% rat plasma at 37 degree Centigrade,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626925,1,Intermediate,10116.0,,50597,
9614,Half life period in SD rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626926,1,Intermediate,10116.0,,50597,
9615,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626927,1,Intermediate,10116.0,,50597,
9616,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626928,1,Intermediate,10116.0,,50597,
9617,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626929,1,Intermediate,10116.0,,50597,
9618,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626930,1,Intermediate,10116.0,,50597,
9619,Half life period in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626931,1,Intermediate,10116.0,,50597,
9620,Half life period in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626932,1,Intermediate,10116.0,,50597,
9621,Half life period in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626933,1,Intermediate,10116.0,,50597,
9622,Half life period in rat after oral administration at 10.5 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873826,1,Intermediate,10116.0,,50597,
9623,Half life period in rat after oral administration at 11.2 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626934,1,Intermediate,10116.0,,50597,
9624,Half life period in rat after oral administration at 13 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626935,1,Intermediate,10116.0,,50597,
9625,Half life period in rat after oral administration at 9.7 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626936,1,Intermediate,10116.0,,50597,
9626,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626937,1,Intermediate,10116.0,,50597,
9627,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625906,1,Intermediate,10116.0,,50597,
9628,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625907,1,Intermediate,10116.0,,50597,
9629,PK study was carried to determine AUC (area under curve) value in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625908,1,Intermediate,10116.0,,50597,
9630,Pharmacokinetic parameter AUC after intravenous administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625909,1,Intermediate,10116.0,,50597,
9631,Pharmacokinetic parameter AUC after oral administration to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625910,1,Intermediate,10116.0,,50597,
9632,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625911,1,Intermediate,10116.0,,50597,
9633,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625912,1,Intermediate,10116.0,,50597,
9634,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626538,1,Intermediate,10116.0,,50597,
9635,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876794,1,Intermediate,10116.0,,50597,
9636,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626539,1,Intermediate,10116.0,,50597,
9637,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626540,1,Intermediate,10116.0,,50597,
9638,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626541,1,Intermediate,10116.0,,50597,
9639,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626542,1,Intermediate,10116.0,,50597,
9640,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626543,1,Intermediate,10116.0,,50597,
9641,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626544,1,Intermediate,10116.0,,50597,
9642,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626545,1,Intermediate,10116.0,,50597,
9643,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626546,1,Intermediate,10116.0,,50597,
9644,Pharmacokinetic parameter area under curve was reported,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626547,1,Intermediate,10116.0,,50597,
9645,Pharmacokinetic property (AUC) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626548,1,Intermediate,10116.0,,50597,
9646,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626549,1,Intermediate,10116.0,,50597,
9647,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626550,1,Intermediate,10116.0,,50597,
9648,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626551,1,Intermediate,10116.0,,50597,
9649,Pharmacokinetic property was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623777,1,Intermediate,10116.0,,50597,
9650,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623778,1,Intermediate,10116.0,,50597,
9651,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623779,1,Intermediate,10116.0,,50597,
9652,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623780,1,Intermediate,10116.0,,50597,
9653,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622015,1,Intermediate,10116.0,,50597,
9654,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622016,1,Intermediate,10116.0,,50597,
9655,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622017,1,Intermediate,10116.0,,50597,
9656,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622018,1,Intermediate,10116.0,,50597,
9657,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622019,1,Intermediate,10116.0,,50597,
9658,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622020,1,Intermediate,10116.0,,50597,
9659,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622021,1,Intermediate,10116.0,,50597,
9660,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622022,1,Intermediate,10116.0,,50597,
9661,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622023,1,Intermediate,10116.0,,50597,
9662,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622024,1,Intermediate,10116.0,,50597,
9663,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622693,1,Intermediate,10116.0,,50597,
9664,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622694,1,Intermediate,10116.0,,50597,
9665,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622695,1,Intermediate,10116.0,,50597,
9666,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622696,1,Intermediate,10116.0,,50597,
9667,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622697,1,Intermediate,10116.0,,50597,
9668,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622874,1,Intermediate,10116.0,,50597,
9669,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622875,1,Intermediate,10116.0,,50597,
9670,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622876,1,Intermediate,10116.0,,50597,
9671,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622877,1,Intermediate,10116.0,,50597,
9672,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622878,1,Intermediate,10116.0,,50597,
9673,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622879,1,Intermediate,10116.0,,50597,
9674,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877602,1,Intermediate,10116.0,,50597,
9675,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622880,1,Intermediate,10116.0,,50597,
9676,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622881,1,Intermediate,10116.0,,50597,
9677,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622882,1,Intermediate,10116.0,,50597,
9678,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622883,1,Intermediate,10116.0,,50597,
9679,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622884,1,Intermediate,10116.0,,50597,
9680,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622885,1,Intermediate,10116.0,,50597,
9681,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622886,1,Intermediate,10116.0,,50597,
9682,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622887,1,Intermediate,10116.0,,50597,
9683,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622888,1,Intermediate,10116.0,,50597,
9684,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622889,1,Intermediate,10116.0,,50597,
9685,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622890,1,Intermediate,10116.0,,50597,
9686,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622891,1,Intermediate,10116.0,,50597,
9687,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL877603,1,Intermediate,10116.0,,50597,
9688,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622892,1,Intermediate,10116.0,,50597,
9689,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622893,1,Intermediate,10116.0,,50597,
9690,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622894,1,Intermediate,10116.0,,50597,
9691,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622895,1,Intermediate,10116.0,,50597,
9692,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622896,1,Intermediate,10116.0,,50597,
9693,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622897,1,Intermediate,10116.0,,50597,
9694,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622898,1,Intermediate,10116.0,,50597,
9695,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622899,1,Intermediate,10116.0,,50597,
9696,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622900,1,Intermediate,10116.0,,50597,
9697,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624114,1,Intermediate,10116.0,,50597,
9698,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624115,1,Intermediate,10116.0,,50597,
9699,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624116,1,Intermediate,10116.0,,50597,
9700,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624117,1,Intermediate,10116.0,,50597,
9701,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624118,1,Intermediate,10116.0,,50597,
9702,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624119,1,Intermediate,10116.0,,50597,
9703,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624120,1,Intermediate,10116.0,,50597,
9704,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624121,1,Intermediate,10116.0,,50597,
9705,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624122,1,Intermediate,10116.0,,50597,
9706,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624123,1,Intermediate,10116.0,,50597,
9707,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624124,1,Intermediate,10116.0,,50597,
9708,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624125,1,Intermediate,10116.0,,50597,
9709,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624126,1,Intermediate,10116.0,,50597,
9710,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624127,1,Intermediate,10116.0,,50597,
9711,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624128,1,Intermediate,10116.0,,50597,
9712,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL624129,1,Intermediate,10116.0,,50597,
9713,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL624130,1,Intermediate,10116.0,,50597,
9714,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL622340,1,Intermediate,10116.0,,50597,
9715,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL622341,1,Intermediate,10116.0,,50597,
9716,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622342,1,Intermediate,10116.0,,50597,
9717,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622343,1,Intermediate,10116.0,,50597,
9718,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622344,1,Intermediate,10116.0,,50597,
9719,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622345,1,Intermediate,10116.0,,50597,
9720,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622346,1,Intermediate,10116.0,,50597,
9721,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622347,1,Intermediate,10116.0,,50597,
9722,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622348,1,Intermediate,10116.0,,50597,
9723,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622349,1,Intermediate,10116.0,,50597,
9724,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622350,1,Intermediate,10116.0,,50597,
9725,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622351,1,Intermediate,10116.0,,50597,
9726,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622352,1,Intermediate,10116.0,,50597,
9727,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622353,1,Intermediate,10116.0,,50597,
9728,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622354,1,Intermediate,10116.0,,50597,
9729,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622355,1,Intermediate,10116.0,,50597,
9730,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622356,1,Intermediate,10116.0,,50597,
9731,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622357,1,Intermediate,10116.0,,50597,
9732,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622358,1,Intermediate,10116.0,,50597,
9733,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622359,1,Intermediate,10116.0,,50597,
9734,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874393,1,Intermediate,10116.0,,50597,
9735,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622872,1,Intermediate,10116.0,,50597,
9736,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622873,1,Intermediate,10116.0,,50597,
9737,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623047,1,Intermediate,10116.0,,50597,
9738,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623048,1,Intermediate,10116.0,,50597,
9739,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623049,1,Intermediate,10116.0,,50597,
9740,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623050,1,Intermediate,10116.0,,50597,
9741,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623051,1,Intermediate,10116.0,,50597,
9742,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623052,1,Intermediate,10116.0,,50597,
9743,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626343,1,Intermediate,10116.0,,50597,
9744,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626344,1,Intermediate,10116.0,,50597,
9745,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626345,1,Intermediate,10116.0,,50597,
9746,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626346,1,Intermediate,10116.0,,50597,
9747,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626347,1,Intermediate,10116.0,,50597,
9748,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626348,1,Intermediate,10116.0,,50597,
9749,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626349,1,Intermediate,10116.0,,50597,
9750,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626350,1,Intermediate,10116.0,,50597,
9751,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626351,1,Intermediate,10116.0,,50597,
9752,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627650,1,Intermediate,10116.0,,50597,
9753,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627651,1,Intermediate,10116.0,,50597,
9754,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627652,1,Intermediate,10116.0,,50597,
9755,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627653,1,Intermediate,10116.0,,50597,
9756,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627654,1,Intermediate,10116.0,,50597,
9757,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627835,1,Intermediate,10116.0,,50597,
9758,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627836,1,Intermediate,10116.0,,50597,
9759,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627837,1,Intermediate,10116.0,,50597,
9760,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627838,1,Intermediate,10116.0,,50597,
9761,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875338,1,Intermediate,10116.0,,50597,
9762,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627839,1,Intermediate,10116.0,,50597,
9763,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627840,1,Intermediate,10116.0,,50597,
9764,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627841,1,Intermediate,10116.0,,50597,
9765,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627842,1,Intermediate,10116.0,,50597,
9766,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627843,1,Intermediate,10116.0,,50597,
9767,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627844,1,Intermediate,10116.0,,50597,
9768,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627845,1,Intermediate,10116.0,,50597,
9769,Half life period in rat by iv administration at a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627846,1,Intermediate,10116.0,,50597,
9770,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627847,1,Intermediate,10116.0,,50597,
9771,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873821,1,Intermediate,10116.0,,50597,
9772,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626079,1,Intermediate,10116.0,,50597,
9773,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626080,1,Intermediate,10116.0,,50597,
9774,Half life period was evaluated in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626081,1,Intermediate,10116.0,,50597,
9775,Half life period was evaluated in rat plasma; Not tested,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875344,1,Intermediate,10116.0,,50597,
9776,Half life period was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626082,1,Intermediate,10116.0,,50597,
9777,"Half life period was evaluated in rats, iv",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626250,1,Intermediate,10116.0,,50597,
9778,Half life period after intravenous administration at 5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626251,1,Intermediate,10116.0,,50597,
9779,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626252,1,Intermediate,10116.0,,50597,
9780,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626253,1,Intermediate,10116.0,,50597,
9781,Half life stability of compound was evaluated in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626254,1,Intermediate,10116.0,,50597,
9782,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626255,1,Intermediate,10116.0,,50597,
9783,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626256,1,Intermediate,10116.0,,50597,
9784,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626257,1,Intermediate,10116.0,,50597,
9785,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626258,1,Intermediate,10116.0,,50597,
9786,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626259,1,Intermediate,10116.0,,50597,
9787,Half in rat i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626260,1,Intermediate,10116.0,,50597,
9788,Half period in rat after intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875345,1,Intermediate,10116.0,,50597,
9789,Half-life after repeated oral dose of compound at 1 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626261,1,Intermediate,10116.0,,50597,
9790,Half-life measured in in vitro Cathepsin B assay in rat liver,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626262,1,Intermediate,10116.0,,50597,
9791,Half-life of compound was determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626263,1,Intermediate,10116.0,,50597,
9792,Half-life at 10 mg/kg in rat upon intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625270,1,Intermediate,10116.0,,50597,
9793,Half-life determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625271,1,Intermediate,10116.0,,50597,
9794,Half-life determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625272,1,Intermediate,10116.0,,50597,
9795,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625273,1,Intermediate,10116.0,,50597,
9796,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625274,1,Intermediate,10116.0,,50597,
9797,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625275,1,Intermediate,10116.0,,50597,
9798,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625276,1,Intermediate,10116.0,,50597,
9799,Half-life in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625277,1,Intermediate,10116.0,,50597,
9800,Half-life in rat plasma was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625278,1,Intermediate,10116.0,,50597,
9801,Half-life in rat plasma; Not tested,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625279,1,Intermediate,10116.0,,50597,
9802,Half-life in rat serum,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL625280,1,Intermediate,10116.0,,50597,
9803,Half-life in rat serum; na is not available,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL876797,1,Intermediate,10116.0,,50597,
9804,Half-life was calculated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625281,1,Intermediate,10116.0,,50597,
9805,Half-life was calculated in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL873827,1,Intermediate,10116.0,,50597,
9806,Half-life was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625282,1,Intermediate,10116.0,,50597,
9807,Half-life was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625283,1,Intermediate,10116.0,,50597,
9808,Half-life after administration of 20 mg/Kg oral dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625284,1,Intermediate,10116.0,,50597,
9809,Half-life after administration of 3.2 mg/kg intravenously in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625285,1,Intermediate,10116.0,,50597,
9810,Half-life after intravenous administration in female rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625286,1,Intermediate,10116.0,,50597,
9811,Half-life after intravenous administration in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625287,1,Intermediate,10116.0,,50597,
9812,Half-life after intravenous dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625288,1,Intermediate,10116.0,,50597,
9813,Half-life in a rat liver homogenate preparation,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625289,1,Intermediate,10116.0,,50597,
9814,Half-life in plasma of rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625290,1,Intermediate,10116.0,,50597,
9815,Half-life in plasma of rat at dose of 3-10 mgkg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876798,1,Intermediate,10116.0,,50597,
9816,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625291,1,Intermediate,10116.0,,50597,
9817,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625292,1,Intermediate,10116.0,,50597,
9818,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625293,1,Intermediate,10116.0,,50597,
9819,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622832,1,Intermediate,10116.0,,50597,
9820,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622833,1,Intermediate,10116.0,,50597,
9821,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622834,1,Intermediate,10116.0,,50597,
9822,Half-life in rat after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622835,1,Intermediate,10116.0,,50597,
9823,Half-life in rat after po administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622836,1,Intermediate,10116.0,,50597,
9824,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622837,1,Intermediate,10116.0,,50597,
9825,Half-life in rat at 3 mg/kg dose administered intravenously,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622838,1,Intermediate,10116.0,,50597,
9826,Half-life in rat brain homogenate,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622839,1,Intermediate,10116.0,,50597,
9827,Half-life in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622840,1,Intermediate,10116.0,,50597,
9828,Half-life in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622841,1,Intermediate,10116.0,,50597,
9829,Half-life in Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622842,1,Intermediate,10116.0,,50597,
9830,Half-life in vitro in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622843,1,Intermediate,10116.0,,50597,
9831,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622844,1,Intermediate,10116.0,,50597,
9832,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622845,1,Intermediate,10116.0,,50597,
9833,The area under the curve of compound was measured at the dose of 100 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622846,1,Intermediate,10116.0,,50597,
9834,The area under the curve of compound was measured at the dose of 300 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622847,1,Intermediate,10116.0,,50597,
9835,The area under the curve of compound was measured at the dose of 30 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622848,1,Intermediate,10116.0,,50597,
9836,Bioavailability as oral AUC in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622849,1,Intermediate,10116.0,,50597,
9837,The plasma concentration versus time curve (AUC) was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622850,1,Intermediate,10116.0,,50597,
9838,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876807,1,Intermediate,10116.0,,50597,
9839,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622851,1,Intermediate,10116.0,,50597,
9840,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622852,1,Intermediate,10116.0,,50597,
9841,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622853,1,Intermediate,10116.0,,50597,
9842,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622854,1,Intermediate,10116.0,,50597,
9843,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622855,1,Intermediate,10116.0,,50597,
9844,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622856,1,Intermediate,10116.0,,50597,
9845,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622857,1,Intermediate,10116.0,,50597,
9846,AUC in rat after po administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622858,1,Intermediate,10116.0,,50597,
9847,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622859,1,Intermediate,10116.0,,50597,
9848,Area under curve value 24 hr after 10 mg/kg iv administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622860,1,Intermediate,10116.0,,50597,
9849,Area under curve value 24 hr after 10 mg/kg oral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622861,1,Intermediate,10116.0,,50597,
9850,Area under curve value 24 hr after 2 mg/kg iv administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622862,1,Intermediate,10116.0,,50597,
9851,Area under curve value 24 hr after 2 mg/kg oral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622863,1,Intermediate,10116.0,,50597,
9852,Area under curve value 6 hr after po administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623817,1,Intermediate,10116.0,,50597,
9853,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623818,1,Intermediate,10116.0,,50597,
9854,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623819,1,Intermediate,10116.0,,50597,
9855,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623820,1,Intermediate,10116.0,,50597,
9856,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623821,1,Intermediate,10116.0,,50597,
9857,AUC normalized for dose (AUCN) in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623822,1,Intermediate,10116.0,,50597,
9858,Area under curve in rat after p.o. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623823,1,Intermediate,10116.0,,50597,
9859,Area under curve in rat after p.o. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623824,1,Intermediate,10116.0,,50597,
9860,Area under curve in rat after p.o. administration; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623825,1,Intermediate,10116.0,,50597,
9861,Area under curve in rat after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622070,1,Intermediate,10116.0,,50597,
9862,Area under curve (carotid artery) value of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622071,1,Intermediate,10116.0,,50597,
9863,Bioavailability expressed as the area under curve of rat carotid artery,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622072,1,Intermediate,10116.0,,50597,
9864,Area under curve in male SD rats was observed after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622073,1,Intermediate,10116.0,,50597,
9865,Area under curve of the compound was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622074,1,Intermediate,10116.0,,50597,
9866,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622075,1,Intermediate,10116.0,,50597,
9867,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622076,1,Intermediate,10116.0,,50597,
9868,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622077,1,Intermediate,10116.0,,50597,
9869,Area under curve (portal vein) value of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622078,1,Intermediate,10116.0,,50597,
9870,Bioavailability expressed as the area under curve of rat portal vein,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622079,1,Intermediate,10116.0,,50597,
9871,Area Under plasma concentration time curve in rat upon peroral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622080,1,Intermediate,10116.0,,50597,
9872,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877612,1,Intermediate,10116.0,,50597,
9873,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622081,1,Intermediate,10116.0,,50597,
9874,Compound was evaluated for oral bioavailability in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622082,1,Intermediate,10116.0,,50597,
9875,Compound was evaluated for oral bioavailability in rats after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622083,1,Intermediate,10116.0,,50597,
9876,Compound was evaluated for oral bioavailability in rats; 30-80,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622084,1,Intermediate,10116.0,,50597,
9877,Compound was evaluated for oral bioavailability in rats; 50-60,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622085,1,Intermediate,10116.0,,50597,
9878,Compound was evaluated for oral bioavailability in rats; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622086,1,Intermediate,10116.0,,50597,
9879,Compound was evaluated for oral bioavailability in rats; peptide,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622087,1,Intermediate,10116.0,,50597,
9880,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622088,1,Intermediate,10116.0,,50597,
9881,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622089,1,Intermediate,10116.0,,50597,
9882,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623685,1,Intermediate,10116.0,,50597,
9883,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623686,1,Intermediate,10116.0,,50597,
9884,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL623687,1,Intermediate,10116.0,,50597,
9885,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL623688,1,Intermediate,10116.0,,50597,
9886,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL623689,1,Intermediate,10116.0,,50597,
9887,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Stomach,,945.0,BAO_0000218,CHEMBL622485,1,Intermediate,10116.0,,50597,
9888,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622486,1,Intermediate,10116.0,,50597,
9889,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL877613,1,Intermediate,10116.0,,50597,
9890,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622487,1,Intermediate,10116.0,,50597,
9891,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622488,1,Intermediate,10116.0,,50597,
9892,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622489,1,Intermediate,10116.0,,50597,
9893,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622490,1,Intermediate,10116.0,,50597,
9894,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622491,1,Intermediate,10116.0,,50597,
9895,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622492,1,Intermediate,10116.0,,50597,
9896,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622493,1,Intermediate,10116.0,,50597,
9897,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622494,1,Intermediate,10116.0,,50597,
9898,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622495,1,Intermediate,10116.0,,50597,
9899,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622496,1,Intermediate,10116.0,,50597,
9900,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622497,1,Intermediate,10116.0,,50597,
9901,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622498,1,Intermediate,10116.0,,50597,
9902,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624918,1,Intermediate,10116.0,,50597,
9903,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624919,1,Intermediate,10116.0,,50597,
9904,Biodistribution of compound in rat blood after 5 min of administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624920,1,Intermediate,10116.0,,50597,
9905,Biodistribution of compound in rat blood after 5 min of administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624921,1,Intermediate,10116.0,,50597,
9906,Biodistribution of compound in rat brain after 5 min of administration,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624922,1,Intermediate,10116.0,,50597,
9907,Biodistribution of compound in rat heart after 5 min of administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624923,1,Intermediate,10116.0,,50597,
9908,Biodistribution of compound in rat heart after 5 min of administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624924,1,Intermediate,10116.0,,50597,
9909,Biodistribution of compound in rat kidney after 5 min of administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624925,1,Intermediate,10116.0,,50597,
9910,Biodistribution of compound in rat kidney after 5 min of administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624926,1,Intermediate,10116.0,,50597,
9911,Biodistribution of compound in rat liver after 5 min of administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624927,1,Intermediate,10116.0,,50597,
9912,Biodistribution of compound in rat liver after 5 min of administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL874402,1,Intermediate,10116.0,,50597,
9913,Biodistribution of compound in rat lung after 5 min of administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624928,1,Intermediate,10116.0,,50597,
9914,Biodistribution of compound in rat lung after 5 min of administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624929,1,Intermediate,10116.0,,50597,
9915,Biodistribution of compound in rat muscle after 5 min of administration,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624930,1,Intermediate,10116.0,,50597,
9916,Biodistribution of compound in rat muscle after 5 min of administration.,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624931,1,Intermediate,10116.0,,50597,
9917,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624932,1,Intermediate,10116.0,,50597,
9918,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624933,1,Intermediate,10116.0,,50597,
9919,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624934,1,Intermediate,10116.0,,50597,
9920,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624935,1,Intermediate,10116.0,,50597,
9921,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624936,1,Intermediate,10116.0,,50597,
9922,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624937,1,Intermediate,10116.0,,50597,
9923,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624938,1,Intermediate,10116.0,,50597,
9924,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624939,1,Intermediate,10116.0,,50597,
9925,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624940,1,Intermediate,10116.0,,50597,
9926,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874403,1,Intermediate,10116.0,,50597,
9927,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624941,1,Intermediate,10116.0,,50597,
9928,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624942,1,Intermediate,10116.0,,50597,
9929,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624943,1,Intermediate,10116.0,,50597,
9930,% Bioavailability after 1 day of the drug administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624944,1,Intermediate,10116.0,,50597,
9931,% Bioavailability after 4 day of the drug administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624945,1,Intermediate,10116.0,,50597,
9932,Absolute bioavailability was evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624946,1,Intermediate,10116.0,,50597,
9933,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624947,1,Intermediate,10116.0,,50597,
9934,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624948,1,Intermediate,10116.0,,50597,
9935,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624949,1,Intermediate,10116.0,,50597,
9936,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622025,1,Intermediate,10116.0,,50597,
9937,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622026,1,Intermediate,10116.0,,50597,
9938,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622027,1,Intermediate,10116.0,,50597,
9939,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622028,1,Intermediate,10116.0,,50597,
9940,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622029,1,Intermediate,10116.0,,50597,
9941,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622208,1,Intermediate,10116.0,,50597,
9942,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622209,1,Intermediate,10116.0,,50597,
9943,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622210,1,Intermediate,10116.0,,50597,
9944,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622211,1,Intermediate,10116.0,,50597,
9945,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622212,1,Intermediate,10116.0,,50597,
9946,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622213,1,Intermediate,10116.0,,50597,
9947,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874404,1,Intermediate,10116.0,,50597,
9948,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620452,1,Intermediate,10116.0,,50597,
9949,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620453,1,Intermediate,10116.0,,50597,
9950,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL620454,1,Intermediate,10116.0,,50597,
9951,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624067,1,Intermediate,10116.0,,50597,
9952,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624068,1,Intermediate,10116.0,,50597,
9953,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL624069,1,Intermediate,10116.0,,50597,
9954,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL624070,1,Intermediate,10116.0,,50597,
9955,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL624071,1,Intermediate,10116.0,,50597,
9956,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL624072,1,Intermediate,10116.0,,50597,
9957,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL624073,1,Intermediate,10116.0,,50597,
9958,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL624788,1,Intermediate,10116.0,,50597,
9959,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL624789,1,Intermediate,10116.0,,50597,
9960,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624790,1,Intermediate,10116.0,,50597,
9961,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624791,1,Intermediate,10116.0,,50597,
9962,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624792,1,Intermediate,10116.0,,50597,
9963,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624793,1,Intermediate,10116.0,,50597,
9964,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL877491,1,Intermediate,10116.0,,50597,
9965,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624957,1,Intermediate,10116.0,,50597,
9966,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624958,1,Intermediate,10116.0,,50597,
9967,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624959,1,Intermediate,10116.0,,50597,
9968,Dissociation constant was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624960,1,Intermediate,10116.0,,50597,
9969,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624961,1,Intermediate,10116.0,,50597,
9970,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624962,1,Intermediate,10116.0,,50597,
9971,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624963,1,Intermediate,10116.0,,50597,
9972,Observed rate constant in 80% rat plasma at 37 degree Centigrade,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624964,1,Intermediate,10116.0,,50597,
9973,LogP value was evaluated in the in situ rat gut perfusion assay,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624965,1,Intermediate,10116.0,,50597,
9974,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624966,1,Intermediate,10116.0,,50597,
9975,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624967,1,Intermediate,10116.0,,50597,
9976,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624968,1,Intermediate,10116.0,,50597,
9977,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624969,1,Intermediate,10116.0,,50597,
9978,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624970,1,Expert,10116.0,,50597,
9979,Half-life was evaluated after 10 uM/kg of intra arterial administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624971,1,Intermediate,10116.0,,50597,
9980,Half-life was evaluated after 20 uM/kg of peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624972,1,Intermediate,10116.0,,50597,
9981,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624973,1,Intermediate,10116.0,,50597,
9982,Half-life was evaluated in plasma of rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624974,1,Intermediate,10116.0,,50597,
9983,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624975,1,Intermediate,10116.0,,50597,
9984,Half-life was evaluated in rats at an oral dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877492,1,Intermediate,10116.0,,50597,
9985,Half-life was measured in rat after an iv dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624976,1,Intermediate,10116.0,,50597,
9986,Half-life period of compound in rats after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624977,1,Intermediate,10116.0,,50597,
9987,Half-life period of compound was measured in rat plasma.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626848,1,Intermediate,10116.0,,50597,
9988,Half-life period of compound was measured in rat plasma; ND is not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626849,1,Intermediate,10116.0,,50597,
9989,Half-life period of compound was measured in rat plasma; not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626850,1,Intermediate,10116.0,,50597,
9990,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626851,1,Intermediate,10116.0,,50597,
9991,Half-life period in rat by iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626852,1,Intermediate,10116.0,,50597,
9992,Half-life period in rats following intravenous administration at 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626853,1,Intermediate,10116.0,,50597,
9993,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626854,1,Intermediate,10116.0,,50597,
9994,Half-life period was determined for the compound in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627486,1,Intermediate,10116.0,,50597,
9995,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627487,1,Intermediate,10116.0,,50597,
9996,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627488,1,Intermediate,10116.0,,50597,
9997,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627489,1,Intermediate,10116.0,,50597,
9998,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627490,1,Intermediate,10116.0,,50597,
9999,Half-life was determined in rat after intravenous administration (0.5 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873829,1,Intermediate,10116.0,,50597,
10000,Half-life was determined in rat at a dose of 1 mpk i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627655,1,Intermediate,10116.0,,50597,
10001,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625994,1,Intermediate,10116.0,,50597,
10002,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625995,1,Intermediate,10116.0,,50597,
10003,Half-life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625996,1,Intermediate,10116.0,,50597,
10004,In vitro half life in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625850,1,Intermediate,10116.0,,50597,
10005,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625851,1,Intermediate,10116.0,,50597,
10006,In vitro half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625852,1,Intermediate,10116.0,,50597,
10007,In vivo half life period after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625853,1,Intermediate,10116.0,,50597,
10008,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625854,1,Intermediate,10116.0,,50597,
10009,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874450,1,Intermediate,10116.0,,50597,
10010,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625855,1,Intermediate,10116.0,,50597,
10011,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625856,1,Intermediate,10116.0,,50597,
10012,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625857,1,Intermediate,10116.0,,50597,
10013,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873831,1,Intermediate,10116.0,,50597,
10014,Longer half-life in rat (i.v.) at 0.5 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625858,1,Intermediate,10116.0,,50597,
10015,Longer half-life in rat (p.o.) at 2.0 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625859,1,Intermediate,10116.0,,50597,
10016,Pharmacokinetic property (half life) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625860,1,Intermediate,10116.0,,50597,
10017,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625861,1,Intermediate,10116.0,,50597,
10018,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625862,1,Intermediate,10116.0,,50597,
10019,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625863,1,Intermediate,10116.0,,50597,
10020,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625864,1,Intermediate,10116.0,,50597,
10021,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625865,1,Intermediate,10116.0,,50597,
10022,Pharmacokinetic half time was determined intravenously in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625866,1,Intermediate,10116.0,,50597,
10023,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625867,1,Intermediate,10116.0,,50597,
10024,Plasma half life of hydrolysis of the compound,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625868,1,Intermediate,10116.0,,50597,
10025,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625869,1,Intermediate,10116.0,,50597,
10026,Plasma half life period was calculated in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL874451,1,Intermediate,10116.0,,50597,
10027,Plasma half-life in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625870,1,Intermediate,10116.0,,50597,
10028,Plasma half-life in Sprague-Dawley rats; Not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625871,1,Intermediate,10116.0,,50597,
10029,Plasma half-life in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625872,1,Intermediate,10116.0,,50597,
10030,Plasma half-life in rats; <MQL,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625873,1,Intermediate,10116.0,,50597,
10031,Plasma half-life period (0-8 h) was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625874,1,Intermediate,10116.0,,50597,
10032,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625875,1,Intermediate,10116.0,,50597,
10033,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625876,1,Intermediate,10116.0,,50597,
10034,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631258,1,Intermediate,10116.0,,50597,
10035,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631259,1,Intermediate,10116.0,,50597,
10036,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631260,1,Intermediate,10116.0,,50597,
10037,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631261,1,Intermediate,10116.0,,50597,
10038,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631262,1,Intermediate,10116.0,,50597,
10039,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631263,1,Intermediate,10116.0,,50597,
10040,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631264,1,Intermediate,10116.0,,50597,
10041,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631265,1,Intermediate,10116.0,,50597,
10042,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631266,1,Intermediate,10116.0,,50597,
10043,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631267,1,Intermediate,10116.0,,50597,
10044,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631268,1,Intermediate,10116.0,,50597,
10045,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631269,1,Intermediate,10116.0,,50597,
10046,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631270,1,Intermediate,10116.0,,50597,
10047,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631271,1,Intermediate,10116.0,,50597,
10048,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631272,1,Intermediate,10116.0,,50597,
10049,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631273,1,Intermediate,10116.0,,50597,
10050,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631274,1,Intermediate,10116.0,,50597,
10051,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631275,1,Intermediate,10116.0,,50597,
10052,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626984,1,Intermediate,10116.0,,50597,
10053,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626985,1,Intermediate,10116.0,,50597,
10054,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626986,1,Intermediate,10116.0,,50597,
10055,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626987,1,Intermediate,10116.0,,50597,
10056,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626988,1,Intermediate,10116.0,,50597,
10057,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626989,1,Intermediate,10116.0,,50597,
10058,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626990,1,Intermediate,10116.0,,50597,
10059,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626991,1,Intermediate,10116.0,,50597,
10060,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626992,1,Intermediate,10116.0,,50597,
10061,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626993,1,Intermediate,10116.0,,50597,
10062,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL874593,1,Intermediate,10116.0,,50597,
10063,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626994,1,Intermediate,10116.0,,50597,
10064,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626995,1,Intermediate,10116.0,,50597,
10065,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626190,1,Intermediate,10116.0,,50597,
10066,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626191,1,Intermediate,10116.0,,50597,
10067,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626364,1,Intermediate,10116.0,,50597,
10068,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626365,1,Intermediate,10116.0,,50597,
10069,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626366,1,Intermediate,10116.0,,50597,
10070,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626367,1,Intermediate,10116.0,,50597,
10071,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626368,1,Intermediate,10116.0,,50597,
10072,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626369,1,Intermediate,10116.0,,50597,
10073,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626370,1,Intermediate,10116.0,,50597,
10074,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626371,1,Intermediate,10116.0,,50597,
10075,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626372,1,Intermediate,10116.0,,50597,
10076,Bioavailability after a dose of 10 mg/kg p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626373,1,Intermediate,10116.0,,50597,
10077,Bioavailability after peroral administration (10 mg/kg) was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626374,1,Intermediate,10116.0,,50597,
10078,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626375,1,Intermediate,10116.0,,50597,
10079,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626376,1,Intermediate,10116.0,,50597,
10080,Bioavailability in rat po was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626377,1,Intermediate,10116.0,,50597,
10081,Bioavailability of compound at 10 mg/kg in rat after oral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626378,1,Intermediate,10116.0,,50597,
10082,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626379,1,Intermediate,10116.0,,50597,
10083,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626380,1,Intermediate,10116.0,,50597,
10084,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626381,1,Intermediate,10116.0,,50597,
10085,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626382,1,Intermediate,10116.0,,50597,
10086,Bioavailability in rat (Sprague-Dawley) (female),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626383,1,Intermediate,10116.0,,50597,
10087,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874652,1,Intermediate,10116.0,,50597,
10088,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626384,1,Intermediate,10116.0,,50597,
10089,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626385,1,Intermediate,10116.0,,50597,
10090,Bioavailability in rat at an oral dose of 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626386,1,Intermediate,10116.0,,50597,
10091,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626387,1,Intermediate,10116.0,,50597,
10092,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626388,1,Intermediate,10116.0,,50597,
10093,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626389,1,Intermediate,10116.0,,50597,
10094,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626390,1,Intermediate,10116.0,,50597,
10095,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626391,1,Intermediate,10116.0,,50597,
10096,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626392,1,Intermediate,10116.0,,50597,
10097,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626393,1,Intermediate,10116.0,,50597,
10098,Bioavailability was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623026,1,Intermediate,10116.0,,50597,
10099,Bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623027,1,Intermediate,10116.0,,50597,
10100,Bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623028,1,Intermediate,10116.0,,50597,
10101,Bioavailability in rat after 1 day dosing,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623029,1,Intermediate,10116.0,,50597,
10102,Bioavailability in rat after 4 day dosing,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623030,1,Intermediate,10116.0,,50597,
10103,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623031,1,Intermediate,10116.0,,50597,
10104,Bioavailability after IV dosing at 1 mg/kg in rat; no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623032,1,Intermediate,10116.0,,50597,
10105,Bioavailability after oral administration at a dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623033,1,Intermediate,10116.0,,50597,
10106,Bioavailability after oral administration at a dose of 4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623034,1,Intermediate,10116.0,,50597,
10107,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623035,1,Intermediate,10116.0,,50597,
10108,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623036,1,Intermediate,10116.0,,50597,
10109,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623037,1,Intermediate,10116.0,,50597,
10110,Bioavailability by intravenous administration of 3.4 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623038,1,Intermediate,10116.0,,50597,
10111,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL874385,1,Intermediate,10116.0,,50597,
10112,Bioavailability in rat (Fisher) (fasted),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623039,1,Intermediate,10116.0,,50597,
10113,Bioavailability in monkey after po administration of 10 mg/kg dose,1,U,,Primates,,,,,,,BAO_0000218,CHEMBL623040,0,Intermediate,9443.0,,22224,
10114,Oral bioavailability in monkey (dose 10 mg/kg),1,U,,Primates,,,,,,,BAO_0000218,CHEMBL623041,0,Intermediate,9443.0,,22224,
10115,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623741,1,Intermediate,10116.0,,50597,
10116,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623742,1,Intermediate,10116.0,,50597,
10117,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623743,1,Intermediate,10116.0,,50597,
10118,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623744,1,Intermediate,10116.0,,50597,
10119,Bioavailability in rat (dose 2.0 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623745,1,Intermediate,10116.0,,50597,
10120,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623746,1,Intermediate,10116.0,,50597,
10121,Oral bioavailability in rat (dose 5 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623747,1,Intermediate,10116.0,,50597,
10122,Bioavailability in rat after po administration of 30 mg/kg dose,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623748,0,Intermediate,10116.0,,22224,
10123,Bioavailability in rat after po administration of 30 mg/kg dose,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623916,0,Intermediate,10116.0,,22224,
10124,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623917,1,Intermediate,10116.0,,50597,
10125,Bioavailability in rat (dose 2 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623918,1,Intermediate,10116.0,,50597,
10126,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874386,1,Intermediate,10116.0,,50597,
10127,Bioavailability in rat; Only traces detected in rat plasma,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623919,1,Intermediate,10116.0,,50597,
10128,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623920,1,Intermediate,10116.0,,50597,
10129,Bioavailability upon oral administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623148,1,Intermediate,10116.0,,50597,
10130,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623149,1,Intermediate,10116.0,,50597,
10131,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623150,1,Intermediate,10116.0,,50597,
10132,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623151,1,Intermediate,10116.0,,50597,
10133,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623152,1,Intermediate,10116.0,,50597,
10134,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623153,1,Expert,10116.0,,50597,
10135,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623154,1,Expert,10116.0,,50597,
10136,In vitro and metabolic stability was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623155,1,Intermediate,10116.0,,50597,
10137,In vitro metabolic stability in rat hepatocytes,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623156,1,Intermediate,10116.0,,50597,
10138,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623157,1,Intermediate,10116.0,,50597,
10139,Metabolic rate for compound was observed in rat hepatocytes,1,N,,Rattus norvegicus,,,,Liver,Hepatocyte,2107.0,BAO_0000218,CHEMBL623158,1,Intermediate,10116.0,,50597,401.0
10140,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623159,1,Intermediate,10116.0,,50597,
10141,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874390,1,Intermediate,10116.0,,50597,
10142,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623160,1,Intermediate,10116.0,,50597,
10143,Metabolism of compound in rat S9 microsomes; Trace,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623161,1,Intermediate,10116.0,,50597,
10144,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623162,1,Intermediate,10116.0,,50597,
10145,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623163,1,Intermediate,10116.0,,50597,
10146,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623164,1,Intermediate,10116.0,,50597,
10147,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623165,1,Intermediate,10116.0,,50597,
10148,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623166,1,Intermediate,10116.0,,50597,
10149,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624983,1,Intermediate,10116.0,,50597,
10150,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624984,1,Intermediate,10116.0,,50597,
10151,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624985,1,Intermediate,10116.0,,50597,
10152,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622970,1,Intermediate,10116.0,,50597,
10153,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622971,1,Intermediate,10116.0,,50597,
10154,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622972,1,Intermediate,10116.0,,50597,
10155,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622973,1,Intermediate,10116.0,,50597,
10156,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622974,1,Intermediate,10116.0,,50597,
10157,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622975,1,Intermediate,10116.0,,50597,
10158,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622976,1,Intermediate,10116.0,,50597,
10159,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622977,1,Intermediate,10116.0,,50597,
10160,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624351,1,Intermediate,10116.0,,50597,
10161,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624352,1,Intermediate,10116.0,,50597,
10162,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624353,1,Intermediate,10116.0,,50597,
10163,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622397,1,Intermediate,10116.0,,50597,
10164,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622398,1,Intermediate,10116.0,,50597,
10165,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622399,1,Intermediate,10116.0,,50597,
10166,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622400,1,Intermediate,10116.0,,50597,
10167,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628428,1,Intermediate,10116.0,,50597,
10168,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628590,1,Intermediate,10116.0,,50597,
10169,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628591,1,Intermediate,10116.0,,50597,
10170,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628592,1,Intermediate,10116.0,,50597,
10171,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628593,1,Intermediate,10116.0,,50597,
10172,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875333,1,Intermediate,10116.0,,50597,
10173,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628594,1,Intermediate,10116.0,,50597,
10174,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628595,1,Intermediate,10116.0,,50597,
10175,Stability in rat plasma was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628596,1,Intermediate,10116.0,,50597,
10176,Stability in rat plasma was determined; ND= no data,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628597,1,Intermediate,10116.0,,50597,
10177,Tested for plasma half life period in rat (0-8 hr),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628598,1,Intermediate,10116.0,,50597,
10178,Tested for plasma half life period in rat (0-8 hr); Not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628599,1,Intermediate,10116.0,,50597,
10179,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628600,1,Intermediate,10116.0,,50597,
10180,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628601,1,Intermediate,10116.0,,50597,
10181,Tested for the half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628602,1,Intermediate,10116.0,,50597,
10182,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628603,1,Intermediate,10116.0,,50597,
10183,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628604,1,Intermediate,10116.0,,50597,
10184,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628605,1,Intermediate,10116.0,,50597,
10185,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628606,1,Intermediate,10116.0,,50597,
10186,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628607,1,Intermediate,10116.0,,50597,
10187,The biological half life the compound was measured at the dose of 100 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628608,1,Intermediate,10116.0,,50597,
10188,The biological half life the compound was measured at the dose of 30 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628609,1,Intermediate,10116.0,,50597,
10189,The compound was evaluated for plasma half life period in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628610,1,Intermediate,10116.0,,50597,
10190,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL873819,1,Intermediate,10116.0,,50597,
10191,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628611,1,Intermediate,10116.0,,50597,
10192,The pharmacokinetic parameter half-life period in vivo in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628612,1,Intermediate,10116.0,,50597,
10193,"The pharmacokinetic property, Half-life was determined",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628613,1,Intermediate,10116.0,,50597,
10194,"The pharmacokinetic property, Half-life in rat in vivo",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628614,1,Intermediate,10116.0,,50597,
10195,"The pharmacokinetic property, Half-life was determined; ND denotes no data",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628615,1,Intermediate,10116.0,,50597,
10196,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628616,1,Intermediate,10116.0,,50597,
10197,The plasma half life period in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627924,1,Intermediate,10116.0,,50597,
10198,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627925,1,Intermediate,10116.0,,50597,
10199,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627926,1,Intermediate,10116.0,,50597,
10200,t1/2 (apparent elimination)of the compound was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627927,1,Intermediate,10116.0,,50597,
10201,t1/2 value in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627928,1,Intermediate,10116.0,,50597,
10202,Half life in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627539,1,Intermediate,10116.0,,50597,
10203,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876790,1,Intermediate,10116.0,,50597,
10204,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL858186,1,Intermediate,10116.0,,50597,
10205,Half-life period in fasted rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627540,1,Intermediate,10116.0,,50597,
10206,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627541,1,Intermediate,10116.0,,50597,
10207,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627715,1,Intermediate,10116.0,,50597,
10208,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627716,1,Intermediate,10116.0,,50597,
10209,Maximum time required to achieve Cmax was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627717,1,Intermediate,10116.0,,50597,
10210,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627718,1,Intermediate,10116.0,,50597,
10211,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627719,1,Intermediate,10116.0,,50597,
10212,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627720,1,Intermediate,10116.0,,50597,
10213,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627721,1,Intermediate,10116.0,,50597,
10214,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627722,1,Intermediate,10116.0,,50597,
10215,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627723,1,Intermediate,10116.0,,50597,
10216,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626058,1,Intermediate,10116.0,,50597,
10217,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626059,1,Intermediate,10116.0,,50597,
10218,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626060,1,Intermediate,10116.0,,50597,
10219,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626061,1,Intermediate,10116.0,,50597,
10220,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876791,1,Intermediate,10116.0,,50597,
10221,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626062,1,Intermediate,10116.0,,50597,
10222,Tmax at the dose of 2 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626063,1,Intermediate,10116.0,,50597,
10223,Tmax at the dose of 5 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626064,1,Intermediate,10116.0,,50597,
10224,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626065,1,Intermediate,10116.0,,50597,
10225,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626066,1,Intermediate,10116.0,,50597,
10226,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626067,1,Intermediate,10116.0,,50597,
10227,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626068,1,Intermediate,10116.0,,50597,
10228,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626069,1,Intermediate,10116.0,,50597,
10229,Percent total excretion of 3-methoxyacetaminophen glucuronide,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626070,1,Intermediate,10116.0,,50597,
10230,Percent total excretion of N-methoxyacetaminophen glucuronide,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626071,1,Intermediate,10116.0,,50597,
10231,Percent total excretion of N-methoxyacetaminophen sulfate,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626072,1,Intermediate,10116.0,,50597,
10232,Percent total excretion of acetaminophen,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626073,1,Intermediate,10116.0,,50597,
10233,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626741,1,Intermediate,10116.0,,50597,
10234,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626742,1,Intermediate,10116.0,,50597,
10235,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626743,1,Intermediate,10116.0,,50597,
10236,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876792,1,Intermediate,10116.0,,50597,
10237,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626744,1,Intermediate,10116.0,,50597,
10238,Compound was tested for antidiuretic activity in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626745,1,Intermediate,10116.0,,50597,
10239,AUC in rat after 3mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626746,1,Intermediate,10116.0,,50597,
10240,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626747,1,Intermediate,10116.0,,50597,
10241,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626748,1,Intermediate,10116.0,,50597,
10242,Bioavailability administered orally at a dose of 10 mg/kg to rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626749,1,Intermediate,10116.0,,50597,
10243,Oral Bioavailability was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626750,1,Intermediate,10116.0,,50597,
10244,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626751,1,Intermediate,10116.0,,50597,
10245,Oral bioavailability in rat; Not performed.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626913,1,Intermediate,10116.0,,50597,
10246,Bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626914,1,Intermediate,10116.0,,50597,
10247,Bioavailability was determined; ND denotes no data,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626915,1,Intermediate,10116.0,,50597,
10248,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626916,1,Intermediate,10116.0,,50597,
10249,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626917,1,Intermediate,10116.0,,50597,
10250,Binding towards rat plasma protein at 10 uM,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626918,1,Intermediate,10116.0,,50597,
10251,Binding towards rat plasma protein at 100 uM,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626919,1,Intermediate,10116.0,,50597,
10252,Bioavailability in rat (dose 20 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626920,1,Intermediate,10116.0,,50597,
10253,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621976,1,Intermediate,10116.0,,50597,
10254,Bioavailability in rat after 5 mg/kg oral gavage,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877599,1,Intermediate,10116.0,,50597,
10255,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621977,1,Intermediate,10116.0,,50597,
10256,Bioavailability in rat (dose 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621978,1,Intermediate,10116.0,,50597,
10257,Bioavailability in rat (dose 3 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621979,1,Intermediate,10116.0,,50597,
10258,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621980,1,Intermediate,10116.0,,50597,
10259,Bioavailability of the compound in rats after administration of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621981,1,Intermediate,10116.0,,50597,
10260,Bioavailability after administration of 10 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621982,1,Intermediate,10116.0,,50597,
10261,Bioavailability after administration of 2 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL882953,1,Intermediate,10116.0,,50597,
10262,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621983,1,Intermediate,10116.0,,50597,
10263,Bioavailability in dogs was determined; high,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621984,1,Intermediate,10116.0,,50597,
10264,Bioavailability in monkey after intravenous administration at 1 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621985,1,Intermediate,10116.0,,50597,
10265,Bioavailability in monkey after peroral administration at 10 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621986,1,Intermediate,10116.0,,50597,
10266,Bioavailability in rat after intravenous administration at 1 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621987,1,Intermediate,10116.0,,50597,
10267,Bioavailability in rat after intravenous administration at 2 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877600,1,Intermediate,10116.0,,50597,
10268,Bioavailability in rat after peroral administration at 30 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621988,1,Intermediate,10116.0,,50597,
10269,Bioavailability in rat after peroral administration at at 100 mpk,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621989,1,Intermediate,10116.0,,50597,
10270,Bioavailability in rats was evaluated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621990,1,Intermediate,10116.0,,50597,
10271,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621991,1,Intermediate,10116.0,,50597,
10272,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621992,1,Intermediate,10116.0,,50597,
10273,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621993,1,Intermediate,10116.0,,50597,
10274,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621994,1,Intermediate,10116.0,,50597,
10275,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621995,1,Intermediate,10116.0,,50597,
10276,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621996,1,Intermediate,10116.0,,50597,
10277,Oral bioavailability in rat (dose 10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621997,1,Intermediate,10116.0,,50597,
10278,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621998,1,Intermediate,10116.0,,50597,
10279,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621999,1,Intermediate,10116.0,,50597,
10280,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622000,1,Intermediate,10116.0,,50597,
10281,Bioavailability was measured in rat after oral administration; 2-4,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622001,1,Intermediate,10116.0,,50597,
10282,Bioavailability was measured in rat after oral administration; 3-7,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622002,1,Intermediate,10116.0,,50597,
10283,Bioavailability in rat (intraduodenal administration),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622003,1,Intermediate,10116.0,,50597,
10284,Bioavailability in rat (intraduodenal administration),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877601,1,Intermediate,10116.0,,50597,
10285,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624871,1,Intermediate,10116.0,,50597,
10286,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622004,1,Intermediate,10116.0,,50597,
10287,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL882954,1,Intermediate,10116.0,,50597,
10288,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622005,1,Intermediate,10116.0,,50597,
10289,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622006,1,Intermediate,10116.0,,50597,
10290,Bioavailability was measured in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622007,1,Intermediate,10116.0,,50597,
10291,Bioavailability was reported,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622008,1,Intermediate,10116.0,,50597,
10292,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622009,1,Intermediate,10116.0,,50597,
10293,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622010,1,Intermediate,10116.0,,50597,
10294,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622011,1,Intermediate,10116.0,,50597,
10295,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622012,1,Intermediate,10116.0,,50597,
10296,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622013,1,Intermediate,10116.0,,50597,
10297,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622014,1,Intermediate,10116.0,,50597,
10298,Bioavailability was determined at 3 mg/kg po dose in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624749,1,Intermediate,10116.0,,50597,
10299,Oral bioavailability in rat (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624750,1,Intermediate,10116.0,,50597,
10300,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624751,1,Intermediate,10116.0,,50597,
10301,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624752,1,Intermediate,10116.0,,50597,
10302,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624753,1,Intermediate,10116.0,,50597,
10303,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624754,1,Intermediate,10116.0,,50597,
10304,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624755,1,Intermediate,10116.0,,50597,
10305,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624756,1,Intermediate,10116.0,,50597,
10306,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624757,1,Intermediate,10116.0,,50597,
10307,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624758,1,Intermediate,10116.0,,50597,
10308,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622270,1,Intermediate,10116.0,,50597,
10309,Bioavailability in rat (Sprague-Dawley),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622271,1,Intermediate,10116.0,,50597,
10310,Bioavailability in rat at the dose of 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622272,1,Intermediate,10116.0,,50597,
10311,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622273,1,Intermediate,10116.0,,50597,
10312,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622274,1,Intermediate,10116.0,,50597,
10313,Bioavailability value of compound in rats was determined after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622275,1,Intermediate,10116.0,,50597,
10314,Oral bioavailability in rat (dose 20 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622276,1,Intermediate,10116.0,,50597,
10315,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622277,1,Intermediate,10116.0,,50597,
10316,Oral bioavailability in rat (dose 5 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622278,1,Intermediate,10116.0,,50597,
10317,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622279,1,Intermediate,10116.0,,50597,
10318,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622280,1,Intermediate,10116.0,,50597,
10319,Compound was evaluated for oral bioavailability in rats; 15-27 %,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624083,1,Intermediate,10116.0,,50597,
10320,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624084,1,Intermediate,10116.0,,50597,
10321,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624085,1,Intermediate,10116.0,,50597,
10322,Compound was tested for bioavailability in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624086,1,Intermediate,10116.0,,50597,
10323,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624087,1,Intermediate,10116.0,,50597,
10324,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624088,1,Intermediate,10116.0,,50597,
10325,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL624089,0,Intermediate,9544.0,,22224,
10326,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624090,0,Intermediate,10116.0,,22224,
10327,Evaluated for the bioavailability in rat (in vivo),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624091,1,Intermediate,10116.0,,50597,
10328,F value of compound in rats was determined after peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624092,1,Intermediate,10116.0,,50597,
10329,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624093,1,Intermediate,10116.0,,50597,
10330,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624094,1,Intermediate,10116.0,,50597,
10331,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624095,1,Intermediate,10116.0,,50597,
10332,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624096,1,Intermediate,10116.0,,50597,
10333,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624097,1,Intermediate,10116.0,,50597,
10334,Maximum fall in carotid flow in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624098,1,Intermediate,10116.0,,50597,
10335,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874392,1,Intermediate,10116.0,,50597,
10336,Oral bioavailability in rat (dose 5 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624099,1,Intermediate,10116.0,,50597,
10337,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624100,1,Intermediate,10116.0,,50597,
10338,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624101,1,Intermediate,10116.0,,50597,
10339,Oral bioavailability in rat (male Wistar),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624102,1,Intermediate,10116.0,,50597,
10340,Oral bioavailability after administration (30 mg/kg) in rat; good,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624103,1,Intermediate,10116.0,,50597,
10341,Oral bioavailability at the dose of 2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624104,1,Intermediate,10116.0,,50597,
10342,Oral bioavailability determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624105,1,Intermediate,10116.0,,50597,
10343,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624106,1,Intermediate,10116.0,,50597,
10344,Oral bioavailability in rat (dose single 10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624107,1,Intermediate,10116.0,,50597,
10345,Oral bioavailability in rat (dose single 10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623943,1,Intermediate,10116.0,,50597,
10346,Oral bioavailability in rat (dose 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623944,1,Intermediate,10116.0,,50597,
10347,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623945,1,Intermediate,10116.0,,50597,
10348,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623946,1,Intermediate,10116.0,,50597,
10349,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623947,1,Intermediate,10116.0,,50597,
10350,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623948,1,Intermediate,10116.0,,50597,
10351,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623949,1,Intermediate,10116.0,,50597,
10352,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623950,1,Intermediate,10116.0,,50597,
10353,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874398,1,Intermediate,10116.0,,50597,
10354,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623951,1,Intermediate,10116.0,,50597,
10355,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623952,1,Intermediate,10116.0,,50597,
10356,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623953,1,Intermediate,10116.0,,50597,
10357,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623954,1,Intermediate,10116.0,,50597,
10358,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623955,1,Intermediate,10116.0,,50597,
10359,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623956,1,Intermediate,10116.0,,50597,
10360,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627807,1,Intermediate,10116.0,,50597,
10361,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627808,1,Intermediate,10116.0,,50597,
10362,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627809,1,Intermediate,10116.0,,50597,
10363,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627810,1,Intermediate,10116.0,,50597,
10364,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627811,1,Intermediate,10116.0,,50597,
10365,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627812,1,Intermediate,10116.0,,50597,
10366,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627813,1,Intermediate,10116.0,,50597,
10367,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627814,1,Intermediate,10116.0,,50597,
10368,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875336,1,Intermediate,10116.0,,50597,
10369,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627815,1,Intermediate,10116.0,,50597,
10370,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627816,1,Intermediate,10116.0,,50597,
10371,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627817,1,Intermediate,10116.0,,50597,
10372,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627818,1,Intermediate,10116.0,,50597,
10373,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627819,1,Intermediate,10116.0,,50597,
10374,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627820,1,Intermediate,10116.0,,50597,
10375,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627821,1,Intermediate,10116.0,,50597,
10376,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628464,1,Intermediate,10116.0,,50597,
10377,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626239,1,Intermediate,10116.0,,50597,
10378,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626240,1,Intermediate,10116.0,,50597,
10379,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626241,1,Intermediate,10116.0,,50597,
10380,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626242,1,Intermediate,10116.0,,50597,
10381,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626243,1,Intermediate,10116.0,,50597,
10382,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626244,1,Intermediate,10116.0,,50597,
10383,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626907,1,Intermediate,10116.0,,50597,
10384,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626908,1,Intermediate,10116.0,,50597,
10385,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626909,1,Intermediate,10116.0,,50597,
10386,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626910,1,Intermediate,10116.0,,50597,
10387,Percent total excretion of acetaminophen cysteine conjugate,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875342,1,Intermediate,10116.0,,50597,
10388,Percent total excretion of acetaminophen glucuronide,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626911,1,Intermediate,10116.0,,50597,
10389,Percent total excretion of acetaminophen sulfate,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626912,1,Intermediate,10116.0,,50597,
10390,Percent total excretion of acetaminophen-mercapturic acid,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627065,1,Intermediate,10116.0,,50597,
10391,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627066,1,Intermediate,10116.0,,50597,
10392,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627067,1,Intermediate,10116.0,,50597,
10393,Biodistribution of compound in rat muscle after 5 min of administration,1,U,,ratrat,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627068,0,Autocuration,8656.0,,22224,
10394,Biodistribution of compound in rat muscle after 5 min of administration.,1,U,,ratrat,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627069,0,Autocuration,8656.0,,22224,
10395,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,,,,BAO_0000218,CHEMBL627070,0,Autocuration,9940.0,,22224,
10396,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,,,,BAO_0000218,CHEMBL627071,0,Autocuration,9940.0,,22224,
10397,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,,,,BAO_0000218,CHEMBL627072,0,Autocuration,9940.0,,22224,
10398,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,,,,BAO_0000218,CHEMBL627073,0,Autocuration,9940.0,,22224,
10399,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,,,,BAO_0000218,CHEMBL625387,0,Autocuration,9940.0,,22224,
10400,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,,,,BAO_0000218,CHEMBL625388,0,Autocuration,9940.0,,22224,
10401,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625389,0,Autocuration,9940.0,,22224,
10402,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,U,,Ovis aries,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875343,0,Autocuration,9940.0,,22224,
10403,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1,N,,Serpentes,,,,,,,BAO_0000218,CHEMBL876795,1,Intermediate,8570.0,,50497,
10404,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1,N,,Serpentes,,,,,,,BAO_0000218,CHEMBL626552,1,Intermediate,8570.0,,50497,
10405,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1,N,,Serpentes,,,,,,,BAO_0000218,CHEMBL626553,1,Intermediate,8570.0,,50497,
10406,The human biological plasma half life of the compound,1,U,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000366,CHEMBL626554,0,Autocuration,9606.0,,22224,
10407,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626555,1,Intermediate,10116.0,,50597,
10408,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626556,1,Intermediate,10116.0,,50597,
10409,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626557,1,Intermediate,10116.0,,50597,
10410,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626558,1,Intermediate,10116.0,,50597,
10411,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626559,1,Intermediate,10116.0,,50597,
10412,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626560,1,Intermediate,10116.0,,50597,
10413,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876803,1,Intermediate,10116.0,,50597,
10414,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627964,1,Intermediate,10116.0,,50597,
10415,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627965,1,Intermediate,10116.0,,50597,
10416,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627966,1,Intermediate,10116.0,,50597,
10417,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627967,1,Intermediate,10116.0,,50597,
10418,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627968,1,Intermediate,10116.0,,50597,
10419,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627969,1,Intermediate,10116.0,,50597,
10420,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627970,1,Intermediate,10116.0,,50597,
10421,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627971,1,Intermediate,10116.0,,50597,
10422,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627972,1,Intermediate,10116.0,,50597,
10423,Dissociation constant against binding to human cyclophilin A,1,D,,Homo sapiens,,,,,,,BAO_0000357,CHEMBL856029,9,Expert,9606.0,,180,
10424,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,1,H,,Bos taurus,,,,,,,BAO_0000019,CHEMBL627973,8,Expert,9913.0,,11591,
10425,-Log C was determined by performing the electroshock minimum test,1,U,,,,,,,,,BAO_0000019,CHEMBL627974,0,Autocuration,,,22224,
10426,-Log C was determined by performing the foot shock test,1,U,,,,,,,,,BAO_0000019,CHEMBL627975,0,Autocuration,,,22224,
10427,-Log C was determined by performing the incl screen test,1,U,,,,,,,,,BAO_0000019,CHEMBL627976,0,Autocuration,,,22224,
10428,-Log C was determined by performing the maximum electroshock test,1,U,,,,,,,,,BAO_0000019,CHEMBL627977,0,Autocuration,,,22224,
10429,-Log C was determined by performing the pentylenetetrazole test,1,U,,,,,,,,,BAO_0000019,CHEMBL627978,0,Autocuration,,,22224,
10430,Tested for experimental arotinoid inhibitory dose,1,U,,,,,,,,,BAO_0000019,CHEMBL627979,0,Autocuration,,,22224,
10431,Negative log transformed activity,1,U,,,,,,,,,BAO_0000019,CHEMBL876804,0,Autocuration,,,22224,
10432,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",1,U,,,,,,,,,BAO_0000019,CHEMBL627980,0,Autocuration,,,22224,
10433,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL627981,1,Intermediate,10141.0,,50512,
10434,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL627982,1,Intermediate,10141.0,,50512,
10435,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL627983,1,Intermediate,10141.0,,50512,
10436,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,1,N,,Cavia porcellus,,,,Ileum,,2116.0,BAO_0000218,CHEMBL627984,1,Intermediate,10141.0,,50512,
10437,Solubility in water was determined; values expressed as -log,1,U,,,,,,,,,BAO_0000100,CHEMBL627985,0,Autocuration,,,22229,
10438,Ratio of Kcat to that of Km was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL627986,0,Autocuration,,,22224,
10439,Observed first order rate constant,1,U,,,,,,,,,BAO_0000019,CHEMBL627987,0,Autocuration,,,22224,
10440,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,1,U,,,,,,,,,BAO_0000019,CHEMBL627988,0,Autocuration,,,22224,
10441,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627989,1,Intermediate,10116.0,,50597,
10442,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627990,1,Intermediate,10116.0,,50597,
10443,Oral Bioavailability after administration of 10 mg/kg in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876805,1,Intermediate,10116.0,,50597,
10444,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627991,1,Intermediate,10116.0,,50597,
10445,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627992,1,Intermediate,10116.0,,50597,
10446,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627993,1,Intermediate,10116.0,,50597,
10447,Oral bioavailability at 1 mg/kg was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622817,1,Intermediate,10116.0,,50597,
10448,Oral bioavailability at 10 mg/kg was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622818,1,Intermediate,10116.0,,50597,
10449,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622819,1,Intermediate,10116.0,,50597,
10450,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL872267,1,Intermediate,10116.0,,50597,
10451,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622820,1,Intermediate,10116.0,,50597,
10452,Oral bioavailability after intravenous administration in rats at 24 uM/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622821,1,Intermediate,10116.0,,50597,
10453,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622822,1,Intermediate,10116.0,,50597,
10454,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622823,1,Intermediate,10116.0,,50597,
10455,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622824,1,Intermediate,10116.0,,50597,
10456,Oral bioavailability in rat at a dose of 3 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622825,1,Intermediate,10116.0,,50597,
10457,Oral bioavailability in rat after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622901,1,Intermediate,10116.0,,50597,
10458,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622902,1,Intermediate,10116.0,,50597,
10459,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621844,1,Intermediate,10116.0,,50597,
10460,Oral bioavailability in Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621845,1,Intermediate,10116.0,,50597,
10461,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621846,1,Intermediate,10116.0,,50597,
10462,Oral bioavailability in rat (dose 30 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621847,1,Intermediate,10116.0,,50597,
10463,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877609,1,Intermediate,10116.0,,50597,
10464,Bioavailability in rat (dose 3 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621848,1,Intermediate,10116.0,,50597,
10465,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621849,1,Intermediate,10116.0,,50597,
10466,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622030,1,Intermediate,10116.0,,50597,
10467,Percent oral bioavailability determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622031,1,Intermediate,10116.0,,50597,
10468,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622032,1,Intermediate,10116.0,,50597,
10469,The compound was evaluated for bioavailability in rats; 32-51,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622033,1,Intermediate,10116.0,,50597,
10470,Bioavailability in rat (dose 20 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622034,1,Intermediate,10116.0,,50597,
10471,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622035,1,Intermediate,10116.0,,50597,
10472,Bioavailability percent in rat at the dose of 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL882966,1,Intermediate,10116.0,,50597,
10473,Bioavailability was evaluated after 20 uM/kg of peroral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622036,1,Intermediate,10116.0,,50597,
10474,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622037,1,Intermediate,10116.0,,50597,
10475,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622038,1,Intermediate,10116.0,,50597,
10476,Bioavailability in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622039,1,Intermediate,10116.0,,50597,
10477,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622040,1,Intermediate,10116.0,,50597,
10478,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622041,1,Intermediate,10116.0,,50597,
10479,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622042,1,Intermediate,10116.0,,50597,
10480,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622043,1,Intermediate,10116.0,,50597,
10481,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622044,1,Intermediate,10116.0,,50597,
10482,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL622045,1,Intermediate,10116.0,,50597,
10483,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL622046,1,Intermediate,10116.0,,50597,
10484,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL622047,1,Intermediate,10116.0,,50597,
10485,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL877610,1,Intermediate,10116.0,,50597,
10486,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622048,1,Intermediate,10116.0,,50597,
10487,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622049,1,Intermediate,10116.0,,50597,
10488,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622050,1,Intermediate,10116.0,,50597,
10489,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622051,1,Intermediate,10116.0,,50597,
10490,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622052,1,Intermediate,10116.0,,50597,
10491,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622053,1,Intermediate,10116.0,,50597,
10492,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622054,1,Intermediate,10116.0,,50597,
10493,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622055,1,Intermediate,10116.0,,50597,
10494,Oral bioavailability in rats was determined; High,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622056,1,Intermediate,10116.0,,50597,
10495,Oral bioavailability in the rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622057,1,Intermediate,10116.0,,50597,
10496,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628008,1,Intermediate,10116.0,,50597,
10497,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622058,1,Intermediate,10116.0,,50597,
10498,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622059,1,Intermediate,10116.0,,50597,
10499,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622060,1,Intermediate,10116.0,,50597,
10500,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622061,1,Intermediate,10116.0,,50597,
10501,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622062,1,Intermediate,10116.0,,50597,
10502,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622063,1,Intermediate,10116.0,,50597,
10503,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877611,1,Expert,10116.0,,50597,
10504,Oral bioavailability of compound in Sprague Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622064,1,Intermediate,10116.0,,50597,
10505,Oral bioavailability of compound in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622065,1,Intermediate,10116.0,,50597,
10506,Oral bioavailability in rat (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622066,1,Intermediate,10116.0,,50597,
10507,Oral bioavailability of compound in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622067,1,Intermediate,10116.0,,50597,
10508,Oral bioavailability of compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622068,1,Intermediate,10116.0,,50597,
10509,Oral bioavailability of compound was determined in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622069,1,Intermediate,10116.0,,50597,
10510,Oral bioavailability at a dose of 30 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624796,1,Intermediate,10116.0,,50597,
10511,Oral bioavailability in rat (dose 10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624797,1,Intermediate,10116.0,,50597,
10512,Oral bioavailability in rat (dose 10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623053,1,Intermediate,10116.0,,50597,
10513,Oral bioavailability evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623054,1,Intermediate,10116.0,,50597,
10514,Oral bioavailability in fasted rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623055,1,Intermediate,10116.0,,50597,
10515,Oral bioavailability in fed rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623056,1,Intermediate,10116.0,,50597,
10516,Oral bioavailability in rat (mature male) (dose 30 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623057,1,Intermediate,10116.0,,50597,
10517,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623058,1,Intermediate,10116.0,,50597,
10518,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623059,1,Intermediate,10116.0,,50597,
10519,Oral bioavailability in rat after administration of 10 mg/kg po,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623060,1,Intermediate,10116.0,,50597,
10520,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623061,1,Intermediate,10116.0,,50597,
10521,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623062,1,Intermediate,10116.0,,50597,
10522,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623063,1,Intermediate,10116.0,,50597,
10523,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623064,1,Intermediate,10116.0,,50597,
10524,Oral bioavailability in ratrs,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623065,1,Intermediate,10116.0,,50597,
10525,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623066,1,Intermediate,10116.0,,50597,
10526,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623067,1,Intermediate,10116.0,,50597,
10527,Oral bioavailability in rats was determined; High,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623068,1,Intermediate,10116.0,,50597,
10528,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623069,1,Intermediate,10116.0,,50597,
10529,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623070,1,Intermediate,10116.0,,50597,
10530,Oral bioavailability was calculated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623071,1,Intermediate,10116.0,,50597,
10531,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623072,1,Intermediate,10116.0,,50597,
10532,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623073,1,Intermediate,10116.0,,50597,
10533,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623074,1,Intermediate,10116.0,,50597,
10534,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623075,1,Intermediate,10116.0,,50597,
10535,Oral bioavailability after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623076,1,Intermediate,10116.0,,50597,
10536,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623077,1,Intermediate,10116.0,,50597,
10537,Oral bioavailability in rat (Sprague-Dawley),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623078,1,Intermediate,10116.0,,50597,
10538,Oral bioavailability in Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623079,1,Intermediate,10116.0,,50597,
10539,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623080,1,Intermediate,10116.0,,50597,
10540,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623081,1,Intermediate,10116.0,,50597,
10541,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623082,1,Intermediate,10116.0,,50597,
10542,Oral bioavailability in fasted rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874400,1,Intermediate,10116.0,,50597,
10543,Oral bioavailability in fed rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623083,1,Intermediate,10116.0,,50597,
10544,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623084,1,Intermediate,10116.0,,50597,
10545,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623085,1,Intermediate,10116.0,,50597,
10546,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623086,1,Intermediate,10116.0,,50597,
10547,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623087,1,Intermediate,10116.0,,50597,
10548,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623088,1,Intermediate,10116.0,,50597,
10549,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623089,1,Intermediate,10116.0,,50597,
10550,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623090,1,Intermediate,10116.0,,50597,
10551,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623091,1,Intermediate,10116.0,,50597,
10552,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623092,1,Intermediate,10116.0,,50597,
10553,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623093,1,Intermediate,10116.0,,50597,
10554,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874401,1,Intermediate,10116.0,,50597,
10555,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623094,1,Intermediate,10116.0,,50597,
10556,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623095,1,Intermediate,10116.0,,50597,
10557,Oral bioavailability in rat after peroral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623096,1,Intermediate,10116.0,,50597,
10558,Oral bioavailability in rat after peroral administration at 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624913,1,Intermediate,10116.0,,50597,
10559,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624914,1,Intermediate,10116.0,,50597,
10560,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624915,1,Intermediate,10116.0,,50597,
10561,Oral bioavailability in rat; Not measured,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624916,1,Intermediate,10116.0,,50597,
10562,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624917,1,Intermediate,10116.0,,50597,
10563,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625157,1,Intermediate,10116.0,,50597,
10564,In vitro metabolic potential in rat liver microsomes,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625158,1,Intermediate,10116.0,,50597,
10565,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625159,1,Intermediate,10116.0,,50597,
10566,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625160,1,Intermediate,10116.0,,50597,
10567,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625161,1,Intermediate,10116.0,,50597,
10568,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625162,1,Intermediate,10116.0,,50597,
10569,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625163,1,Intermediate,10116.0,,50597,
10570,Oral bioavailability in rats at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625164,1,Intermediate,10116.0,,50597,
10571,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625165,1,Intermediate,10116.0,,50597,
10572,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625166,1,Intermediate,10116.0,,50597,
10573,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625167,1,Intermediate,10116.0,,50597,
10574,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625168,1,Intermediate,10116.0,,50597,
10575,Plasma clearance of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625169,1,Intermediate,10116.0,,50597,
10576,Plasma clearance at 10 mg/kg in rat upon intravenous administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626264,1,Intermediate,10116.0,,50597,
10577,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626265,1,Intermediate,10116.0,,50597,
10578,The compound was tested for plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626266,1,Intermediate,10116.0,,50597,
10579,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626267,1,Intermediate,10116.0,,50597,
10580,Plasma concentration upon oral administration of 1 mg/Kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626268,1,Intermediate,10116.0,,50597,
10581,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626269,1,Intermediate,10116.0,,50597,
10582,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626270,1,Intermediate,10116.0,,50597,
10583,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626271,1,Intermediate,10116.0,,50597,
10584,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626272,1,Intermediate,10116.0,,50597,
10585,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626273,1,Intermediate,10116.0,,50597,
10586,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875346,1,Intermediate,10116.0,,50597,
10587,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626274,1,Intermediate,10116.0,,50597,
10588,Compound was tested for protein binding in rat plasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626275,1,Intermediate,10116.0,,50597,
10589,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624646,1,Intermediate,10116.0,,50597,
10590,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624647,1,Intermediate,10116.0,,50597,
10591,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624648,1,Intermediate,10116.0,,50597,
10592,Area under curve ratio was determined (po/iv) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624649,1,Intermediate,10116.0,,50597,
10593,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624650,1,Intermediate,10116.0,,50597,
10594,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624651,1,Intermediate,10116.0,,50597,
10595,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624652,1,Intermediate,10116.0,,50597,
10596,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624653,1,Intermediate,10116.0,,50597,
10597,Ratio of AUCbrain to AUCplasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624654,1,Intermediate,10116.0,,50597,
10598,Ratio of brain to plasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624655,1,Intermediate,10116.0,,50597,
10599,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624656,1,Intermediate,10116.0,,50597,
10600,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624657,1,Intermediate,10116.0,,50597,
10601,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624658,1,Intermediate,10116.0,,50597,
10602,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624659,1,Intermediate,10116.0,,50597,
10603,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624660,1,Intermediate,10116.0,,50597,
10604,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624661,1,Intermediate,10116.0,,50597,
10605,Steady state brain :blood ratio was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624662,1,Intermediate,10116.0,,50597,
10606,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625199,1,Intermediate,10116.0,,50597,
10607,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625200,1,Intermediate,10116.0,,50597,
10608,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625201,1,Intermediate,10116.0,,50597,
10609,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625202,1,Intermediate,10116.0,,50597,
10610,Percentage recovery after 3h incubation with rat hapatocytes was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625203,1,Intermediate,10116.0,,50597,
10611,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625204,1,Intermediate,10116.0,,50597,
10612,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625205,1,Intermediate,10116.0,,50597,
10613,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625206,1,Intermediate,10116.0,,50597,
10614,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",1,U,,,,,,,,,BAO_0000019,CHEMBL625207,0,Autocuration,,,22224,
10615,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,1,U,,,,,,,,,BAO_0000019,CHEMBL625208,0,Autocuration,,,22224,
10616,In vivo absorption in Caco-2 cell line monolayers was determined,1,N,,Homo sapiens,,,,,Caco-2,,BAO_0000218,CHEMBL625209,1,Intermediate,9606.0,,50587,495.0
10617,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625210,0,Autocuration,,,22229,
10618,Area under curve was determine after peroral administration at 10 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625211,1,Intermediate,10116.0,,50597,
10619,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL625212,1,Intermediate,9544.0,,50797,
10620,Area under curve was determine after peroral administration at 160 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625213,1,Intermediate,10116.0,,50597,
10621,Area under curve was determine after peroral administration at 20 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625214,1,Intermediate,10116.0,,50597,
10622,Area under curve was determine after peroral administration at 50 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874542,1,Intermediate,10116.0,,50597,
10623,Calculated partition coefficient (clogP) (AlogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625215,0,Autocuration,,,22229,
10624,Activated partial thromboplastin time measured,1,U,,,,,,,,,BAO_0000019,CHEMBL625216,0,Autocuration,,,22224,
10625,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),1,U,,,,,,,,,BAO_0000100,CHEMBL625217,0,Autocuration,,,22224,
10626,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),1,U,,,,,,,,,BAO_0000100,CHEMBL625218,0,Autocuration,,,22224,
10627,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622864,1,Intermediate,9615.0,,50588,
10628,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622865,1,Intermediate,10116.0,,50597,
10629,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622866,1,Intermediate,10116.0,,50597,
10630,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622867,1,Intermediate,9615.0,,50588,
10631,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1,N,,Cavia porcellus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876808,1,Intermediate,10141.0,,50512,
10632,AUC in brain,1,U,,,,,,Brain,,955.0,BAO_0000019,CHEMBL627725,0,Autocuration,,,22224,
10633,AUC in serum,1,U,,,,,,Serum,,1977.0,BAO_0000019,CHEMBL627726,0,Autocuration,,,22224,
10634,AUC was determined,1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627727,0,Autocuration,,,22224,
10635,AUC of the compound.,1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627728,0,Autocuration,,,22224,
10636,AUC value (0-4 hr),1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627729,0,Autocuration,,,22224,
10637,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627730,0,Autocuration,,,22224,
10638,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627731,0,Autocuration,,,22224,
10639,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627732,0,Autocuration,,,22224,
10640,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL627733,0,Autocuration,,,22224,
10641,AUC(area under curve) was determined after intravenous administration in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627734,1,Intermediate,10116.0,,50597,
10642,AUC(area under curve) was determined after oral administration in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627735,1,Intermediate,10116.0,,50597,
10643,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1,N,,Cavia porcellus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627736,1,Intermediate,10141.0,,50512,
10644,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876809,1,Intermediate,10116.0,,50597,
10645,Area Under Curve after oral dosing of 100 uM/Kg,1,U,,,,,,,,,BAO_0000019,CHEMBL627737,0,Autocuration,,,22224,
10646,Area Under Curve after oral dosing of 30 uM/Kg,1,U,,,,,,,,,BAO_0000019,CHEMBL627738,0,Autocuration,,,22224,
10647,Area Under Curve was measured by ploting the graph between concentration verses time,1,U,,,,,,,,,BAO_0000019,CHEMBL627739,0,Autocuration,,,22224,
10648,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626143,1,Intermediate,9615.0,,50588,
10649,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626144,0,Autocuration,314293.0,,22224,
10650,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626145,1,Intermediate,9986.0,,50592,
10651,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626146,1,Intermediate,10116.0,,50597,
10652,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626147,1,Intermediate,10116.0,,50597,
10653,Area under curve (AUC) was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL626148,0,Autocuration,,,22224,
10654,Area under curve (AUC) following ip administration at 1 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626149,0,Autocuration,,,22224,
10655,Area under curve (AUC) was determined; ND is Not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL626150,0,Autocuration,,,22224,
10656,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626151,1,Intermediate,9615.0,,50588,
10657,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626152,1,Intermediate,9615.0,,50588,
10658,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626153,1,Intermediate,9615.0,,50588,
10659,Area under curve (AUR) was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL626154,0,Autocuration,,,22224,
10660,Area under curve at 1 uM/dg administered intravenously,1,U,,,,,,,,,BAO_0000019,CHEMBL626155,0,Autocuration,,,22224,
10661,Area under curve at 10 uM/dg administered perorally,1,U,,,,,,,,,BAO_0000019,CHEMBL626156,0,Autocuration,,,22224,
10662,Area under curve at 2 uM/dg administered intravenously,1,U,,,,,,,,,BAO_0000019,CHEMBL626157,0,Autocuration,,,22224,
10663,Area under curve at 20 uM/dg administered perorally,1,U,,,,,,,,,BAO_0000019,CHEMBL626158,0,Autocuration,,,22224,
10664,Area under curve at a peroral dose of 3 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626159,1,Intermediate,9615.0,,50588,
10665,Area under curve at a peroral dose of 3 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626160,1,Intermediate,10116.0,,50597,
10666,Area under curve at an iv dose of 1 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626161,1,Intermediate,9615.0,,50588,
10667,Area under curve at an iv dose of 1 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626162,1,Intermediate,10116.0,,50597,
10668,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,1,U,,,,,,,,,BAO_0000019,CHEMBL626163,0,Autocuration,,,22224,
10669,Area under curve gives the effective duration for the angiotensin II antagonist effect.,1,U,,,,,,,,,BAO_0000019,CHEMBL626164,0,Autocuration,,,22224,
10670,Area under curve measured as conc vs time after intravenous administration to mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626165,1,Intermediate,10090.0,,50594,
10671,Area under curve measured as conc vs time after peroral administration to mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626166,1,Intermediate,10090.0,,50594,
10672,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626167,1,Intermediate,9615.0,,50588,
10673,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626168,1,Intermediate,9615.0,,50588,
10674,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL877463,1,Intermediate,9615.0,,50588,
10675,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626169,1,Intermediate,9615.0,,50588,
10676,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626170,1,Intermediate,10116.0,,50597,
10677,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626171,1,Intermediate,10116.0,,50597,
10678,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626172,1,Intermediate,10116.0,,50597,
10679,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626173,1,Intermediate,10116.0,,50597,
10680,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626174,1,Intermediate,10116.0,,50597,
10681,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626175,1,Intermediate,10116.0,,50597,
10682,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626176,1,Intermediate,10116.0,,50597,
10683,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626177,1,Intermediate,10116.0,,50597,
10684,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622499,1,Intermediate,10116.0,,50597,
10685,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622500,1,Intermediate,10116.0,,50597,
10686,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622501,1,Intermediate,10116.0,,50597,
10687,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622502,1,Intermediate,10116.0,,50597,
10688,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622503,1,Intermediate,10116.0,,50597,
10689,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL877614,1,Intermediate,10116.0,,50597,
10690,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624839,1,Intermediate,10116.0,,50597,
10691,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624840,1,Intermediate,10116.0,,50597,
10692,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624841,1,Intermediate,10116.0,,50597,
10693,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624842,1,Intermediate,10116.0,,50597,
10694,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624843,1,Intermediate,10116.0,,50597,
10695,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624844,1,Intermediate,10116.0,,50597,
10696,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624845,1,Intermediate,10116.0,,50597,
10697,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL621904,1,Intermediate,10116.0,,50597,
10698,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621905,1,Intermediate,10116.0,,50597,
10699,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL874382,1,Intermediate,10116.0,,50597,
10700,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL621906,1,Intermediate,10116.0,,50597,
10701,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL621907,1,Intermediate,10116.0,,50597,
10702,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622096,1,Intermediate,10116.0,,50597,
10703,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622097,1,Intermediate,10116.0,,50597,
10704,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622098,1,Intermediate,10116.0,,50597,
10705,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622099,1,Intermediate,10116.0,,50597,
10706,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622100,1,Intermediate,10116.0,,50597,
10707,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622101,1,Intermediate,10116.0,,50597,
10708,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622102,1,Intermediate,10116.0,,50597,
10709,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622103,1,Intermediate,10116.0,,50597,
10710,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622104,1,Intermediate,10116.0,,50597,
10711,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622105,1,Intermediate,10116.0,,50597,
10712,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622106,1,Intermediate,10116.0,,50597,
10713,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622107,1,Intermediate,10116.0,,50597,
10714,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622108,1,Intermediate,10116.0,,50597,
10715,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622109,1,Intermediate,10116.0,,50597,
10716,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622110,1,Intermediate,10116.0,,50597,
10717,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622111,1,Intermediate,10116.0,,50597,
10718,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL874383,1,Intermediate,10116.0,,50597,
10719,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL622112,1,Intermediate,10116.0,,50597,
10720,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL622113,1,Intermediate,10116.0,,50597,
10721,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL622114,1,Intermediate,10116.0,,50597,
10722,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622115,1,Intermediate,10116.0,,50597,
10723,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622116,1,Intermediate,10116.0,,50597,
10724,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622117,1,Intermediate,10116.0,,50597,
10725,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622118,1,Intermediate,10116.0,,50597,
10726,Oral bioavailability in rats at 6 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622119,1,Intermediate,10116.0,,50597,
10727,Oral bioavailability in rat (dose 6 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622120,1,Intermediate,10116.0,,50597,
10728,Oral bioavailability in rats at 6 mg/kg dose; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622121,1,Intermediate,10116.0,,50597,
10729,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622122,1,Intermediate,10116.0,,50597,
10730,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622123,1,Intermediate,10116.0,,50597,
10731,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622124,1,Intermediate,10116.0,,50597,
10732,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622125,1,Intermediate,10116.0,,50597,
10733,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622126,1,Intermediate,10116.0,,50597,
10734,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620455,1,Intermediate,10116.0,,50597,
10735,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620456,1,Intermediate,10116.0,,50597,
10736,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620457,1,Intermediate,10116.0,,50597,
10737,Oral bioavailability was evaluated; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620458,1,Intermediate,10116.0,,50597,
10738,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620459,1,Intermediate,10116.0,,50597,
10739,Oral bioavailability in rat by oral dosing,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620460,1,Intermediate,10116.0,,50597,
10740,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620461,1,Intermediate,10116.0,,50597,
10741,Oral bioavailability in rat (Sprague-Dawley),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620462,1,Intermediate,10116.0,,50597,
10742,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620463,1,Intermediate,10116.0,,50597,
10743,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620464,1,Intermediate,10116.0,,50597,
10744,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620465,1,Intermediate,10116.0,,50597,
10745,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620466,1,Intermediate,10116.0,,50597,
10746,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620467,1,Intermediate,10116.0,,50597,
10747,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620468,1,Intermediate,10116.0,,50597,
10748,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620469,1,Intermediate,10116.0,,50597,
10749,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620470,1,Intermediate,10116.0,,50597,
10750,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620471,1,Intermediate,10116.0,,50597,
10751,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620472,1,Intermediate,10116.0,,50597,
10752,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620473,1,Intermediate,10116.0,,50597,
10753,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620474,1,Intermediate,10116.0,,50597,
10754,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620475,1,Intermediate,10116.0,,50597,
10755,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620476,1,Intermediate,10116.0,,50597,
10756,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620477,1,Intermediate,10116.0,,50597,
10757,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620478,1,Intermediate,10116.0,,50597,
10758,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618768,1,Intermediate,10116.0,,50597,
10759,Oral bioavailability in rat after oral administration at 13 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618769,1,Intermediate,10116.0,,50597,
10760,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618770,1,Intermediate,10116.0,,50597,
10761,Oral bioavailability (dose 20 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618771,1,Intermediate,10116.0,,50597,
10762,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618772,1,Intermediate,10116.0,,50597,
10763,Oral bioavailability in rat at 10 mg/kg of the compound,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618773,1,Intermediate,10116.0,,50597,
10764,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875842,1,Intermediate,10116.0,,50597,
10765,Bioavailability in rat (dose 3 mg/kg i.v.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618774,1,Intermediate,10116.0,,50597,
10766,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618775,1,Intermediate,10116.0,,50597,
10767,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618776,1,Intermediate,10116.0,,50597,
10768,Percent bioavailability (F) in rats after iv administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618777,1,Intermediate,10116.0,,50597,
10769,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618778,1,Intermediate,10116.0,,50597,
10770,Bioavailability in rat (dose 5 uM/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618779,1,Intermediate,10116.0,,50597,
10771,Oral bioavailability,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618780,1,Intermediate,10116.0,,50597,
10772,Bioavailability in rat (dose 2 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618781,1,Intermediate,10116.0,,50597,
10773,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618782,1,Intermediate,10116.0,,50597,
10774,Oral bioavailability in rat (dose 20 mg/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618783,1,Intermediate,10116.0,,50597,
10775,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618784,1,Intermediate,10116.0,,50597,
10776,Percent oral bioavailability evaluated in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618785,1,Intermediate,10116.0,,50597,
10777,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618786,1,Intermediate,10116.0,,50597,
10778,Percent oral bioavailability in rat; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618787,1,Intermediate,10116.0,,50597,
10779,Oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618788,1,Intermediate,10116.0,,50597,
10780,Bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618789,1,Intermediate,10116.0,,50597,
10781,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618790,1,Intermediate,10116.0,,50597,
10782,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618791,1,Intermediate,10116.0,,50597,
10783,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875843,1,Intermediate,10116.0,,50597,
10784,Oral bioavailability in rat (dose 20 mg/kg p.o.),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL618792,1,Intermediate,10116.0,,50597,
10785,Cmax at a dose of 30 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623395,1,Intermediate,10116.0,,50597,
10786,Cmax in monkeys at a dose of 1 mg/kg,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL623396,0,Autocuration,314293.0,,22224,
10787,Cmax in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623397,1,Intermediate,10116.0,,50597,
10788,Cmax in rats at a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623398,1,Intermediate,10116.0,,50597,
10789,Cmax was measured in mice after an oral dose of 50 mg/kg.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623399,1,Intermediate,10090.0,,50594,
10790,"Cmax value at a dose of 12.7 uM/kg, po",1,U,,,,,,,,,BAO_0000218,CHEMBL623400,0,Autocuration,,,22224,
10791,"Cmax value at a dose of 6.3 uM/kg, iv",1,U,,,,,,,,,BAO_0000218,CHEMBL623401,0,Autocuration,,,22224,
10792,"Cmax value at a dose of 7.1 uM/kg, iv",1,U,,,,,,,,,BAO_0000218,CHEMBL623402,0,Autocuration,,,22224,
10793,Cmax value of compound was determined after 1 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL623403,0,Autocuration,,,22224,
10794,Cmax value of the compound,1,U,,,,,,,,,BAO_0000218,CHEMBL623404,0,Autocuration,,,22224,
10795,Cmax value administered intraintestinal in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625997,1,Intermediate,10116.0,,50597,
10796,Cmax value administered perorally was determined in rat; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625998,1,Intermediate,10116.0,,50597,
10797,Cmax value at the dose of 2.3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL625999,0,Autocuration,,,22224,
10798,Cmax value at the dose of 5 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626000,0,Autocuration,,,22224,
10799,Cmax value in the period of 8 hr after dosing. ,1,U,,,,,,,,,BAO_0000218,CHEMBL626001,0,Autocuration,,,22224,
10800,Cmax value at a oral dose of 20 mg/kg; Not tested,1,U,,,,,,,,,BAO_0000218,CHEMBL626002,0,Autocuration,,,22224,
10801,Cmax value at a oral dose of 20 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626003,0,Autocuration,,,22224,
10802,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626004,1,Intermediate,10116.0,,50597,
10803,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL626005,1,Intermediate,10141.0,,50512,
10804,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626006,1,Intermediate,10116.0,,50597,
10805,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626007,1,Intermediate,10116.0,,50597,
10806,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626008,1,Intermediate,10090.0,,50594,
10807,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL626009,1,Intermediate,9615.0,,50588,
10808,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626010,1,Intermediate,9615.0,,50588,
10809,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626011,1,Intermediate,10090.0,,50594,
10810,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626012,1,Intermediate,10090.0,,50594,
10811,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626013,1,Intermediate,10090.0,,50594,
10812,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL626014,1,Intermediate,10090.0,,50594,
10813,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL877496,1,Intermediate,10090.0,,50594,
10814,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626015,1,Intermediate,9615.0,,50588,
10815,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626016,1,Intermediate,9615.0,,50588,
10816,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626017,1,Intermediate,9615.0,,50588,
10817,Bioavailability as maximal plasma concentration in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626018,1,Intermediate,9615.0,,50588,
10818,Bioavailability as maximal plasma concentration in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626692,1,Intermediate,9615.0,,50588,
10819,Bioavailability as maximal plasma concentration in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626693,1,Intermediate,10116.0,,50597,
10820,Bioavailability as maximal plasma concentration in rats,1,U,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626694,0,Autocuration,10116.0,,22224,
10821,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL626695,1,Intermediate,9615.0,,50588,
10822,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL626696,1,Intermediate,9615.0,,50588,
10823,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL626697,1,Intermediate,9615.0,,50588,
10824,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL626859,1,Intermediate,9615.0,,50588,
10825,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL626860,1,Intermediate,9615.0,,50588,
10826,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL626861,1,Intermediate,9615.0,,50588,
10827,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626296,1,Intermediate,10116.0,,50597,
10828,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626297,0,Autocuration,,,22224,
10829,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626298,0,Autocuration,,,22224,
10830,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626299,1,Intermediate,10116.0,,50597,
10831,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626300,1,Intermediate,10116.0,,50597,
10832,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626301,1,Intermediate,10116.0,,50597,
10833,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626962,1,Intermediate,10116.0,,50597,
10834,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626963,1,Intermediate,10116.0,,50597,
10835,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626964,1,Intermediate,10116.0,,50597,
10836,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626965,1,Intermediate,9541.0,,100710,
10837,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626966,1,Intermediate,10090.0,,50594,
10838,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626967,1,Intermediate,10090.0,,50594,
10839,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626968,1,Intermediate,9541.0,,100710,
10840,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626969,1,Intermediate,10116.0,,50597,
10841,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627126,1,Intermediate,10116.0,,50597,
10842,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631276,1,Intermediate,10116.0,,50597,
10843,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631277,1,Intermediate,10116.0,,50597,
10844,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631278,1,Intermediate,10116.0,,50597,
10845,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL874457,1,Intermediate,10116.0,,50597,
10846,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631279,1,Intermediate,10116.0,,50597,
10847,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631280,1,Intermediate,10116.0,,50597,
10848,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631281,1,Intermediate,10116.0,,50597,
10849,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631968,1,Intermediate,10116.0,,50597,
10850,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631969,1,Intermediate,10116.0,,50597,
10851,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631970,1,Intermediate,10116.0,,50597,
10852,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631971,1,Intermediate,10116.0,,50597,
10853,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL631972,1,Intermediate,10116.0,,50597,
10854,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630435,1,Intermediate,10116.0,,50597,
10855,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630436,1,Intermediate,10116.0,,50597,
10856,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630437,1,Intermediate,10116.0,,50597,
10857,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630438,1,Intermediate,10116.0,,50597,
10858,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630439,1,Intermediate,10116.0,,50597,
10859,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630440,1,Intermediate,10116.0,,50597,
10860,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630441,1,Intermediate,10116.0,,50597,
10861,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630442,1,Intermediate,10116.0,,50597,
10862,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625234,1,Intermediate,10116.0,,50597,
10863,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625235,1,Intermediate,10116.0,,50597,
10864,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625236,1,Intermediate,10116.0,,50597,
10865,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625237,1,Intermediate,10116.0,,50597,
10866,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626125,1,Intermediate,10116.0,,50597,
10867,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626126,1,Intermediate,10116.0,,50597,
10868,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626127,1,Intermediate,10116.0,,50597,
10869,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626128,1,Intermediate,10116.0,,50597,
10870,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626129,1,Intermediate,10116.0,,50597,
10871,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626130,1,Intermediate,10116.0,,50597,
10872,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626131,1,Intermediate,10116.0,,50597,
10873,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626132,1,Intermediate,10116.0,,50597,
10874,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626752,1,Intermediate,10116.0,,50597,
10875,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626753,1,Intermediate,10116.0,,50597,
10876,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626754,1,Intermediate,10116.0,,50597,
10877,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626755,1,Intermediate,10116.0,,50597,
10878,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626756,1,Intermediate,10116.0,,50597,
10879,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626757,1,Intermediate,10116.0,,50597,
10880,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626758,1,Intermediate,10116.0,,50597,
10881,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626759,1,Intermediate,10116.0,,50597,
10882,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626760,1,Intermediate,10116.0,,50597,
10883,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626394,1,Intermediate,9615.0,,50588,
10884,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626395,1,Intermediate,9615.0,,50588,
10885,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626396,1,Intermediate,9615.0,,50588,
10886,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626397,1,Intermediate,9615.0,,50588,
10887,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626398,1,Intermediate,9615.0,,50588,
10888,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626399,1,Intermediate,9615.0,,50588,
10889,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874653,1,Intermediate,10116.0,,50597,
10890,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626400,1,Intermediate,10116.0,,50597,
10891,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626401,1,Intermediate,10116.0,,50597,
10892,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626402,1,Intermediate,10116.0,,50597,
10893,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626403,1,Intermediate,10116.0,,50597,
10894,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626404,1,Intermediate,10116.0,,50597,
10895,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626405,1,Intermediate,10116.0,,50597,
10896,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625529,1,Intermediate,10116.0,,50597,
10897,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625530,1,Intermediate,10116.0,,50597,
10898,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625531,1,Intermediate,10116.0,,50597,
10899,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625532,1,Intermediate,10116.0,,50597,
10900,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625533,1,Intermediate,10116.0,,50597,
10901,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875474,1,Intermediate,10116.0,,50597,
10902,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625534,1,Intermediate,10116.0,,50597,
10903,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625535,1,Intermediate,10116.0,,50597,
10904,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625536,1,Intermediate,10116.0,,50597,
10905,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625537,1,Intermediate,10116.0,,50597,
10906,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625538,1,Intermediate,10116.0,,50597,
10907,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625539,1,Intermediate,10116.0,,50597,
10908,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625540,1,Intermediate,10116.0,,50597,
10909,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625541,1,Intermediate,10116.0,,50597,
10910,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625542,1,Intermediate,10116.0,,50597,
10911,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625543,1,Intermediate,10116.0,,50597,
10912,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625544,1,Intermediate,10116.0,,50597,
10913,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625545,1,Intermediate,9615.0,,50588,
10914,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625546,1,Intermediate,9615.0,,50588,
10915,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625547,1,Intermediate,9615.0,,50588,
10916,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625548,1,Intermediate,9615.0,,50588,
10917,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625549,1,Intermediate,9615.0,,50588,
10918,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625550,1,Intermediate,9615.0,,50588,
10919,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625551,1,Intermediate,9615.0,,50588,
10920,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875475,1,Intermediate,9615.0,,50588,
10921,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625552,1,Intermediate,9615.0,,50588,
10922,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625553,1,Intermediate,9615.0,,50588,
10923,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625554,1,Intermediate,9615.0,,50588,
10924,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625555,1,Intermediate,9615.0,,50588,
10925,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625556,1,Intermediate,9615.0,,50588,
10926,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624986,1,Intermediate,9615.0,,50588,
10927,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624987,1,Intermediate,9615.0,,50588,
10928,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624988,1,Intermediate,9615.0,,50588,
10929,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624989,1,Intermediate,9615.0,,50588,
10930,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624990,1,Intermediate,9615.0,,50588,
10931,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL874391,1,Intermediate,9615.0,,50588,
10932,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624991,1,Intermediate,9615.0,,50588,
10933,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624992,1,Intermediate,9615.0,,50588,
10934,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624993,1,Intermediate,9615.0,,50588,
10935,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624994,1,Intermediate,9615.0,,50588,
10936,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624995,1,Intermediate,9615.0,,50588,
10937,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624996,1,Intermediate,9615.0,,50588,
10938,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624997,1,Intermediate,9615.0,,50588,
10939,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624998,1,Intermediate,9615.0,,50588,
10940,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624999,1,Intermediate,9615.0,,50588,
10941,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL882955,1,Intermediate,9615.0,,50588,
10942,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625000,1,Intermediate,9615.0,,50588,
10943,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625001,1,Intermediate,9615.0,,50588,
10944,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625089,1,Intermediate,9615.0,,50588,
10945,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625090,1,Intermediate,9615.0,,50588,
10946,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625091,1,Intermediate,9615.0,,50588,
10947,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625092,1,Intermediate,9615.0,,50588,
10948,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625093,1,Intermediate,9615.0,,50588,
10949,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625094,1,Intermediate,9615.0,,50588,
10950,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL625095,1,Intermediate,9615.0,,50588,
10951,Compound was evaluated for its bioavailability in the dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625096,1,Intermediate,9615.0,,50588,
10952,Compound was evaluated for its bioavailability in the rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625097,1,Intermediate,10116.0,,50597,
10953,Compound was evaluated for oral bioavailability,1,U,,,,,,,,,BAO_0000218,CHEMBL882956,0,Autocuration,,,22224,
10954,Compound was evaluated for percentage of Oral bioavailability in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625098,1,Intermediate,10116.0,,50597,
10955,Bioavailability in guinea pig,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL625099,0,Autocuration,10141.0,,22224,
10956,Compound was evaluated for the oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625100,1,Intermediate,10116.0,,50597,
10957,Compound was evaluated for the oral bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625101,1,Intermediate,9615.0,,50588,
10958,Compound was evaluated for the oral bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874396,1,Intermediate,10116.0,,50597,
10959,Bioavailability in dog (dosed i.v.),1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625102,0,Autocuration,9615.0,,22224,
10960,Compound was tested for in vivo bioavailability in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625103,1,Intermediate,9615.0,,50588,
10961,Compound was tested for in vivo bioavailability in hamsters,1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL625104,1,Intermediate,10026.0,,100712,
10962,Compound was tested for in vivo bioavailability in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625105,0,Autocuration,314293.0,,22224,
10963,Compound was tested for in vivo bioavailability in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625106,1,Intermediate,10116.0,,50597,
10964,Oral bioavailability in mouse,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625107,0,Autocuration,10090.0,,22224,
10965,Compound was tested for percent of oral bioavailability in mice; 56-74,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625108,1,Intermediate,10090.0,,50594,
10966,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625109,0,Autocuration,10090.0,,22224,
10967,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL625110,0,Autocuration,9541.0,,22224,
10968,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL625111,0,Autocuration,9541.0,,22224,
10969,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625112,1,Intermediate,10090.0,,50594,
10970,Oral bioavailability in nude mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875334,1,Intermediate,10090.0,,50594,
10971,Bioavailability in monkey (i.d. dosing),1,U,,Primates,,,,,,,BAO_0000218,CHEMBL628617,0,Autocuration,9443.0,,22224,
10972,Bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628618,0,Autocuration,10116.0,,22224,
10973,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,1,U,,,,,,,,,BAO_0000218,CHEMBL628619,0,Autocuration,,,22224,
10974,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,1,U,,,,,,,,,BAO_0000218,CHEMBL628620,0,Autocuration,,,22224,
10975,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL628621,1,Intermediate,9541.0,,100710,
10976,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL628622,1,Intermediate,9541.0,,100710,
10977,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL628623,1,Intermediate,9541.0,,100710,
10978,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628624,1,Intermediate,9541.0,,100710,
10979,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628625,1,Intermediate,10090.0,,50594,
10980,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628626,1,Intermediate,9541.0,,100710,
10981,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627041,1,Intermediate,10090.0,,50594,
10982,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627042,1,Intermediate,10090.0,,50594,
10983,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627043,1,Intermediate,10090.0,,50594,
10984,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627044,0,Autocuration,,,22224,
10985,Cmax in mouse plasma,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627045,1,Intermediate,10090.0,,50594,
10986,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627046,0,Autocuration,,,22224,
10987,Maximal plasma concentration in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627047,1,Intermediate,10116.0,,50597,
10988,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627048,1,Intermediate,10116.0,,50597,
10989,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627049,1,Intermediate,10116.0,,50597,
10990,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627050,1,Intermediate,10116.0,,50597,
10991,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627051,1,Intermediate,10116.0,,50597,
10992,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627052,1,Intermediate,10116.0,,50597,
10993,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627053,1,Intermediate,10116.0,,50597,
10994,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627054,1,Intermediate,10116.0,,50597,
10995,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627055,1,Intermediate,10090.0,,50594,
10996,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627056,1,Intermediate,10090.0,,50594,
10997,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627057,1,Intermediate,10090.0,,50594,
10998,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627058,1,Intermediate,10090.0,,50594,
10999,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626211,1,Intermediate,10090.0,,50594,
11000,Maximum Concentration of the compound.,1,U,,,,,,,,,BAO_0000218,CHEMBL626212,0,Autocuration,,,22224,
11001,Maximum Concentration was measured after iv administration into Beagle dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626213,1,Intermediate,9615.0,,50588,
11002,Maximum Concentration was measured after iv administration into Beagle dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626214,1,Intermediate,9615.0,,50588,
11003,Maximum Concentration was measured after po administration into Beagle dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626215,1,Intermediate,9615.0,,50588,
11004,Maximum Concentration was measured after po administration into Beagle dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626216,1,Intermediate,9615.0,,50588,
11005,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626217,0,Autocuration,,,22224,
11006,Maximum blood level reached after an iv dose of 12.2 uM/kg,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626218,0,Autocuration,,,22224,
11007,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626219,0,Autocuration,,,22224,
11008,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626220,0,Autocuration,,,22224,
11009,Maximum blood level reached after an oral dose of 5.0 mg/kg,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626221,0,Autocuration,,,22224,
11010,Maximum blood level reached at dose of 10.6 uM/kg orally,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626222,0,Autocuration,,,22224,
11011,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL626223,1,Intermediate,10141.0,,50512,
11012,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL626224,1,Intermediate,10141.0,,50512,
11013,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL626225,1,Intermediate,10116.0,,50597,
11014,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL626226,1,Intermediate,10116.0,,50597,
11015,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL626227,1,Intermediate,10116.0,,50597,
11016,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL626228,1,Intermediate,10116.0,,50597,
11017,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626229,1,Intermediate,10116.0,,50597,
11018,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626921,1,Intermediate,10116.0,,50597,
11019,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876793,1,Intermediate,10116.0,,50597,
11020,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625309,1,Intermediate,10116.0,,50597,
11021,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,N,,Bacillus subtilis,,,,,,,BAO_0000218,CHEMBL625310,1,Intermediate,1423.0,,50278,
11022,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625311,0,Autocuration,314293.0,,22224,
11023,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625312,1,Intermediate,10116.0,,50597,
11024,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625313,0,Autocuration,,,22224,
11025,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625314,1,Intermediate,10090.0,,50594,
11026,Maximum concentration in male rats after iv administration of 20 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625315,1,Intermediate,10116.0,,50597,
11027,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625316,1,Intermediate,10116.0,,50597,
11028,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625317,1,Intermediate,10116.0,,50597,
11029,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625318,1,Intermediate,10116.0,,50597,
11030,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625319,1,Intermediate,10116.0,,50597,
11031,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625320,1,Intermediate,10116.0,,50597,
11032,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625321,1,Intermediate,10116.0,,50597,
11033,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625322,1,Intermediate,10116.0,,50597,
11034,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL876801,1,Intermediate,10116.0,,50597,
11035,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625323,1,Intermediate,10116.0,,50597,
11036,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625324,1,Intermediate,10116.0,,50597,
11037,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625325,1,Intermediate,10116.0,,50597,
11038,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625326,1,Intermediate,10116.0,,50597,
11039,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625327,1,Intermediate,10116.0,,50597,
11040,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625328,1,Intermediate,10116.0,,50597,
11041,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625329,1,Intermediate,10116.0,,50597,
11042,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625330,1,Intermediate,10116.0,,50597,
11043,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627774,1,Intermediate,10116.0,,50597,
11044,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627775,1,Intermediate,10116.0,,50597,
11045,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627949,1,Intermediate,10116.0,,50597,
11046,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627950,1,Intermediate,10116.0,,50597,
11047,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627951,1,Intermediate,10116.0,,50597,
11048,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627952,1,Intermediate,10116.0,,50597,
11049,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627953,1,Intermediate,10116.0,,50597,
11050,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627954,1,Intermediate,10116.0,,50597,
11051,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627955,1,Intermediate,10116.0,,50597,
11052,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627956,1,Intermediate,10116.0,,50597,
11053,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL876802,1,Intermediate,10116.0,,50597,
11054,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627957,1,Intermediate,10116.0,,50597,
11055,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627958,1,Intermediate,10116.0,,50597,
11056,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627959,1,Intermediate,10116.0,,50597,
11057,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627960,1,Intermediate,10116.0,,50597,
11058,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627961,1,Intermediate,10116.0,,50597,
11059,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627962,1,Intermediate,10116.0,,50597,
11060,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627963,1,Intermediate,10116.0,,50597,
11061,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624759,1,Intermediate,10116.0,,50597,
11062,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624760,1,Intermediate,10116.0,,50597,
11063,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624761,1,Intermediate,10116.0,,50597,
11064,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877607,1,Intermediate,10116.0,,50597,
11065,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624762,1,Intermediate,10116.0,,50597,
11066,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624763,1,Intermediate,10116.0,,50597,
11067,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624764,1,Intermediate,10116.0,,50597,
11068,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624765,1,Intermediate,10116.0,,50597,
11069,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624766,1,Intermediate,10116.0,,50597,
11070,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624767,1,Intermediate,9615.0,,50588,
11071,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624768,1,Intermediate,9615.0,,50588,
11072,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624769,1,Intermediate,9615.0,,50588,
11073,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624770,1,Intermediate,9615.0,,50588,
11074,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624771,1,Intermediate,9615.0,,50588,
11075,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624772,1,Intermediate,9615.0,,50588,
11076,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624773,1,Intermediate,10116.0,,50597,
11077,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624774,1,Intermediate,10116.0,,50597,
11078,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624775,1,Intermediate,10116.0,,50597,
11079,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624776,1,Intermediate,10116.0,,50597,
11080,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624777,1,Intermediate,10116.0,,50597,
11081,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624778,1,Intermediate,10116.0,,50597,
11082,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624779,1,Intermediate,10116.0,,50597,
11083,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624780,1,Intermediate,10116.0,,50597,
11084,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624781,1,Intermediate,10116.0,,50597,
11085,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877608,1,Intermediate,10116.0,,50597,
11086,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624782,1,Intermediate,10116.0,,50597,
11087,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624783,1,Intermediate,10116.0,,50597,
11088,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624784,1,Intermediate,10116.0,,50597,
11089,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624785,1,Intermediate,10116.0,,50597,
11090,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624786,1,Intermediate,10116.0,,50597,
11091,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624787,1,Intermediate,10116.0,,50597,
11092,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628676,1,Intermediate,10116.0,,50597,
11093,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621842,1,Intermediate,10116.0,,50597,
11094,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL621843,1,Intermediate,10116.0,,50597,
11095,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623873,1,Intermediate,10116.0,,50597,
11096,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623874,1,Intermediate,10116.0,,50597,
11097,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623875,1,Intermediate,10116.0,,50597,
11098,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623876,1,Intermediate,10116.0,,50597,
11099,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623877,1,Intermediate,9615.0,,50588,
11100,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623878,1,Intermediate,9615.0,,50588,
11101,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623879,1,Intermediate,9615.0,,50588,
11102,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623880,1,Intermediate,9615.0,,50588,
11103,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623881,1,Intermediate,9615.0,,50588,
11104,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623957,1,Intermediate,9615.0,,50588,
11105,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623958,1,Intermediate,9615.0,,50588,
11106,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623959,1,Intermediate,9615.0,,50588,
11107,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623960,1,Intermediate,9615.0,,50588,
11108,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623961,1,Intermediate,9615.0,,50588,
11109,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623962,1,Intermediate,9615.0,,50588,
11110,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624676,1,Intermediate,9615.0,,50588,
11111,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624677,1,Intermediate,9615.0,,50588,
11112,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624678,1,Intermediate,9615.0,,50588,
11113,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624679,1,Intermediate,9615.0,,50588,
11114,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624680,1,Intermediate,9615.0,,50588,
11115,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,1,U,,,,,,,,,BAO_0000218,CHEMBL624849,0,Autocuration,,,22224,
11116,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,1,U,,,,,,,,,BAO_0000218,CHEMBL624850,0,Autocuration,,,22224,
11117,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,1,U,,,,,,,,,BAO_0000218,CHEMBL874399,0,Autocuration,,,22224,
11118,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,1,U,,,,,,,,,BAO_0000218,CHEMBL624851,0,Autocuration,,,22224,
11119,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,1,U,,,,,,,,,BAO_0000218,CHEMBL624852,0,Autocuration,,,22224,
11120,Oral bioavailability in rat (dose 10 mg/kg),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624853,0,Autocuration,10116.0,,22224,
11121,Oral bioavailability in rat (Sprague-Dawley),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624854,0,Autocuration,10116.0,,22224,
11122,Oral bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624855,0,Autocuration,10116.0,,22224,
11123,Oral bioavailability in rats was determined in vivo,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624856,0,Autocuration,10116.0,,22224,
11124,Oral bioavailability in dog,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL882957,0,Autocuration,9615.0,,22224,
11125,Oral bioavailability of compound in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL624857,0,Autocuration,314293.0,,22224,
11126,Oral bioavailability of compound in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622202,1,Intermediate,10116.0,,50597,
11127,Bioavailability in rat of PMEA prodrug,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622203,0,Autocuration,10116.0,,22224,
11128,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625522,1,Intermediate,10116.0,,50597,
11129,Serum conc at 3 hours following 25 mg/kg dose,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL622868,0,Autocuration,9544.0,,22224,
11130,Urine conc 0-5 hours following 25 mg/kg dose,1,U,,Macaca mulatta,,,,Urine,,1088.0,BAO_0000218,CHEMBL622869,0,Autocuration,9544.0,,22224,
11131,Urine conc 0-24 hours following 25 mg/kg dose,1,U,,Macaca mulatta,,,,Urine,,1088.0,BAO_0000218,CHEMBL622870,0,Autocuration,9544.0,,22224,
11132,Oral bioavailability in African green monkeys; 20-25,1,U,,Chlorocebus aethiops,,,,,,,BAO_0000218,CHEMBL622871,0,Autocuration,9534.0,,22224,
11133,Oral bioavailability in cynomolgus monkey.,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL620560,1,Intermediate,9541.0,,100710,
11134,Oral bioavailability in dog,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620561,0,Autocuration,9615.0,,22224,
11135,Oral bioavailability in dog at 10 mg/kg oral dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620562,1,Intermediate,9615.0,,50588,
11136,Oral bioavailability in hamster at 10 mg/kg oral dose,1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL620563,1,Intermediate,10026.0,,100712,
11137,Oral bioavailability in rat at 10 mg/kg oral dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620564,1,Intermediate,10116.0,,50597,
11138,Oral bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL872265,0,Autocuration,10116.0,,22224,
11139,Oral bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620565,0,Autocuration,10116.0,,22224,
11140,Oral bioavailability,1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL620566,0,Autocuration,9347.0,,22224,
11141,Oral bioavailability was determined; range 49-102%,1,U,,,,,,,,,BAO_0000218,CHEMBL620567,0,Autocuration,,,22224,
11142,Oral bioavailability was determined in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620568,1,Intermediate,9615.0,,50588,
11143,Oral bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620569,0,Autocuration,10116.0,,22224,
11144,Oral bioavailability,1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL620570,0,Autocuration,9347.0,,22224,
11145,Oral bioavailability was determined; Not orally available,1,U,,,,,,,,,BAO_0000218,CHEMBL620571,0,Autocuration,,,22224,
11146,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620572,1,Intermediate,10090.0,,50594,
11147,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620573,0,Autocuration,10090.0,,22224,
11148,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,1,U,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620574,0,Autocuration,10090.0,,22224,
11149,Oral bioavailability in Rhesus monkey,1,U,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL620575,0,Autocuration,9544.0,,22224,
11150,Oral bioavailability in dog (female mongrel),1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620576,0,Autocuration,9615.0,,22224,
11151,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,1,U,,,,,,,,,BAO_0000218,CHEMBL875846,0,Autocuration,,,22224,
11152,Oral bioavailability in dog,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL620577,0,Autocuration,9615.0,,22224,
11153,Percentage Bioavailability was evaluated.,1,U,,,,,,,,,BAO_0000218,CHEMBL620578,0,Autocuration,,,22224,
11154,Bioavailability in rat administered i.d.,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL620579,0,Autocuration,10116.0,,22224,
11155,Bioavailability,1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL621248,0,Autocuration,9347.0,,22224,
11156,Bioavailability in dog (male Beagle) i.v. administration,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625390,0,Autocuration,9615.0,,22224,
11157,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625391,0,Autocuration,10116.0,,22224,
11158,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),1,U,,Primates,,,,,,,BAO_0000218,CHEMBL872266,0,Autocuration,9443.0,,22224,
11159,Oral bioavailability in rat (Sprague-Dawley) (male),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625392,0,Autocuration,10116.0,,22224,
11160,The oral bioavailability was measured on rats after oral administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625393,1,Intermediate,10116.0,,50597,
11161,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625394,1,Intermediate,10116.0,,50597,
11162,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL625395,1,Intermediate,9544.0,,50797,
11163,Bioavailability in rat (dose 10 mg/kg i.d.),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625396,0,Autocuration,10116.0,,22224,
11164,Bioavailability in dog (male Beagle) i.v. administration,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625397,0,Autocuration,9615.0,,22224,
11165,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625398,1,Intermediate,10090.0,,50594,
11166,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL625399,1,Intermediate,10090.0,,50594,
11167,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL626074,1,Intermediate,10090.0,,50594,
11168,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626075,1,Intermediate,10090.0,,50594,
11169,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626076,1,Intermediate,10116.0,,50597,
11170,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,N,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626077,1,Intermediate,9544.0,,50797,
11171,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626078,1,Intermediate,10116.0,,50597,
11172,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL625846,0,Autocuration,,,22224,
11173,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL625847,0,Autocuration,,,22224,
11174,Maximum concentration observed in rats at an oral dose of 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625848,1,Expert,10116.0,,50597,
11175,Maximum concentration of compound in plasma administered orally to rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625849,1,Intermediate,10116.0,,50597,
11176,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626023,1,Intermediate,9615.0,,50588,
11177,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626024,1,Intermediate,9615.0,,50588,
11178,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626025,1,Intermediate,9615.0,,50588,
11179,Maximum concentration after 10 mg/kg by oral administration,1,U,,,,,,,,,BAO_0000218,CHEMBL626026,0,Autocuration,,,22224,
11180,Maximum concentration at a dose of 1.5 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626027,0,Autocuration,,,22224,
11181,Maximum concentration at a dose of 2.0 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626028,0,Autocuration,,,22224,
11182,Maximum concentration in dog plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626029,1,Intermediate,9615.0,,50588,
11183,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626030,0,Autocuration,,,22224,
11184,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626031,0,Autocuration,,,22224,
11185,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626032,0,Autocuration,,,22224,
11186,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626033,0,Autocuration,,,22224,
11187,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626034,0,Autocuration,,,22224,
11188,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626035,1,Intermediate,9615.0,,50588,
11189,Maximum concentration in plasma at Tmax,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626036,0,Autocuration,,,22224,
11190,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626037,1,Expert,9615.0,,50588,
11191,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1,N,,Cricetinae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626038,1,Intermediate,10026.0,,100712,
11192,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626039,1,Intermediate,10116.0,,50597,
11193,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626040,1,Intermediate,10116.0,,50597,
11194,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1,N,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626041,1,Intermediate,9986.0,,50592,
11195,Maximum concentration was calculated,1,U,,,,,,,,,BAO_0000218,CHEMBL626042,0,Autocuration,,,22224,
11196,Maximum concentration was calculated.,1,U,,,,,,,,,BAO_0000218,CHEMBL626043,0,Autocuration,,,22224,
11197,Maximum concentration at a peroral dose of 10 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626044,0,Autocuration,,,22224,
11198,Maximum concentration of the drug at 10 uM/dg administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626045,0,Autocuration,,,22224,
11199,Maximum concentration of the drug at 2 uM/dg administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL626046,0,Autocuration,,,22224,
11200,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626047,1,Intermediate,9615.0,,50588,
11201,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1,N,,Cricetinae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626048,1,Intermediate,10026.0,,100712,
11202,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626049,1,Intermediate,10116.0,,50597,
11203,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626050,1,Intermediate,10116.0,,50597,
11204,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL874541,1,Intermediate,9615.0,,50588,
11205,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1,N,,Cricetinae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622826,1,Intermediate,10026.0,,100712,
11206,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1,N,,Cricetinae,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622827,1,Intermediate,10026.0,,100712,
11207,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622828,1,Intermediate,10116.0,,50597,
11208,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622829,1,Intermediate,10116.0,,50597,
11209,Maximum concentration reached following intravenous administration in male rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876806,1,Intermediate,10116.0,,50597,
11210,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622830,1,Intermediate,9615.0,,50588,
11211,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622831,1,Intermediate,10116.0,,50597,
11212,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626794,1,Intermediate,9615.0,,50588,
11213,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626795,1,Intermediate,10116.0,,50597,
11214,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626796,1,Intermediate,10116.0,,50597,
11215,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626797,1,Intermediate,10116.0,,50597,
11216,Maximum drug concentration is determined after oral dosing in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626798,1,Intermediate,10116.0,,50597,
11217,Maximum observed concentration in oral (5 mg/kg) fasted dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626799,1,Intermediate,9615.0,,50588,
11218,Maximum observed concentration in oral (5 mg/kg) fed dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626800,1,Intermediate,9615.0,,50588,
11219,Maximum plasma concentration,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626801,0,Autocuration,,,22224,
11220,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876816,1,Intermediate,10116.0,,50597,
11221,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626802,1,Intermediate,10116.0,,50597,
11222,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626803,1,Intermediate,9615.0,,50588,
11223,Maximum plasma concentration following oral administration of 30 umol/kg,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626804,0,Autocuration,,,22224,
11224,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626805,1,Intermediate,10116.0,,50597,
11225,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626309,1,Intermediate,10116.0,,50597,
11226,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626310,1,Intermediate,10116.0,,50597,
11227,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626311,1,Intermediate,10116.0,,50597,
11228,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626312,1,Intermediate,10116.0,,50597,
11229,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626313,1,Intermediate,10116.0,,50597,
11230,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626314,1,Intermediate,10116.0,,50597,
11231,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626315,1,Intermediate,10116.0,,50597,
11232,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626316,1,Intermediate,10116.0,,50597,
11233,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626317,1,Intermediate,10116.0,,50597,
11234,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626318,1,Intermediate,10116.0,,50597,
11235,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626319,1,Intermediate,10116.0,,50597,
11236,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626320,1,Intermediate,10116.0,,50597,
11237,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875053,1,Intermediate,10116.0,,50597,
11238,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626321,1,Intermediate,10116.0,,50597,
11239,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626322,1,Intermediate,10116.0,,50597,
11240,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626323,1,Intermediate,10116.0,,50597,
11241,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626324,1,Intermediate,10116.0,,50597,
11242,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626325,1,Intermediate,10116.0,,50597,
11243,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626326,1,Intermediate,10116.0,,50597,
11244,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626327,1,Intermediate,10116.0,,50597,
11245,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626328,1,Intermediate,10116.0,,50597,
11246,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626329,1,Intermediate,10116.0,,50597,
11247,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626330,1,Intermediate,10116.0,,50597,
11248,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626331,1,Intermediate,10116.0,,50597,
11249,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626332,1,Intermediate,10116.0,,50597,
11250,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626333,1,Intermediate,10116.0,,50597,
11251,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626334,1,Intermediate,10116.0,,50597,
11252,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626335,1,Intermediate,10116.0,,50597,
11253,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624798,1,Intermediate,10116.0,,50597,
11254,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624799,1,Intermediate,10116.0,,50597,
11255,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624800,1,Intermediate,10116.0,,50597,
11256,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624801,1,Intermediate,10116.0,,50597,
11257,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624802,1,Intermediate,10116.0,,50597,
11258,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624803,1,Intermediate,10116.0,,50597,
11259,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624804,1,Intermediate,10116.0,,50597,
11260,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624805,1,Intermediate,10116.0,,50597,
11261,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL624806,1,Intermediate,10116.0,,50597,
11262,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624807,1,Intermediate,10116.0,,50597,
11263,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624808,1,Intermediate,10116.0,,50597,
11264,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624809,1,Intermediate,10116.0,,50597,
11265,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624810,1,Intermediate,10116.0,,50597,
11266,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877618,1,Intermediate,10116.0,,50597,
11267,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624811,1,Intermediate,10116.0,,50597,
11268,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624812,1,Intermediate,10116.0,,50597,
11269,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624813,1,Intermediate,10116.0,,50597,
11270,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624814,1,Intermediate,10116.0,,50597,
11271,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624815,1,Intermediate,10116.0,,50597,
11272,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624816,1,Intermediate,10116.0,,50597,
11273,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624817,1,Intermediate,10116.0,,50597,
11274,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624818,1,Intermediate,9615.0,,50588,
11275,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624819,1,Intermediate,9615.0,,50588,
11276,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624820,1,Intermediate,9615.0,,50588,
11277,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624821,1,Intermediate,9615.0,,50588,
11278,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624822,1,Intermediate,9615.0,,50588,
11279,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624823,1,Intermediate,9615.0,,50588,
11280,Observed diffusion coefficient in organic solvent for Escherichia coli,1,N,,Escherichia coli,,,,,,,BAO_0000218,CHEMBL624824,1,Intermediate,562.0,,50212,
11281,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624825,1,Intermediate,10116.0,,50597,
11282,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624826,1,Intermediate,10116.0,,50597,
11283,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,Cardiac atrium,,2081.0,BAO_0000218,CHEMBL876817,1,Intermediate,10116.0,,50597,
11284,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,Cardiac atrium,,2081.0,BAO_0000218,CHEMBL624827,1,Intermediate,10116.0,,50597,
11285,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624828,1,Intermediate,10116.0,,50597,
11286,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624829,1,Intermediate,10116.0,,50597,
11287,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624830,1,Intermediate,10116.0,,50597,
11288,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624831,1,Intermediate,10116.0,,50597,
11289,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,Cardiac atrium,,2081.0,BAO_0000218,CHEMBL624832,1,Intermediate,10116.0,,50597,
11290,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,Cardiac atrium,,2081.0,BAO_0000218,CHEMBL624833,1,Intermediate,10116.0,,50597,
11291,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624834,1,Intermediate,10116.0,,50597,
11292,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624835,1,Intermediate,10116.0,,50597,
11293,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624836,1,Intermediate,10116.0,,50597,
11294,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624837,1,Intermediate,10116.0,,50597,
11295,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624838,1,Intermediate,10116.0,,50597,
11296,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622188,1,Intermediate,10116.0,,50597,
11297,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622189,1,Intermediate,10116.0,,50597,
11298,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622190,1,Intermediate,10116.0,,50597,
11299,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625170,1,Intermediate,10116.0,,50597,
11300,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625171,1,Intermediate,10116.0,,50597,
11301,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625172,1,Intermediate,10116.0,,50597,
11302,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625173,1,Intermediate,10116.0,,50597,
11303,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625174,1,Intermediate,10116.0,,50597,
11304,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625175,1,Intermediate,10116.0,,50597,
11305,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625176,1,Intermediate,10116.0,,50597,
11306,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625177,1,Intermediate,10116.0,,50597,
11307,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625178,1,Intermediate,10116.0,,50597,
11308,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625179,1,Intermediate,10116.0,,50597,
11309,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625180,1,Intermediate,10116.0,,50597,
11310,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",1,U,,,,,,,,,BAO_0000218,CHEMBL625181,0,Autocuration,,,22224,
11311,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625182,1,Intermediate,10090.0,,50594,
11312,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625183,1,Intermediate,10116.0,,50597,
11313,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875848,1,Intermediate,10116.0,,50597,
11314,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622260,1,Intermediate,10116.0,,50597,
11315,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622261,1,Intermediate,10116.0,,50597,
11316,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622262,1,Intermediate,10116.0,,50597,
11317,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622263,1,Intermediate,10116.0,,50597,
11318,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622418,1,Intermediate,10116.0,,50597,
11319,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622419,1,Intermediate,10116.0,,50597,
11320,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623388,1,Intermediate,10090.0,,50594,
11321,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623389,1,Intermediate,10090.0,,50594,
11322,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623390,1,Intermediate,10090.0,,50594,
11323,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623391,1,Intermediate,10090.0,,50594,
11324,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL623392,1,Intermediate,10090.0,,50594,
11325,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL623393,1,Intermediate,10090.0,,50594,
11326,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623394,1,Intermediate,10090.0,,50594,
11327,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618885,1,Intermediate,10090.0,,50594,
11328,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618886,1,Intermediate,10090.0,,50594,
11329,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618887,1,Intermediate,10090.0,,50594,
11330,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619535,1,Intermediate,10090.0,,50594,
11331,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL619536,1,Intermediate,10090.0,,50594,
11332,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL619537,1,Intermediate,10090.0,,50594,
11333,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619705,1,Intermediate,10090.0,,50594,
11334,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619706,1,Intermediate,10090.0,,50594,
11335,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL619707,1,Intermediate,10090.0,,50594,
11336,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL619708,1,Intermediate,10090.0,,50594,
11337,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625219,1,Intermediate,10090.0,,50594,
11338,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL625220,1,Intermediate,10090.0,,50594,
11339,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL625221,1,Intermediate,10090.0,,50594,
11340,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625222,1,Intermediate,10090.0,,50594,
11341,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625223,1,Intermediate,10090.0,,50594,
11342,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625224,1,Intermediate,10090.0,,50594,
11343,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625225,1,Intermediate,10090.0,,50594,
11344,Biodistribution in Rat blood after 24 hours of iv administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625226,1,Intermediate,10116.0,,50597,
11345,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625227,1,Intermediate,10116.0,,50597,
11346,Biodistribution in Rat blood after 30 minutes of iv administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625228,1,Intermediate,10116.0,,50597,
11347,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL875354,1,Intermediate,10116.0,,50597,
11348,Biodistribution in Rat blood after 5 minutes of iv administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625229,1,Intermediate,10116.0,,50597,
11349,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625230,1,Intermediate,10116.0,,50597,
11350,Biodistribution in Rat heart after 24 hours of iv administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625231,1,Intermediate,10116.0,,50597,
11351,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625900,1,Intermediate,10116.0,,50597,
11352,Biodistribution in Rat heart after 30 minutes of iv administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625901,1,Intermediate,10116.0,,50597,
11353,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625902,1,Intermediate,10116.0,,50597,
11354,Biodistribution in Rat heart after 5 minutes of iv administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625903,1,Intermediate,10116.0,,50597,
11355,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625904,1,Intermediate,10116.0,,50597,
11356,Biodistribution in Rat liver after 24 hours of iv administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625905,1,Intermediate,10116.0,,50597,
11357,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627861,1,Intermediate,10116.0,,50597,
11358,Biodistribution in Rat liver after 30 minutes of iv administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627862,1,Intermediate,10116.0,,50597,
11359,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627863,1,Intermediate,10116.0,,50597,
11360,Biodistribution in Rat liver after 30 minutes of iv administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627769,1,Intermediate,10116.0,,50597,
11361,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627770,1,Intermediate,9615.0,,50588,
11362,Cmax in cynomolgus monkey (PO dose),1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL627771,1,Intermediate,9541.0,,100710,
11363,Cmax in rat (PO dose),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627772,1,Intermediate,10116.0,,50597,
11364,Cmax in rat (PO dose),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627773,1,Intermediate,10116.0,,50597,
11365,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621922,1,Intermediate,10116.0,,50597,
11366,Cmax in rat plasma after oral dose (10 mg/kg),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621923,1,Intermediate,10116.0,,50597,
11367,Cmax in plasma after oral dose (10 mg/kg),1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621924,0,Autocuration,,,22224,
11368,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621925,1,Intermediate,9615.0,,50588,
11369,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621926,0,Autocuration,314293.0,,22224,
11370,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1,N,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621927,1,Intermediate,9986.0,,50592,
11371,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621928,1,Intermediate,10116.0,,50597,
11372,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621929,1,Intermediate,10116.0,,50597,
11373,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621930,1,Intermediate,10090.0,,50594,
11374,Maximum plasma concentration after oral dosing in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621931,1,Intermediate,10116.0,,50597,
11375,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621932,0,Autocuration,,,22224,
11376,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621933,0,Autocuration,,,22224,
11377,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621934,1,Intermediate,9615.0,,50588,
11378,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621935,1,Intermediate,9615.0,,50588,
11379,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621936,1,Intermediate,10116.0,,50597,
11380,Maximum plasma concentration was determined,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621937,0,Autocuration,,,22224,
11381,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621938,0,Autocuration,,,22224,
11382,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621939,0,Autocuration,,,22224,
11383,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621940,0,Autocuration,,,22224,
11384,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621941,0,Autocuration,,,22224,
11385,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL621942,0,Autocuration,,,22224,
11386,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626178,0,Autocuration,,,22224,
11387,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626179,0,Autocuration,,,22224,
11388,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626180,0,Autocuration,,,22224,
11389,Plasma Cmax in rat (PO dose),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626181,1,Intermediate,10116.0,,50597,
11390,Maximum serum concentration after po dose of 5.22 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626182,1,Intermediate,10116.0,,50597,
11391,Maximum serum concentration after po dose of 5.46 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626183,1,Intermediate,10116.0,,50597,
11392,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626184,1,Intermediate,10116.0,,50597,
11393,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626185,1,Intermediate,10116.0,,50597,
11394,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626186,1,Intermediate,9615.0,,50588,
11395,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL877589,1,Intermediate,9615.0,,50588,
11396,Maximum concentration of the drug at 1 uM/dg administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL626187,0,Autocuration,,,22224,
11397,Maximum concentration of the drug at 20 uM/dg administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626188,0,Autocuration,,,22224,
11398,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL626189,0,Autocuration,,,22224,
11399,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL626855,0,Autocuration,,,22224,
11400,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL623781,0,Autocuration,,,22224,
11401,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL623782,0,Autocuration,,,22224,
11402,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623783,1,Intermediate,10116.0,,50597,
11403,Cmax in dog plasma after 1mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623784,1,Intermediate,9615.0,,50588,
11404,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623785,1,Intermediate,9615.0,,50588,
11405,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623786,1,Intermediate,10116.0,,50597,
11406,Oral maximum concentration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623787,1,Intermediate,10116.0,,50597,
11407,Oral maximum concentration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623788,1,Intermediate,10116.0,,50597,
11408,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623789,1,Intermediate,10090.0,,50594,
11409,Peak concentration in blood after intravenous administration to mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL623790,1,Intermediate,10090.0,,50594,
11410,Peak concentration in blood after peroral administration to mice,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL623791,1,Intermediate,10090.0,,50594,
11411,Peak concentration in rat plasma was determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623792,1,Intermediate,10116.0,,50597,
11412,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623793,0,Autocuration,314293.0,,22224,
11413,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623794,1,Intermediate,10090.0,,50594,
11414,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623795,1,Intermediate,10116.0,,50597,
11415,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623796,1,Intermediate,10116.0,,50597,
11416,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623797,1,Intermediate,10116.0,,50597,
11417,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623798,1,Intermediate,10116.0,,50597,
11418,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623799,1,Intermediate,10116.0,,50597,
11419,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624490,1,Intermediate,10116.0,,50597,
11420,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624491,1,Intermediate,10116.0,,50597,
11421,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624492,1,Intermediate,10116.0,,50597,
11422,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624493,1,Intermediate,10116.0,,50597,
11423,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL877595,1,Intermediate,10116.0,,50597,
11424,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624494,1,Intermediate,10116.0,,50597,
11425,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624495,1,Intermediate,10116.0,,50597,
11426,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL624681,1,Intermediate,10116.0,,50597,
11427,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624682,1,Intermediate,10116.0,,50597,
11428,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624683,1,Intermediate,10116.0,,50597,
11429,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624684,1,Intermediate,10116.0,,50597,
11430,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624685,1,Intermediate,10116.0,,50597,
11431,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624686,1,Intermediate,10116.0,,50597,
11432,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624687,1,Intermediate,10116.0,,50597,
11433,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624688,1,Intermediate,10116.0,,50597,
11434,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627161,1,Intermediate,10116.0,,50597,
11435,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622127,1,Intermediate,10116.0,,50597,
11436,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622128,1,Intermediate,10116.0,,50597,
11437,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874384,1,Intermediate,10116.0,,50597,
11438,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624898,1,Intermediate,10116.0,,50597,
11439,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624899,1,Intermediate,10116.0,,50597,
11440,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624900,1,Intermediate,10116.0,,50597,
11441,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624901,1,Intermediate,10116.0,,50597,
11442,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624902,1,Intermediate,10116.0,,50597,
11443,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624903,1,Intermediate,10116.0,,50597,
11444,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624904,1,Intermediate,10116.0,,50597,
11445,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624905,1,Intermediate,10116.0,,50597,
11446,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624906,1,Intermediate,10116.0,,50597,
11447,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624907,1,Intermediate,10116.0,,50597,
11448,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624908,1,Intermediate,10116.0,,50597,
11449,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624909,1,Intermediate,10116.0,,50597,
11450,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624910,1,Intermediate,10116.0,,50597,
11451,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624911,1,Intermediate,10116.0,,50597,
11452,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL874388,1,Intermediate,10116.0,,50597,
11453,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624912,1,Intermediate,10116.0,,50597,
11454,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622930,1,Intermediate,10116.0,,50597,
11455,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623121,1,Intermediate,10116.0,,50597,
11456,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623122,1,Intermediate,10116.0,,50597,
11457,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623123,1,Intermediate,10116.0,,50597,
11458,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623124,1,Intermediate,10116.0,,50597,
11459,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623125,1,Intermediate,10116.0,,50597,
11460,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623126,1,Intermediate,10116.0,,50597,
11461,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623127,1,Intermediate,10116.0,,50597,
11462,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623128,1,Intermediate,10116.0,,50597,
11463,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623129,1,Intermediate,10116.0,,50597,
11464,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623130,1,Intermediate,10116.0,,50597,
11465,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623131,1,Intermediate,10116.0,,50597,
11466,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623132,1,Intermediate,10116.0,,50597,
11467,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623133,1,Intermediate,10116.0,,50597,
11468,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623134,1,Intermediate,10116.0,,50597,
11469,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874389,1,Intermediate,10116.0,,50597,
11470,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623135,1,Intermediate,10116.0,,50597,
11471,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623136,1,Intermediate,10116.0,,50597,
11472,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623137,1,Intermediate,10116.0,,50597,
11473,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623138,1,Intermediate,10116.0,,50597,
11474,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623139,1,Intermediate,10116.0,,50597,
11475,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623140,1,Intermediate,10116.0,,50597,
11476,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623141,1,Intermediate,10116.0,,50597,
11477,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623142,1,Intermediate,10116.0,,50597,
11478,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623143,1,Intermediate,10116.0,,50597,
11479,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623144,1,Intermediate,10090.0,,50594,
11480,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623405,1,Intermediate,10116.0,,50597,
11481,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624074,1,Intermediate,10116.0,,50597,
11482,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624075,1,Intermediate,10116.0,,50597,
11483,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624076,1,Intermediate,10116.0,,50597,
11484,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624077,1,Intermediate,10116.0,,50597,
11485,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624078,1,Intermediate,10116.0,,50597,
11486,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624079,1,Intermediate,10116.0,,50597,
11487,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624261,1,Intermediate,10116.0,,50597,
11488,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624262,1,Intermediate,10116.0,,50597,
11489,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624263,1,Intermediate,10116.0,,50597,
11490,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624264,1,Intermediate,10116.0,,50597,
11491,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624265,1,Intermediate,10116.0,,50597,
11492,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624266,1,Intermediate,10116.0,,50597,
11493,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624267,1,Intermediate,10116.0,,50597,
11494,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624268,1,Intermediate,10116.0,,50597,
11495,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875227,1,Intermediate,10116.0,,50597,
11496,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624269,1,Intermediate,10116.0,,50597,
11497,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624270,1,Intermediate,10116.0,,50597,
11498,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624271,1,Intermediate,10116.0,,50597,
11499,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624272,1,Intermediate,10116.0,,50597,
11500,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624273,1,Intermediate,10116.0,,50597,
11501,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624274,1,Intermediate,10116.0,,50597,
11502,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624275,1,Intermediate,10116.0,,50597,
11503,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624276,1,Intermediate,10116.0,,50597,
11504,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624277,1,Intermediate,10116.0,,50597,
11505,% dose converted to 2-amino-5-chlorophenyl sulfate,1,U,,,,,,,,,BAO_0000019,CHEMBL624278,0,Autocuration,,,22224,
11506,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),1,U,,,,,,,,,BAO_0000019,CHEMBL624279,0,Autocuration,,,22224,
11507,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL624280,1,Intermediate,10116.0,,50597,
11508,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL624281,1,Intermediate,10116.0,,50597,
11509,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL622933,1,Intermediate,10116.0,,50597,
11510,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL622934,1,Intermediate,10116.0,,50597,
11511,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622935,1,Intermediate,10116.0,,50597,
11512,Biodistribution in Rat liver after 5 minutes of iv administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622936,1,Intermediate,10116.0,,50597,
11513,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL875228,1,Intermediate,10116.0,,50597,
11514,Biodistribution in Rat lung after 24 hours of iv administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622937,1,Intermediate,10116.0,,50597,
11515,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622938,1,Intermediate,10116.0,,50597,
11516,Biodistribution in Rat lung after 30 minutes of iv administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL619736,1,Intermediate,10116.0,,50597,
11517,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625117,1,Intermediate,10116.0,,50597,
11518,Biodistribution in Rat lung after 5 minutes of iv administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625118,1,Intermediate,10116.0,,50597,
11519,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625119,1,Intermediate,10116.0,,50597,
11520,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL625120,1,Intermediate,10116.0,,50597,
11521,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625121,1,Intermediate,10116.0,,50597,
11522,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",1,N,,Rattus norvegicus,,,,Thalamus,,10000006.0,BAO_0000218,CHEMBL625122,1,Intermediate,10116.0,,50597,
11523,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL622204,1,Intermediate,10116.0,,50597,
11524,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL877503,1,Intermediate,10116.0,,50597,
11525,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627127,1,Intermediate,10116.0,,50597,
11526,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,U,,,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL627128,0,Autocuration,,,22224,
11527,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,U,,,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL627129,0,Autocuration,,,22224,
11528,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,U,,,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL627130,0,Autocuration,,,22224,
11529,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL627131,1,Intermediate,10116.0,,50597,
11530,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL627132,1,Intermediate,10116.0,,50597,
11531,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL627133,1,Intermediate,10116.0,,50597,
11532,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL627134,1,Intermediate,10116.0,,50597,
11533,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL627135,1,Intermediate,10116.0,,50597,
11534,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL627136,1,Intermediate,10116.0,,50597,
11535,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628435,1,Intermediate,10116.0,,50597,
11536,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628436,1,Intermediate,10116.0,,50597,
11537,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628437,1,Intermediate,10116.0,,50597,
11538,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL628438,1,Intermediate,10116.0,,50597,
11539,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL628439,1,Intermediate,10116.0,,50597,
11540,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL628440,1,Intermediate,10116.0,,50597,
11541,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL628441,1,Intermediate,10116.0,,50597,
11542,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL628442,1,Intermediate,10116.0,,50597,
11543,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL628443,1,Intermediate,10116.0,,50597,
11544,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628444,1,Intermediate,10116.0,,50597,
11545,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628445,1,Intermediate,10116.0,,50597,
11546,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL877504,1,Intermediate,10116.0,,50597,
11547,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628446,1,Intermediate,10116.0,,50597,
11548,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626874,1,Intermediate,10116.0,,50597,
11549,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626875,1,Intermediate,10116.0,,50597,
11550,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626876,1,Intermediate,10116.0,,50597,
11551,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626877,1,Intermediate,10116.0,,50597,
11552,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626878,1,Intermediate,10116.0,,50597,
11553,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL626879,1,Intermediate,10116.0,,50597,
11554,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626880,0,Autocuration,314293.0,,22224,
11555,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626881,1,Intermediate,10090.0,,50594,
11556,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626882,1,Intermediate,10116.0,,50597,
11557,Peak plasma concentration was measured in dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626883,1,Intermediate,9615.0,,50588,
11558,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626884,1,Intermediate,10116.0,,50597,
11559,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626885,1,Intermediate,10116.0,,50597,
11560,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626886,1,Intermediate,10116.0,,50597,
11561,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626887,1,Intermediate,10116.0,,50597,
11562,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626888,1,Intermediate,10116.0,,50597,
11563,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626889,1,Intermediate,9615.0,,50588,
11564,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626761,0,Autocuration,314293.0,,22224,
11565,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626762,1,Intermediate,9615.0,,50588,
11566,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626763,1,Intermediate,9615.0,,50588,
11567,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626764,1,Intermediate,10116.0,,50597,
11568,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626765,1,Intermediate,10116.0,,50597,
11569,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626766,1,Intermediate,9615.0,,50588,
11570,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626767,1,Intermediate,10116.0,,50597,
11571,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626768,1,Intermediate,10116.0,,50597,
11572,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626769,1,Intermediate,9615.0,,50588,
11573,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL874463,1,Intermediate,9615.0,,50588,
11574,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626770,0,Autocuration,314293.0,,22224,
11575,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626771,0,Autocuration,314293.0,,22224,
11576,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626772,1,Intermediate,10116.0,,50597,
11577,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL626773,1,Intermediate,9541.0,,100710,
11578,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626774,1,Intermediate,10090.0,,50594,
11579,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626775,1,Intermediate,9615.0,,50588,
11580,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626776,1,Intermediate,9615.0,,50588,
11581,Maximum concentration (Cmax) in rat when administered orally,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626777,1,Intermediate,10116.0,,50597,
11582,Maximal concentration in monkey plasma after 25 mg/kg oral dose,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626778,0,Autocuration,314293.0,,22224,
11583,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626779,0,Autocuration,10116.0,,22224,
11584,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626780,0,Autocuration,10116.0,,22224,
11585,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626781,0,Autocuration,,,22224,
11586,Pharmacokinetic profile Cmax was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632164,1,Intermediate,10116.0,,50597,
11587,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL632165,1,Intermediate,9615.0,,50588,
11588,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL632166,1,Intermediate,10090.0,,50594,
11589,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL632167,1,Intermediate,9615.0,,50588,
11590,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL632168,1,Intermediate,10090.0,,50594,
11591,Cmax in rat plasma,1,U,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632169,0,Autocuration,10116.0,,22224,
11592,Cmax in dog plasma after 30mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632170,1,Intermediate,9615.0,,50588,
11593,Cmax in rat plasma after 30mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632171,1,Intermediate,10116.0,,50597,
11594,Plasma level in rats at 30 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632172,1,Intermediate,10116.0,,50597,
11595,Tested for maximum plasma concentration in mice,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632173,1,Intermediate,10090.0,,50594,
11596,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632174,1,Intermediate,10116.0,,50597,
11597,The Cmax values in female wistar rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632175,1,Intermediate,10116.0,,50597,
11598,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632176,1,Intermediate,9615.0,,50588,
11599,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632177,1,Intermediate,10116.0,,50597,
11600,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632178,1,Intermediate,10116.0,,50597,
11601,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632179,1,Intermediate,10116.0,,50597,
11602,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632180,1,Intermediate,10116.0,,50597,
11603,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632181,1,Intermediate,10116.0,,50597,
11604,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632182,1,Intermediate,10116.0,,50597,
11605,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,1,U,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL632183,0,Autocuration,10090.0,,22224,
11606,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL632184,1,Intermediate,9615.0,,50588,
11607,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874470,1,Intermediate,10116.0,,50597,
11608,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631302,1,Intermediate,10116.0,,50597,
11609,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631303,1,Intermediate,10116.0,,50597,
11610,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631304,1,Intermediate,10116.0,,50597,
11611,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631305,1,Intermediate,10116.0,,50597,
11612,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631306,1,Intermediate,10116.0,,50597,
11613,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631307,1,Intermediate,10116.0,,50597,
11614,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631308,1,Intermediate,10116.0,,50597,
11615,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625557,1,Intermediate,10116.0,,50597,
11616,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625558,1,Intermediate,10116.0,,50597,
11617,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625559,1,Intermediate,10116.0,,50597,
11618,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625560,1,Intermediate,10116.0,,50597,
11619,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625561,1,Intermediate,10116.0,,50597,
11620,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625562,1,Intermediate,10116.0,,50597,
11621,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL875320,1,Intermediate,10116.0,,50597,
11622,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625563,1,Intermediate,10116.0,,50597,
11623,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625564,1,Intermediate,10116.0,,50597,
11624,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL625565,1,Intermediate,10116.0,,50597,
11625,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL625566,1,Intermediate,10116.0,,50597,
11626,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL625567,1,Intermediate,10116.0,,50597,
11627,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL625568,1,Intermediate,10116.0,,50597,
11628,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL628217,1,Intermediate,10116.0,,50597,
11629,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL628218,1,Intermediate,10116.0,,50597,
11630,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL628219,1,Intermediate,10116.0,,50597,
11631,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL628220,1,Intermediate,10116.0,,50597,
11632,Distribution in the blood after 120 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628221,0,Autocuration,,,22224,
11633,Distribution in the blood after 15 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628222,0,Autocuration,,,22224,
11634,Distribution in the blood after 30 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628223,0,Autocuration,,,22224,
11635,Distribution in the blood after 5 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628224,0,Autocuration,,,22224,
11636,Distribution in the blood after 60 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628225,0,Autocuration,,,22224,
11637,Distribution in the blood after 90 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628226,0,Autocuration,,,22224,
11638,Distribution in the bone after 120 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628227,0,Autocuration,,,22224,
11639,Distribution in the bone after 15 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL875481,0,Autocuration,,,22224,
11640,Distribution in the bone after 30 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628228,0,Autocuration,,,22224,
11641,Distribution in the bone after 5 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628229,0,Autocuration,,,22224,
11642,Distribution in the bone after 60 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628230,0,Autocuration,,,22224,
11643,Distribution in the bone after 90 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628231,0,Autocuration,,,22224,
11644,Distribution in the heart after 120 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628232,0,Autocuration,,,22224,
11645,Distribution in the heart after 15 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628233,0,Autocuration,,,22224,
11646,Distribution in the heart after 30 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628234,0,Autocuration,,,22224,
11647,Distribution in the heart after 5 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628235,0,Autocuration,,,22224,
11648,Distribution in the heart after 60 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628236,0,Autocuration,,,22224,
11649,Distribution in the heart after 90 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628237,0,Autocuration,,,22224,
11650,Distribution in the kidneys after 120 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628238,0,Autocuration,,,22224,
11651,Distribution in the kidneys after 15 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628239,0,Autocuration,,,22224,
11652,Distribution in the kidneys after 30 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628240,0,Autocuration,,,22224,
11653,Distribution in the kidneys after 5 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628241,0,Autocuration,,,22224,
11654,Distribution in the kidneys after 60 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628242,0,Autocuration,,,22224,
11655,Distribution in the kidneys after 90 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL875482,0,Autocuration,,,22224,
11656,Distribution in the liver after 120 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628243,0,Autocuration,,,22224,
11657,Distribution in the liver after 15 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628244,0,Autocuration,,,22224,
11658,Distribution in the liver after 30 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628245,0,Autocuration,,,22224,
11659,Distribution in the liver after 5 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628246,0,Autocuration,,,22224,
11660,Distribution in the liver after 60 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628247,0,Autocuration,,,22224,
11661,Distribution in the liver after 90 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628248,0,Autocuration,,,22224,
11662,Distribution in the lung after 120 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628249,0,Autocuration,,,22224,
11663,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625452,1,Intermediate,10090.0,,50594,
11664,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625453,1,Intermediate,10090.0,,50594,
11665,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625454,1,Intermediate,10090.0,,50594,
11666,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623844,1,Intermediate,10090.0,,50594,
11667,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623845,1,Intermediate,10116.0,,50597,
11668,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623846,1,Intermediate,10116.0,,50597,
11669,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,1,U,,,,,,,,,BAO_0000218,CHEMBL623847,0,Autocuration,,,22224,
11670,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623848,1,Intermediate,9541.0,,100710,
11671,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623849,1,Intermediate,9541.0,,100710,
11672,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623850,1,Intermediate,9541.0,,100710,
11673,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623851,1,Intermediate,9541.0,,100710,
11674,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL623852,0,Autocuration,314293.0,,22224,
11675,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL624551,1,Intermediate,9669.0,,50506,
11676,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL624552,1,Intermediate,9669.0,,50506,
11677,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL624553,0,Autocuration,314293.0,,22224,
11678,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL624554,0,Autocuration,314293.0,,22224,
11679,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624555,1,Intermediate,10116.0,,50597,
11680,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624741,1,Intermediate,10116.0,,50597,
11681,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624742,1,Intermediate,9615.0,,50588,
11682,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL624743,1,Intermediate,10026.0,,100712,
11683,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877606,1,Intermediate,10116.0,,50597,
11684,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL624744,0,Autocuration,,,22224,
11685,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL624745,0,Autocuration,,,22224,
11686,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL624746,0,Autocuration,,,22224,
11687,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL624747,0,Autocuration,,,22224,
11688,Oral absorption expressed as Area under curve was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL624748,0,Autocuration,,,22224,
11689,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622504,1,Intermediate,9615.0,,50588,
11690,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622505,1,Intermediate,9615.0,,50588,
11691,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL622506,1,Intermediate,10026.0,,100712,
11692,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL622507,1,Intermediate,10026.0,,100712,
11693,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622508,1,Intermediate,10116.0,,50597,
11694,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL622509,0,Autocuration,,,22224,
11695,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622510,1,Intermediate,10116.0,,50597,
11696,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622511,1,Intermediate,10116.0,,50597,
11697,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL622512,1,Intermediate,9541.0,,100710,
11698,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL622513,1,Intermediate,9541.0,,100710,
11699,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL622514,1,Intermediate,9541.0,,100710,
11700,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622515,1,Intermediate,9615.0,,50588,
11701,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622516,1,Intermediate,9615.0,,50588,
11702,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622517,1,Intermediate,10116.0,,50597,
11703,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622518,1,Intermediate,10116.0,,50597,
11704,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622519,1,Intermediate,10116.0,,50597,
11705,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622520,1,Intermediate,10116.0,,50597,
11706,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622521,1,Intermediate,10116.0,,50597,
11707,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL625113,1,Intermediate,10090.0,,50594,
11708,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL625114,1,Intermediate,10116.0,,50597,
11709,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL874397,1,Intermediate,10116.0,,50597,
11710,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625115,1,Intermediate,10116.0,,50597,
11711,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625116,1,Intermediate,10116.0,,50597,
11712,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL623932,1,Intermediate,10116.0,,50597,
11713,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL623933,1,Intermediate,10116.0,,50597,
11714,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL623934,1,Intermediate,10116.0,,50597,
11715,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL623935,1,Intermediate,10116.0,,50597,
11716,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL623936,1,Intermediate,10116.0,,50597,
11717,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL623937,1,Intermediate,10116.0,,50597,
11718,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL623938,1,Intermediate,10116.0,,50597,
11719,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623939,1,Intermediate,10090.0,,50594,
11720,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623940,1,Intermediate,10090.0,,50594,
11721,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623941,1,Intermediate,10090.0,,50594,
11722,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627216,1,Intermediate,10090.0,,50594,
11723,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623942,1,Intermediate,10090.0,,50594,
11724,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618793,1,Intermediate,10090.0,,50594,
11725,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618794,1,Intermediate,10090.0,,50594,
11726,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL618795,1,Intermediate,10090.0,,50594,
11727,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618796,1,Intermediate,10090.0,,50594,
11728,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618797,1,Intermediate,10090.0,,50594,
11729,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618798,1,Intermediate,10090.0,,50594,
11730,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618799,1,Intermediate,10090.0,,50594,
11731,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618800,1,Intermediate,10090.0,,50594,
11732,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618801,1,Intermediate,10090.0,,50594,
11733,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618802,1,Intermediate,10090.0,,50594,
11734,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL618803,1,Intermediate,10090.0,,50594,
11735,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618804,1,Intermediate,10090.0,,50594,
11736,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618805,1,Intermediate,10090.0,,50594,
11737,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618806,1,Intermediate,10090.0,,50594,
11738,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618807,1,Intermediate,10090.0,,50594,
11739,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618808,1,Intermediate,10090.0,,50594,
11740,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL618809,1,Intermediate,10090.0,,50594,
11741,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618810,1,Intermediate,10090.0,,50594,
11742,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618811,1,Intermediate,10090.0,,50594,
11743,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL875844,1,Intermediate,10090.0,,50594,
11744,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618812,1,Intermediate,10090.0,,50594,
11745,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL618813,1,Intermediate,10090.0,,50594,
11746,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618814,1,Intermediate,10090.0,,50594,
11747,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618815,1,Intermediate,10090.0,,50594,
11748,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618816,1,Intermediate,10090.0,,50594,
11749,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL618817,1,Intermediate,10090.0,,50594,
11750,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL620544,1,Intermediate,10090.0,,50594,
11751,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626230,1,Intermediate,10116.0,,50597,
11752,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626231,1,Intermediate,10116.0,,50597,
11753,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626232,1,Intermediate,10116.0,,50597,
11754,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626233,1,Intermediate,9615.0,,50588,
11755,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626234,1,Intermediate,10116.0,,50597,
11756,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL875341,1,Intermediate,10116.0,,50597,
11757,The maximum plasma concentration (100 mg/kg) administered orally in human,1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626235,1,Intermediate,9606.0,,50587,
11758,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,1,U,,Callithrix,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626236,0,Autocuration,9481.0,,22224,
11759,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626237,0,Autocuration,314293.0,,22224,
11760,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626238,1,Intermediate,9615.0,,50588,
11761,The maximum plasma concentration (200 mg/kg) administered orally in human,1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622412,1,Intermediate,9606.0,,50587,
11762,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623114,1,Intermediate,10116.0,,50597,
11763,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,1,U,,Callithrix,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623115,0,Autocuration,9481.0,,22224,
11764,The maximum plasma concentration (25 mg/kg) administered orally in monkey,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623116,0,Autocuration,314293.0,,22224,
11765,The maximum plasma concentration (30 mg/kg) administered orally in dog,1,U,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623117,0,Autocuration,9615.0,,22224,
11766,The maximum plasma concentration (400 mg/kg) administered orally in human,1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623118,1,Intermediate,9606.0,,50587,
11767,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623119,1,Intermediate,10116.0,,50597,
11768,The maximum plasma concentration (50 mg/kg) administered orally in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623120,1,Intermediate,10116.0,,50597,
11769,The maximum plasma concentration (800 mg/kg) administered orally in human,1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623286,1,Intermediate,9606.0,,50587,
11770,The maximum plasma concentration was measured on rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623287,1,Intermediate,10116.0,,50597,
11771,The maximum plasma concentration was measured on rats after oral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623288,1,Intermediate,10116.0,,50597,
11772,Plasma drug Cmax in rat (PO dose),1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623289,1,Intermediate,10116.0,,50597,
11773,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL623290,0,Autocuration,,,22224,
11774,maximum Plasma concentration in Dog was determined after Peroral administration,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623291,1,Intermediate,9615.0,,50588,
11775,maximum Plasma concentration in Rats was determined after Peroral administration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623292,1,Intermediate,10116.0,,50597,
11776,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623293,1,Intermediate,9615.0,,50588,
11777,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623294,0,Autocuration,314293.0,,22224,
11778,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623295,1,Intermediate,10116.0,,50597,
11779,maximum concentration was measured when administered through oral route in mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623296,1,Intermediate,10090.0,,50594,
11780,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875349,1,Intermediate,10090.0,,50594,
11781,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,1,U,,Simiiformes,,,,,,,BAO_0000019,CHEMBL623297,0,Autocuration,314293.0,,22224,
11782,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,1,U,,Simiiformes,,,,,,,BAO_0000019,CHEMBL623298,0,Autocuration,314293.0,,22224,
11783,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,1,U,,Simiiformes,,,,,,,BAO_0000019,CHEMBL623299,0,Autocuration,314293.0,,22224,
11784,Pharmacokinetic parameter was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623300,1,Intermediate,10116.0,,50597,
11785,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623301,1,Intermediate,10090.0,,50594,
11786,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623302,1,Intermediate,10090.0,,50594,
11787,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623303,1,Intermediate,10090.0,,50594,
11788,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623304,1,Intermediate,10090.0,,50594,
11789,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623305,1,Intermediate,10090.0,,50594,
11790,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623306,1,Intermediate,10116.0,,50597,
11791,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623307,1,Intermediate,10116.0,,50597,
11792,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623308,1,Intermediate,10116.0,,50597,
11793,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623309,1,Intermediate,10090.0,,50594,
11794,Plasma Concentration after 120 min of oral administration to mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623310,1,Intermediate,10090.0,,50594,
11795,Plasma Concentration after 30 min of oral administration to mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623311,1,Intermediate,10090.0,,50594,
11796,Plasma Concentration after 60 min of oral administration to mice,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL623312,1,Intermediate,9541.0,,100710,
11797,Plasma Concentration after 60 min of oral administration to mice; Not determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL875350,1,Intermediate,10090.0,,50594,
11798,Plasma Concentration after 90 min of oral administration to mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628635,1,Intermediate,10090.0,,50594,
11799,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628636,1,Intermediate,10116.0,,50597,
11800,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628637,1,Intermediate,10116.0,,50597,
11801,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628058,1,Intermediate,10116.0,,50597,
11802,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628059,1,Intermediate,10116.0,,50597,
11803,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628060,1,Intermediate,10116.0,,50597,
11804,Distribution in the lung after 15 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628061,0,Autocuration,,,22224,
11805,Distribution in the lung after 30 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628062,0,Autocuration,,,22224,
11806,Distribution in the lung after 5 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628063,0,Autocuration,,,22224,
11807,Distribution in the lung after 60 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628064,0,Autocuration,,,22224,
11808,Distribution in the lung after 90 min of intravenous administration,1,U,,,,,,,,,BAO_0000019,CHEMBL628065,0,Autocuration,,,22224,
11809,Distribution in the muscle after 120 min of intravenous administration,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000019,CHEMBL628066,0,Autocuration,,,22224,
11810,Distribution in the muscle after 15 min of intravenous administration,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000019,CHEMBL628067,0,Autocuration,,,22224,
11811,Distribution in the muscle after 30 min of intravenous administration,1,N,,Mus musculus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL874646,1,Intermediate,10090.0,,50594,
11812,Distribution in the muscle after 5 min of intravenous administration,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000019,CHEMBL628068,0,Autocuration,,,22224,
11813,Distribution in the muscle after 60 min of intravenous administration,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000019,CHEMBL628069,0,Autocuration,,,22224,
11814,Distribution in the muscle after 90 min of intravenous administration,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000019,CHEMBL628070,0,Autocuration,,,22224,
11815,Distribution in the spleen after 120 min of intravenous administration,1,U,,,,,,Spleen,,2106.0,BAO_0000019,CHEMBL628071,0,Autocuration,,,22224,
11816,Distribution in the spleen after 15 min of intravenous administration,1,U,,,,,,Spleen,,2106.0,BAO_0000019,CHEMBL628072,0,Autocuration,,,22224,
11817,Distribution in the spleen after 30 min of intravenous administration,1,U,,,,,,Spleen,,2106.0,BAO_0000019,CHEMBL628073,0,Autocuration,,,22224,
11818,Distribution in the spleen after 5 min of intravenous administration,1,U,,,,,,Spleen,,2106.0,BAO_0000019,CHEMBL628074,0,Autocuration,,,22224,
11819,Distribution in the spleen after 60 min of intravenous administration,1,U,,,,,,Spleen,,2106.0,BAO_0000019,CHEMBL628075,0,Autocuration,,,22224,
11820,Distribution in the spleen after 90 min of intravenous administration,1,U,,,,,,Spleen,,2106.0,BAO_0000019,CHEMBL628076,0,Autocuration,,,22224,
11821,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Adrenal cortex,,1235.0,BAO_0000218,CHEMBL628077,1,Intermediate,10116.0,,50597,
11822,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628078,1,Intermediate,10116.0,,50597,
11823,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628079,1,Intermediate,10116.0,,50597,
11824,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL628080,1,Intermediate,10116.0,,50597,
11825,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL628081,1,Intermediate,10116.0,,50597,
11826,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Adrenal cortex,,1235.0,BAO_0000218,CHEMBL628082,1,Intermediate,10116.0,,50597,
11827,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL874647,1,Intermediate,10116.0,,50597,
11828,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626406,1,Intermediate,10116.0,,50597,
11829,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL626407,1,Intermediate,10116.0,,50597,
11830,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626408,1,Intermediate,10116.0,,50597,
11831,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626409,1,Intermediate,10116.0,,50597,
11832,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626410,1,Intermediate,10116.0,,50597,
11833,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626411,1,Intermediate,10116.0,,50597,
11834,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626412,1,Intermediate,10116.0,,50597,
11835,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626413,1,Intermediate,10116.0,,50597,
11836,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626414,1,Intermediate,10116.0,,50597,
11837,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626415,1,Intermediate,10116.0,,50597,
11838,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626416,1,Intermediate,10116.0,,50597,
11839,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627062,1,Intermediate,10116.0,,50597,
11840,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627063,1,Intermediate,10116.0,,50597,
11841,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627064,1,Intermediate,10116.0,,50597,
11842,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627227,1,Intermediate,10116.0,,50597,
11843,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627228,1,Intermediate,10116.0,,50597,
11844,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627229,1,Intermediate,10116.0,,50597,
11845,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625792,1,Intermediate,10116.0,,50597,
11846,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625793,1,Intermediate,10116.0,,50597,
11847,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625794,1,Intermediate,10116.0,,50597,
11848,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625795,1,Intermediate,10116.0,,50597,
11849,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625796,1,Intermediate,10090.0,,50594,
11850,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625797,1,Intermediate,9615.0,,50588,
11851,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625798,1,Intermediate,9615.0,,50588,
11852,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL875613,0,Autocuration,,,22224,
11853,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625799,0,Autocuration,,,22224,
11854,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625800,0,Autocuration,,,22224,
11855,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625801,0,Autocuration,,,22224,
11856,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625802,0,Autocuration,,,22224,
11857,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625803,0,Autocuration,,,22224,
11858,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,1,U,,,,,,,,,BAO_0000019,CHEMBL625804,0,Autocuration,,,22224,
11859,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL622530,0,Autocuration,,,22224,
11860,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622531,1,Intermediate,10090.0,,50594,
11861,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622532,1,Intermediate,10090.0,,50594,
11862,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623176,1,Intermediate,10090.0,,50594,
11863,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623177,1,Intermediate,10090.0,,50594,
11864,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623178,1,Intermediate,10090.0,,50594,
11865,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623179,1,Intermediate,10090.0,,50594,
11866,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623180,1,Intermediate,10090.0,,50594,
11867,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623181,1,Intermediate,10090.0,,50594,
11868,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624131,1,Intermediate,10090.0,,50594,
11869,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624132,1,Intermediate,10090.0,,50594,
11870,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624133,1,Intermediate,10090.0,,50594,
11871,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624846,1,Intermediate,10090.0,,50594,
11872,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624847,1,Intermediate,10090.0,,50594,
11873,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL624848,1,Intermediate,10090.0,,50594,
11874,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625012,1,Intermediate,10090.0,,50594,
11875,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625013,1,Intermediate,10090.0,,50594,
11876,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625014,1,Intermediate,10090.0,,50594,
11877,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625015,1,Intermediate,10090.0,,50594,
11878,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625016,1,Intermediate,10090.0,,50594,
11879,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625017,1,Intermediate,10090.0,,50594,
11880,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625018,1,Intermediate,10090.0,,50594,
11881,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625019,1,Intermediate,10090.0,,50594,
11882,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625020,1,Intermediate,10090.0,,50594,
11883,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625021,1,Intermediate,10090.0,,50594,
11884,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625022,1,Intermediate,10116.0,,50597,
11885,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625023,1,Intermediate,10090.0,,50594,
11886,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL625024,1,Intermediate,9541.0,,100710,
11887,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL627626,1,Intermediate,9541.0,,100710,
11888,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,1,U,,,,,,Brain,,955.0,BAO_0000218,CHEMBL627627,0,Autocuration,,,22224,
11889,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,1,U,,,,,,Serum,,1977.0,BAO_0000218,CHEMBL627628,0,Autocuration,,,22224,
11890,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,1,U,,,,,,Brain,,955.0,BAO_0000218,CHEMBL627629,0,Autocuration,,,22224,
11891,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,1,U,,,,,,Serum,,1977.0,BAO_0000218,CHEMBL627630,0,Autocuration,,,22224,
11892,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),1,U,,,,,,,,,BAO_0000019,CHEMBL627631,0,Autocuration,,,22224,
11893,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),1,U,,,,,,,,,BAO_0000218,CHEMBL629515,0,Autocuration,,,22224,
11894,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629516,1,Intermediate,10090.0,,50594,
11895,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629517,1,Intermediate,10090.0,,50594,
11896,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629518,1,Intermediate,10090.0,,50594,
11897,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL877499,1,Intermediate,10090.0,,50594,
11898,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629519,1,Intermediate,10090.0,,50594,
11899,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629520,1,Intermediate,10090.0,,50594,
11900,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629521,1,Intermediate,10090.0,,50594,
11901,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629522,1,Intermediate,10090.0,,50594,
11902,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629523,1,Intermediate,10090.0,,50594,
11903,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629524,1,Intermediate,10090.0,,50594,
11904,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629525,1,Intermediate,10090.0,,50594,
11905,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629526,1,Intermediate,10090.0,,50594,
11906,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629527,1,Intermediate,10090.0,,50594,
11907,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629528,1,Intermediate,10090.0,,50594,
11908,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629529,1,Intermediate,10090.0,,50594,
11909,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629530,1,Intermediate,10090.0,,50594,
11910,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629531,1,Intermediate,10090.0,,50594,
11911,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628656,1,Intermediate,10090.0,,50594,
11912,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628657,1,Intermediate,10090.0,,50594,
11913,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628658,1,Intermediate,10116.0,,50597,
11914,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628659,1,Intermediate,10116.0,,50597,
11915,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877500,1,Intermediate,10116.0,,50597,
11916,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628660,1,Intermediate,10116.0,,50597,
11917,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628661,1,Intermediate,10116.0,,50597,
11918,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628662,1,Intermediate,10116.0,,50597,
11919,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628663,1,Intermediate,10116.0,,50597,
11920,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628664,1,Intermediate,10116.0,,50597,
11921,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628665,1,Intermediate,10116.0,,50597,
11922,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628666,1,Intermediate,10116.0,,50597,
11923,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628667,1,Intermediate,10116.0,,50597,
11924,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628668,1,Intermediate,10116.0,,50597,
11925,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628669,1,Intermediate,10116.0,,50597,
11926,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628670,1,Intermediate,10116.0,,50597,
11927,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628671,1,Intermediate,10116.0,,50597,
11928,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL628672,1,Intermediate,10116.0,,50597,
11929,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL630300,1,Intermediate,10116.0,,50597,
11930,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL629787,1,Intermediate,10116.0,,50597,
11931,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL629788,1,Intermediate,10116.0,,50597,
11932,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629789,1,Intermediate,10116.0,,50597,
11933,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629790,1,Intermediate,10116.0,,50597,
11934,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629791,1,Intermediate,10116.0,,50597,
11935,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629792,1,Intermediate,10116.0,,50597,
11936,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629793,1,Intermediate,10116.0,,50597,
11937,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629794,1,Intermediate,10116.0,,50597,
11938,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874459,1,Intermediate,10116.0,,50597,
11939,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629795,1,Intermediate,10116.0,,50597,
11940,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629796,1,Intermediate,10116.0,,50597,
11941,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629797,1,Intermediate,10116.0,,50597,
11942,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629798,1,Intermediate,10116.0,,50597,
11943,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Adrenal gland,,2369.0,BAO_0000218,CHEMBL629799,1,Intermediate,10116.0,,50597,
11944,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Adrenal gland,,2369.0,BAO_0000218,CHEMBL629800,1,Intermediate,10116.0,,50597,
11945,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Adrenal gland,,2369.0,BAO_0000218,CHEMBL629801,1,Intermediate,10116.0,,50597,
11946,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,1,N,,Rattus norvegicus,,,,Adrenal gland,,2369.0,BAO_0000218,CHEMBL629802,1,Intermediate,10116.0,,50597,
11947,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Adrenal gland,,2369.0,BAO_0000218,CHEMBL629803,1,Intermediate,10116.0,,50597,
11948,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629804,1,Intermediate,10116.0,,50597,
11949,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629805,1,Intermediate,10116.0,,50597,
11950,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629806,1,Intermediate,10116.0,,50597,
11951,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629807,1,Intermediate,10116.0,,50597,
11952,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629808,1,Intermediate,10116.0,,50597,
11953,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629809,1,Intermediate,10116.0,,50597,
11954,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629810,1,Intermediate,10116.0,,50597,
11955,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629811,1,Intermediate,10116.0,,50597,
11956,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629812,1,Intermediate,10116.0,,50597,
11957,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629813,1,Intermediate,10116.0,,50597,
11958,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL874460,1,Intermediate,10116.0,,50597,
11959,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629814,1,Intermediate,10116.0,,50597,
11960,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629815,1,Intermediate,10116.0,,50597,
11961,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629816,1,Intermediate,10116.0,,50597,
11962,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629817,1,Intermediate,10116.0,,50597,
11963,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626643,1,Intermediate,10116.0,,50597,
11964,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626644,1,Intermediate,10116.0,,50597,
11965,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626806,1,Intermediate,10116.0,,50597,
11966,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626807,1,Intermediate,10116.0,,50597,
11967,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627261,1,Intermediate,10116.0,,50597,
11968,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627262,1,Intermediate,10116.0,,50597,
11969,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627263,1,Intermediate,10116.0,,50597,
11970,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627264,1,Intermediate,10116.0,,50597,
11971,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627265,1,Intermediate,10116.0,,50597,
11972,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627266,1,Intermediate,10116.0,,50597,
11973,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627267,1,Intermediate,10116.0,,50597,
11974,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627268,1,Intermediate,10116.0,,50597,
11975,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627269,1,Intermediate,10116.0,,50597,
11976,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627270,1,Intermediate,10116.0,,50597,
11977,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627271,1,Intermediate,10116.0,,50597,
11978,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627946,1,Intermediate,10116.0,,50597,
11979,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875472,1,Intermediate,10116.0,,50597,
11980,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627947,1,Intermediate,10116.0,,50597,
11981,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627948,1,Intermediate,10116.0,,50597,
11982,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628113,1,Intermediate,10116.0,,50597,
11983,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628114,1,Intermediate,10116.0,,50597,
11984,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628115,1,Intermediate,10116.0,,50597,
11985,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628116,1,Intermediate,10116.0,,50597,
11986,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628117,1,Intermediate,10116.0,,50597,
11987,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628118,1,Intermediate,10116.0,,50597,
11988,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628119,1,Intermediate,10116.0,,50597,
11989,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628120,1,Intermediate,10116.0,,50597,
11990,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628121,1,Intermediate,10116.0,,50597,
11991,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628122,1,Intermediate,10116.0,,50597,
11992,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627297,1,Intermediate,10116.0,,50597,
11993,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627298,1,Intermediate,10116.0,,50597,
11994,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627299,1,Intermediate,10116.0,,50597,
11995,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627300,1,Intermediate,10116.0,,50597,
11996,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627301,1,Intermediate,10116.0,,50597,
11997,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627302,1,Intermediate,10116.0,,50597,
11998,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627303,1,Intermediate,10116.0,,50597,
11999,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627304,1,Intermediate,10116.0,,50597,
12000,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627305,1,Intermediate,10116.0,,50597,
12001,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627306,1,Intermediate,10116.0,,50597,
12002,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623982,1,Intermediate,10116.0,,50597,
12003,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623983,1,Intermediate,10116.0,,50597,
12004,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623984,1,Intermediate,10116.0,,50597,
12005,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623985,1,Intermediate,10116.0,,50597,
12006,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623986,1,Intermediate,10116.0,,50597,
12007,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623987,1,Intermediate,10116.0,,50597,
12008,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623988,1,Intermediate,10116.0,,50597,
12009,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623989,1,Intermediate,10116.0,,50597,
12010,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622215,1,Intermediate,10116.0,,50597,
12011,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622216,1,Intermediate,10116.0,,50597,
12012,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877481,1,Intermediate,10116.0,,50597,
12013,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),1,U,,,,,,,,,BAO_0000218,CHEMBL622217,0,Autocuration,,,22224,
12014,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622218,1,Intermediate,10090.0,,50594,
12015,Pharmacokinetic profile AUC was evaluated in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622219,1,Intermediate,10116.0,,50597,
12016,Pharmacokinetic property (Area under curve),1,U,,,,,,,,,BAO_0000019,CHEMBL622220,0,Autocuration,,,22224,
12017,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622221,1,Intermediate,9615.0,,50588,
12018,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622222,1,Intermediate,10090.0,,50594,
12019,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL622223,1,Intermediate,9615.0,,50588,
12020,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622224,1,Intermediate,10090.0,,50594,
12021,Plasma concentration (AUC) was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL622225,0,Autocuration,,,22224,
12022,Plasma concentration (AUC) was determined; Not detectable,1,U,,,,,,,,,BAO_0000019,CHEMBL622226,0,Autocuration,,,22224,
12023,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL624154,1,Intermediate,10141.0,,50512,
12024,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624155,1,Intermediate,10116.0,,50597,
12025,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624156,1,Intermediate,10116.0,,50597,
12026,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624157,1,Intermediate,10116.0,,50597,
12027,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624158,1,Intermediate,10116.0,,50597,
12028,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624159,1,Intermediate,10116.0,,50597,
12029,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624160,1,Intermediate,10116.0,,50597,
12030,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624161,1,Intermediate,10116.0,,50597,
12031,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624162,1,Intermediate,10116.0,,50597,
12032,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624163,1,Intermediate,9615.0,,50588,
12033,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624164,1,Intermediate,10116.0,,50597,
12034,The AUC(0-infinity) values in female wistar rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624165,1,Intermediate,10116.0,,50597,
12035,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624166,1,Intermediate,10116.0,,50597,
12036,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624167,1,Intermediate,10116.0,,50597,
12037,The AUC(0-t)values in female wistar rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624168,1,Intermediate,10116.0,,50597,
12038,The Area under the concentration time curve of compound was measured on rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624169,1,Intermediate,10116.0,,50597,
12039,The area under curve (100 mg/kg) administered orally in humans,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624170,1,Intermediate,9606.0,,50587,
12040,The area under curve (12.5 mg/kg) administered intravenously in marmoset,1,U,,Callithrix,,,,,,,BAO_0000218,CHEMBL624171,0,Autocuration,9481.0,,22224,
12041,The area under curve (12.5 mg/kg) administered intravenously in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL624172,0,Autocuration,314293.0,,22224,
12042,The area under curve (15 mg/kg) administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624173,1,Intermediate,9615.0,,50588,
12043,The area under curve (200 mg/kg) administered orally in humans,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL877488,1,Intermediate,9606.0,,50587,
12044,The area under curve (25 mg/kg) administered intravenously in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624174,1,Intermediate,10116.0,,50597,
12045,The area under curve (25 mg/kg) administered orally in marmoset,1,U,,Callithrix,,,,,,,BAO_0000218,CHEMBL624175,0,Autocuration,9481.0,,22224,
12046,The area under curve (25 mg/kg) administered orally in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL624176,0,Autocuration,314293.0,,22224,
12047,The area under curve (30 mg/kg) administered orally in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624177,1,Intermediate,9615.0,,50588,
12048,The area under curve (400 mg/kg) administered orally in humans,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624178,1,Intermediate,9606.0,,50587,
12049,The area under curve (50 mg/kg) administered orally in fasted rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624179,1,Intermediate,10116.0,,50597,
12050,The area under curve (50 mg/kg) administered orally in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627689,1,Intermediate,10116.0,,50597,
12051,The area under curve (800 mg/kg) administered orally in humans,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL627690,1,Intermediate,9606.0,,50587,
12052,The compound was evaluated for area under the curve,1,U,,,,,,,,,BAO_0000019,CHEMBL627691,0,Autocuration,,,22224,
12053,The compound was evaluated for area under the curve in marmosets,1,U,,Callithrix,,,,,,,BAO_0000019,CHEMBL627692,0,Autocuration,9481.0,,22224,
12054,The compound was evaluated for area under the curve in marmosets,1,U,,Callithrix,,,,,,,BAO_0000019,CHEMBL627693,0,Autocuration,9481.0,,22224,
12055,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627694,1,Intermediate,10116.0,,50597,
12056,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627695,1,Intermediate,10116.0,,50597,
12057,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),1,U,,,,,,,,,BAO_0000218,CHEMBL627696,0,Autocuration,,,22224,
12058,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627697,1,Intermediate,10116.0,,50597,
12059,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627698,1,Intermediate,10116.0,,50597,
12060,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627699,1,Intermediate,10116.0,,50597,
12061,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627700,1,Intermediate,10116.0,,50597,
12062,Total drug exposure is determined after oral dosing in rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627701,1,Intermediate,10116.0,,50597,
12063,Total drug exposure (5 mg/kg) when administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL627702,0,Autocuration,,,22224,
12064,Total drug exposure (5 mg/kg) when administered orally,1,U,,,,,,,,,BAO_0000218,CHEMBL627703,0,Autocuration,,,22224,
12065,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626873,0,Autocuration,314293.0,,22224,
12066,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629583,1,Intermediate,10116.0,,50597,
12067,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629584,1,Intermediate,9615.0,,50588,
12068,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629585,1,Intermediate,9615.0,,50588,
12069,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629586,1,Intermediate,10116.0,,50597,
12070,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL629587,1,Intermediate,10116.0,,50597,
12071,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629588,1,Intermediate,10116.0,,50597,
12072,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629589,1,Intermediate,10116.0,,50597,
12073,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629590,1,Intermediate,10116.0,,50597,
12074,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629591,1,Intermediate,10116.0,,50597,
12075,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629592,1,Intermediate,10116.0,,50597,
12076,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629593,1,Intermediate,10116.0,,50597,
12077,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629594,1,Intermediate,10116.0,,50597,
12078,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL629595,1,Intermediate,10116.0,,50597,
12079,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630290,1,Intermediate,10116.0,,50597,
12080,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627137,1,Intermediate,10116.0,,50597,
12081,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627138,1,Intermediate,10116.0,,50597,
12082,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627139,1,Intermediate,10116.0,,50597,
12083,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627140,1,Intermediate,10116.0,,50597,
12084,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627141,1,Intermediate,10116.0,,50597,
12085,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627142,1,Intermediate,10116.0,,50597,
12086,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627143,1,Intermediate,10116.0,,50597,
12087,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL874449,1,Intermediate,10116.0,,50597,
12088,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627144,1,Intermediate,10116.0,,50597,
12089,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627145,1,Intermediate,10116.0,,50597,
12090,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627146,1,Intermediate,10116.0,,50597,
12091,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627147,1,Intermediate,10116.0,,50597,
12092,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627148,1,Intermediate,10116.0,,50597,
12093,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627149,1,Intermediate,10116.0,,50597,
12094,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL632160,1,Intermediate,10116.0,,50597,
12095,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL632161,1,Intermediate,10116.0,,50597,
12096,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL632162,1,Intermediate,10116.0,,50597,
12097,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL632163,1,Intermediate,10116.0,,50597,
12098,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL874469,1,Intermediate,10116.0,,50597,
12099,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627182,1,Intermediate,10116.0,,50597,
12100,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627183,1,Intermediate,10116.0,,50597,
12101,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627184,1,Intermediate,10116.0,,50597,
12102,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627185,1,Intermediate,10116.0,,50597,
12103,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627186,1,Intermediate,10116.0,,50597,
12104,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627187,1,Intermediate,10116.0,,50597,
12105,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627188,1,Intermediate,10116.0,,50597,
12106,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627189,1,Intermediate,10116.0,,50597,
12107,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627190,1,Intermediate,10116.0,,50597,
12108,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627191,1,Intermediate,10116.0,,50597,
12109,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627192,1,Intermediate,10116.0,,50597,
12110,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627193,1,Intermediate,10116.0,,50597,
12111,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL874590,1,Intermediate,10116.0,,50597,
12112,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627194,1,Intermediate,10116.0,,50597,
12113,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627195,1,Intermediate,10116.0,,50597,
12114,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL627196,1,Intermediate,10116.0,,50597,
12115,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL627197,1,Intermediate,10116.0,,50597,
12116,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL627198,1,Intermediate,10116.0,,50597,
12117,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL627199,1,Intermediate,10116.0,,50597,
12118,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Female gonad,,992.0,BAO_0000218,CHEMBL627200,1,Intermediate,10116.0,,50597,
12119,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627201,1,Intermediate,10116.0,,50597,
12120,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627202,1,Intermediate,10116.0,,50597,
12121,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627203,1,Intermediate,10116.0,,50597,
12122,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627204,1,Intermediate,10116.0,,50597,
12123,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627205,1,Intermediate,10116.0,,50597,
12124,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627206,1,Intermediate,10116.0,,50597,
12125,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627207,1,Intermediate,10116.0,,50597,
12126,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627208,1,Intermediate,10116.0,,50597,
12127,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627209,1,Intermediate,10116.0,,50597,
12128,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627210,1,Intermediate,10116.0,,50597,
12129,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627211,1,Intermediate,10116.0,,50597,
12130,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627212,1,Intermediate,10116.0,,50597,
12131,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL627213,1,Intermediate,10116.0,,50597,
12132,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626599,1,Intermediate,10116.0,,50597,
12133,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626600,1,Intermediate,10116.0,,50597,
12134,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL626601,1,Intermediate,10116.0,,50597,
12135,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,1,U,,,,,,,,,BAO_0000019,CHEMBL627484,0,Autocuration,,,22224,
12136,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627485,1,Intermediate,9541.0,,100710,
12137,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628147,1,Intermediate,9541.0,,100710,
12138,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628148,1,Intermediate,9541.0,,100710,
12139,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628149,1,Intermediate,9615.0,,50588,
12140,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628150,1,Intermediate,9615.0,,50588,
12141,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628318,1,Intermediate,9615.0,,50588,
12142,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628319,1,Intermediate,9615.0,,50588,
12143,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875609,1,Intermediate,9615.0,,50588,
12144,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,1,U,,,,,,,,,BAO_0000019,CHEMBL628320,0,Autocuration,,,22224,
12145,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,1,U,,,,,,,,,BAO_0000019,CHEMBL628321,0,Autocuration,,,22224,
12146,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,1,U,,,,,,,,,BAO_0000019,CHEMBL628322,0,Autocuration,,,22224,
12147,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,1,U,,,,,,,,,BAO_0000019,CHEMBL628323,0,Autocuration,,,22224,
12148,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,1,U,,,,,,,,,BAO_0000019,CHEMBL628324,0,Autocuration,,,22224,
12149,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,1,U,,,,,,,,,BAO_0000019,CHEMBL628325,0,Autocuration,,,22224,
12150,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,1,U,,,,,,,,,BAO_0000019,CHEMBL628326,0,Autocuration,,,22224,
12151,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,Adrenal medulla,,1236.0,BAO_0000218,CHEMBL628327,1,Intermediate,9615.0,,50588,
12152,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1,N,,Canis lupus familiaris,,,,Adrenal medulla,,1236.0,BAO_0000218,CHEMBL628328,1,Intermediate,9615.0,,50588,
12153,"Concentration of compound in blood of dog 1, after administering intravenously",1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL628329,1,Intermediate,9615.0,,50588,
12154,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628330,1,Intermediate,10116.0,,50597,
12155,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628331,1,Intermediate,10116.0,,50597,
12156,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628332,1,Intermediate,10116.0,,50597,
12157,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628333,1,Intermediate,10116.0,,50597,
12158,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628334,1,Intermediate,10116.0,,50597,
12159,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628335,1,Intermediate,10116.0,,50597,
12160,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628336,1,Intermediate,10116.0,,50597,
12161,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628337,1,Intermediate,10116.0,,50597,
12162,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628338,1,Intermediate,10116.0,,50597,
12163,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL875610,1,Intermediate,10116.0,,50597,
12164,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628339,1,Intermediate,10116.0,,50597,
12165,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628340,1,Intermediate,10116.0,,50597,
12166,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628341,1,Intermediate,10116.0,,50597,
12167,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622214,1,Intermediate,10116.0,,50597,
12168,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623167,1,Intermediate,10116.0,,50597,
12169,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623168,1,Intermediate,10116.0,,50597,
12170,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623169,1,Intermediate,10116.0,,50597,
12171,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623170,1,Intermediate,10116.0,,50597,
12172,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627224,1,Intermediate,10116.0,,50597,
12173,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL875634,1,Intermediate,10116.0,,50597,
12174,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627225,1,Intermediate,10116.0,,50597,
12175,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627226,1,Intermediate,10116.0,,50597,
12176,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626083,1,Intermediate,10116.0,,50597,
12177,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626084,1,Intermediate,10116.0,,50597,
12178,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626085,1,Intermediate,10116.0,,50597,
12179,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626086,1,Intermediate,10116.0,,50597,
12180,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626087,1,Intermediate,10116.0,,50597,
12181,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626088,1,Intermediate,10116.0,,50597,
12182,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626089,1,Intermediate,10116.0,,50597,
12183,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626090,1,Intermediate,10116.0,,50597,
12184,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626091,1,Intermediate,10116.0,,50597,
12185,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626092,1,Intermediate,10116.0,,50597,
12186,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626093,1,Intermediate,10116.0,,50597,
12187,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626094,1,Intermediate,10116.0,,50597,
12188,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626095,1,Intermediate,10116.0,,50597,
12189,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL626096,1,Intermediate,10116.0,,50597,
12190,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626097,0,Autocuration,314293.0,,22224,
12191,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626098,1,Intermediate,10116.0,,50597,
12192,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626099,0,Autocuration,,,22224,
12193,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626100,0,Autocuration,,,22224,
12194,AUC 0-inf in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626101,1,Intermediate,9615.0,,50588,
12195,AUC 0-inf in guinea pig,1,N,,Cavia porcellus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626102,1,Intermediate,10141.0,,50512,
12196,AUC 0-t in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626103,1,Intermediate,9615.0,,50588,
12197,AUC 0-t in guinea pig,1,N,,Cavia porcellus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628391,1,Intermediate,10141.0,,50512,
12198,The compound was tested for brain to plasma partition in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628392,1,Intermediate,10116.0,,50597,
12199,The compound was tested for brain to plasma partition in rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628393,1,Intermediate,10116.0,,50597,
12200,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,1,U,,,,,,Blood,,178.0,BAO_0000019,CHEMBL628394,0,Autocuration,,,22224,
12201,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628395,1,Intermediate,9615.0,,50588,
12202,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL628396,0,Autocuration,314293.0,,22224,
12203,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL628397,1,Intermediate,9986.0,,50592,
12204,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628398,1,Intermediate,10116.0,,50597,
12205,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL628399,1,Intermediate,9544.0,,50797,
12206,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628400,1,Intermediate,9615.0,,50588,
12207,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874907,1,Intermediate,10116.0,,50597,
12208,Area under curve of the compound was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL628401,0,Autocuration,,,22224,
12209,AUC in monkeys at a dose of 1 mg/kg,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628402,0,Autocuration,314293.0,,22224,
12210,AUC in rats at a dose of 1 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628403,1,Intermediate,10116.0,,50597,
12211,Compound was evaluated for the overall absorbance loss at pH of 2,1,U,,,,,,,,,BAO_0000019,CHEMBL628404,0,Autocuration,,,22224,
12212,Compound was evaluated for the overall absorbance loss at pH of 4,1,U,,,,,,,,,BAO_0000019,CHEMBL628405,0,Autocuration,,,22224,
12213,Compound was evaluated for the overall absorbance loss at pH of 7,1,U,,,,,,,,,BAO_0000019,CHEMBL628406,0,Autocuration,,,22224,
12214,Compound was evaluated for its absorption in the rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628407,1,Intermediate,10116.0,,50597,
12215,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628408,1,Intermediate,10116.0,,50597,
12216,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629171,1,Intermediate,10116.0,,50597,
12217,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629172,1,Intermediate,10116.0,,50597,
12218,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629173,1,Intermediate,10116.0,,50597,
12219,In vitro percent permeability into rat ileum,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629174,1,Intermediate,10116.0,,50597,
12220,In vitro percent permeability into rat ileum; Range is 10-17,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629175,1,Intermediate,10116.0,,50597,
12221,In vitro percent permeability into rat ileum; Range is 10-18,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629176,1,Intermediate,10116.0,,50597,
12222,In vitro percent permeability into rat ileum; Range is 10-19,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629177,1,Intermediate,10116.0,,50597,
12223,In vitro percent permeability into rat ileum; Range is 12-15,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629178,1,Intermediate,10116.0,,50597,
12224,In vitro percent permeability into rat ileum; Range is 13-19,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631869,1,Intermediate,10116.0,,50597,
12225,In vitro percent permeability into rat ileum; Range is 14-17,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631870,1,Intermediate,10116.0,,50597,
12226,In vitro percent permeability into rat ileum; Range is 15-18,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631871,1,Intermediate,10116.0,,50597,
12227,In vitro percent permeability into rat ileum; Range is 2-5,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631872,1,Intermediate,10116.0,,50597,
12228,In vitro percent permeability into rat ileum; Range is 23-42,1,U,,,,,,Ileum,,2116.0,BAO_0000221,CHEMBL875775,0,Autocuration,,,22224,
12229,In vitro percent permeability into rat ileum; Range is 28-36,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631873,1,Intermediate,10116.0,,50597,
12230,In vitro percent permeability into rat ileum; Range is 29-35,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631874,1,Intermediate,10116.0,,50597,
12231,In vitro percent permeability into rat ileum; Range is 46-66,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631875,1,Intermediate,10116.0,,50597,
12232,In vitro percent permeability into rat ileum; Range is 50-68,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631876,1,Intermediate,10116.0,,50597,
12233,In vitro percent permeability into rat ileum; Range is 78-81,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631877,1,Intermediate,10116.0,,50597,
12234,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631878,1,Intermediate,10116.0,,50597,
12235,In vitro percent permeability into rat ileum; nd indicates not detected,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631879,1,Intermediate,10116.0,,50597,
12236,In vitro percent permeability into rat ileum; nt indicates not detected,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631880,1,Intermediate,10116.0,,50597,
12237,In vitro percent permeability into rat ileum; nt indicates not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631881,1,Intermediate,10116.0,,50597,
12238,Compound was tested for oral absorption in bile-duct cannulated rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631882,1,Intermediate,10116.0,,50597,
12239,Compound was tested for oral absorption in bile-duct cannulated rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630749,1,Intermediate,10116.0,,50597,
12240,Oral absorption using Caco-2 cell monolayers.,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL630750,1,Intermediate,9606.0,,50587,
12241,Percent of the drug absorbed after administration to humans was determined,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL630253,1,Intermediate,9606.0,,50587,
12242,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL630254,1,Intermediate,10116.0,,50597,
12243,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL630255,1,Intermediate,10116.0,,50597,
12244,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL630256,1,Intermediate,10116.0,,50597,
12245,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL875781,1,Intermediate,10116.0,,50597,
12246,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630257,1,Intermediate,10116.0,,50597,
12247,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630258,1,Intermediate,10116.0,,50597,
12248,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630259,1,Intermediate,10116.0,,50597,
12249,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL630260,1,Intermediate,10116.0,,50597,
12250,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL630261,1,Intermediate,10116.0,,50597,
12251,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630262,1,Intermediate,10116.0,,50597,
12252,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630263,1,Intermediate,10116.0,,50597,
12253,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630264,1,Intermediate,10116.0,,50597,
12254,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630265,1,Intermediate,10116.0,,50597,
12255,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630266,1,Intermediate,10116.0,,50597,
12256,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630267,1,Intermediate,10116.0,,50597,
12257,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630268,1,Intermediate,10116.0,,50597,
12258,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630269,1,Intermediate,10116.0,,50597,
12259,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630270,1,Intermediate,10116.0,,50597,
12260,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630141,1,Intermediate,10116.0,,50597,
12261,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630142,1,Intermediate,10116.0,,50597,
12262,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630143,1,Intermediate,10116.0,,50597,
12263,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630144,1,Intermediate,10116.0,,50597,
12264,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,1,N,,Rattus norvegicus,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL630145,1,Intermediate,10116.0,,50597,
12265,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,1,N,,Rattus norvegicus,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL630146,1,Intermediate,10116.0,,50597,
12266,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630147,1,Intermediate,10116.0,,50597,
12267,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630148,1,Intermediate,10116.0,,50597,
12268,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630149,1,Intermediate,10116.0,,50597,
12269,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630150,1,Intermediate,10116.0,,50597,
12270,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630151,1,Intermediate,10116.0,,50597,
12271,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL632031,1,Intermediate,10116.0,,50597,
12272,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL632032,1,Intermediate,10116.0,,50597,
12273,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632033,1,Intermediate,10116.0,,50597,
12274,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632034,1,Intermediate,10116.0,,50597,
12275,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL632035,1,Intermediate,10116.0,,50597,
12276,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632036,1,Intermediate,10116.0,,50597,
12277,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL632037,1,Intermediate,10116.0,,50597,
12278,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632038,1,Intermediate,10116.0,,50597,
12279,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632039,1,Intermediate,10116.0,,50597,
12280,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632040,1,Intermediate,10116.0,,50597,
12281,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL632041,1,Intermediate,10116.0,,50597,
12282,"Concentration of compound in blood of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,Blood,,178.0,BAO_0000218,CHEMBL632042,1,Intermediate,9615.0,,50588,
12283,"Concentration of compound in left ventricle of dog 1, after administering intravenously",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL632043,1,Intermediate,9615.0,,50588,
12284,"Concentration of compound in left ventricle of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL632044,1,Intermediate,9615.0,,50588,
12285,"Concentration of compound in liver of dog 1, after administering intravenously",1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL632045,1,Intermediate,9615.0,,50588,
12286,"Concentration of compound in liver of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,Liver,,2107.0,BAO_0000218,CHEMBL632046,1,Intermediate,9615.0,,50588,
12287,"Concentration of compound in lung of dog 1, after administering intravenously",1,N,,Canis lupus familiaris,,,,Lung,,2048.0,BAO_0000218,CHEMBL632047,1,Intermediate,9615.0,,50588,
12288,"Concentration of compound in lung of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,Lung,,2048.0,BAO_0000218,CHEMBL632048,1,Intermediate,9615.0,,50588,
12289,"Concentration of compound in muscle of dog 1, after administering intravenously",1,N,,Canis lupus familiaris,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL632049,1,Intermediate,9615.0,,50588,
12290,"Concentration of compound in muscle of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL876418,1,Intermediate,9615.0,,50588,
12291,"Concentration of compound in spleen of dog 1,after administering intravenously",1,N,,Canis lupus familiaris,,,,Spleen,,2106.0,BAO_0000218,CHEMBL632050,1,Intermediate,9615.0,,50588,
12292,"Concentration of compound in spleen of dog 2, after administering intravenously",1,N,,Canis lupus familiaris,,,,Spleen,,2106.0,BAO_0000218,CHEMBL632051,1,Intermediate,9615.0,,50588,
12293,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,1,U,,,,,,,,,BAO_0000218,CHEMBL632052,0,Autocuration,,,22224,
12294,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,1,U,,,,,,,,,BAO_0000218,CHEMBL632053,0,Autocuration,,,22224,
12295,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,1,U,,,,,,,,,BAO_0000218,CHEMBL632054,0,Autocuration,,,22224,
12296,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,1,U,,,,,,,,,BAO_0000218,CHEMBL632055,0,Autocuration,,,22224,
12297,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,1,U,,,,,,,,,BAO_0000218,CHEMBL631181,0,Autocuration,,,22224,
12298,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL631182,0,Autocuration,,,22224,
12299,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL631183,0,Autocuration,,,22224,
12300,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL631184,0,Autocuration,,,22224,
12301,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL629774,0,Autocuration,,,22224,
12302,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL629775,0,Autocuration,,,22224,
12303,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL876549,0,Autocuration,,,22224,
12304,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628172,0,Autocuration,,,22224,
12305,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628173,0,Autocuration,,,22224,
12306,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628174,0,Autocuration,,,22224,
12307,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628175,0,Autocuration,,,22224,
12308,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628176,0,Autocuration,,,22224,
12309,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628177,0,Autocuration,,,22224,
12310,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628178,0,Autocuration,,,22224,
12311,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628179,0,Autocuration,,,22224,
12312,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,1,U,,,,,,,,,BAO_0000218,CHEMBL628180,0,Autocuration,,,22224,
12313,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628181,0,Autocuration,,,22224,
12314,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628182,0,Autocuration,,,22224,
12315,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628183,0,Autocuration,,,22224,
12316,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,1,U,,,,,,,,,BAO_0000218,CHEMBL628184,0,Autocuration,,,22224,
12317,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628185,0,Autocuration,,,22224,
12318,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL875617,0,Autocuration,,,22224,
12319,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,1,U,,,,,,,,,BAO_0000218,CHEMBL628186,0,Autocuration,,,22224,
12320,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628187,0,Autocuration,,,22224,
12321,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628188,0,Autocuration,,,22224,
12322,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628189,0,Autocuration,,,22224,
12323,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,1,U,,,,,,,,,BAO_0000218,CHEMBL628190,0,Autocuration,,,22224,
12324,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628191,0,Autocuration,,,22224,
12325,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,1,U,,,,,,,,,BAO_0000218,CHEMBL626513,0,Autocuration,,,22224,
12326,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626514,1,Intermediate,10116.0,,50597,
12327,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626515,1,Intermediate,10116.0,,50597,
12328,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626516,1,Intermediate,10116.0,,50597,
12329,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626517,1,Intermediate,10116.0,,50597,
12330,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626518,1,Intermediate,10116.0,,50597,
12331,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626519,1,Intermediate,10116.0,,50597,
12332,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626520,1,Intermediate,10116.0,,50597,
12333,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626521,1,Intermediate,10116.0,,50597,
12334,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626522,1,Intermediate,10116.0,,50597,
12335,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626523,1,Intermediate,10116.0,,50597,
12336,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626524,1,Intermediate,10116.0,,50597,
12337,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626688,1,Intermediate,10116.0,,50597,
12338,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626689,1,Intermediate,10116.0,,50597,
12339,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626690,1,Intermediate,10116.0,,50597,
12340,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626691,1,Intermediate,10116.0,,50597,
12341,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL627319,1,Intermediate,10116.0,,50597,
12342,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624052,1,Intermediate,10116.0,,50597,
12343,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624053,1,Intermediate,10116.0,,50597,
12344,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624054,1,Intermediate,10116.0,,50597,
12345,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624055,1,Intermediate,10116.0,,50597,
12346,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624056,1,Intermediate,10116.0,,50597,
12347,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL624057,1,Intermediate,10116.0,,50597,
12348,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL622281,1,Intermediate,10116.0,,50597,
12349,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL622282,1,Intermediate,10116.0,,50597,
12350,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL622283,1,Intermediate,10116.0,,50597,
12351,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL622284,1,Intermediate,10116.0,,50597,
12352,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL622285,1,Intermediate,10116.0,,50597,
12353,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL622286,1,Intermediate,10116.0,,50597,
12354,Distribution coefficient (D %) between octanol and buffer of pH 7.4,1,U,,,,,,,,,BAO_0000100,CHEMBL622287,0,Autocuration,,,22224,
12355,Partition coefficient (logD7.4),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622288,1,Intermediate,10090.0,,50594,
12356,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622289,1,Intermediate,10090.0,,50594,
12357,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622290,1,Intermediate,10090.0,,50594,
12358,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622291,1,Intermediate,10090.0,,50594,
12359,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622292,1,Intermediate,10090.0,,50594,
12360,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622293,1,Intermediate,10090.0,,50594,
12361,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL622294,1,Intermediate,10090.0,,50594,
12362,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL622295,1,Intermediate,10090.0,,50594,
12363,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL622296,1,Intermediate,10116.0,,50597,
12364,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL874409,1,Intermediate,10116.0,,50597,
12365,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622297,1,Intermediate,10116.0,,50597,
12366,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622298,1,Intermediate,10116.0,,50597,
12367,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622299,1,Intermediate,10116.0,,50597,
12368,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622300,1,Intermediate,10116.0,,50597,
12369,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622301,1,Intermediate,10116.0,,50597,
12370,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622302,1,Intermediate,10116.0,,50597,
12371,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622303,1,Intermediate,10116.0,,50597,
12372,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622304,1,Intermediate,10116.0,,50597,
12373,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622305,1,Intermediate,10116.0,,50597,
12374,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622306,1,Intermediate,10116.0,,50597,
12375,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626864,1,Intermediate,10116.0,,50597,
12376,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626865,1,Intermediate,10116.0,,50597,
12377,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626866,1,Intermediate,10116.0,,50597,
12378,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626867,1,Intermediate,10116.0,,50597,
12379,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626868,1,Intermediate,10116.0,,50597,
12380,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626869,1,Intermediate,10116.0,,50597,
12381,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626870,1,Intermediate,10116.0,,50597,
12382,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626871,1,Intermediate,10116.0,,50597,
12383,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626872,1,Intermediate,10116.0,,50597,
12384,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632185,1,Intermediate,10116.0,,50597,
12385,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL632186,1,Intermediate,10116.0,,50597,
12386,Amount of acetic acid produced by the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL629310,0,Autocuration,,,22224,
12387,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL629311,0,Autocuration,,,22224,
12388,Log of (Cbrain/Cblood) in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629312,1,Intermediate,10116.0,,50597,
12389,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000221,CHEMBL629313,0,Autocuration,,,22224,
12390,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000221,CHEMBL629314,0,Autocuration,,,22224,
12391,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000221,CHEMBL629315,0,Autocuration,,,22224,
12392,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000219,CHEMBL629316,0,Autocuration,,,22224,
12393,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000221,CHEMBL629317,0,Autocuration,,,22224,
12394,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629318,0,Autocuration,,,22224,
12395,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL877497,0,Autocuration,,,22224,
12396,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629319,0,Autocuration,,,22224,
12397,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629320,0,Autocuration,,,22224,
12398,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629496,0,Autocuration,,,22224,
12399,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629497,0,Autocuration,,,22224,
12400,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629498,0,Autocuration,,,22224,
12401,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629499,0,Autocuration,,,22224,
12402,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629500,0,Autocuration,,,22224,
12403,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629501,0,Autocuration,,,22224,
12404,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),1,U,,,,,,,,,BAO_0000019,CHEMBL629502,0,Autocuration,,,22224,
12405,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,1,U,,,,,,,,,BAO_0000218,CHEMBL629503,0,Autocuration,,,22224,
12406,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629504,1,Intermediate,9615.0,,50588,
12407,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,1,U,,,,,,,,,BAO_0000019,CHEMBL629505,0,Autocuration,,,22224,
12408,Compound was evaluated for total body clearance,1,U,,,,,,,,,BAO_0000019,CHEMBL629506,0,Autocuration,,,22224,
12409,Compound was evaluated for volume of distribution at steady state,1,U,,,,,,,,,BAO_0000019,CHEMBL629507,0,Autocuration,,,22224,
12410,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,1,U,,,,,,,,,BAO_0000019,CHEMBL877498,0,Autocuration,,,22224,
12411,Percentage of the diamine which is monoprotonated at pH 7.4,1,U,,,,,,,,,BAO_0000019,CHEMBL629508,0,Autocuration,,,22224,
12412,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,1,U,,,,,,,,,BAO_0000019,CHEMBL629509,0,Autocuration,,,22224,
12413,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629510,1,Intermediate,10116.0,,50597,
12414,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629511,1,Intermediate,10116.0,,50597,
12415,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629512,1,Intermediate,10116.0,,50597,
12416,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629513,1,Intermediate,10116.0,,50597,
12417,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629514,1,Intermediate,10116.0,,50597,
12418,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628447,1,Intermediate,10116.0,,50597,
12419,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628448,1,Intermediate,10116.0,,50597,
12420,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628449,1,Intermediate,10116.0,,50597,
12421,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631119,1,Intermediate,10116.0,,50597,
12422,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631120,1,Intermediate,10116.0,,50597,
12423,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631121,1,Intermediate,10116.0,,50597,
12424,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL874458,1,Intermediate,10116.0,,50597,
12425,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631122,1,Intermediate,10116.0,,50597,
12426,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631123,1,Intermediate,10116.0,,50597,
12427,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631124,1,Intermediate,10116.0,,50597,
12428,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631125,1,Intermediate,10116.0,,50597,
12429,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631290,1,Intermediate,10116.0,,50597,
12430,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631291,1,Intermediate,10116.0,,50597,
12431,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631292,1,Intermediate,10116.0,,50597,
12432,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631293,1,Intermediate,10116.0,,50597,
12433,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631294,1,Intermediate,10116.0,,50597,
12434,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631295,1,Intermediate,10116.0,,50597,
12435,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631296,1,Intermediate,10116.0,,50597,
12436,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631297,1,Intermediate,10116.0,,50597,
12437,Maximum biodistribution (Bmax) was determined.,1,U,,,,,,,,,BAO_0000218,CHEMBL631298,0,Autocuration,,,22224,
12438,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631299,1,Intermediate,10090.0,,50594,
12439,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631300,1,Intermediate,10090.0,,50594,
12440,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631301,1,Intermediate,10090.0,,50594,
12441,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630291,1,Intermediate,10090.0,,50594,
12442,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,1,U,,,,,,,,,BAO_0000218,CHEMBL630292,0,Autocuration,,,22224,
12443,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL630293,0,Autocuration,,,22224,
12444,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL630294,0,Autocuration,,,22224,
12445,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,1,U,,,,,,,,,BAO_0000218,CHEMBL630295,0,Autocuration,,,22224,
12446,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL630296,0,Autocuration,,,22224,
12447,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626782,0,Autocuration,,,22224,
12448,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626783,0,Autocuration,,,22224,
12449,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,1,U,,,,,,,,,BAO_0000218,CHEMBL626784,0,Autocuration,,,22224,
12450,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL626785,0,Autocuration,,,22224,
12451,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626786,0,Autocuration,,,22224,
12452,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626787,0,Autocuration,,,22224,
12453,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,1,U,,,,,,,,,BAO_0000218,CHEMBL626788,0,Autocuration,,,22224,
12454,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625927,0,Autocuration,,,22224,
12455,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625928,1,Intermediate,10116.0,,50597,
12456,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625929,1,Intermediate,10116.0,,50597,
12457,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625930,1,Intermediate,10116.0,,50597,
12458,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625931,1,Intermediate,10116.0,,50597,
12459,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627230,1,Intermediate,10116.0,,50597,
12460,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627231,1,Intermediate,10116.0,,50597,
12461,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627232,1,Intermediate,10116.0,,50597,
12462,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627233,1,Intermediate,10116.0,,50597,
12463,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL875470,1,Intermediate,10116.0,,50597,
12464,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627234,1,Intermediate,10116.0,,50597,
12465,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627235,1,Intermediate,10116.0,,50597,
12466,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627236,1,Intermediate,10116.0,,50597,
12467,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627237,1,Intermediate,10116.0,,50597,
12468,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627238,1,Intermediate,10116.0,,50597,
12469,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627239,1,Intermediate,10116.0,,50597,
12470,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627240,1,Intermediate,10116.0,,50597,
12471,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627241,1,Intermediate,10116.0,,50597,
12472,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627242,1,Intermediate,10116.0,,50597,
12473,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627243,1,Intermediate,10116.0,,50597,
12474,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627244,1,Intermediate,10116.0,,50597,
12475,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627245,1,Intermediate,10116.0,,50597,
12476,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627246,1,Intermediate,10116.0,,50597,
12477,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627247,1,Intermediate,10116.0,,50597,
12478,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627248,1,Intermediate,10116.0,,50597,
12479,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627249,1,Intermediate,10116.0,,50597,
12480,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625569,1,Intermediate,10116.0,,50597,
12481,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625570,1,Intermediate,10116.0,,50597,
12482,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625571,1,Intermediate,10116.0,,50597,
12483,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625572,1,Intermediate,10116.0,,50597,
12484,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625573,1,Intermediate,10116.0,,50597,
12485,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625574,1,Intermediate,10116.0,,50597,
12486,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626245,1,Intermediate,10116.0,,50597,
12487,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626246,1,Intermediate,10116.0,,50597,
12488,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626247,0,Autocuration,,,22224,
12489,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626248,0,Autocuration,,,22224,
12490,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626249,0,Autocuration,,,22224,
12491,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626420,0,Autocuration,,,22224,
12492,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626421,0,Autocuration,,,22224,
12493,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626422,0,Autocuration,,,22224,
12494,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626423,0,Autocuration,,,22224,
12495,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626424,0,Autocuration,,,22224,
12496,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626425,1,Intermediate,9615.0,,50588,
12497,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875476,1,Intermediate,10116.0,,50597,
12498,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL626426,1,Intermediate,9541.0,,100710,
12499,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,1,U,,,,,,,,,BAO_0000100,CHEMBL626427,0,Autocuration,,,22224,
12500,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,1,U,,,,,,,,,BAO_0000100,CHEMBL626428,0,Autocuration,,,22224,
12501,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,1,U,,,,,,,,,BAO_0000019,CHEMBL626429,0,Autocuration,,,22224,
12502,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL625025,0,Autocuration,,,22224,
12503,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625026,1,Intermediate,10116.0,,50597,
12504,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625027,1,Intermediate,10116.0,,50597,
12505,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL874410,1,Intermediate,10116.0,,50597,
12506,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625028,1,Intermediate,10116.0,,50597,
12507,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625029,1,Intermediate,10116.0,,50597,
12508,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625030,1,Intermediate,10116.0,,50597,
12509,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625031,1,Intermediate,10116.0,,50597,
12510,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625032,1,Intermediate,10116.0,,50597,
12511,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625033,1,Intermediate,10116.0,,50597,
12512,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625034,1,Intermediate,10116.0,,50597,
12513,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624872,1,Intermediate,10116.0,,50597,
12514,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624873,1,Intermediate,10116.0,,50597,
12515,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624874,1,Intermediate,10116.0,,50597,
12516,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624875,1,Intermediate,10116.0,,50597,
12517,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624876,1,Intermediate,10116.0,,50597,
12518,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624877,1,Intermediate,10116.0,,50597,
12519,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624878,1,Intermediate,10116.0,,50597,
12520,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624879,1,Intermediate,10116.0,,50597,
12521,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624880,1,Intermediate,10116.0,,50597,
12522,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624881,1,Intermediate,10116.0,,50597,
12523,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL624882,1,Intermediate,10116.0,,50597,
12524,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624883,1,Intermediate,10116.0,,50597,
12525,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624884,1,Intermediate,10116.0,,50597,
12526,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624885,1,Intermediate,10116.0,,50597,
12527,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624886,1,Intermediate,10116.0,,50597,
12528,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624887,1,Intermediate,10116.0,,50597,
12529,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624888,1,Intermediate,10116.0,,50597,
12530,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624889,1,Intermediate,10116.0,,50597,
12531,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL624890,1,Intermediate,10116.0,,50597,
12532,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621964,1,Intermediate,10116.0,,50597,
12533,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL621965,1,Intermediate,10116.0,,50597,
12534,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621966,1,Intermediate,10116.0,,50597,
12535,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL621967,1,Intermediate,10116.0,,50597,
12536,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL622164,1,Intermediate,10116.0,,50597,
12537,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),1,U,,,,,,,,,BAO_0000019,CHEMBL623097,0,Autocuration,,,22224,
12538,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),1,U,,,,,,,,,BAO_0000019,CHEMBL623098,0,Autocuration,,,22224,
12539,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,1,U,,,,,,,,,BAO_0000019,CHEMBL623099,0,Autocuration,,,22224,
12540,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,1,U,,,,,,,,,BAO_0000019,CHEMBL623100,0,Autocuration,,,22224,
12541,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628673,1,Intermediate,10116.0,,50597,
12542,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628674,1,Intermediate,10116.0,,50597,
12543,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628675,1,Intermediate,10116.0,,50597,
12544,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627644,1,Intermediate,10116.0,,50597,
12545,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627645,1,Intermediate,10116.0,,50597,
12546,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627646,1,Intermediate,10116.0,,50597,
12547,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627647,1,Intermediate,10116.0,,50597,
12548,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627648,1,Intermediate,10116.0,,50597,
12549,Free level in rat plasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627649,1,Intermediate,10116.0,,50597,
12550,Level reaching in blood plasma of rat or human was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL628313,0,Autocuration,,,22224,
12551,Log (Cbrain/Cblood) in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628314,1,Intermediate,10116.0,,50597,
12552,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,1,U,,,,,,,,,BAO_0000019,CHEMBL628315,0,Autocuration,,,22224,
12553,Mean percentage of compound transport through membrane; expressed as membrane transport,1,U,,,,,,,,,BAO_0000019,CHEMBL628316,0,Autocuration,,,22224,
12554,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,1,U,,,,,,,,,BAO_0000218,CHEMBL628317,0,Autocuration,,,22224,
12555,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,1,U,,,,,,,,,BAO_0000019,CHEMBL628473,0,Autocuration,,,22224,
12556,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL628474,0,Autocuration,,,22224,
12557,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,1,U,,,,,,,,,BAO_0000019,CHEMBL628475,0,Autocuration,,,22224,
12558,Net water uptake by a carrier mediated transport (%cm) mechanism,1,U,,,,,,,,,BAO_0000019,CHEMBL628476,0,Autocuration,,,22224,
12559,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL628477,0,Autocuration,314293.0,,22224,
12560,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL628478,1,Intermediate,9669.0,,50506,
12561,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL628479,1,Intermediate,9669.0,,50506,
12562,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL628480,0,Autocuration,314293.0,,22224,
12563,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL628481,0,Autocuration,314293.0,,22224,
12564,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628482,1,Intermediate,10116.0,,50597,
12565,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628483,1,Intermediate,10116.0,,50597,
12566,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628484,1,Intermediate,10116.0,,50597,
12567,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628485,1,Intermediate,10116.0,,50597,
12568,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628486,1,Intermediate,9541.0,,100710,
12569,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628487,1,Intermediate,9606.0,,50587,
12570,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628488,1,Intermediate,10116.0,,50597,
12571,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628489,1,Intermediate,10116.0,,50597,
12572,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628490,1,Intermediate,10116.0,,50597,
12573,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL628491,1,Intermediate,9541.0,,100710,
12574,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL877507,1,Intermediate,9541.0,,100710,
12575,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,U,,,,,,,,,BAO_0000218,CHEMBL628492,0,Autocuration,,,22224,
12576,% metabolized in monkey S-9 after 2 hours (10 ug/mL),1,U,,Simiiformes,,,,,,,BAO_0000019,CHEMBL628493,0,Autocuration,314293.0,,22224,
12577,% metabolized in monkey S-9 after 2 hours (1 ug/ml),1,U,,Simiiformes,,,,,,,BAO_0000019,CHEMBL628494,0,Autocuration,314293.0,,22224,
12578,% metabolized in monkey S-9 after 2 hours (10 ug/ml),1,U,,Simiiformes,,,,,,,BAO_0000019,CHEMBL628495,0,Autocuration,314293.0,,22224,
12579,Permeability in Caco-2 assay at 10E-6,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL628496,1,Intermediate,9606.0,,50587,
12580,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,1,U,,,,,,Brain,,955.0,BAO_0000218,CHEMBL628497,0,Autocuration,,,22224,
12581,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,1,U,,,,,,Brain,,955.0,BAO_0000218,CHEMBL628498,0,Autocuration,,,22224,
12582,Plasma protein binding was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL628499,0,Autocuration,,,22224,
12583,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL627656,0,Autocuration,,,22224,
12584,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,1,U,,,,,,,,,BAO_0000218,CHEMBL627657,0,Autocuration,,,22224,
12585,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL626808,0,Autocuration,,,22224,
12586,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626809,0,Autocuration,,,22224,
12587,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626810,0,Autocuration,,,22224,
12588,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,1,U,,,,,,,,,BAO_0000218,CHEMBL626811,0,Autocuration,,,22224,
12589,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,1,U,,,,,,,,,BAO_0000218,CHEMBL874465,0,Autocuration,,,22224,
12590,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626812,0,Autocuration,,,22224,
12591,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626813,0,Autocuration,,,22224,
12592,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,1,U,,,,,,,,,BAO_0000218,CHEMBL626814,0,Autocuration,,,22224,
12593,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,1,U,,,,,,,,,BAO_0000019,CHEMBL626815,0,Autocuration,,,22224,
12594,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL628566,0,Autocuration,,,22224,
12595,Calculated partition coefficient (clogP) (CLOGP3 V3.4),1,U,,,,,,,,,BAO_0000100,CHEMBL628567,0,Autocuration,,,22229,
12596,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL628568,0,Autocuration,,,22229,
12597,C max in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628569,1,Intermediate,9615.0,,50588,
12598,C max in guinea pig,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL628570,1,Intermediate,10141.0,,50512,
12599,C max value was evaluated,1,U,,,,,,,,,BAO_0000218,CHEMBL628571,0,Autocuration,,,22224,
12600,Cmax value after oral dose of 0.1 mg//kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628572,0,Autocuration,,,22224,
12601,Cmax value after oral dose of 0.3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628573,0,Autocuration,,,22224,
12602,Cmax value after oral dose of 1 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628574,0,Autocuration,,,22224,
12603,Cmax value after oral dose of 10 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628575,0,Autocuration,,,22224,
12604,Cmax value after oral dose of 23.4 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628576,0,Autocuration,,,22224,
12605,Cmax value after oral dose of 3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628577,0,Autocuration,,,22224,
12606,Cmax value after oral dose of 3.87 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL628578,0,Autocuration,,,22224,
12607,Cmax value in female Beagle dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL874466,1,Intermediate,9615.0,,50588,
12608,Cmax value in male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628579,1,Intermediate,10116.0,,50597,
12609,Cmax value in rat plasma when administered 20 mg/kg perorally,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628580,1,Intermediate,10116.0,,50597,
12610,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628581,1,Intermediate,9615.0,,50588,
12611,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628582,1,Intermediate,9615.0,,50588,
12612,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628583,1,Intermediate,9615.0,,50588,
12613,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625782,0,Autocuration,314293.0,,22224,
12614,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625783,1,Intermediate,9986.0,,50592,
12615,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625784,1,Intermediate,10116.0,,50597,
12616,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1,N,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625785,1,Intermediate,9544.0,,50797,
12617,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625786,1,Intermediate,10116.0,,50597,
12618,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,1,U,,,,,,,,,BAO_0000019,CHEMBL874467,0,Autocuration,,,22224,
12619,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625787,1,Intermediate,9615.0,,50588,
12620,cytotoxicity against HIV protease enzyme.,1,N,,Human immunodeficiency virus,,,,,,,BAO_0000218,CHEMBL625964,1,Intermediate,12721.0,,50677,
12621,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625965,1,Intermediate,10090.0,,50594,
12622,Apparent clearance in mice after oral administration of 100 mg/kg of dose,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625966,1,Intermediate,10090.0,,50594,
12623,The plasma clearance in dog.,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625967,1,Intermediate,9615.0,,50588,
12624,The plasma clearance in rat.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625968,1,Intermediate,10116.0,,50597,
12625,Clearance from plasma in male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625969,1,Intermediate,10116.0,,50597,
12626,Clearance from plasma in male cynomolgus monkeys,1,N,,Macaca fascicularis,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625970,1,Intermediate,9541.0,,100710,
12627,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625971,1,Intermediate,9615.0,,50588,
12628,Clearance of compound in dog plasma,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625972,1,Intermediate,9615.0,,50588,
12629,Clearance of compound in human plasma,1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625973,1,Intermediate,9606.0,,50587,
12630,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625974,1,Intermediate,9615.0,,50588,
12631,Clearance of compound when administered intravenously as an individual dose to a single dog.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625975,1,Intermediate,9615.0,,50588,
12632,"Clearance (10 mg/kg, intravenously) in dog plasma",1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625976,1,Intermediate,9615.0,,50588,
12633,Clearance value in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625977,1,Intermediate,9615.0,,50588,
12634,Clearance value in guinea pig,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL625978,1,Intermediate,10141.0,,50512,
12635,Clearance values in rats after iv administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874468,1,Intermediate,10116.0,,50597,
12636,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625421,0,Autocuration,,,22224,
12637,In vivo clearance (5 mg/kg) was determined in rabbits,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625422,1,Intermediate,9986.0,,50592,
12638,Plasma Clearance rate was determined for the compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625423,1,Intermediate,10116.0,,50597,
12639,Plasma Clearance rate was determined for the compound in squirrel monkeys,1,U,,Saimiri,,,,,,,BAO_0000218,CHEMBL625424,0,Autocuration,9520.0,,22224,
12640,Plasma clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625425,1,Intermediate,10116.0,,50597,
12641,Plasma clearance of the compound,1,U,,,,,,,,,BAO_0000218,CHEMBL625426,0,Autocuration,,,22224,
12642,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL625427,1,Intermediate,10141.0,,50512,
12643,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL625428,1,Intermediate,10141.0,,50512,
12644,Plasma clearance was determined,1,U,,,,,,,,,BAO_0000218,CHEMBL625429,0,Autocuration,,,22224,
12645,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625430,1,Intermediate,9615.0,,50588,
12646,Plasma clearance rate was determined for the compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625431,1,Intermediate,10116.0,,50597,
12647,Plasma clearance rate was determined for the compound in squirrel monkeys,1,U,,Saimiri,,,,,,,BAO_0000218,CHEMBL627307,0,Autocuration,9520.0,,22224,
12648,Slow clearance (CL) was determined,1,U,,,,,,,,,BAO_0000218,CHEMBL627308,0,Autocuration,,,22224,
12649,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627309,0,Autocuration,,,22224,
12650,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,1,U,,,,,,,,,BAO_0000218,CHEMBL627310,0,Autocuration,,,22224,
12651,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627311,0,Autocuration,,,22224,
12652,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627312,0,Autocuration,,,22224,
12653,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627313,0,Autocuration,,,22224,
12654,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627314,0,Autocuration,,,22224,
12655,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627315,0,Autocuration,,,22224,
12656,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627316,0,Autocuration,,,22224,
12657,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627317,0,Autocuration,,,22224,
12658,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627318,0,Autocuration,,,22224,
12659,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL627999,0,Autocuration,,,22224,
12660,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628000,0,Autocuration,,,22224,
12661,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628001,0,Autocuration,,,22224,
12662,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL628002,0,Autocuration,,,22224,
12663,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625610,0,Autocuration,,,22224,
12664,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625611,0,Autocuration,,,22224,
12665,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625612,0,Autocuration,,,22224,
12666,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625613,0,Autocuration,,,22224,
12667,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL875479,0,Autocuration,,,22224,
12668,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625614,0,Autocuration,,,22224,
12669,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL625615,0,Autocuration,,,22224,
12670,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,1,U,,,,,,,,,BAO_0000218,CHEMBL626302,0,Autocuration,,,22224,
12671,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626303,1,Intermediate,10116.0,,50597,
12672,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627420,1,Intermediate,10116.0,,50597,
12673,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627421,1,Intermediate,10116.0,,50597,
12674,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625695,1,Intermediate,10116.0,,50597,
12675,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625696,1,Intermediate,10116.0,,50597,
12676,Distribution of compound in mice brain was measured after 1 hr,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL875606,1,Intermediate,10090.0,,50594,
12677,Distribution of compound in mice brain was measured after 24 hr r,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625697,1,Intermediate,10090.0,,50594,
12678,Distribution of compound in mice brain was measured after 2 hr,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625698,1,Intermediate,10090.0,,50594,
12679,Distribution of compound in mice brain was measured after 3 hr,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625699,1,Intermediate,10090.0,,50594,
12680,Distribution of compound in mice brain was measured after 6 hr,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL625700,1,Intermediate,10090.0,,50594,
12681,Distribution of compound in mice liver was measured after 1 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625701,1,Intermediate,10090.0,,50594,
12682,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625702,1,Intermediate,10090.0,,50594,
12683,Distribution of compound in mice liver was measured after 2 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625703,1,Intermediate,10090.0,,50594,
12684,Distribution of compound in mice liver was measured after 3 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625704,1,Intermediate,10090.0,,50594,
12685,Distribution of compound in mice liver was measured after 6 hr,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625705,1,Intermediate,10090.0,,50594,
12686,Distribution in dog adrenal medulla 30 min after administration.,1,N,,Canis lupus familiaris,,,,Adrenal medulla,,1236.0,BAO_0000218,CHEMBL625706,1,Intermediate,9615.0,,50588,
12687,Distribution in dog adrenal medulla 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Adrenal medulla,,1236.0,BAO_0000218,CHEMBL625707,1,Intermediate,9615.0,,50588,
12688,Distribution in female dog Ovary 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625708,1,Intermediate,9615.0,,50588,
12689,Distribution in female dog Ovary 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625709,1,Intermediate,9615.0,,50588,
12690,Distribution in female dog adipose 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624180,1,Intermediate,9615.0,,50588,
12691,Distribution in female dog adipose 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624181,1,Intermediate,9615.0,,50588,
12692,Distribution in female dog adrenal cortex 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Adrenal cortex,,1235.0,BAO_0000218,CHEMBL624182,1,Intermediate,9615.0,,50588,
12693,Distribution in female dog adrenal cortex 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Adrenal cortex,,1235.0,BAO_0000218,CHEMBL624183,1,Intermediate,9615.0,,50588,
12694,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624184,1,Intermediate,10116.0,,50597,
12695,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL877489,1,Intermediate,10116.0,,50597,
12696,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624185,1,Intermediate,10116.0,,50597,
12697,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624186,1,Intermediate,10116.0,,50597,
12698,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624187,1,Intermediate,10116.0,,50597,
12699,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL624188,1,Intermediate,10116.0,,50597,
12700,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624189,1,Intermediate,10116.0,,50597,
12701,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624190,1,Intermediate,10116.0,,50597,
12702,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624191,1,Intermediate,10116.0,,50597,
12703,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624192,1,Intermediate,10116.0,,50597,
12704,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624193,1,Intermediate,10116.0,,50597,
12705,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624194,1,Intermediate,10116.0,,50597,
12706,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624891,1,Intermediate,10116.0,,50597,
12707,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624892,1,Intermediate,10116.0,,50597,
12708,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL624893,1,Intermediate,10116.0,,50597,
12709,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627632,1,Intermediate,10116.0,,50597,
12710,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627633,1,Intermediate,10116.0,,50597,
12711,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627634,1,Intermediate,10116.0,,50597,
12712,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627635,1,Intermediate,10116.0,,50597,
12713,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627636,1,Intermediate,10116.0,,50597,
12714,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626816,1,Intermediate,10116.0,,50597,
12715,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626817,1,Intermediate,10116.0,,50597,
12716,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626818,1,Intermediate,10116.0,,50597,
12717,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626819,1,Intermediate,10116.0,,50597,
12718,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626820,1,Intermediate,10116.0,,50597,
12719,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626821,1,Intermediate,10116.0,,50597,
12720,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626822,1,Intermediate,10116.0,,50597,
12721,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626823,1,Intermediate,10116.0,,50597,
12722,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626824,1,Intermediate,10116.0,,50597,
12723,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626825,1,Intermediate,10116.0,,50597,
12724,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626826,1,Intermediate,10116.0,,50597,
12725,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626827,1,Intermediate,10116.0,,50597,
12726,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626828,1,Intermediate,10116.0,,50597,
12727,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626829,1,Intermediate,10116.0,,50597,
12728,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL626830,1,Intermediate,10116.0,,50597,
12729,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627150,1,Intermediate,10116.0,,50597,
12730,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627151,1,Intermediate,10116.0,,50597,
12731,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627152,1,Intermediate,10116.0,,50597,
12732,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627153,1,Intermediate,10116.0,,50597,
12733,Rate of acetate production by the compound was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL627154,0,Autocuration,,,22224,
12734,Rate of acetate production by the compound was determined; Not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL627155,0,Autocuration,,,22224,
12735,Rate of hydrolysis of nitrocefin by compound was evaluated in water,1,U,,,,,,,,,BAO_0000019,CHEMBL627156,0,Autocuration,,,22224,
12736,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,1,U,,,,,,,,,BAO_0000019,CHEMBL627157,0,Autocuration,,,22224,
12737,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL627158,1,Intermediate,9986.0,,50592,
12738,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,N,,Oryctolagus cuniculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627159,1,Intermediate,9986.0,,50592,
12739,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627160,1,Intermediate,10090.0,,50594,
12740,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628540,1,Intermediate,10116.0,,50597,
12741,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628541,1,Intermediate,10116.0,,50597,
12742,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628542,1,Intermediate,10116.0,,50597,
12743,Solubility after at a pH 1.2,1,U,,,,,,,,,BAO_0000100,CHEMBL628543,0,Autocuration,,,22229,
12744,Solubility after at pH 1.2,1,U,,,,,,,,,BAO_0000100,CHEMBL628544,0,Autocuration,,,22229,
12745,Solubility after injection of water,1,U,,,,,,,,,BAO_0000100,CHEMBL628545,0,Autocuration,,,22229,
12746,Statistical significance of IC 50 values; Expressed as R value,1,U,,,,,,,,,BAO_0000019,CHEMBL628546,0,Autocuration,,,22224,
12747,Systemic availability with respect to methyldopa was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL874455,0,Autocuration,,,22224,
12748,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628547,1,Intermediate,10116.0,,50597,
12749,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL628548,1,Intermediate,10116.0,,50597,
12750,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628549,1,Intermediate,9986.0,,50592,
12751,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628550,1,Intermediate,9986.0,,50592,
12752,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628551,1,Intermediate,9986.0,,50592,
12753,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628552,1,Intermediate,9986.0,,50592,
12754,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628553,1,Intermediate,9986.0,,50592,
12755,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628554,1,Intermediate,9986.0,,50592,
12756,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628555,1,Intermediate,9986.0,,50592,
12757,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628556,1,Intermediate,9986.0,,50592,
12758,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628557,1,Intermediate,9986.0,,50592,
12759,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628558,1,Intermediate,9986.0,,50592,
12760,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628559,1,Intermediate,9986.0,,50592,
12761,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628560,1,Intermediate,9986.0,,50592,
12762,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874456,1,Intermediate,9986.0,,50592,
12763,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628561,1,Intermediate,9986.0,,50592,
12764,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL628562,1,Intermediate,9986.0,,50592,
12765,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628563,1,Intermediate,9986.0,,50592,
12766,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628564,1,Intermediate,9986.0,,50592,
12767,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628565,1,Intermediate,9986.0,,50592,
12768,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631248,1,Intermediate,9986.0,,50592,
12769,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631249,1,Intermediate,9986.0,,50592,
12770,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627214,1,Intermediate,9986.0,,50592,
12771,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL874591,1,Intermediate,9986.0,,50592,
12772,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL627215,1,Intermediate,9986.0,,50592,
12773,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL625471,1,Intermediate,9986.0,,50592,
12774,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625472,1,Intermediate,9986.0,,50592,
12775,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL625473,1,Intermediate,9986.0,,50592,
12776,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625474,1,Intermediate,9615.0,,50588,
12777,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625475,1,Intermediate,9615.0,,50588,
12778,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625476,1,Intermediate,10116.0,,50597,
12779,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625477,1,Intermediate,10116.0,,50597,
12780,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625478,1,Intermediate,10116.0,,50597,
12781,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,1,N,,Rattus norvegicus,,,,esophageal tunica muscularis mucosae,,,BAO_0000218,CHEMBL625479,1,Intermediate,10116.0,,50597,
12782,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,1,N,,Rattus norvegicus,,,,esophageal tunica muscularis mucosae,,,BAO_0000218,CHEMBL625480,1,Intermediate,10116.0,,50597,
12783,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625481,1,Intermediate,10116.0,,50597,
12784,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625482,1,Intermediate,10116.0,,50597,
12785,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625483,1,Intermediate,10116.0,,50597,
12786,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625484,1,Intermediate,10116.0,,50597,
12787,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625485,1,Intermediate,10116.0,,50597,
12788,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625486,1,Intermediate,9615.0,,50588,
12789,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625487,1,Intermediate,10116.0,,50597,
12790,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625488,1,Intermediate,10116.0,,50597,
12791,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625489,1,Intermediate,10116.0,,50597,
12792,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625490,1,Intermediate,10116.0,,50597,
12793,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625491,1,Intermediate,9615.0,,50588,
12794,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625492,1,Intermediate,10116.0,,50597,
12795,plasma clearance in human,1,N,,Homo sapiens,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625493,1,Intermediate,9606.0,,50587,
12796,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625494,1,Intermediate,10116.0,,50597,
12797,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625495,1,Intermediate,10116.0,,50597,
12798,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625496,1,Intermediate,10116.0,,50597,
12799,1-Octanol/water partition coefficient measured at 7.4,1,U,,,,,,,,,BAO_0000100,CHEMBL625497,0,Autocuration,,,22229,
12800,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625498,0,Autocuration,,,22229,
12801,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL625499,0,Autocuration,,,22224,
12802,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625500,0,Autocuration,,,22229,
12803,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625501,0,Autocuration,,,22229,
12804,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625502,0,Autocuration,,,22229,
12805,Calculated partition coefficient (clogP) (relative to BAY K 8644),1,U,,,,,,,,,BAO_0000100,CHEMBL625503,0,Autocuration,,,22229,
12806,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625504,0,Autocuration,,,22229,
12807,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625505,0,Autocuration,,,22229,
12808,Calculated partition coefficient of the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL625506,0,Autocuration,,,22229,
12809,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL625507,0,Autocuration,,,22224,
12810,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625508,0,Autocuration,,,22229,
12811,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625509,0,Autocuration,,,22229,
12812,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625510,0,Autocuration,,,22229,
12813,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL883125,0,Autocuration,,,22229,
12814,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625511,0,Autocuration,,,22229,
12815,Partition coefficient of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL874650,0,Autocuration,,,22224,
12816,Partition coefficient of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL625512,0,Autocuration,,,22224,
12817,Partition coefficient of compound was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL625513,0,Autocuration,,,22224,
12818,Partition coefficient was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL625514,0,Autocuration,,,22224,
12819,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625515,0,Autocuration,,,22229,
12820,partition coefficient of compound was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL625516,0,Autocuration,,,22229,
12821,The total body administered intravenously in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625517,1,Intermediate,9615.0,,50588,
12822,The total body administered intravenously in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625518,1,Intermediate,10116.0,,50597,
12823,Time taken for the administration to female NIH mice weighing 25-30 g.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625519,1,Intermediate,10090.0,,50594,
12824,Time taken for the administration,1,U,,,,,,,,,BAO_0000019,CHEMBL625520,0,Autocuration,,,22224,
12825,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL874651,1,Intermediate,9615.0,,50588,
12826,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625521,0,Autocuration,314293.0,,22224,
12827,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL623171,1,Intermediate,9986.0,,50592,
12828,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623853,1,Intermediate,10116.0,,50597,
12829,Plasma clearance for the compound was determined.,1,U,,,,,,,,,BAO_0000019,CHEMBL623854,0,Autocuration,,,22224,
12830,CLog P value of the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL874405,0,Autocuration,,,22224,
12831,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL623855,0,Autocuration,,,22229,
12832,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL623856,0,Autocuration,,,22229,
12833,ClogP value of the compound; nd ='no data',1,U,,,,,,,,,BAO_0000100,CHEMBL623857,0,Autocuration,,,22224,
12834,ClogP value of the compound; nd ='not determined',1,U,,,,,,,,,BAO_0000100,CHEMBL623858,0,Autocuration,,,22224,
12835,CLog P was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL623859,0,Autocuration,,,22224,
12836,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL839829,0,Autocuration,,,22229,
12837,CLogP was calculated,1,U,,,,,,,,,BAO_0000019,CHEMBL623860,0,Autocuration,,,22224,
12838,CLogP value was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL623861,0,Autocuration,,,22224,
12839,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,1,U,,,,,,,,,BAO_0000019,CHEMBL623862,0,Autocuration,,,22224,
12840,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL874406,0,Autocuration,,,22229,
12841,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL623863,0,Autocuration,,,22229,
12842,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624021,0,Autocuration,,,22229,
12843,Distribution in female dog adrenal medulla 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Adrenal medulla,,1236.0,BAO_0000218,CHEMBL624022,1,Intermediate,9615.0,,50588,
12844,Distribution in female dog adrenal medulla 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Adrenal medulla,,1236.0,BAO_0000218,CHEMBL624023,1,Intermediate,9615.0,,50588,
12845,Distribution in female dog bile 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624024,1,Intermediate,9615.0,,50588,
12846,Distribution in female dog bile 72 hr after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624025,1,Intermediate,9615.0,,50588,
12847,Distribution in female dog blood 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624026,1,Intermediate,9615.0,,50588,
12848,Distribution in female dog blood 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624027,1,Intermediate,9615.0,,50588,
12849,Distribution in female dog heart 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624028,1,Intermediate,9615.0,,50588,
12850,Distribution in female dog heart 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624029,1,Intermediate,9615.0,,50588,
12851,Distribution in female dog kidney 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624030,1,Intermediate,9615.0,,50588,
12852,Distribution in female dog kidney 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624031,1,Intermediate,9615.0,,50588,
12853,Distribution in female dog large intestine 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Intestine,,160.0,BAO_0000218,CHEMBL624032,1,Intermediate,9615.0,,50588,
12854,Distribution in female dog large intestine 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Intestine,,160.0,BAO_0000218,CHEMBL874407,1,Intermediate,9615.0,,50588,
12855,Distribution in female dog liver 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624033,1,Intermediate,9615.0,,50588,
12856,Distribution in female dog liver 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624034,1,Intermediate,9615.0,,50588,
12857,Distribution in female dog lung 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624035,1,Intermediate,9615.0,,50588,
12858,Distribution in female dog lung 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624036,1,Intermediate,9615.0,,50588,
12859,Distribution in female dog muscle 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624037,1,Intermediate,9615.0,,50588,
12860,Distribution in female dog muscle 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL624038,1,Intermediate,9615.0,,50588,
12861,Distribution in female dog pancreas 24 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624039,1,Intermediate,9615.0,,50588,
12862,Distribution in female dog pancreas 72 hours after administration.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624040,1,Intermediate,9615.0,,50588,
12863,Distribution in female dog small intestine 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Intestine,,160.0,BAO_0000218,CHEMBL624041,1,Intermediate,9615.0,,50588,
12864,Distribution in female dog small intestine 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Intestine,,160.0,BAO_0000218,CHEMBL624042,1,Intermediate,9615.0,,50588,
12865,Distribution in female dog spleen 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624043,1,Intermediate,9615.0,,50588,
12866,Distribution in female dog spleen 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Spleen,,2106.0,BAO_0000218,CHEMBL624044,1,Intermediate,9615.0,,50588,
12867,Distribution in female dog stomach 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Stomach,,945.0,BAO_0000218,CHEMBL624045,1,Intermediate,9615.0,,50588,
12868,Distribution in female dog stomach 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Stomach,,945.0,BAO_0000218,CHEMBL624046,1,Intermediate,9615.0,,50588,
12869,Distribution in female dog thyroid 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624047,1,Intermediate,9615.0,,50588,
12870,Distribution in female dog thyroid 72 hours after administration.,1,N,,Canis lupus familiaris,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL624048,1,Intermediate,9615.0,,50588,
12871,Distribution in female dog urine 24 hours after administration.,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL874408,1,Intermediate,9615.0,,50588,
12872,Distribution in female dog urine 72 hr after administration.,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL624049,1,Intermediate,9615.0,,50588,
12873,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL624050,0,Autocuration,,,22224,
12874,Plasma concentration at 7 hr after intravenous dosing,1,U,,,,,,,,,BAO_0000019,CHEMBL624051,0,Autocuration,,,22224,
12875,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623278,1,Intermediate,10116.0,,50597,
12876,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623279,1,Intermediate,10116.0,,50597,
12877,Plasma concentration of 3 mg/kg iv after 1 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623280,1,Intermediate,10116.0,,50597,
12878,Plasma concentration of 3 mg/kg iv after 2 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623963,1,Intermediate,10116.0,,50597,
12879,Plasma concentration of 3 mg/kg iv after 4 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623964,1,Intermediate,10116.0,,50597,
12880,Plasma concentration of 3 mg/kg iv after 6 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623965,1,Intermediate,10116.0,,50597,
12881,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623966,1,Intermediate,10116.0,,50597,
12882,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874415,1,Intermediate,10116.0,,50597,
12883,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623967,1,Intermediate,10116.0,,50597,
12884,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623968,1,Intermediate,10116.0,,50597,
12885,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623969,1,Intermediate,10116.0,,50597,
12886,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628409,1,Intermediate,10116.0,,50597,
12887,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628410,1,Intermediate,10116.0,,50597,
12888,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628411,1,Intermediate,10116.0,,50597,
12889,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628412,1,Intermediate,10116.0,,50597,
12890,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,1,U,,,,,,,,,BAO_0000019,CHEMBL628413,0,Autocuration,,,22224,
12891,The concentration in plasmat; Not determined,1,U,,,,,,Plasma,,1969.0,BAO_0000019,CHEMBL628414,0,Autocuration,,,22224,
12892,Tissue level at 10 mg/kg/po in wistar rats in blood,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628415,1,Intermediate,10116.0,,50597,
12893,Tissue level at 10 mg/kg/po in wistar rats in brown fat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628416,1,Intermediate,10116.0,,50597,
12894,Tissue level at 10 mg/kg/po in wistar rats in heart,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628417,1,Intermediate,10116.0,,50597,
12895,Tissue level at 10 mg/kg/po in wistar rats in liver,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL874908,1,Intermediate,10116.0,,50597,
12896,Tissue level at 10 mg/kg/po in wistar rats in plasma,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628418,1,Intermediate,10116.0,,50597,
12897,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL628419,1,Intermediate,10116.0,,50597,
12898,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628420,1,Intermediate,10116.0,,50597,
12899,Water solubility at 37 degree C.,1,U,,,,,,,,,BAO_0000019,CHEMBL628421,0,Autocuration,,,22224,
12900,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626726,0,Autocuration,,,22229,
12901,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626727,0,Autocuration,,,22229,
12902,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626728,1,Intermediate,10116.0,,50597,
12903,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626729,1,Intermediate,10116.0,,50597,
12904,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626730,1,Intermediate,10116.0,,50597,
12905,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626731,1,Intermediate,10116.0,,50597,
12906,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL626732,1,Intermediate,10116.0,,50597,
12907,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626733,1,Intermediate,10116.0,,50597,
12908,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626734,1,Intermediate,10116.0,,50597,
12909,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626735,1,Intermediate,10116.0,,50597,
12910,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL874909,1,Intermediate,10116.0,,50597,
12911,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL626736,1,Intermediate,10116.0,,50597,
12912,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL626737,1,Intermediate,10116.0,,50597,
12913,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630999,1,Intermediate,10116.0,,50597,
12914,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL631000,1,Intermediate,10116.0,,50597,
12915,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL631001,1,Intermediate,10116.0,,50597,
12916,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL631002,1,Intermediate,10116.0,,50597,
12917,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631003,1,Intermediate,10116.0,,50597,
12918,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631004,1,Intermediate,10116.0,,50597,
12919,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631005,1,Intermediate,10116.0,,50597,
12920,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631006,1,Intermediate,10116.0,,50597,
12921,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631007,1,Intermediate,10116.0,,50597,
12922,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL631008,1,Intermediate,10116.0,,50597,
12923,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL631009,1,Intermediate,10116.0,,50597,
12924,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL631010,1,Intermediate,10116.0,,50597,
12925,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL631011,1,Intermediate,10116.0,,50597,
12926,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL631012,1,Intermediate,10116.0,,50597,
12927,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630271,1,Intermediate,10116.0,,50597,
12928,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630272,1,Intermediate,10116.0,,50597,
12929,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630273,1,Intermediate,10116.0,,50597,
12930,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630274,1,Intermediate,10116.0,,50597,
12931,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630275,1,Intermediate,10116.0,,50597,
12932,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875782,1,Intermediate,10116.0,,50597,
12933,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630276,1,Intermediate,10116.0,,50597,
12934,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630277,1,Intermediate,10116.0,,50597,
12935,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630278,1,Intermediate,10116.0,,50597,
12936,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630279,1,Intermediate,10116.0,,50597,
12937,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,1,U,,,,,,,,,BAO_0000019,CHEMBL630280,0,Autocuration,,,22224,
12938,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,U,,,,,,,,,BAO_0000019,CHEMBL630281,0,Autocuration,,,22224,
12939,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL630282,1,Intermediate,9986.0,,50592,
12940,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL630283,1,Intermediate,9986.0,,50592,
12941,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),1,U,,,,,,,,,BAO_0000019,CHEMBL630284,0,Autocuration,,,22224,
12942,Alkylating activity was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL630285,0,Autocuration,,,22224,
12943,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),1,U,,,,Microsomes,,,,,BAO_0000251,CHEMBL630286,0,Autocuration,,,22224,
12944,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL630069,1,Intermediate,9986.0,,50592,
12945,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL630070,1,Intermediate,9986.0,,50592,
12946,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL630071,1,Intermediate,9986.0,,50592,
12947,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL630072,1,Intermediate,9986.0,,50592,
12948,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL875110,1,Intermediate,9986.0,,50592,
12949,Compound was tested for antidiuretic activity in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630073,1,Intermediate,10116.0,,50597,
12950,Compound was tested for inactivation kinetic values,1,U,,,,,,,,,BAO_0000019,CHEMBL630074,0,Autocuration,,,22224,
12951,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,1,U,,,,,,,,,BAO_0000218,CHEMBL630075,0,Autocuration,,,22224,
12952,Dissociation rate calculated from the first-order equation using the t1/2 value,1,U,,,,,,,,,BAO_0000019,CHEMBL630076,0,Autocuration,,,22224,
12953,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,1,U,,,,,,,,,BAO_0000100,CHEMBL630077,0,Autocuration,,,22229,
12954,Aqueous solubility was measured,1,U,,,,,,,,,BAO_0000100,CHEMBL630078,0,Autocuration,,,22229,
12955,Aqueous solubility was measured at a pH 4,1,U,,,,,,,,,BAO_0000100,CHEMBL630079,0,Autocuration,,,22229,
12956,Aqueous solubility (pH 7),1,U,,,,,,,,,BAO_0000100,CHEMBL630080,0,Autocuration,,,22229,
12957,Aqueous solubility was measured at a pH 9,1,U,,,,,,,,,BAO_0000100,CHEMBL630081,0,Autocuration,,,22229,
12958,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",1,U,,,,,,,,,BAO_0000019,CHEMBL630082,0,Autocuration,,,22224,
12959,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",1,U,,,,,,,,,BAO_0000019,CHEMBL630083,0,Autocuration,,,22224,
12960,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",1,U,,,,,,,,,BAO_0000019,CHEMBL630084,0,Autocuration,,,22224,
12961,Aqueous solubility of the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL629198,0,Autocuration,,,22229,
12962,Aqueous solubility at 37 degree Celsius at pH 7.38,1,U,,,,,,,,,BAO_0000100,CHEMBL629199,0,Autocuration,,,22229,
12963,Aqueous solubility in pH 7.4 phosphate buffer,1,U,,,,,,,,,BAO_0000100,CHEMBL629200,0,Autocuration,,,22229,
12964,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629201,1,Intermediate,9615.0,,50588,
12965,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629202,1,Intermediate,9615.0,,50588,
12966,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL875111,1,Intermediate,9606.0,,50587,
12967,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL629203,1,Intermediate,9606.0,,50587,
12968,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL629204,1,Intermediate,9606.0,,50587,
12969,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL629205,1,Intermediate,9606.0,,50587,
12970,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL629206,1,Intermediate,9606.0,,50587,
12971,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,1,U,,,,,,,,,BAO_0000019,CHEMBL631185,0,Autocuration,,,22224,
12972,Compound was evaluated for the average bile flow rat in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631186,1,Intermediate,10116.0,,50597,
12973,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL631187,1,Intermediate,9986.0,,50592,
12974,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL631188,1,Intermediate,9986.0,,50592,
12975,Average half life period was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL876419,0,Autocuration,,,22224,
12976,Average half life period was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631189,0,Autocuration,,,22224,
12977,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL631190,1,Intermediate,10298.0,,50602,
12978,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL631191,1,Intermediate,10298.0,,50602,
12979,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL631192,1,Intermediate,10298.0,,50602,
12980,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL632400,1,Intermediate,10298.0,,50602,
12981,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL630564,1,Intermediate,10298.0,,50602,
12982,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL630565,1,Intermediate,10298.0,,50602,
12983,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL630566,1,Intermediate,10298.0,,50602,
12984,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL631229,1,Intermediate,10298.0,,50602,
12985,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL631230,1,Intermediate,10298.0,,50602,
12986,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL876428,0,Autocuration,,,22229,
12987,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631231,0,Autocuration,,,22229,
12988,Calculated partition coefficient (clogP) (MacLogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631232,0,Autocuration,,,22229,
12989,Hydrophilicity was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631233,0,Autocuration,,,22224,
12990,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631234,0,Autocuration,,,22229,
12991,Increased absorption was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL883126,0,Autocuration,,,22224,
12992,Lipophilicity value was evaluated,1,U,,,,,,,,,BAO_0000100,CHEMBL631235,0,Autocuration,,,22224,
12993,Log P value of the compound.,1,U,,,,,,,,,BAO_0000100,CHEMBL631236,0,Autocuration,,,22224,
12994,Partition coefficient of compound was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631237,0,Autocuration,,,22224,
12995,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631238,0,Autocuration,,,22229,
12996,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL876429,0,Autocuration,,,22229,
12997,Partition coefficient was measured by medchem software; Not calculated,1,U,,,,,,,,,BAO_0000019,CHEMBL631414,0,Autocuration,,,22224,
12998,Partition coefficient was measured by octanol-water using standard shake-flask method,1,U,,,,,,,,,BAO_0000100,CHEMBL631415,0,Autocuration,,,22224,
12999,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631416,0,Autocuration,,,22229,
13000,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL631417,0,Autocuration,,,22224,
13001,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631418,0,Autocuration,,,22229,
13002,The Octanol/Water partition coefficient CLogP,1,U,,,,,,,,,BAO_0000100,CHEMBL631419,0,Autocuration,,,22229,
13003,The pharmacokinetic parameter C Log p was reported,1,U,,,,,,,,,BAO_0000019,CHEMBL631420,0,Autocuration,,,22224,
13004,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631421,0,Autocuration,,,22229,
13005,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631422,0,Autocuration,,,22229,
13006,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL631423,0,Autocuration,,,22229,
13007,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL876430,1,Intermediate,10116.0,,50597,
13008,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631424,1,Intermediate,10116.0,,50597,
13009,Compound was administered intravenously in dog to evaluate plasma clearance values,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631425,1,Intermediate,9615.0,,50588,
13010,Compound was administered intravenously in monkey to evaluate plasma clearance values,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631426,0,Autocuration,314293.0,,22224,
13011,Compound was administered intravenously in mouse to evaluate plasma clearance values,1,N,,Mus musculus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631427,1,Intermediate,10090.0,,50594,
13012,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631428,1,Intermediate,9615.0,,50588,
13013,Intrinsic clearance in Rhesus liver microsome,1,N,,Macaca mulatta,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL631429,1,Intermediate,9544.0,,50797,
13014,Intrinsic clearance in dog liver microsome,1,N,,Canis lupus familiaris,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL631430,1,Intermediate,9615.0,,50588,
13015,Intrinsic clearance in rat liver microsome,1,N,,Rattus norvegicus,,Microsomes,,Liver,,2107.0,BAO_0000218,CHEMBL631431,1,Intermediate,10116.0,,50597,
13016,Low plasma clearance was calculated in rhesus monkey,1,N,,Macaca mulatta,,,,Plasma,,1969.0,BAO_0000218,CHEMBL631432,1,Intermediate,9544.0,,50797,
13017,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631433,1,Intermediate,9615.0,,50588,
13018,Plasma clearance after intravenous dose of 0.3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL631434,0,Autocuration,,,22224,
13019,Plasma clearance after intravenous dose of 1 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL631435,0,Autocuration,,,22224,
13020,Plasma clearance after intravenous dose of 3 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL631436,0,Autocuration,,,22224,
13021,Plasma clearance after intravenous dose of 3.87 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL631437,0,Autocuration,,,22224,
13022,Plasma clearance after peroral administration at 10 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631438,1,Intermediate,10116.0,,50597,
13023,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL876431,1,Intermediate,9544.0,,50797,
13024,Plasma clearance after peroral administration at 10 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631439,1,Intermediate,9615.0,,50588,
13025,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631440,1,Intermediate,10116.0,,50597,
13026,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),1,U,,,,,,,,,BAO_0000019,CHEMBL631441,0,Autocuration,,,22224,
13027,Critical Micellar concentration was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631442,0,Autocuration,,,22224,
13028,Critical Micellar concentration of the compound. was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL626525,0,Autocuration,,,22224,
13029,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,1,U,,,,,,,,,BAO_0000019,CHEMBL627168,0,Autocuration,,,22224,
13030,Critical micellar concentration was measured in water by the dye solubilization method,1,U,,,,,,,,,BAO_0000019,CHEMBL875618,0,Autocuration,,,22224,
13031,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,1,U,,,,,,,,,BAO_0000019,CHEMBL626612,0,Autocuration,,,22224,
13032,CMR value (relative to BAY K 8644),1,U,,,,,,,,,BAO_0000019,CHEMBL626613,0,Autocuration,,,22224,
13033,Carbamoylating activity was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL626614,0,Autocuration,,,22224,
13034,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL626615,0,Autocuration,314293.0,,22224,
13035,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,1,U,,,,,,,,,BAO_0000019,CHEMBL626616,0,Autocuration,,,22224,
13036,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,1,U,,,,,,,,,BAO_0000019,CHEMBL626617,0,Autocuration,,,22224,
13037,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626618,1,Intermediate,9615.0,,50588,
13038,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626619,1,Intermediate,10116.0,,50597,
13039,"Clearance rate at 0.46 mg/kg, iv, in dogs",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626620,1,Intermediate,9615.0,,50588,
13040,"Clearance rate at 5.5 mg/kg, iv, in rat",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626621,1,Intermediate,10116.0,,50597,
13041,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL626622,1,Intermediate,9541.0,,100710,
13042,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL626623,1,Intermediate,9541.0,,100710,
13043,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626624,1,Intermediate,9615.0,,50588,
13044,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626625,1,Intermediate,10116.0,,50597,
13045,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL626626,1,Intermediate,10116.0,,50597,
13046,Tested for the total clearance of the compound,1,U,,,,,,,,,BAO_0000218,CHEMBL626627,0,Autocuration,,,22224,
13047,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626628,1,Intermediate,9615.0,,50588,
13048,Total body clearance was determined,1,U,,,,,,,,,BAO_0000218,CHEMBL626629,0,Autocuration,,,22224,
13049,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626630,1,Intermediate,10116.0,,50597,
13050,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626631,1,Intermediate,10116.0,,50597,
13051,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626632,0,Autocuration,,,22229,
13052,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626633,0,Autocuration,,,22229,
13053,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626634,0,Autocuration,,,22229,
13054,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626635,0,Autocuration,,,22229,
13055,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626636,0,Autocuration,,,22229,
13056,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,1,U,,,,,,,,,BAO_0000100,CHEMBL626637,0,Autocuration,,,22229,
13057,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL626638,1,Intermediate,4754.0,,50339,
13058,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL626639,1,Intermediate,4754.0,,50339,
13059,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL626640,1,Intermediate,4754.0,,50339,
13060,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL626641,1,Intermediate,4754.0,,50339,
13061,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL627272,1,Intermediate,4754.0,,50339,
13062,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL627273,1,Intermediate,4754.0,,50339,
13063,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL627441,1,Intermediate,4754.0,,50339,
13064,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL628355,1,Intermediate,4754.0,,50339,
13065,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL628356,1,Intermediate,4754.0,,50339,
13066,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL628357,1,Intermediate,4754.0,,50339,
13067,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL628358,1,Intermediate,4754.0,,50339,
13068,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),1,N,,Pneumocystis carinii,,,,,,,BAO_0000218,CHEMBL622307,1,Intermediate,4754.0,,50339,
13069,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,1,U,,,,,,,,,BAO_0000019,CHEMBL622527,0,Autocuration,,,22224,
13070,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,1,U,,,,,,,,,BAO_0000019,CHEMBL622528,0,Autocuration,,,22224,
13071,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,1,U,,,,,,,,,BAO_0000019,CHEMBL622529,0,Autocuration,,,22224,
13072,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,1,U,,,,,,,,,BAO_0000019,CHEMBL622992,0,Autocuration,,,22224,
13073,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,1,U,,,,,,,,,BAO_0000019,CHEMBL622993,0,Autocuration,,,22224,
13074,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,1,U,,,,,,,,,BAO_0000019,CHEMBL622994,0,Autocuration,,,22224,
13075,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622995,1,Intermediate,10116.0,,50597,
13076,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622996,1,Intermediate,10116.0,,50597,
13077,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622997,1,Intermediate,10116.0,,50597,
13078,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622998,1,Intermediate,10116.0,,50597,
13079,Cp max following ip administration at 1 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL622999,0,Autocuration,,,22224,
13080,Maximum concentration in plasma was reported at 0.5 hour,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623000,0,Autocuration,,,22224,
13081,Maximum concentration in plasma was reported at 2 hour,1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL623001,0,Autocuration,,,22224,
13082,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL623002,1,Intermediate,10090.0,,50594,
13083,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),1,U,,,,,,,,,BAO_0000100,CHEMBL623003,0,Autocuration,,,22229,
13084,Steady state concentration was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL623004,0,Autocuration,,,22224,
13085,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL623005,0,Autocuration,,,22224,
13086,Partition coefficient (logD7.4),1,U,,,,,,,,,BAO_0000019,CHEMBL623006,0,Autocuration,,,22224,
13087,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623007,1,Intermediate,10116.0,,50597,
13088,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL623008,1,Intermediate,10116.0,,50597,
13089,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL876654,1,Intermediate,10116.0,,50597,
13090,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623009,1,Intermediate,10116.0,,50597,
13091,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623010,1,Intermediate,10116.0,,50597,
13092,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623011,1,Intermediate,10116.0,,50597,
13093,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL623012,1,Intermediate,10116.0,,50597,
13094,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,1,U,,,,,,,,,BAO_0000019,CHEMBL623013,0,Autocuration,,,22224,
13095,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,U,,,,,,,,,BAO_0000019,CHEMBL623014,0,Autocuration,,,22224,
13096,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL623015,0,Autocuration,,,22224,
13097,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL623016,0,Autocuration,,,22224,
13098,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL624858,0,Autocuration,,,22224,
13099,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624859,1,Intermediate,10116.0,,50597,
13100,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624860,1,Intermediate,10116.0,,50597,
13101,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624861,1,Intermediate,10116.0,,50597,
13102,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624862,1,Intermediate,10116.0,,50597,
13103,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624863,1,Intermediate,10116.0,,50597,
13104,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876655,1,Intermediate,10116.0,,50597,
13105,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624864,1,Intermediate,9615.0,,50588,
13106,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624865,1,Intermediate,9615.0,,50588,
13107,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624866,1,Intermediate,9615.0,,50588,
13108,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624867,1,Expert,9615.0,,50588,
13109,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL624868,1,Intermediate,9615.0,,50588,
13110,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628450,1,Intermediate,9615.0,,50588,
13111,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628451,1,Intermediate,9615.0,,50588,
13112,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628452,1,Intermediate,9615.0,,50588,
13113,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628453,1,Intermediate,9615.0,,50588,
13114,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628454,1,Intermediate,9615.0,,50588,
13115,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628455,1,Intermediate,9615.0,,50588,
13116,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628456,1,Intermediate,9615.0,,50588,
13117,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628457,1,Intermediate,9615.0,,50588,
13118,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL877505,1,Intermediate,9615.0,,50588,
13119,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628458,1,Intermediate,9615.0,,50588,
13120,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628459,1,Intermediate,9615.0,,50588,
13121,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628460,1,Intermediate,9615.0,,50588,
13122,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628461,1,Intermediate,9615.0,,50588,
13123,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",1,U,,,,,,,,,BAO_0000218,CHEMBL628462,0,Autocuration,,,22224,
13124,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628463,1,Intermediate,9615.0,,50588,
13125,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625666,1,Expert,10116.0,,50597,
13126,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,U,,,,,,,,,BAO_0000218,CHEMBL625667,0,Autocuration,,,22224,
13127,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625668,1,Expert,10116.0,,50597,
13128,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625669,1,Intermediate,10116.0,,50597,
13129,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,1,U,,,,,,,,,BAO_0000019,CHEMBL625670,0,Autocuration,,,22224,
13130,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625671,1,Intermediate,10116.0,,50597,
13131,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL625672,1,Intermediate,10298.0,,50602,
13132,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL625673,1,Intermediate,10298.0,,50602,
13133,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL625674,1,Intermediate,10298.0,,50602,
13134,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL625675,1,Intermediate,10298.0,,50602,
13135,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL627637,1,Intermediate,10298.0,,50602,
13136,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL627638,1,Intermediate,10298.0,,50602,
13137,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL627639,1,Intermediate,10298.0,,50602,
13138,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL627640,1,Intermediate,10298.0,,50602,
13139,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL627641,1,Intermediate,10298.0,,50602,
13140,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL627642,1,Intermediate,10298.0,,50602,
13141,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL877506,1,Intermediate,10298.0,,50602,
13142,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627275,1,Intermediate,10090.0,,50594,
13143,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL627643,1,Intermediate,9669.0,,50506,
13144,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL631246,1,Intermediate,9669.0,,50506,
13145,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL631247,1,Intermediate,9669.0,,50506,
13146,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL629532,1,Intermediate,9669.0,,50506,
13147,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL629533,1,Intermediate,9669.0,,50506,
13148,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL629534,1,Intermediate,9669.0,,50506,
13149,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,1,N,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL629535,1,Intermediate,9669.0,,50506,
13150,Pharmacokinetic parameter :drug bound to plasma was reported,1,U,,,,,,,,,BAO_0000019,CHEMBL625932,0,Autocuration,,,22224,
13151,compound was evaluated for drug bound in plasma,1,U,,,,,,,,,BAO_0000019,CHEMBL625933,0,Autocuration,,,22224,
13152,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625934,1,Intermediate,10116.0,,50597,
13153,Bioavailability,1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL625935,0,Autocuration,9347.0,,22224,
13154,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625936,1,Intermediate,10116.0,,50597,
13155,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625937,1,Intermediate,10116.0,,50597,
13156,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625938,1,Intermediate,9615.0,,50588,
13157,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1,N,,Rattus norvegicus,,,,Bile,,1970.0,BAO_0000218,CHEMBL625939,1,Intermediate,10116.0,,50597,
13158,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1,N,,Rattus norvegicus,,,,Bile,,1970.0,BAO_0000218,CHEMBL625940,1,Intermediate,10116.0,,50597,
13159,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1,N,,Rattus norvegicus,,,,Bile,,1970.0,BAO_0000218,CHEMBL874464,1,Intermediate,10116.0,,50597,
13160,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1,N,,Rattus norvegicus,,,,Bile,,1970.0,BAO_0000218,CHEMBL625941,1,Intermediate,10116.0,,50597,
13161,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1,N,,Rattus norvegicus,,,,Bile,,1970.0,BAO_0000218,CHEMBL625942,1,Intermediate,10116.0,,50597,
13162,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1,N,,Rattus norvegicus,,,,Bile,,1970.0,BAO_0000218,CHEMBL625943,1,Intermediate,10116.0,,50597,
13163,In vitro protein binding in human serum at 5 ug/ml,1,N,,Homo sapiens,,,,Serum,,1977.0,BAO_0000218,CHEMBL625944,1,Intermediate,9606.0,,50587,
13164,Serum protein binding ability was measured,1,U,,,,,,,,,BAO_0000019,CHEMBL625945,0,Autocuration,,,22224,
13165,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),1,U,,,,,,,,,BAO_0000019,CHEMBL625946,0,Autocuration,,,22224,
13166,Oral bioavailability in dog,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625947,0,Autocuration,9615.0,,22224,
13167,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625948,1,Intermediate,10116.0,,50597,
13168,Absolute oral bioavailability at an iv dose of 14 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL625949,0,Autocuration,,,22224,
13169,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL625950,0,Autocuration,,,22224,
13170,Oral bioavailability (dose 15 mg/kg i.v.),1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL625951,0,Autocuration,9347.0,,22224,
13171,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,1,U,,,,,,,,,BAO_0000218,CHEMBL625952,0,Autocuration,,,22224,
13172,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,1,U,,,,,,,,,BAO_0000218,CHEMBL625953,0,Autocuration,,,22224,
13173,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,1,U,,,,,,,,,BAO_0000218,CHEMBL625954,0,Autocuration,,,22224,
13174,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,1,U,,,,,,,,,BAO_0000218,CHEMBL882959,0,Autocuration,,,22224,
13175,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625955,1,Intermediate,9615.0,,50588,
13176,Bioavailability in ferret,1,U,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL625956,0,Autocuration,9669.0,,22224,
13177,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL625957,1,Intermediate,9541.0,,100710,
13178,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625958,1,Intermediate,10116.0,,50597,
13179,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625959,1,Intermediate,10116.0,,50597,
13180,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626642,1,Intermediate,10116.0,,50597,
13181,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631330,1,Intermediate,10116.0,,50597,
13182,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631331,1,Intermediate,10116.0,,50597,
13183,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631332,1,Intermediate,10116.0,,50597,
13184,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631333,1,Intermediate,10116.0,,50597,
13185,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632018,1,Intermediate,10116.0,,50597,
13186,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632019,1,Intermediate,10116.0,,50597,
13187,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632020,1,Intermediate,10116.0,,50597,
13188,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632021,1,Intermediate,10116.0,,50597,
13189,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632022,1,Intermediate,10116.0,,50597,
13190,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632023,1,Intermediate,10116.0,,50597,
13191,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632024,1,Intermediate,10116.0,,50597,
13192,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874472,1,Intermediate,10116.0,,50597,
13193,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632025,1,Intermediate,10116.0,,50597,
13194,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632026,1,Intermediate,10116.0,,50597,
13195,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632027,1,Intermediate,10116.0,,50597,
13196,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632028,1,Intermediate,10116.0,,50597,
13197,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626430,1,Intermediate,10116.0,,50597,
13198,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626431,1,Intermediate,10116.0,,50597,
13199,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626432,1,Intermediate,10116.0,,50597,
13200,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626433,1,Intermediate,10116.0,,50597,
13201,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626434,1,Intermediate,10116.0,,50597,
13202,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627280,1,Intermediate,10116.0,,50597,
13203,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627281,1,Intermediate,10116.0,,50597,
13204,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627282,1,Intermediate,10116.0,,50597,
13205,Total body clearance was measured at given dose,1,U,,,,,,,,,BAO_0000019,CHEMBL627283,0,Autocuration,,,22224,
13206,Total body clearance was measured at given dose.,1,U,,,,,,,,,BAO_0000218,CHEMBL627284,0,Autocuration,,,22224,
13207,Metabolic clearance from the body in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627285,1,Intermediate,10116.0,,50597,
13208,Renal clearance from the body,1,U,,,,,,,,,BAO_0000218,CHEMBL627286,0,Autocuration,,,22224,
13209,Renal clearance from the body in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875477,1,Intermediate,10116.0,,50597,
13210,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627287,1,Intermediate,10116.0,,50597,
13211,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL627288,1,Intermediate,9615.0,,50588,
13212,Total clearance from the body in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627289,1,Intermediate,10116.0,,50597,
13213,Clearance into cortex from rat plasma or PBS,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627290,1,Intermediate,10116.0,,50597,
13214,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,1,U,,,,,,,,,BAO_0000218,CHEMBL627291,0,Autocuration,,,22224,
13215,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,1,U,,,,,,,,,BAO_0000218,CHEMBL627292,0,Autocuration,,,22224,
13216,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,1,U,,,,,,,,,BAO_0000218,CHEMBL627293,0,Autocuration,,,22224,
13217,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,U,,,,,,,,,BAO_0000218,CHEMBL627294,0,Autocuration,,,22224,
13218,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,1,U,,,,,,,,,BAO_0000218,CHEMBL875478,0,Autocuration,,,22224,
13219,Clearance was determined,1,U,,,,,,,,,BAO_0000218,CHEMBL627295,0,Autocuration,,,22224,
13220,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627296,1,Intermediate,10090.0,,50594,
13221,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,1,N,,Oryctolagus cuniculus,,,,,,,BAO_0000218,CHEMBL626119,1,Intermediate,9986.0,,50592,
13222,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626120,1,Intermediate,10116.0,,50597,
13223,Clearance in rat after iv dose (100 ug/kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626121,1,Intermediate,10116.0,,50597,
13224,Clearance in guinea pig,1,U,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL626122,0,Autocuration,10141.0,,22224,
13225,Compound was evaluated for clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626123,1,Intermediate,10116.0,,50597,
13226,Compound was evaluated for the clearance in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL623456,1,Intermediate,9615.0,,50588,
13227,Compound was evaluated for the clearance in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623457,1,Intermediate,10116.0,,50597,
13228,Compound was tested in vivo for clearance after iv administration in the rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623458,1,Intermediate,10116.0,,50597,
13229,IV clearance determined at an iv dose of 14 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL623459,0,Autocuration,,,22224,
13230,IV clearance determined at an iv dose of 15.2 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL875484,0,Autocuration,,,22224,
13231,IV clearance determined at an iv dose of 15 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL623460,0,Autocuration,,,22224,
13232,IV clearance determined at an peroral dose of 30 mg/kg.,1,U,,,,,,,,,BAO_0000218,CHEMBL623461,0,Autocuration,,,22224,
13233,IV clearance determined at an peroral dose of 30.2 mg/kg.,1,U,,,,,,,,,BAO_0000218,CHEMBL623462,0,Autocuration,,,22224,
13234,IV clearance determined at an peroral dose of 30.3 mg/kg.,1,U,,,,,,,,,BAO_0000218,CHEMBL627386,0,Autocuration,,,22224,
13235,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627387,1,Intermediate,10116.0,,50597,
13236,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627388,1,Intermediate,10116.0,,50597,
13237,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627389,1,Intermediate,10116.0,,50597,
13238,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627390,1,Intermediate,10116.0,,50597,
13239,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627391,1,Intermediate,10116.0,,50597,
13240,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627392,1,Intermediate,10116.0,,50597,
13241,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627393,1,Intermediate,10116.0,,50597,
13242,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,1,N,,Rattus norvegicus,,,,Trachea,,3126.0,BAO_0000218,CHEMBL627394,1,Intermediate,10116.0,,50597,
13243,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627395,1,Intermediate,10116.0,,50597,
13244,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL875485,1,Intermediate,10116.0,,50597,
13245,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627396,1,Intermediate,10116.0,,50597,
13246,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627397,1,Intermediate,10116.0,,50597,
13247,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL627398,1,Intermediate,10116.0,,50597,
13248,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL627399,1,Intermediate,10116.0,,50597,
13249,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627400,1,Intermediate,10116.0,,50597,
13250,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627401,1,Intermediate,10116.0,,50597,
13251,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627402,1,Intermediate,10116.0,,50597,
13252,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627403,1,Intermediate,10116.0,,50597,
13253,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL627404,1,Intermediate,10116.0,,50597,
13254,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623101,1,Intermediate,10116.0,,50597,
13255,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL877480,1,Intermediate,10116.0,,50597,
13256,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,1,N,,Rattus norvegicus,,,,Trachea,,3126.0,BAO_0000218,CHEMBL623102,1,Intermediate,10116.0,,50597,
13257,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL623103,1,Intermediate,10116.0,,50597,
13258,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL623104,1,Intermediate,10116.0,,50597,
13259,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623105,1,Intermediate,10116.0,,50597,
13260,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623106,1,Intermediate,10116.0,,50597,
13261,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL623107,1,Intermediate,10116.0,,50597,
13262,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL623108,1,Intermediate,10116.0,,50597,
13263,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL623109,1,Intermediate,10116.0,,50597,
13264,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL623110,1,Intermediate,10116.0,,50597,
13265,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL623111,1,Intermediate,10116.0,,50597,
13266,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625060,1,Intermediate,10116.0,,50597,
13267,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625061,1,Intermediate,10116.0,,50597,
13268,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625062,1,Intermediate,10116.0,,50597,
13269,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625063,1,Intermediate,10116.0,,50597,
13270,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,1,N,,Rattus norvegicus,,,,Trachea,,3126.0,BAO_0000218,CHEMBL625064,1,Intermediate,10116.0,,50597,
13271,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,1,N,,Rattus norvegicus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL625065,1,Intermediate,10116.0,,50597,
13272,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL625066,1,Intermediate,10116.0,,50597,
13273,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625067,1,Intermediate,10116.0,,50597,
13274,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625068,1,Intermediate,10116.0,,50597,
13275,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL622159,1,Intermediate,10116.0,,50597,
13276,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,1,N,,Rattus norvegicus,,,,Intestine,,160.0,BAO_0000218,CHEMBL622160,1,Intermediate,10116.0,,50597,
13277,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL622161,1,Intermediate,10116.0,,50597,
13278,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL622162,1,Intermediate,10116.0,,50597,
13279,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL622163,1,Intermediate,10116.0,,50597,
13280,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622313,1,Intermediate,10116.0,,50597,
13281,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622314,1,Intermediate,10116.0,,50597,
13282,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622315,1,Intermediate,10116.0,,50597,
13283,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,1,N,,Rattus norvegicus,,,,Trachea,,3126.0,BAO_0000218,CHEMBL622316,1,Intermediate,10116.0,,50597,
13284,Normal diffusion coefficient in water for Escherichia coli,1,N,,Escherichia coli,,,,,,,BAO_0000218,CHEMBL877486,1,Intermediate,562.0,,50212,
13285,Average max percent decrease in RVR (renal vascular resistance) was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL622317,0,Autocuration,,,22224,
13286,Average max percent decrease in RVR (renal vascular resistance) was determined.,1,U,,,,,,,,,BAO_0000019,CHEMBL622318,0,Autocuration,,,22224,
13287,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL622319,0,Autocuration,,,22224,
13288,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL622320,0,Autocuration,,,22224,
13289,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL622321,0,Autocuration,,,22224,
13290,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL622322,0,Autocuration,,,22224,
13291,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,1,U,,,,,,,,,BAO_0000019,CHEMBL622323,0,Autocuration,,,22224,
13292,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622324,1,Intermediate,10116.0,,50597,
13293,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622325,1,Intermediate,9615.0,,50588,
13294,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622326,1,Intermediate,9615.0,,50588,
13295,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL877487,1,Intermediate,9615.0,,50588,
13296,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622327,1,Intermediate,9615.0,,50588,
13297,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622328,1,Intermediate,9615.0,,50588,
13298,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622329,1,Intermediate,9615.0,,50588,
13299,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622330,1,Intermediate,9615.0,,50588,
13300,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622331,1,Intermediate,9615.0,,50588,
13301,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622332,1,Intermediate,9615.0,,50588,
13302,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622333,1,Intermediate,9615.0,,50588,
13303,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL627658,0,Autocuration,314293.0,,22224,
13304,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL630428,0,Autocuration,314293.0,,22224,
13305,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL630429,0,Autocuration,314293.0,,22224,
13306,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL630430,0,Autocuration,314293.0,,22224,
13307,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL630431,0,Autocuration,314293.0,,22224,
13308,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630432,1,Intermediate,10116.0,,50597,
13309,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630433,1,Intermediate,10116.0,,50597,
13310,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630434,1,Intermediate,10116.0,,50597,
13311,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629372,1,Intermediate,10116.0,,50597,
13312,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629553,1,Intermediate,10116.0,,50597,
13313,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629554,1,Intermediate,10116.0,,50597,
13314,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874447,1,Intermediate,10116.0,,50597,
13315,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629555,1,Intermediate,10116.0,,50597,
13316,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629556,1,Intermediate,10116.0,,50597,
13317,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629557,1,Intermediate,10116.0,,50597,
13318,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629558,1,Intermediate,10116.0,,50597,
13319,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629559,1,Intermediate,10116.0,,50597,
13320,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629560,1,Intermediate,10116.0,,50597,
13321,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629561,1,Intermediate,9615.0,,50588,
13322,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629562,1,Intermediate,9615.0,,50588,
13323,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629563,1,Intermediate,9615.0,,50588,
13324,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629564,1,Intermediate,9615.0,,50588,
13325,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629565,1,Intermediate,9615.0,,50588,
13326,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629566,1,Intermediate,9615.0,,50588,
13327,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629567,1,Intermediate,9615.0,,50588,
13328,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629568,1,Intermediate,9615.0,,50588,
13329,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629569,1,Intermediate,9615.0,,50588,
13330,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL629570,1,Intermediate,9615.0,,50588,
13331,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL629571,0,Autocuration,314293.0,,22224,
13332,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629572,0,Autocuration,10116.0,,22224,
13333,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629573,0,Autocuration,10116.0,,22224,
13334,Bioavailability (dose 20 mg/kg),1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL629574,0,Autocuration,9347.0,,22224,
13335,Bioavailability in dog,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629575,0,Autocuration,9615.0,,22224,
13336,Bioavailability in rat (Sprague-Dawley) (male),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874448,0,Autocuration,10116.0,,22224,
13337,Bioavailability in monkey (dose 10 mg/kg i.d.),1,U,,Primates,,,,,,,BAO_0000218,CHEMBL629576,0,Autocuration,9443.0,,22224,
13338,Bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629577,0,Autocuration,10116.0,,22224,
13339,Bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629578,0,Autocuration,10116.0,,22224,
13340,Bioavailability in dog (dose 3.0 mg/kg p.o.),1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629579,0,Autocuration,9615.0,,22224,
13341,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL882958,0,Autocuration,9615.0,,22224,
13342,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,1,N,,Pan troglodytes,,,,,,,BAO_0000218,CHEMBL629580,1,Intermediate,9598.0,,50505,
13343,Bioavailability,1,U,,Eutheria,,,,,,,BAO_0000218,CHEMBL629581,0,Autocuration,9347.0,,22224,
13344,Bioavailability in squirrel monkey,1,U,,Saimiri,,,,,,,BAO_0000218,CHEMBL629582,0,Autocuration,9520.0,,22224,
13345,Bioavailability was evaluated in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628522,1,Intermediate,9615.0,,50588,
13346,Bioavailability was evaluated in hamster,1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL625432,1,Intermediate,10026.0,,100712,
13347,Bioavailability in rat,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625433,0,Autocuration,10116.0,,22224,
13348,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625434,1,Intermediate,10116.0,,50597,
13349,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL625435,1,Intermediate,10116.0,,50597,
13350,Bioavailability in rat (dose 10 mg/kg p.o.),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625436,0,Autocuration,10116.0,,22224,
13351,Bioavailability was measured in cynomolgus monkeys.,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL874588,1,Intermediate,9541.0,,100710,
13352,Bioavailability was measured in nude mice.,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625437,1,Intermediate,10090.0,,50594,
13353,Bioavailability in ferret (dose 10 mg/kg i.d.),1,U,,Mustela putorius furo,,,,,,,BAO_0000218,CHEMBL625438,0,Autocuration,9669.0,,22224,
13354,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625439,0,Autocuration,314293.0,,22224,
13355,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625440,0,Autocuration,314293.0,,22224,
13356,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),1,U,,Simiiformes,,,,,,,BAO_0000218,CHEMBL625441,0,Autocuration,314293.0,,22224,
13357,Bioavailability in rat (dose 10 mg/kg i.d.),1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625442,0,Autocuration,10116.0,,22224,
13358,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625443,1,Intermediate,10116.0,,50597,
13359,Bioavailability was determined; extremely poor,1,U,,,,,,,,,BAO_0000218,CHEMBL625444,0,Autocuration,,,22224,
13360,% bioavailability in mice after oral administration of prodrug,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625445,1,Intermediate,10090.0,,50594,
13361,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625446,1,Intermediate,9615.0,,50588,
13362,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL882960,1,Intermediate,9615.0,,50588,
13363,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625447,1,Intermediate,9615.0,,50588,
13364,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625448,1,Intermediate,9615.0,,50588,
13365,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625449,1,Intermediate,9615.0,,50588,
13366,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL874589,1,Intermediate,9615.0,,50588,
13367,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625450,1,Intermediate,9615.0,,50588,
13368,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625451,1,Intermediate,9615.0,,50588,
13369,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626584,1,Intermediate,9615.0,,50588,
13370,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626585,1,Intermediate,9615.0,,50588,
13371,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626586,1,Intermediate,9615.0,,50588,
13372,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626587,1,Intermediate,9615.0,,50588,
13373,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626588,1,Intermediate,9615.0,,50588,
13374,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626589,1,Intermediate,9615.0,,50588,
13375,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626590,1,Intermediate,9615.0,,50588,
13376,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626591,1,Intermediate,9615.0,,50588,
13377,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL627181,1,Intermediate,9615.0,,50588,
13378,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628083,1,Intermediate,9615.0,,50588,
13379,IV clearance determined at an peroral dose of 15 mg/kg.,1,U,,,,,,,,,BAO_0000218,CHEMBL628084,0,Autocuration,,,22224,
13380,Mouse oral clearance was measured against Hymenolepiasis nana.,1,N,,Hymenolepis nana,,,,,,,BAO_0000218,CHEMBL628085,1,Expert,102285.0,,50064,
13381,Mouse oral clearance was measured against Nematospiroides dubius,1,N,,Heligmosomoides polygyrus,,,,,,,BAO_0000218,CHEMBL628086,1,Expert,6339.0,,50545,
13382,Mouse oral clearance was measured against N. dubius; NT is Not Tested,1,U,,,,,,,,,BAO_0000218,CHEMBL628087,0,Autocuration,,,22224,
13383,Mouse oral clearance was measured against N. nana; NT is Not Tested,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628088,1,Intermediate,10090.0,,50594,
13384,Mouse oral clearance was measured against N. nana; NT is Not Tested,1,U,,,,,,,,,BAO_0000218,CHEMBL628089,0,Autocuration,,,22224,
13385,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL628090,0,Autocuration,,,22224,
13386,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL628091,0,Autocuration,,,22224,
13387,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL628092,0,Autocuration,,,22224,
13388,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL628093,0,Autocuration,,,22224,
13389,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL875607,0,Autocuration,,,22224,
13390,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL625710,0,Autocuration,,,22224,
13391,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL625711,0,Autocuration,,,22224,
13392,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL625712,0,Autocuration,,,22224,
13393,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,1,U,,,,,,,,,BAO_0000218,CHEMBL625713,0,Autocuration,,,22224,
13394,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625714,1,Intermediate,9615.0,,50588,
13395,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL625715,1,Intermediate,9544.0,,50797,
13396,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625716,1,Intermediate,10116.0,,50597,
13397,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625717,1,Intermediate,10116.0,,50597,
13398,Plasma clearance was determined for the compound in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625718,1,Intermediate,10116.0,,50597,
13399,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625719,1,Intermediate,10116.0,,50597,
13400,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625720,1,Intermediate,10116.0,,50597,
13401,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625721,1,Intermediate,10116.0,,50597,
13402,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625722,1,Intermediate,10116.0,,50597,
13403,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625723,1,Intermediate,10116.0,,50597,
13404,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,1,N,,Heligmosomoides polygyrus,,,,,,,BAO_0000218,CHEMBL625724,1,Intermediate,6339.0,,50545,
13405,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,1,N,,Heligmosomoides polygyrus,,,,,,,BAO_0000218,CHEMBL625725,1,Intermediate,6339.0,,50545,
13406,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,1,N,,Heligmosomoides polygyrus,,,,,,,BAO_0000218,CHEMBL625726,1,Intermediate,6339.0,,50545,
13407,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,1,N,,Heligmosomoides polygyrus,,,,,,,BAO_0000218,CHEMBL875608,1,Intermediate,6339.0,,50545,
13408,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,1,N,,Heligmosomoides polygyrus,,,,,,,BAO_0000218,CHEMBL625727,1,Intermediate,6339.0,,50545,
13409,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,1,U,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625728,0,Autocuration,10116.0,,22224,
13410,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625729,0,Autocuration,10116.0,,22224,
13411,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625730,0,Autocuration,10116.0,,22224,
13412,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1,U,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625731,0,Autocuration,10116.0,,22224,
13413,Urinary clearance was determined in rat at 25 mg/kg os dosage,1,U,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626417,0,Autocuration,10116.0,,22224,
13414,Urinary clearance was determined at 100 mg/kg oral dosage in human,1,N,,Homo sapiens,,,,Urine,,1088.0,BAO_0000218,CHEMBL626418,1,Intermediate,9606.0,,50587,
13415,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL626419,1,Intermediate,9615.0,,50588,
13416,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626592,1,Intermediate,9615.0,,50588,
13417,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626593,1,Intermediate,10116.0,,50597,
13418,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626594,1,Intermediate,10116.0,,50597,
13419,Clearance rate in dogs,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625035,1,Intermediate,9615.0,,50588,
13420,Compound was measured for intrinsic clearance,1,U,,,,,,,,,BAO_0000019,CHEMBL625036,0,Autocuration,,,22224,
13421,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625037,0,Autocuration,,,22229,
13422,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625038,0,Autocuration,,,22229,
13423,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625039,0,Autocuration,,,22229,
13424,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625040,0,Autocuration,,,22229,
13425,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625041,0,Autocuration,,,22229,
13426,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625042,0,Autocuration,,,22229,
13427,Partition coefficient of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL874411,0,Autocuration,,,22224,
13428,Permeability,1,U,,,,,,,,,BAO_0000019,CHEMBL625043,0,Autocuration,,,22224,
13429,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625044,0,Autocuration,,,22229,
13430,Partition coefficient (logD),1,U,,,,,,,,,BAO_0000019,CHEMBL625045,0,Autocuration,,,22224,
13431,Calculated partition coefficient (clogP) (CLOGP3 V3.4),1,U,,,,,,,,,BAO_0000100,CHEMBL625046,0,Autocuration,,,22229,
13432,Calculated partition coefficient (clogP) (CLOGP3 V3.4),1,U,,,,,,,,,BAO_0000100,CHEMBL625047,0,Autocuration,,,22229,
13433,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625048,0,Autocuration,,,22229,
13434,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625049,0,Autocuration,,,22229,
13435,Calculated logarithm of partition coefficient (P) was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL625050,0,Autocuration,,,22229,
13436,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625051,0,Autocuration,,,22229,
13437,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL874412,0,Autocuration,,,22229,
13438,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625052,0,Autocuration,,,22229,
13439,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL625053,0,Autocuration,,,22229,
13440,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL623250,0,Autocuration,,,22224,
13441,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL623251,0,Autocuration,,,22224,
13442,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL623252,0,Autocuration,,,22224,
13443,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL623253,0,Autocuration,,,22224,
13444,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL623254,0,Autocuration,,,22224,
13445,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,1,U,,,,,,,,,BAO_0000019,CHEMBL623255,0,Autocuration,,,22224,
13446,Percent degradation of compound at a pH of 1 over a 18 hr period,1,U,,,,,,,,,BAO_0000019,CHEMBL626831,0,Autocuration,,,22224,
13447,Percent degradation of compound at pH of 1 over an 18 hr period,1,U,,,,,,,,,BAO_0000019,CHEMBL877494,0,Autocuration,,,22224,
13448,Delta Logarithm of Partition Coefficient value was determined.,1,U,,,,,,,,,BAO_0000019,CHEMBL626832,0,Autocuration,,,22224,
13449,Delta logPoct-cyc,1,U,,,,,,,,,BAO_0000019,CHEMBL626833,0,Autocuration,,,22224,
13450,Lipophilicity estimated on reversed phase TLC,1,U,,,,,,,,,BAO_0000100,CHEMBL626834,0,Autocuration,,,22224,
13451,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,1,U,,,,,,,,,BAO_0000019,CHEMBL626835,0,Autocuration,,,22224,
13452,Delta logPoct-cyc,1,U,,,,,,,,,BAO_0000019,CHEMBL626836,0,Autocuration,,,22224,
13453,Change in logarithm of partition coefficient of the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL626837,0,Autocuration,,,22229,
13454,Delta logD (pH 6.5),1,U,,,,,,,,,BAO_0000019,CHEMBL626838,0,Autocuration,,,22224,
13455,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",1,U,,,,,,,,,BAO_0000100,CHEMBL626839,0,Autocuration,,,22224,
13456,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,1,U,,,,,,,,,BAO_0000019,CHEMBL626840,0,Autocuration,,,22224,
13457,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),1,U,,,,,,,,,BAO_0000019,CHEMBL626841,0,Autocuration,,,22224,
13458,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,1,U,,,,,,,,,BAO_0000219,CHEMBL626842,0,Autocuration,,,22224,
13459,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,1,U,,,,,,,,,BAO_0000219,CHEMBL626843,0,Autocuration,,,22224,
13460,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626844,1,Intermediate,10116.0,,50597,
13461,Amount of deuterium retained was reported after normal workup in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL877495,1,Intermediate,10116.0,,50597,
13462,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626845,1,Intermediate,10116.0,,50597,
13463,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626846,1,Intermediate,10116.0,,50597,
13464,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626847,1,Intermediate,10116.0,,50597,
13465,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628677,1,Intermediate,10116.0,,50597,
13466,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628678,1,Intermediate,10116.0,,50597,
13467,Compound was subjected to electrochemical oxidation,1,U,,,,,,,,,BAO_0000019,CHEMBL628679,0,Autocuration,,,22224,
13468,Compound was subjected to photochemical oxidation,1,U,,,,,,,,,BAO_0000019,CHEMBL628680,0,Autocuration,,,22224,
13469,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,1,U,,,,,,,,,BAO_0000019,CHEMBL628681,0,Autocuration,,,22224,
13470,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,1,U,,,,,,,,,BAO_0000019,CHEMBL628682,0,Autocuration,,,22224,
13471,Oxidation of compound by methemoglobin in presence of hydroperoxide,1,U,,,,,,,,,BAO_0000019,CHEMBL628683,0,Autocuration,,,22224,
13472,Percent diffusion through fuzzy rat skin after 48 h of incubation,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628684,1,Intermediate,10116.0,,50597,
13473,Dissociation constant (pKa),1,U,,,,,,,,,BAO_0000100,CHEMBL877501,0,Autocuration,,,22229,
13474,Dissociation constant value of the compound; ND means not determined.,1,U,,,,,,,,,BAO_0000100,CHEMBL628685,0,Autocuration,,,22224,
13475,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628686,1,Intermediate,10116.0,,50597,
13476,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL628687,1,Intermediate,10116.0,,50597,
13477,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628688,1,Intermediate,10116.0,,50597,
13478,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628689,1,Intermediate,10116.0,,50597,
13479,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628690,1,Intermediate,10116.0,,50597,
13480,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL629363,1,Intermediate,10116.0,,50597,
13481,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629364,1,Intermediate,10116.0,,50597,
13482,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629365,1,Intermediate,10116.0,,50597,
13483,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629366,1,Intermediate,10116.0,,50597,
13484,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629367,1,Intermediate,10116.0,,50597,
13485,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL629368,1,Intermediate,10116.0,,50597,
13486,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL877502,1,Intermediate,10116.0,,50597,
13487,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,1,N,,Mus musculus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL629369,1,Intermediate,10090.0,,50594,
13488,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL629370,1,Intermediate,10090.0,,50594,
13489,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL629371,0,Autocuration,314293.0,,22224,
13490,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL626276,0,Autocuration,314293.0,,22224,
13491,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL626277,0,Autocuration,314293.0,,22224,
13492,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL631250,0,Autocuration,314293.0,,22224,
13493,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631251,1,Intermediate,10116.0,,50597,
13494,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631252,1,Intermediate,10116.0,,50597,
13495,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631253,1,Intermediate,10116.0,,50597,
13496,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631254,1,Intermediate,10116.0,,50597,
13497,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631255,1,Intermediate,10116.0,,50597,
13498,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631256,1,Intermediate,10116.0,,50597,
13499,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631257,1,Intermediate,10116.0,,50597,
13500,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628009,1,Intermediate,10116.0,,50597,
13501,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628010,1,Intermediate,10116.0,,50597,
13502,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628011,1,Intermediate,10116.0,,50597,
13503,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628012,1,Intermediate,10116.0,,50597,
13504,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628013,1,Intermediate,10116.0,,50597,
13505,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628014,1,Intermediate,10116.0,,50597,
13506,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628015,1,Intermediate,9615.0,,50588,
13507,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628016,1,Intermediate,9615.0,,50588,
13508,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL874461,1,Intermediate,9615.0,,50588,
13509,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628017,1,Intermediate,9615.0,,50588,
13510,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628018,1,Intermediate,9615.0,,50588,
13511,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628019,1,Intermediate,9615.0,,50588,
13512,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628020,1,Intermediate,9615.0,,50588,
13513,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628021,1,Intermediate,9615.0,,50588,
13514,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628022,1,Intermediate,9615.0,,50588,
13515,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL628023,1,Intermediate,9615.0,,50588,
13516,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL628024,0,Autocuration,314293.0,,22224,
13517,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL628025,0,Autocuration,314293.0,,22224,
13518,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL628026,0,Autocuration,314293.0,,22224,
13519,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL628027,0,Autocuration,314293.0,,22224,
13520,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1,U,,Simiiformes,,,,Urine,,1088.0,BAO_0000218,CHEMBL628028,0,Autocuration,314293.0,,22224,
13521,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628029,1,Intermediate,10116.0,,50597,
13522,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628030,1,Intermediate,10116.0,,50597,
13523,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628031,1,Intermediate,10116.0,,50597,
13524,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628032,1,Intermediate,10116.0,,50597,
13525,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628033,1,Intermediate,10116.0,,50597,
13526,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628034,1,Intermediate,10116.0,,50597,
13527,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628035,1,Intermediate,10116.0,,50597,
13528,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628036,1,Intermediate,10116.0,,50597,
13529,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874462,1,Intermediate,10116.0,,50597,
13530,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628037,1,Intermediate,9615.0,,50588,
13531,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628123,1,Intermediate,9615.0,,50588,
13532,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628124,1,Intermediate,9615.0,,50588,
13533,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628125,1,Intermediate,9615.0,,50588,
13534,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628126,1,Intermediate,9615.0,,50588,
13535,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628127,1,Intermediate,9615.0,,50588,
13536,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628128,1,Intermediate,9615.0,,50588,
13537,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628129,1,Intermediate,9615.0,,50588,
13538,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628130,1,Intermediate,9615.0,,50588,
13539,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628131,1,Intermediate,9615.0,,50588,
13540,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628132,1,Intermediate,9615.0,,50588,
13541,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628133,1,Intermediate,9615.0,,50588,
13542,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628134,1,Intermediate,9615.0,,50588,
13543,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628135,1,Intermediate,9615.0,,50588,
13544,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628136,1,Intermediate,9615.0,,50588,
13545,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628137,1,Intermediate,9615.0,,50588,
13546,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628138,1,Intermediate,9615.0,,50588,
13547,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628139,1,Intermediate,9615.0,,50588,
13548,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628140,1,Intermediate,9615.0,,50588,
13549,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628141,1,Intermediate,9615.0,,50588,
13550,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628142,1,Intermediate,9615.0,,50588,
13551,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628143,1,Intermediate,9615.0,,50588,
13552,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628144,1,Intermediate,9615.0,,50588,
13553,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628145,1,Intermediate,9615.0,,50588,
13554,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL628146,1,Intermediate,9615.0,,50588,
13555,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625355,1,Intermediate,9615.0,,50588,
13556,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625356,1,Intermediate,9615.0,,50588,
13557,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625357,1,Intermediate,9615.0,,50588,
13558,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625527,1,Intermediate,9615.0,,50588,
13559,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875473,1,Intermediate,9615.0,,50588,
13560,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL625528,1,Intermediate,9615.0,,50588,
13561,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626304,1,Intermediate,10116.0,,50597,
13562,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1,N,,Canis lupus familiaris,,,,Artery,,1637.0,BAO_0000218,CHEMBL624138,1,Intermediate,9615.0,,50588,
13563,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624139,0,Autocuration,,,22229,
13564,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624140,0,Autocuration,,,22229,
13565,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624141,0,Autocuration,,,22229,
13566,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624142,0,Autocuration,,,22229,
13567,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624143,0,Autocuration,,,22229,
13568,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624144,0,Autocuration,,,22229,
13569,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624145,0,Autocuration,,,22229,
13570,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624146,0,Autocuration,,,22229,
13571,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624147,0,Autocuration,,,22229,
13572,Calculated partition coefficient (clogP) (MacLogP),1,U,,,,,,,,,BAO_0000100,CHEMBL883123,0,Autocuration,,,22229,
13573,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL624148,0,Autocuration,,,22224,
13574,Kinetic parameter was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL874416,0,Autocuration,,,22224,
13575,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624149,0,Autocuration,,,22229,
13576,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL624150,0,Autocuration,,,22229,
13577,Lipophilicity was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL624151,0,Autocuration,,,22224,
13578,Lipophilicity was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL624152,0,Autocuration,,,22224,
13579,Lipophilicity was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL622139,0,Autocuration,,,22224,
13580,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL622140,0,Autocuration,,,22229,
13581,Lipophilicity was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL622141,0,Autocuration,,,22224,
13582,Lipophilicity in octanol-water,1,U,,,,,,,,,BAO_0000100,CHEMBL622142,0,Autocuration,,,22224,
13583,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL622143,0,Autocuration,,,22229,
13584,Octanol-water partition coefficient was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL622144,0,Autocuration,,,22229,
13585,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL877473,0,Autocuration,,,22224,
13586,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL622145,0,Autocuration,,,22229,
13587,Partition coefficient was determined; ND means not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL622146,0,Autocuration,,,22224,
13588,Calculated partition coefficient (clogP),1,U,,,,,,,,,BAO_0000100,CHEMBL622147,0,Autocuration,,,22229,
13589,Partition coefficient of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL622148,0,Autocuration,,,22224,
13590,Permeability was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL883124,0,Autocuration,,,22224,
13591,The compound was evaluated for the partition coefficient,1,U,,,,,,,,,BAO_0000100,CHEMBL622149,0,Autocuration,,,22229,
13592,Partition coefficient (logP),1,U,,,,,,,,,BAO_0000019,CHEMBL622150,0,Autocuration,,,22224,
13593,The lipophilicity was reported,1,U,,,,,,,,,BAO_0000100,CHEMBL622151,0,Autocuration,,,22224,
13594,logarithm of the octanol-water partition coefficient for the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL622152,0,Autocuration,,,22229,
13595,Clogp value was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL622153,0,Autocuration,,,22224,
13596,Clp at a dose of 1.5 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL877474,0,Autocuration,,,22224,
13597,Clp at a dose of 2.0 mg/kg,1,U,,,,,,,,,BAO_0000218,CHEMBL622154,0,Autocuration,,,22224,
13598,"Clp, plasma clearance at a dose of 10 mg/kg",1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622155,0,Autocuration,,,22224,
13599,"Clp, plasma clearance at a dose of 50 mg/kg",1,U,,,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622156,0,Autocuration,,,22224,
13600,Compound was tested for plasma clearance in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622157,1,Intermediate,10116.0,,50597,
13601,Compound was tested for plasma clearance in rat; Not determined,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622158,1,Intermediate,10116.0,,50597,
13602,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622807,1,Intermediate,10116.0,,50597,
13603,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL622808,1,Intermediate,9544.0,,50797,
13604,Plasma clearance by iv administration at a dose 0.003 ug/mL,1,U,,,,,,,,,BAO_0000218,CHEMBL622809,0,Autocuration,,,22224,
13605,Plasma clearance determined,1,U,,,,,,,,,BAO_0000218,CHEMBL622810,0,Autocuration,,,22224,
13606,Plasma clearance after iv administration at 3 mg/kg in hamster,1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL876653,1,Intermediate,10026.0,,100712,
13607,Plasma clearance after iv administration at 4 mg/kg in hamster,1,N,,Cricetinae,,,,,,,BAO_0000218,CHEMBL622811,1,Intermediate,10026.0,,100712,
13608,Rate of clearance in rat was determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622986,1,Intermediate,10116.0,,50597,
13609,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622987,1,Intermediate,10116.0,,50597,
13610,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622988,1,Intermediate,10116.0,,50597,
13611,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622989,1,Intermediate,10116.0,,50597,
13612,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622990,1,Intermediate,10116.0,,50597,
13613,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1,U,,Simiiformes,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622991,0,Autocuration,314293.0,,22224,
13614,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622227,1,Intermediate,10116.0,,50597,
13615,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL622228,1,Intermediate,9615.0,,50588,
13616,Clpl value in rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622229,1,Intermediate,10116.0,,50597,
13617,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,1,N,,Cavia porcellus,,,,,,,BAO_0000218,CHEMBL622230,1,Intermediate,10141.0,,50512,
13618,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL622231,1,Intermediate,10116.0,,50597,
13619,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,1,N,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL622232,1,Intermediate,9541.0,,100710,
13620,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622233,0,Autocuration,,,22224,
13621,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622234,0,Autocuration,,,22224,
13622,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622235,0,Autocuration,,,22224,
13623,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622236,0,Autocuration,,,22224,
13624,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622237,0,Autocuration,,,22224,
13625,Cmax in minutes at a po dose of 10.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL877482,0,Autocuration,,,22224,
13626,Cmax in minutes at a po dose of 20.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622238,0,Autocuration,,,22224,
13627,Cmax in minutes at a po dose of 40.0(pmol/g/h).,1,U,,,,,,,,,BAO_0000218,CHEMBL622239,0,Autocuration,,,22224,
13628,Cmax was calculated as maximum concentration reached in the blood,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL622240,0,Autocuration,,,22224,
13629,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL622241,0,Autocuration,,,22224,
13630,Cmax was determine after peroral administration at 10 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631013,1,Intermediate,10116.0,,50597,
13631,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,N,,Macaca mulatta,,,,,,,BAO_0000218,CHEMBL631014,1,Intermediate,9544.0,,50797,
13632,Cmax was determine after peroral administration at 10 mpk in dog,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631015,1,Intermediate,9615.0,,50588,
13633,Cmax was determine after peroral administration at 160 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631016,1,Intermediate,10116.0,,50597,
13634,Cmax was determine after peroral administration at 20 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631017,1,Intermediate,10116.0,,50597,
13635,Cmax was determine after peroral administration at 50 mpk in Rat,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631018,1,Intermediate,10116.0,,50597,
13636,Cmax was determined,1,U,,,,,,,,,BAO_0000218,CHEMBL631019,0,Autocuration,,,22224,
13637,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL875761,1,Intermediate,10090.0,,50594,
13638,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL631020,1,Intermediate,10090.0,,50594,
13639,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL631669,1,Intermediate,10090.0,,50594,
13640,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL631670,1,Intermediate,10090.0,,50594,
13641,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,1,N,,Mus musculus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL631671,1,Intermediate,10090.0,,50594,
13642,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631672,1,Intermediate,10116.0,,50597,
13643,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631673,1,Intermediate,10116.0,,50597,
13644,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631856,1,Intermediate,10116.0,,50597,
13645,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631857,1,Intermediate,10116.0,,50597,
13646,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631858,1,Intermediate,10116.0,,50597,
13647,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631859,1,Intermediate,10116.0,,50597,
13648,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631860,1,Intermediate,10116.0,,50597,
13649,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631861,1,Intermediate,10116.0,,50597,
13650,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631862,1,Intermediate,10116.0,,50597,
13651,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631863,1,Intermediate,10116.0,,50597,
13652,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631864,1,Intermediate,10116.0,,50597,
13653,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631865,1,Intermediate,10116.0,,50597,
13654,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631866,1,Intermediate,10116.0,,50597,
13655,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629360,1,Intermediate,10116.0,,50597,
13656,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629361,1,Intermediate,10116.0,,50597,
13657,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL629362,1,Intermediate,10116.0,,50597,
13658,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630740,1,Intermediate,10116.0,,50597,
13659,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630741,1,Intermediate,10116.0,,50597,
13660,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630742,1,Intermediate,10116.0,,50597,
13661,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630743,1,Intermediate,10116.0,,50597,
13662,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630744,1,Intermediate,10116.0,,50597,
13663,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630745,1,Intermediate,10116.0,,50597,
13664,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630746,1,Intermediate,10116.0,,50597,
13665,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630747,1,Intermediate,10116.0,,50597,
13666,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630748,1,Intermediate,10116.0,,50597,
13667,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632056,1,Intermediate,10116.0,,50597,
13668,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632057,1,Intermediate,10116.0,,50597,
13669,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632058,1,Intermediate,10116.0,,50597,
13670,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632059,1,Intermediate,10116.0,,50597,
13671,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632060,1,Intermediate,10116.0,,50597,
13672,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632061,1,Intermediate,10116.0,,50597,
13673,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629207,1,Intermediate,10116.0,,50597,
13674,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629208,1,Intermediate,10116.0,,50597,
13675,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629209,1,Intermediate,10116.0,,50597,
13676,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629210,1,Intermediate,10116.0,,50597,
13677,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629211,1,Intermediate,10116.0,,50597,
13678,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629212,1,Intermediate,10116.0,,50597,
13679,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629213,1,Intermediate,10116.0,,50597,
13680,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629214,1,Intermediate,10116.0,,50597,
13681,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629215,1,Intermediate,10116.0,,50597,
13682,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL635154,1,Intermediate,10116.0,,50597,
13683,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629216,1,Intermediate,10116.0,,50597,
13684,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629217,1,Intermediate,10116.0,,50597,
13685,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629218,1,Intermediate,10116.0,,50597,
13686,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629219,1,Intermediate,10116.0,,50597,
13687,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629220,1,Intermediate,10116.0,,50597,
13688,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629221,1,Intermediate,10116.0,,50597,
13689,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631127,1,Intermediate,10116.0,,50597,
13690,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631128,1,Intermediate,10116.0,,50597,
13691,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631129,1,Intermediate,10116.0,,50597,
13692,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631130,1,Intermediate,10116.0,,50597,
13693,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631131,1,Intermediate,10116.0,,50597,
13694,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631132,1,Intermediate,10116.0,,50597,
13695,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631133,1,Intermediate,10116.0,,50597,
13696,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631134,1,Intermediate,10116.0,,50597,
13697,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875120,1,Intermediate,10116.0,,50597,
13698,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631135,1,Intermediate,10116.0,,50597,
13699,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631136,1,Intermediate,10116.0,,50597,
13700,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631137,1,Intermediate,10116.0,,50597,
13701,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631138,1,Intermediate,10116.0,,50597,
13702,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631139,1,Intermediate,10116.0,,50597,
13703,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631140,1,Intermediate,10116.0,,50597,
13704,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631141,1,Intermediate,10116.0,,50597,
13705,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631142,1,Intermediate,10116.0,,50597,
13706,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631143,1,Intermediate,10116.0,,50597,
13707,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631144,1,Intermediate,10116.0,,50597,
13708,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631145,1,Intermediate,9615.0,,50588,
13709,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631146,1,Intermediate,9615.0,,50588,
13710,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631147,1,Intermediate,9615.0,,50588,
13711,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631148,1,Intermediate,9615.0,,50588,
13712,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631149,1,Intermediate,9615.0,,50588,
13713,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631150,1,Intermediate,9615.0,,50588,
13714,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631151,1,Intermediate,9615.0,,50588,
13715,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631152,1,Intermediate,9615.0,,50588,
13716,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631443,1,Intermediate,9615.0,,50588,
13717,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631444,1,Intermediate,9615.0,,50588,
13718,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631445,1,Intermediate,9615.0,,50588,
13719,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631446,1,Intermediate,9615.0,,50588,
13720,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631447,1,Intermediate,9615.0,,50588,
13721,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631448,1,Intermediate,9615.0,,50588,
13722,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631449,1,Intermediate,9615.0,,50588,
13723,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL631450,1,Intermediate,9615.0,,50588,
13724,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629724,1,Intermediate,9615.0,,50588,
13725,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL629725,1,Intermediate,10090.0,,50594,
13726,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL629726,1,Intermediate,10090.0,,50594,
13727,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629727,1,Intermediate,10090.0,,50594,
13728,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630404,1,Intermediate,10090.0,,50594,
13729,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630405,1,Intermediate,10090.0,,50594,
13730,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630406,1,Intermediate,10090.0,,50594,
13731,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL630407,1,Intermediate,10090.0,,50594,
13732,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL630573,1,Intermediate,10090.0,,50594,
13733,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL630574,1,Intermediate,10090.0,,50594,
13734,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL630575,1,Intermediate,10090.0,,50594,
13735,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630576,1,Intermediate,10090.0,,50594,
13736,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630577,1,Intermediate,10090.0,,50594,
13737,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630578,1,Intermediate,10090.0,,50594,
13738,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630579,1,Intermediate,10090.0,,50594,
13739,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630580,1,Intermediate,10090.0,,50594,
13740,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630581,1,Intermediate,10090.0,,50594,
13741,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630582,1,Intermediate,10090.0,,50594,
13742,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630583,1,Intermediate,10090.0,,50594,
13743,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630584,1,Intermediate,10090.0,,50594,
13744,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630585,1,Intermediate,10090.0,,50594,
13745,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630586,1,Intermediate,10090.0,,50594,
13746,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630587,1,Intermediate,10090.0,,50594,
13747,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630588,1,Intermediate,10090.0,,50594,
13748,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630589,1,Intermediate,10090.0,,50594,
13749,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL630590,1,Intermediate,10090.0,,50594,
13750,Removal of 238-Plutonium(IV) in feces at 24 h,1,U,,,,,,Feces,,1988.0,BAO_0000019,CHEMBL630591,0,Autocuration,,,22224,
13751,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),1,U,,,,,,Feces,,1988.0,BAO_0000019,CHEMBL630592,0,Autocuration,,,22224,
13752,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,1,U,,,,,,,,,BAO_0000019,CHEMBL630593,0,Autocuration,,,22224,
13753,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),1,U,,,,,,,,,BAO_0000019,CHEMBL630594,0,Autocuration,,,22224,
13754,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630595,0,Autocuration,,,22224,
13755,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630596,0,Autocuration,,,22224,
13756,Removal of 238-Plutonium(IV) in urine after 0-24 h,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630597,0,Autocuration,,,22224,
13757,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630598,0,Autocuration,,,22224,
13758,Removal of 238-Plutonium(IV) in urine after 0-4 h,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630599,0,Autocuration,,,22224,
13759,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630600,0,Autocuration,,,22224,
13760,Removal of 238-Plutonium(IV) in urine after 4-24 h,1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630601,0,Autocuration,,,22224,
13761,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630602,0,Autocuration,,,22224,
13762,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630603,0,Autocuration,,,22224,
13763,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),1,U,,,,,,Urine,,1088.0,BAO_0000019,CHEMBL630604,0,Autocuration,,,22224,
13764,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624869,1,Intermediate,10116.0,,50597,
13765,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL624870,1,Intermediate,10116.0,,50597,
13766,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623189,1,Intermediate,10116.0,,50597,
13767,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623190,1,Intermediate,10116.0,,50597,
13768,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623191,1,Intermediate,10116.0,,50597,
13769,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623192,1,Intermediate,10116.0,,50597,
13770,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623193,1,Intermediate,10116.0,,50597,
13771,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623194,1,Intermediate,10116.0,,50597,
13772,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623195,1,Intermediate,10116.0,,50597,
13773,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623196,1,Intermediate,10116.0,,50597,
13774,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623197,1,Intermediate,10116.0,,50597,
13775,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623198,1,Intermediate,10116.0,,50597,
13776,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623199,1,Intermediate,10116.0,,50597,
13777,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623200,1,Intermediate,10116.0,,50597,
13778,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623201,1,Intermediate,10116.0,,50597,
13779,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623202,1,Intermediate,10116.0,,50597,
13780,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623203,1,Intermediate,10116.0,,50597,
13781,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623204,1,Intermediate,10116.0,,50597,
13782,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623205,1,Intermediate,10116.0,,50597,
13783,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623206,1,Intermediate,10116.0,,50597,
13784,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623207,1,Intermediate,10116.0,,50597,
13785,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623208,1,Intermediate,10116.0,,50597,
13786,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623209,1,Intermediate,10116.0,,50597,
13787,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL623210,1,Intermediate,10116.0,,50597,
13788,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623211,1,Intermediate,10116.0,,50597,
13789,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL623212,1,Intermediate,10116.0,,50597,
13790,Tested in vitro for intrinsic activity relative to quinpirole,1,U,,,,,,,,,BAO_0000019,CHEMBL623213,0,Autocuration,,,22224,
13791,"Relative ion enhancement, determined in pulsed ultrafiltration",1,U,,,,,,,,,BAO_0000019,CHEMBL623214,0,Autocuration,,,22224,
13792,% ionization at the pH 7.4 at 37 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL623215,0,Autocuration,,,22224,
13793,Percentage ionization was measured,1,U,,,,,,,,,BAO_0000019,CHEMBL623216,0,Autocuration,,,22224,
13794,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,1,N,,Bos taurus,,,,,,,BAO_0000218,CHEMBL623217,1,Intermediate,9913.0,,50591,
13795,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,1,U,,,,,,,,,BAO_0000019,CHEMBL623218,0,Autocuration,,,22224,
13796,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,1,U,,,,,,,,,BAO_0000019,CHEMBL623913,0,Autocuration,,,22224,
13797,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,1,U,,,,,,,,,BAO_0000019,CHEMBL623914,0,Autocuration,,,22224,
13798,Compound was evaluated for the partition coefficient in octanol/water,1,U,,,,,,,,,BAO_0000100,CHEMBL623915,0,Autocuration,,,22229,
13799,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),1,U,,,,,,,,,BAO_0000100,CHEMBL624080,0,Autocuration,,,22229,
13800,Equilibrium constant measured by the pulse radiolysis at pH 7,1,U,,,,,,,,,BAO_0000019,CHEMBL624081,0,Autocuration,,,22224,
13801,In vitro hydrolytic rate constant determined in human blood,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL624082,1,Intermediate,9606.0,,50587,
13802,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL625054,1,Intermediate,9606.0,,50587,
13803,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,1,U,,,,,,,,,BAO_0000019,CHEMBL877485,0,Autocuration,,,22224,
13804,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625055,1,Intermediate,10090.0,,50594,
13805,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625056,1,Intermediate,10090.0,,50594,
13806,In vitro oxidation of compound in presence of human plasma,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL625057,1,Intermediate,9606.0,,50587,
13807,In vitro oxidation of compound in presence of hydrogen peroxide,1,U,,,,,,,,,BAO_0000019,CHEMBL625058,0,Autocuration,,,22224,
13808,In vitro oxidation of compound in presence of mouse brain homogenate,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625059,1,Intermediate,10090.0,,50594,
13809,In vitro oxidation of compound in presence of mouse liver homogenate,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629536,1,Intermediate,10090.0,,50594,
13810,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629537,1,Intermediate,10116.0,,50597,
13811,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629538,1,Intermediate,10116.0,,50597,
13812,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629539,1,Intermediate,10116.0,,50597,
13813,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL874445,1,Intermediate,10116.0,,50597,
13814,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629540,1,Intermediate,10116.0,,50597,
13815,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629541,1,Intermediate,10116.0,,50597,
13816,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629542,1,Intermediate,10116.0,,50597,
13817,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630243,1,Intermediate,10116.0,,50597,
13818,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630244,1,Intermediate,10116.0,,50597,
13819,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630245,1,Intermediate,10116.0,,50597,
13820,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630246,1,Intermediate,10116.0,,50597,
13821,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630247,1,Intermediate,10116.0,,50597,
13822,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630248,1,Intermediate,10116.0,,50597,
13823,Biodistribution in rat blood at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630249,1,Intermediate,10116.0,,50597,
13824,Biodistribution in rat blood at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630250,1,Intermediate,10116.0,,50597,
13825,Biodistribution in rat blood at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630251,1,Intermediate,10116.0,,50597,
13826,Biodistribution in rat blood at 3 hr after dose administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630252,1,Intermediate,10116.0,,50597,
13827,Biodistribution in rat blood at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL630408,1,Intermediate,10116.0,,50597,
13828,Biodistribution in rat cerebellum at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630409,1,Intermediate,10116.0,,50597,
13829,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL874446,1,Intermediate,10116.0,,50597,
13830,Biodistribution in rat cerebellum at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630410,1,Intermediate,10116.0,,50597,
13831,Biodistribution in rat cerebellum at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630411,1,Intermediate,10116.0,,50597,
13832,Biodistribution in rat cerebellum at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630412,1,Intermediate,10116.0,,50597,
13833,Biodistribution in rat cerebellum at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630413,1,Intermediate,10116.0,,50597,
13834,Biodistribution in rat cerebellum at 3 hr after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630414,1,Intermediate,10116.0,,50597,
13835,Biodistribution in rat cerebellum at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL630415,1,Intermediate,10116.0,,50597,
13836,Biodistribution in rat cortex at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630416,1,Intermediate,10116.0,,50597,
13837,Biodistribution in rat cortex at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630417,1,Intermediate,10116.0,,50597,
13838,Biodistribution in rat cortex at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630418,1,Intermediate,10116.0,,50597,
13839,Biodistribution in rat cortex at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630419,1,Intermediate,10116.0,,50597,
13840,Biodistribution in rat cortex at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630420,1,Intermediate,10116.0,,50597,
13841,Biodistribution in rat cortex at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630421,1,Intermediate,10116.0,,50597,
13842,Biodistribution in rat cortex at 3 hr after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630422,1,Intermediate,10116.0,,50597,
13843,Biodistribution in rat cortex at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630423,1,Intermediate,10116.0,,50597,
13844,Biodistribution in rat heart at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630424,1,Intermediate,10116.0,,50597,
13845,Biodistribution in rat heart at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630425,1,Intermediate,10116.0,,50597,
13846,Biodistribution in rat heart at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL629462,1,Intermediate,10116.0,,50597,
13847,Biodistribution in rat heart at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630426,1,Intermediate,10116.0,,50597,
13848,Biodistribution in rat heart at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL630427,1,Intermediate,10116.0,,50597,
13849,Biodistribution in rat heart at 3 hr after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625877,1,Intermediate,10116.0,,50597,
13850,Biodistribution in rat heart at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625878,1,Intermediate,10116.0,,50597,
13851,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625879,1,Intermediate,10116.0,,50597,
13852,Biodistribution in rat hippocampus at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625880,1,Intermediate,10116.0,,50597,
13853,Biodistribution in rat hippocampus at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625881,1,Intermediate,10116.0,,50597,
13854,Biodistribution in rat hippocampus at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625882,1,Intermediate,10116.0,,50597,
13855,Biodistribution in rat hippocampus at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625883,1,Intermediate,10116.0,,50597,
13856,Biodistribution in rat kidney at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625884,1,Intermediate,10116.0,,50597,
13857,Biodistribution in rat kidney at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625885,1,Intermediate,10116.0,,50597,
13858,Biodistribution in rat kidney at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628649,1,Intermediate,10116.0,,50597,
13859,Biodistribution in rat kidney at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628650,1,Intermediate,10116.0,,50597,
13860,Biodistribution in rat kidney at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628651,1,Intermediate,10116.0,,50597,
13861,Biodistribution in rat kidney at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628652,1,Intermediate,10116.0,,50597,
13862,Biodistribution in rat kidney at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL628653,1,Intermediate,10116.0,,50597,
13863,Biodistribution in rat liver at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628654,1,Intermediate,10116.0,,50597,
13864,Biodistribution in rat liver at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL628655,1,Intermediate,10116.0,,50597,
13865,Biodistribution in rat liver at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625238,1,Intermediate,10116.0,,50597,
13866,Biodistribution in rat liver at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625239,1,Intermediate,10116.0,,50597,
13867,Biodistribution in rat liver at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625240,1,Intermediate,10116.0,,50597,
13868,Biodistribution in rat liver at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625241,1,Intermediate,10116.0,,50597,
13869,Biodistribution in rat liver at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625242,1,Intermediate,10116.0,,50597,
13870,Biodistribution in rat lung at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL874587,1,Intermediate,10116.0,,50597,
13871,Biodistribution in rat lung at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625405,1,Intermediate,10116.0,,50597,
13872,Biodistribution in rat lung at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625406,1,Intermediate,10116.0,,50597,
13873,Biodistribution in rat lung at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625407,1,Intermediate,10116.0,,50597,
13874,Biodistribution in rat lung at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625408,1,Intermediate,10116.0,,50597,
13875,Biodistribution in rat lung at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625409,1,Intermediate,10116.0,,50597,
13876,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625410,1,Intermediate,10116.0,,50597,
13877,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625411,1,Intermediate,10116.0,,50597,
13878,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625412,1,Intermediate,10116.0,,50597,
13879,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625413,1,Intermediate,10116.0,,50597,
13880,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625414,1,Intermediate,10116.0,,50597,
13881,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625415,1,Intermediate,10116.0,,50597,
13882,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1,N,,Rattus norvegicus,,,,Thoracic aorta,,1515.0,BAO_0000218,CHEMBL625416,1,Intermediate,10116.0,,50597,
13883,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625417,1,Intermediate,10116.0,,50597,
13884,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL625418,1,Intermediate,10116.0,,50597,
13885,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625419,1,Intermediate,10116.0,,50597,
13886,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625420,1,Intermediate,10116.0,,50597,
13887,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626996,1,Intermediate,10116.0,,50597,
13888,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL626997,1,Intermediate,10116.0,,50597,
13889,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626998,1,Intermediate,10116.0,,50597,
13890,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626999,1,Intermediate,10116.0,,50597,
13891,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627000,1,Intermediate,10090.0,,50594,
13892,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627001,1,Intermediate,10090.0,,50594,
13893,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627002,1,Intermediate,10090.0,,50594,
13894,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627003,1,Intermediate,10090.0,,50594,
13895,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627004,1,Intermediate,10090.0,,50594,
13896,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627005,1,Intermediate,10090.0,,50594,
13897,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874594,1,Intermediate,10090.0,,50594,
13898,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627006,1,Intermediate,10090.0,,50594,
13899,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627007,1,Intermediate,10090.0,,50594,
13900,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627884,1,Intermediate,10090.0,,50594,
13901,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627885,1,Intermediate,10090.0,,50594,
13902,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627886,1,Intermediate,10090.0,,50594,
13903,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627887,1,Intermediate,10090.0,,50594,
13904,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627888,1,Intermediate,10090.0,,50594,
13905,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628057,1,Intermediate,10090.0,,50594,
13906,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627405,1,Intermediate,10090.0,,50594,
13907,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627406,1,Intermediate,9615.0,,50588,
13908,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627407,1,Intermediate,9615.0,,50588,
13909,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627408,1,Intermediate,9615.0,,50588,
13910,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627409,1,Intermediate,9615.0,,50588,
13911,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL875486,1,Intermediate,9615.0,,50588,
13912,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627410,1,Intermediate,9615.0,,50588,
13913,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627411,1,Intermediate,9615.0,,50588,
13914,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627412,1,Intermediate,9615.0,,50588,
13915,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627413,1,Intermediate,9615.0,,50588,
13916,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627414,1,Intermediate,9615.0,,50588,
13917,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627415,1,Intermediate,9615.0,,50588,
13918,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627416,1,Intermediate,9615.0,,50588,
13919,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627417,1,Intermediate,9615.0,,50588,
13920,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627418,1,Intermediate,9615.0,,50588,
13921,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627419,1,Intermediate,9615.0,,50588,
13922,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627320,1,Intermediate,9615.0,,50588,
13923,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627321,1,Intermediate,9615.0,,50588,
13924,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627322,1,Intermediate,10116.0,,50597,
13925,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627323,1,Intermediate,10116.0,,50597,
13926,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627491,1,Intermediate,10116.0,,50597,
13927,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627492,1,Intermediate,10116.0,,50597,
13928,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627493,1,Intermediate,10116.0,,50597,
13929,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627494,1,Intermediate,10116.0,,50597,
13930,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627495,1,Intermediate,10116.0,,50597,
13931,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627496,1,Intermediate,10116.0,,50597,
13932,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627497,1,Intermediate,10116.0,,50597,
13933,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627498,1,Intermediate,10116.0,,50597,
13934,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627499,1,Intermediate,10116.0,,50597,
13935,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627500,1,Intermediate,10116.0,,50597,
13936,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627501,1,Intermediate,10116.0,,50597,
13937,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625616,1,Intermediate,10116.0,,50597,
13938,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625617,1,Intermediate,10116.0,,50597,
13939,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625618,1,Intermediate,10116.0,,50597,
13940,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625619,1,Intermediate,10116.0,,50597,
13941,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625620,1,Intermediate,10116.0,,50597,
13942,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625621,1,Intermediate,10116.0,,50597,
13943,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625622,1,Intermediate,10116.0,,50597,
13944,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625788,1,Intermediate,10116.0,,50597,
13945,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625789,1,Intermediate,10116.0,,50597,
13946,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625790,1,Intermediate,10116.0,,50597,
13947,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625791,1,Intermediate,10116.0,,50597,
13948,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL622334,1,Intermediate,10116.0,,50597,
13949,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622335,1,Intermediate,10116.0,,50597,
13950,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622336,1,Intermediate,10116.0,,50597,
13951,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622337,1,Intermediate,10116.0,,50597,
13952,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622338,1,Intermediate,10116.0,,50597,
13953,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL622339,1,Intermediate,10116.0,,50597,
13954,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL624153,1,Intermediate,10116.0,,50597,
13955,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628430,1,Intermediate,10116.0,,50597,
13956,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628431,1,Intermediate,10116.0,,50597,
13957,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628432,1,Intermediate,10116.0,,50597,
13958,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628433,1,Intermediate,10116.0,,50597,
13959,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL628434,1,Intermediate,10116.0,,50597,
13960,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626789,1,Intermediate,10116.0,,50597,
13961,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626790,1,Intermediate,10116.0,,50597,
13962,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626791,1,Intermediate,10116.0,,50597,
13963,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626792,1,Intermediate,10116.0,,50597,
13964,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL626793,1,Intermediate,10116.0,,50597,
13965,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627436,1,Intermediate,10116.0,,50597,
13966,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627437,1,Intermediate,10116.0,,50597,
13967,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627438,1,Intermediate,10116.0,,50597,
13968,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627439,1,Intermediate,10116.0,,50597,
13969,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627440,1,Intermediate,10116.0,,50597,
13970,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627602,1,Intermediate,10116.0,,50597,
13971,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627603,1,Intermediate,10116.0,,50597,
13972,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627604,1,Intermediate,10116.0,,50597,
13973,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627605,1,Intermediate,10116.0,,50597,
13974,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627606,1,Intermediate,10116.0,,50597,
13975,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627607,1,Intermediate,10116.0,,50597,
13976,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627608,1,Intermediate,10116.0,,50597,
13977,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627609,1,Intermediate,10116.0,,50597,
13978,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627610,1,Intermediate,10116.0,,50597,
13979,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627611,1,Intermediate,10116.0,,50597,
13980,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627612,1,Intermediate,10116.0,,50597,
13981,Octanol:water partition coefficient is evaluated,1,U,,,,,,,,,BAO_0000100,CHEMBL627613,0,Autocuration,,,22229,
13982,Partition coefficient in 1-octanol/water system,1,U,,,,,,,,,BAO_0000100,CHEMBL627614,0,Autocuration,,,22224,
13983,Partition coefficient in 1-octanol/water system measured using radio active compounds,1,U,,,,,,,,,BAO_0000100,CHEMBL627615,0,Autocuration,,,22224,
13984,Partition coefficient in octanol/water system was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL627616,0,Autocuration,,,22224,
13985,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,1,U,,,,,,,,,BAO_0000100,CHEMBL627617,0,Autocuration,,,22224,
13986,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL627618,0,Autocuration,,,22224,
13987,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL627619,0,Autocuration,,,22224,
13988,Pseudo-first-order rate constant of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL627620,0,Autocuration,,,22224,
13989,Pseudo-first-order rate constant with 1-min time point,1,U,,,,,,,,,BAO_0000019,CHEMBL627621,0,Autocuration,,,22224,
13990,Pseudo-first-order rate constant without 1-min time point,1,U,,,,,,,,,BAO_0000019,CHEMBL627622,0,Autocuration,,,22224,
13991,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,1,U,,,,,,,,,BAO_0000019,CHEMBL627623,0,Autocuration,,,22224,
13992,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,1,U,,,,,,,,,BAO_0000019,CHEMBL627624,0,Autocuration,,,22224,
13993,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,1,U,,,,,,,,,BAO_0000019,CHEMBL627625,0,Autocuration,,,22224,
13994,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL628523,0,Autocuration,,,22224,
13995,The alkaline hydrolysis second order rate constant(K OH) of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL628524,0,Autocuration,,,22224,
13996,The efflux rate constant of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL628525,0,Autocuration,,,22224,
13997,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,1,U,,,,,,,,,BAO_0000019,CHEMBL625732,0,Autocuration,,,22224,
13998,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,1,U,,,,,,,,,BAO_0000019,CHEMBL625733,0,Autocuration,,,22224,
13999,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,1,U,,,,,,,,,BAO_0000019,CHEMBL625734,0,Autocuration,,,22224,
14000,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL625913,0,Autocuration,,,22224,
14001,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,1,U,,,,,,,,,BAO_0000019,CHEMBL625914,0,Autocuration,,,22224,
14002,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,1,U,,,,,,,,,BAO_0000019,CHEMBL625915,0,Autocuration,,,22224,
14003,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,1,U,,,,,,,,,BAO_0000019,CHEMBL625916,0,Autocuration,,,22224,
14004,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),1,U,,,,,,,,,BAO_0000019,CHEMBL625917,0,Autocuration,,,22224,
14005,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625918,0,Autocuration,,,22224,
14006,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625919,0,Autocuration,,,22224,
14007,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625920,0,Autocuration,,,22224,
14008,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL874453,0,Autocuration,,,22224,
14009,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625921,0,Autocuration,,,22224,
14010,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,1,U,,,,,,,,,BAO_0000019,CHEMBL625922,0,Autocuration,,,22224,
14011,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625923,0,Autocuration,,,22224,
14012,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625924,0,Autocuration,,,22224,
14013,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625925,0,Autocuration,,,22224,
14014,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL625926,0,Autocuration,,,22224,
14015,Biodistribution in rat lung at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627704,1,Intermediate,10116.0,,50597,
14016,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627705,1,Intermediate,10116.0,,50597,
14017,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627706,1,Intermediate,10116.0,,50597,
14018,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627707,1,Intermediate,10116.0,,50597,
14019,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627708,1,Intermediate,10116.0,,50597,
14020,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628361,1,Intermediate,10116.0,,50597,
14021,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628362,1,Intermediate,10116.0,,50597,
14022,Biodistribution in rat striatum at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628363,1,Intermediate,10116.0,,50597,
14023,Biodistribution in rat striatum at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628364,1,Intermediate,10116.0,,50597,
14024,Biodistribution in rat striatum at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628365,1,Intermediate,10116.0,,50597,
14025,Biodistribution in rat striatum at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL874454,1,Intermediate,10116.0,,50597,
14026,Biodistribution in rat striatum at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628531,1,Intermediate,10116.0,,50597,
14027,Biodistribution in rat striatum at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628532,1,Intermediate,10116.0,,50597,
14028,Biodistribution in rat striatum at 3 hr after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628533,1,Intermediate,10116.0,,50597,
14029,Biodistribution in rat striatum at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Striatum,,2435.0,BAO_0000218,CHEMBL628534,1,Intermediate,10116.0,,50597,
14030,Biodistribution in rat thyroid at 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL628535,1,Intermediate,10116.0,,50597,
14031,Biodistribution in rat thyroid at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL628536,1,Intermediate,10116.0,,50597,
14032,Biodistribution in rat thyroid at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL628537,1,Intermediate,10116.0,,50597,
14033,Biodistribution in rat thyroid at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL628538,1,Intermediate,10116.0,,50597,
14034,Biodistribution in rat thyroid at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL628539,1,Intermediate,10116.0,,50597,
14035,Biodistribution in rat thyroid at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630297,1,Intermediate,10116.0,,50597,
14036,Biodistribution in rat thyroid at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL630298,1,Intermediate,10116.0,,50597,
14037,Biodistribution in rest of brain of rat 120 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL630299,1,Intermediate,10116.0,,50597,
14038,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL628094,1,Intermediate,10116.0,,50597,
14039,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL628095,1,Intermediate,10116.0,,50597,
14040,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL874648,1,Intermediate,10116.0,,50597,
14041,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL628096,1,Intermediate,10116.0,,50597,
14042,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL628097,1,Intermediate,10116.0,,50597,
14043,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL628098,1,Intermediate,10116.0,,50597,
14044,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628099,0,Autocuration,,,22224,
14045,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628100,0,Autocuration,,,22224,
14046,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),1,U,,,,,,,,,BAO_0000019,CHEMBL628101,0,Autocuration,,,22224,
14047,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628102,0,Autocuration,,,22224,
14048,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628103,0,Autocuration,,,22224,
14049,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628104,0,Autocuration,,,22224,
14050,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628105,0,Autocuration,,,22224,
14051,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",1,U,,,,,,,,,BAO_0000019,CHEMBL628106,0,Autocuration,,,22224,
14052,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628107,1,Intermediate,10116.0,,50597,
14053,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1,U,,,,,,Urine,,1088.0,BAO_0000218,CHEMBL628108,0,Autocuration,,,22224,
14054,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628109,1,Intermediate,10116.0,,50597,
14055,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1,U,,,,,,Urine,,1088.0,BAO_0000218,CHEMBL625299,0,Autocuration,,,22224,
14056,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625300,1,Intermediate,10116.0,,50597,
14057,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625301,1,Intermediate,10116.0,,50597,
14058,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625302,1,Intermediate,10116.0,,50597,
14059,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874649,1,Intermediate,10116.0,,50597,
14060,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625303,1,Intermediate,10116.0,,50597,
14061,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625463,1,Intermediate,10116.0,,50597,
14062,In vitro metabolism in human liver microsomes,1,N,,Homo sapiens,,,,Liver,,2107.0,BAO_0000218,CHEMBL625464,1,Intermediate,9606.0,,50587,
14063,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL625465,1,Intermediate,9606.0,,50587,
14064,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625466,1,Intermediate,9615.0,,50588,
14065,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625467,1,Intermediate,9615.0,,50588,
14066,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625468,1,Intermediate,10116.0,,50597,
14067,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625469,1,Intermediate,10116.0,,50597,
14068,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625470,1,Intermediate,10116.0,,50597,
14069,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL632418,1,Intermediate,10116.0,,50597,
14070,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627250,1,Intermediate,10116.0,,50597,
14071,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627251,1,Intermediate,10116.0,,50597,
14072,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627252,1,Intermediate,10116.0,,50597,
14073,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627253,1,Intermediate,10116.0,,50597,
14074,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627254,1,Intermediate,10116.0,,50597,
14075,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875471,1,Intermediate,10116.0,,50597,
14076,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627255,1,Intermediate,10116.0,,50597,
14077,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627256,1,Intermediate,10116.0,,50597,
14078,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627257,1,Intermediate,10116.0,,50597,
14079,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627258,1,Intermediate,10116.0,,50597,
14080,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627259,1,Intermediate,10116.0,,50597,
14081,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627260,1,Intermediate,10116.0,,50597,
14082,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623256,1,Intermediate,10116.0,,50597,
14083,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874413,1,Intermediate,10116.0,,50597,
14084,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623257,1,Intermediate,10116.0,,50597,
14085,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623258,1,Intermediate,10116.0,,50597,
14086,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623259,1,Intermediate,10116.0,,50597,
14087,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623260,1,Intermediate,10116.0,,50597,
14088,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623261,1,Intermediate,10116.0,,50597,
14089,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623262,1,Intermediate,10116.0,,50597,
14090,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623263,1,Intermediate,10116.0,,50597,
14091,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623264,1,Intermediate,10116.0,,50597,
14092,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623265,1,Intermediate,10116.0,,50597,
14093,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623266,1,Intermediate,10116.0,,50597,
14094,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623267,1,Intermediate,10116.0,,50597,
14095,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623268,1,Intermediate,10116.0,,50597,
14096,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623269,1,Intermediate,10116.0,,50597,
14097,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623270,1,Intermediate,10116.0,,50597,
14098,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623271,1,Intermediate,10116.0,,50597,
14099,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623272,1,Intermediate,10116.0,,50597,
14100,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623273,1,Intermediate,10116.0,,50597,
14101,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623274,1,Intermediate,10116.0,,50597,
14102,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL874414,1,Intermediate,10116.0,,50597,
14103,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623275,1,Intermediate,10116.0,,50597,
14104,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629150,1,Intermediate,10116.0,,50597,
14105,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623276,1,Intermediate,10116.0,,50597,
14106,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623277,1,Intermediate,10116.0,,50597,
14107,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623112,1,Intermediate,10116.0,,50597,
14108,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623113,1,Intermediate,10116.0,,50597,
14109,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623800,1,Intermediate,10116.0,,50597,
14110,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623801,1,Intermediate,10116.0,,50597,
14111,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL623802,1,Intermediate,10116.0,,50597,
14112,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL623803,1,Intermediate,10116.0,,50597,
14113,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL623970,1,Intermediate,10116.0,,50597,
14114,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Uterus,,995.0,BAO_0000218,CHEMBL623971,1,Intermediate,10116.0,,50597,
14115,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623972,1,Intermediate,10116.0,,50597,
14116,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623973,1,Intermediate,10116.0,,50597,
14117,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623974,1,Intermediate,10116.0,,50597,
14118,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL623975,1,Intermediate,10116.0,,50597,
14119,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623976,1,Intermediate,10116.0,,50597,
14120,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623977,1,Intermediate,10116.0,,50597,
14121,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623978,1,Intermediate,10116.0,,50597,
14122,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL623979,1,Intermediate,10116.0,,50597,
14123,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623980,1,Intermediate,10116.0,,50597,
14124,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL623981,1,Intermediate,10116.0,,50597,
14125,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626278,1,Intermediate,10116.0,,50597,
14126,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626279,1,Intermediate,10116.0,,50597,
14127,Biodistribution in mice bladder plus excreted urine was determined,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626280,1,Intermediate,10090.0,,50594,
14128,"Percentage biodistribution in mouse blood, 10 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626281,1,Intermediate,10090.0,,50594,
14129,"Percentage biodistribution in mouse blood, 30 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626282,1,Intermediate,10090.0,,50594,
14130,"Percentage biodistribution in mouse blood, 5 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626283,1,Intermediate,10090.0,,50594,
14131,"Percentage biodistribution in mouse blood, 60 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626284,1,Intermediate,10090.0,,50594,
14132,"Percentage biodistribution in mouse brain, 10 minutes post injection",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL626285,1,Intermediate,10090.0,,50594,
14133,"Percentage biodistribution in mouse brain, 30 minutes post injection",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL626286,1,Intermediate,10090.0,,50594,
14134,"Percentage biodistribution in mouse brain, 5 minutes post injection",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL626287,1,Intermediate,10090.0,,50594,
14135,"Percentage biodistribution in mouse brain, 60 minutes post injection",1,N,,Mus musculus,,,,Brain,,955.0,BAO_0000218,CHEMBL626288,1,Intermediate,10090.0,,50594,
14136,"Percentage biodistribution in mouse heart, 10 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626289,1,Intermediate,10090.0,,50594,
14137,"Percentage biodistribution in mouse heart, 30 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626290,1,Intermediate,10090.0,,50594,
14138,"Percentage biodistribution in mouse heart, 5 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL626291,1,Intermediate,10090.0,,50594,
14139,"Percentage biodistribution in mouse heart, 60 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL839888,1,Intermediate,10090.0,,50594,
14140,"Percentage biodistribution in mouse intestine, 10 minutes post injection",1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL626292,1,Intermediate,10090.0,,50594,
14141,"Percentage biodistribution in mouse intestine, 30 minutes post injection",1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL626293,1,Intermediate,10090.0,,50594,
14142,"Percentage biodistribution in mouse intestine, 5 minutes post injection",1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL626294,1,Intermediate,10090.0,,50594,
14143,"Percentage biodistribution in mouse intestine, 60 minutes post injection",1,N,,Mus musculus,,,,Intestine,,160.0,BAO_0000218,CHEMBL626295,1,Intermediate,10090.0,,50594,
14144,"Percentage biodistribution in mouse liver, 10 minutes post injection",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627659,1,Intermediate,10090.0,,50594,
14145,"Percentage biodistribution in mouse liver, 30 minutes of post injection",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627660,1,Intermediate,10090.0,,50594,
14146,"Percentage biodistribution in mouse liver, 5 minutes post injection",1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627661,1,Intermediate,10090.0,,50594,
14147,Biodistribution in mice liver at 60 minutes of post injection,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL627662,1,Intermediate,10090.0,,50594,
14148,Biodistribution in mice lungs at 10 min of post injection,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627663,1,Intermediate,10090.0,,50594,
14149,"Percentage biodistribution in mouse lung, 30 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627664,1,Intermediate,10090.0,,50594,
14150,"Percentage biodistribution in mousee lung, 5 minutes post injection",1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL627665,1,Intermediate,10090.0,,50594,
14151,Biodistribution in mice lungs at 60 min of post injection,1,N,,Mus musculus,,,,Lung,,2048.0,BAO_0000218,CHEMBL627666,1,Intermediate,10090.0,,50594,
14152,Percentage biodistribution in mouse spleen,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627667,1,Intermediate,10090.0,,50594,
14153,Percentage biodistribution in mouse stomach,1,N,,Mus musculus,,,,Stomach,,945.0,BAO_0000218,CHEMBL627668,1,Intermediate,10090.0,,50594,
14154,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1,N,,Mus musculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627669,1,Intermediate,10090.0,,50594,
14155,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,1,U,,,,,,Urinary bladder,,1255.0,BAO_0000218,CHEMBL627670,0,Autocuration,,,22224,
14156,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL627671,0,Autocuration,,,22224,
14157,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,1,U,,,,,,Bone element,,1474.0,BAO_0000218,CHEMBL627672,0,Autocuration,,,22224,
14158,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,1,U,,,,,,,,,BAO_0000218,CHEMBL627673,0,Autocuration,,,22224,
14159,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,1,U,,,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627674,0,Autocuration,,,22224,
14160,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,1,U,,,,,,Liver,,2107.0,BAO_0000218,CHEMBL627675,0,Autocuration,,,22224,
14161,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,1,U,,,,,,Lung,,2048.0,BAO_0000218,CHEMBL627676,0,Autocuration,,,22224,
14162,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627677,0,Autocuration,,,22224,
14163,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL627678,0,Autocuration,,,22224,
14164,Affinity for protein binding expressed as association constant in fresh rat serum,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL627679,1,Intermediate,10116.0,,50597,
14165,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,1,U,,,,,,,,,BAO_0000019,CHEMBL627680,0,Autocuration,,,22224,
14166,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL627681,0,Autocuration,,,22224,
14167,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,1,U,,,,,,,,,BAO_0000019,CHEMBL627682,0,Autocuration,,,22224,
14168,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,1,U,,,,,,,,,BAO_0000019,CHEMBL627683,0,Autocuration,,,22224,
14169,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,1,U,,,,,,,,,BAO_0000019,CHEMBL627684,0,Autocuration,,,22224,
14170,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",1,U,,,,,,,,,BAO_0000019,CHEMBL874441,0,Autocuration,,,22224,
14171,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,1,U,,,,,,,,,BAO_0000019,CHEMBL627685,0,Autocuration,,,22224,
14172,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",1,U,,,,,,,,,BAO_0000019,CHEMBL627686,0,Autocuration,,,22224,
14173,Apparent rate constant Koff for inactivation of dTMP synthase.,1,U,,,,,,,,,BAO_0000019,CHEMBL627687,0,Autocuration,,,22224,
14174,The irreversible inhibitor activity by second order rate equation.,1,U,,,,,,,,,BAO_0000019,CHEMBL627688,0,Autocuration,,,22224,
14175,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628038,1,Intermediate,10116.0,,50597,
14176,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628039,1,Intermediate,10116.0,,50597,
14177,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628040,1,Intermediate,10116.0,,50597,
14178,Dissociation rate calculated from the first-order equation using t1/2 value,1,U,,,,,,,,,BAO_0000019,CHEMBL628041,0,Autocuration,,,22224,
14179,The compound was tested for Binding constant against DNA,1,U,,,,,,,,,BAO_0000019,CHEMBL630226,0,Autocuration,,,22224,
14180,First order rate constant for cyclization of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL628042,0,Autocuration,,,22224,
14181,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,1,U,,,,,,,,,BAO_0000019,CHEMBL625232,0,Autocuration,,,22224,
14182,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,1,U,,,,,,,,,BAO_0000019,CHEMBL625233,0,Autocuration,,,22224,
14183,Hydrolysis rate constant was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL625979,0,Autocuration,,,22224,
14184,Observed first order rate constant,1,U,,,,,,,,,BAO_0000019,CHEMBL625980,0,Autocuration,,,22224,
14185,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,1,U,,,,,,,,,BAO_0000019,CHEMBL625981,0,Autocuration,,,22224,
14186,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,1,U,,,,,,,,,BAO_0000019,CHEMBL625982,0,Autocuration,,,22224,
14187,Second-order rate constant for attack on PNPA at 25 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL625983,0,Autocuration,,,22224,
14188,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625984,0,Autocuration,,,22224,
14189,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625985,0,Autocuration,,,22224,
14190,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625986,0,Autocuration,,,22224,
14191,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625987,0,Autocuration,,,22224,
14192,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625988,0,Autocuration,,,22224,
14193,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625989,0,Autocuration,,,22224,
14194,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625990,0,Autocuration,,,22224,
14195,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625991,0,Autocuration,,,22224,
14196,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625992,0,Autocuration,,,22224,
14197,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL625993,0,Autocuration,,,22224,
14198,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL631973,0,Autocuration,,,22224,
14199,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632143,0,Autocuration,,,22224,
14200,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632144,0,Autocuration,,,22224,
14201,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632145,0,Autocuration,,,22224,
14202,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632146,0,Autocuration,,,22224,
14203,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632147,0,Autocuration,,,22224,
14204,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632148,0,Autocuration,,,22224,
14205,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632149,0,Autocuration,,,22224,
14206,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632150,0,Autocuration,,,22224,
14207,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL632151,0,Autocuration,,,22224,
14208,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL632152,1,Intermediate,9606.0,,50587,
14209,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL632153,1,Intermediate,9606.0,,50587,
14210,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL632154,1,Intermediate,9606.0,,50587,
14211,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL632155,1,Intermediate,10298.0,,50602,
14212,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL632156,1,Intermediate,10298.0,,50602,
14213,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL632157,1,Intermediate,10298.0,,50602,
14214,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL632158,1,Intermediate,10298.0,,50602,
14215,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL632159,1,Intermediate,10298.0,,50602,
14216,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL626305,1,Intermediate,10298.0,,50602,
14217,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL626306,1,Intermediate,10298.0,,50602,
14218,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL626307,1,Intermediate,10298.0,,50602,
14219,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL626308,1,Intermediate,10298.0,,50602,
14220,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL626479,1,Intermediate,10298.0,,50602,
14221,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,1,N,,Human herpesvirus 1,,,,,,,BAO_0000218,CHEMBL626480,1,Intermediate,10298.0,,50602,
14222,Calculated partition coefficient (clogP) (MlogP),1,U,,,,,,,,,BAO_0000100,CHEMBL626481,0,Autocuration,,,22229,
14223,Equipotent potent ratio relative to carbachol (nicotinic activity),1,U,,,,,,,,,BAO_0000019,CHEMBL626482,0,Autocuration,,,22224,
14224,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626483,1,Intermediate,9615.0,,50588,
14225,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL626484,1,Intermediate,9615.0,,50588,
14226,Solubility at pH 7.4 in micro g/mL;NA denotes available,1,U,,,,,,,,,BAO_0000100,CHEMBL626485,0,Autocuration,,,22229,
14227,Solubility at pH 7.4 in micro g/mL;NA denotes not available,1,U,,,,,,,,,BAO_0000100,CHEMBL626486,0,Autocuration,,,22229,
14228,Solubility at pH 7.4 in ug/mL;NA denotes not available,1,U,,,,,,,,,BAO_0000100,CHEMBL626487,0,Autocuration,,,22229,
14229,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,N,,Canis lupus familiaris,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626488,1,Intermediate,9615.0,,50588,
14230,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1,N,,Rattus norvegicus,,,,Serum,,1977.0,BAO_0000218,CHEMBL626489,1,Intermediate,10116.0,,50597,
14231,Area under the MAP curve measured over 5 min; ND means Not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL626490,0,Autocuration,,,22224,
14232,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,1,U,,,,,,,,,BAO_0000100,CHEMBL626491,0,Autocuration,,,22224,
14233,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,1,U,,,,,,,,,BAO_0000100,CHEMBL626492,0,Autocuration,,,22229,
14234,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,1,U,,,,,,,,,BAO_0000019,CHEMBL626493,0,Autocuration,,,22224,
14235,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626494,1,Intermediate,10116.0,,50597,
14236,Half life after oral tested,1,U,,,,,,,,,BAO_0000218,CHEMBL626495,0,Autocuration,,,22224,
14237,Half life was determined in plasma of rat; NT indicates not tested,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626496,1,Intermediate,10116.0,,50597,
14238,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626497,1,Intermediate,10116.0,,50597,
14239,Oral bioavailability after oral tested,1,U,,,,,,,,,BAO_0000218,CHEMBL626498,0,Autocuration,,,22224,
14240,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626499,1,Intermediate,10116.0,,50597,
14241,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626500,1,Intermediate,10116.0,,50597,
14242,half life was determined in plasma of rat; NT indicates not tested,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626501,1,Intermediate,10116.0,,50597,
14243,half life was determined in plasma of rat; NT means not tested,1,N,,Rattus norvegicus,,,,Plasma,,1969.0,BAO_0000218,CHEMBL626502,1,Intermediate,10116.0,,50597,
14244,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626503,1,Intermediate,10116.0,,50597,
14245,Mean sodium excretion in rats (Control/Drug treatment value); inactive,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626504,1,Intermediate,10116.0,,50597,
14246,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626505,1,Intermediate,10116.0,,50597,
14247,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626506,1,Intermediate,10116.0,,50597,
14248,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626507,1,Intermediate,10116.0,,50597,
14249,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626508,1,Intermediate,10116.0,,50597,
14250,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626509,1,Intermediate,10116.0,,50597,
14251,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875480,1,Intermediate,10116.0,,50597,
14252,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626510,1,Intermediate,10116.0,,50597,
14253,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626511,1,Intermediate,10116.0,,50597,
14254,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL626512,1,Intermediate,10116.0,,50597,
14255,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628208,1,Intermediate,10116.0,,50597,
14256,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628209,1,Intermediate,10116.0,,50597,
14257,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628210,1,Intermediate,10116.0,,50597,
14258,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628211,1,Intermediate,10116.0,,50597,
14259,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628212,1,Intermediate,10116.0,,50597,
14260,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628213,1,Intermediate,10116.0,,50597,
14261,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628214,1,Intermediate,10116.0,,50597,
14262,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628215,1,Intermediate,10116.0,,50597,
14263,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628216,1,Intermediate,10116.0,,50597,
14264,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626595,1,Intermediate,10116.0,,50597,
14265,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626596,1,Intermediate,10116.0,,50597,
14266,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626597,1,Intermediate,10116.0,,50597,
14267,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626598,1,Intermediate,10116.0,,50597,
14268,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622242,1,Intermediate,10116.0,,50597,
14269,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622243,1,Intermediate,10116.0,,50597,
14270,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622244,1,Intermediate,10116.0,,50597,
14271,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622245,1,Intermediate,10116.0,,50597,
14272,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622246,1,Intermediate,10116.0,,50597,
14273,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622247,1,Intermediate,10116.0,,50597,
14274,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622248,1,Intermediate,10116.0,,50597,
14275,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL877483,1,Intermediate,10116.0,,50597,
14276,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL622249,1,Intermediate,10116.0,,50597,
14277,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622250,1,Intermediate,9615.0,,50588,
14278,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622251,1,Intermediate,9615.0,,50588,
14279,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622252,1,Intermediate,9615.0,,50588,
14280,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622253,1,Intermediate,9615.0,,50588,
14281,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622254,1,Intermediate,9615.0,,50588,
14282,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622255,1,Intermediate,9615.0,,50588,
14283,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622256,1,Intermediate,9615.0,,50588,
14284,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622257,1,Intermediate,9615.0,,50588,
14285,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622258,1,Intermediate,9615.0,,50588,
14286,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622259,1,Intermediate,9615.0,,50588,
14287,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622927,1,Intermediate,9615.0,,50588,
14288,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622928,1,Intermediate,9615.0,,50588,
14289,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL622929,1,Intermediate,9615.0,,50588,
14290,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL623182,1,Intermediate,9615.0,,50588,
14291,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL623183,1,Intermediate,9615.0,,50588,
14292,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623184,1,Intermediate,10116.0,,50597,
14293,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623185,1,Intermediate,10116.0,,50597,
14294,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL877484,1,Intermediate,10116.0,,50597,
14295,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627274,1,Intermediate,10116.0,,50597,
14296,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623186,1,Intermediate,10116.0,,50597,
14297,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623187,1,Intermediate,10116.0,,50597,
14298,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL623188,1,Intermediate,10116.0,,50597,
14299,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628055,1,Intermediate,10116.0,,50597,
14300,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628056,1,Intermediate,10116.0,,50597,
14301,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628200,1,Intermediate,10116.0,,50597,
14302,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628201,1,Intermediate,10116.0,,50597,
14303,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628202,1,Intermediate,10116.0,,50597,
14304,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628203,1,Intermediate,10116.0,,50597,
14305,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628204,1,Intermediate,10116.0,,50597,
14306,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628205,1,Intermediate,10116.0,,50597,
14307,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628206,1,Intermediate,10116.0,,50597,
14308,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL628207,0,Autocuration,,,22224,
14309,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627220,0,Autocuration,,,22224,
14310,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627221,0,Autocuration,,,22224,
14311,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627222,0,Autocuration,,,22224,
14312,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,1,U,,,,,,,,,BAO_0000218,CHEMBL627223,0,Autocuration,,,22224,
14313,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL632062,0,Autocuration,,,22224,
14314,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,1,U,,,,,,Spleen,,2106.0,BAO_0000218,CHEMBL632063,0,Autocuration,,,22224,
14315,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,1,U,,,,,,Urinary bladder,,1255.0,BAO_0000218,CHEMBL632064,0,Autocuration,,,22224,
14316,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL632065,0,Autocuration,,,22224,
14317,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,1,U,,,,,,Bone element,,1474.0,BAO_0000218,CHEMBL632066,0,Autocuration,,,22224,
14318,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,1,U,,,,,,,,,BAO_0000218,CHEMBL632067,0,Autocuration,,,22224,
14319,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,1,U,,,,,,Kidney,,2113.0,BAO_0000218,CHEMBL629188,0,Autocuration,,,22224,
14320,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,1,U,,,,,,Liver,,2107.0,BAO_0000218,CHEMBL629189,0,Autocuration,,,22224,
14321,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,1,U,,,,,,Lung,,2048.0,BAO_0000218,CHEMBL629190,0,Autocuration,,,22224,
14322,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629191,0,Autocuration,,,22224,
14323,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL629192,0,Autocuration,,,22224,
14324,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629193,0,Autocuration,,,22224,
14325,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL629194,0,Autocuration,,,22224,
14326,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,1,U,,,,,,,,,BAO_0000218,CHEMBL629195,0,Autocuration,,,22224,
14327,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629373,0,Autocuration,,,22224,
14328,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,1,U,,,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629374,0,Autocuration,,,22224,
14329,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL629375,0,Autocuration,,,22224,
14330,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,1,U,,,,,,Urinary bladder,,1255.0,BAO_0000218,CHEMBL629376,0,Autocuration,,,22224,
14331,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL629377,0,Autocuration,,,22224,
14332,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,1,U,,,,,,Bone element,,1474.0,BAO_0000218,CHEMBL629378,0,Autocuration,,,22224,
14333,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,1,U,,,,,,,,,BAO_0000218,CHEMBL629379,0,Autocuration,,,22224,
14334,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,1,U,,,,,,Kidney,,2113.0,BAO_0000218,CHEMBL629151,0,Autocuration,,,22224,
14335,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,1,U,,,,,,Liver,,2107.0,BAO_0000218,CHEMBL629152,0,Autocuration,,,22224,
14336,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,1,U,,,,,,Lung,,2048.0,BAO_0000218,CHEMBL629153,0,Autocuration,,,22224,
14337,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629154,0,Autocuration,,,22224,
14338,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL629155,0,Autocuration,,,22224,
14339,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL629156,0,Autocuration,,,22224,
14340,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629157,0,Autocuration,,,22224,
14341,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL629158,0,Autocuration,,,22224,
14342,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,1,U,,,,,,,,,BAO_0000218,CHEMBL629159,0,Autocuration,,,22224,
14343,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629160,0,Autocuration,,,22224,
14344,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,1,U,,,,,,Spleen,,2106.0,BAO_0000218,CHEMBL629161,0,Autocuration,,,22224,
14345,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,1,U,,,,,,Urinary bladder,,1255.0,BAO_0000218,CHEMBL629162,0,Autocuration,,,22224,
14346,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL629163,0,Autocuration,,,22224,
14347,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,1,U,,,,,,Bone element,,1474.0,BAO_0000218,CHEMBL629164,0,Autocuration,,,22224,
14348,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,1,U,,,,,,,,,BAO_0000218,CHEMBL629165,0,Autocuration,,,22224,
14349,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,1,U,,,,,,Liver,,2107.0,BAO_0000218,CHEMBL629166,0,Autocuration,,,22224,
14350,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,1,U,,,,,,Lung,,2048.0,BAO_0000218,CHEMBL629167,0,Autocuration,,,22224,
14351,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL629168,0,Autocuration,,,22224,
14352,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,1,U,,,,,,,,,BAO_0000019,CHEMBL629169,0,Autocuration,,,22224,
14353,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,1,U,,,,,,,,,BAO_0000019,CHEMBL629170,0,Autocuration,,,22224,
14354,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,1,U,,,,,,,,,BAO_0000019,CHEMBL631153,0,Autocuration,,,22224,
14355,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,1,U,,,,,,,,,BAO_0000019,CHEMBL875121,0,Autocuration,,,22224,
14356,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,1,U,,,,,,,,,BAO_0000019,CHEMBL631154,0,Autocuration,,,22224,
14357,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,1,U,,,,,,,,,BAO_0000019,CHEMBL631155,0,Autocuration,,,22224,
14358,Hydrolysis rate constant was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631156,0,Autocuration,,,22224,
14359,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL631157,0,Autocuration,,,22224,
14360,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL631158,0,Autocuration,,,22224,
14361,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL631159,0,Autocuration,,,22224,
14362,Observed second order rate constant,1,U,,,,,,,,,BAO_0000019,CHEMBL631160,0,Autocuration,,,22224,
14363,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,1,U,,,,,,,,,BAO_0000019,CHEMBL631161,0,Autocuration,,,22224,
14364,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,1,U,,,,,,,,,BAO_0000019,CHEMBL631162,0,Autocuration,,,22224,
14365,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,1,U,,,,,,,,,BAO_0000019,CHEMBL630313,0,Autocuration,,,22224,
14366,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL630314,0,Autocuration,,,22224,
14367,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL630315,0,Autocuration,,,22224,
14368,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630316,0,Autocuration,,,22224,
14369,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630986,0,Autocuration,,,22224,
14370,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630987,0,Autocuration,,,22224,
14371,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630988,0,Autocuration,,,22224,
14372,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630989,0,Autocuration,,,22224,
14373,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630990,0,Autocuration,,,22224,
14374,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630991,0,Autocuration,,,22224,
14375,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630992,0,Autocuration,,,22224,
14376,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630993,0,Autocuration,,,22224,
14377,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,U,,,,,,,,,BAO_0000019,CHEMBL630994,0,Autocuration,,,22224,
14378,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630995,1,Intermediate,10116.0,,50597,
14379,Association constant for compound at 31 degree C was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL629252,0,Autocuration,,,22224,
14380,Calculated antagonist equilibrium dissociation constant of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL629253,0,Autocuration,,,22224,
14381,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,1,U,,,,,,,,,BAO_0000019,CHEMBL629944,0,Autocuration,,,22224,
14382,Dissociation constants vs LTE4 on guinea pig trachea,1,N,,Cavia porcellus,,,,Trachea,,3126.0,BAO_0000218,CHEMBL629945,1,Intermediate,10141.0,,50512,
14383,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",1,U,,,,,,,,,BAO_0000019,CHEMBL629946,0,Autocuration,,,22224,
14384,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",1,U,,,,,,,,,BAO_0000019,CHEMBL629947,0,Autocuration,,,22224,
14385,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",1,U,,,,,,,,,BAO_0000019,CHEMBL629948,0,Autocuration,,,22224,
14386,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",1,U,,,,,,,,,BAO_0000019,CHEMBL856024,0,Autocuration,,,22224,
14387,Affinity constant KD value was derived from TMP,1,U,,,,,,,,,BAO_0000019,CHEMBL629949,0,Autocuration,,,22224,
14388,Apparent dissociation (binding) rate constant was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL629950,0,Autocuration,,,22224,
14389,Dissociation constant (KD) of the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL630127,0,Autocuration,,,22224,
14390,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,1,U,,,,,,,,,BAO_0000100,CHEMBL630128,0,Autocuration,,,22224,
14391,Dissociation constant from ESR titration experiments,1,U,,,,,,,,,BAO_0000100,CHEMBL630129,0,Autocuration,,,22224,
14392,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),1,U,,,,,,,,,BAO_0000019,CHEMBL630130,0,Autocuration,,,22224,
14393,Dissociation constant was evaluated.,1,U,,,,,,,,,BAO_0000100,CHEMBL875234,0,Autocuration,,,22224,
14394,Dissociation constant was reported,1,U,,,,,,,,,BAO_0000100,CHEMBL630131,0,Autocuration,,,22224,
14395,Dissociation constant was determined in rat pituitary cells.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630132,1,Intermediate,10116.0,,50597,
14396,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,1,U,,,,,,,,,BAO_0000019,CHEMBL630133,0,Autocuration,,,22224,
14397,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,1,U,,,,,,,,,BAO_0000019,CHEMBL630134,0,Autocuration,,,22224,
14398,Equilibrium dissociation constant of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL630135,0,Autocuration,,,22224,
14399,Equilibrium dissociation constant was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL630136,0,Autocuration,,,22224,
14400,Kinetic constant KD was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL630137,0,Autocuration,,,22224,
14401,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,1,U,,,,,,,,,BAO_0000019,CHEMBL630138,0,Autocuration,,,22224,
14402,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,1,U,,,,,,,,,BAO_0000019,CHEMBL630139,0,Autocuration,,,22224,
14403,Rate constant for hydrolysis in aqueous acetone.,1,U,,,,,,,,,BAO_0000019,CHEMBL630140,0,Autocuration,,,22224,
14404,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,1,U,,,,,,,,,BAO_0000019,CHEMBL875235,0,Autocuration,,,22224,
14405,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876439,1,Intermediate,10116.0,,50597,
14406,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630605,1,Intermediate,10116.0,,50597,
14407,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630606,1,Intermediate,10116.0,,50597,
14408,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630607,1,Intermediate,10116.0,,50597,
14409,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630608,1,Intermediate,10116.0,,50597,
14410,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630609,1,Intermediate,10116.0,,50597,
14411,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630610,1,Intermediate,10116.0,,50597,
14412,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630611,1,Intermediate,10116.0,,50597,
14413,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629552,1,Intermediate,10116.0,,50597,
14414,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629733,1,Intermediate,10116.0,,50597,
14415,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629734,1,Intermediate,10116.0,,50597,
14416,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629735,1,Intermediate,10116.0,,50597,
14417,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629736,1,Intermediate,10116.0,,50597,
14418,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629737,1,Intermediate,10116.0,,50597,
14419,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629738,1,Intermediate,10116.0,,50597,
14420,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629739,1,Intermediate,10116.0,,50597,
14421,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629740,1,Intermediate,10116.0,,50597,
14422,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629741,1,Intermediate,10116.0,,50597,
14423,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629742,1,Intermediate,10116.0,,50597,
14424,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629743,1,Intermediate,10116.0,,50597,
14425,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629744,1,Intermediate,10116.0,,50597,
14426,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629745,1,Intermediate,10116.0,,50597,
14427,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629746,1,Intermediate,10116.0,,50597,
14428,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629747,1,Intermediate,10116.0,,50597,
14429,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629748,1,Intermediate,10116.0,,50597,
14430,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629749,1,Intermediate,10116.0,,50597,
14431,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629750,1,Intermediate,10116.0,,50597,
14432,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629751,1,Intermediate,10116.0,,50597,
14433,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629752,1,Intermediate,10116.0,,50597,
14434,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629753,1,Intermediate,10116.0,,50597,
14435,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629754,1,Intermediate,10116.0,,50597,
14436,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629755,1,Intermediate,10116.0,,50597,
14437,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629756,1,Intermediate,10116.0,,50597,
14438,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629757,1,Intermediate,10116.0,,50597,
14439,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629758,1,Intermediate,10116.0,,50597,
14440,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629759,1,Intermediate,10116.0,,50597,
14441,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629760,1,Intermediate,10116.0,,50597,
14442,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876443,1,Intermediate,10116.0,,50597,
14443,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629761,1,Intermediate,9615.0,,50588,
14444,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629762,1,Intermediate,9615.0,,50588,
14445,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629763,1,Intermediate,10090.0,,50594,
14446,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629764,1,Intermediate,10090.0,,50594,
14447,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629765,1,Intermediate,10090.0,,50594,
14448,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629766,1,Intermediate,10090.0,,50594,
14449,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629767,1,Intermediate,10090.0,,50594,
14450,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629768,1,Intermediate,9615.0,,50588,
14451,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629769,1,Intermediate,10090.0,,50594,
14452,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629770,1,Intermediate,9615.0,,50588,
14453,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,1,N,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL629771,1,Intermediate,9615.0,,50588,
14454,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629772,1,Intermediate,10090.0,,50594,
14455,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL629773,1,Intermediate,10090.0,,50594,
14456,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625455,1,Intermediate,10090.0,,50594,
14457,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625456,1,Intermediate,10090.0,,50594,
14458,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL625457,1,Intermediate,10090.0,,50594,
14459,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625458,1,Intermediate,10116.0,,50597,
14460,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625459,1,Intermediate,10116.0,,50597,
14461,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875483,1,Intermediate,10116.0,,50597,
14462,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL634779,1,Intermediate,10116.0,,50597,
14463,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625460,1,Intermediate,10116.0,,50597,
14464,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626117,1,Intermediate,10116.0,,50597,
14465,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626118,1,Intermediate,10116.0,,50597,
14466,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628342,1,Intermediate,10116.0,,50597,
14467,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628343,1,Intermediate,10116.0,,50597,
14468,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628344,1,Intermediate,10116.0,,50597,
14469,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628345,1,Intermediate,10116.0,,50597,
14470,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628346,1,Intermediate,10116.0,,50597,
14471,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628347,1,Intermediate,10116.0,,50597,
14472,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628348,1,Intermediate,10116.0,,50597,
14473,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628349,1,Intermediate,10116.0,,50597,
14474,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875611,1,Intermediate,10116.0,,50597,
14475,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628350,1,Intermediate,10116.0,,50597,
14476,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628351,1,Intermediate,10116.0,,50597,
14477,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628352,1,Intermediate,10116.0,,50597,
14478,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628353,1,Intermediate,10116.0,,50597,
14479,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628354,1,Intermediate,10116.0,,50597,
14480,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626667,1,Intermediate,10116.0,,50597,
14481,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626668,1,Intermediate,10116.0,,50597,
14482,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626669,1,Intermediate,10116.0,,50597,
14483,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626670,1,Intermediate,10116.0,,50597,
14484,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626671,1,Intermediate,10116.0,,50597,
14485,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626672,1,Intermediate,10116.0,,50597,
14486,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626673,1,Intermediate,10116.0,,50597,
14487,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626674,1,Intermediate,10116.0,,50597,
14488,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626675,1,Intermediate,10116.0,,50597,
14489,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626676,1,Intermediate,10116.0,,50597,
14490,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626677,1,Intermediate,10116.0,,50597,
14491,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626678,1,Intermediate,10116.0,,50597,
14492,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626679,1,Intermediate,10116.0,,50597,
14493,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875612,1,Intermediate,10116.0,,50597,
14494,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626680,1,Intermediate,10116.0,,50597,
14495,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626681,1,Intermediate,10116.0,,50597,
14496,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626682,1,Intermediate,10116.0,,50597,
14497,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626683,1,Intermediate,10116.0,,50597,
14498,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626684,1,Intermediate,10116.0,,50597,
14499,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626685,1,Intermediate,10116.0,,50597,
14500,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626686,1,Intermediate,10116.0,,50597,
14501,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626687,1,Intermediate,10116.0,,50597,
14502,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624978,1,Intermediate,10116.0,,50597,
14503,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624979,1,Intermediate,10116.0,,50597,
14504,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624980,1,Intermediate,10116.0,,50597,
14505,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL624981,1,Intermediate,10116.0,,50597,
14506,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL624982,1,Intermediate,9615.0,,50588,
14507,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627564,0,Autocuration,,,22224,
14508,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627565,0,Autocuration,,,22224,
14509,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,1,U,,,,,,,,,BAO_0000218,CHEMBL627566,0,Autocuration,,,22224,
14510,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627567,0,Autocuration,,,22224,
14511,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,1,U,,,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627568,0,Autocuration,,,22224,
14512,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,1,U,,,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627569,0,Autocuration,,,22224,
14513,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,1,U,,,,,,Urinary bladder,,1255.0,BAO_0000218,CHEMBL627570,0,Autocuration,,,22224,
14514,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,1,U,,,,,,Blood,,178.0,BAO_0000218,CHEMBL627571,0,Autocuration,,,22224,
14515,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,1,U,,,,,,Bone element,,1474.0,BAO_0000218,CHEMBL627572,0,Autocuration,,,22224,
14516,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,1,U,,,,,,,,,BAO_0000218,CHEMBL627573,0,Autocuration,,,22224,
14517,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,1,U,,,,,,Kidney,,2113.0,BAO_0000218,CHEMBL627574,0,Autocuration,,,22224,
14518,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,1,U,,,,,,Liver,,2107.0,BAO_0000218,CHEMBL627575,0,Autocuration,,,22224,
14519,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,1,U,,,,,,Lung,,2048.0,BAO_0000218,CHEMBL627576,0,Autocuration,,,22224,
14520,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627577,0,Autocuration,,,22224,
14521,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627578,0,Autocuration,,,22224,
14522,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627579,0,Autocuration,,,22224,
14523,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627580,0,Autocuration,,,22224,
14524,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627581,0,Autocuration,,,22224,
14525,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,1,U,,,,,,,,,BAO_0000218,CHEMBL627582,0,Autocuration,,,22224,
14526,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627583,0,Autocuration,,,22224,
14527,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,1,U,,,,,,Spleen,,2106.0,BAO_0000218,CHEMBL627584,0,Autocuration,,,22224,
14528,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,1,U,,,,,,Prostate gland,,2367.0,BAO_0000218,CHEMBL627585,0,Autocuration,,,22224,
14529,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,1,U,,,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL627586,0,Autocuration,,,22224,
14530,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627587,1,Intermediate,10116.0,,50597,
14531,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL627588,1,Intermediate,10116.0,,50597,
14532,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628250,1,Intermediate,10116.0,,50597,
14533,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628251,1,Intermediate,10116.0,,50597,
14534,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL628252,1,Intermediate,10116.0,,50597,
14535,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL628253,1,Intermediate,10116.0,,50597,
14536,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL628254,1,Intermediate,10116.0,,50597,
14537,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL877493,1,Intermediate,10116.0,,50597,
14538,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628255,1,Intermediate,10116.0,,50597,
14539,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628256,1,Intermediate,10116.0,,50597,
14540,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL628257,1,Intermediate,10116.0,,50597,
14541,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL628258,1,Intermediate,10116.0,,50597,
14542,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628259,1,Intermediate,10116.0,,50597,
14543,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628429,1,Intermediate,10116.0,,50597,
14544,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL626862,1,Intermediate,10116.0,,50597,
14545,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL626863,1,Intermediate,10116.0,,50597,
14546,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL625886,1,Intermediate,10116.0,,50597,
14547,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL625887,1,Intermediate,10116.0,,50597,
14548,Biodistribution of the [11C]-radiolabeled compound in rat cortex,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625888,1,Intermediate,10116.0,,50597,
14549,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625889,1,Intermediate,10116.0,,50597,
14550,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625890,1,Intermediate,10116.0,,50597,
14551,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL625891,1,Intermediate,10116.0,,50597,
14552,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL625892,1,Intermediate,10116.0,,50597,
14553,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL625893,1,Intermediate,10116.0,,50597,
14554,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,1,N,,Rattus norvegicus,,,,Cerebellum,,2037.0,BAO_0000218,CHEMBL625894,1,Intermediate,10116.0,,50597,
14555,Biodistribution of the [18F]-radiolabeled compound in rat cortex,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625895,1,Intermediate,10116.0,,50597,
14556,Reaction rate parameter value for phosphate with transfer with respect to ATP,1,U,,,,,,,,,BAO_0000019,CHEMBL625896,0,Autocuration,,,22224,
14557,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",1,U,,,,,,,,,BAO_0000019,CHEMBL625897,0,Autocuration,,,22224,
14558,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",1,U,,,,,,,,,BAO_0000019,CHEMBL625898,0,Autocuration,,,22224,
14559,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",1,U,,,,,,,,,BAO_0000019,CHEMBL625899,0,Autocuration,,,22224,
14560,Reaction rate parameter value for phosphate with transfer with respect to ATP,1,U,,,,,,,,,BAO_0000019,CHEMBL626124,0,Autocuration,,,22224,
14561,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,1,N,,Escherichia coli,,,,,,,BAO_0000218,CHEMBL628500,1,Intermediate,562.0,,50212,
14562,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL857856,1,Intermediate,10116.0,,50597,
14563,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628501,1,Intermediate,10116.0,,50597,
14564,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",1,U,,,,,,,,,BAO_0000019,CHEMBL628502,0,Autocuration,,,22224,
14565,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,1,U,,,,,,,,,BAO_0000019,CHEMBL628503,0,Autocuration,,,22224,
14566,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL628504,0,Autocuration,,,22224,
14567,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL628505,0,Autocuration,,,22224,
14568,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",1,U,,,,,,,,,BAO_0000019,CHEMBL874452,0,Autocuration,,,22224,
14569,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL628506,0,Autocuration,,,22224,
14570,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL628507,0,Autocuration,,,22224,
14571,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",1,U,,,,,,,,,BAO_0000019,CHEMBL628508,0,Autocuration,,,22224,
14572,Michaelis constant (KM) was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL628509,0,Autocuration,,,22224,
14573,Reaction rate parameter value for phosphate with transfer with respect to ATP,1,U,,,,,,,,,BAO_0000019,CHEMBL628510,0,Autocuration,,,22224,
14574,Substrate concentration for half maximal velocity was reported for rat hexokinase I,1,U,,,,,,,,,BAO_0000019,CHEMBL628511,0,Autocuration,,,22224,
14575,Substrate concentration for half maximal velocity was reported for rat hexokinase II,1,U,,,,,,,,,BAO_0000019,CHEMBL628512,0,Autocuration,,,22224,
14576,Substrate concentration for half maximal velocity was reported for rat hexokinase III,1,U,,,,,,,,,BAO_0000019,CHEMBL628513,0,Autocuration,,,22224,
14577,Substrate concentration for half maximal velocity was reported for yeast hexokinase,1,U,,,,,,,,,BAO_0000019,CHEMBL628514,0,Autocuration,,,22224,
14578,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,1,U,,,,,,,,,BAO_0000019,CHEMBL628515,0,Autocuration,,,22224,
14579,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,1,U,,,,,,,,,BAO_0000019,CHEMBL628516,0,Autocuration,,,22224,
14580,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),1,U,,,,,,,,,BAO_0000019,CHEMBL628517,0,Autocuration,,,22224,
14581,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),1,U,,,,,,,,,BAO_0000019,CHEMBL628518,0,Autocuration,,,22224,
14582,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,1,U,,,,,,,,,BAO_0000019,CHEMBL628519,0,Autocuration,,,22224,
14583,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,1,U,,,,,,,,,BAO_0000019,CHEMBL628520,0,Autocuration,,,22224,
14584,Binding constant was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL628521,0,Autocuration,,,22224,
14585,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL630443,0,Autocuration,,,22224,
14586,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,1,U,,,,,,,,,BAO_0000019,CHEMBL630444,0,Autocuration,,,22224,
14587,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,1,U,,,,,,,,,BAO_0000019,CHEMBL857732,0,Autocuration,,,22224,
14588,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,1,U,,,,,,,,,BAO_0000100,CHEMBL630445,0,Autocuration,,,22224,
14589,Catalytic rate constant of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL630446,0,Autocuration,,,22224,
14590,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,1,U,,,,,,,,,BAO_0000019,CHEMBL630447,0,Autocuration,,,22224,
14591,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),1,U,,,,,,,,,BAO_0000019,CHEMBL630448,0,Autocuration,,,22224,
14592,Catalytic rate constant against phospholipase A2 was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL630449,0,Autocuration,,,22224,
14593,"Compound was evaluated for catalytic constant, Kcat",1,U,,,,,,,,,BAO_0000019,CHEMBL630450,0,Autocuration,,,22224,
14594,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL630451,0,Autocuration,,,22224,
14595,Kcat calculated from 0.693/T1/2,1,U,,,,,,,,,BAO_0000019,CHEMBL630452,0,Autocuration,,,22224,
14596,Kcat was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL630453,0,Autocuration,,,22224,
14597,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,1,U,,,,,,,,,BAO_0000019,CHEMBL630454,0,Autocuration,,,22224,
14598,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,1,U,,,,,,,,,BAO_0000019,CHEMBL630455,0,Autocuration,,,22224,
14599,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,1,U,,,,,,,,,BAO_0000019,CHEMBL631487,0,Autocuration,,,22224,
14600,Kcat value was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631488,0,Autocuration,,,22224,
14601,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL876440,0,Autocuration,,,22224,
14602,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL631489,0,Autocuration,,,22224,
14603,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL857742,0,Autocuration,,,22224,
14604,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",1,U,,,,,,,,,BAO_0000019,CHEMBL631490,0,Autocuration,,,22224,
14605,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL631491,0,Autocuration,,,22224,
14606,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL631492,0,Autocuration,,,22224,
14607,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",1,U,,,,,,,,,BAO_0000019,CHEMBL631493,0,Autocuration,,,22224,
14608,Kinetic parameter for rate of conversion to PABA was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL631494,0,Autocuration,,,22224,
14609,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL631495,0,Autocuration,,,22224,
14610,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,N,,Rattus norvegicus,,,,Feces,,1988.0,BAO_0000218,CHEMBL631496,1,Intermediate,10116.0,,50597,
14611,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631497,1,Intermediate,10116.0,,50597,
14612,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631498,1,Intermediate,10116.0,,50597,
14613,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629776,1,Intermediate,10116.0,,50597,
14614,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629777,1,Intermediate,10116.0,,50597,
14615,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL629778,1,Intermediate,10116.0,,50597,
14616,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630456,1,Intermediate,10116.0,,50597,
14617,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630457,1,Intermediate,10116.0,,50597,
14618,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630458,1,Intermediate,10116.0,,50597,
14619,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630459,1,Intermediate,10116.0,,50597,
14620,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630460,1,Intermediate,10116.0,,50597,
14621,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL876550,1,Intermediate,10116.0,,50597,
14622,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630461,1,Intermediate,10116.0,,50597,
14623,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630462,1,Intermediate,10116.0,,50597,
14624,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630463,1,Intermediate,10116.0,,50597,
14625,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630464,1,Intermediate,10116.0,,50597,
14626,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630465,1,Intermediate,10116.0,,50597,
14627,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630466,1,Intermediate,10116.0,,50597,
14628,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630467,1,Intermediate,10116.0,,50597,
14629,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630633,1,Intermediate,10116.0,,50597,
14630,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630634,1,Intermediate,10116.0,,50597,
14631,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630635,1,Intermediate,10116.0,,50597,
14632,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630636,1,Intermediate,10116.0,,50597,
14633,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630637,1,Intermediate,10116.0,,50597,
14634,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL630638,1,Intermediate,9986.0,,50592,
14635,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL630639,1,Intermediate,9986.0,,50592,
14636,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL630640,1,Intermediate,9986.0,,50592,
14637,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL876551,1,Intermediate,9986.0,,50592,
14638,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630641,1,Intermediate,9986.0,,50592,
14639,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630642,1,Intermediate,9986.0,,50592,
14640,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630643,1,Intermediate,9986.0,,50592,
14641,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630644,1,Intermediate,9986.0,,50592,
14642,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL630645,1,Intermediate,9986.0,,50592,
14643,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL625599,1,Intermediate,9986.0,,50592,
14644,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL625600,1,Intermediate,9986.0,,50592,
14645,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL625601,1,Intermediate,9986.0,,50592,
14646,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,N,,Oryctolagus cuniculus,,,,Feces,,1988.0,BAO_0000218,CHEMBL625602,1,Intermediate,9986.0,,50592,
14647,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627470,1,Intermediate,9986.0,,50592,
14648,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627471,1,Intermediate,9986.0,,50592,
14649,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627472,1,Intermediate,9986.0,,50592,
14650,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627473,1,Intermediate,9986.0,,50592,
14651,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,N,,Oryctolagus cuniculus,,,,Urine,,1088.0,BAO_0000218,CHEMBL627474,1,Intermediate,9986.0,,50592,
14652,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627475,1,Intermediate,10116.0,,50597,
14653,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL627476,1,Intermediate,10116.0,,50597,
14654,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627477,1,Intermediate,9615.0,,50588,
14655,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627478,1,Intermediate,9615.0,,50588,
14656,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627479,1,Intermediate,9615.0,,50588,
14657,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627480,1,Intermediate,9615.0,,50588,
14658,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627481,1,Intermediate,9615.0,,50588,
14659,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627482,1,Intermediate,9615.0,,50588,
14660,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL627483,1,Intermediate,9615.0,,50588,
14661,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL875636,1,Intermediate,9615.0,,50588,
14662,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625764,1,Intermediate,9615.0,,50588,
14663,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625765,1,Intermediate,9615.0,,50588,
14664,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625766,1,Intermediate,9615.0,,50588,
14665,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625767,1,Intermediate,9615.0,,50588,
14666,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625768,1,Intermediate,9615.0,,50588,
14667,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625769,1,Intermediate,9615.0,,50588,
14668,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625770,1,Intermediate,9615.0,,50588,
14669,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625771,1,Intermediate,9615.0,,50588,
14670,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625772,1,Intermediate,9615.0,,50588,
14671,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,N,,Canis lupus familiaris,,,,Urine,,1088.0,BAO_0000218,CHEMBL625773,1,Intermediate,9615.0,,50588,
14672,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625774,1,Intermediate,10116.0,,50597,
14673,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625775,1,Intermediate,10116.0,,50597,
14674,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625776,1,Intermediate,10116.0,,50597,
14675,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625777,1,Intermediate,10116.0,,50597,
14676,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625778,1,Intermediate,10116.0,,50597,
14677,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625779,1,Intermediate,10116.0,,50597,
14678,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625780,1,Intermediate,10116.0,,50597,
14679,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL625781,1,Intermediate,10116.0,,50597,
14680,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875637,1,Intermediate,10116.0,,50597,
14681,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626473,1,Intermediate,10116.0,,50597,
14682,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626474,1,Intermediate,10116.0,,50597,
14683,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626475,1,Intermediate,10116.0,,50597,
14684,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626476,1,Intermediate,10116.0,,50597,
14685,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL634397,1,Intermediate,10116.0,,50597,
14686,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL626477,1,Intermediate,10116.0,,50597,
14687,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631069,1,Intermediate,10116.0,,50597,
14688,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631070,1,Intermediate,10116.0,,50597,
14689,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631071,1,Intermediate,10116.0,,50597,
14690,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631072,1,Intermediate,10116.0,,50597,
14691,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631073,1,Intermediate,10116.0,,50597,
14692,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631074,1,Intermediate,10116.0,,50597,
14693,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631075,1,Intermediate,10116.0,,50597,
14694,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631725,1,Intermediate,10116.0,,50597,
14695,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631726,1,Intermediate,10116.0,,50597,
14696,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631727,1,Intermediate,10116.0,,50597,
14697,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631728,1,Intermediate,10116.0,,50597,
14698,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631729,1,Intermediate,10116.0,,50597,
14699,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631730,1,Intermediate,10116.0,,50597,
14700,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631731,1,Intermediate,10116.0,,50597,
14701,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631910,1,Intermediate,10116.0,,50597,
14702,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,1,N,,Rattus norvegicus,,,,Hippocampus,,10000000.0,BAO_0000218,CHEMBL631911,1,Intermediate,10116.0,,50597,
14703,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL631912,1,Intermediate,10116.0,,50597,
14704,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1,N,,Rattus norvegicus,,,,Hypothalamus,,1898.0,BAO_0000218,CHEMBL631913,1,Intermediate,10116.0,,50597,
14705,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631914,1,Intermediate,10116.0,,50597,
14706,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631915,1,Intermediate,10116.0,,50597,
14707,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL875778,1,Intermediate,10116.0,,50597,
14708,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631916,1,Intermediate,10116.0,,50597,
14709,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631917,1,Intermediate,10116.0,,50597,
14710,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631918,1,Intermediate,10116.0,,50597,
14711,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631919,1,Intermediate,10116.0,,50597,
14712,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631920,1,Intermediate,10116.0,,50597,
14713,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631921,1,Intermediate,10116.0,,50597,
14714,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631922,1,Intermediate,10116.0,,50597,
14715,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL631923,1,Intermediate,10116.0,,50597,
14716,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631924,1,Intermediate,10116.0,,50597,
14717,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630234,1,Intermediate,10116.0,,50597,
14718,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630235,1,Intermediate,10116.0,,50597,
14719,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630236,1,Intermediate,10116.0,,50597,
14720,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630237,1,Intermediate,10116.0,,50597,
14721,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630238,1,Intermediate,10116.0,,50597,
14722,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630239,1,Intermediate,10116.0,,50597,
14723,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630303,1,Intermediate,10116.0,,50597,
14724,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630304,1,Intermediate,10116.0,,50597,
14725,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630305,1,Intermediate,10116.0,,50597,
14726,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630306,1,Intermediate,10116.0,,50597,
14727,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630307,1,Intermediate,10116.0,,50597,
14728,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630308,1,Intermediate,10116.0,,50597,
14729,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630309,1,Intermediate,10116.0,,50597,
14730,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL629309,1,Intermediate,10116.0,,50597,
14731,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL629993,1,Intermediate,10116.0,,50597,
14732,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL629994,1,Intermediate,10116.0,,50597,
14733,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL629995,1,Intermediate,10116.0,,50597,
14734,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL631993,1,Intermediate,10116.0,,50597,
14735,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL631994,1,Intermediate,10116.0,,50597,
14736,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL631995,1,Intermediate,10116.0,,50597,
14737,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631996,1,Intermediate,10116.0,,50597,
14738,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631997,1,Intermediate,10116.0,,50597,
14739,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631998,1,Intermediate,10116.0,,50597,
14740,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631999,1,Intermediate,10116.0,,50597,
14741,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL632000,1,Intermediate,10116.0,,50597,
14742,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL632001,1,Intermediate,10116.0,,50597,
14743,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL874424,1,Intermediate,10116.0,,50597,
14744,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL632002,1,Intermediate,10116.0,,50597,
14745,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL632003,1,Intermediate,10116.0,,50597,
14746,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL632004,0,Autocuration,,,22224,
14747,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632005,0,Autocuration,,,22224,
14748,Compound was tested for amidase rate in the presence of N62C screen enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632006,0,Autocuration,,,22224,
14749,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632007,0,Autocuration,,,22224,
14750,Compound was tested for amidase rate in the presence of S166C screen enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632008,0,Autocuration,,,22224,
14751,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632009,0,Autocuration,,,22224,
14752,Compound was tested for esterase rate in the presence of N62C screen enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632010,0,Autocuration,,,22224,
14753,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL857750,0,Autocuration,,,22224,
14754,Compound was tested for esterase rate in the presence of S166C screen enzyme,1,U,,,,,,,,,BAO_0000019,CHEMBL632011,0,Autocuration,,,22224,
14755,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,U,,,,,,,,,BAO_0000019,CHEMBL632012,0,Autocuration,,,22224,
14756,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,U,,,,,,,,,BAO_0000019,CHEMBL632013,0,Autocuration,,,22224,
14757,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",1,U,,,,,,,,,BAO_0000019,CHEMBL632014,0,Autocuration,,,22224,
14758,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,U,,,,,,,,,BAO_0000019,CHEMBL629622,0,Autocuration,,,22224,
14759,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,U,,,,,,,,,BAO_0000019,CHEMBL629623,0,Autocuration,,,22224,
14760,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",1,U,,,,,,,,,BAO_0000019,CHEMBL629624,0,Autocuration,,,22224,
14761,Ratio of Kcat to that of Km was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL629625,0,Autocuration,,,22224,
14762,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",1,U,,,,,,,,,BAO_0000019,CHEMBL629626,0,Autocuration,,,22224,
14763,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",1,U,,,,,,,,,BAO_0000019,CHEMBL629627,0,Autocuration,,,22224,
14764,"Compound was evaluated for constant, Kd",1,U,,,,,,,,,BAO_0000019,CHEMBL629628,0,Autocuration,,,22224,
14765,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,1,U,,,,,,,,,BAO_0000019,CHEMBL629629,0,Autocuration,,,22224,
14766,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,1,U,,,,,,,,,BAO_0000019,CHEMBL629630,0,Autocuration,,,22224,
14767,Dissociation Constant of compound determined,1,U,,,,,,,,,BAO_0000019,CHEMBL856030,0,Autocuration,,,22224,
14768,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL629631,0,Autocuration,,,22224,
14769,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,1,U,,,,,,,,,BAO_0000019,CHEMBL629632,0,Autocuration,,,22224,
14770,Dissociation constant of compound with Fructose was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629633,0,Autocuration,,,22224,
14771,Dissociation constant of compound with Fructose was determined; Not determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629634,0,Autocuration,,,22224,
14772,Dissociation constant of compound with Lactulose was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629635,0,Autocuration,,,22224,
14773,Dissociation constant of compound with Lactulose was determined; Not determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629636,0,Autocuration,,,22224,
14774,Dissociation constant of the Compound,1,U,,,,,,,,,BAO_0000100,CHEMBL629637,0,Autocuration,,,22224,
14775,Dissociation constant by non-linear regression analysis,1,U,,,,,,,,,BAO_0000100,CHEMBL629638,0,Autocuration,,,22224,
14776,Dissociation constant was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629639,0,Autocuration,,,22224,
14777,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,1,U,,,,,,,,,BAO_0000100,CHEMBL629640,0,Autocuration,,,22224,
14778,Dissociation constant was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629641,0,Autocuration,,,22224,
14779,Dissociation constant was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL631344,0,Autocuration,,,22224,
14780,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631345,1,Intermediate,10116.0,,50597,
14781,The dissociation constant determined by fluorescence displacement assay,1,U,,,,,,,,,BAO_0000019,CHEMBL631346,0,Autocuration,,,22224,
14782,kd value surface plasmon resonance (SPR) method,1,U,,,,,,,,,BAO_0000019,CHEMBL631524,0,Autocuration,,,22224,
14783,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631525,1,Intermediate,10116.0,,50597,
14784,First dissociation constant of the binding of compound to V30M TTR,1,U,,,,,,,,,BAO_0000019,CHEMBL631526,0,Autocuration,,,22224,
14785,Second dissociation constant of the binding of compound to V30M TTR,1,U,,,,,,,,,BAO_0000019,CHEMBL631527,0,Autocuration,,,22224,
14786,"Compound was evaluated for equilibrium constant, Ke",1,U,,,,,,,,,BAO_0000019,CHEMBL631528,0,Autocuration,,,22224,
14787,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,1,U,,,,,,Hypothalamus,,1898.0,BAO_0000019,CHEMBL631529,0,Autocuration,,,22224,
14788,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,1,U,,,,,,Hypothalamus,,1898.0,BAO_0000019,CHEMBL631530,0,Autocuration,,,22224,
14789,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL631531,0,Autocuration,,,22224,
14790,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL631532,0,Autocuration,,,22224,
14791,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL631533,0,Autocuration,,,22224,
14792,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL876552,1,Intermediate,10090.0,,50594,
14793,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631534,1,Intermediate,10090.0,,50594,
14794,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631535,1,Intermediate,10090.0,,50594,
14795,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631536,1,Intermediate,10090.0,,50594,
14796,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631537,1,Intermediate,10090.0,,50594,
14797,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631538,1,Intermediate,10090.0,,50594,
14798,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631539,1,Intermediate,10090.0,,50594,
14799,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631540,1,Intermediate,10090.0,,50594,
14800,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625637,1,Intermediate,10116.0,,50597,
14801,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625638,1,Intermediate,10116.0,,50597,
14802,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL625639,1,Intermediate,10116.0,,50597,
14803,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625640,1,Intermediate,10116.0,,50597,
14804,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625641,1,Intermediate,10116.0,,50597,
14805,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625642,1,Intermediate,10116.0,,50597,
14806,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625643,1,Intermediate,10116.0,,50597,
14807,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625644,1,Intermediate,10116.0,,50597,
14808,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL625645,1,Intermediate,10116.0,,50597,
14809,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625646,1,Intermediate,10116.0,,50597,
14810,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625647,1,Intermediate,10116.0,,50597,
14811,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625648,1,Intermediate,10116.0,,50597,
14812,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL625649,1,Intermediate,10116.0,,50597,
14813,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625650,1,Intermediate,10116.0,,50597,
14814,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL625651,1,Intermediate,10116.0,,50597,
14815,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL625652,1,Intermediate,10116.0,,50597,
14816,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Zone of skin,,14.0,BAO_0000218,CHEMBL625653,1,Intermediate,10116.0,,50597,
14817,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625654,1,Intermediate,10116.0,,50597,
14818,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL625655,1,Intermediate,10116.0,,50597,
14819,Biodistribution of Compound in rat blood after 15 minutes of administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625656,1,Intermediate,10116.0,,50597,
14820,Biodistribution of Compound in rat blood after 2 minutes of administration,1,N,,Rattus norvegicus,,,,Blood,,178.0,BAO_0000218,CHEMBL625657,1,Intermediate,10116.0,,50597,
14821,Biodistribution of Compound in rat brain after 15 minutes of administration,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625658,1,Intermediate,10116.0,,50597,
14822,Biodistribution of Compound in rat brain after 2 minutes of administration,1,N,,Rattus norvegicus,,,,Brain,,955.0,BAO_0000218,CHEMBL625659,1,Intermediate,10116.0,,50597,
14823,Biodistribution of Compound in rat heart after 15 minutes of administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625660,1,Intermediate,10116.0,,50597,
14824,Biodistribution of Compound in rat heart after 2 minutes of administration,1,N,,Rattus norvegicus,,,,Heart,,948.0,BAO_0000218,CHEMBL625661,1,Intermediate,10116.0,,50597,
14825,Biodistribution of Compound in rat liver after 15 minutes of administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625662,1,Intermediate,10116.0,,50597,
14826,Biodistribution of Compound in rat liver after 2 minutes of administration,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL625663,1,Intermediate,10116.0,,50597,
14827,Biodistribution of Compound in rat lung after 15 minutes of administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL875621,1,Intermediate,10116.0,,50597,
14828,Biodistribution of Compound in rat lung after 2 minutes of administration,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL628382,1,Intermediate,10116.0,,50597,
14829,Biodistribution of Compound in rat muscle after 15 minutes of administration,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL628383,1,Intermediate,10116.0,,50597,
14830,Biodistribution of Compound in rat muscle after 2 minutes of administration,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL628384,1,Intermediate,10116.0,,50597,
14831,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628385,1,Intermediate,10116.0,,50597,
14832,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875753,1,Intermediate,10116.0,,50597,
14833,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628386,1,Intermediate,10116.0,,50597,
14834,Organ distribution in rat blood 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628387,1,Intermediate,10116.0,,50597,
14835,Organ distribution in rat blood 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628388,1,Intermediate,10116.0,,50597,
14836,Organ distribution in rat blood 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628389,1,Intermediate,10116.0,,50597,
14837,Organ distribution in rat blood 30 min after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL632756,1,Intermediate,10116.0,,50597,
14838,Organ distribution in rat brain 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628390,1,Intermediate,10116.0,,50597,
14839,Organ distribution in rat brain 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631811,1,Intermediate,10116.0,,50597,
14840,Organ distribution in rat brain 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631812,1,Intermediate,10116.0,,50597,
14841,Organ distribution in rat heart 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631813,1,Intermediate,10116.0,,50597,
14842,Organ distribution in rat heart 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631814,1,Intermediate,10116.0,,50597,
14843,Organ distribution in rat heart 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631815,1,Intermediate,10116.0,,50597,
14844,Organ distribution in rat kidney 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631816,1,Intermediate,10116.0,,50597,
14845,Organ distribution in rat kidney 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL875758,1,Intermediate,10116.0,,50597,
14846,Organ distribution in rat kidney 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631817,1,Intermediate,10116.0,,50597,
14847,Organ distribution in rat liver 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631818,1,Intermediate,10116.0,,50597,
14848,Organ distribution in rat liver 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631819,1,Intermediate,10116.0,,50597,
14849,Organ distribution in rat liver 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL631820,1,Intermediate,10116.0,,50597,
14850,Organ distribution in rat lung 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631821,1,Intermediate,10116.0,,50597,
14851,Organ distribution in rat lung 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631822,1,Intermediate,10116.0,,50597,
14852,Organ distribution in rat lung 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL631823,1,Intermediate,10116.0,,50597,
14853,Organ distribution in rat muscle 2 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631824,1,Intermediate,10116.0,,50597,
14854,Organ distribution in rat muscle 2 hr after intravenous injection,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631825,1,Intermediate,10116.0,,50597,
14855,Organ distribution in rat muscle 30 minutes after intravenous injection,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631826,1,Intermediate,10116.0,,50597,
14856,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631827,1,Intermediate,10090.0,,50594,
14857,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631828,1,Intermediate,10090.0,,50594,
14858,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL631829,1,Intermediate,10090.0,,50594,
14859,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875759,1,Intermediate,10116.0,,50597,
14860,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631830,1,Intermediate,10116.0,,50597,
14861,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631831,1,Intermediate,10116.0,,50597,
14862,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631832,1,Intermediate,10116.0,,50597,
14863,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631833,1,Intermediate,10116.0,,50597,
14864,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631834,1,Intermediate,10116.0,,50597,
14865,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631835,1,Intermediate,10116.0,,50597,
14866,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631836,1,Intermediate,10116.0,,50597,
14867,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631837,1,Intermediate,10116.0,,50597,
14868,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631838,1,Intermediate,10116.0,,50597,
14869,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631839,1,Intermediate,10116.0,,50597,
14870,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631840,1,Intermediate,10116.0,,50597,
14871,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631841,1,Intermediate,10116.0,,50597,
14872,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631842,1,Intermediate,10116.0,,50597,
14873,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631843,1,Intermediate,10116.0,,50597,
14874,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631844,1,Intermediate,10116.0,,50597,
14875,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631845,1,Intermediate,10116.0,,50597,
14876,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631846,1,Intermediate,10116.0,,50597,
14877,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL875760,1,Intermediate,10116.0,,50597,
14878,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL632199,1,Intermediate,10116.0,,50597,
14879,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631847,1,Intermediate,10116.0,,50597,
14880,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL631848,1,Intermediate,10116.0,,50597,
14881,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628707,1,Intermediate,10116.0,,50597,
14882,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628708,1,Intermediate,10116.0,,50597,
14883,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628709,1,Intermediate,10116.0,,50597,
14884,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628710,1,Intermediate,10116.0,,50597,
14885,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628711,1,Intermediate,10116.0,,50597,
14886,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628712,1,Intermediate,10116.0,,50597,
14887,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628713,1,Intermediate,10116.0,,50597,
14888,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,N,,Rattus norvegicus,,,,Urine,,1088.0,BAO_0000218,CHEMBL628714,1,Intermediate,10116.0,,50597,
14889,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL628715,1,Intermediate,10116.0,,50597,
14890,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,1,U,,,,,,,,,BAO_0000019,CHEMBL629179,0,Autocuration,,,22224,
14891,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,1,U,,,,,,,,,BAO_0000019,CHEMBL629180,0,Autocuration,,,22224,
14892,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,1,U,,,,,,,,,BAO_0000019,CHEMBL875108,0,Autocuration,,,22224,
14893,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1,U,,,,,,Adrenal cortex,,1235.0,BAO_0000019,CHEMBL629181,0,Autocuration,,,22224,
14894,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1,U,,,,,,Adrenal cortex,,1235.0,BAO_0000019,CHEMBL629182,0,Autocuration,,,22224,
14895,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629183,0,Autocuration,,,22224,
14896,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629184,0,Autocuration,,,22224,
14897,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1,U,,,,,,Adrenal cortex,,1235.0,BAO_0000019,CHEMBL629185,0,Autocuration,,,22224,
14898,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,1,U,,,,,,Adrenal cortex,,1235.0,BAO_0000019,CHEMBL629186,0,Autocuration,,,22224,
14899,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629187,0,Autocuration,,,22224,
14900,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629887,0,Autocuration,,,22224,
14901,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629888,0,Autocuration,,,22224,
14902,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629889,0,Autocuration,,,22224,
14903,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,1,U,,,,,,Adrenal cortex,,1235.0,BAO_0000019,CHEMBL629890,0,Autocuration,,,22224,
14904,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629891,0,Autocuration,,,22224,
14905,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629892,0,Autocuration,,,22224,
14906,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1,U,,,,,,Adrenal cortex,,1235.0,BAO_0000019,CHEMBL629893,0,Autocuration,,,22224,
14907,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629894,0,Autocuration,,,22224,
14908,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,1,U,,,,,,,,,BAO_0000019,CHEMBL629895,0,Autocuration,,,22224,
14909,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",1,U,,Canis lupus familiaris,,,,,,,BAO_0000218,CHEMBL875109,0,Autocuration,9615.0,,22224,
14910,Absolute bioavailability in male cynomolgus monkeys,1,U,,Macaca fascicularis,,,,,,,BAO_0000218,CHEMBL629896,0,Autocuration,9541.0,,22224,
14911,Absolute bioavailability in maleSprague-Dawley rats,1,U,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL629897,0,Autocuration,10116.0,,22224,
14912,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL629898,1,Intermediate,10116.0,,50597,
14913,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630057,1,Intermediate,10116.0,,50597,
14914,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630058,1,Intermediate,10116.0,,50597,
14915,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630059,1,Intermediate,10116.0,,50597,
14916,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630060,1,Intermediate,10116.0,,50597,
14917,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630061,1,Intermediate,10116.0,,50597,
14918,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630062,1,Intermediate,10116.0,,50597,
14919,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630063,1,Intermediate,10116.0,,50597,
14920,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630064,1,Intermediate,10116.0,,50597,
14921,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630065,1,Intermediate,10116.0,,50597,
14922,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630066,1,Intermediate,10116.0,,50597,
14923,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630067,1,Intermediate,10116.0,,50597,
14924,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Lung,,2048.0,BAO_0000218,CHEMBL630068,1,Intermediate,10116.0,,50597,
14925,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631113,1,Intermediate,10116.0,,50597,
14926,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631114,1,Intermediate,10116.0,,50597,
14927,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631115,1,Intermediate,10116.0,,50597,
14928,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL631116,1,Intermediate,10116.0,,50597,
14929,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630528,1,Intermediate,10116.0,,50597,
14930,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630529,1,Intermediate,10116.0,,50597,
14931,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630530,1,Intermediate,10116.0,,50597,
14932,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630531,1,Intermediate,10116.0,,50597,
14933,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630532,1,Intermediate,10116.0,,50597,
14934,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Muscle tissue,,2385.0,BAO_0000218,CHEMBL630533,1,Intermediate,10116.0,,50597,
14935,Biodistribution in normal mice blood after 120 hr,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL630534,1,Intermediate,10090.0,,50594,
14936,Biodistribution in normal mice blood after 24 hr,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL630535,1,Intermediate,10090.0,,50594,
14937,Biodistribution in normal mice blood after 4 hr,1,N,,Mus musculus,,,,Blood,,178.0,BAO_0000218,CHEMBL630536,1,Intermediate,10090.0,,50594,
14938,Biodistribution in normal mice bone after 120 hr,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL630537,1,Intermediate,10090.0,,50594,
14939,Biodistribution in normal mice bone after 24 hr,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL630538,1,Intermediate,10090.0,,50594,
14940,Biodistribution in normal mice bone after 4 hr,1,N,,Mus musculus,,,,Bone,,10000001.0,BAO_0000218,CHEMBL630539,1,Intermediate,10090.0,,50594,
14941,Biodistribution in normal mice heart after 120 hr,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL630540,1,Intermediate,10090.0,,50594,
14942,Biodistribution in normal mice heart after 24 hr,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL630541,1,Intermediate,10090.0,,50594,
14943,Biodistribution in normal mice heart after 4 hr,1,N,,Mus musculus,,,,Heart,,948.0,BAO_0000218,CHEMBL630542,1,Intermediate,10090.0,,50594,
14944,Biodistribution in normal mice kidney after 120 hr,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630543,1,Intermediate,10090.0,,50594,
14945,Biodistribution in normal mice kidney after 24 hr,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630544,1,Intermediate,10090.0,,50594,
14946,Biodistribution in normal mice kidney after 4 hr,1,N,,Mus musculus,,,,Kidney,,2113.0,BAO_0000218,CHEMBL630545,1,Intermediate,10090.0,,50594,
14947,Biodistribution in normal mice liver after 120 hr,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630546,1,Intermediate,10090.0,,50594,
14948,Biodistribution in normal mice liver after 24 hr,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630547,1,Intermediate,10090.0,,50594,
14949,Biodistribution in normal mice liver after 4 hr,1,N,,Mus musculus,,,,Liver,,2107.0,BAO_0000218,CHEMBL630548,1,Intermediate,10090.0,,50594,
14950,Biodistribution in normal mice spleen after 120 hr,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630549,1,Intermediate,10090.0,,50594,
14951,Biodistribution in normal mice spleen after 24 hr,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630550,1,Intermediate,10090.0,,50594,
14952,Biodistribution in normal mice spleen after 4 hr,1,N,,Mus musculus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL876426,1,Intermediate,10090.0,,50594,
14953,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630551,1,Intermediate,10116.0,,50597,
14954,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630552,1,Intermediate,10116.0,,50597,
14955,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630553,1,Intermediate,10116.0,,50597,
14956,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630554,1,Intermediate,10116.0,,50597,
14957,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630555,1,Intermediate,10116.0,,50597,
14958,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630556,1,Intermediate,10116.0,,50597,
14959,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630557,1,Intermediate,10116.0,,50597,
14960,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630558,1,Intermediate,10116.0,,50597,
14961,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630559,1,Intermediate,10116.0,,50597,
14962,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Spleen,,2106.0,BAO_0000218,CHEMBL630560,1,Intermediate,10116.0,,50597,
14963,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,N,,Rattus norvegicus,,,,Thyroid gland,,2046.0,BAO_0000218,CHEMBL876427,1,Intermediate,10116.0,,50597,
14964,The Kel values in female wistar rats.,1,N,,Rattus norvegicus,,,,,,,BAO_0000218,CHEMBL630561,1,Intermediate,10116.0,,50597,
14965,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL630562,0,Autocuration,,,22224,
14966,Hydrolysis rate constant of the compound,1,U,,,,,,,,,BAO_0000019,CHEMBL630563,0,Autocuration,,,22224,
14967,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,1,U,,,,,,,,,BAO_0000100,CHEMBL629673,0,Autocuration,,,22229,
14968,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL629674,0,Autocuration,,,22224,
14969,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",1,U,,,,,,,,,BAO_0000019,CHEMBL629675,0,Autocuration,,,22224,
14970,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",1,U,,,,,,,,,BAO_0000019,CHEMBL629676,0,Autocuration,,,22224,
14971,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",1,U,,,,,,,,,BAO_0000019,CHEMBL629677,0,Autocuration,,,22224,
14972,Apparent inactivation rate constant was evaluated,1,U,,,,,,,,,BAO_0000019,CHEMBL629678,0,Autocuration,,,22224,
14973,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,1,U,,,,,,,,,BAO_0000019,CHEMBL629679,0,Autocuration,,,22224,
14974,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,1,U,,,,,,,,,BAO_0000019,CHEMBL629680,0,Autocuration,,,22224,
14975,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,1,U,,,,,,,,,BAO_0000019,CHEMBL629681,0,Autocuration,,,22224,
14976,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,1,U,,,,,,,,,BAO_0000019,CHEMBL629682,0,Autocuration,,,22224,
14977,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,1,U,,,,,,,,,BAO_0000019,CHEMBL629683,0,Autocuration,,,22224,
14978,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,1,U,,,,,,,,,BAO_0000019,CHEMBL629684,0,Autocuration,,,22224,
14979,Dissociation constant was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629685,0,Autocuration,,,22224,
14980,Dissociation constant was determined,1,U,,,,,,,,,BAO_0000100,CHEMBL629686,0,Autocuration,,,22224,
14981,Dissociation constant at pH 7.4,1,U,,,,,,,,,BAO_0000100,CHEMBL872932,0,Autocuration,,,22224,
14982,Dissociation constant in presence of 1 mM dithiothreitol,1,U,,,,,,,,,BAO_0000100,CHEMBL629687,0,Autocuration,,,22224,
14983,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,1,U,,,,,,,,,BAO_0000019,CHEMBL872931,0,Autocuration,,,22224,
14984,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,1,U,,,,,,,,,BAO_0000019,CHEMBL628151,0,Autocuration,,,22224,
14985,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,1,U,,,,,,,,,BAO_0000019,CHEMBL628152,0,Autocuration,,,22224,
14986,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,1,U,,,,,,,,,BAO_0000019,CHEMBL628153,0,Autocuration,,,22224,
14987,Kinetic constant for aromatization of androstenedione,1,U,,,,,,,,,BAO_0000019,CHEMBL628154,0,Autocuration,,,22224,
14988,Kinetic constant for aromatization of testosterone,1,U,,,,,,,,,BAO_0000019,CHEMBL628155,0,Autocuration,,,22224,
14989,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,1,U,,,,,,,,,BAO_0000019,CHEMBL628156,0,Autocuration,,,22224,
14990,Local inhibition constant was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL628157,0,Autocuration,,,22224,
14991,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,1,N,,Saccharomyces cerevisiae,,,,,,,BAO_0000218,CHEMBL857533,1,Intermediate,4932.0,,50347,
14992,Dissociation constant value of the compound,1,U,,,,,,,,,BAO_0000100,CHEMBL628158,0,Autocuration,,,22224,
14993,In vitro permeability through cornea without epithelium,1,U,,,,,,Cornea,,964.0,BAO_0000019,CHEMBL628159,0,Autocuration,,,22224,
14994,In vitro permeability through intact cornea,1,U,,,,,,Cornea,,964.0,BAO_0000019,CHEMBL875616,0,Autocuration,,,22224,
14995,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,1,N,,Oryctolagus cuniculus,,,,Cornea,,964.0,BAO_0000218,CHEMBL628160,1,Intermediate,9986.0,,50592,
14996,Rate of enzyme inactivation for the compound was determined,1,U,,,,,,,,,BAO_0000019,CHEMBL628161,0,Autocuration,,,22224,
14997,In vitro permeability through cornea without epithelium,1,U,,,,,,Cornea,,964.0,BAO_0000019,CHEMBL628162,0,Autocuration,,,22224,
14998,In vitro permeability through intact cornea,1,U,,,,,,Cornea,,964.0,BAO_0000019,CHEMBL628163,0,Autocuration,,,22224,
14999,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628164,0,Autocuration,,,22224,
15000,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628165,0,Autocuration,,,22224,
15001,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628166,0,Autocuration,,,22224,
15002,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628167,0,Autocuration,,,22224,
15003,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628168,0,Autocuration,,,22224,
15004,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628169,0,Autocuration,,,22224,
15005,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628170,0,Autocuration,,,22224,
15006,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628171,0,Autocuration,,,22224,
15007,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL627434,0,Autocuration,,,22224,
15008,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL627435,0,Autocuration,,,22224,
15009,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628110,0,Autocuration,,,22224,
15010,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628111,0,Autocuration,,,22224,
15011,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628112,0,Autocuration,,,22224,
15012,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628260,0,Autocuration,,,22224,
15013,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,U,,,,,,,,,BAO_0000019,CHEMBL628261,0,Autocuration,,,22224,
15014,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628262,1,Intermediate,10090.0,,50594,
15015,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,1,N,,Homo sapiens,,,,,,,BAO_0000218,CHEMBL628263,1,Intermediate,9606.0,,50587,
15016,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628264,1,Intermediate,10090.0,,50594,
15017,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628265,1,Intermediate,10090.0,,50594,
15018,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628266,1,Intermediate,10090.0,,50594,
15019,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628267,1,Intermediate,10090.0,,50594,
15020,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628268,1,Intermediate,10090.0,,50594,
15021,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628269,1,Intermediate,10090.0,,50594,
15022,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628270,1,Intermediate,10090.0,,50594,
15023,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628271,1,Intermediate,10090.0,,50594,
15024,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),1,N,,Mus musculus,,,,,,,BAO_0000218,CHEMBL628272,1,Intermediate,10090.0,,50594,
